insert into public.patient_type (id, title) values (1, 'Adult');
insert into public.patient_type (id, title) values (2, 'Pediatric');

insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (2, null, 1, null, null, 'Head & Neck Malignancies');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (4, null, 1, null, null, 'Thoracic');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (6, null, 1, null, null, 'Gynecologic Malignancy');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (7, null, 1, null, null, 'Urinary Tract');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (9, 9, 1, null, null, 'Biliary Tract Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (10, 9, 1, null, null, 'Hepatocellular Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (11, null, 1, null, null, 'Lymphoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (12, null, 1, null, null, 'Leukemia');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (14, 4, 1, null, null, 'Thymoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (19, null, 2, null, null, 'Sarcoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (20, null, 2, null, null, 'Lymphoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (21, null, 2, null, null, 'Leukemias');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (23, 23, 1, null, null, 'Harmone-Refractory');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (24, 23, 1, null, null, 'Hormonal');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (27, null, 1, null, null, 'Kaposi''s Sarcoma- AIDS Related');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (28, null, 1, null, null, 'Unknown Primary');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (29, 11, 1, null, null, 'AIDS-Related');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (30, 11, 1, null, null, 'Hodgkin''s');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (31, 11, 1, null, null, 'Non-Hodgkin''s');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (32, 12, 1, null, null, 'Acute Lymphocytic Leukemia (ALL)');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (35, 12, 1, null, null, 'Chronic Myeloid Leukemia (CML)');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (36, 12, 1, null, null, 'Hairy Cell Leukemia');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (37, null, 1, null, null, 'Myeloma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (38, null, 2, null, null, 'CNS Tumors');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (39, null, 2, null, null, 'Neuroblastoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (40, null, 2, null, null, 'Retinoblastoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (41, null, 2, null, null, 'Hepatoblastoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (42, null, 2, null, null, 'Wilms'' Tumor');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (43, 19, 2, null, null, 'Osteosarcoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (44, 19, 2, null, null, 'Soft tissue and Bone');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (45, 20, 2, null, null, 'Hodgkin''s');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (46, 20, 2, null, null, 'Non-Hodgkin''s');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (47, 21, 2, null, null, 'Acute Lymphocytic Leukemia');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (48, 21, 2, null, null, 'Acute Myeloid Leukemia');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (100, 7, 1, '378,378,378,379,379,380,378,380,379,381,382,383,384,385,386,387,388,389,390,390,391,392,391,392,393,392,383', null, 'Bladder Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (94, 3, 1, '646,647,648,649,650,651,651,652,653,653,654,655,656,657,658,659,660,661,662,663,664,665', null, 'Esophageal');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (95, 3, 1, '644,645,717,644,718,719,720,721,722,723,724,725,727,727,728,729,730,731,732,733,734', null, 'Hepatobiliary');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (97, 4, 1, null, null, 'Non-Small Cell Lung Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (105, 13, 0, '416,416,416,416,417,417,416,417,417,417,418,416,418,416,417,418,416,418,417,419,419,418,416,417,416,416,417,417,427,417,427,419,427,419,427,417,419,428,428,417,428,417,419,428,429,428,429,427,429,418,428,429,429,419,428', null, 'Extensive Stage');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (113, 5, 0, null, null, 'BRCA Mutated ');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (13, 4, 1, null, null, 'Small Cell Lung Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (5, null, 1, '378,398,398,398,501,502,503,504,505,506,506,507,508,509,510,511,511,512,513,514,515,516,517,518,519,518,520,521,522,521', null, 'Breast Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (106, 97, 0, '455,455,455,456,455,456,455,456,456,457,457,458,457,458,457,458,458,455,458,458,457,457,458,457,458,457,457,457,459,459,460,457,457,460,457,460,460,457,460,458,461,458,461,462,461,462,461,462,462,463,457,463,460,463,463,464,463,464,455,464,465,465,456,465,458,457,460,461,461,462,463,463,464,465,464,459,455,456,466,466,456,466,467,458,467,467,467,468,468,467,468,469,462,469,468,469,469,469,458,457,460,462,464,464,463,467,455,455,463,460,463,470,470,470,470,470,468,470,457,458,459,459,458,461,469,467,465,463,465,462,468,470', null, 'Adenocarcinoma, Large Cell, NOS');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (22, 7, 1, null, null, 'Kidney Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (101, 7, 1, null, null, 'Prostate Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (108, null, 1, null, null, 'Skin');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (104, 13, 0, '397,397,415,397,415,397,415,397,415,415,415,397,397,415,397,397', null, 'Limited Stage');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (15, 5, 1, '400,401,402,403,404,405,406,407,408,409,409,410,411,403,401,412,412,413,414,438,439,440,441,442,443,444,445,446,447,409,448,449,401,450,451,452,453,454,443', null, 'HER-2 Neu Negative');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (111, 108, 1, '587,587,587,587,588,588,587,588,588,588', null, 'Basal Cell Carcinoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (17, 5, 1, '430,431,430,432,433,434,435,436,437', null, 'Hormonal Therapy');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (107, 97, 0, '471,471,471,472,471,472,471,473,473,473,474,474,472,472,473,474,475,475,476,475,476,475,476,476,477,477,471,477,478,478,479,479,480,481,479,480,478,480,480,479,482,482,483,483,481', null, 'Squamous Cell Carcinoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (99, 6, 1, '559,560,561,562,562,563,564,565,566,567,568,569,570,571,572,573,574,575,574,576,577,578,579,580,581,582,583,584,585', null, 'Ovarian');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (18, 6, 1, '396,396,396,523,524,525,526,527,526,525,527,523,524,525,528,526,527,529,530,531,532,533,534,535,536,537,538,539,540,541,542,543', null, 'Cervical');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (98, 6, 1, '544,545,546,547,548,549,550,551,552,553,554,555,556,557,558', null, 'Endometrial');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (16, 5, 1, '395,395,395,395,399,420,421,422,423,424,425,426,424,484,485,486,487,488,489,487,490,491,492,493,494,495,496,497,496,496,498,499,500,499', null, 'HER-2 Neu Positive');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (109, 108, 1, null, null, 'Melanoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (110, 108, 1, null, null, 'Squamous Cell Carcinoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (114, 5, 0, null, null, 'PIK3CA Mutated ');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (112, 108, 1, null, null, 'Merkel Cell Carcinoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (34, 12, 1, '586,586,587,586,586,586,586,586,586,586,586,586', null, 'Chronic Lymphocytic Leukemia (CLL)');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (96, 3, 1, '699,700,701,702,703,704,703,705,706,707,708,709,709,710,711,712,713,714,715,716,715', null, 'Pancreatic');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (92, 3, 1, '666,667,668,669,674,675,676,677,678,679,680,681,682,683,683,684,685,686,687,688,689,690,691,692', null, 'Gastric');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (3, null, 1, null, null, 'Gastrointestinal');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (93, 3, 1, '589,590,591,592,593,594,595,596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,726,735,736,737,738,739,740,741,742,743,744,745', null, 'Colorectal');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (8, 3, 1, '693,694,695,696,697,698', null, 'Gastrointestinal Stromal Tumor (GIST)');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (91, 3, 1, '394,394,635,636,637,638,639,640,641,640,639,642,643,642,643', null, 'Anal');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (33, 12, 1, '671,671,671,671,671,671,672,672,673,672,673', null, 'Acute Myeloid Leukemia (AML)');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (1, null, 1, '670,670,670', null, 'CNS Tumors');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (26, null, 1, '746,746', null, 'Sarcoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (119, null, 1, null, null, 'Adrenocortical Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (117, 12, 0, null, null, 'Myelodysplastic Syndrome');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (118, 97, 0, null, null, 'ROS1 Rearrangement Positive');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (115, 97, 0, null, null, 'EGFR-1 Mutation Positive');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (116, 97, 0, null, null, 'ALK Rearrangement Positive');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (103, 7, 0, null, null, 'Testicular Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (102, 7, 1, null, null, 'Penile Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (120, null, 1, null, null, 'Thyroid Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (121, null, 1, null, null, 'Waldenstrom''s Macroglobulinemia');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (122, null, 1, null, null, 'NTRK Gene Fusion Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (123, null, 1, null, null, 'Malignant Mesothelioma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (124, null, 1, null, null, 'Carcinoid Tumors and Neuroendocrine Tumors');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (125, 31, 0, null, null, 'Low-Grade Lymphoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (126, 31, 0, null, null, 'Intermediate-Grade Lymphoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (127, 31, 0, null, null, 'High-Grade Lymphoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (128, 31, 0, null, null, 'Primary CNS Lymphoma.');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (129, 11, 0, null, null, 'Cutaneous T-cell Lyphoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (130, null, 1, null, null, 'Osteogenic Sarcoma');

insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (273, 'Ofatumumab : Arzerra', 'Ofatumumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ofatumumab &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ofatumumab &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li></ul>', 'Low', '<b>Ofatumumab</b>', 'Arzerra [package insert]. <br> Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single agent CD20 immunotherapy in fluda-rabine-refractory chronic lymphocytic leukemia. $J Clin Oncol. 2010;28:1749-1755.$', null, '<p><strong>Previously untreated CLL:</strong><br><strong>Ofatumumab: </strong>300 mg IV on Day 1 followed by 1,000 mg IV on Day 8 (Cycle 1)<br>Then: 1,000 mg IV on Day 1 of subsequent 28-day cycles for a minimum of 3 cycles until best response or a maximum of 12 cycles.</p><p><br><strong>Refractory CLL:</strong><br><strong>Ofatumumab:</strong> 300 mg IV, initial dose,<br>Followed 1 week later by<br><strong>Ofatumumab:</strong> 2,000 mg IV, &nbsp;every week for 7 weeks</p><p>Followed 4 weeks later by<br><strong>Ofatumumab:</strong> 2,000 mg IV, &nbsp;every 4 weeks for 4 doses.<br>Repeat every 28 days for 4 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (682, '', 'FP + Trastuzumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> No dose reduction.</li></ul><p>&nbsp;<strong>Cardiac Impairment</strong></p><ul><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'High', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>800 mg/m<sup>2</sup>&nbsp;IV continuous infusion on days 1-5</p>

<p><strong>Cisplatin:&nbsp;</strong>80 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Trastuzumab:&nbsp;</strong>8 mg/kg IV loading dose, then 6 mg/kg IV every 3 weeks.</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (3, 'Temozolomide : Temodar', 'Temozolomide+RT', '<b>Hepatic Impairment</b><ul><li>Temozolomide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'Moderate for IV<br> <=75 mg/m<sup>2</sup> PO is minimal-low;<br> >75 mg/m<sup>2</sup> PO is moderate-high   ', '<b>Temozolomide+RT</b>', 'Stupp R, et al.  Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma.$N Engl J Med 2005; 352:987-996$', null, '<b>Temozolomide</b> 75 mg/m<sup>2</sup> daily along with radiation<br> <b>FOLLOWED 28 DAYS LATER BY</b><br><b>Temozolomide<sup>e</sup></b> 150 mg/m<sup>2</sup> daily for 5 days<br>Repeat every 28 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (6, 'Temozolomide : Temodar', 'Temozolomide', '<b>Hepatic Impairment</b><ul><li>Temozolomide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'Moderate for IV<br> >75 mg/m<sup>2</sup> PO is moderate-high   ', '<b>Temozolomide</b>', 'Gállego Pérez-Larraya J, et al.Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.$J Clin Oncol. 2011 Aug 1;29(22):3050-5. doi: 10.1200/JCO.2011.34.8086. Epub 2011 Jun 27$', null, '<b>Temozolomide</b> 150 mg/m<sup>2</sup> every day for 5 days per 28-day cycle<br> ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (817, null, 'Hydroxyurea', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Hydroxyurea: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction &nbsp; &nbsp;&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong></li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Hydroxyurea: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> &nbsp;If<strong> </strong>CrCl ≥60 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;60 mL/min: Reduce initial dose by 50%.</li></ul>', 'Low', null, null, null, '<p><strong>Hydroxyurea:</strong> 1-5 g/day PO</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (809, null, 'Linker Regimen', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Daunorubicin:</strong><br>If bilirubin 1.2-3 mg/dL: 75% of usual dosage.<br>If bilirubin 3.1-5 mg/dL: 50% of usual dosage.<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL: 50% of usual dosage.<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL: Do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>L-Asparaginase: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Do not use in patients with severe hepatic impairment.</li><li><strong>Teniposide:</strong><br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 3 mg/dL: 50% of usual dosage.</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 5 mg/dL: Do not use</li><li><strong>Leucovorin:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Daunorubicin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>L-Asparaginase:</strong><br>No dose reduction</li><li><strong>Teniposide:</strong><br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min: 50% of normal dosage.<br>If CrCl &lt; 30 mL/min: Do not use</li><li><strong>Leucovorin:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Remission induction:</strong></p><p><strong>Daunorubicin:</strong> 50 mg/m2 IV every 24 hours on days 1-3 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Vincristine:</strong> &nbsp;2 mg IV on days 1, 8, 15 and 22 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Prednisone:</strong> 60 mg/m2 PO divided into 3 doses on days 1-28 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>L-Asparaginase:</strong> 6,000 units/m2 IM on days 17-28.</p><p>If bone marrow on day 14 is positive for residual leukemia,</p><p><strong>Daunorubicin:</strong> 50 mg/m2 IV on day 15</p><p>&nbsp;If bone marrow on day 28 is positive for residual leukemia,</p><p><strong>Daunorubicin:</strong> 50 mg/m2 IV on days 29 and 30 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Vincristine:</strong> &nbsp;2 mg IV on days 29 and 36 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Prednisone:</strong> 60 mg/m2 PO on days 29 to 42 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>L-Asparaginase:</strong> 6,000 units/m2 IM on days 29 to 35.</p><p><strong>Consolidation therapy:</strong></p><p><strong>Treatment A</strong> (cycles 1, 3, 5, and 7)</p><p><strong>Daunorubicin:</strong> 50 mg/m2 IV on days 1 and 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Vincristine:</strong> &nbsp;2 mg IV on days 1 and 8 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Prednisone:</strong> 60 mg/m2 PO on days 1 to 14 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>L-Asparaginase:</strong> 12,000 units/m2 on days 2, 4, 7, 9, 11, and 14</p><p><strong>Treatment B</strong> (cycles 2, 4, 6, and 8)</p><p><strong>Teniposide: </strong>165 mg/m2 IV on days 1, 4, 8, and 11</p><p><strong>Cytarabine:</strong> 300 mg/m2 IV on days 1, 4, 8, and 11</p><p><strong>Treatment C</strong> (cycle 9)</p><p><strong>Methotrexate:</strong> 690 mg/m2 IV over 42 hours&nbsp;</p><p><strong>Leucovorin:</strong> 15 mg/m2 IV every 6 hours for 12 doses beginning at 42 hours.</p><p>&nbsp;</p><p><strong>Maintenance Therapy</strong></p><p><strong>Methotrexate:</strong> 20 mg/m2 PO weekly.</p><p><strong>6 Mercaptopurine:</strong> 75 mg/m2 PO daily</p><p>Continue for a total of 30 months of complete response.</p><p><strong>CNS Prophylaxis</strong><br><strong>Cranial irradiation:</strong> 1,800 Gy in 10 fractions over 12-14 days<br><strong>Methotrexate:</strong> 12 mg IT weekly for 6 weeks<br>Begin within 1 week of complete response.<br>In patients with documented CNS involvement at the time of diagnosis, intrathecal<br>chemotherapy should begin during induction chemotherapy.<br><strong>Methotrexate: </strong>12 mg IT weekly for 10 doses<br><strong>Cranial irradiation:</strong> 2,800 cGy</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (39, 'Cisplatin : CDDP<br>Gemcitabine : Gemzar, various', 'Gemcitabine + Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Low', '<b>Gemcitabine + Cisplatin</b>', '$Thongprasert S, et al. Ann Oncol 2005;16:279-281$', null, '<b>Gemcitabine</b> 1,250 mg/m<sup>2</sup> IV on Day 1, 8<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV on Day 1<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1043, null, 'Venetoclax + Rituximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Venetoclax:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If mild to moderate impairment (Child-Pugh classes A and B): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): Reduce dose by 50%.</li><li><strong>Rituximab:</strong><br>Dose modification not provided by the manufacturer</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Venetoclax: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If<strong>&nbsp;</strong>CrCl ≥15 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If<strong>&nbsp;</strong>CrCl &lt;15 mL/min: Dosage adjustment not provided by the manufacturer.</li><li><strong>Rituximab:</strong><br>Dose modification not provided by the manufacturer</li></ul>', 'Low', null, null, null, '<p><strong>Venetoclax:</strong> 20 mg/day PO on days 1-7<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 50 mg/day PO on days 8-14<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 100 mg/day PO on days 15-21<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 200 mg/day PO on days 22-28 and then 400 mg/day PO daily<br><strong>Venetoclax:</strong> 400 mg PO daily<br><strong>Rituximab:</strong> 375 mg/m2 IV on day 1 of cycle 1, then 500 mg/m IV on day 1 of cycles 2-6<br>Repeat cycle every 28 days for up to 6 cycles. After cycle 6, venetoclax is continued at 400 mg PO daily for up to 2 years.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (14, 'Cisplatin : CDDP<br>Fluorouracil : 5-FU', '5-Fluorouracil + Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'High', '<b>5-Fluorouracil + Cisplatin</b>', '$Kies MS, et al. Cancer 1987;60:2156-2160.$', null, '<b>5-Fluorouracil</b>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5<br><b>Cisplatin</b>100 mg/m<sup>2</sup> IV on day 1<br>Repeat cycle on weeks 1, 5, 8, and 11.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (15, 'Cisplatin : CDDP', 'Irinotecan + Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Irinotecan:<br>No dose reduction </li></ul>', 'High', '<b>Irinotecan + Cisplatin</b>', '$Ilson DH, et al. J Clin Oncol 1999;17:3270-3275.$', null, '<b>Irinotecan</b>65 mg/m<sup>2</sup> IV weekly for 4 weeks<br><b>Cisplatin</b>30 mg/m<sup>2</sup> IV weekly for 4 weeks<br>Repeat cycle every 6 weeks.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (16, 'Cisplatin : CDDP<br>Paclitaxel : Taxol', 'Paclitaxel + Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'High', '<b>Paclitaxel + Cisplatin</b>', '$Ilson DH, et al. J Clin Oncol 1998;16:1826-1834.$', null, '<b>Paclitaxel</b>200 mg/m<sup>2</sup> IV over 24 hours on day 1<br><b>Cisplatin</b>75 mg/m<sup>2</sup> IV on day 2<br>Repeat cycle every 21 days. G-CSF support is recommended.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (17, 'Capecitabine : Xeloda<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'Capecitabine + Oxaliplatin', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>Capecitabine + Oxaliplatin</b>', '$Van Meerten E, et al. Br J Cancer 2007;96:1348-1352.$', null, '<b>Capecitabine</b>1,000 mg/m<sup>2</sup> PO bid on days 1-14<br><b>Oxaliplatin</b>130 mg/m<sup>2</sup> IV on day 1<br>Repeat cycle every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (18, 'Cisplatin : CDDP<br>Epirubicin : Ellence, various', 'ECF', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'High', '<b>ECF</b>', '$Cunningham D, et al. N Engl J Med 2008;358:36-46.$', null, '<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Cisplatin</b>60 mg/m<sup>2</sup> IV on day 1<br><b>5-Fluorouracil</b>200 mg/m<sup>2</sup>/day IV continuous infusion for 24 weeks.<br>Repeat cycle every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (818, null, 'Interferon alpha-2a', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Interferon alfa</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Interferon alfa</strong>:<br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Interferon-alpha-2a:</strong> 9 million U/day SC</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (19, 'Epirubicin : Ellence, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'EOF', '<b>Hepatic Impairment</b><ul><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>EOF</b>', '$Cunningham D, et al. N Engl J Med 2008;358:36-46.$', null, '<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Oxaliplatin</b>130 mg/m<sup>2</sup> IV on day 1<br><b>5-Fluorouracil</b>200 mg/m<sup>2</sup>/day IV continuous infusion for 24 weeks<br>Repeat cycle every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (20, 'Capecitabine : Xeloda<br>Cisplatin : CDDP<br>Epirubicin : Ellence, various', 'ECX', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'High', '<b>ECX</b>', '$Cunningham D, et al. N Engl J Med 2008;358:36-46.$', null, '<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Cisplatin</b>60 mg/m<sup>2</sup> IV on day 1<br><b>Capecitabine</b>625 mg/m<sup>2</sup> PO bid continuously<br>Repeat cycle every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (91, 'Crizotinib : Xalkori', 'Crizotinib', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Moderate-High', '<b>Crizotinib</b>', 'Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic Lymphoma Kinase inhabitation in non-small-cell lung cancer. $N engl J Med.2010;363(18):1693-1703.$<br> Xalkori [packages insert]. $New York, NY: Pfizer labs;2011.$', null, '<b>Crizotinib</b> 250 mg PO bid in 28-day cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (21, 'Capecitabine : Xeloda<br>Epirubicin : Ellence, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'EOX', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>EOX</b>', '$Cunningham D, et al. N Engl J Med 2008;358:36-46.$', null, '<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Oxaliplatin</b>130 mg/m<sup>2</sup> IV on day 1<br><b>Capecitabine</b>625 mg/m<sup>2</sup> PO bid times 21 days<br>Repeat cycle every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (22, 'Paclitaxel : Taxol', 'Paclitaxel', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Moderate', '<b>Paclitaxel</b>', '$Ajani JA, et al. Semin Oncol 1995;22 (Suppl 6):35-40.$', null, '<b>Paclitaxel</b>250 mg/m<sup>2</sup> IV over 24 hours on day 1<br>Repeat cycle every 21 days. G-CSF support is recommended.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (23, 'Cisplatin : CDDP<br>Docetaxel : Taxotere<br>Fluorouracil : 5-FU', 'DCF', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'High', '<b>DCF</b>', 'Van Custem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus florouracil compared with cisplatin and flouorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. $J Clin Oncol. 2006;24(31):4991-4997$', null, '<b>Docetaxel</b> 75mg/m<sup>2</sup> IV over 1 hour, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV over 1-3 hours, day 1<br> <b>Fluorouracil</b> 750 mg/m<sup>2</sup>/d CIVI, days 1-5<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (24, 'Cisplatin : CDDP<br>Docetaxel : Taxotere', 'Docetaxel/Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li></ul>', 'High', '<b>Docetaxel/Cisplatin</b>', 'Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. $Ann Oncol. 2000;11(3):301-306$', null, '<b>Docetaxel</b> 85 mg/m<sup>2</sup> IV over 1 hour, day 1,<br> <b>FOLLOWED BY</b><br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV over 1 hour, day 1<br> Repeat every 21 days for a maximum of 8 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (25, 'Cisplatin : CDDP<br>Epirubicin : Ellence, various', 'ECF', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'High', '<b>ECF</b>', 'Waters JS, Norman A, Cunningham D, et al. Long-term survival afer epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. $Br J Cancer. 1999;80(1-2):269-272.$', null, '<b>Epirubicin</b> 50 mg/m<sup>2</sup> IV, day 1<br> <b>Cisplatin</b> 60 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 200 mg/m<sup>2</sup>/d CIVI, for up to 6 months<br> Repeat every 21 days for a maximum of 8 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (26, 'Etoposide : VP-16<br>Fluorouracil : 5-FU', 'ELF', '<b>Hepatic Impairment</b><ul><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Low', '<b>ELF</b>', 'Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional flurorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gasttrointestinal Tract Cancer Cooperative Group. $J Clin Oncol. 2000;18(41):2648-2657$', null, '<b>Leucovorin calcium</b> 300 mg/m<sup>2</sup>/d IV over 10 minutes, <b>FOLLOWED BY</b><br> <b>Etoposide</b> 120 mg/m<sup>2</sup>/d IV over 50 minutes,<br> <b>THEN</b><br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup>/d IV  bolus<br> Give all agents on days 1-3; repeat every 22 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (27, 'Fluorouracil : 5-FU', '5-FU/LV and Radiation', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Low', '<b>5-FU/LV and Radiation</b>', 'Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy afer surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. $N Engl J Med. 2001;345(10):725-730.$', null, '<b>Fluorouracil</b> 425 mg/m<sup>2</sup>/d for 5 days<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup>/d for 5 days,<br> <b>FOLLOWED BY</b><br> <b>RT</b> 4,500 cGy (180cGy/d), 5 days a week for 5 weeks<br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup>/d IV, on the first 4 and last 3 days of RT<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup>/d, on the first 4 and last 3 days of RT,<br> <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 425 mg/m<sup>2</sup>/d for 5 days<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup>/d for 5 days<br>repeat 28 days X 2 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (28, 'Capecitabine : Xeloda<br>Cisplatin : CDDP<br>Fluorouracil : 5-FU<br>Trastuzumab : Herceptin', 'Trastuzumab + Cisplatin + Capecitabine or Fluorouracil', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'High day 1, low for the remaining treatment days', '<b>Trastuzumab + Cisplatin + Capecitabine or Fluorouracil</b>', 'Bang YJ, Van Cutsem E, Feyereislava A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 open-label, randomised controlled trial. $Lancet. 2010;376(99742):687-697.$', null, '<b>Trastuzumab</b> 8 mg/kg IV, day 1 of the first cycle <b>THEN</b>  6 mg/kg IV, day 1<br><br> <b>Cisplatin</b> 80 mg/m<sup>2</sup> IV, day 1. <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid, days 1-14 <br> Repeat  every 21 days<br> <b>OR</b><br> <b>Fluorouracil</b> 800 mg/m<sup>2</sup>/d CIVI for 5 days of each 3-week cycle<br> Repeat for 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (31, 'Gemcitabine : Gemzar, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'GEMOX', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>GEMOX</b>', '$Taieb J, et al. Cancer 2003;98:2664-2670.$', null, '<b>Gemcitabine</b>1,000 mg/m<sup>2</sup> IV on day 1<br><b>Oxaliplatin</b>100 mg/m<sup>2</sup> IV on day 2<br>Repeat cycle every 2 weeks.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (32, 'Oxaliplatin : Eloxatin, Oxaliplatin, various', 'FOLFOX4', '<b>Hepatic Impairment</b><ul><li>Leucovorin:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Leucovorin:<br>No dose reduction</li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>FOLFOX4', '$Qin S, et al. J Clin Oncol 2010;28:303S (abstract 408).$', null, '<b>Oxaliplatin</b>85 mg/m<sup>2</sup> IV on day 1<br><b>5-Fluorouracil</b>400 mg/m<sup>2</sup> IV bolus, followed by 600 mg/m<sup>2</sup> IV continuous infusio for 22 hours on days 1 and 2<br><b>Leucovorin</b>200 mg/m<sup>2</sup> IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil<br>Repeat cycle every 2 weeks.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (33, 'Bevacizumab : Avastin<br>Erlotinib : Tarceva', 'Bevacizumab + Erlotinib', '<b>Hepatic Impairment</b><ul><li>Erlotinib:<br>If AST > 3 upper normal limit, 50 mg  <br>                                                        If direct bilirubin 1-7 mg/dL, 75 mg </li></ul><b>Renal Impairment</b><ul><li>Erlotinib:<br>No dose reduction </li></ul>', 'Low', '<b>Bevacizumab + Erlotinib</b>', '$Thomas MB, et al. J Clin Oncol 2009;27:843-850.$', null, '<b>Bevacizumab</b>10 mg/kg IV on days 1 and 14<br><b>Erlotinib</b>150 mg PO daily<br>Repeat cycle every 28 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (34, 'Sorafenib : Nexavar', 'Sorafenib', '<b>Hepatic Impairment</b><ul><li>Sorafenib:<br>If Child-Pugh A or B, no dose reduction     <br>                                                 If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Sorafenib:<br>No dose reduction </li></ul>', 'Low', '<b>Sorafenib</b>', '$Llovet J, et al. N Engl J Med 2008;359:378-390.$', null, '<b>Sorafenib</b>400 mg PO bid.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (35, 'Doxorubicin : Adriamycin, various', 'Doxorubicin', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Moderate', '<b>Doxorubicin</b>', '$Venook AP. J Clin Oncol 1994;12:1323-1334.$', null, '<b>Doxorubicin</b>20-30 mg/m<sup>2</sup> IV weekly<br>Repeat cycle every week.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (36, 'Cisplatin : CDDP', 'Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'High', '<b>Cisplatin</b>', '$Okada S, et al. Oncology 1993;50:22-26.$', null, '<b>Cisplatin</b>80 mg/m<sup>2</sup> IV on day 1<br>Repeat cycle every week.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (37, 'Capecitabine : Xeloda', 'Capecitabine', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>', 'Moderate', '<b>Capecitabine</b>', '$Patt YZ, et al. Cancer 2004;101:578-586.$', null, '<b>Capecitabine</b>1,000 mg/m<sup>2</sup> PO bid on days 1-14<br>Repeat cycle every 21 days. PO bid on days 1-14.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (38, 'Bevacizumab : Avastin', 'Bevacizumab', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Bevacizumab</b>', '$Siegel AB, et al. J Clin Oncol 2008;26:2992-2998.$', null, '<b>Bevacizumab</b>10 mg/kg IV on day 1<br>Repeat cycle every 14 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (164, 'Topotecan : Hycamtin', 'Topotecan', '<b>Hepatic Impairment</b><ul><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>', 'Low', '<b>Topotecan</b>', 'ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. $J Clin Oncol. 1997;15(6):2183-2193.$', null, '<b>Topotecan</b> 1.5 mg/m<sup>2</sup>/d IV over 30 minutes, days 1-5<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (40, 'Capecitabine : Xeloda<br>Gemcitabine : Gemzar, various', 'Gemcitabine + Capecitabine', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Moderate', '<b>Gemcitabine + Capecitabine</b>', '$Knox JJ, et al. J Clin Oncol 2005;23:2332-2338.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV on Day 1, 8<br> <b>Capecitabine</b> 650 mg/m<sup>2</sup> PO BID on Days 1-14<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (41, 'Gemcitabine : Gemzar, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'Gemcitabine + Oxaliplatin', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>Gemcitabine + Oxaliplatin</b>', '$Andre T, et al. Ann Oncol 2004;15:1339-1343.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV on Day 1<br> <b>Oxaliplatin</b> 100 mg/m<sup>2</sup> on Day 2<br> Repeat cycle every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (42, 'Cisplatin : CDDP', '5-Fluorouracil + Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'High', '<b>5-Fluorouracil + Cisplatin</b>', '$Taieb J, et al. Ann Oncol 2002;13:1192-1196.$', null, '<b>5-FU</b> 400 mg/m<sup>2</sup> on Day 1<br> <b>FOLLOWED BY</b> 600 mg/m<sup>2</sup> continuous infusion over 22 hours on days 1 and 2<br> <b>Cisplatin</b> 50 mg /m<sup>2</sup> IV on day 2<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (43, 'Capecitabine : Xeloda<br>Cisplatin : CDDP', 'Capecitabine + Cisplatin', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'High', '<b>Capecitabine + Cisplatin</b>', '$Hong YS, et al. Cancer Chemother Pharmacol 2007;60:321-328.$', null, '<b>Capecitabine</b> 1,250 mg/m<sup>2</sup> PO bid on days 1-14<br> <b>Cisplatin</b> 60 mg/m<sup>2</sup> IV on day 2<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (44, 'Capecitabine : Xeloda<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'Capecitabine + Oxaliplatin', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>Capecitabine + Oxaliplatin</b>', '$Nehis O, et al. Br J Cancer 2008;98:309-315.$', null, '<b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid on days 1-14<br> <b>Oxaliplatin</b> 130 mg/m<sup>2</sup> IV on day 1<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (45, 'Capecitabine : Xeloda', 'Capecitabine', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>', 'Moderate', '<b>Capecitabine</b>', '$Patt YZ, et al. Cancer 2004;101:578-586.$', null, '<b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid on days 1-14<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (46, 'Docetaxel : Taxotere', 'Docetaxel', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>', 'Moderate', '<b>Docetaxel</b>', '$Papakostas P, et al. Eur J Cancer 2001;37:1833-1838.$', null, '<b>Docetaxel</b> 100 mg/m<sup>2</sup> IV on day 1<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (47, 'Gemcitabine : Gemzar, various', 'Gemcitabine', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Moderate', '<b>Gemcitabine</b>', '$Park JS, et al. Jpn J Clin Oncol 2005;35:68-73.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV on days 1 and 8<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (890, null, 'Avelumab + Axitinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Avelumab:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Axitinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If mild impairment (Child-Pugh class A): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (Child-Pugh class B): Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C):&nbsp;<strong> </strong>Dosage adjustments not provided by the manufacturer.</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Avelumab:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Axitinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> If<strong> </strong>CrCl 15 to &lt;89 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;15 mL/min:&nbsp;<strong> </strong>Dosage adjustments not provided by the manufacturer.</li></ul>', 'Low', null, null, null, '<p><strong>Avelumab:</strong> 10 mg/kg IV on day 1<br><strong>Axitinib:</strong> 5 mg PO BID daily</p><p>Repeat cycle every 2 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (48, 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'FOLFIRINOX', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>FOLFIRINOX</b>', 'Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. $N Engl J Med. 2011;364(19):1817-1825.$', null, '<b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV over 2 hours <b>FOLLOWED BY Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours with the addition, after 30 minutes <b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes; <b>IMMEDIATELY FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus, <b>THEN</b><br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> IV over 46 hours<br> Repeat cycle every 2 weeks', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (49, 'Capecitabine : Xeloda<br>Gemcitabine : Gemzar, various', 'Gemcitabine/Capecitabine', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Low', '<b>Gemcitabine/Capecitabine</b>', 'Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. $J Clin Oncol. 2007;25(16):221-2217.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV over 30 minutes, days 1, 8<br> <b>Capecitabine</b> 650 mg/m<sup>2</sup> PO bid, days 1-14<br> Repeat every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (50, 'Erlotinib : Tarceva<br>Gemcitabine : Gemzar, various', 'Gemcitabine/Erlotinib', '<b>Hepatic Impairment</b><ul><li>Erlotinib:<br>If AST > 3 upper normal limit, 50 mg  <br>                                                        If direct bilirubin 1-7 mg/dL, 75 mg </li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Erlotinib:<br>No dose reduction </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Low', '<b>Gemcitabine/Erlotinib</b>', 'Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer institute of Canada Clinical Trials Group. $J Clin Oncol. 2007;25(15):1960-1966.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV over 30 minutes once weekly for 7 weeks,<br> <b>FOLLOWED BY</b> 1 week of rest<br> <b>Erlotinib</b> 100 <b>OR</b> 150 mg/d PO<br> Repeat subsequent cycles once weekly for 3 consecutive weeks out of every 4 weeks', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (51, 'Gemcitabine : Gemzar, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'GEMOX', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>GEMOX</b>', 'Louvet C, Labianca R, Hammel P, at al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. $J Clin Oncol. 2005;23(15):3509-3516.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup>, day 1 as 100-minute infusion<br> <b>Oxaliplatin</b> 100 mg/m<sup>2</sup>, day 2 as 2-hour infusion<br> Repeat every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (52, 'Gemcitabine : Gemzar, various', 'Gemcitabine', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Low', '<b>Gemcitabine</b>', 'Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survivial and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. $J Clin Oncol. 1997;15(6):2403-2413.$', null, '<b>Gemcitabine 1,000 mg/m<sup>2</sup> IV over 30 minutes once weekly for 7 weeks,<br> <b>FOLLOWED BY</b> 1 week of rest<br> Repeat subsequent cycles once weekly for 3 consecutive weeks out of every 4 weeks', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (53, 'Cetuximab : Erbitux', 'Cetuximab/Irinotecan', '<b>Hepatic Impairment</b><ul><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Irinotecan:<br>No dose reduction </li></ul>', 'Moderate', '<b>Cetuximab/Irinotecan</b>', 'Cunningham D, Humblet Z, Siena S,et al. Cetuximab monothherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. $N Engl J Med. 2004;351(4):337-345.$', null, '<b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose,<b>THEN</b> 250 mg/m<sup>2</sup> IV every 7 days<br> <b>Irinotecan</b> 350 mg/m<sup>2</sup> IV every 21 days<br> <b>OR</b> 180 mg/m<sup>2</sup> IV every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (54, '', '5-FU/LV (Mayo regimen)', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low ', '<b>5-FU/LV (Mayo regimen)</b>', 'Poon MA, O''Connell MJ, Moertel CG. Biochemical modulation of fluorouracil: evidence of significant improvement of surival and quality of life in patients with advanced colorectal carcinoma. $J Clin Oncol. 1989;7(10):1407-1418$', null, '<b>Fluorouracil</b> 370mg/m<sup>2</sup>/d IV bolus 1 hour after start of leucovorin, days 1-5<br> <b>FOLLOWING Leucovorin calcium</b> 200 mg/m<sup>2</sup>/d IV bolus, days 1-5<br> Repeat at 4 and 8 weeks, and every 5 weeks thereafter', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (55, 'Fluorouracil : 5-FU', '5-FU/LV (Roswell Park regimen)', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Low', '<b>5-FU/LV (Roswell Park regimen)</b>', 'Petreli N, Douglass HO Jr, Herrera L, et al. The modulation of fluroouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. $J Clin Oncol. 1989;7(10):1419-1426$<br> Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previoulsy untreated patients with advanced colorectal carcinoma. $J Clin Oncol. 1987;5(10):1559-1565.$', null, '<b>Fluorouracil</b> 600 mg/m<sup>2</sup>/d IV bolus 1 hour after start of leucovorin, days 1,8, 15, 22, 29, 35<br> <b>Leucovorin calcium</b> 500 mg/m<sup>2</sup>/d IV over 2 hours, days 1, 8, 15, 22, 29, 35<br> Repeat every 8 weeks', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (56, 'Bevacizumab : Avastin<br>Fluorouracil : 5-FU', '5-FU/LV + Bevacizumab', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Low', '<b>5-FU/LV + Bevacizumab</b>', 'Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumb to flurouracil/leucovorin improves survival for patients with metastatic colorectal cancer. $J Clin Oncol. 2005;23(16):3706-3712.$<br> Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin; an active regimen for firstline metastatic colorectal cancer. $J Clin Oncol. 2005;23(15):3502-3508$', null, '<b>Fluorouracil</b> 600 mg/m<sup>2</sup>/d IV bolus 1 hour after start of leucovorin, days 1,8, 15, 22, 29, 35<br> <b>Leucovorin calcium</b> 500 mg/m<sup>2</sup>/d IV over 2 hours, days 1, 8, 15, 22, 29, 35<br> Repeat every 8 weeks<br> <b>Bevacizumab</b> 5mg/kg IV<br> Repeat every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (57, 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'FLOX', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>FLOX</b>', 'Kuebler JP, Wieand HS, O''Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. $J Clin Oncol. 2007;25(16):2198-2204.$', null, '<b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV over 2 hours, days 1, 15, 29<br> <b>Leucovorin calcium</b> 500 mg/m<sup>2</sup> IV over 2 hours, days 1, 8, 15, 22, 29, 36<br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup> IV bolus 1 hour after the infusion begins, days 1, 8, 15, 22,    29, 36<br> Repeat every 8 weeks for 3 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (58, 'Fluorouracil : 5-FU', 'FOLFIRI', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Moderate', '<b>FOLFIRI</b>', 'Tournigand C, Andre T, Achille E, et al. FOLFIRI  followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. $J Clin Oncol. 2004;22(2):229-237$', null, '<b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes, day 1<br> <b>Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours during irinotecan infusion,<br> <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus,<br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> CIVI over 46 hours<br> Repeat every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (59, 'Bevacizumab : Avastin<br>Fluorouracil : 5-FU', 'FOLFIRI + Bevacizumab', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Moderate', '<b>FOLFIRI + Bevacizumab</b>', 'Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. $J Clin Oncol. 2007;25(30):4779-4786.$', null, '<b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes, day 1<br> <b>Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours, day 1<br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus, day 1<br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> CIVI over 46 hours, day 1<br> <b>Bevacizumab</b> 5 mg/kg IV, day 1<br> Repeat every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (60, 'Cetuximab : Erbitux<br>Fluorouracil : 5-FU', 'FOLFIRI + Cetuximab', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Moderate', '<b>FOLFIRI + Cetuximab</b>', 'Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. $J Clin Oncol. 2007;25:4000 (abstract).$', null, '<b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes, day 1<br> <b>Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours during irinotecan infusion,<br> <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus,<br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> CIVI over 46 hours<br> Repeat every 14 days<br> <b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose, <b>THERE AFTER</b> 250mg/m<sup>2</sup> IV weekly', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (61, 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'FOLFOX4', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>FOLFOX4</b>', 'Richard M. Goldberg, et al.Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer.$http://jco.ascopubs.org/content/24/25/4085.abstract$', null, '<b>Day 1</b><br><b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV AND <br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> over 120 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours,<br><b>Day 2</b><br><b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> IV over 120 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours,<br> Repeat  every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (72, '', 'Irinotecan', '<b>Hepatic Impairment</b><ul><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Irinotecan:<br>No dose reduction </li></ul>', 'Moderate', '<b>Irinotecan</b>', 'Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. $J Clin Oncol. 1997;15(1):251-260$<br> Camptosar [package insert]. New York, NY: Pfizer; 2010.<br> Conti JA, Kemeny NE, jSaltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. $J Clin Oncol. 1996;14(3):709-715.$<br> Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. $Lancet. 1998;352(9138):1413-1418.$', null, '<b>Irinotecan</b> 125 mg/m<sup>2</sup>/d IV over 90 minutes, days 1,8, 15,22 <b>FOLLOWED BY</b> 2 weeks rest<br> Repeat every 6 weeks<br> <b>OR</b><br> <b>Irinotecan</b> 350 mg/m<sup>2</sup> IV over 90 minutes<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (62, 'Bevacizumab : Avastin<br>Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'FOLFOX4 + Bevacizumab', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>FOLFOX4 + Bevacizumab</b>', 'Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. $J Clin Oncol. 2008;26(18)2013-2019.$', null, '<b>Day 1</b><br><b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV <b>AND</b><br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> over 120 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours, <br><b>Bevacizumab</b> 5 mg/kg IV.<br><b>Day 2</b><br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> IV over 120 minutes, day 2, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours,<br> Repeat  every 14 days <br> Repeat every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (63, 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'FOLFOX4 + panitumumab ', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>FOLFOX4 + panitumumab</b> ', 'Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. $J Clin Oncol. 2010;28(31):4697-4705.$', null, '<b>Panitumumab</b> 6 mg/kg IV over 60 minutes <br> <b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV, day 1<br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> IV on day 1<br> <b>FOLLOWED BY Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus, <b>FOLLOWED BY Fluorouracil</b> 600mg/m<sup>2</sup> IV infusion over 22 hours on days 1 and 2<br> Repeat cycle every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (66, '', 'XELIRI', '<b>Hepatic Impairment</b><ul><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Irinotecan:<br>No dose reduction </li></ul>', 'Moderate', '<b>XELIRI</b>', 'Patt YZ, Lee F, Liebman JE, et al. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer. $Am J Clin Oncol. 2007;30(4):350-357$', null, '<b>Irinotecan</b> 250 mg/m<sup>2</sup> IV over 30-90 minutes, day 1<br> <b>Cappecitabine 1,000 mg/m<sup>2</sup> PO bid, days 1-14<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (67, 'Oxaliplatin : Eloxatin, Oxaliplatin, various', 'XELOX', '<b>Hepatic Impairment</b><ul><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>XELOX</b>', 'Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin); active first-line therapy for patients with metastatic colorectal cancer. $J Clin Oncol. 2004;22(11):2084-2091$', null, '<b>Oxaliplatin</b> 130 mg/m<sup>2</sup> IV, day 1<br> <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid from evening day 1 to 14<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (68, 'Bevacizumab : Avastin<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'XELOX + Bevacizumab', '<b>Hepatic Impairment</b><ul><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>XELOX + Bevacizumab</b>', 'Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. $J Clin Oncol. 2008;26(18)2013-2019.$', null, ' <b>Oxaliplatin</b> 130 mg/m<sup>2</sup> IV, day 1<br><b>Bevacizumab</b> 7.5 mg/kg IV, day 1<br> <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid from evening day 1 to 14<br> Repeat every 21 days<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (69, 'Capecitabine : Xeloda', 'Capecitabine', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>', 'Low', '<b>Capecitabine</b>', 'Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III Study. $J Clin Oncol. 2001;19(21):4097-4106$', null, '<b>Capecitabine</b> 1,000- 1,250 mg/m<sup>2</sup>/d PO bid, days 1-14, <b>FOLLOWED BY</b> 7 days rest<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (70, 'Cetuximab : Erbitux', 'Cetuximab', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Cetuximab</b>', 'Erbitux [package insert]. $Branchburg, NJ, and Princeton, NJ: ImClone Systems/ Bristol-Myers Squibb; 2011.$', null, '<b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose over 120 minutes, <b>FOLLOWED BY</b> 250 mg/m<sup>2</sup> IV over 60 minutes<br> Repeat every 7 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (71, 'Fluorouracil : 5-FU', '5-FU', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Low', '<b>5-FU</b>', 'Kemeny N, Israel K, Niedzwieki D, et al. Randomized study of continuous-infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. $J Clin Oncol. 1990;8(2):313-318.$<br> Schmoll HJ. Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents. $lEur J Cancer. 1996;32A(suppl 5):S18-S22.$', null, '<b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d CIVI, days 1-5<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (77, 'Imatinib : Gleevec', 'Imatinib', '<b>Hepatic Impairment</b><ul><li>Imatinib:<br>If bilirubin < 3 upper normal limit, no dose reduction <br>                            If bilirubin > 3 upper normal limit, use with caution </li></ul><b>Renal Impairment</b><ul><li>Imatinib:<br>No dose reduction </li></ul>', 'Low', '<b>Imatinib</b>', 'Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase: S0033. $J Clin Oncol. 2008;26(4):626-632$', null, '<b>Imatinib mesylate</b> 400-800 mg PO, daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (78, 'Nilotinib : Tasigna', 'Nilotinib', '<b>Hepatic Impairment</b><ul><li>Nilotinib:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Nilotinib:<br>Not tested. Not renally excreted </li></ul>', 'Low', '<b>Nilotinib</b>', 'Montemurro M, Schoffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. $Eur J Cancer. 2009;45:2293-2297.$', null, '<b>Nilotinib</b> 400 mg PO bid', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (80, 'Carboplatin : Paraplatin<br>Paclitaxel : Taxol', 'Carbo-Tax', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Moderate', '<b>Carbo-Tax</b>', 'Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. $N Engl J Med. 2002;346(2):92-98.$', null, '<b>Paclitaxel</b> 225mg/m<sup>2</sup> IV over 3 hours, day 1<br> <b>Carboplatin</b> dose targeted by AUC of 6 mg/mL/min, day 1<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (81, 'Cisplatin : CDDP<br>Pemetrexed : Alimta', 'Cisplatin/Pemetrexed', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Pemetrexed:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Pemetrexed:<br>If CrCl > 45 mL/min, no dose reduction    <br>                                                                        If CrCl < 45 mL/min, do not use </li></ul>', 'High', '<b>Cisplatin/Pemetrexed</b>', 'Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. $J Clin Oncol. 2008;26(21):3543-3551.$', null, '<b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> <b>Pemetrexed</b> 500 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for up to 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (82, 'Cetuximab : Erbitux<br>Cisplatin : CDDP<br>Vinorelbine : Navelbine', 'Cisplatin/Vinorelbine/Cetuximab', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Vinorelbine:<br>No dose reduction</li></ul>', 'High', '<b>Cisplatin/Vinorelbine/Cetuximab</b>', 'Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. $Lancet. 2009;373(9674):1525-1531.$', null, '<b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose, <b>THEN</b><br> 250 mg/m<sup>2</sup>/wk<br> <b>Cisplatin</b> 80 mg/m<sup>2</sup> IV, day 1<br> <b>Vinorelbine</b> 25 mg/m<sup>2</sup> IV, days 1, 8<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (83, 'Cisplatin : CDDP<br>Docetaxel : Taxotere', 'Docetaxel/Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li></ul>', 'High', '<b>Docetaxel/Cisplatin</b>', 'Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. $N Engl J Med. 2002;346(2):92-98.$', null, '<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (84, 'Cisplatin : CDDP<br>Gemcitabine : Gemzar, various', 'Gemcitabine/Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'High', '<b>Gemcitabine/Cisplatin</b>', 'Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. $N Engl J Med. 2002;346(2):92-98.$<b> Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. $J Clin Oncol. 1999;17(1):12-18.$', null, '<b>Gemcitabine</b> 1,000mg/m<sup>2</sup> /d IV,days 1,8,15<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> IV, day 1<br> Repeat every 28 days<br> <b>OR</b><br> <b>Gemcitabine</b> 1,250 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> IV over 60 minutes, day 1<br> Repeat every 21 days                                         ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (891, null, 'Estramustine + Vinblastine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Estramustine:</strong><br>No dose reduction</li><li><strong>Vinblastine:</strong><br>&nbsp;If serum bilirubin 1.5 to 3 mg/dL: Administer 50% of the dose &nbsp; &nbsp; &nbsp; &nbsp;If serum bilirubin &gt;3 times ULN: Do not use.</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Estramustine:</strong><br>No dose reduction</li><li><strong>Vinblastine:</strong><br>&nbsp;No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Estramustine:</strong> 600 mg/m2 PO daily on days 1-42<br><strong>Vinblastine:</strong> 4 mg/m2 IV weekly for 6 weeks</p><p>Repeat cycle every 8 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (85, 'Docetaxel : Taxotere<br>Gemcitabine : Gemzar, various', 'Gemcitabine/Docetaxel', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Low', '<b>Gemcitabine/Docetaxel</b>', 'Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomized multicentre trial. $Lancet. 2001;357(9267):1478-1484.$', null, '<b>Gemcitabine</b> 1,100 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8<br> <b>Docetaxel</b> 100 mg/m<sup>2</sup> IV over 1 hour, day 8<br>  Repeat every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (86, 'Gemcitabine : Gemzar, various<br>Paclitaxel : Taxol', 'Gemcitabine/Paclitaxel', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Low', '<b>Gemcitabine/Paclitaxel</b>', 'Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. $J Clin Oncol. 2002;20(17):3578-3585.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8<br> <b>Paclitaxel</b> 200 mg/m<sup>2</sup> IV over 3 hours, day 1<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (87, 'Gemcitabine : Gemzar, various<br>Vinorelbine : Navelbine', 'Gemcitabine/Vinorelbine', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Vinorelbine:<br>No dose reduction</li></ul>', 'Low', '<b>Gemcitabine/Vinorelbine</b>', 'Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. $J Clin Oncol. 2000;18(13):2529-2536.$<br> Chen YM, Perng, RP, Yang KY, et al. A multi-gemcitabine in previously untreated inoperable (stageIIIB/IV) non-small-cell lung cancer. $Chest. 2000;117(6):1583-1589.$<br> Hainsworth JD, Burris HA 3rd, Litchy S, et al. Gemcitabine and vinorelbine in the second-line treatment of non-small-celll lung carcinoma patients: a Minnie Pearl Cancer Research Network phase II trial. $Cancer. 2000;88(6):1353-1358.$', null, '<b>Gemcitabine</b> 1,200 mg/m<sup>2</sup>/d IV, days 1, 8<br> <b>Vinorelbine</b> 30 mg/m<sup>2</sup>/d IV, days 1, 8<br> Repeat every 21 days<br> <b>OR</b><br> <b>Gemcitabine</b> 800-1,000 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8, 15<br> <b>Vinorelbine</b> 20 mg/m<sup>2</sup>/d IV over 10-30 minutes, days 1, 8, 15<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (88, 'Cisplatin : CDDP<br>Paclitaxel : Taxol', 'PC', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'High', '<b>PC</b>', 'Schiller JH, Hamington D, Belani CP, et al. Comparison of four chemotherapy regiments for advanced non-small-cell lung cancer. $N Eng/J Med.2002;346(2);92-98.$<br> Smit EF., van Meerbeeck JP,lianes P,et al.Three-arm randomaized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advance m=non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of cancer Lung Group-EORTC 08975. $J Clin Oncol.2003;21(21):3909-3917.$                                                                                                                                                ', null, '<b>Paclitaxel</b> 135mg/m<sup>2</sup> over 24hours, day 1<br> <b>Cisplatin</b> 75mg/m<sup>2</sup> IV, day 2<br> Repeat every 21 days<br> <b>OR</b><br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> over 3 hours,day 1<br> <b>Cisplatin</b> 80 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days   ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (89, 'Bevacizumab : Avastin<br>Carboplatin : Paraplatin<br>Paclitaxel : Taxol', 'PCB', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Moderate', '<b>PCB</b>', 'Sandler A, Gray R, Perry MC,et al. Paclitaxel-carboplatin alone or with bevacizumab for non small-cell lung cancer. $N Engl J Med. 2006;355(24):2542-2550.$', null, '<b>Paclitaxel</b> 200 mg/m<sup>2</sup> IV, day 1<br> <b>Carboplatin</b> AUC of IV ,day 1<br> <b>Bevacizumab</b> 15 mg/kg IV, day 1<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (189, 'Docetaxel : Taxotere<br>Prednisone : various', 'Docetaxel/Prednisone', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>', 'Low', '<b>Docetaxel/Prednisone</b>', 'Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. $N Engl J Med. 2004;351(15):1502-1512.$', null, '<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV over 1 hour, day 1<br> <b>Prednisone</b> 5 mg PO bid, days 1-21<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (90, 'Cisplatin : CDDP<br>Vinorelbine : Navelbine', 'Vinorelbine/Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Vinorelbine:<br>No dose reduction</li></ul>', 'High', '<b>Vinorelbine/Cisplatin</b>', 'Douillard JY, Rosell R, De Lena M,et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-III A non small-cell lung cancer  (Adjuvant Naverlbine International Trialist Association [ANITA): a randomised controlled trial. $Lancet Oncol.2006:7(9):719-727.$ ', null, '<b>Vinorelbine</b> 30 mg/m<sup>2</sup> IV over 20 minutes, day 1,8,15,22.<br> <b>Cisplatin</b> 100mg/m<sup>2</sup> IV over 1 hour day 1.<br>Repeat cycle every 28 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (92, 'Docetaxel : Taxotere', 'Docetaxel', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>', 'Low', '<b>Docetaxel</b>', 'Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. $J Clin Oncol. 2000;18(10):2095-2103.$<br> Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-lung cancer previously treated with platinum-containing chemotherapy regimens. $J Clin Oncol. 2000;18(12):2354-2362.$', null, '<b>Docetaxel</b> 75mg/m<sup>2</sup> IV over 1hour.<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (93, 'Erlotinib : Tarceva', 'Erlotinib', '<b>Hepatic Impairment</b><ul><li>Erlotinib:<br>If AST > 3 upper normal limit, 50 mg  <br>                                                        If direct bilirubin 1-7 mg/dL, 75 mg </li></ul><b>Renal Impairment</b><ul><li>Erlotinib:<br>No dose reduction </li></ul>', 'Low', '<b>Erlotinib</b>', 'Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non small cell  lung cancer Institute of Canada Clinical trials group study BR 21. $J Clin Oncol. 2008;26(14):2350-2357.$<br> Tarceva [packaga insert]. $Melville, NY south San Fransisco, CA:OSI Pharmaceuticals Inc & Genentich Inc;2010.$', null, '<b>Erlotinib</b> 150mg PO daily at least 1hour before <b>OR</b> 2 Hours after eating', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (94, 'Gemcitabine : Gemzar, various', 'Gemcitabine', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Low', '<b>Gemcitabine</b>', 'Crino L, Mosconi AM, Scaglotti G, et al.              Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. $J Clin Oncol. 1999;17(7):2081-2085.$<br> Ricci S, Anonuzzo A, Galli L, et al. Gemcitabine monotherapy in elderly paients with advanced non-smell-cell lung cancer: a multicenter phase II study. $Lung Cancer.2000;27(2):75-80.$', null, '<b>Gemcitabine</b> 1000 mg/m<sup>2</sup>/d IV over 30 minutes, day 1,8,15<br> <br>  Repeat every 28 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (95, 'Pemetrexed : Alimta', 'Pemetrexed', '<b>Hepatic Impairment</b><ul><li>Pemetrexed:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Pemetrexed:<br>If CrCl > 45 mL/min, no dose reduction    <br>                                                                        If CrCl < 45 mL/min, do not use </li></ul>', 'Low', '<b>Pemetrexed</b>', 'Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III study of premtrexed versus docetaxel in patients with non-smell-cell lung cancer previously treated with chemotherapy. $J Clin Oncol. 2004;22(9):1589-1597.$', null, '<b>Pemetrexed</b> 500mg/m<sup>2</sup> IV over 10 minutes<br> Repeat every 21 days ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (96, 'Vinorelbine : Navelbine', 'Vinorelbine', '<b>Hepatic Impairment</b><ul><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Vinorelbine:<br>No dose reduction</li></ul>', 'Low', '<b>Vinorelbine</b>', 'Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesin and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. $J Clin Oncol.1994;12(2):360-367.$', null, '<b>Vinorelbine</b> 30 mg/m<sup>2</sup> IV over 20 minutes, day 1,8,15,22.<br> Repeat every 7 days .', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (97, 'Carboplatin : Paraplatin', 'Carboplatin/Irinotecan', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Moderate', '<b>Carboplatin/Irinotecan</b>', 'Hermes A, Bergman B, Bremnes R, et al           Irinotecan plus carboplatin in extensive versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. $J Clin Oncol. 2008:26(26):4261-4267.$', null, '<b>Carboplatin</b> AUC of 5 IV, day 1<br> <b>Irinotecan</b> 175mg/m<sup>2</sup> IV, day 1<br> Repeat every 21days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (98, 'Cisplatin : CDDP', 'Cisplatin + CPT-11', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Irinotecan:<br>No dose reduction </li></ul>', 'High', '<b>Cisplatin + CPT-11</b>', 'Noda K, Nishiwaki Y, Kawahara M, et al.                     Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. $N Engl J Med. 2002;346(2):85-91.$', null, '<b>Cisplatin</b> 60mg/m<sup>2</sup>, day 1<br> <b>Irinotecan</b> 60mg/m<sup>2</sup>/d, days 1, 8, 15<br> Repeat every 28days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (190, 'Flutamide : various', 'FL', '<b>Hepatic Impairment</b><ul><li>Leuprolide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'N/A', '<b>FL</b>', 'Sarosdy MF, Schellhammer PF, Johnson R, Carroll K, Kolvenbag GJCM. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy? $Urology. 2000;55(3):391-396.$', null, '<b>Flutamide</b> 250 mg PO tid <b>WITH</b><br> <b>Leuprolide acetate depot</b> 7.5 mg IM<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (99, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR', 'CAV', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'High', '<b>CAV</b>', '$Roth  BJ, et al. J Clin Oncol 1992;10:282-291.$', null, '<b>Cyclophosphamide</b>  1,000 mg/m<sup>2</sup>IV on day 1.  <br>                                              <b>Doxorubicin</b> 40 mg/m<sup>2</sup>IV on day 1.<br>                                                                <b>Vincristine</b> 1 mg/m<sup>2</sup>IV on day 1. (maximum, 2 mg) <br>Repeat cycle every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (357, 'Zelboraf', 'Vemurafinib', '', 'Minimal', '<b>Vemurafinib</b>', 'Sosman JA, Kim KB, Schuchter L, Survival in BRAF V600-Mutant advanced Melanoma treated with Vemurafenib. $N Engl J Med. 2012 Feb 23; 366(8): 707–714 .$', null, '<b>Vemurafenib</b> 960 mg po BID', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (100, 'Carboplatin : Paraplatin<br>Paclitaxel : Taxol', 'Carboplatin + Paclitaxel', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Moderate', '<b>Carboplatin + Paclitaxel</b>', '$Neubauer M, et al. J Clin Oncol2004;22:1872-1877$', null, '<b>Carboplatin</b>AUC of 2, IV on days1,8, and 15.<br><b>Paclitaxel</b> 80 mg/m<sup>2</sup> IV on days 1,8, and 15. Repeat cycle every 28 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (101, 'Carboplatin : Paraplatin<br>Etoposide : VP-16', 'EC', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Moderate', '<b>EC</b>', 'Viren M, Liippo K, Ojala a, et al. Carboplatin and etoposide in extensive small-cell lung cancer. $Acta Oncal. 1994;33(8):921-924.$', null, '<b>Etoposide</b> 100mg/m<sup>2</sup>/d IV, days 1-3<br><b>Carboplatin</b> 450mg/m<sup>2</sup> IV, day 1<br> Repeat every 28 days for 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (102, 'Cisplatin : CDDP<br>Etoposide : VP-16', 'EP', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>EP</b>', 'Ihde DC, Mulshine JL, Kramer BS, et al.  Prospective randomized comparision of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. $J Clin Oncol.1994; 12(10):2022-2034.$', null, '<b>Etoposide</b> 80mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cisplatin</b> 80mg/m<sup>2</sup> IV, day 1 (Standard dose)<br> Repeat every 21 days <b>OR</b><br> <b>Etoposide</b> 80mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Cisplatin</b> 27mg/m<sup>2</sup> IV, days 1-5(high dose)<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (103, 'Etoposide : VP-16', 'Etoposide', '<b>Hepatic Impairment</b><ul><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Low', '<b>Etoposide</b>', 'Johnson DH. Recent developments in chemotherapy treatment of small-cell lung cancer. $Semin Oncol. 1993;20(4):315-325.$', null, '<b>Etoposide</b> 160 mg/m<sup>2</sup>/d PO, days 1-5<br> Repeat every 28 days<br> <b>OR</b><br> <b>Etoposide</b> 50 mg PO bid for 14 days<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (104, 'Paclitaxel : Taxol', 'Paclitaxel', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Low', '<b>Paclitaxel</b>', 'Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. $J Clin Oncol. 1995;13(6):1430-1435.$<br> Kirschling RJ, Grill JP, Marks RS, et al. Paclitaxel and G-CSF in previously untreated patients with extensive-stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. $Am J Clin Oncol. 1999;22(5):517-522$<br>', null, '<b>Paclitaxel</b> 250 mg/m<sup>2</sup> IV over 24 hours<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (105, 'Topotecan : Hycamtin', 'Topotecan IV', '<b>Hepatic Impairment</b><ul><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>', 'Low', '<b>Topotecan IV</b>', 'Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. $J Clin Oncol.1997;15(5):2090-2096.$<br> von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. $J Clin Oncol. 1999;17(2):658-667.$', null, '<b>Topotecan</b> 1.5 mg/m<sup>2</sup>/d IV over 30 minutes, days 1-5<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (106, 'Topotecan : Hycamtin', 'Topotecan PO', '<b>Hepatic Impairment</b><ul><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>', 'Low', '<b>Topotecan PO</b>', 'Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. $J Clin Oncol. 2007;25(15):2086-2092.$ $Erratum in: J Clin Oncol. 2007;25(22):3387.$', null, '<b>Topotecan</b> 2.3 mg/m<sup>2</sup>/d PO, days 1-5<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (509, 'Ado-trastuzumab emtansine: Kadcyla', 'Ado-Trastuzumab Emtansine', '', 'Minimal', '', 'Verma S, Miles D, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-91.', 'METASTATIC', '<p><strong>Ado-trastuzumab</strong>: 3.6mg/kg IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1044, null, 'ldelalisib + Rituximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>ldelalisib:</strong><br>If SGOT or SGPT and bilirubin&nbsp;&lt; 1.5 times ULN: 100% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If SGOT or SGPT &gt;2.5 times ULN or bilirubin &gt;1.5 times ULN. Monitor closely for toxicity.</li><li><strong>Rituximab:</strong><br>Dose modification not provided by the manufacturer</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>ldelalisib:</strong><br>If CrCl ≥15 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt; 15 mL/min: Dose modification not provided by the manufacturer</li><li><strong>Rituximab:</strong><br>Dose modification not provided by the manufacturer</li></ul>', 'Low', null, null, null, '<p><strong>ldelalisib:</strong> 150 mg PO bid</p><p><strong>Rituximab: </strong>375 mg/m2 IV on day 1, then 500 mg/m2 IV every 2 weeks for 4 doses and then every 4 weeks for 3 doses for a total of 8 doses.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (892, null, 'Paclitaxel + Estramustine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Estramustine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel</strong>:<br>No dose reduction</li><li><strong>Estramustine:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Paclitaxel:</strong> 120 mg/m2 IV continuous infusion on days 1-4<br><strong>Estramustine</strong>: 600 mg/m2 PO daily, starting 24 hours before paclitaxel<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (893, null, 'Mitoxantrone + Prednisone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Mitoxantrone:</strong><br>If bilirubin &gt; 3 mg/dL, reduce dose by 25%</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Mitoxantrone:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Mitoxantrone: </strong>12 mg/m2 IV on day 1<br><strong>Prednisone:</strong> 5 mg PO bid daily</p><p>Repeat cycle every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (722, '', 'Gemcitabine + Nab-Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Nab-Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin 1.2 to ≤1.8 mg/dL:100% dosage<br>If bilirubin &gt;1.8 to ≤3.6 mg/dL: Reduce dose by 75%<br>If bilirubin &gt; 3.6 mg/dL, do not use</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Nab-Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: There are no dosage adjustments provided because of insufficient data.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p><strong>Nab-Paclitaxel:&nbsp;</strong>125 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p>Repeat cycle every 28 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (112, 'Carboplatin : Paraplatin<br>Paclitaxel : Taxol', 'Carboplatin + Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin:</strong><br>Dosing based on AUC</li><li><strong>Paclitaxel:</strong><br>No dose reduction</li></ul>', 'Moderate', '<b>Carboplatin + Paclitaxel</b>', 'Lemma GL, et al.$ J Clin Oncol 2011;29:2060-2065.$', null, '<p><strong>Carboplatin:</strong> AUC of 6, IV on day 1&nbsp;<br><strong>Paclitaxel: </strong>225 mg/m2 IV on day 1<br>Repeat cycle every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (111, 'Gemcitabine : Gemzar, various<br>Topotecan : Hycamtin', 'Gemcitabine + Topotecan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Topotecan:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Topotecan:</strong><br>If CrCl &gt; 40 mL/min, no dose reduction&nbsp;<br>If CrCl 20-39 mL/min, reduce to 0.75 mg/m2</li></ul>', 'Moderate', '<b>Gemcitabine + Topotecan</b>', 'William WN, et al.$Am J Clin Oncol 2009;32:15-19.$', null, '<p><strong>Gemcitabine: </strong>1000 mg/m2 IV on days 1,8, and 15.<br><strong>Topotecan: </strong>0.75-1.5 mg/m2 IV on days 1,8, and 15.<br>Repeat cycle every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (110, 'Cisplatin : CDDP<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various', 'VIP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Ifosfamide:</strong><br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Ifosfamide</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥10 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose by 25%</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul>', 'High', '<b>VIP</b>', 'Loehrer PJ, et al.$Cancer 2001;91:2010-2015.$', null, '<p><strong>Etoposide(VP-I6):</strong> 75 mg/m2 IV on days 1-4<br><strong>Ifosfamide:</strong> 1200 mg/m2 IV on days 1-4<br><strong>Cisplatin:</strong> 20 mg/m2 IV on days 1-4<br><strong>Mesna:</strong> 240 mg/m2 IV before first ifosfamide dose, then 4 and 8 hours later on days 1-4.<br>Repeat cycle every 21 days for a total of 4 cycles. G-CSF support at 5 micrograms/kg/day on days 5-15.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (113, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various', 'AC', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'High', '<b>AC</b>', 'Fisher B,Brown AM,Dimitor NV,et al.Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide,methotrexade,and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors:results from the National Surgical Adjuvant Breast and Bowel Project B-15. $J Clin Oncol. 1990;8(9):1483-1496$', null, '<b>Doxorubicin</b> 60mg/m<sup>2</sup> IV,day 1<br> <b>Cyclophosphamide</b> 600mg/m<sup>2</sup>  IV,day 1<br> Repeat every 21 days for 4 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (689, '', 'Irinotecan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>250 mg/m2&nbsp;IV on day 1</p><p>Repeat every 3 weeks. The dose of irinotecan can be increased to 350 mg/m2 based on toxicity.</p>', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1045, null, 'Obinutuzumab + Chlorambucil', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Obinutuzumab:</strong><br>Dosage adjustment not provided by the manufacturer.</li><li><strong>Chlorambucil:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Obinutuzumab:</strong><br>No dose reduction</li><li><strong>Chlorambucil:</strong><br>If CrCl &gt;50 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 10 to 50 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;10 mL/min: Reduce dose by 50%</li></ul>', 'Low', null, null, null, '<p><strong>Obinutuzumab:</strong> 100 mg IV on day 1, cycle 1; 900 mg IV on day 2, cycle 1; 1,000 mg IV on days 8 and 15 of cycle 1; 1,000 mg IV on day 1 of cycles 2-6<br><strong>Chlorambucil:</strong> 0.5 mg/kg PO on days 1 and 15<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (123, 'Cyclophosphamide : Cytoxan<br>Epirubicin : Ellence, various<br>Fluorouracil : 5-FU', 'FEC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Fluorouracil:</strong><br>If bilirubin &lt; 5 mg/dL, no dose reduction&nbsp;<br>If bilirubin &gt; 5 mg/dL, do not use&nbsp;<br>No dose reduction for infusional administration</li><li><strong>Epirubicin: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin 1.2 to 3 mg/dL: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;3 to 5 mg/dL: Reduce dose by 75% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;5 mg/dL: Do not use it.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Fluorouracil:</strong><br>No dose reduction</li><li><strong>Epirubicin:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If creatinine &gt;5 mg/dL: Reduce dose by 50%.</li></ul>', 'High', '<b>FEC</b>', 'Levine MN, Bramwell VH, Pritchard KI, et al. Randomized tiral of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. $J Clin Oncol. 1998;16(8):2651:2658.$<br> French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose intensity and duration of treatment. $J Clin Oncol. 2000;18(7):3115-3124.$', null, '<p><strong>Cyclophosphamide:</strong> 75 mg/m2/d PO, days 1-14<br><strong>Epirubicin:</strong> 60 mg/m2/d IV, days 1,8<br><strong>Fluorouracil:</strong> 500 mg/m2 IV, days 1,8<br>Repeat every 28 days for 6 cycles<br><strong>OR</strong><br><strong>Cyclophosphamide:</strong> 500 mg/m2 IV, day 1<br><strong>Epirubicin:</strong> 100 mg/m2 IV, day 1<br><strong>Fluorouracil:</strong> 500 mg/m2 IV, day 1<br>Repeat every 21 days for 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (115, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol<br>Trastuzumab : Herceptin', 'AC  Paclitaxel/Trastuzumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Trastuzumab: &nbsp; &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dosage modification.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>No dose reduction</li><li><strong>Trastuzumab: &nbsp; &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dosage modification. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Cardiac Impairment</strong></li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong> </strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'High ', '<b>AC  Paclitaxel/Trastuzumab</b>', 'Romond EH,perez EA,Bryant J.et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. $N Engl J Med. 2005;353(16):1673-1684.$ ', null, '<p><strong>Doxorubicin:</strong> 60 mg/m2 IV, day 1<br><strong>Cyclophosphamide: </strong>600 mg/m2 IV, day 1<br>Repeat every 21 days for 4 cycles, followed by<br><strong>Paclitaxel:</strong> 175 mg/m2 IV over 3 hours, day 1<br>Repeat every 21 days for 4 cycles.<br><strong>OR</strong><br><strong>Paclitaxel:</strong> 80 mg/m2 IV over 1 hour, weekly X 12&nbsp;<br><strong>Trastuzumab:</strong> (concurrently with paclitaxel) 4 mg/kg IV over 90 minutes, day 1<br><strong>FOLLOWED BY</strong><br>2 mg/kg IV weekly for 51 additional weeks</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (819, null, 'Interferon + Cytarabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Interferon alfa</strong>:<br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Interferon alfa</strong>:<br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li></ul>', 'Low', null, null, null, '<p><strong>Interferon-alpha-2b:</strong> 5 million U/m2 SC daily</p><p><strong>Cytarabine: </strong>20 mg/m2 SC daily for 10 days.</p><p>Repeat cytarabine on a monthly basis. The dose of interferon should be<br>decreased by 50% when the neutrophil count drops below 1500/mm3, platelet<br>count drops below 100,000/m3, or both. When the neutrophil count drops below 1,000/mm, platelet count drops below 50,000/mm, or both then interferon and cytarabine should be discontinued.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (691, '', 'Pembrolizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Pembrolizumab:&nbsp;</strong>200 mg IV on day 1</p>

<p>Repeat cycle every 3 weeks.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1046, null, 'Venetoclax + Obinituzumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Obinutuzumab:</strong><br>Dosage adjustment not provided by the manufacturer.</li><li><strong>Venetoclax:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If mild to moderate impairment (Child-Pugh classes A and B): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): Reduce dose by 50%.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Obinutuzumab:</strong><br>No dose reduction.</li><li><strong>Venetoclax: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If<strong>&nbsp;</strong>CrCl ≥15 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If<strong>&nbsp;</strong>CrCl &lt;15 mL/min: Dosage adjustment not provided by the manufacturer.</li></ul>', 'Low', null, null, null, '<p><strong>Obinituzumab:</strong> 100 mg IV on day 1 and 900 mg lV on day 2 (or 1,000 mg on day 1), 1,000 mg on day 8 and 1,000 mg on day 15 of cycle 1, and subsequently 1,000 mg on day 1 of cycles 2 through 6.<br><strong>Venetoclax:</strong> Start on day 22 of cycle 1 with a 5-week dose ramp-up (1 week each of 20, 50, 100, and 200 mg P0, then 400 mg P0 daily for 1 week), thereafter at 400 mg PO daily until completion of cycle 12.<br>Repeat cycle every 28 days for up to 6 cycles with obinituzumab and 12 cycles with<br>venetoclax.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (690, '', 'Ramucirumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ramucirumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ramucirumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Ramucirumab:&nbsp;</strong>8 mg/kg IV on day 1</p>

<p>Repeat cycle every 14 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1047, null, 'Cladribine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cladribine: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dosage adjustment not provided because of insufficient data. &nbsp;&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong></li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cladribine:</strong><br>If CrCl 10-50 mL/min: Dose reduction by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;10 mL/min: Dose reduction by 50%</li></ul>', 'Low', null, null, null, '<p><strong>Cladribine:</strong> 0.09 mg/kg/day IV continuous infusion on days 1-7<br>Repeat cycle every 28-35 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1048, null, 'Prednisone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Prednisone: </strong>20-30 mg/m2/day PO for 1-3 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (121, 'Bevacizumab : Avastin<br>Paclitaxel : Taxol', 'Bevacizumab/Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Bevacizumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dosage adjustment provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel:</strong><br>No dose reduction</li><li><strong>Bevacizumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dosage adjustment provided by the manufacturer</li></ul>', 'Low', '<b>Bevacizumab/Paclitaxel</b>', 'Miller KD. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. $J Clin Oncol. 2003;3(6):421-422$', null, '<p><strong>Bevacizumab:</strong> 10 mg/kg IV on days 1, and 15<br><strong>Paclitaxel:</strong> 90 mg/m2 IV over 1 hour on days 1, 8, and 15<br>Repeat cycle every 28 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1049, null, 'Rituximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Rituximab:</strong><br>Dose modification not provided by the manufacturer</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Rituximab:</strong><br>Dose modification not provided by the manufacturer</li></ul>', 'Low', null, null, null, '<p><strong>Rituximab:</strong> 375 mg/m2 IV weekly for 4 weeks<br>Repeat cycle every 6 months for a total of 4 courses.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (124, 'Cyclophosphamide : Cytoxan<br>Fluorouracil : 5-FU', 'CMF', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Moderate for IV, Moderate-High for PO', '<b>CMF</b>', 'Amadori D, Nanni O, Marangolo M, et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapdly proliferating breast cancer: a randomized multicenter study. $J Clin Oncol. 2000:18(17):3125-3134.$<br> Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results.$ JAMA. 1995:273(7):542-547.$', null, '<b>Cyclophosphamide </b>100 mg/m<sup>2</sup>/d PO, days 1-14<br> <b>Methotrexate</b> 40 mg/m<sup>2</sup>/d IV, days 1,8<br> <b>Fluorouracil</b> 600 mg/m<sup>2</sup>/d IV, days 1, 8<br> Repeat every 28 days for up to 6 cycles<br> <b>OR</b><br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup> IV, day 1<br> <b>Methotrexate</b> 40 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 600 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for up to 12 courses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (692, '', 'TAS-102', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>TAS-102:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &lt;1.2 to 1.8 mg/dL: 100 % dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin &gt;1.8 to 3.6 mg/dL: Do not initiate therapy.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>TAS-102:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100% dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 15 to 29 mL/min: Decrease dosage from 35 mg/m2 to 20 mg/m2</li></ul><p>If unable to tolerate the 20 mg/m2 dose: Decrease the dose to 15 mg/m2. If unable to tolerate the 15 mg/m2 dose: Permanently stop the treatment with trifluridine/tipiracil.</p>', 'Moderate', '', '', 'METASTATIC', '<p><strong>TAS-102:&nbsp;</strong>35 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-5 and 8-12</p>

<p>Repeat cycle every 28 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1050, null, 'Pentostatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pentostatin:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pentostatin:</strong><br>If CrCl 46-60 mL/min: Reduce dose by 30%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31-45 mL/min: Reduce dose by 40%&nbsp;<br>If CrCl &lt;30 mL/min: Use alternative drug.</li></ul>', 'Low', null, null, null, '<p><strong>Pentostatin:</strong> 4 mg/m2 IV on day 1<br>Repeat cycle every 14 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (723, '', 'Capecitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Capecitabine:</strong>&nbsp;1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p>Repeat cycle every 21 days. Dose may be reduced to 825-900 mg/m<sup>2</sup> PO twice daily on days 1-14.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (128, 'Capecitabine : Xeloda<br>Lapatinib : Tykerb', 'Lapatinib/Capecitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine:</strong><br>No dose reduction</li><li><strong>Lapatinib:</strong><br>If Child-Pugh C, reduce dose to 750 mg/d</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine:</strong><br>If CrCl 30-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Lapatinib:</strong><br>Not studied. Only 2% eliminated by kidneys</li></ul>', 'Low', '<b>Lapatinib/Capecitabine</b>', 'Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. $N Engl J Med. 2006;355(26):2733-2743.$', null, '<p><strong>Lapatinib:</strong> 1,250 mg PO 1 hour before breakfast, daily<br><strong>Capecitabine:</strong> 1,000 mg/m2 PO bid, days 1-14<br>Repeat every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (129, 'Lapatinib : Tykerb<br>Letrozole : Femara', 'Lapatinib/Letrozole', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lapatinib:</strong><br>If Child-Pugh C, reduce dose to 750 mg/day</li><li><strong>Letrozole:</strong><br>If Child-Pugh A or B, no dose reduction&nbsp;<br>If Child-Pugh C, reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lapatinib:</strong><br>Not studied. Only 2% eliminated by kidneys</li><li><strong>Letrozole:</strong><br>If CrCl &gt; 10 mL/min, no dose reduction</li></ul>', 'Low', '<b>Lapatinib/Letrozole</b>', 'Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. $J Clin Oncol. 200927(33):5538-5546.$', null, '<p><strong>Lapatinib</strong> 1,500 mg PO, daily (days 1 - 28)<br><strong>Letrozole</strong> 2.5 mg PO, daily (days 1 - 28)</p><p>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (693, '', 'Imatinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Imatinib</strong>:<br>If bilirubin &lt; 3 upper normal limit, no dose reduction<br>If bilirubin &gt; 3 upper normal limit, use with caution</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Imatinib</strong>:<br>If CrCl 40 to 59 mL/min: Maximum dose recommended-600 mg. &nbsp; If CrCl 20 to 39 mL/min: Reduce dose by 50%; dose may be increased as tolerated; maximum recommended dose: 400 mg. &nbsp; If CrCl &lt;20 mL/minute: Use caution; 100 mg daily dose has been tolerated in a limited number of patients with severe impairment.</li></ul>', 'Moderate', '', '', 'ADJUVANT', '<p><strong>Imatinib:&nbsp;</strong>400 mg/day&nbsp;PO</p><p>Continue treatment for a total of 3 years.</p>', 8);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (694, '', 'Imatinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Imatinib</strong>:<br>If bilirubin &lt; 3 upper normal limit, no dose reduction<br>If bilirubin &gt; 3 upper normal limit, use with caution</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Imatinib</strong>:<br>If CrCl 40 to 59 mL/min: Maximum dose recommended-600 mg. &nbsp; If CrCl 20 to 39 mL/min: Reduce dose by 50%; dose may be increased as tolerated; maximum recommended dose: 400 mg. &nbsp; If CrCl &lt;20 mL/minute: Use caution; 100 mg daily dose has been tolerated in a limited number of patients with severe impairment.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Imatinib:&nbsp;</strong>400 mg/day PO</p><p>Treatment to be continued until disease progression. May increase dose to 600 mg/day if no response is seen. In patients with KIT exon 9 (or exon 11) mutation, use a dose of 800 mg/day (400 mg twice daily).</p>', 8);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1051, null, 'Bendamustine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin&nbsp;1.5-3 upper normal limit, or bilirubin &gt; 3 upper normal limit: Do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If CrCl &lt; 30 mL/min: Do not use</li></ul>', 'Moderate', null, null, null, '<p><strong>Bendamustine:</strong> 100 mg/m2 IV on days 1 and 2<br>Repeat cycle every 28 days for up to 6 cycles.</p><p><strong>OR</strong></p><p><br><strong>Bendamustine:</strong> 60 mg/m2 IV on days 1-5<br>Repeat cycle every 28 days. In patients &gt;70 years, use dose of 50 mg/m2.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (720, '', 'Capecitabine + Cisplatin', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Renal Impairment:&nbsp;</strong></li><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'High', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,250 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 2</p>

<p>Repeat cycle every 21 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (765, null, 'Cladribine/Rituximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cladribine:</strong><br>No dose reduction</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cladribine:</strong><br>If CrCl 10-50 mL/min: Dose reduction by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;10 mL/min: Dose reduction by 50%</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Cladribine:&nbsp;</strong>0.15 mg/kg/day Day1-5</p><p><strong>Rituximab: &nbsp;</strong>375 mg/m2 weekly x 8</p><p>&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1052, null, 'Lenalidomide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>If CrCl &gt;60 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 30 to 60 mL/min: 5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min not requiring dialysis: 2.5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min requiring dialysis: 2.5 mg once daily (administer after dialysis on dialysis days).</li></ul>', 'Low', null, null, null, '<p><strong>Lenalidomide:</strong> 10 mg PO daily on days 1-28<br>Increase dose by 5 mg every 28 days up to a maximum of 25 mg daily until disease<br>progression or toxicity.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (358, 'Yervoy', 'Ipilumimab', '', 'Minimal', '<b>Ipilumimab</b>', 'Hodi FS, O''Day SJ, McDermott DF, et al. Improved survival with Ipilumimab in patients with Metastatic Melanoma. $N Engl J Med 2010; 363:711-723. $', null, '<b>Ipilumimab</b>  IV 3 mg/kg  every 3 weks upto 4 doses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (142, 'Exemestane : Aromasin, various', 'Exemestane', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Exemestane:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Exemestane:</strong><br>No dose reduction</li></ul>', 'NA', '<b>Exemestane</b>', 'Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase in hibitors: a phase II trial. $J Clin Oncol. 2000;18(11):2234-2244.$<br> Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. $J Clin Oncol. 2000;18(7):1399-1411.$<br> Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. $N Engl J Med. 2004;350(11):1081-1092.$', null, '<p><strong>Exemestane:</strong> 25 mg PO once daily</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (134, 'Carboplatin : Paraplatin<br>Docetaxel : Taxotere<br>Trastuzumab : Herceptin', 'TCH', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Moderate for combination therapy, low for trastuzumab monotherapy', '<b>TCH</b>', 'Pegram M, Forbes J, Pienkowski T, et al. BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). $J Clin Oncol. 2007;25:LBA 1008 (abstract).$', null, '<p><strong>Docetaxel:</strong> 75 mg/m2 IV, day 1<br><strong>Carboplatin:</strong> AUC of 6 day 1&nbsp;<br>Repeat every 21 days for 8 cycles<br><strong>Trastuzumab:</strong> 4 mg/kg IV,<br><strong>FOLLOWED BY</strong><br><strong>Trastuzumab:</strong> 2 mg/kg IV weekly during chemotherapy, <strong>THEN</strong> 6 mg/kg IV<br>Repeat every 21 days for 1 year</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1134, null, 'Daratumumab + Bortezomib + Dexamethasone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Daratumumab:</strong>&nbsp;<br>There are no dosage adjustments provided in the manufacturer''s labeling</li><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin&nbsp;1-1.5 times upper normal limit: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin&nbsp;&gt;1.5 times upper normal limit: Reduce the initial dose to 0.7 mg/m2.</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Daratumumab:</strong>&nbsp;<br>There are no dosage adjustments provided in the manufacturer''s labeling</li><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Daratumumab:</strong> 16 mg/kg IV weekly on cycles 1-3<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 16 mg/kg IV on day 1 of cycles 4-8<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 16 mg/kg IV on day 1 of cycles 9+<br><strong>Bortezomib:</strong> 1.3 mg/m2 IV on days 1, 4, 8, and 11 on cycles 1-8<br><strong>Dexamethasone:</strong> 20 mg P0 on days 1, 2, 4, 5, 8, 9, 11, and 12 on cycles 1-8<br>Continue treatment until disease progression or toxicity.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (698, '', 'Regorafenib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Regorafenib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Regorafenib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Regorafenib:&nbsp;</strong>160 mg/day PO for 21 days</p>

<p>Repeat cycle every 28 days.</p>
', 8);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (945, null, 'R-GemOx', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Rituximab:</strong><br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Gemcitabine:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Rituximab:</strong><br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Gemcitabine:</strong>&nbsp;<strong>&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Moderate', null, null, null, '<p><strong>Rituximab: </strong>375 mg/m2 IV on day 1<br><strong>Gemcitabine:</strong> 1,000 mg/m2 IV on day 2<br><strong>Oxaliplatin: </strong>50 mg/m2 IV on day 2<br>Repeat cycle every 2 weeks for a total of 8 cycles.<br><strong>OR</strong><br><strong>Rituximab: </strong>375 mg/m2 IV on day 0<br><strong>Gemcitabine:</strong> 1,000 mg/m2 IV on day 1<br><strong>Oxaliplatin:</strong> 100 mg/m2 IV on day 1<br>Repeat cycle every 2 weeks for a total of 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (146, '', 'Megestrol', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Megestrol:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Megestrol:</strong><br>No dose reduction</li></ul>', 'N/A', '<b>Megestrol</b>', 'Buzdar A, Douma J, et al. Phase III, multicenter, double-blind, randomized study of letrozole, and aromatiase inhibitor, for advanced breast cancer versus megestrol acetate. $J Clin Oncol. 2001;19(14):3357-3366.$', null, '<p><strong>Megestrol:</strong> 40 mg PO, every 6 hours</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (153, 'Carboplatin : Paraplatin<br>Docetaxel : Taxotere', 'Carbo-Docetaxel', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Moderate', '<b>Carbo-Docetaxel</b>', 'Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. $J Natl Cancer Inst. 2004;96(22):1682-1691.$', null, '<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV over 1 hour, day 1,<br> <b>FOLLOWED BY</b><br> <b>Carboplatin</b> dose AUC of 5 IV over 1 hour day 1<br> Repeat every 21 days for 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (154, 'Carboplatin : Paraplatin<br>Paclitaxel : Taxol', 'Carbo-Tax', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Moderate', '<b>Carbo-Tax</b>', 'Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. $J Clin Oncol. 2000;18(17):3084-3092.$', null, '<b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours, day 1<br> <b>Carboplatin</b> dose AUC of 5 IV  day 1<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (155, 'Carboplatin : Paraplatin', 'CD (Doxil/Carboplatin)', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li></ul>', 'Moderate', '<b>CD (Doxil/Carboplatin)</b>', 'Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relppase. $J Clin Oncol. 2010;28:3323-3329.$', null, '<b>Liposomal doxorubicin</b> 30 mg/m<sup>2</sup> IV, day 1 <b>Carboplatin</b>AUC of 5 IV day 1<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (148, 'Tamoxifen : Nolvadex', 'Tamoxifen', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Tamoxifen:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Tamoxifen:</strong><br>No dose reduction</li></ul>', 'N/A', '<b>Tamoxifen</b>', 'Hackshaw A, Roughton M, et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. $J Clin Oncol. 2011;29(13):1657-1663.$', null, '<p><strong>Tamoxifen:</strong> 20 mg PO once daily</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (143, 'Fulvestrant : Faslodex', 'Fulvestrant', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Fulvestrant:</strong><br>If SGOT, SGPT, bilirubin and alkaline phosphatase &lt; 2 upper normal limit, no dose reduction<br>If SGOT, SGPT, bilirubin and alkaline phosphatase &gt; 2 upper normal limit, unknown</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Fulvestrant:</strong><br>No dose reduction</li></ul>', 'N/A', '<b>Fulvestrant</b>', 'Di Leo A, et al.Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.$J Clin Oncol. 2010 Oct 20;28(30):4594-600$', null, '<p><strong>Fulvestrant:</strong> 500 mg IM loading dose on day 1, then 500 mg IM on days 15 and 29.</p><p>&nbsp;Continue treatment on a monthly basis until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (149, '', 'Toremifene', '<p><strong>Hepatic Impairment</strong></p><ul><li>Toremifene:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li>Toremifene:<br>No dose reduction</li></ul>', 'N/A', '<b>Toremifene</b>', 'Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. $J Clin Oncol. 1995;13(10):2556-2566.$<br> Fareston [package insert]. $Memphis, TN: GTx, Inc,:2011.$', null, '<p><strong>Toremifene:</strong> 60 mg PO, daily</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (156, 'Cisplatin : CDDP<br>Paclitaxel : Taxol', 'CT', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'High', '<b>CT</b>', 'McGuire WP, Hoskins WJ, Brady MF, et al. Cyclo-phosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. $N Engl J Med. 1996;334(1):1-6.$<br> Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. $J Clin Oncol. 2000;18(17):3084-3092.$', null, '<b>Paclitaxel</b> 135 mg/m<sup>2</sup> CIVI over 24 hours, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for 6 cycles<br> <b>OR</b><br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (157, 'Carboplatin : Paraplatin<br>Gemcitabine : Gemzar, various', 'GC', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Moderate', '<b>GC</b>', 'Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. $J Clin Oncol. 2006;24(29):4699-4707.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV, days 1, 8<br> <b>Carboplatin</b> AUC of 4, IV, day 1<br> Repeat every 21 days for 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (158, 'Cisplatin : CDDP<br>Paclitaxel : Taxol', 'Intraperitoneal CT', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'High', '<b>Intraperitoneal CT</b>', 'Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. $N Engl J Med. 2006;354(1):34-43.$', null, '<b>Paclitaxel</b> 135 mg/m<sup>2</sup> CIVI over 24 hours, day 1<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> IP, day 2<br> <b>Paclitaxel</b> 60 mg/m<sup>2</sup> IP, day 8<br> Repeat every 21 days for 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (159, 'Altretamine : Hexalen', 'Altretamine', '<b>Hepatic Impairment</b><ul><li>Altretamine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul></ul>', 'Moderate-High', '<b>Altretamine</b>', 'Markman M, Blessing JA, Moore D, Ball H, Lentz SS. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. $Gynecol Oncol. 1998;69(3):226-229.$', null, '<b>Altretamine</b> 260 mg/m<sup>2</sup>/d PO in 4 divided doses for 14 days<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (160, 'Bevacizumab : Avastin', 'Bevacizumab', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Bevacizumab</b>', 'Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistant or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. $J Clin Oncol. 2007;25(33):5165-5171.$', null, '<b>Bevacizumab</b> 15 mg/kg IV, day 1<br> Repeat every 21 days until disease progression ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (161, 'Gemcitabine : Gemzar, various', 'Gemcitabine', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Low', '<b>Gemcitabine</b>', 'Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2'', 2'' difluorodeoxycytidine) in previously treated ovarian cancer patients. $J Natl Cancer Inst. 1994;86(20):1530-1533.$', null, '<b>Gemcitabine</b> 800 mg/m<sup>2</sup>/d, days 1, 8, 15<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (191, 'Flutamide : various<br>Goserelin : Zoladex', 'FZ', '<b>Hepatic Impairment</b><ul><li>Goserelin:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Goserelin:<br>No dose reduction </li></ul>', 'N/A', '<b>FZ</b>', 'Zoladex 3.6 mg, Zoladex 10.8 mg [package inserts]. Wilmington, DE: AstraZeneca; 2010. Roach M, Bae K, Speight J, et al. Short-term androgen deprivation therapy and external beam radiotherapy for locally advanced prostate cancer: Long-term results of RJOG 8610. $J Clin Oncol. 2009;26(4):585-591.$', null, '<b>Flutamide</b> 250 mg PO tid <b>WITH</b><br> <b>Goserelin acetate implant</b> 3.6 mg SQ<br> Repeat every 28 days, beginning 8 weeks prior to Radiation theraupy for 4 cycles<br> <b>OR</b><br> <b>Goserelin acetate implant</b> 3.6 mg SQ 8 weeks prior to Radiation theraupy <b>AND</b><br> <b>Goserelin acetate implant</b> 10.8 mg SQ 4 weeks prior to Radiation theraupy', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (162, 'Paclitaxel : Taxol', 'Paclitaxel', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Low', '<b>Paclitaxel</b>', 'ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. $J Clin Oncol. 1997;15(6):2183-2193.$', null, '<b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (163, '', 'Pegylated liposomal doxorubicin', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Pegylated liposomal doxorubicin</b>', 'Gordon AN, Granai CO, Rose CG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. $J Clin Oncol. 2000;18(17):3093-3100.$<br> Doxil [package insert]. $Raritan, NJ: Centocor Ortho Biotech Products, LP;2010.$', null, '<b>Pegylated liposomal doxorubicin</b> 50 mg/m<sup>2</sup> IV every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (165, 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various', 'Cisplatin/Doxorubicin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'High', '<b>Cisplatin/Doxorubicin</b>', 'Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. $J Clin Oncol. 2006;24(1):36-44.$', null, '<b>Doxorubicin</b> 60 mg/m<sup>2</sup> IV day 1<br> <b>Cisplatin</b> 50 mg/m<sup>2</sup> IV, day 1, cycles 1-7<br> Repeat every 21 days upto 8 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (166, 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol', 'TAP', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'High', '<b>TAP</b>', 'Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastimin advanced endometrial carcinoma: a Gynecologic Oncology Group Study. $J Clin Oncol. 2004;22(11):2159-2166.$', null, '<b>Doxorubicin</b> 45 mg/m<sup>2</sup>, day 1<br> <b>FOLLOWED BY</b><br> <b>Cisplatin</b> 50 mg/m<sup>2</sup>, day 1<br> <b>Paclitaxel</b> 160 mg/m<sup>2</sup> over 3 hours, day 2<br> <b>Filgrastim</b> 5 mcg/kg d SQ, days 3-12<br> <b>OR</b><br>Repeat every 21 days for a maximum of 7 cycles<br><b>PEG-Filgastrim</b>6 mg SQ on day 3.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (167, 'Doxorubicin : Adriamycin, various', 'Doxorubicin', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Moderate', '<b>Doxorubicin</b>', 'Thigpen JT, Brady MF, Homesly HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. $J Clin Oncol. 2004;22(19):3902-3908.$', null, '<b>Doxorubicin</b> 60 mg/m<sup>2</sup> IV every 21 days (maximum cumulative dose, 500 mg/m<sup>2</sup>)<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (168, '', 'Medroxy-progesterone', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'N/A', '<b>Medroxy-progesterone</b>', 'Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecological Oncology Group. $J Clin Oncol. 1999;17(6):1736-1744.$', null, '<b>Medroxyprogesterone acetate</b> 200 mg/d PO', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (188, 'Docetaxel : Taxotere<br>Estramustine : Estracyte', 'Docetaxel/Estramustine', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Estramustine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>', 'Moderate-High', '<b>Docetaxel/Estramustine</b>', 'Petrylak DP, Tangen CM, Hussain MA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. $N Engl J Med. 2004;351(15):1513-1520.$', null, '<b>Docetaxel</b> 60 mg/m<sup>2</sup> IV, day 2<br><b>Estramustine</b> 280 mg PO tid, days 1-5<br> Repeat every 21 days until progression or to a maximum of 12 cycles ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (947, null, 'Tisagenlecleucel (Kymriah)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL: Reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Fludarabine:</strong><br>No dose reduction</li><li><strong>Tisagenlecleucel:</strong><br>Dosage adjustments have not been studied yet.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-29 mL/min: Reduce dose by 25%<br>If CrCl &lt; 10 mL/min: Reduce dose by 50%</li><li><strong>Fludarabine:</strong><br>If CrCl 10-50 mL/min: Reduce dose by 25%&nbsp;<br>If CrCl &lt;10 mL/min: Reduce dose by 50%</li><li><strong>Tisagenlecleucel:</strong><br>Dosage adjustments have not been studied yet.</li></ul>', 'Moderate', null, null, null, '<p><strong>Cyclophosphamide:</strong> 250 mg/m2 IV on days -5, -4, and -3<br><strong>Fludarabine:</strong> 25 mg/m2 IV on day -5, -4, and -3<br><strong>Tisagenlecleucel:</strong> 0.6-6.0 x 10^8 CAR-positive T cells/kg body weight IV on day 1</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (820, null, 'Moxetumomab pasudotox-tdfx', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Moxetumomab pasudotox-tdfx: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Moxetumomab pasudotox-tdfx: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Moxetumomab pasudotox-tdfx:</strong> 0.04 mg/kg IV on days 1, 3 and 5.</p><p>Repeat cycle every 28 days for 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1154, null, 'Doxorubicin + Olaratumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Olaratumab:</strong><br><strong>&nbsp; </strong>There are no dosage adjustments provided in the manufacturer’s labeling</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Olaratumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>There are no dosage adjustments provided in the manufacturer’s labeling</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Doxorubicin: </strong>75 mg/m2 IV on day1<br><strong>Olaratumab: </strong>15 mg/kg IV on days 1 and 8<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (360, 'Dabrafenib:Tafilnar<br> Trametinib:Mekinist', 'Dabrafenib/Trametinib', '', 'Minimal', '<b>Dabrafenib/Trametinib</b>', 'Robert c, Karaszewska B, Schachter J, et al. Improved overall Survival in Melanoma with combines Dabrafenib and Trametinib. $ N Engl J Med. 2015 Jan 1;372(1):30-9.$', null, '<bDabrafenibt</b> 150 mg PO  BID <br> Trametinib</b>2 mg once daily ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (171, 'Cisplatin : CDDP<br>Topotecan : Hycamtin', 'Cisplatin/Topotecan', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>', 'High', '<b>Cisplatin/Topotecan</b>', 'Long HJ, Bundy BN, Grendys EC, et al. Randomized Phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. $J Clin Oncol. 2005;23(21):4626-4633.$', null, '<b>Cisplatin</b> 50 mg/m<sup>2</sup> IV, day 1<br> <b>Topotecan</b> 0.75 mg/m<sup>2</sup>/d IV, days 1-3<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (178, 'Sunitinib : Sutent', 'Sunitinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Sunitinib:</strong><br>If Child-Pugh A or B, no dose reduction&nbsp;<br>If Child-Pugh C, reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Sunitinib:</strong><br>If CrCl &gt; 42 mL/min, no dose reduction</li></ul>', 'Low', '<b>Sunitinib</b>', 'Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. $N Engl J Med. 2007;356(2):115-124$', null, '<p><strong>Sunitinib malate:</strong> 50 mg PO daily for 28 days&nbsp;<br>Repeat cycle every 6 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (894, null, 'Docetaxel + Estramustine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li><li><strong>Estramustine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>Estramustine:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Docetaxel:</strong> 35 mg/m2 IV on day 2 of weeks 1 and 2<br><strong>Estramustine:</strong> 420 mg PO for the first 4 doses and 280 mg PO for the next 5 doses on days 1-3 of weeks 1 and 2.</p><p>Repeat cycle every 21 days. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Dexamethasone is administered at 4 mg PO bid on days 1-3 of weeks 1 and 2.<br><strong>OR</strong><br><strong>Docetaxel:</strong> 60 mg/m2 IV on day 2<br><strong>Estramustine:</strong> 280 mg PO tid on days 1-5</p><p>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (180, 'Carboplatin : Paraplatin<br>Gemcitabine : Gemzar, various', 'Gemcitabine/Carboplatin', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Moderate', '<b>Gemcitabine/Carboplatin</b>', 'Bamias A, Moulopoulos LA, Koutras A, et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. $Cancer. 2006;106(2):297-303.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV over 30 minutes, days 1 and 8<br> <b>Carboplatin</b> AUC of 5 IV over 1 hour, day 1<br> Repeat cycle every 21 days upto 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (181, 'Cisplatin : CDDP<br>Gemcitabine : Gemzar, various', 'Gemcitabine/Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'High', '<b>Gemcitabine/Cisplatin</b>', 'von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and ciplatin in advanced or metastatic bladder cancer: results of a large, randomized, mulinational, multicenter, phase III study. $J Clin Oncol. 2000;18(17):3068-3077.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup>/d IV over 30-60 minutes, days 1,8,15<br> <b>Cisplatin</b> 70mg/m<sup>2</sup> IV, day 2<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (182, 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various<br>Vinblastine : Velban', 'MVAC', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li><li>Vinblastine:<br>No dose reduction </li></ul>', 'High', '<b>MVAC</b>', 'von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and ciplatin in advanced or metastatic bladder cancer: results of a large, randomized, mulinational, multicenter, phase III study. $J Clin Oncol. 2000;18(17):3068-3077.$', null, '<b>Methotrexate</b> 30 mg/m<sup>2</sup>/d IV, days 1, 15, 22<br> <b>Vinblastine</b> 3 mg/m<sup>2</sup>/d IV, days 2, 15,22<br> <b>Doxorubicin</b> 30 mg/m<sup>2</sup> IV, day 2<br> <b>Cisplatin</b> 70 mg/m<sup>2</sup> IV, day 2<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (347, 'Beleodaq', 'Belinostat', '', 'Minimal', '<b>Belinostat</b>', 'Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.$Br J Haematol. 2015 Mar;168(6):811-9.$', null, '<b>Belinostat</b> 1000 mg/m<sup>2</sup>  days 1-5, <br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (193, 'Bicalutamide : Casodex<br>Goserelin : Zoladex', 'Bicalutamide/Leuprolide.  ', '<b>Hepatic Impairment</b><ul><li>Bicalutamide:<br>No dose reduction</li><li>Goserelin:<br>No dose reduction </li><li>Leuprolide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Bicalutamide:<br>No dose reduction </li><li>Goserelin:<br>No dose reduction </li></ul>', 'N/A', 'Bicalutamide/Leuprolide.  ', 'Schellhammer P, Sharifi R, Block N, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. $Urology. 1995;45(5):745:752.$', null, '<b>Bicalutamide</b> 50 mg/d PO <b>WITH</b><br> <b>Leuprolide acetate depot</b> 7.5 mg IM<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (179, '', 'Temsirolimus', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Temsirolimus:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Temsirolimus:</strong><br>No dose reduction</li></ul>', 'Low', '<b>Temsirolimus</b>', 'Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. $N Engl J Med. 2007;356(22):2271-2281.$', null, '<p><strong>Temsirolimus:</strong> 25 mg IV over 30 minutes weekly.</p><p>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (183, 'Bleomycin : Blenoxane<br>Cisplatin : CDDP<br>Etoposide : VP-16', 'BEP', '<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>BEP</b>', 'Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, jSouthwest Oncology Group, and Cancer and Leukemia Group B Study. $J Clin Oncol. 1998;16(4):1287-1293.$', null, '<b>Bleomycin</b> 30 units IV bolus, weekly for 12 weeks<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV over 30-60 minutes,days 1-5<br> <b>Cisplatin</b> 20 mg/m<sup>2</sup>/d IV over 30-60 minutes, days 1-5<br> Repeat every 21 days for 4 courses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (184, 'Cisplatin : CDDP<br>Etoposide : VP-16', 'EP', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>EP</b>', 'Motzer RJ, Sheinfeld J, Mazumdar M, et al. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. $J Clin Oncol. 1995;13(11):2700-2704.$', null, '<b>Etoposide</b> 100 mg/m<sup>2</sup>/d CIVI, days 1-5<br> <b>Cisplatin</b> 20 mg/m<sup>2</sup>/d IV, days 1-5<br> Repeat after 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (185, 'Cisplatin : CDDP<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various<br>Paclitaxel : Taxol', 'TIP', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'High', '<b>TIP</b>', 'Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. $J Oncol. 2005;23(27):6549-6555.$', null, '<b>Paclitaxel</b> 250 mg/m<sup>2</sup>/d CIVI over 24 hours, day 1<br> <b>Ifosfamide</b> 1,500 mg/m<sup>2</sup>/d IV over 1 hour, days 2-5<br> <b>Cisplatin</b> 25 mg/m<sup>2</sup>/d IV over 30 minutes, days 2-5<br> <b>Mesna</b> 500 mg/m<sup>2</sup> IV before ifosfamide, and at 4 and 8 hours after ifosfamide daily, days 2-5<br> <b>Peg-Filgrastim</b> 6 mcg SQ, days 6<br> Repeat every 21 days for 4 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (186, 'Cisplatin : CDDP<br>Etoposide : VP-16<br>Mesna : Mesnex, various<br>Vinblastine : Velban', 'VIP', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Mesna:<br>No dose reduction</li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vinblastine:<br>No dose reduction </li></ul>', 'High', '<b>VIP</b>', 'Loehrer PJ, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ-cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. $Ann Intern Med. 1988;109(7):540-546.$', null, '<b>Vinblastine</b> 0.11 mg/kg/d IV, days 1, 2<br> <b>OR</b><br> <b>Etoposide</b> 75 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>AND</b><br> <b>Infosfamide</b> 1,2000 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Cisplatin</b> 20mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Mesna</b> 400 mg IV 15 minutes prior to ifosfamide, <b>THEN</b> 1,200 mg/d CIVI, days 1-5<br> Repeat every 21 days for 4 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (187, 'Cabazitaxel : Jevtana<br>Prednisone : various', 'Cabazitaxel', '<b>Hepatic Impairment</b><ul><li>Cabazitaxel:<br></li></ul><b>Renal Impairment</b><ul><li>Cabazitaxel:<br>Caution should be used in patients with severe renal impairment (creatinine clearence of <30 ml/hr)</li></ul>', 'Low', '<b>Cabazitaxel</b>', 'de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. $Lancet. 2010;376(9747):1147-1154.$', null, '<b>Cabazitaxel</b> 25 mg/m<sup>2</sup> IV over 1 hour, day 1<br> <b>Prednisone</b> 10 mg PO daily<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1155, null, 'Gemcitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Gemcitabine:</strong> 1,200 mg/m2 IV on days 1 and 8<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (192, 'Mitoxantrone : Novantrone<br>Prednisone : various', 'Mitoxantrone/Prednisone', '<b>Hepatic Impairment</b><ul><li>Mitoxantrone:<br>If bilirubin > 3 mg/dL, reduce dose by 25%</li></ul><b>Renal Impairment</b><ul><li>Mitoxantrone:<br>No dose reduction</li></ul>', 'Low', '<b>Mitoxantrone/Prednisone</b>', 'Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisonealone for symptptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. $J Clin Oncol. 1996;14(6)1756-1764.$', null, '<b>Mitoxantrone</b> 12 mg/m<sup>2</sup> IV, day 1<br> <b>Prednisone</b> 5 mg PO bid<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (262, 'Cytarabine : Ara-C', 'HiDAC', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li></ul><b>Renal Impairment</b><ul></ul>', 'Moderate', '<b>HiDAC</b>', 'Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid deukemia. Cancer and Leukemia Group B. $N Engl J Med. 1994;331(14):896-903.$', null, 'For patients <60 years of age:<br> <b>Cytarabine</b> 3,000 mg/m<sup>2</sup> CIVI over 3 hours, every 12 hours, days 1, 3, 5<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (194, 'Degarelix : Firmagon', 'Degarelix', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'N/A', '<b>Degarelix</b>', 'Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. $BJU Int. 2008;102(11):1531-1538.$', null, '<b>Degarelix</b> 240 mg SQ <br> <b>FOLLOWED BY</b><br> 80 mg SQ<br> Repeat every 28 days for 13 courses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (195, 'Abaraterone : Zytiga', 'Abaraterone', '<b>Hepatic Impairment</b><ul><li>Abaraterone:<br>No dosage adjustment is necessary for patients with baseline mild hepatic impairment. <br>In patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the recommended dose of ZYTIGA to 250 mg once daily. If elevations in ALT or AST >5X ULN or total bilirubin >3X ULN occur in patients with baseline moderate hepatic impairment, discontinue ZYTIGA treatment. <br> The safety of ZYTIGA in patients with baseline severe hepatic impairment has not been studied. These patients should not receive ZYTIGA. For patients who develop hepatotoxicity during treatment, interruption of treatment</li></ul><b>Renal Impairment</b><ul><li>Abaraterone:<br>No dose adjustment needed</li></ul>', 'Low', '<b>Abaraterone</b>', 'Ryan CJ, et al. "Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy". $N. Engl. J. Med. 368 (2): 138–48.$', null, '<b>Abaraterone</b>1000 mg PO once daily on empty stomach<br> <b>Prednisone</b> 5 mg PO twice daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (198, 'Goserelin : Zoladex', 'Goserelin', '<b>Hepatic Impairment</b><ul><li>Goserelin:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Goserelin:<br>No dose reduction </li></ul>', 'N/A', '<b>Goserelin</b>', 'Zoladex 3.6 mg, Zoladex 10.8 mg [package inserts]. $Wilmington, DE: AstraZeneca; 2010.$  ', null, '<b>Goserelin acetae implant</b> 3.6 mg SQ every 28 days or 10.8 mg SQ every 12 weeks.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (199, '', 'Leuprolide', '<b>Hepatic Impairment</b><ul><li>Leuprolide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'N/A', '<b>Leuprolide</b>', 'Lupron Depot 7.5 mg, 22.5 mg, 30 mg [package insers]. $North Chicago, IL: Abbot Laboratories; 2011.$', null, '<b>Leuprolide acetate depot</b> 7.5 mg IM every 28 days <br>22.5 mg IM every 3 months, <br><b>OR</b> <br>30 mg IM every 4 months', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (200, 'Nilutamide : Nilandron', 'Nilutamide', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul><li>Nilutamide:<br>No dose reduction</li></ul>', 'N/A', '<b>Nilutamide</b>', 'Dijkman GA, Janknegt RA, et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate speific antigen normalization. International Anadron Study Group. $J Urol. 1997;158(1):160-163.$', null, '<b>Nilutamide</b> 300 mg/d PO, days 1-30, <b>THEN</b> 150 mg/d PO, in combination with surgical castration; begin on same day or day after castration', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (201, 'Prednisone : various', 'Prednisone', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'N/A', '<b>Prednisone</b>', 'Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisonealone for symptptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. $J Clin Oncol. 1996;14(6)1756-1764.$', null, '<b>Prednisone</b> 5 mg PO bid', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (202, 'Sipuleucel-T : Provenge', 'Sipuleucel-T', '<b>Hepatic Impairment</b><ul><li>Sipuleucel-T:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Sipuleucel-T:<br>Unknown</li></ul>', 'N/A', '<b>Sipuleucel-T</b>', 'Provenge [package insert]. $Parsippany, NJ: Watson Pharma, Inc.; 2011.$', null, '<b>Sipuleucel-T</b> Administer 3 doses at 14-day intervals', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (203, '', 'Triptorelin', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'N/A', '<b>Triptorelin</b>', 'Trelstar [package insert]. $Parsippany, NJ: Watson Pharma, Inc.; 2011.$', null, '<b>Triptorelin pamoate depot</b> 3.75 mg IM<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (895, null, 'Docetaxel + Prednisone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li><li><strong>Prednisone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>Prednisone:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Docetaxel:</strong> 75 mg/m2 IV on day 1<br><strong>Prednisone:</strong> 5 mg PO bid<br>Repeat the cycle every 21 days for up to a total of 10 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (401, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin, various<br>Paclitaxel: Taxol', 'AC/Paclitaxel (q3weekly)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Citron ML, Berry DA, et al. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-9.', 'ADJUVANT', '<p><strong>Doxorubicin</strong>: 60mg/m2&nbsp;IV on day 1<br><strong>Cyclophosphamide</strong>: 600mg/m2&nbsp;IV on day 1</p><p>Repeat every 21 days for 4 cycles, followed by</p><p><strong>Paclitaxel</strong>: 175mg/m2&nbsp;IV on day 1</p><p>Repeat every 21 days for 4&nbsp;cycles.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (208, 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various<br>Ifosfamide : Ifex', 'Methotrexate/Cisplatin/Doxorubicin Ifosfamide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Ifosfamide:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Ifosfamide</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥10 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose by 25%</li></ul>', 'High', '<b>Methotrexate/Cisplatin/Doxorubicin Ifosfamide</b>', 'Ferrrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. $J Clin Oncol. 2005;23(34):8845-8852.$', null, '<p><strong>Methotrexate:</strong> 12,000 mg/m2 IV over 4 hours day 1<br><strong>Leucovorin calcium:</strong> 8 mg/m2 IV every 6 hours for 11 doses beginning 24 hours from the start of the Methotrexate infusion, days 1, 42 (preoperatively); days 133, 196, 238 (postoperatively)<br><strong>Cisplatin:</strong> 120 mg/m2 IV continuous infusion over 48 hours, days 7-8, 49-50 (preoperatively); days 140-141, 203-204, 245-246 (postoperatively).&nbsp;<br><strong>Doxorubicin:</strong> 75 mg/m2 continuous infusion over 24 hours, days 7, 49 (preoperatively); days 98, 161 (postoperatively). Doxorubicin was increased to 90 mg/m2 IV over 24 hours for postoperative treatment courses<br><strong>Ifosfamide:</strong> 3,000 mg/m2/d CIVI for 5 days with equimolar doses of mesna, days 28-32, 70-74 (preooperatively); days 119-123, 182-186, 224-228 (postoperatively)</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (766, null, 'Azacitidine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Azacitidine:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Azacitidine:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Azacitidine:&nbsp;</strong>75 mg/m2 subcutaneous daily x 7 days</p><p>Repeat cycles every 28 days. Patients should be treated for at least 4 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (209, 'Doxorubicin : Adriamycin, various', 'Doxorubicin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Doxorubicin:</strong><br>No dose reduction</li></ul>', 'Moderate', '<b>Doxorubicin</b>', 'Nielsen OS, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas: a study of the EORTC soft tissue and bone sarcoma group. $Br J Cancer. 1998;78(12):1634-1639.$', null, '<p><strong>Doxorubicin:</strong> 75 mg/m2 IV on day 1.<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (214, 'Carboplatin : Paraplatin<br>paclitaxel : Taxol', 'Carbo-Tax', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose.</li><li><strong>Paclitaxel:</strong><br>No dose reduction</li></ul>', 'High', '<b>Carbo-Tax</b>', 'Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary Carcinoma: a Phase II Hellenic Cooperative Oncology Group Study. $J Clin Oncol. 2000; 18(17):3101-3107.$                                                      ', null, '<p><strong>Carboplatin:</strong> AUC of 6 IV over 30 minutes on day 1.<br>Followed by<br><strong>Paclitaxel:</strong> 200 mg/m2 IV over 3 hours, day 1<br><strong>Filgrastim: </strong>300 mcg/day SQ, days 5-12<br>Repeat every 21 days for a total of 6 or 8 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (896, null, 'Docetaxel + Prednisone + Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Docetaxel:</strong> 75 mg/m2 IV on day 1<br><strong>Prednisone:</strong> 5 mg PO bid<br><strong>Bevacizumab: </strong>15 mg/kg IV on day 1</p><p>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1156, null, 'Ifosfamide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ifosfamide</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ifosfamide</strong>:<br>&nbsp;If CrCl ≥10 mL/min: 100% normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: 75% normal dose.</li></ul>', 'Moderate', null, null, null, '<p><strong>Ifosfamide:</strong> 3,000 mg/m2/day IV on days 1-3<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (898, null, 'Abiraterone + Prednisone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Abiraterone: &nbsp;&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (Child-Pugh class A): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (Child-Pugh class B): &nbsp;Reduce dose to 250 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (Child-Pugh class C): Do not use.</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Abiraterone:</strong>&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Abiraterone:</strong> 1,000 mg PO daily<br><strong>Prednisone:</strong> 5 mg PO bid<br>Continue until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1157, null, 'Doxorubicin Liposome', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Doxorubicin Liposome:</strong><br>There are no dosage adjustments provided in the manufacturer''s labeling. But since doxorubicin is predominantly hepatically eliminated and consider decreasing the dose of doxorubicin (liposomal) in patients with serum bilirubin ≥1.2 mg/dL.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Doxorubicin Liposome:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Doxorubicin liposome:</strong> 50 mg/m2 IV on day 1<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (899, null, 'Docetaxel + Leuprolide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li><li><strong>Leuprolide:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>Leuprolide:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Docetaxel: </strong>75 mg/m2 IV on day 1 and every 28 days<br><strong>Leuprolide:</strong> 7.5 mg IM on day 1 and every 21 days<br>Continue until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (213, '', 'Pegylated liposomal Doxorubicin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Liposomal Doxorubicin:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Liposomal Doxorubicin:</strong><br>No dose reduction</li></ul>', 'Low', '<b>Pegylated liposomal doxorubicin</b>', 'Udhrain A, et al.Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma.$Int J Nanomedicine. 2007 September; 2(3): 345–352.$', null, '<p><strong>Pegylated liposomal Doxorubicin:</strong> 20 mg/m2 IV on day 1.</p><p>Repeat every 3 weeks as tolerated.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (900, null, 'Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel</strong>:<br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Paclitaxel:</strong> 135-170 mg/m2 IV as a 24-hour infusion on day 1.<br>Repeat cycle every 3 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br><strong>OR &nbsp; &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<br><strong>Paclitaxel:</strong> 150 mg/m2 IV as a 1-hour infusion weekly for 6 weeks<br>Repeat cycle every 8 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (243, '', 'Romidepsin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Romidepsin:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;1 to 1.5 times ULN: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;1.5 to 3 times ULN: Reduce initial dose to 7 mg/m2. &nbsp; If bilirubin &gt;3 times ULN: Reduce initial dose to 5 mg/m2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Romidepsin:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '<b>Romidepsin</b>', 'Istodax [package insert]. $Summit , NJ: Celgene Corporation; 2011.$', null, '<p><strong>Romidepsin:</strong> 14mg/m2 IV on days 1,8,and 15.<br>Repeat every 28 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (897, null, 'Cabazitaxel + Prednisone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cabazitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If mild impairment (total bilirubin &gt;1 to ≤1.5 times ULN or AST ≥1.5 times ULN): 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If moderate impairment (total bilirubin &gt;1.5 to ≤3 times ULN and any AST): &nbsp;Reduce initial dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (total bilirubin &gt;3 times ULN): Do not use.</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cabazitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥15 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;15 mL/min and ESRD: Use with caution and monitor closely.</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Cabazitaxel:</strong> 25 mg/m2 IV on day 1<br><strong>Prednisone:</strong> 10 mg PO daily</p><p>Repeat cycle every 21 days. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br><strong>OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<br><strong>Cabazitaxel:</strong> 20 mg/m2 IV on day 1<br><strong>Prednisone: </strong>10 mg PO daily</p><p>Repeat cycle every 21 days. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br><strong>OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<br><strong>Cabazitaxel:</strong> 10 mg/m2 IV on days 1, 8, 15, and 22.<br><strong>Prednisone:</strong> 5 mg PO bid</p><p>Repeat cycle every 5 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (280, 'Bortezomib : Velcade', 'Bortezomib/Doxil', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li></ul>', 'Low', '<b>Bortezomib/Doxil</b>', 'Doxil [package insert]. $Raritan, NJ: Centocor Ortho Biotech Products, LP; 2010.$<br> Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. $J clin Oncol. 2007;25(25):3892.$', null, '<b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV, bolus days 1, 4, 8, 11<br> <b>Pegylated liposomal doxorubicin</b> 30 mg/m<sup>2</sup> IV over 1 hour, day 4<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (218, 'Docetaxel : Taxotere<br>Gemcitabine : Gemzar, various', 'Gemcitabine/Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul>', 'Low', '<b>Gemcitabine/Docetaxel</b>', 'Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. $Cancer. 2004; 100(6): 1257-1261.$', null, '<p><strong>Gemcitabine:</strong> 1,000 mg/m2 IV over 30 minutes, days 1 and 8<br><strong>Docetaxel:</strong> 75 mg/m2 IV over 1 hour, day 8<br>Repeat every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (220, 'Carboplatin : Paraplatin<br>Etoposide : VP-16<br>Paclitaxel : Taxol', 'Paclitaxel + Carboplatin + Etoposide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose.</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Paclitaxel:</strong><br>No dose reduction</li></ul>', 'High', '<b>Paclitaxel/Carboplatin/Etoposide</b>', 'Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neutroendocrine carcinoma: a Minnie Pearl Cancer Network Study. $J Clin Oncol. 2006;24(22):3548-3554.$', null, '<p><strong>Paclitaxel:</strong> 200 mg/m2 IV over 1 hour, day 1<br><strong>Carboplatin:</strong> AUC of 6, IV on day 1<br><strong>Etoposide:</strong> 50 mg PO alternating with 100mg PO on days 1-10<br>Repeat every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (901, null, 'Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Docetaxel:</strong> 75 mg/m2 IV on day 1</p><p>Repeat cycle every 21 days.<br><strong>OR</strong><br><strong>Docetaxel:</strong> 20-40 mg/m2 weekly for 3 weeks<br><br>Repeat cycle every 4 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (902, null, 'Estramustine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Estramustine:</strong>&nbsp;<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Estramustine:</strong>&nbsp;<br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Estramustine:</strong> 14 mg/kg/day PO in 3-4 divided doses</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (903, null, 'Goserelin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Goserelin:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Goserelin:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'N/A', null, null, null, '<p><strong>Goserelin:</strong> 3.6 mg SC on day 1<br>Repeat cycle every 28 days.<br><strong>OR</strong><br><strong>Goserelin:</strong> 10.8 mg SC on day 1<br>Repeat cycle every 12 weeks.<br>&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (831, null, 'Interferon Alpha- 2b (Adjuvant)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Interferon alfa- 2b</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Interferon alfa-2b</strong>:<br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Interferon alfa- 2b</strong>: 20 million U/m2 IV, 5 times weekly for 4 weeks, then 10 million IU/m2 SC, 3 times weekly for 48 weeks.<br>Treatment is for a total of 1 year.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (224, 'Bendamustine : Treanda<br>Rituximab : Rituxan', 'BR', '<b>Hepatic Impairment</b><ul><li>Bendamustine:<br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin 1.5-3 upper normal limit, or bilirubin > 3 upper normal limit, do not use </li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Bendamustine:<br>If CrCl < 40 mL/min, do not use </li></ul>', 'Moderate', '<b>BR</b>', 'Rummel MK, Niederle N, Mascmeyere G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared too CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and matle cell lymphomas: Final results of a randomized phase III study of StiL (Study Group of Indolent Lymphomas, Germany). $Presented at :51st American Society of Hematology Annual Meeting; December 5-8, 2009; New Orleans, LA. Abstract 405.$', null, '<b>Rituximab</b> 375mg/m<sup>2</sup> IV, day 1<br> <b>Bendamustine</b> 90 mg/m<sup>2</sup> IV, days 1, 2<br> Repeat every 28 days for 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1158, null, 'Pazopanib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pazopanib:</strong><br>If mild impairment (AST &gt; ULN and total bilirubin ≤ ULN <strong>or</strong> total bilirubin &gt;1 to ≤1.5 times ULN and any AST): 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If moderate impairment (total bilirubin &gt;1.5 to ≤3 times ULN and any AST): Reduce initial dose to 200 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (total bilirubin &gt;3 times ULN and any AST): Avoid use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pazopanib:</strong><br>No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Pazopanib:</strong> 800 mg PO daily</p><p>Continue treatment until disease progression</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1161, null, 'Ixazomib + Dexamethasone + Rituximab (IDR)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Rituximab:</strong><br>Dose modification not provided by the manufacturer</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li><li><strong>Ixazomib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (Child-Pugh class A): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (Child-Pugh class B and C): Reduce initial dose to 3 mg once weekly on days 1, 8, and 15 of a 28-day treatment cycle</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Rituximab:</strong><br>Dose modification not provided by the manufacturer</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li><li><strong>Ixazomib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &gt;30 mL/min: No dosage reduction &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Reduce initial dose to 3 mg once weekly on days 1, 8, and 15 of a 28-day treatment cycle</li></ul>', 'Low', null, null, null, '<p><strong>Ixazomib:</strong> 4 mg/day PO on days 1,8, and 15<br><strong>Dexamethasone:</strong> 20 mg/day PO on days 1, 8, 15, and 22<br><strong>Rituximab: </strong>375 mg/m2 IV on day 1<br>Repeat cycle every 28 days for up to 6 cycles of induction.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (240, '', 'Ibritumomab tiuxetan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ibritumomab tiuxetan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ibritumomab tiuxetan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li></ul>', 'Low', '<b>Ibritumomab tiuxetan</b>', 'Zevalin [package insert]. $San Deigo, CA: IDEC Pharmaceutical Coorporation; 2010.$<br> Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevali radiommunotherapy for low-grade, follicular, or transofrmed B-cell non-Hodgikin''s lymphoma. $Crit Rev Oncol Hematol. 2001;39(1-2):181-194.$', null, '<p><strong>Ibritumomab tiuxetan</strong> is given in 2 steps:<br>Step 1: <strong>Rituximab</strong> 250 mg/m2 infusion followed with 4 hours by 5.0 mCi (1.6 mg total antibody dose) of <strong>In- 111 Ibritumomab tiuxetan</strong> administered as a 10-minute IV push<br>Step 2: (7-9 days after step 1): <strong>Rituximab</strong> 250 mg/m2 infusion followed with 4 hours by<br><strong>Y-90 ibritumomab tiuxetan</strong> 0.4 mCi/kg (maximum, 32 mCi) administered as a 10-minute IV push.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (830, null, 'Dabrafenib + Trametinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Dabrafenib:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Trametinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Dabrafenib:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Trametinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Dabrafenib:</strong> 150 mg PO bid<br><strong>Trametinib:</strong> 2 mg PO daily<br>Continue treatment for up to 12 months.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (832, null, 'Peg-Interferon Alpha-2b', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Peg-Interferon Alpha-2b:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Peg-Interferon Alpha-2b:</strong><br>If CrCl &gt;50 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 30 to 50 mL/min: Reduce initial dose to 4.5 μg/kg/week and reduce maintenance dose to 2.25 μg/kg/week. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min and ESRD on dialysis: Reduce initial dose to 3 mcg/kg/week and reduce maintenance dose to 1.5 mcg/kg/week.</li></ul>', 'Low', null, null, null, '<p><strong>Peg-Interferon Alpha-2b: </strong>6 μg/kg SC weekly for 8 weeks, then 3 μg/kg SC weekly for up to 5 years.<br>Treatment is for up to a total of 5 years&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1135, null, 'Elotuzumab + Lenalidomide + Dexamethasone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Elotuzumab:</strong><br>There are no dosage adjustments provided in the manufacturer''s labeling</li><li><strong>Lenalidomide:</strong><br>No dose reduction.</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Elotuzumab:</strong><br>There are no dosage adjustments provided in the manufacturer''s labeling</li><li><strong>Lenalidomide:</strong><br>If CrCl &gt;60 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 30 to 60 mL/min: 5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min not requiring dialysis: 2.5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min requiring dialysis: 2.5 mg once daily (administer after dialysis on dialysis days).</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Elotuzumab:</strong> 10 mg/kg IV on days 1, 8, 15, and 22<br><strong>Lenalidomide: </strong>25 mg PO on days 1-21<br><strong>Dexamethasone:</strong> 8 mg IV prior to elotuzumab infusion and 28 mg PO on days 1, 8, 15, and 22 and 40 mg PO on day 28<br>Repeat cycle every 28 days for two cycles followed by:<br><strong>Elotuzumab: </strong>10 mg/kg IV on days 1 and 15<br><strong>Lenalidomide:</strong> 25 mg PO on days 1-21<br><strong>Dexamethasone: </strong>8 mg IV prior to elotuzumab infusion and 28 mg PO on days 1 and 15, and 40 mg PO on days 22 and 28<br>Repeat cycle every 28 days until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (904, null, 'Goserelin (Adjuvant therapy)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Goserelin:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Goserelin:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'N/A', null, null, null, '<p><strong>Goserelin:</strong> 3.6 mg SC on day 1<br>Repeat cycle every 28 days for 24 months.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (229, 'Cisplatin : CDDP<br>Cytarabine : Ara-C<br>Dexamethasone : various', 'DHAP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Dexamethasone:</strong><br>No dose reduction</li><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Dexamethasone:</strong><br>No dose reduction</li><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li></ul>', 'High', '<b>DHAP</b>', 'Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). $Blood. 1988;71(1):117-122.$', null, '<p><strong>Dexamethasone:</strong> 40 mg/day PO or IV over 24 hours, days 1-4<br><strong>Cisplatin:</strong> 100 mg/m2 continuous infusion over 24 hours, day 1<br><strong>Cytarabine:</strong> 2,000 mg/m2 IV over 3 hours every 12 hours for 2 doses, day 2<br>Repeat cycle every 21-28 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (230, 'Cisplatin : CDDP<br>Cytarabine : Ara-C<br>Etoposide : VP-16<br>Methylprednisolone : Depo-Medrol, Solu-Medrol, various', 'ESHAP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Methylprednisolone:</strong>&nbsp;<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Methylprednisolone:</strong>&nbsp;<br>No dose reduction</li></ul>', 'High', '<b>ESHAP</b>', 'Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP- an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. $J Clin Oncol. 1994; 12(6): 1169-1176.$<br> Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. $J Clin Oncol. 1995; 13(7): 1734-1741.$', null, '<p><strong>Etoposide:</strong> 40 mg/m2/d IV, days 1-4<br><strong>Methylprednisolone:</strong> 500 mg/d IV, days 1-5<br><strong>Cytarabine:</strong> 2,000 mg/m2 IV over 2-3 hours, day 5<br><strong>Cisplatin:</strong> 25 mg/m2/day continuous infusion, days 1-4<br><strong>OR</strong><br><strong>Etoposide:</strong> 60 mg/m2/d IV, days 1-4<br><strong>Methylprednisolone:</strong> 500 mg/d IV, days 1-4<br><strong>Cisplatin:</strong> 25 mg/m2/day continuous infusion, days 1-4<br><strong>Cytarabine:</strong> 2,000 mg/m2 IV over 2 hours, day 5, immediately following completion of cisplatin<br>Repeat every 21-28 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (241, 'Pralatrexate : Folotyn', 'Pralatrexate', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pralatrexate: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pralatrexate: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If<strong> </strong>eGFR ≥30 mL/min/1.73 m2: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If eGFR 15 to &lt;30 mL/min/1.73 m2: Reduce dose to 15 mg/m2</li></ul>', 'Low', '<b>Pralatrexate</b>', 'Folotyn [package insert]. $Westminster, CO: Allos Therapeutics Inc.; 2012.$', null, '<p><strong>Pralatrexate:</strong> 30 mg/m2 IV, weekly for 6 weeks<br>Repeat every 7 weeks</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (246, 'Vorinostat : Zolinza', 'Vorinostat', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vorinostat:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vorinostat:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '<b>Vorinostat</b>', 'Zolinza [package insert].', null, '<p><strong>Vorinostat:</strong> 400 mg PO daily with food.</p><p>Continue until disease progression or unacceptable toxicity.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (905, null, 'Degarelix', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Degarelix: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If mild or moderate impairment (Child-Pugh class A and B): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): Dosage adjustments not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Degarelix:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If<strong> </strong>CrCl 50 to 80 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;50 mL/min: Dosage adjustments not provided by the manufacturer.</li></ul>', 'N/A', null, null, null, '<p><strong>Degarelix:</strong> 240 mg SC starting dose followed 28 days later by the first maintenance dose of 80 mg SC<br>Repeat maintenance dose every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (906, null, 'Leuprolide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Leuprolide:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Leuprolide:</strong><br>No dose reduction</li></ul>', 'N/A', null, null, null, '<p><strong>Leuprolide:</strong> 7.5 mg SC on day 1<br>Repeat cycle every 28 days.<br><br><strong>OR</strong><br><strong>Leuprolide:</strong> 22.5 mg SC on day 1<br>Repeat cycle every 12 weeks.&nbsp;</p><p><br><strong>OR</strong><br><strong>Leuprolide: </strong>30 mg SC on day 1<br>Repeat cycle every 16 weeks</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (237, '', 'Brentuximab vedotin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Brentuximab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If mild impairment (Child-Pugh class A): Reduce dose to 1.2 mg/kg. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If moderate to severe impairment (Child-Pugh class B or C): Avoid use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Brentuximab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Avoid use.</li></ul>', 'Low', '<b>Brentuximab vedotin</b>', 'Advani RH, Shustov AR, Brice P, et al.                                     Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: A Phase 2 study update. $Blood (ASH Annula Meeting Abstracts). 2011; 118:443.$<br> Adcetris [package insert]. $Bothell, WA: Seattle Genetics; 2011.$', null, '<p><strong>Brentuximab:</strong> 1.8 mg/kg IV over 30 minutes, day 1<br>Repeat every 21 days for up to 16 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (238, '', 'Denileukin diftitox', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Denileukin diftitox:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Denileukin diftitox:</strong><br>No dose reduction</li></ul>', 'Low', '<b>Denileukin diftitox</b>', 'Olsen E, Duvic M Frankel A, et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. $J Clin Oncol. 2001; 19(2):376-388.$', null, '<p><strong>Denileukin diftitox:</strong> 9 OR 18 mcg/kg/d/IV over 15-60 minutes, days 1-5<br>Repeat every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (239, 'Fludarabine : Fludara', 'Fludarabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Fludarabine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Fludarabine:</strong><br>If CrCl 30-70 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'Low', '<b>Fludarabine</b>', 'Klasa RJ,Meyer RM, Shustic C, et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisione in patients with recurrent low-grade Non-Hodgikin''s lymphoma previously treated with an alkylating agent or alkylatic containing regimen. $J Clin Oncol. 2002;20(24):4649-4654.$', null, '<p><strong>Fludarabine:</strong> 25 mg/m2/day IV over 10 minutes, days 1-5<br>Repeat every 28 days for up to 8 courses</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (233, 'Carboplatin : Paraplatin<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various<br>Rituximab : Rituxan', 'RICE', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Ifosfamide:</strong><br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% dosage.</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Ifosfamide</strong>:<br>&nbsp;If CrCl ≥10 mL/min: 100% normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: 75% normal dose.</li><li><strong>Rituximab:</strong><br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul>', 'High', '<b>RICE</b>', 'Kewalramani T, Zelenetz AD, Nimer SD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. $Blood. 2004; 103(10):3684-3688.$', null, '<p><strong>Rituximab:</strong> 375 mg/m2 IV, day 1 every 14 days<br><strong>Ifosfamide:</strong> 5,000 mg/m2 with mesna 5,000 mg/m2 CIVI over 24 hours, day 4<br><strong>Carboplatin:</strong> AUC of 5 (maximum 800 mg) IV, day 4<br><strong>Etoposide:</strong> 100 mg/m2/d CIVI, days 3-5</p><p><strong>Mesna:</strong> 5,000 mg/m2 IV in combination with ifosfamide dose.<br>Repeat every 14 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (232, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Prednisone : various<br>Rituximab : Rituxan<br>Vincristine : Oncovin, VCR', 'R-EPOCH', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Rituximab:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Rituximab:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Moderate', '<b>R-EPOCH</b>', 'Jermann M, jost M, Taverna C, et al. Rituximab EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. $Ann Oncol. 2004; 15(3):511-516$.', null, '<p><strong>Rituximab:</strong> 375 mg/m2 IV, day 1<br><strong>Etoposide:</strong> 65 mg/m2/d CIVI, days 2-4<br><strong>Doxorubicin:</strong> 15 mg/m2/d CIVI, days 2-4<br><strong>Vincristine:</strong> 0.5 mg/m2/d CIVI, days 2-4<br><strong>Cyclophosphamide:</strong> 750 mg/m2 IV, day 5<br><strong>Prednisone:</strong> 60 mg/m2/d PO, days 1-14<br>Repeat every 21 days for 4 -6 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (907, null, 'Bicalutamide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bicalutamide:&nbsp;</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bicalutamide:&nbsp;</strong><br>No dose reduction</li></ul>', 'N/A', null, null, null, '<p><strong>Bicalutamide: </strong>50 mg PO daily<br>In patients refractory to other anti-androgen agents, may start with a higher dose<br>of 150 mg PO daily.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (908, null, 'Flutamide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Flutamide:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If mild or moderate impairment (Child-Pugh class A and B): Dosage adjustments not provided by the manufacturer. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Flutamide: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> No dose reduction.</li></ul>', 'N/A', null, null, null, '<p><strong>Flutamide:</strong> 250 mg PO tid.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (839, null, 'Flutamide + Goserelin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Flutamide:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If mild or moderate impairment (Child-Pugh class A and B): Dosage adjustments not provided by the manufacturer. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): Do not use.</li><li><strong>Goserelin:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Flutamide:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Goserelin:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'N/A', null, null, null, '<p><strong>Flutamide:</strong> 250 mg PO tid<br><strong>Goserelin:</strong> 10.8 mg SC every 12 weeks<br>&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (259, '', 'Arsenic', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Moderate', '<b>Arsenic</b>', 'Trisenox [package insert]. $Frazer, PA: Cephalon; 2010.$', null, '<b>Arsenic trioxide</b> 0.15 mg/kg IV, daily until remission, not to exceed 60 doses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (249, 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various<br>Vincristine : Oncovin, VCR', 'CODOX-M/IVAC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Ifosfamide:</strong><br>No dose reduction</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Ifosfamide</strong>:<br>&nbsp;If CrCl ≥10 mL/min: 100% normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: 75% normal dose.</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'Moderate', '<b>CODOX-M/IVAC</b>', 'Wang ES, Strauss DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphosphamide, doxorucibicin, high-dose methotrecate/ ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC)for human immunodeficiency virus-associated Burkitt lymphoma. $Cancer. 2003;98(6): 1196-1205.$', null, '<p><strong>CYCLES 1 and 3 (CODOX-M)</strong><br><strong>Cyclophosphamide</strong> 800 mg/m2 IV, day 1<br><strong>Cyclophosphamide</strong> 200 mg/m2/d IV, days 2-5<br><strong>Doxorubicin</strong> 40 mg/m2 IV, day 1<br><strong>Vincristine</strong> 1.5 mg/m2 IV, days 1, 8 for cycle 1,days 1, 8, 15 for cycle 2<br><strong>Methotrexate</strong> 1,200 mg/m2 IV over 1 h, day 10, <strong>THEN</strong> 240 mg/m2/h CIVI for the next 23 hours<br><strong>Leucovorin calcium</strong> 50 mg IV q6h, begining 36 hours from the start of Methotrexate until Methotrexate level &lt;0.05 mcM<br><strong>Filgrastim</strong> beginning 24 h from the start of leucovorin until ANC&gt;1,000<br>CNS PROPHYLAXIS<br><strong>Cytarabine</strong> 70 mg IT, days 1, 3<br><strong>Methotrexate 12 mg IT, day 15</strong><br><strong>CYCLES 2 AND 4 (IVAC)</strong><br><strong>Ifosofamide 1,500 mg/m2 IV, days 1-5</strong><br><strong>Mesna 1,500 mg/m2 IV, days 1-5</strong><br><strong>Etoposide 60 mg/m2 IV, days 1-5</strong><br><strong>Cytarabine 2,000 mg/m2 IV q 12h, days 1 and 2</strong><br><strong>Filgrastim beginning 24 h after completion of chemotherapy until ANC &gt;1,000</strong><br><strong>CNS PROPHYLAXIS</strong><br><strong>Methotrexate 12 mg IT, day 15</strong><br><strong>Additional IT Treatment for CNS disease- positive patients:</strong><br><strong>Cycle 1: cytarabine 70 mg IT, days 1,3,5, and Methotrexate 12 mg IT, days 15,17</strong><br><strong>Cycle 3: cytarabine 70 mg IT, days 1,3, and Methotrexate 12 mg IT, day 15</strong></p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (833, null, 'DTIC + Carmustine + Cisplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Dacarbazine:</strong><br>No dose reduction</li><li><strong>Carmustine:</strong><br>No dose reduction</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Dacarbazine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 20%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 45 mL/min: Reduce dose to 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≤30 mL/min: Reduce dose to 30%.</li><li><strong>Carmustine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 20%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 45 mL/min: Reduce dose to 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≤30 mL/min: Do not use.</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose to 25%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose to 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li></ul>', 'High', null, null, null, '<p><strong>Dacarbazine:</strong> 220 mg/m2 IV on days 1-3<br><strong>Carmustine:</strong> 150 mg/m2 IV on day 1<br><strong>Cisplatin:</strong> 25 mg/m2 IV on days 1-3<br>Repeat cycle with dacarbazine and cisplatin every 21 days and carmustine every<br>42 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (834, null, 'IFN + DTIC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Interferon alfa- 2b</strong>:<br>No dose reduction</li><li><strong>Dacarbazine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Interferon alfa-2b</strong>:<br>No dose reduction</li><li><strong>Dacarbazine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 20%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 45 mL/min: Reduce dose to 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≤30 mL/min: Reduce dose to 30%.</li></ul>', 'High', null, null, null, '<p><strong>Interferon Alpha-2b: </strong>15 million IU/m2 IV on days 1-5, 8-12, and 15-19 as induction therapy<br><strong>Interferon Alpha-2b:</strong> 10 million IU/m2 SC 3 times weekly after induction therapy.<br><strong>Dacarbazine:</strong> 200 mg/m2 IV on days 22-26.<br><br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (541, 'Pemetrexed: Alimta', 'Pemetrexed', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pemetrexed</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pemetrexed</strong>:<br>If CrCl &gt; 45 mL/min: 100% dosage<br>If CrCl &lt; 45 mL/min: Do not use</li></ul>', 'Low', '', 'Lorusso D, Ferrandina G, et al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol. 2010;21(1):61-6.', '', '<p><strong>Pemetrexed:</strong>&nbsp;500 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p><p>Folic acid 400 to 1,000 µg PO once daily and vitamin B12 at 1,000 µg IM to start 7 days prior to the first dose of pemetrexed and repeated every 21 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1031, null, 'Infusion 5-FU + Radiation Therapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>5-Fluorouracil:</strong> 225 mg/m2/day IV continuous infusion throughout the entire course of radiation therapy<br><strong>Radiation therapy:</strong> 180 cGy/day for 5 days per week (total dose, 5,040 cGy)<br>Followed by surgical resection and then adjuvant chemotherapy with capecitabine,<br>5-FU/LV, or FOLFOX4 for a total of 4 months.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1032, null, 'Capecitabine + Radiation Therapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine:</strong><br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'Low', null, null, null, '<p><strong>Capecitabine:</strong> 825 mg/m2 PO bid throughout the entire course of radiation therapy or<br>900-1,000 mg/m2 PO bid on days 1-5 of each week of radiation therapy.<br><br><strong>Radiation therapy: </strong>180 cGy/day for 5 days per week (total dose, 5,040 cGy)<br>Followed by surgical resection and then adjuvant chemotherapy with capecitabine,<br>5-FU, or 5-FU/LV for a total of 4 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (278, 'Pentostatin : Nipent', 'Pentostatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pentostatin:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pentostatin:</strong><br>If CrCl 46-60 mL/min: Reduce dose by 30%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31-45 mL/min: Reduce dose by 40%&nbsp;<br>If CrCl &lt;30 mL/min: Use alternative drug.</li></ul>', 'Low', '<b>Pentostatin</b>', 'Cassileth PA, et al.$J Clin Oncol. 1991;9:243-246.$', null, '<b>Pentostatin:</b> 4 mg/m<sup>2</sup> IV on day 1 <br>Repeat cycle every 14 days for 6 cycles ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (253, '', 'Nelarabine', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Nelarabine</b>', 'Arranon [package insert]. $Research Triangle Park, NC: GlaxoSmithKline;2011.$', null, '<b>Nelarabine</b> 1,500 mg/m<sup>2</sup>/d IV, days 1, 3 and 5', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (254, '', 'ATRA/Arsenic', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Moderate', '<b>ATRA/Arsenic</b>', 'Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans-retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. $Blood. 2006;107(9):3469-3473.$', null, '<b>All-trans-retinoic acid (ATRA)</b> 45 mg/m<sup>2</sup> PO in 2 divided doses daily<br> <b>Arsenic trioxide</b> 0.15 mg/kg/d IV over 1 hour, daily beginning day 10 and continued until <5% blasts and absence of promyelocytes', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (910, null, 'Apalutamide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Apalutamide:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Dosage adjustments not provided by the manufacturer. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Apalutamide: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> Dosage adjustments not provided by the manufacturer. &nbsp;&nbsp;</li></ul>', 'N/A', null, null, null, '<p><strong>Apalutamide:</strong> 240 mg PO daily</p><p>Continue until disease progression or unacceptable toxicity.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1136, null, 'Selinexor', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Selinexor:</strong><br>There are no dosage adjustments provided in the manufacturer''s labeling</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Selinexor:</strong><br>There are no dosage adjustments provided in the manufacturer''s labeling</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Selinexor:</strong> 80 mg PO on days 1 and 3<br><strong>Dexamethasone:</strong> 20 mg P0 on days 1 and 3<br>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (264, 'Bendamustine : Treanda<br>Rituximab : Rituxan', 'BR', '<b>Hepatic Impairment</b><ul><li>Bendamustine:<br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin 1.5-3 upper normal limit, or bilirubin > 3 upper normal limit, do not use </li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Bendamustine:<br>If CrCl < 40 mL/min, do not use </li></ul>', 'Moderate', '<b>BR</b>', 'Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG). $J Clin Oncol. 2011;29(26)3559-3566.$', null, '<b>Bendamustine</b> 90 mg/m<sup>2</sup> IV on days 1 and 2<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV for the first cycle and 500 mg/m<sup>2</sup> for subsequent cycles<br> Repeat every 28 days for up to 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (277, 'Cladribine : 2-CdA', 'Cladribine', '<b>Hepatic Impairment</b><ul><li>Cladribine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Cladribine</b>', 'Saven A, et al. $Blood 1992;79:1111-1120.$', null, '<b>Cladribine:</b>0.09 mg/kg/day IV continuous infusion on days 1 to 7 <br>Administer one cycle', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (256, 'Cytarabine : Ara-C<br>Etoposide : VP-16<br>Idarubicin : Idamycin<br>Mitoxantrone : Novantrone', 'Idarubicin/Cytarabine/Etoposide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Daunorubicin:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Idarubicin:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 25%<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Mitoxantrone:</strong><br>If bilirubin &gt; 3 mg/dL, reduce dose by 25%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Daunorubicin:</strong><br>If Cr &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Idarubicin:</strong><br>If CrCl &lt; 10 mL/min, reduce dose by 25%</li><li><strong>Mitoxantrone:</strong><br>No dose reduction</li></ul>', 'Moderate', '<b>Idarubicin/Cytarabine/Etoposide</b>', 'Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA group study AML-10. $J Clin Oncol. 2009;32(10):5397-5403.$', null, '<p><strong>Cytarabine:</strong> 25 mg/m2 IV, followed by 100 mg/m2 CIVI, days 1-10<br><strong>Etoposide:</strong> 100 mg/m2 IV, days 1-5<br><strong>Daunorubicin:</strong> 50 mg/m2 IV, days 1, 3, 5<br><strong>OR</strong><br><strong>Mitoxantrone:</strong> 12 mg/m2 IV, days 1, 3, 5<br><strong>OR</strong><br><strong>Idarubicin:</strong> 10 mg/m2 IV, days 1, 3, 5</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (849, null, 'IFoVP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ifosfamide</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ifosfamide</strong>:<br>&nbsp;If CrCl ≥10 mL/min: 100% normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: 75% normal dose.</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Ifosfamide:</strong> 1,800 mg/m2/day IV, days 1-5<br><strong>Etoposide:</strong> 100 mg/m2/d IV over 1 hour, days 1-5<br><strong>Mesna:</strong> 2,880 mg/m2/day IV, days 1-5<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (767, null, 'Decitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Decitabine: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Decitabine: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Decitabine:</strong>&nbsp;15 mg/m2 IV continuous infusion over 3 hrs every 8 hours for 3 days&nbsp;</p><p>Repeat cycle every 4 weeks. Patients should be treated for at least 4 cycles.</p><p><strong>OR</strong></p><p><strong>Decitabine:</strong>&nbsp;20 mg/m2 IV continuous infusion over 1 hour for 5 days</p><p>Repeat cycle every 4-6 weeks. Patients should be treated for at least 4 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (268, 'Cyclophosphamide : Cytoxan<br>Pentostatin : Nipent<br>Rituximab : Rituxan', 'PCR', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL: Reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Pentostatin:</strong><br>No dose reduction</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-29 mL/min: Reduce dose by 25%<br>If CrCl &lt; 10 mL/min: Reduce dose by 50%</li><li><strong>Pentostatin:</strong><br>If CrCl 46-60 mL/min: Reduce dose by 30%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31-45 mL/min: Reduce dose by 40%&nbsp;<br>If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul>', 'Moderate', '<b>PCR</b>', 'Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. $Blood. 2007;109(2):405-411.$', null, '<p><strong>Pentostatin:</strong> 2 mg/m2 IV on day 1<br><strong>Cyclophosphamide:</strong> 600 mg/m2 IV on day 1<br><strong>Rituximab:</strong> 375 mg/m2 IV on day 1<br>Repeat every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (267, 'Fludarabine : Fludara<br>Rituximab : Rituxan', 'FR', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Fludarabine:</strong><br>No dose reduction</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Fludarabine:</strong><br>If CrCl 10-50 mL/min: Reduce dose by 25%&nbsp;<br>If CrCl &lt;10 mL/min: Reduce dose by 50%</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul>', 'Low', '<b>FR</b>', 'Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lympocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). $Blood. 2003;101(1):6-14$', null, '<p><strong>Fludarabine:</strong> 25 mg/m2 IV over 20-30 minutes, days 1-5<br><strong>Rituximab:</strong> 375 mg/m2 IV on days 1 and 4 of cycle 1and then on day 1 thereafter.</p><p>Repeat every 28 days for a total of 6 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1137, null, 'Daratumumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Daratumumab:</strong>&nbsp;<br>There are no dosage adjustments provided in the manufacturer''s labeling</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Daratumumab:</strong>&nbsp;<br>There are no dosage adjustments provided in the manufacturer''s labeling</li></ul>', 'Low', null, null, null, '<p><strong>Daratumumab:</strong> 16 mg/kg IV on days 1, 8, 15, 22, 29, 36, 42, and 49; followed by once every 2 weeks for 16 weeks; followed by once every 4 weeks<br>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (777, null, 'Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Docetaxel:</strong> 100 mg/m2 IV over 1 hour, day1<br><br>Repeat every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (274, 'Dasatinib : Sprycel', 'Dasatinib', '<b>Hepatic Impairment</b><ul><li>Dasatinib:<br>Unknown. Metabolism mainly hepatic </li></ul><b>Renal Impairment</b><ul><li>Dasatinib:<br>Unknown. < 4% excreted by kidney </li></ul>', 'Low', '<b>Dasatinib</b>', 'Kantarijan H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid deukemia. $N Engl J Med. 2010;362(24):2260-2270.$', null, '<b>Dasatinib</b> 100 mg PO, daily (chronic phase)<br> <b>OR</b><br> <b>Dasatinib</b> 140 mg PO, daily (accelerated or blast phase)', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (272, 'Fludarabine : Fludara', 'Fludarabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Fludarabine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Fludarabine:</strong><br>If CrCl 10-50 mL/min: Reduce dose by 25%&nbsp;<br>If CrCl &lt;10 mL/min: Reduce dose by 50%</li></ul>', 'Low', '<b>Fludarabine</b>', 'Eichhorst BF, Busch R, Stilgenbauer S, et al. First line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. $Blood. 2009;114:3382-3391.$', null, '<p><strong>Fludarabine:</strong> 20-30 mg/m2 IV over 30 minutes , days 1-5<br>Repeat every 28 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (909, null, 'Nilutamide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nilutamide:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If mild or moderate impairment (Child-Pugh class A and B): Dosage adjustments not provided by the manufacturer. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nilutamide:</strong>&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustments not provided by the manufacturer.&nbsp;</li></ul>', 'N/A', null, null, null, '<p><strong>Nilutamide:</strong> 300 mg PO on days 1-30, then 150 mg PO daily.</p><p>&nbsp;Therapy should be discontinued in patients with evidence of disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (342, 'Tagrisso', 'Osimertinib', '', 'Minimal', '<b>Osimertinib</b>', 'Mitsudomi T, Tsai C, Shepherd F, et al. AZD9291 in pre-treated T790M positive advanced non-small cell lung carcinoma:AURA 2 phase II study. Presented at 16th world conference on lung cancer:September 6-9; Denverm CO. Abstract 1406. $', null, '<b>Osimertinib</b> 80 mg  PO daily<br> ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (361, 'Cotellic', 'Cobimetinib/Vemurafenib', '', 'Minimal', '<b>Cobimetinib/Vemurafenib</b>', 'Larkin J, Ascierto PA, Dreno B. Combined Vemurafenib and Cobimetinib in BRAF-mutated Melanoma. $N Engl J Med. 2014 Nov 13;371(20):1867-76. $', null, '<b>Cobimetinib</b> 60 mg once daily<br>Vemurafenib</b>960 mg twice a day from day1-21, on a 28 day cycle ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (282, 'Bortezomib : Velcade<br>Thalidomide : Thalomid', 'Bortezomib/Thalidomide/Dexamethasone (VTD)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin&nbsp;1-1.5 times upper normal limit: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin&nbsp;&gt;1.5 times upper normal limit: Reduce the initial dose to 0.7 mg/m2.</li><li><strong>Thalidomide:</strong>&nbsp;<br>No dose reduction</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li><li><strong>Thalidomide:</strong>&nbsp;<br>No dose reduction</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'Low', '<b>Bortezomib/Thalidomide/Dexamethasone (VTD)</b>', 'Cazo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. $Lancet. 2010;18;376(9758):2075-2085.$', null, '<p><strong>Bortezomib:</strong> 1.3 mg/m2 IV bolus, days 1, 4, 8, and 11<br><strong>Thalidomide:</strong> 100 mg PO daily for 14 days and 200 mg daily thereafter<br><strong>Dexamethasone:</strong> 40 mg PO daily on days 1, 2, 4, 5, 8, 9, 11, and 12; total of 320 mg per cycle</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (284, 'Cisplatin : CDDP<br>Dexamethasone : various<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Thalidomide : Thalomid', 'DT-PACE', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Dexamethasone:</strong><br>No dose reduction</li><li><strong>Thalidomide:</strong>&nbsp;<br>No dose reduction</li><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Dexamethasone:</strong><br>No dose reduction</li><li><strong>Thalidomide:</strong>&nbsp;<br>No dose reduction</li><li><strong>Cisplatin:</strong><br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', '<b>DT-PACE</b>', 'Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. $J Clin Oncol. 2003;21(14):2732-2739.$', null, '<p><strong>Dexamethasone:</strong> 40 mg PO, days 1-4<br><strong>Thalidomide:</strong> 400 mg/day PO at night.<br><strong>Cisplatin:</strong> 10 mg/m2/day CIVI, days 1-4<br><strong>Doxorubicin:</strong> 10 mg/m2/day CIVI, days 1-4<br><strong>Etoposide:</strong> 40 mg/m2/day CIVI, days 1-4</p><p>Repeat cycle every 4 to 6 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (288, 'Bortezomib : Velcade<br>Dexamethasone : various<br>Lenalidomide : Revlimid', 'RVD', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>No dose reduction.</li><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin&nbsp;1-1.5 times upper normal limit: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin&nbsp;&gt;1.5 times upper normal limit: Reduce the initial dose to 0.7 mg/m2.</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>If CrCl &gt;60 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 30 to 60 mL/min: 5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min not requiring dialysis: 2.5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min requiring dialysis: 2.5 mg once daily (administer after dialysis on dialysis days).</li><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'Low', '<b>RVD</b>', 'Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. $Blood. 2010;116(5):679-686.$', null, '<p><strong>Lenalidomide:</strong> 25 mg/day PO, days 1-14<br><strong>Bortezomib:</strong> 1.3 mg/m2 IV or SC, days 1, 4, 8, 11<br><strong>Dexamethasone:</strong> 20 mg/day PO days 1, 2, 4, 5, 8, 9, 11, 12 (cycles 1-4)<br>Repeat every 21 days for 8 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (911, null, 'Darolutamide', '<p><strong>Hepatic impairment</strong></p><ul><li><strong>Darolutamide: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If mild impairment (Child-Pugh class A): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (Child-Pugh class B): Reduce the dose to 300 mg twice daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (Child-Pugh class C): Dosage adjustments not provided by the manufacturer.</li></ul><p><strong>Renal impairment</strong></p><ul><li><strong>Darolutamide: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 30 to 89 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 15 to 29 mL/min (not receiving hemodialysis): Reduce the dose to 300 mg twice daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;15 mL/min: Dosage adjustments not provided by the manufacturer.</li></ul>', 'N/A', null, null, null, '<p><strong>Darolutamide: </strong>600 mg PO bid</p><p>Continue until disease progression or unacceptable toxicity.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (912, null, 'Prednisone', '<p><strong>Hepatic impairment</strong></p><ul><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal impairment</strong></p><ul><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Prednisone: </strong>5 mg PO bid.<br><strong>OR</strong><br><strong>Prednisone:</strong> 5 mg PO qid.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (293, 'Thalidomide : Thalomid', 'Thalidomide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Thalidomide:</strong>&nbsp;<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Thalidomide:</strong>&nbsp;<br>No dose reduction</li></ul>', 'Low', '<b>Thalidomide</b>', 'Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. $N Engl J Med. 1999;341(21):1565-1571.$ $ Erratum in N Engl J Med. 2000;342(5):364.$', null, '<p><strong>Thalidomide:</strong> 200 mg PO daily at bedtime (increased dose every 2 weeks for 6 weeks up to a dose of 800 mg/day)</p><p>Continue treatment until disease progression or unacceptable toxicity.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (296, 'Cisplatin : CDDP<br>Etoposide : VP-16', 'CDDP/VP-16', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>CDDP/VP-16</b>', 'Kovnar EH, Kellie SJ, Horowitz ME, et al. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study. $J Clin Oncol. 1990;8(2):330-336.$', null, '<b>Cisplatin</b> 90 mg/m<sup>2</sup> IV, day 1<br> <b>Etoposide</b> 150 mg/m<sup>2</sup>/d IV, days 3, 4<br> Repeat every 21 days for 4 courses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (362, 'Keytruda', 'Pembrolizumab', '', 'Minimal', '<b>Pembrolizumab</b>', 'Robert C, Schachter J, Long GV, et al.  Pembrolizumab versus Ipilumimab in Advanced Melanoma. $N Engl J Med 2015; 372:2521-2532. $', null, '<b>Pembrolizumab</b> 2 mg /kg IV<br> Every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (292, 'Dexamethasone : various', 'Dexamethasone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'Low', '<b>Dexamethasone</b>', 'Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. $Blood. 1992;80(4):887-890.$', null, '<p><strong>Dexamethasone:</strong> 40 mg IV or PO on days 1-4, 9-12, 17-20.<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (306, 'Carboplatin : Paraplatin<br>Etoposide : VP-16<br>Vincristine : Oncovin, VCR', 'Chemoreduction', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin:</strong><br>Dosing based on AUC</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'High', '<b>Chemoreduction</b>', 'Sussman DA, Escalona-Benz E, Benz MS, et al. Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy. $Arch Ophthalmol. 2003;121(7):979-984.$', null, '<p><strong>Vincristine:</strong> 0.05 mg/kg (for age &lt;12 months)<br><strong>OR</strong> 1.5-2 mg/m2 (for age &gt;12 months)<br><strong>Carboplatin:</strong> 20 mg/kg (for age &lt;12 months)<br><strong>OR </strong>550-600 mg/m2<strong> </strong>(for age &gt;12 months)<br><strong>Etoposide phosphate: </strong>5 mg/kg (for age &lt;12 months) or 150 mg/m2 (for age &gt;12 months)</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (913, null, 'Ketoconazole', '<p><strong>Hepatic impairment</strong></p><ul><li><strong>Ketoconazole: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Use is contraindicated in acute or chronic liver disease.</li></ul><p><strong>Renal impairment</strong></p><ul><li><strong>Ketoconazole: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'N/A', null, null, null, '<p><strong>Ketoconazole:</strong> 1,200 mg PO daily.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (328, '', '6-MP/ MTX', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Moderate', '<b>6-MP/ MTX</b>', 'Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. $Blood. 2000;95(11):3310-3322.$', null, '<b>Mercaptopurine</b> 25 mg/m<sup>2</sup>/d PO, days 1-56<br> <b>Methotrexate</b> 5,000 mg/m<sup>2</sup> IV over 24 hours, days 8, 22, 36, 50<br> <b>Methotrexate</b> 12 mg/d IT (adjust dose for children<3 years), days 8, 22, 36, 50', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (343, 'Keytruda', 'Pembrolizumab', '', 'Minimal', '<b>Pembrolizumab</b>', 'Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small cell lung cancer. $N Engl J Med 2015; 372:2018-2028.$', null, '<b>Pembrolizumab</b> 2 mg /kg IV<br> Every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (344, 'Imbruvica', 'ibrutinib', '', 'Minimal', '<b>ibrutinib</b>', 'Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.$N Engl J Med. 2013 Aug 8;369(6):507-16.$', null, '<b>Ibrutinib</b> 560 mg PO daily (for Mantle Cell Lymphoma)<br>420 mg PO daily for Waldenstrom''s <br> ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (345, 'Gilotrif', 'Afatinib', '', 'Minimal', '<b>Afatinib</b>', 'Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.$J Clin Oncol. 2013 Sep 20;31(27):3327-34.$', null, '<b>Afatinib</b> 40 mg PO daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (951, null, 'Vorinostat (Peripheral T-cell lymphoma)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vorinostat:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild to moderate impairment (total bilirubin 1 to 3 times ULN or AST &gt; ULN): Reduce dose to 300 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (total bilirubin &gt;3 times ULN): &nbsp;Dosage adjustments not provided in the manufacturer''s labeling.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vorinostat:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Vorinostat:</strong> 400 mg PO daily with food.</p><p>Continue treatment until disease progression or unacceptable toxicity. If toxicity is observed, the dose may be decreased to 300 mg PO daily.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (297, 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Etoposide : VP-16<br>Vincristine : Oncovin, VCR', 'COPE or "Baby Brain I"', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'High', '<b>COPE or "Baby Brain I"</b>', 'Duffner id, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than 3 years of age with malignant brain tumors. $N Engl J Med. 1993;328(24):1725-1731.', null, '<p>CYCLE A<br><strong>Vincristine:</strong> 0.065 mg/kg/day (maximum, 1.5 mg) IV, days 1, 8<br><strong>Cyclophosphamide:</strong> 65 mg/kg/d IV over 30 minutes, day 1</p><p><br>CYCLE B<br><strong>Cisplatin:</strong> 4 mg/kg/d IV over 6 hours, day 1<br><strong>Etoposide:</strong> 6.5 mg/kg/d IV over 1 hour, days 3, 4</p><p><br>Regimens given in alternating 28-day cycles in the sequence AABAAB</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1162, null, 'Bendamustine + Rituximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin&nbsp;1.5-3 upper normal limit, or bilirubin &gt; 3 upper normal limit: Do not use</li><li><strong>Rituximab:</strong><br>Dose modification not provided by the manufacturer</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If CrCl &lt; 30 mL/min: Do not use</li><li><strong>Rituximab:</strong><br>Dose modification not provided by the manufacturer</li></ul>', 'Moderate', null, null, null, '<p><strong>Bendamustine:</strong> 90 mg/m2 IV on days 1 and 2<br><strong>Rituximab:</strong> 375 mg/m2 IV on day 1<br>Repeat cycle every 28 days for 4 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (914, null, 'Sipuleucel-T', '<p><strong>Hepatic impairment</strong></p><ul><li><strong>Sipuleucel-T:</strong>&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustments not provided by the manufacturer. &nbsp;</li></ul><p><strong>Renal impairment</strong></p><ul><li><strong>Sipuleucel-T:</strong>&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dosage adjustments not provided by the manufacturer. &nbsp;</li></ul>', 'N/A', null, null, null, '<p><strong>Sipuleucel-T:</strong> Administer contents of infusion bag IV over 60 minutes on day 1<br>Repeat cycle every 2 weeks for a total of 3 doses.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (307, 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various', 'CD', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'High', '<b>CD</b>', 'Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach- results of the first prospective study of the International Society of Pediatric Oncology. $J Clin Oncol. 2000;18(22):3819-3828.$', null, '<b>Cisplatin</b> 80 mg/m<sup>2</sup> CI over 24 hours (>1 year of age) <b>OR</b> 3 mg/kg (<1 year of age) IV over 6 hours with post-hydration fluid<br> <br>Doxorubicin</b> 30 mg/m<sup>2</sup>/d CIVI over 48 hours, days 2, 3<br> Administer 4 cycles before surgery, 2 cycles after surgery', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (654, '', '5-Fluorouracil + Cisplatin', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Renal Impairment:&nbsp;</strong> &nbsp; &nbsp;</li><li><strong>5-Fluorouracil</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li></ul>', 'High', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5</p>

<p><strong>Cisplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle on weeks 1, 5, 8, and 11.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (650, '', '5-Fluorouracil + Cisplatin + Radiation Therapy (FFD French regimen)', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Renal Impairment:&nbsp;</strong></li><li><strong>5-Fluorouracil</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', ' High', '', '', 'NEOADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>800 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5</p>

<p><strong>Cisplatin:&nbsp;</strong>15 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p><strong>Radiation Therapy:&nbsp;</strong>200 cGy/day for 5 days per week to a total dose of 6,600 cGy over 6.5 weeks</p>

<p>Chemotherapy is given concurrently with radiation therapy for 2 cycles starting on days 1 and 22, followed by surgical resection.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (651, '', '5-Fluorouracil + Cisplatin + Radiation Therapy (Hopkins/Yale regimen)', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Paclitaxel</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Renal Impairment:&nbsp;</strong></li><li><strong>5-Fluorouracil</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li></ul>', 'High', '', '', '', '<p><strong>5-Fluorouracil:</strong>&nbsp;225 mg/m<sup>2</sup>/day IV continuous infusion on days 1-30</p>

<p><strong>Cisplatin:&nbsp;</strong>20 mg/m<sup>2</sup>/day IV on days 1-5 and 26-30</p>

<p><strong>Radiation Therapy:&nbsp;</strong>200 cGy/day to a total dose of 4,400 cGy</p>

<p>Chemotherapy is given concurrently with radiation therapy. Followed by esophagectomy and then adjuvant chemotherapy in patients who had total gross removal of disease with negative margins.</p>

<p><strong>Adjuvant Chemotherapy:</strong></p>

<p><strong>Paclitaxel:&nbsp;</strong>135 mg/m<sup>2</sup>&nbsp;IV for 24 hours on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;IV on day 2</p>

<p>Adjuvant chemotherapy is given 8-12 weeks after esophagectomy, and each cycle is given every 21 days for a total of 3 cycles.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (915, null, 'Enzalutamide', '<p><strong>Hepatic impairment</strong></p><ul><li><strong>Enzalutamide: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal impairment</strong></p><ul><li><strong>Enzalutamide: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If CrCl 30 to 89 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Dosage adjustments not provided by the manufacturer.</li></ul>', 'N/A', null, null, null, '<p><strong>Enzalutamide:</strong> 160 mg PO daily&nbsp;</p><p>Continue until disease progression or unacceptable toxicity.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (309, 'Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various', 'IFoVP', '<b>Hepatic Impairment</b><ul><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>IFoVP</b>', 'Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. $J Clin Oncol. 1987;5(8):1191-1198.$', null, '<b>Ifosfamide</b> 1,800 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV over 1 hour, days 1-5<br> <b>Mesna</b> 2,880 mg/m<sup>2</sup>/d IV, days 1-5<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (346, 'Iressa', 'Gefitinib', '', 'Minimal', '<b>Gefitinib</b>', 'Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. $N Engl J Med. 2010 Jun 24;362(25):2380-8.$', null, '<b>Gefitinib</b> 250 mg PO daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1053, null, 'Ibrutinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ibrutinib:</strong> &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (Child-Pugh class A): Decrease dose to 140 mg PO daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If moderate impairment (Child-Pugh class B): Decrease dose to 70 mg PO daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (Child-Pugh class C): Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ibrutinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Dosage adjustment not provided by the manufacturer.</li></ul>', 'Low', null, null, null, '<p><strong>Ibrutinib:</strong> 560 mg PO daily<br>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (359, 'Ipilumimab:Yeroy<br> Nivolumab:Opdivo', 'Ipilumimab/Nivolumab', '', 'Minimal', '<b>Ipilumimab/Nivolumab</b>', 'Postow, MA, Chesney J, Pavlick AC, et al. Nivolumab and Ipilumimab versus Ipilumimab in untreated melanoma. $N Engl J Med. 2015 May 21;372(21):2006-17. $', null, '<b>Ipilumimab</b> 3mg/kg  IV <br> Nivolumab </b> 1 mg/kg IV<br> every 3 weeks  x 4 cycles <br> followed by Nivolumab 3 mg/kg  every 3 weeks until disease progression on unaccceptable toxicity', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (329, '', 'MTX/6-MP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 5 mg/dL: Do not use</li><li><strong>6-Mercaptopurine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min: 50% of normal dosage.<br>If CrCl &lt; 30 mL/min: Do not use</li><li><strong>6-Mercaptopurine:</strong><br>No dose reduction</li></ul>', 'Low', '<b>MTX/6-MP</b>', 'Camitta B, Leventhal B, Lauer S, et al. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of chldhood: a Pediatric Oncology Group study. $J Clin Oncol. 1989;7(10):1539-1544.$', null, '<p><strong>Methotrexate:</strong> 20 mg/m2 IM weekly, weeks 25-130<br><strong>Mercaptopurine:</strong> 50 mg/m2/day PO, weeks 25-130</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (311, 'Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various', 'VP/high-dose Ifos', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Ifosfamide:</strong><br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Ifosfamide</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥10 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose by 25%</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul>', 'High', '<b>VP/high-dose Ifos</b>', 'Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. $J Clin Oncol. 2002;20(2):426-433.', null, '<p><strong>Etoposide:</strong> 100 mg/m2 days 1-5<br><strong>Ifosfamide:</strong> 3,500 mg/m2 days 1-5<br><strong>Mesna:</strong> 700 mg/m2 over 4 hours, then mesna 700 mg/m2 at hour 4, 7, 10, 13, days 1-5<br><strong>GCF:</strong> 5 mcg/kg/day begin day 6<br>Repeat cycle every 3 weeks for a total of 2 courses.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1054, null, 'Venetoclax', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Venetoclax:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If mild to moderate impairment (Child-Pugh classes A and B): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): Reduce dose by 50%.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Venetoclax: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If<strong>&nbsp;</strong>CrCl ≥15 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If<strong>&nbsp;</strong>CrCl &lt;15 mL/min: Dosage adjustment not provided by the manufacturer.</li></ul>', 'Low', null, null, null, '<p><strong>Venetoclax:</strong> 20 mg/day PO on days 1-7<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 50 mg/day PO on days 8-14<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 100 mg/day PO on days 15-21<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 200 mg/day PO on days 22-28 and<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; then 400 mg/day PO daily<br>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1055, null, 'Duvelisib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Duvelisib:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Duvelisib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If<strong> </strong>CrCl 23 to 80 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling; however, this level of renal impairment had no clinically significant effect on duvelisib exposure.</li></ul><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;23 mL/minute: &nbsp;Dosage adjustment not provided by the manufacturer.</p>', 'Low', null, null, null, '<p><strong>Duvelisib: </strong>25 mg P0 bid<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (321, 'Dexamethasone : various<br>Prednisone : various<br>Vincristine : Oncovin, VCR', 'VCR/Asparaginase/Dex/MTX', '<b>Hepatic Impairment</b><ul><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate for MTX agent IT, minimal for others', '<b>VCR/Asparaginase/Dex/MTX</b>', 'Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children''s Cancer Group. $Blood 2003;101(10):3809-3817.$', null, '<b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, days 0,7, 14, 21<br> <b>Asparaginase</b> 6,000 units/m<sup>2</sup> IM, 3 times weekly for 9 doses, starting on days 2-4<br> <b>Dexamethasone</b> 6 mg/m<sup>2</sup>/d PO in 3 equal doses (was substituted for prednisone)<br> <b>Methotrexate</b> 8, 10, or 12 mg IT, age-adjusted, days 0, 14 (also days 7, 21 for patients with CNS disease at diagnosis)<br> <b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1163, null, 'Dexamethasone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Dexamethasone:</strong> 40 mg IV or PO on days 1-4, 9-12, and 17-20.<br>Repeat cycle every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (316, 'Cyclophosphamide : Cytoxan<br>Dactinomycin : Actinomycin<br>Vincristine : Oncovin, VCR', 'VAC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Dactinomycin:</strong><br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Dactinomycin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'High', '<b>VAC</b>', 'Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. $J Clin Oncol. 2001;19(12):3091-3102.$', null, '<p><strong>Vincristine:</strong> 1.5 mg/m2 ( max 2 mg) IV weekly for 3 weeks<br><strong>Dactinomycin:</strong> 0.015 mg/kg/d (maximum, 0.5 mg/kg/day) IV for 5 days<br><strong>Cyclophosphamide:</strong> 2,200 mg/m2 IV, day 1</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (313, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR', 'VCR/Cyclophosphamide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'High', '<b>VCR/Cyclophosphamide</b>', 'Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing''s sarcoma and primitive neuroectodermal tumor of bone. $N Engl J Med. 2003;348(8):694-701.$', null, '<p><strong>Vincristine:</strong> 2 mg/m2 IV, day 1<br><strong>Doxorubicin:</strong> 75 mg/m2 IV bolus, day 1<br><strong>Cyclophosphamide:</strong> 1,200 mg/m2 IV, day 1<br>Repeat every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (317, 'Bleomycin : Blenoxane<br>Dacarbazine : DTIC<br>Doxorubicin : Adriamycin, various<br>Vinblastine : Velban', 'ABVD', '<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Dacarbazine:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Dacarbazine:<br>If CrCl 10-50 mL/min, reduce dose by 25%    <br>                                                                  If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vinblastine:<br>No dose reduction </li></ul>', 'High', '<b>ABVD</b>', 'Fryer CJ, Hutchinson RJ, Krailo M, et al. Efficacy and toxicity of 12 courses of ABVD therapy followed by low-dose regional radiation in advanced Hodgkin''s disease in children: a report from the Children''s Cancer Study Group. $J Clin Oncol. 1990;8(12):1971-1980.$', null, '<b>Doxorubicin</b> 25 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Bleomycin</b> 10 units/m<sup>2</sup>/d IV, days 1, 15<br> <b>Vinblastine</b> 6 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Dacarbazine</b> 375 mg/m<sup>2</sup>/d IV, days 1, 15<br> Repeat every 14 days for 12 courses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (419, 'Cisplatin: Platinol
Etoposide: Vepesid
Durvalumab: Imfinzi', 'Cisplatin + Etoposide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: &nbsp;Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min: Reduce dose by 25%<br>If CrCl &lt; 10 mL/min: Reduce dose by 50%</li></ul>', 'High', '', 'Marcello I., Boni L., Ambrosio F. et al. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. Journal of Clinical Oncology 2017 35:12, 1281-1287.

Sundstrom, S., Bremnes RM., Kaasa, S., et al. Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up. Journal of Clinical Oncology 2002 20:24, 4665-4672.

Niell, H.B., Herndon II, J.E, Miller, A.A., et al. Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732. Journal of Clinical Oncology 2005 23:16, 3752-3759.

Ihde D.C., Mulshine J.L., Kramer, B.S., et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.Journal of Clinical Oncology 1994 12:10, 2022-2034.', '', '<p><strong>Cisplatin:</strong> 80&nbsp;mg/m2&nbsp;IV on day 1<br><strong>Etoposide</strong> 80&nbsp;mg/m2&nbsp;IV on days 1, 2, 3</p><p>Repeat cycle every 21 days.</p>', 105);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (952, null, 'Romidepsin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Romidepsin:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;1 to 1.5 times ULN: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;1.5 to 3 times ULN: Reduce initial dose to 7 mg/m2. &nbsp; If bilirubin &gt;3 times ULN: Reduce initial dose to 5 mg/m2</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Romidepsin:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Romidepsin:</strong> 14mg/m2 IV on days 1, 8, and 15.<br>Repeat every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (355, 'Opdivo', 'Nivolumab', '', 'Minimal', '<b>Nivolumab</b>', 'Motzer RJ, Escudier B, McDermott DF, et al.  Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma. $N Engl J Med. 2015 Nov 5;373(19):1803-13. $', null, '<b>Nivolumab</b> 3 mg/kg IV<br> Repeat Every 14 Days<br> Until disease progression or Unacceptable toxicity', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (356, 'Inlyta', 'Axitinib', '', 'Minimal', '<b>Axitinib</b>', 'Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus Sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial. $Lancet Oncol. 2013 May;14(6):552-62. $', null, '<b>Axitinib <br>5 mg po BID', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (319, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Prednisone : various<br>Vincristine : Oncovin, VCR', 'CHOP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Moderate', '<b>CHOP</b>', 'Link MP, Donaldson SS, Berard CW, Shuster JJ, Murphy JB. Results of treatment of childhood localized non-Hodgkin''s lymphoma with combination chemotherapy with or without radiotherapy. $N Engl J Med. 1990;322(17):1169-1174.$', null, '<p><strong>Cyclophosphamide:</strong> 750 mg/m2/day IV, days 1, 22<br><strong>Doxorubicin:</strong> 40 mg/m2/day IV, days 1, 22<br><strong>Vincristine:</strong> 1.5 mg/m2 IV weekly for 6 doses<br><strong>Prednisone:</strong> 40 mg/m2/day PO for 28 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (5, 'Bevacizumab : Avastin', 'Bevacizumab', '<p><strong>Hepatic Impairment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Bevacizumab:</strong>&nbsp;No dose reduction.</p><p><strong>Renal Impairment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Bevacizumab:</strong>&nbsp;No dose reduction.</p>', 'Low', '<b>Bevacizumab</b>', 'Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab plus irinotecan at tumor progression in recuurent glioblastoma. $J Clin Oncol. 2009;27(5):740-745.$                                                           Raizer JJ, Grimm S, et al. Aphase 2 trial of single-agent bevacizumab plus irinotecan at tumor progression in recurrent high- grade schedule for patients with recurrent high- grade gliomas. $Cancer.2010;116(22):597-5305.$', null, '<p><strong>Bevacizumab:</strong> 15 mg/kg IV on day 1.<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1056, null, 'Topotecan + Cisplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Topotecan</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Topotecan</strong>:<br>If CrCl &gt; 40 mL/min, no dose reduction<br>If CrCl 20-39 mL/min, reduce to 0.75 mg/m2/dose</li></ul>', 'High', null, null, null, '<p><strong>Topotecan: </strong>1.7 mg/m2/day PO on days 1-5<br><strong>Cisplatin: </strong>60 mg/m2 IV on day 5<br><br>Repeat cycle every 21 days up to 4 cycles or 2 cycles beyond best response.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (953, null, 'Rituximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Rituximab:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Rituximab:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Rituximab:</strong> 375 mg/m2 IV on days 1, 8, 15, and 22.<br>Repeat one additional cycle.<br><br><strong>OR</strong></p><p><strong>Rituximab:</strong> 375 mg/m2 IV on days 1, 8, 15, and 22 followed by 375 mg/m2 IV at week 12 and at months 5, 7, and 9.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (324, 'Dexamethasone : various<br>Vincristine : Oncovin, VCR', 'OD', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL: Reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL: Do not use</li><li><strong>Dexamethasone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>L-Asparaginase: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Do not use in patients with severe hepatic impairment.</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL: Reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL: Do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Dexamethasone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>L-Asparaginase:</strong><br>No dose reduction</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min: Reduce dose by 50%<br>If CrCl &lt; 30 mL/min: Do not use</li></ul>', 'Moderate', '<b>OD</b>', 'Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children''s Cancer Group. $Blood 2003;101(10):3809-3817.$', null, '<p><strong>Dexamethasone:</strong> 6 mg/m2/d PO, days 1-28<br><strong>Asparaginase:</strong> 6,000 units/m2 IM, 3 times weekly for 9 doses<br><strong>Vincristine:</strong> 1.5 mg/m2 IV, days 0, 7, 14, 21<br><strong>Methotrexate:</strong> 8-12 mg IT, age-adjusted dosing schedule</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (325, '', 'PVDA', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Daunorubicin:</strong><br>If bilirubin 1.2-3 mg/dL: 75% of usual dosage.<br>If bilirubin 3.1-5 mg/dL: 50% of usual dosage.<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL: 50% of usual dosage.<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL: Do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>L-Asparaginase: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Do not use in patients with severe hepatic impairment.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Daunorubicin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>L-Asparaginase:</strong><br>No dose reduction</li></ul>', 'Moderate', '<b>PVDA</b>', 'Lauer SJ, Camitta BM, Leventhal BG, et al. Intensive alternating drug pairs for treatment of hgh-risk chidhood acute lymphoblastic leukemia. Apediatric Oncology Group pilot study. $Cancer. 1993;71(9):2854-2861.$', null, '<p><strong>Prednisone:</strong> 40 mg/m2/day PO, days 1-28<br><strong>Vincristine:</strong> 1.5 mg/m2/day IV, days 2, 8, 15, 22<br><strong>Daunorubicin:</strong> 25 mg/m2/day IV, days 2, 8, 15, 22<br><strong>Asparaginase:</strong> 5,000 units/m2/day IM, days 2, 5, 8, 12, 15, 19</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (332, 'Cytarabine : Ara-C<br>Thioguanine : 6-TG', 'DAT', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Daunorubicin:</strong><br>If bilirubin 1.2-3 mg/dL: 75% of usual dosage.<br>If bilirubin 3.1-5 mg/dL: 50% of usual dosage.<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 3 mg/dL: 50% of usual dosage.</li><li><strong>6-Thioguanine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Daunorubicin:</strong><br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>6-Thioguanine:</strong><br>No dose reduction</li></ul>', 'Moderate', '<b>DAT</b>', 'Ravindranath Y, Steuber CP, Krischer J, et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. $J Clin Oncol. 1991;9(4):572-580.$', null, '<p><strong>Daunorubicin:</strong> 45 mg/m2/day IV, days 1-3<br><strong>Cytarabine:</strong> 100 mg/m2/day IV, days 1-7<br><strong>Thioguanine:</strong> 100 mg/m2/day PO, days 1-7</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1057, null, 'Carboplatin + Paclitaxel + Etoposide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Paclitaxel:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on&nbsp;<strong>mg/m2</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Paclitaxel:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', null, null, null, '<p><strong>Carboplatin:</strong> AUC of 6, IV on day 1<br><strong>Paclitaxel:</strong> 200 mg/m2 IV over 1 hour on day 1<br><strong>Etoposide:</strong> 50 mg alternating with 100 mg PO on days 1-10<br><br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1058, null, 'Carboplatin + Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Carboplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li><li><strong>Carboplatin</strong>:<br>Dosing based on&nbsp;<strong>mg/m2</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li></ul>', 'Moderate', null, null, null, '<p><strong>Carboplatin:</strong> AUC of 2, IV on days 1, 8, and 15<br><strong>Paclitaxel:</strong> 80 mg/m2 IV on days 1, 8, and 15<br><br>Repeat cycle every 28 days for 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (337, 'Opdivo', 'Nivolumab', '', 'Minimal', '<b>Nivolumab</b>', 'Rizvi, NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. $Lancet Oncol. 2015 Mar;16(3):257-65.$', null, '<b>Nivolumab</b> 3 mg/kg IV<br> Repeat Every 14 Days<br> Until disease progression or Unacceptable toxicity', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (338, 'Docetaxel:Taxotere<br> Ramicurimab:Cyramza', 'Docetaxel/Ramucirumab', '', 'Moderate', '<b>Docetaxel/Ramucirumab</b>', 'Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. $Lancet. 2014 Aug 23;384(9944):665-73.$', null, '<b>Docetaxel</b>75 mg/m <sup>2</sup>IV<br> Repeat Every 21 Days<br> <b>Ramucirumab</b> 10 mg/kg IV  <br> Repeat Every 21 days<br>Until disease pogression or Unacceptable toxicity', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (339, 'Alecensa', 'Alectinib', '', 'Minimal', '<b>Alectinib</b>', 'Ou SI, Ahn Js, Petris LD, et al. Alectinib in Crizotinib refractory ALK-rearranged non-small cell lung cancer: A phase II global study. $ J Clin Oncol. 2015 Nov 23. pii: JCO639443. $', null, '<b>Alectinib</b> 600 mg PO BID<br>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (340, 'Zykadia', 'Ceritinib', '', 'Minimal', '<b>Ceritinib</b>', 'Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. $N Engl J Med. 2014 Mar 27;370(13):1189-97.$', null, '<b>Ceritinib</b> 750 mg  PO daily<br> ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (341, 'Necitumumab:Portrazza<br> Gemcitabine:Gemzar<br> Cisplatin<br>Various', 'Necitumumab/Gemcitabine/Cisplatin', '', 'Severe', '<b>Necitumumab<br>Gemcitabine<br>Cisplatin</b>', 'Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first line therapy in patients with stage IV sqaumous non-small cell lung cancer (SQUIRE): an open label, randomised, controlled phase 3 trial. $Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1.$', null, '<b>Necitumumab</b> 800 mg IV Day 1 and 8<br><b>Gemcitabine</b>1250 mg/m <sup>2</sup> IV<br><b>Cisplatin</b> 75 mg/m<sup>2</sup>IV<br>Repeat every 21 days<br>Continue Necitumumab until disease progression or intolerable toxicity', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (348, 'Adcetris', 'Brentuximab Vedotin', '', 'Minimal', '<b>Brentuximab Vedotin</b>', 'Moscowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin''s lymphoma at risk of relapse or progression: a randomised, double-blind, placebo-controlled, phase 3 trial. $Lancet. 2015 May 9;385(9980):1853-62. $', null, '<b>Bretuximab Vedotin</b> 1.8 mg/ kg<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (349, 'Idelalisib:Zydelig<br> Rituximab:Rituxan', 'Idelalisib/Rituximab', '', 'Minimal', '<b>Idelalisib/Rituximab</b>', 'Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. $N Engl J Med. 2014 Mar 13;370(11):997-1007.$', null, '<b>Idelalisib</b> 150 mg  po BID <br> Rituximab 375 mg/m<sup>2</sup> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (350, 'Imbruvica', 'Ibrutinib', '', 'Minimal', '<b>Ibrutinib</b>', 'Byrd JC, Brown JR, O''brien S .Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.$N Engl J Med. 2014 Jul 17;371(3):213-23.$', null, '<b>Ibrutinib</b> 420 mg PO daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (351, 'Ofatumumab:Arzerra<br> Chlorambucil:Various', 'Ofatumumab/Chlorambucil', '', 'Minimal', '<b>Ofatumumab<br>Chlorambucil</b>', 'Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukemia  (Complimet1 (: A rondomised, multicentre, open-label phase 3 trial. $Lancet. 2015 May 9;385(9980):1873-83. $', null, '<b>Ofatumumab</b> 300mg IV on Day 1 and 1000 mg on day 8, Cycle 1. Subsequent cycles 1000 mg IV on Day 1 only <br><b>Chlorambucil</b> PO 10 mg/m<sup>2</sup>, day 1 to 7. Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (352, 'Blincyto', 'Blinatumomab', '', 'Minimal', '<b>Blinatumomab</b>', '', null, '<b>Blinatumomab</b> 9  mcg/day on days 1-7, 28 mcg/day on days 8-28 of the first 42 day cycle<br>28 mcg/day on day1-28 in later cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (353, 'Ixazomib:Ninlaro<br> Lenalidamide:Revlimid<br> Dexamethasone:Decadron', 'Ixazomib/Lenolidamide/Dexamethasone', '', 'Moderate', '<b>Ixazomib/Lenolidamide/Dexamethasone</b>', 'Kumar SK, Berdeja JG, Niesvizky, R. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously unreated multiple myeloma . $Lancet Oncol. 2014 Dec;15(13):1503-12. $', null, '<b>Ixazomib</b> 4 mg PO  on days 1,8,15<br> <br> <b>Lenalidomide</b> 25mg PO on day 1 thru 21<br> <b>Dexamethasone</b> 40 mg PO, days 1,8,15,22<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (354, 'Darzalex', 'Daratumumab', '', 'Minimal ', '<b>Daratumumab</b>', 'Lokhorst HM, Plesner T, Laubach JP, et al Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. $N Engl J Med. 2015 Sep 24;373(13):1207-19.$', null, '<b>Daratumumab</b> 16 mg/kg  every 7 days x 8 weeks <br> every 14 days x 16 weeks<br>then every 4 weeks until disease progression', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (363, 'Elotuzumab:Empliciti<br> Lenalidomide:Revlimid<br> Dexamethasone:Decadron, various', 'Elotuzumab/Lenalidomide/Dexamethasone', '', 'Minimal', '<b>Elotuzumab<br>Lenalidomide<br>Dexamethasone</b>', 'Lonial S, Dimopoulous M, Palumbo A, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma .$ N Engl J Med. 2015 Aug 13;373(7):621-31. $', null, '<b>Elotuzumab</b> 10 mg/Kg IV  Weekly x2 and then Every 2 weeks<br> <b>Lenalidomide</b> 25 mg po daily  from day 1-21 (3 weeks)<br> <b>Dexamethasone </b> 8 mg IV prior to Elotuzumab infusion and then 28 mg orally, In weeks without Elotuzumab  40 mg PO every week', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (364, 'Lonsurf', 'Trifluridine/Tipiracil', '', 'Minimal', '<b>Trifluridine/Tipiracil</b>', 'Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer.$ N Engl J Med. 2015 May 14;372(20):1909-19..$Lancet Oncol. 2014 Oct;15(11):1195-206. $', null, '<b>Trifluridine/Tipiracil</b>  35  mg/m<sup>2</sup>  PO twice daily days 1 through 5 and 8 through 12<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (365, 'Ramucirumab:Cyramza', 'Ramicirumab/FOLFIRI', '', 'Moderate', '<b>Ramicirumab/FOLFIRI</b>', 'Tabernero J, Yoshino T, Cohn Al, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. $ Lancet Oncol. 2015 May;16(5):499-508. $', null, '<b>Ramicirumab</b> 8 mg/kg IV <br> <b>Irinotecan  </b> 180 mg/m<sup>2</sup>  over 90 minutes <br> <b>Leucovorin</b> Calcium 400 mg/m<sup>2</sup> IV<br>FOLLOWED BY<br><b>Fluorouracil</b> 400 mg<sup>2</sup> IV<br> <b>Fluorouracil</b> 2,400 mg<sup>2</sup>  CIVI over 46 hours<br>Repeat every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (960, null, 'Belinostat (Peripheral T-cell lymphoma)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Belinostat:</strong><br>Dosage adjustments have not been studied yet.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Belinostat:</strong><br>Dosage adjustments have not been studied yet.</li></ul>', 'Low', null, null, null, '<p><strong>Belinostat:</strong> 1,000 mg/m2 IV on days 1-5<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (366, 'Ramucirumab:Cyramza<br> Paclitaxel:Taxol', 'Ramucirumab/Paclitaxel', '', 'Moderate', '<b>Ramucirumab/Paclitaxel</b>', 'Wilke H, Muro K, Van Custem E, et al. Ramucirumab plus paclitaxel versus placebo plus palcitaxel in patients with previously treated advanced gastric or gastro-esophageal junction adenocarcinoma I RAINBOW): a double-blind, randomised phase 3 trial. $Lancet Oncol. 2014 Oct;15(11):1224-35. $', null, '<b>Ramucirumab</b> 8 mg/kg IV  on days 1 and 15<br>  <b>Paclitaxel</b> 80 mg/m<sup>2</sup>  IV on days 1, 8, 15<br>Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (367, 'Cyramza', 'Ramucirumab', '', 'Minimal', '<b>Ramucirumab</b>', 'Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-esophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. $ Lancet. 2014 Jan 4;383(9911):31-9. $', null, '<b>Ramucirumab</b> 8 mg/kg IV  every 2 weeks<br>  ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (368, 'Liposomal Irinotecan:Onivyde', 'Irinotecan liposome/Fluorouracil/Leucovorin', '', 'Moderate', '<b>Irinotecan liposome<br>Fluorouracil<br>Leucovorin</b>', 'Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open label, phase 3 trial. $ Lancet. 2015 Nov 20. pii: S0140-6736(15)00986-1. $', null, '<b>Irinotecan liposome</b> 70 mg/m<sup>2</sup> IV <br> <b>Fluorouracil</b> 2400 mg/m<sup>2</sup>  IV over 46 hours<br> <b>Leucovorin</b> 400mg/m<sup>2</sup> IV <br> Repeat every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (369, 'nab-paclitaxel:Abraxane<br> Gemcitabine:Gemzar', 'nab-Paclitaxel/Gemcitabine', '', 'Moderate', '<b>nab-Paclitaxel/Gemcitabine</b>', 'Von Hoff DD, Ervin T, Arena FP, et al. Incrased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. $ N Engl J Med. 2013 Oct 31;369(18):1691-703. $', null, '<b>nab-Paclitaxel</b> 125 mg/m<sup>2</sup> IV<br> <br> <b>Gemcitabine</b>  1000 mg/m<sup>2</sup>  days 1, 8, 15<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (370, 'Pablociclib:Ibrance<br> Letrozole:Femara', 'Pablociclib/Letrozole', '', 'Minimal', '<b>Pablociclib/Letrozole</b>', 'Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/Trio-18): a randomised phase 2 study. $Lancet Oncol. 2015 Jan;16(1):25-35. $', null, '<b>Pablociclib</b>125 mg PO  on days 1 through 21<br>  <b>Letrozole</b> 2.5 mg PO daily<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (371, 'Everolimus:Afinitor<br> Exemestane:Aromasin', 'Everolimus/Exemestane', '', 'Minimal', '<b>Everolimus/Exemestane</b>', 'Beck JT, Hortobogyi GN, Campone M, et al. Everolimus plus exemestane as first-line therapy in HR +, HER2 - advanced breast cancer in BOLERO-2. $ Breast Cancer Res Treat. 2014 Feb;143(3):459-67. $', null, '<b>Everolimus</b> 10 mg PO daily <br>  <b>Exemestane</b> 25 mg PO daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (372, 'Pertuzumab:Perjeta<br> Trastuzumab:Herceptin<br> Docetaxel:Taxotere', 'Pertuzumab/Trastuzumab/Docetaxel', '', 'Moderate', '<b>Pertuzumab/Trastuzumab/Docetaxel</b>', 'Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. $ N Engl J Med. 2012 Jan 12;366(2):109-19. S', null, '<b>Pertuzuamb</b>840  mg IV loading dose followed by 420 mg <br><b>Docetaxel</b> 75 mg/m<sup>2</sup> IV<br> <b>Trastuzumab</b> 8 mg/kg loading dose followed by 6 mg/kg<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (373, 'Kadcyla', 'ado-trastuzumab', '', 'Minimal', '<b>ado-trastuzumab</b>', 'Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. $ N Engl J Med. 2012 Nov 8;367(19):1783-91. $', null, '<b>ado-trastuzumab</b>3.6 mg/kg IV every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (374, 'Bosulif', 'Bosutinib', '', 'Minimal', '<b>Bosutinib</b>', 'Cortes JE, et al. Bosutinib versus Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.$ J Clin Oncol.2012  October 30;(28):3486-3492. $', null, '<b>Bosutinib</b> 500 mg po daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (375, 'Iclusig', 'Ponatinib', '', 'Minimal', '<b>Ponatinib</b>', 'Cortes JE, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemia.$N Engl J Med.2013 Nov 7;369(19):1783-96. $', null, '<b>Ponatinib</b> 45 mg po daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (376, 'Synribo', 'Omacetaxine', '', 'Minimal', '<b>Omacetaxine</b>', 'Cortes JE, et al. phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phaseCML with T315I mutation.$Blood.2012 Sep;120(13):2573-2580.$', null, '<b>Omacetaxine</b> 1.25 mg<sup>2</sup>  SQ twice daily for 14 days on a 28 day cycle (Induction)<br>1.25 mg<sup>2</sup>  SQ twice daily for 7 days on a 28 day cycle (maintenance)', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (377, 'Obinutuzumab : Gazyva', 'Obinutuzumab/Chlorambucil', '', 'Minimal', '<b>Obinutuzumab/Chlorambucil</b>', 'Goede V, et. al. Obinutuzumab plus chlorambulcil in patients with CLL and coexisting conditions. $N Engl J Med. 2014 Mar 20;370(12):1101-10.$', null, '<b>Obinutuzumab/Chlorambucil</b><br><b>Cycle 1:</b><br>100 mg IV on day 1 and 900 mg IV on day 2, 1,000 mg on day 8 and 15<br><b>Cycle 2-6:</b><br>1,000 mg IV on day 1<br><b>Chlorambucil</b><br>0.5 mg/kg on Day 1 and 15 of each cycle', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (302, 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16', 'A<sub>1</sub>', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', '<b>A<sub>1</sub></b>', 'Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. $J Pediatr Hematol Oncol. 2002;24(8):613-621.$', null, '<b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day 1<br> <b>Doxorubicin</b> 40 mg/m<sup>2</sup> IV, day 3<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Cisplatin</b> 90 mg/m<sup>2</sup> IV, day 5', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (385, 'Nivolumab (Opdivo)', 'Nivolumab monotherapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', '', 'CheckMate 275: Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar;18(3):312-322. Epub 2017 Jan 25.', 'METASTATIC', '<h4>&nbsp;</h4><p><strong>Nivolumab (Opdivo):</strong> 240 mg IV on day 1</p><p>Repeat cycle every 14 days. May also consider administering at 480 mg IV on day 1 with cycles repeated every 28 days.</p>', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1059, null, 'CAV', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Cyclophosphamide:</strong> 1,000 mg/m2 IV on day 1<br><strong>Doxorubicin:</strong> 40 mg/m2 IV on day 1<br><strong>Vincristine:</strong> 1mg/m2 IV on day 1 (maximum, 2 mg)<br>Repeat cycle every 21 days&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1061, null, 'Etoposide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'Low', null, null, null, '<p><strong>Etoposide:</strong> 160 mg/m2 PO on days 1-5<br>Repeat cycle every 28 days.</p><p>OR</p><p><br><strong>Etoposide:</strong> 50 mg/m2/day PO on days 1-21<br>Repeat cycle as tolerated.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (380, 'Gemcitabine (Gemzar), Cisplatin (Platinum) ', 'Gemcitabine and Cisplatin (single-dose cisplatin)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul>', 'High', '', 'Dash A, Pettus JA 4th, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008 Nov 1;113(9):2471-7', 'NEOADJUVANT', '<h4>&nbsp;</h4><p><strong>Cisplatin (Platinol): </strong>75 mg/m2&nbsp;IV on day 1.</p><p><strong>Gemcitabine (Gemzar):</strong>&nbsp;1,000 mg/m2&nbsp;IV once per day on days 1, 8, 15.</p><p>Repeat cycle every 28 days.</p>', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (602, '', 'Oxaliplatin + 5-Fluorouracil + Leucovorin (FOLFOX6)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2&nbsp;</sup>IV continuous infusion for 46 hours</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (334, 'Azacitidine : Vidaza<br>Cytarabine : Ara-C<br>Etoposide : VP-16', 'HI-C DAZE', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Daunorubicin:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Azacitidine:</strong><br>Dosage adjustment not provided by the manufacturer. Use is contraindicated in patients with advanced malignant hepatic tumors.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 40%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 45 mL/minute: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Daunorubicin:</strong><br>If Cr &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Azacitidine: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> No dose reduction.</li></ul>', 'High', '<b>HI-C DAZE</b>', 'Hurwitz CA, Mounce KG, Grier HE. Treatment of patients with acute myelogenous leukemia: review of clinical trials of the past decade. $J Pediatr Hematol Oncol. 1995;17(3):185-197.$', null, '<p><strong>Daunorubicin:</strong> 30 mg/m2/d IV, days 1-3<br><strong>Cytarabine:</strong> 3,000 mg/m2/d IV every 12 hours, days 1-4<br><strong>Etoposide:</strong> 200 mg/m2/d IV, days 1-3, 6-8<br><strong>Azacitidine:</strong> 150 mg/m2/d IV, days 3-5, 8-10</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (335, '', 'MACE (Consolidation)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Amsacrine:</strong><br>If bilirubin &gt;2 mg/dL: Reduce dose by at least 50%.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 40%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 45 mL/minute: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Amsacrine: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If serum creatinine 1.2 to 1.8 mg/dL: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If serum creatinine &gt;2 to 3 mg/dL or oliguric patients: Reduce initial dose by 30% to 40%.</li></ul>', 'Low', '<b>MACE/consolidation</b>', 'Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council''s 10th AML trial. $Br J Haematol. 1998;101(1):130-140.$', null, '<p><strong>Amsacrine:</strong> 100 mg/m2 IV (1-hour infusion), days 1-5<br><strong>Cytarabine:</strong> 200 mg/m2 CIVI, days 1-5<br><strong>Etoposide:</strong> 100 mg/m2 IV (1-hour infusion), days 1-5</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1164, null, 'EP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', null, null, null, '<p><strong>Etoposide:</strong> 100 mg/m2/day IV on days 1-5<br><strong>Cisplatin: </strong>20 mg/m2/day IV on days 1-5<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (387, 'Docetaxel (Taxotere)', '', '<table cellspacing="0">
	<tbody>
		<tr>
			<td><strong>Myelotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Docetaxel should only be administered if the absolute neutrophil count is &gt;1500 cells/microL. Reduce docetaxel to 60 mg/m<sup>2</sup>&nbsp;for subsequent cycles for severe prolonged neutropenia (&lt;500 cells/microL lasting seven days or more), febrile neutropenia, or an infection with life-threatening consequences.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Cutaneous, mucosal, and neurologic toxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>For severe or cumulative cutaneous reactions (erythema, desquamation), grade 3 or 4 stomatitis or &gt;grade 2 neurosensory signs and/or symptoms, reduce docetaxel dose to 60 mg/m<sup>2</sup>&nbsp;Discontinue docetaxel if toxicity persists at the lower dose.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Hepatotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Docetaxel dose reduction may be needed for patients who develop significant alterations in transaminases and alkaline phosphatase during therapy. Docetaxel should not be administered to patients with a serum bilirubin above the ULN or to patients with transaminase elevations &gt;1.5 times the ULN in conjunction with alkaline phosphatase &gt;2.5 times the ULN.</li>
			</ul>
			</td>
		</tr>
	</tbody>
</table>
', 'low', '', 'McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997 May;15(5):1853-7', 'METASTATIC', '<h4>Chemotherapy</h4>

<ul>
	<li>Docetaxel (Taxotere)&nbsp;75 mg/m<sup>2</sup>&nbsp;IV once on day 1</li>
</ul>

<p><strong>21-day cycles</strong></p>
', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (390, 'Erdafitinib (Balversa)', 'Erdafitinib monotherapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Erdafitinib (Balversa):</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Erdafitinib (Balversa):</strong><br>No dose reduction</li></ul>', 'Low', '', 'BLC2001: Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O''Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019 Jul 25;381(4):338-348.', 'METASTATIC', '<h4>Biomarker eligibility criteria</h4><h4>Alterations: FGFR3 mutation, FGFR2 fusion, or FGFR3 fusion</h4><p><strong>Erdafitinib (Balversa):</strong>&nbsp;8 mg PO once per day</p><ul><li>If serum phosphorus level and tolerability are acceptable at days 14 to 21, increase to 9 mg PO once per day</li><li>Additional dose adjustments per package insert</li></ul><p>Continue until disease progression or unacceptable toxicity occurs.</p>', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (391, 'Carboplatin (Paraplatin), Gemcitabine (Gemzar)', 'Carboplatin + Gemcitabine (AUC4.5/1000)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Carboplatin:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Carboplatin</strong>:<br>Dosing based on&nbsp;<strong>mg/m2</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: &nbsp;Reduce dose to 50% of the usual dose. &nbsp; If GFR &lt;10 mL/min: Reduce dose to 75% of the usual dose.</li></ul>', 'High', '', 'De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Skoneczna I, Marreaud S, de Wit R, Sylvester R. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. J Clin Oncol. 2009 Nov 20;27(33):5634-9', 'METASTATIC', '<h4><strong>Gemcitabine (Gemzar):&nbsp;</strong>1000 mg/m2&nbsp;IV over 30 minutes once per day on days 1 &amp; 8,&nbsp;given first.</h4><h4><strong>Carboplatin (Paraplatin):</strong>&nbsp;AUC 4.5, IV over 60 minutes once on day 1,&nbsp;given second.</h4><h4>Repeat cycle every 21-days for up to 6 cycles.</h4><p>Patients who achieved complete response were given two additional cycles of treatment.</p>', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1060, null, 'CAE', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', null, null, null, '<p><strong>Cyclophosphamide:</strong> 1,000 mg/m2 IV on day 1<br><strong>Doxorubicin:</strong> 45 mg/m2 IV on day 1<br><strong>Etoposide:</strong> 50 mg/m2 IV on days 1-5<br><br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (850, null, 'VAD', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Dactinomycin:</strong><br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Dactinomycin:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Vincristine:</strong> 1.5 mg/m2 IV weekly for 10 weeks, then every 3 weeks for 15 weeks<br><strong>Dactinomycin:</strong> 1.5 mg/m2 IV every 6 weeks for 26 weeks<br><strong>Doxorubicin:</strong> 40 mg/m2 IV every 6 weeks for 1 year (stage III)<br><strong>OR</strong><br><strong>Vincristine:</strong> 1.5 mg/m2 IV, day 1<br><strong>Dactinomycin:</strong> 15 mcg/kg/d IV, days 1-5 or 60 mcg/kg IV, day 1<br>Repeat every 6 weeks.</p><p>&nbsp;If stage III or IV add: <strong>Doxorubicin:</strong> 20 mg/m2 IV, day 1, and RT</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (398, 'Cyclophosphamide: Cytoxan<br>Docetaxel: Taxotere<br>Doxorubicin: Adriamycin, various', 'AC/Docetaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li>Cyclophosphamide:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li>Docetaxel:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li>Doxorubicin:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt;5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li>Cyclophosphamide:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li>Docetaxel:<br />
	No dose reduction</li>
	<li>Doxorubicin:<br />
	No dose reduction</li>
</ul>
', 'High for AC, low for docetaxel', '', 'Swain SM, Jeong JH, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053-2065.', 'NEOADJUVANT', '<p><strong>Doxorubicin</strong> 60mg/m<sup>2</sup> IV, day 1<br />
<strong>Cyclophosphamide</strong> 600mg/m<sup>2</sup> IV, day 1<br />
Repeat every 21 days for 4 cycles<br />
<br />
<strong>FOLLOWED BY</strong><br />
<br />
<strong>Docetaxel</strong> 100 mg/m<sup>2</sup> IV, day 1<br />
Repeat every 21 days for 4 cycles</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (628, '', 'FOLFIRI + Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>180 mg/m2&nbsp;IV on day 1</p><p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m2&nbsp;IV bolus on day 1, followed by 2,400 mg/m2&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p><p><strong>Leucovorin:&nbsp;</strong>400 mg/m2&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p><p><strong>Bevacizumab:&nbsp;</strong>5 mg/kg IV every 2 weeks</p><p>Repeat every 2 weeks.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (858, null, 'Sunitinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Sunitinib:</strong><br>If Child-Pugh A or B, no dose reduction&nbsp;<br>If Child-Pugh C, reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Sunitinib:</strong><br>If CrCl &gt; 42 mL/min, no dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Sunitinib:</strong> 50 mg/day PO for 28 days.</p><p>Repeat cycle every 6 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1062, null, 'Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Paclitaxel: </strong>80-100 mg/m2 IV weekly for 3 weeks<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (399, 'Carboplatin: Paraplatin<br>Docetaxel: Taxotere<br>Pertuzumab: Perjeta<br>Trastuzumab: Herceptin', 'TCHP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Docetaxel</strong>:<br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li><li><strong>Trastuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Pertuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on AUC</li><li><strong>Docetaxel</strong>:<br>No dose reduction</li><li><strong>Trastuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Pertuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p>&nbsp;</p><p>&nbsp;<strong>Cardiac Impairment</strong></p><ul><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'High', '', 'Schneeweiss A, Chia S, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278-84.', 'NEOADJUVANT', '<p><strong>Docetaxel</strong>: 75 mg/m2&nbsp;IV on day 1<br><strong>Carboplatin</strong>: AUC 6, IV on day 1<br><strong>Pertuzumab</strong>: 840 mg IV loading dose on day 1 and then 420 mg IV every 3 weeks<br><strong>Trastuzumab</strong>: 8 mg/kg IV loading dose on day 1 and then 6 mg/kg IV every 3 weeks</p><p>Repeat cycle every 21 days.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (499, 'Abemaciclib: Verzenio<br>Anastrozole: Arimidex', 'Abemaciclib/Anastrozole', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Abemaciclib</strong><br>Child-Pugh C: Reduce dosing frequency to once daily</li><li><strong>Anastrozole</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Anastrozole</strong>:<br>No dose reduction</li><li><strong>Abemaciclib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100 % dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: &nbsp;No dosage adjustments because of insufficient data.</li></ul>', 'Low', '', 'Goetz MP, Toi M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-3646.', 'METASTATIC', '<p><strong>Abemaciclib:</strong>&nbsp;150 mg PO BID<br><strong>Anastrozole:</strong>&nbsp;1 mg PO daily</p><p>Repeat cycle every 28 days.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (437, 'Everolimus: Afinitor<br>Exemestane: Aromasin', 'Everolimus/Exemestane', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Everolimus</strong><br />
	Mild (Child Pugh A): Decrease dose to 7.5 mg daily<br />
	Moderate (Child Pugh B): Decrease dose to 5 mg daily<br />
	Severe (Child Pugh C): Decrease dose to 2.5 mg daily</li>
	<li><strong>Exemestane</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Everolimus</strong>:<br />
	No dose reduction</li>
	<li><strong>Exemestane</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Baselga J, Campone M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.  N Engl J Med. 2012;366(6):520-9.', 'ADJUVANT', '<p><strong>Everolimus:</strong>&nbsp;10 mg PO daily<br><strong>Exemestane:</strong> 25 mg PO daily</p>', 17);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (603, '', 'Oxaliplatin + 5-Fluorouracil + Leucovorin (FOLFOX7)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>2,400 mg/m<sup>2</sup>&nbsp;IV continous infusion on days 1 and 2 for 46 hours</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p>

<p><strong>OR</strong></p>

<p><strong>L-Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (604, '', 'Oxaliplatin + 5-Fluorouracil + Leucovorin (mFOLFOX7)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>3,000 mg/m<sup>2</sup>&nbsp;IV continuous infusion on days 1 and 2 for 46 hours</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (859, null, 'Pazopanib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pazopanib:&nbsp;</strong><br>If bilirubin ≤1.5 times ULN: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;1.5 to 3 times ULN: &nbsp;Reduce dose to 200 mg daily &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;3 times ULN: Consider the use of alternative drug</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pazopanib:&nbsp;</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Pazopanib: </strong>800 mg PO daily<br>Continue treatment until disease progression</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (733, '', 'Pembrolizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', '', '<p><strong>Pembrolizumab:&nbsp;</strong>10 mg/kg IV on day 1</p>

<p>Repeat cycle every 14 days. May also give 200 mg IV on day 1 every 3 weeks.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1063, null, 'Topotecan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Topotecan</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Topotecan</strong>:<br>If CrCl &gt; 40 mL/min, no dose reduction<br>If CrCl 20-39 mL/min, reduce to 0.75 mg/m2/dose</li></ul>', 'Low', null, null, null, '<p><strong>Topotecan: </strong>1.5 mg/m2 IV on days 1 to 5.</p><p>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (475, 'Carboplatin: Paraplatin
Docetaxel: Taxotere', 'Carboplatin + Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Docetaxel:</strong><br>No dose reduction</li></ul>', 'High', '', '1. Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011 Nov 10;29(32):4320-6. Epub 2011 Oct 11.
2. Fossella F, et al. J Clin Oncol 2003; 21:3016.
3. Docetaxel injection. United States Prescribing Information. US National Library of Medicine.
4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Carboplatin:</strong> AUC 6, IV on day 1<br><strong>Docetaxel:</strong> 75 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p>', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (516, 'Gemcitabine: Gemzar', 'Gemcitabine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Carmichael J, Walling J, et al. Phase II activity of gemcitabine in advanced breast cancer. Semin Oncol. 1996;23(5 Suppl 10):77-81.', 'METASTATIC', '<p><strong>Gemcitabine</strong>&nbsp;725mg/m<sup>2</sup>&nbsp;IV weekly for 3 weeks.</p>

<p>Repeat cycle every 28 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (500, 'Abemaciclib: Verzenio<br>Letrozole: Femara', 'Abemaciclib/Letrozole', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Abemaciclib</strong><br>Child-Pugh C: Reduce dosing frequency to once daily</li><li><strong>Letrozole</strong>:<br>If Child-Pugh A or B, no dose reduction<br>If Child-Pugh C, reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Letrozole</strong>:<br>If CrCl &gt;10 mL/min, no dose reduction</li><li><strong>Abemaciclib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100 % dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: &nbsp;No dosage adjustments because of insufficient data.</li></ul>', 'Low', '', 'Goetz MP, Toi M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-3646.', 'METASTATIC', '<p><strong>Abemaciclib:</strong>&nbsp;150mg PO BID<br><strong>Letrozole:</strong>&nbsp;2.5mg PO daily</p><p>Repeat cycle every 28 days.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (606, '', 'FOLFOXIRI + Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.<strong>&nbsp;</strong></li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.<strong> &nbsp;</strong></li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>165 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>3,200 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>

<p><strong>Bevacizumab:&nbsp;</strong>5 mg/kg IV on day 1</p>

<p>Repeat cycle every 2 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (607, '', 'FOLFOXIRI + Panitumumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li><li><strong>Panitumumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.<strong>&nbsp;</strong></li><li><strong>Panitumumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.<strong> &nbsp;</strong></li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>150 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>3,000 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>

<p><strong>Panitumumab:&nbsp;</strong>6 mg/kg IV on day 1</p>

<p>Repeat cycle every 2 weeks&nbsp;</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (514, 'Vinorelbine: Navelbine', 'Vinorelbine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Vinorelbine</strong>:<br />
	If bilirubin 2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Vinorelbine</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Fumoleau P, Delozier T, et al. Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience.Semin Oncol. 1995 Apr;22(2 Suppl 5):22-8.', 'METASTATIC', '<p><strong>Vinorelbine:</strong>&nbsp;30 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 2 weeks.</p>', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (821, null, ' Ara-C+Daunorubicin+Gemtuzumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Daunorubicin:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Gemtuzumab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Daunorubicin:</strong><br>If Cr &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Gemtuzumab:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Cytarabine:</strong> 200 mg/m2 IV on days 1-7<br><strong>Daunorubicin:</strong> 60 mg/m2 IV on days 1-3<br><strong>Gemtuzumab:</strong> 3 mg/m2 IV on days 1, 4, and 7.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (405, 'Cyclophosphamide: Cytoxan<br>Docetaxel: Taxotere', 'TC', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Jones SE, Savin MA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24(34):5381-7.', 'ADJUVANT', '<p><strong>Docetaxel</strong> 75 mg/m<sup>2</sup> IV on day 1<br />
<strong>Cyclophosphamide</strong> 600 mg/m<sup>2</sup> IV on day 1</p>

<p>Repeat every 21 days for 4 cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (406, 'Cyclophosphamide: Cytoxan<br>Docetaxel: Taxotere<br>Doxorubicin: Adriamycin, various', 'TAC', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Martin M, Pienkowski T, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302-13.', 'ADJUVANT', '<p><strong>Docetaxel</strong> 75 mg/m<sup>2</sup> IV on day 1<br />
<strong>Doxorubicin</strong> 50 mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Cyclophosphamide</strong> 500 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 21 days for 6 cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (704, '', 'Gemcitabine + Radiation Therapy (ECOG regimen)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'LOCALLY ADVANCED', '<p><strong>Gemcitabine:&nbsp;</strong>600 mg/m2&nbsp;IV weekly for 6 weeks</p><p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day to a total dose of 5,040 cGy. Chemotherapy and radiation therapy started on the same day and given concurrently.</p><p><strong>Four weeks after the completion of chemoradiation:</strong></p><p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m2&nbsp;IV on days 1, 8, and 15</p><p>Repeat cycle every 4 weeks for a total of 5 cycles. This regimen is for patients&nbsp;with locally advanced unresectable pancreatic adenocarcinoma.&nbsp;</p>', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (495, 'Ribociclib: Kisqali<br>Letrozole: Femara', 'Ribociclib/Letrozole', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Ribociclib</strong><br />
	If Child-Pugh A, no dose reduction<br />
	If&nbsp;Child-Pugh B or C, reduce starting dose to 400 mg/day</li>
	<li><strong>Letrozole</strong>:<br />
	If Child-Pugh A or B, no dose reduction<br />
	If Child-Pugh C, reduce dose by 50%</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Ribociclib</strong><br />
	If CrCl &ge;30 mL/min, no dose reduction<br />
	If CrCl 15-30 mL/min, decrease starting dose to 200 mg/day</li>
	<li><strong>Letrozole</strong>:<br />
	If CrCl &gt;10 mL/min, no dose reduction</li>
</ul>
', 'Low', '', 'Hortobagyi GN, Stemmer SN, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738-1748.', 'METASTATIC', '<p><strong>Ribociclib:</strong>&nbsp;600 mg PO daily for 21 days<br><strong>Letrozole:</strong>&nbsp;2.5 mg PO daily</p><p>Repeat cycle every 28 days.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1064, null, 'Gemcitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Gemcitabine:</strong> 1,000 mg/m2 PO on days 1, 8, and 15.</p><p>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (697, '', 'Sorafenib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Sorafenib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Sorafenib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 40 to 59 mL/min: 400 mg twice daily &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 20 to 39 mL/min: 200 mg twice daily &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;20 mL/min: Inadequate data&nbsp;to define dose.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Sorafenib:&nbsp;</strong>400 mg/day PO twice daily</p>

<p>Continue treatment until disease progression.</p>
', 8);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1065, null, 'Nivolumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nivolumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nivolumab:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Nivolumab:</strong> 240 mg IV on day 1</p><p>Repeat cycle every 14 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (412, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin, various<br>Paclitaxel: Taxol', 'A/T/C (dose-dense)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate, low for paclitaxel', '', 'Citron ML, Berry DA, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-9.', 'ADJUVANT', '<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 14 days for 4 cycles.</p>

<p><strong>FOLLOWED BY</strong></p>

<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 14 days for 4 cycles.</p>

<p><strong>FOLLOWED BY&nbsp;</strong></p>

<p><strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;on day 1</p>

<p>Repeat every 14 days for 4 cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (501, 'Tamoxifen: Nolvadex', 'Tamoxifen', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong>:<br />
	No dose reduction</li>
</ul>
', 'N/A', '', 'Jaiyesimi IA, Buzdar AU, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995;13(2):513-29.', 'METASTATIC', '<p><strong>Tamoxifen</strong>&nbsp;20mg PO daily</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (215, 'Carboplatin : Paraplatin<br>Docetaxel : Taxotere', 'Docetaxel/Carboplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin:</strong><br>No dose reduction</li><li><strong>Docetaxel</strong>:<br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose.</li><li><strong>Docetaxel:</strong><br>No dose reduction</li></ul>', 'High', '<b>Docetaxel/Carboplatin</b>', 'Pentheroudakis G, Briasoulis E, Kalofonos HP, et al. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group Phase II study. $Acta Oncol. 2008;47(6): 1148-1155.$', null, '<p><strong>Docetaxel:</strong> 75 mg/m2 IV over 30 minutes, day1<br><strong>Carboplatin:</strong> AUC of 5 IV over 30 minutes, day 1<br>Repeat cycle every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (592, '', 'Oxaliplatin + 5-Fluorouracil + Leucovorin (FOLFOX4)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Moderate', '', '', 'ADJUVANT', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m2&nbsp;IV on day 1</p><p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m2&nbsp;IV bolus, followed by 600 mg/m2&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p><p><strong>Leucovorin:&nbsp;</strong>&nbsp;200 mg/m2&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p><p>Repeat every 2 weeks for a total of 12 cycles (6 months total)</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (730, '', 'Cabozantinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cabozantinib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (Child-Pugh class A): 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If moderate impairment (Child-Pugh class B): Reduce the initial dose to 40 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): Use is not recommended&nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cabozantinib:&nbsp;</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Moderate', '', '', '', '<p><strong>Cabozantinib:</strong>&nbsp;60 mg PO daily</p>

<p>Continue until disease progression. Dose may be reduced to 40 mg daily and 20 mg daily depending on toxicity.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (671, '', 'AML FLT3 positive ( Ara-C+Daunorubicin+Midostaurin)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Daunorubicin:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Midostaurin:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Daunorubicin:</strong><br>If Cr &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Midostaurin:</strong><br>No dose reduction</li></ul>', 'Moderate', '', '', 'INDUCTION', '<p><strong>Cytarabine:</strong> 200 mg/m2 IV on days 1-7<br><strong>Daunorubicin:</strong> 60 mg/m2 IV on days 1-3<br><strong>Midostaurin:</strong> 50 mg/m2 PO bid on days 8-21<br><br>In patients who achieve a complete remission after induction therapy should<br>then receive consolidation therapy.<br><br><strong>Consolidation</strong><br><strong>Cytarabine:</strong> 3,000 mg/m2 IV every 12 hours on days1, 3, and 5<br><strong>Midostaurin:</strong> 50 mg/m2 PO bid on days 8-21<br>Repeat every 28 days for a total of 4 cycles of consolidation therapy.<br>In patients who remain in complete remission after completion of consolidation<br>therapy should then receive maintenance therapy.</p><p><strong>Maintenance</strong></p><p><strong>Midostaurin:</strong> 50 mg/m2 PO bid.</p><p>Repeat every 28 days for a total of 12 cycles.</p>', 33);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (860, null, 'Vandetanib (Medullary carcinoma of the thyroid)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vandetanib:&nbsp;</strong><br>&nbsp;If mild impairment (Child-Pugh class A): 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate and severe impairment (Child-Pugh class B or C): Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vandetanib:&nbsp;</strong><br>If CrCl ≥50 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;50 mL/min: Reduce initial dose to 200 mg once daily and closely monitor QT interval.</li></ul>', 'Low', null, null, null, '<p><strong>Vandetanib: </strong>300 mg PO daily<br>Continue treatment until disease progression</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (502, 'Toremifene: Fareston', 'Toremifene', '', 'N/A', '', 'Hayes DF, Van Zyl JA, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 1995;13(10):2556-66.', 'METASTATIC', '<p><strong>Toremifene</strong> 60mg PO daily</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (503, 'Exemestane: Aromasin, various', 'Exemestane', '', 'N/A', '', 'Lonning PE, Bajetta E, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol. 2000;18(11):2234-4. ', 'METASTATIC', '<p><strong>Exemestane</strong>&nbsp;25mg PO daily</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (504, 'Anastrozole: Arimidex', 'Anastrozole', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Anastrozole</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Anastrozole</strong>:<br />
	No dose reduction</li>
</ul>
', 'N/A', '', 'Buzdar A, Jonat W, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol. 1996;14(7):2000-11.', 'METASTATIC', '<p><strong>Anastrozole</strong>&nbsp;1mg PO daily</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1066, null, 'Pembrolizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (total bilirubin &lt;1 to 1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (total bilirubin &gt;1.5 times ULN): Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Pembrolizumab:</strong> 200 mg IV on day 1</p><p>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (480, 'Cisplatin: Platinol Gemcitabine: Gemzar', 'Cisplatin + Gemcitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul>', 'High', '', 'SQUIRE: Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015 Jul;16(7):763-74. Epub 2015 Jun 1.', 'METASTATIC', '<p><strong>Cisplatin:</strong>&nbsp;100 mg/m2&nbsp;IV over 30 minutes once on day 1<br><strong>Gemcitabine:</strong>&nbsp;1.000 mg/m2&nbsp;IV over 2 hours once per day on days 1, 8, and 15.</p><p>Repeat cycle every 21-days.</p>', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (505, 'Letrozole: Femara', 'Letrozole', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Letrozole</strong>:<br />
	If Child-Pugh A or B, no dose reduction<br />
	If Child-Pugh C, reduce dose by 50%</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Letrozole</strong>:<br />
	If CrCl &gt; 10 mL/min, no dose reduction</li>
</ul>
', 'N/A', '', 'Dombernowsky P, Smith I, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16(2):453-61.', 'METASTATIC', '<p><strong>Letrozole</strong>&nbsp;2.5mg PO daily</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (506, 'Fulvestrant: Faslodex', 'Fulvestrant', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Fulvestrant</strong>:<br />
	If SGOT, SGPT, bilirubin and alkaline phosphatase &lt; 2 upper normal limit, no dose reduction<br />
	If SGOT, SGPT, bilirubin and alkaline phosphatase &gt; 2 upper normal limit, unknown</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Fulvestrant</strong>:<br />
	No dose reduction</li>
</ul>
', 'N/A', '', 'Howell A. Future use of selective estrogen receptor modulators and aromatase inhibitors. Clin Cancer Res. 2001;7(12 Suppl):4402s-4410s --- Di Leo A, Jerusalem G, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594-600.', 'METASTATIC', '<p><strong>Fulvestrant</strong>&nbsp;250mg IM on day 1</p>

<p>Repeat every month.</p>

<p>OR</p>

<p><strong>Fulvestrant</strong>&nbsp;500mg IM loading dose on day 1, then 500mg IM on days 15 and 29</p>

<p>Continue treatment on a monthly basis until disease progression.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (961, null, 'Bortezomib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If<strong> </strong>bilirubin &gt;1 to 1.5 times ULN: 100% of the dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;1.5 ULN: Reduce initial dose to 0.7 mg/m2.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Bortezomib:</strong> 1.3 mg/m2/day IV bolus, days 1,4, 8, and 11<br>Repeat every 21 days for up to 17 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (507, 'Megestrol: Megace', 'Megestrol', '', 'N/A', '', 'Kimmick GG, Muss HB. Endocrine therapy in metastatic breast cancer. Cancer Treat Res. 1998;94:231-54.', 'METASTATIC', '<p><strong>Megestrol</strong> 40mg PO QID</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (727, '', 'FOLFOX4', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Moderate', '', '', '', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (743, '', 'Pembrolizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (total bilirubin &lt;1 to 1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (total bilirubin &gt;1.5 times ULN): Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>Pembrolizumab:&nbsp;</strong>200 mg IV on day 1</p>

<p>Repeat cycle every 3 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (508, 'Trastuzumab: Herceptin', 'Trastuzumab', '', 'Low', '', 'Baselga J, Tripathy D, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999;26(4 Suppl 12):78-83. --- Baselga J, Carbonell X, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 2005;23(10):2162-71.', 'METASTATIC', '<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose, then 2mg/kg IV weekly</p>

<p>Repeat cycle weekly for a total of 10 weeks. In the absence of disease progression, continue weekly maintenance dose of 2mg/kg.</p>

<p>OR</p>

<p><strong>Trastuzumab</strong>&nbsp;8mg/kg IV loading dose, then 6mg/kg IV every 3 weeks.</p>

<p>Continue treatment until disease progression.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (725, '', 'Gemcitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p>Repeat cycle every 21 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (476, 'Carboplatin:Paraplatin
Gemcitabine: Gemzar', 'Carboplatin + Gemcitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Carboplatin:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: &nbsp;Reduce dose to 50% of the usual dose. &nbsp; If GFR &lt;10 mL/min: Reduce dose to 75% of the usual dose</li></ul>', 'High', '', 'Patil V, Noronha V, Joshi A, Chougule A, Kannan S, Bhattacharjee A, Goud S, More S, Chandrasekharan A, Menon N, Srinivas S, Vallathol DH, Dsouza H, Majumdar S, Das S, Zawar A, Khaddar S, Kumar A, Singh G, Kumar KAP, Ravind R, Trivedi V, Behel V, Mahajan A, Janu A, Purandare N, Prabhash K. Phase III non-inferiority study evaluating efficacy and safety of low dose gemcitabine compared to standard dose gemcitabine with platinum in advanced squamous lung cancer. EClinicalMedicine. 2019 Apr 9;9:19-25.

Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S; Norwegian Lung Cancer Study Group. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11. ', '', '<p><strong>Carboplatin:</strong> AUC 5, IV on day 1<br><strong>Gemcitabine:</strong>&nbsp;1,000 mg/m2&nbsp;IV over 30 minutes on days 1 &amp; 8.</p><p>Repeat cycle every 21 days.</p>', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (418, 'Carboplatin: Paraplatin
Etoposide: Vepesid', 'Carboplatin + Etoposide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', '', 'Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007;97(2):162–169. doi:10.1038/sj.bjc.6603810', '', '<p><strong>Carboplatin</strong>:&nbsp;AUC of 6, IV on day 1<br><strong>Etoposide</strong>: 100 mg/m2&nbsp;IV on days 1-3</p><p>Repeat cycle every 28 days</p>', 105);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (864, null, 'Rituximab + Dexamethasone + Cyclophosphamide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL: Reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-29 mL/min: Reduce dose by 25%<br>If CrCl &lt; 10 mL/min: Reduce dose by 50%</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Rituximab:</strong> 375 mg/m2 IV on day 1<br><strong>Dexamethasone: </strong>20 mg IV on day 1<br><strong>Cyclophosphamide:</strong> 100 mg/m2 PO bid<br>Repeat cycle every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1171, null, 'Paclitaxel + Gemcitabine + Oxaliplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Oxaliplatin:&nbsp;</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li></ul>', 'Moderate', null, null, null, '<p><strong>Paclitaxel: </strong>80 mg/m2 IV on days 1 and 8<br><strong>Gemcitabine:</strong> 800 mg/m2 IV on days 1 and 8<br><strong>Oxaliplatin: </strong>130 mg/m2 IV on day 1<br>Repeat cycle every 21 days&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (416, 'Carboplatin: Paraplatin
Etoposide: Vepesid
Atezolizumab: Tecentriq
', 'Carboplatin + Etoposide + Atezolizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Atezolizumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Atezolizumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li></ul>', 'High', '', 'IMpower133: Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018 Dec 6;379(23):2220-2229. Epub 2018 Sep 25. link to original article contains verified protocol PubMed', '', '<p><strong>Carboplatin:</strong> AUC 5, IV on day 1<br><strong>Etoposide:</strong> 100 mg/m2&nbsp;IV on days 1, 2, 3.<br><strong>Atezolizumab:</strong> 1200 mg IV on day 1.</p><p>Repeat cycle every 21 days for 4 cycles followed by&nbsp;</p><p><strong>&nbsp;Atezolizumab: </strong>1,200 mg IV on day 1&nbsp;</p><p>Repeat cycle every 21 days until disease progression or toxicity. May also give atezolizumab at 840 mg IV every 2 weeks or 1,680 mg IV every 4 weeks.</p>', 105);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (511, 'Docetaxel: Taxotere', 'Docetaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Chan S. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy. Oncology (Williston Park). 1997;11(8 Suppl 8):19-24. --- Baselga J, Tabernero JM. Weekly docetaxel in breast cancer: applying clinical data to patient therapy. Oncologist. 2001;6 Suppl 3:26-9.', 'METASTATIC', '<p><strong>Docetaxel:&nbsp;</strong>25 mg/m2&nbsp;IV weekly for 8 weeks, then every other week.</p><p>Continue treatment until disease progression.</p>', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (522, 'Talazoparib: Talzenna', 'Talazoparib', '<h4>Renal impairment</h4>

<ul>
	<li>CrCl 30-59 mL/min: Reduce dose to 0.75mg daily</li>
	<li>CrCl 15-29 mL/min: Reduce dose to 0.5mg daily</li>
</ul>
', 'Moderate', '', 'Litton JK, Rugo HS, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379(8):753-763.', 'METASTATIC', '<p><strong>Talazoparib</strong>&nbsp;1mg PO daily</p>

<p>Repeat cycle every 28 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1172, null, 'Etoposide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'Low', null, null, null, '<p><strong>Etoposide:</strong> 50 mg/m2 q day PO<br>Repeat cycle every 14-21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (429, '', 'Cisplatin + Irinotecan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li></ul>', 'High', '', 'JCOG 9511: Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; JCOG. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):85-91.
SWOG S0124: Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20;27(15):2530-5. Epub 2009 Apr 6.
JCOG 0509: Satouchi M, Kotani Y, Shibata T, Ando M, Nakagawa K, Yamamoto N, Ichinose Y, Ohe Y, Nishio M, Hida T, Takeda K, Kimura T, Minato K, Yokoyama A, Atagi S, Fukuda H, Tamura T, Saijo N. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol. 2014 Apr 20;32(12):1262-8. Epub 2014 Mar 17.', '', '<p><strong>Cisplatin:</strong> 60 mg/m2&nbsp;IV on day 1&nbsp;<br><strong>Irinotecan:</strong> 60 mg/m2&nbsp;IV on days 1, 8, 15</p><p>Repeat cycle every 28 days.</p>', 105);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (866, null, 'Larotrectinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Larotrectinib:</strong>&nbsp;<br>&nbsp;If mild impairment (Child-Pugh class A): 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate and severe impairment (Child-Pugh class B or C): Reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Larotrectinib:</strong>&nbsp;<br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Larotrectinib:</strong> 100 mg PO BID</p><p>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (867, null, 'Entrectinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Entrectinib:</strong><br>&nbsp;If mild impairment (Child-Pugh class A): 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate and severe impairment (Child-Pugh class B or C): Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Entrectinib:</strong><br>If CrCl 30 to &lt;90 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Dosage adjustment not provided by the manufacturer.</li></ul>', 'Low', null, null, null, '<p><strong>Entrectinib:</strong> 600 mg PO daily.</p><p>Continue until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (510, 'Capecitabine: Xeloda', 'Capecitabine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	If CrCl 30-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
</ul>
', 'Low', '', 'Blum JL, Jones SE, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17(2):485-93.', 'METASTATIC', '<p><strong>Capecitabine</strong>&nbsp;1250mg/m<sup>2</sup>&nbsp;PO BID for 2 weeks followed by 1-week rest period</p>

<p>Repeat cycle every 21 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (524, 'Cisplatin: CDDP<br>Paclitaxel: Taxol', 'Paclitaxel/Cisplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li></ul>', 'High', '', 'Morris M, Eifel PJ, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137-43.', '', '<p><strong>Paclitaxel:</strong>&nbsp;135 mg/m2&nbsp;IV over 24 hours on day 1<br><strong>Cisplatin:</strong>&nbsp;75 mg/m2&nbsp;IV on day 2</p><p>Repeat cycle every 21 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (552, 'Cisplatin: CDDP<br>Ifosfamide: Ifex', 'Cisplatin/Ifosfamide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Ifosfamide</strong>:<br>No dose reduction</li><li><strong>Mesna:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Ifosfamide</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥10 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: &nbsp;75% dosage.</li><li><strong>Mesna:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'High', '', 'Wolfson AH, et al. J Clin Oncol 2006;24(18S):5001. ', '', '<p><strong>Cisplatin:</strong>&nbsp;20 mg/m2/day IV on days 1-4<br><strong>Ifosfamide:</strong>&nbsp;1500 mg/m2/day IV on day 1<br><strong>Mesna:</strong>&nbsp;120 mg/m2&nbsp;IV loading dose followed by 1500 mg/m2/day for 24 hours</p><p>Repeat cycle every 21 days for 3 cycles.</p>', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (554, 'Doxorubicin: Adriamycin, various', 'Doxorubicin', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Muss HB. Chemotherapy of metastatic endometrial cancer. Semin Oncol. 1994;21(1):107-13.', '', '<p><strong>Doxorubicin:</strong>&nbsp;60 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p>', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (553, 'Gemcitabine: Gemzar<br>Docetaxel: Taxotere', 'Gemcitabine/Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel</strong>:<br>If bilirubin &gt; upper normal limit: Do not use<br>If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit: Do not use</li><li><strong>Gemcitabine</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel</strong>:<br>No dose reduction</li><li><strong>Gemcitabine</strong>:<br>No dose reduction</li></ul>', 'Low', '', 'Hensley ML, Blessing JA, et al. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109(3):329-34.', '', '<p><strong>Gemcitabine:</strong>&nbsp;900 mg/m2&nbsp;IV on days 1 and 8<br><strong>Docetaxel:</strong>&nbsp;100 mg/m2&nbsp;IV on day 8</p><p>Repeat cycle every 21 days.</p>', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (871, null, 'Gemcitabine + Carboplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Carboplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%&nbsp;</li></ul>', 'High', null, null, null, '<p><strong>Gemcitabine:</strong> 1,000 mg/m² IV on days 1, 8, and 15<br><strong>Carboplatin:</strong> &nbsp;AUC of 5, IV on day 1</p><p>Repeat cycle every 28 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (471, 'Carboplatin: Paraplatin
Pembrolizumab: Keytruda
Paclitaxel: Taxol', 'Carboplatin + Pembrolizumab + Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'High', '', 'KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.
', 'METASTATIC', '<p><strong>Carboplatin:</strong>&nbsp;AUC 6, IV on day 1<br><strong>Paclitaxel:</strong>&nbsp;200 mg/m2&nbsp;IV on day 1<br><strong>Pembrolizumab:&nbsp;</strong>200 mg IV on day 1.</p><p>Repeat cycle every 21 days for up to 4 cycles followed by pembrolizumab for up to a total of 35 treatments</p>', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (478, 'Cisplatin: Platinol
Docetaxel: Taxotere', 'Cisplatin + Docetaxel ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Docetaxel:</strong><br>No dose reduction</li></ul>', 'High', '', 'JOG5208L: Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N; West Japan Oncology Group. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1630-8. Epub 2015 Oct 28.

5501068: Lu S, Chen Z, Hu C, Zhang J, Chen Y, Song Y, Zhao Q, Fan Y, Wu G, Ma Z, Fang J, Yu Q, Liu Z. Nedaplatin plus docetaxel versus cisplatin plus docetaxel as first-line chemotherapy for advanced squamous cell carcinoma of the lung - a multicenter, open-label, randomized, phase III trial. J Thorac Oncol. 2018 Nov;13(11):1743-1749. Epub 2018 Jul 11.', 'METASTATIC', '<p><strong>Cisplatin:</strong>&nbsp;75 mg/m2&nbsp;IV once on day 1<br><strong>Docetaxel:</strong>&nbsp;75 mg/m2&nbsp;IV once on day 1</p><p>Repeat cycle every 21 days.</p>', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (555, 'Megestrol: Megace', 'Megestrol', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Megestrol:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Megestrol:&nbsp; </strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'N/A', '', 'Thigpen JT, Brady MF, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17(6):1736-44.', '', '<p><strong>Megestrol:</strong>&nbsp;160 mg PO daily</p><p>Continue until disease progression or undue toxicity.</p>', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (823, null, ' Ara-C+ Doxorubicin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Cytarabine:</strong> 100 mg/m2/day IV continuous infusion on days 1-7<br><strong>Doxorubicin:</strong> 30 mg/m2 IV on days 1-3.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (481, 'Cisplatin: Platinol
Paclitaxel: Taxol', 'Cisplatin + Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li></ul>', 'High', '', 'COG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.

Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000 Oct 1;18(19):3390-9.

Rosell, R. et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of Oncology, Volume 13, Issue 10, 1539 – 1549

EORTC 08975: Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G; EORTC Lung Cancer Group. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organisation for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol. 2003 Nov 1;21(21):3909-17.
', '', '<p><strong>Cisplatin: </strong>80 mg/m2 IV once on day 1<br><strong>Paclitaxel: </strong>175 mg/m2 IV over 3 hours on day 1</p><p>Repeat cycle every 21 days.</p>', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (717, '', 'Gemcitabine + Capecitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Capecitabine</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p><strong>Capecitabine:&nbsp;</strong>650 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p>Repeat cycle every 21 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (436, 'Anastrozole: Arimidex<br>Goserelin: Zoladex<br>Zoledronic acid: Zometa, various', 'Anastrozole/Goserelin/Zoledronic Acid', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Anastrozole</strong>:<br />
	No dose reduction</li>
	<li><strong>Goserelin</strong>:<br />
	No dose reduction</li>
	<li><strong>Zoledronic acid</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Anastrozole</strong>:<br />
	No dose reduction</li>
	<li><strong>Goserelin</strong>:<br />
	No dose reduction</li>
	<li><strong>Zoledronic acid</strong>:<br />
	CrCl &gt;60 mL/min: 4 mg<br />
	CrCl 50-60 mL/min: 3.5 mg<br />
	CrCl 40-49 mL/min: 3.3 mg<br />
	CrCl 30-39 mL/min: 3 mg<br />
	CrCl &lt;30 mL/min: Not recommended</li>
</ul>
', 'N/A', '', 'Gnant M, Mlineritsch B, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-91.', 'ADJUVANT', '<p><strong>Anastrozole:</strong> 1 mg PO daily<br><strong>Goserelin:</strong>&nbsp;3.6 mg SC every 28 days<br><strong>Zoledronic acid:</strong>&nbsp;4 mg IV every 6 months</p><p>Continue treatment for 3 years.</p>', 17);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (435, 'Tamoxifen: Nolvadex<br>Goserelin: Zoladex<br>Zoledronic acid: Zometa, various', 'Tamoxifen/Goserelin/Zoledronic Acid', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong>:<br />
	No dose reduction</li>
	<li><strong>Goserelin</strong>:<br />
	No dose reduction</li>
	<li><strong>Zoledronic acid</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong>:<br />
	No dose reduction</li>
	<li><strong>Goserelin</strong>:<br />
	No dose reduction</li>
	<li><strong>Zoledronic acid</strong>:<br />
	CrCl &gt;60 mL/min: 4 mg<br />
	CrCl 50-60 mL/min: 3.5 mg<br />
	CrCl 40-49 mL/min: 3.3 mg<br />
	CrCl 30-39 mL/min: 3 mg<br />
	CrCl &lt;30 mL/min: Not recommended</li>
</ul>
', 'N/A', '', 'Gnant M, Mlineritsch B, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-91.', 'ADJUVANT', '<p><strong>Tamoxifen:</strong>&nbsp;20 mg PO daily<br><strong>Goserelin:</strong>&nbsp;3.6 mg SC every 28 days<br><strong>Zoledronic acid:</strong>&nbsp;4 mg IV every 6 months</p><p>Continue treatment for 3 years.</p>', 17);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (434, 'Tamoxifen: Nolvadex<br>Exemestane: Aromasin', 'Tamoxifen/Exemestane', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong>:<br />
	No dose reduction</li>
	<li><strong>Exemestane</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong>:<br />
	No dose reduction</li>
	<li><strong>Exemestane</strong>:<br />
	No dose reduction</li>
</ul>
', 'N/A', '', 'Coombes RC, Hall E, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081-92.', 'ADJUVANT', '<p><strong>Tamoxifen:</strong>&nbsp;20 mg PO daily for 2-3 years, followed by</p><p><strong>Exemestane:</strong>&nbsp;25 mg PO daily for the remainder of 5 years.</p>', 17);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (593, '', 'Oxaliplatin + 5-Fluorouracil + Leucovorin (mFOLFOX7)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Moderate', '', '', 'ADJUVANT', '<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m2&nbsp;IV on day 1</p><p><strong>5-Fluorouracil:&nbsp;</strong>3,000 mg/m2&nbsp;IV continuous infusion on days 1 and 2 for 46 hours</p><p><strong>Leucovorin:&nbsp;</strong>200 mg/m2&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p><p>Repeat every 2 weeks for a total of 12 cycles ( 6 months total).</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (645, '', 'Gemcitabine + Cisplatin', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li></ul>', 'High', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,250 mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;on day 1</p>

<p>Repeat cycle every 21 days.</p>

<p><strong>OR</strong></p>

<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p><strong>Cisplatin:&nbsp;</strong>25 mg/m<sup>2</sup>&nbsp;on days 1 and 8</p>

<p>Repeat cycle every 21 days for 8 cycles.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (448, 'Cyclophosphamide: Cytoxan<br>Epirubicin: Ellence, various<br>5-Fluorouracil: 5-FU', 'FEC-75', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
	<li><strong>Epirubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />
	If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
	<li><strong>Epirubicin</strong><br />
	If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
</ul>
', 'High', '', 'A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. J Clin Oncol. 1991;9(2):305-12.', 'METASTATIC', '<p><strong>5-Fluorouracil:</strong> 500 mg/m2 IV on day 1<br><strong>Epirubicin:</strong> 75 mg/m2 IV on&nbsp;day 1<br><strong>Cyclophosphamide:</strong> 500 mg/m2 IV on day 1</p><p>Repeat cycle every 21 days.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (442, 'Capecitabine: Xeloda<br>Docetaxel: Taxotere', 'XT', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	No dose reduction</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	If CrCl 30-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low ', '', 'O''Shaughnessy J, Miles D, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812-23.', 'METASTATIC', '<p><strong>Capecitabine:</strong>&nbsp;1250 mg/m2&nbsp;PO BID on days 1-14<br><strong>Docetaxel:</strong>&nbsp;75 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (718, '', 'Gemcitabine + Oxaliplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 2</p>

<p>Repeat cycle every 14 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (594, '', 'FLOX', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Moderate', '', '', 'ADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m2&nbsp;IV weekly for 6 weeks, administered 1 hour after LV infusion begun</p><p><strong>Leucovorin:&nbsp;</strong>500 mg/m2&nbsp;IV over 2 hours weekly for 6 weeks, administered before 5-fluorouracil</p><p><strong>Oxaliplatin:</strong>&nbsp;85 mg/m2&nbsp;IV administered before 5-fluorouracil and LV and on days 1, 15, and 29</p><p>Repeat every 8 weeks for a total of 3 cycles (6 months total)</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (629, '', 'XELIRI + Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li><li><strong>Bevacizumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li><li><strong>Bevacizumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Capecitabine:&nbsp;</strong>800 mg/m<sup>2</sup>&nbsp;PO on days 1-14</p>

<p><strong>Bevacizumab:&nbsp;</strong>7.5 mg/kg IV on day 1</p>

<p>Repeat cycle every 3 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (729, '', 'Lenvatinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lenvatinib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lenvatinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Moderate', '', '', '', '<p><strong>Lenvatinib:&nbsp;</strong>12 mg PO daily if body weight &gt; 60 kg, or 8 mg PO daily if body weight &lt; 60 kg</p>

<p>Continue until disease progression. Dose may be reduced to 4 mg daily or 4 mg every other day depending on toxicity.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (719, '', '5-Fluorouracil + Cisplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'High', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1, followed by 600 mg/m<sup>2</sup>&nbsp;IV infusion over 22 hours on days 1 and 2</p>

<p><strong>Cisplatin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 2</p>

<p>Repeat cycle every 21 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1067, null, 'Lorlatinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lorlatinib:</strong> &nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (total bilirubin &lt;1 to 1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (total bilirubin &gt;1.5 times ULN): Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lorlatinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 30 to 89 mL/min: No dosage adjustment necessary. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 15 to &lt;30 mL/min: Reduce dose to 75 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If ESRD requiring dialysis: There are no dosage adjustments provided in the manufacturer''s labeling</li></ul>', 'Low', null, null, null, '<p><strong>Lorlatinib:</strong> 100 mg PO daily.</p><p>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (454, 'Atezolizumab: Tecentriq<br>Nab-paclitaxel: Abraxane', 'Atezolizumab/Nab-Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Atezolizumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No special dosage modification.</li><li><strong>Nab-Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin 1.2 to ≤1.8 mg/dL:100% dosage<br>If bilirubin &gt;1.8 to ≤3.6 mg/dL: Reduce dose by 75%<br>If bilirubin &gt; 3.6 mg/dL, do not use</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Atezolizumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No special dosage modification.</li><li><strong>Nab-Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: There are no dosage adjustments provided because of insufficient data.</li></ul>', 'Low', '', 'Schmid P, Rugo HS, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44-59.', 'METASTATIC', '<p><strong>Atezolizumab:</strong>&nbsp;840 mg IV on days 1 and 15<br><strong>Nab-Paclitaxel:</strong>&nbsp;100 mg/m2&nbsp;IV on days 1, 8, and 15</p><p>Repeat cycle every 28 days.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (447, 'Docetaxel: Taxotere<br>Doxorubicin liposome: Doxil, various', 'Doxorubicin Liposome/Docetaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Dieras V. Review of docetaxel/doxorubicin combination in metastatic breast cancer. Oncology (Williston Park). 1997;11(8 Suppl 8):31-3.', 'METASTATIC', '<p><strong>Doxorubicin liposome:</strong>&nbsp;30 mg/m2&nbsp;on day 1<br><strong>Docetaxel:</strong>&nbsp;60 mg/m2&nbsp;on day 1</p><p>Repeat cycle every 21 days.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (445, 'Capecitabine: Xeloda<br>Ixabepilone: Ixempra', 'XI', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	No dose reduction</li>
	<li><strong>Ixabepilone</strong>:<br />
	If AST and ALT &lt; 2.5 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 40 mg/m<sup>2</sup><br />
	If AST or ALT &gt; 2.5 upper normal limit, or bilirubin &gt; 1 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	If CrCl 30-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Ixabepilone</strong>:<br />
	If CrCl &gt; 30 mL/min, no dose reduction</li>
</ul>
', 'Low', '', 'Thomas ES, Gomez HL, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210-7.', 'METASTATIC', '<p><strong>Capecitabine:</strong>&nbsp;1000 mg/m2&nbsp;PO BID on days 1-14<br><strong>Ixabepilone:</strong>&nbsp;40 mg/m2&nbsp;IV over 3 hours on day 1</p><p>Repeat cycle every 21 days.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (716, '', 'Capecitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,250 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p>May decrease dose to 850-1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14 to reduce the risk of toxicity without compromising clinical efficacy.</p>

<p>Repeat cycle every 21 days.</p>

<p>&nbsp;</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (219, 'Capecitabine : Xeloda<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'Oxaliplatin + Capecitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine:</strong><br>No dose reduction</li><li><strong>Oxaliplatin:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine:</strong><br>If CrCl 30-50 mL/min: Reduce dose by 25%&nbsp;<br>If CrCl &lt; 30 mL/min: Do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl ≥30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Reduce dose by 25%&nbsp;</li></ul>', 'Moderate', '<b>Oxaliplatin Capecitabine</b>', 'Hainsworth JD, Spigel DR, Burris HA, et al. Oxaliplatin and capecitabine inn the treatment of patients with recurrent or refractory carcinoma of unknown primary site: A phase 2 trial of the Sarah Cannon Oncology Research Consortium. $Cancer. 2010; 116(10):2448-2454.$', null, '<p><strong>Oxaliplatin:</strong> 130 mg/m2 IV, day 1<br><strong>Capecitabine:</strong> 1,000 mg/m2 PO, days 1-14<br>Repeat cycle every 21 days up to 6 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1068, null, 'Entrectinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Entrectinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (total bilirubin &lt;1 to 1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (total bilirubin &gt;1.5 times ULN): Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Entrectinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 30 to 90 mL/min: No dosage adjustment necessary. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: There are no dosage adjustments provided in the manufacturer''s labeling.</li></ul>', 'Low', null, null, null, '<p><strong>Entrectinib:</strong> 600 mg PO daily.</p><p>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (450, 'Gemcitabine: Gemzar, various<br>Paclitaxel: Taxol', 'Gemcitabine/Paclitaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'O''Shaughnessy J. Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience. Oncology (Williston Park). 2003;17(12 Suppl 14):15-21.', 'METASTATIC', '<p><strong>Gemcitabine</strong>&nbsp;1250mg/m<sup>2</sup>&nbsp;IV on days 1 and 8<br />
<strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (432, 'Letrozole: Femara', 'Letrozole', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Letrozole</strong>:<br />
	If Child-Pugh A or B, no dose reduction<br />
	If Child-Pugh C, reduce dose by 50%</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Letrozole</strong>:<br />
	If CrCl &gt; 10 mL/min, no dose reduction</li>
</ul>
', 'N/A', '', 'BIG 1-98 Collaborative Group, Mouridsen H, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766-76. ', 'ADJUVANT', '<p><strong>Letrozole:</strong>&nbsp;2.5 mg PO daily</p><p>Repeat daily for 5 to 10 years in patients with ER+ or PR+ tumors.</p>', 17);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (430, 'Tamoxifen: Nolvadex', 'Tamoxifen', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong>:<br />
	No dose reduction</li>
</ul>
', 'N/A', '', 'Fisher B, Dignam J, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89(22):1673-82.', 'ADJUVANT', '<p><strong>Tamoxifen:</strong>&nbsp;20 mg PO daily</p><p>Repeat daily for 5 to 10 years in patients with ER+ tumors or ER status unknown.</p>', 17);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (735, '', 'Capecitabine', '<p>&nbsp;</p><p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'Low', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>Capecitabine:&nbsp;</strong>1,250 mg/m2&nbsp;PO bid on days 1-14</p><p>Repeat every 21 days. The dose may be decreased to 850-1,000 mg/m2&nbsp;PO bid on days 1-14 to reduce the risk of toxicity without compromising clinical efficacy.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (736, '', 'CPT-11 (weekly schedule)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li></ul>', 'Moderate', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>CPT-11:&nbsp;</strong>125 mg/m<sup>2</sup>&nbsp;IV over 90 minutes weekly for 4 weeks</p>

<p>Repeat cycle every 6 weeks.</p>

<p><strong>OR</strong></p>

<p><strong>CPT-11:&nbsp;</strong>125 mg/m<sup>2</sup>&nbsp;IV over 90 minutes weekly for 2 weeks</p>

<p>Repeat cycle every 3 weeks.</p>

<p><strong>OR</strong></p>

<p><strong>CPT-11:&nbsp;</strong>175 mg/m<sup>2</sup>&nbsp;IV on days 1 and 10</p>

<p>Repeat cycle every 3 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (631, '', 'FOLFIRI + Ramucirumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li><li><strong>Ramucirumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li><li><strong>Ramucirumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>

<p><strong>Ramucirumab:&nbsp;</strong>8 mg/kg IV on day 1</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (732, '', 'Nivolumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nivolumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nivolumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', '', '<p><strong>Nivolumab:&nbsp;</strong>240 mg IV on day 1</p>

<p>Repeat cycle every 2 weeks. May also give 480 mg IV on day 1 every 4 weeks.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (608, '', 'Cetuximab + Irinotecan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Cetuximab:&nbsp;</strong>400 mg/m2&nbsp;IV loading dose, then 250 mg/m2&nbsp;IV weekly</p><p><strong>Irinotecan:&nbsp;</strong>350 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days</p><p><strong>OR</strong></p><p><strong>Cetuximab:&nbsp;</strong>400 mg/m2&nbsp;IV loading dose, then 250 mg/m2&nbsp;IV weekly</p><p><strong>Irinotecan:&nbsp;</strong>125 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 14 days</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (515, 'Doxorubicin: Adriamycin, various', 'Doxorubicin', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Torti FM, Bristow MR, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983;99(6):745-9.', 'METASTATIC', '<p><strong>Doxorubicin</strong>&nbsp;20mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 7 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (609, '', 'Capecitabine + Oxaliplatin (XELOX)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Oxaliplatin:&nbsp;</strong><br>&nbsp;If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Reduce initial dose from 85 mg/m2 to 65 mg/m2.</li></ul>', 'Medium', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m2&nbsp;PO bid on days 1-14</p><p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m2&nbsp;IV on day 1</p><p>Repeat every 21 days. May decrease the dose of capecitabine to 850 mg/m2&nbsp;PO twice daily and the dose of oxaliplatin to 100 mg/m2&nbsp;IV to reduce risk of toxicity without compromising clinical efficacy.</p><p><strong>OR</strong></p><p><strong>Capecitabine:&nbsp;</strong>1,750 mg/m2&nbsp;PO twice daily on days 1-7</p><p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m2&nbsp;IV on day 1</p><p>Repeat every 14 days. May decrease dose of capecitabine to 1,000-1,250 mg/m2&nbsp;PO twice daily to reduce the risk of toxicity without compromising clinical efficacy.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (879, null, 'Octreotide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Octreotide:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Octreotide:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'N/A', null, null, null, '<p><strong>Octreotide:</strong> 150-250 μg SC tid.<br>Continue until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (878, null, 'Capecitabine + Temozolomide (Pancreatic Endocrine Carcinoma)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine:</strong><br>No dose reduction</li><li><strong>Temozolomide:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine:</strong><br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Temozolomide:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Capecitabine: </strong>750 mg/day PO on days 1-14<br><strong>Temozolomide:</strong> 200 mg/m2/day PO on days 10-14</p><p>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (433, 'Tamoxifen: Nolvadex<br>Letrozole: Femara', 'Tamoxifen/Letrozole', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong><br />
	No dose reduction</li>
	<li><strong>Letrozole</strong>:<br />
	If Child-Pugh A or B, no dose reduction<br />
	If Child-Pugh C, reduce dose by 50%</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong><br />
	No dose reduction</li>
	<li><strong>Letrozole</strong>:<br />
	If CrCl &gt; 10 mL/min, no dose reduction</li>
</ul>
', 'N/A', '', 'Goss PE, Ingle JN, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262-71.', 'ADJUVANT', '<p><strong>Tamoxifen:</strong>&nbsp;20 mg PO daily for 5 years for ER + patients.</p><p><strong>FOLLOWED BY</strong></p><p><strong>Letrozole:&nbsp;</strong>2.5 mg PO daily for 5 years for ER + patients.</p>', 17);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (824, null, ' Ara-C+ Clofarabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Clofarabine:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 40% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 45 mL/minute: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Clofarabine:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &gt;60 mL/min: 100 % dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 30 to 60 mL/min: Reduce dose by 50% &nbsp;</li></ul>', 'Moderate', null, null, null, '<p><strong>Cytarabine:</strong> 1,000 mg/m2 IV over 2 hours on days 1-5<br><strong>Clofarabine:</strong> 40 mg/m2 IV over 1 hour on days 2-6.</p><p>Repeat cycles every 4-6 weeks for up to a total of 3 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (558, 'Temsirolimus: Torisel', 'Temsirolimus', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Temsirolimus</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Temsirolimus</strong>:<br>No dose reduction</li></ul>', 'Low', '', 'Oza AM, Elit L, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011;29(24):3278-85.', '', '<p><strong>Temsirolimus:</strong>&nbsp;25 mg IV on day 1</p><p>Repeat cycle every 28 days.</p>', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (472, 'Pembrolizumab: Keytruda
nab-Paclitaxal: Abraxane
Carboplatin: Platinol', 'Carboplatin + Pembrolizumab + nab-paclitaxal', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Nab-Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin 1.2 to ≤1.8 mg/dL:100% dosage<br>If bilirubin &gt;1.8 to ≤3.6 mg/dL: Reduce dose by 75%<br>If bilirubin &gt; 3.6 mg/dL, do not use</li><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Nab-Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: There are no dosage adjustments provided because of insufficient data.</li><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'High', '', 'KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Carboplatin:</strong>&nbsp;AUC 6, IV once on day 1<br><strong>Paclitaxel (nanoparticle albumin-bound):</strong> 100 mg/m2&nbsp;IV once per day on days 1, 8, 15.<br><strong>Pembrolizumab:</strong>&nbsp;200 mg IV once on day 1.</p><p>Repeat cycle every 21 days for up to 4 cycles followed by pembrolizumab for up to a total of 35 treatments.</p>', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (571, 'Altretamine: Hexalen', 'Altretamine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Altretamine</strong>:<br />
	No dose reduction&nbsp;</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Altretamine</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Markman M, Blessing JA, et al. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 1998;69(3):226-9.', '', '<p><strong>Altretamine:&nbsp;</strong> 260 &nbsp;mg/m2/day PO in 4 divided doses after meals and at bedtime</p><p>Repeat cycle every 14-21 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (962, null, 'Lenalidomide (Mantle cell lymphoma)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>If CrCl &gt;60 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 30 to 60 mL/min: 5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min not requiring dialysis: 2.5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min requiring dialysis: 2.5 mg once daily (administer after dialysis on dialysis days).</li></ul>', 'Low', null, null, null, '<p><strong>Lenalidomide:</strong> 25 mg/day PO on days 1-21<br>Repeat cycle every 28 days for up to 52 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (227, 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various<br>Vincristine : Oncovin, VCR', 'CODOX-M/IVAC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Ifosfamide:</strong><br>No dose reduction</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Ifosfamide</strong>:<br>&nbsp;If CrCl ≥10 mL/min: 100% normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: 75% normal dose.</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'Moderate', '<b>CODOX-M/IVAC</b>', 'Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt''s lymphoma: results of United Kingdom Lymphoma Group LY06 Study. $Ann Oncol. 2002, 13(8): 1254-1274.$', null, '<p>Cycles 1 AND 3 (CODOX-M)<br><strong>Cyclophosphamide:</strong> 800 mg/m2 IV, day 1<br><strong>Cyclophosphamide:</strong> 600 mg/m2/d IV, days 2-5<br><strong>Doxorubicin:</strong> 40 mg/m2 IV, day 1<br><strong>Vincristine:</strong> 1.5 mg/m2 IV up to a maximum dose of 2 mg, days 1,8 for cycle 1, days 1,8, 15 for cycle 2<br><strong>Methotrexate:</strong> 1,200 mg/m2 IV over 1 hour, day 10, <strong>THEN</strong> 240 mg/m2/h CIVI for the next 23 hours<br><strong>Leucovorin calcium: </strong>192 mg/m2 IV, starting at hour 36 <strong>THEN</strong> 12 mg/m2 every 6 hours until Methotrexate level is &lt;5*10-8 M<br><strong>Filgrastim: </strong>5 mcg/kg/d SQ until ANC &gt;1,000/mm3<br><strong>Methotrexate:</strong> 12mg IT, day 15<br><strong>Leucovorin calcium:</strong> 15 mg PO 24 hours after Methotrexate, day 16<br>CNS PROPHYLAXIS<br><strong>Cytarabine:</strong> 70 mg IT, days 1,3,5<br><strong>Methotrexate:</strong> 12 mg IT, day 12 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Cycles 2 AND 4 (IVAC)<br><strong>Ifosfamide:</strong> 1,500mg/m2 IV over 1 hour, days 1-5<br><strong>Mesna:</strong> 360 mg/m2 IV over 1 hour, <strong>Then</strong> 360 mg/m2 IV every 3 hours for a maximum of 7 doses per 24 hour period, days 1-5<br><strong>Cytarabine:</strong> 2,000 mg/m2 IV over 3 hours every 12 hours, days 1 and 2<br><strong>Methotrexate:</strong> 12 mg IT, day 5<br><strong>Leucovorin calcium:</strong> 15 mg PO 24 hours after Methotrexate, day 6<br><strong>Filgrastim:</strong> 5 mcg/kg/d SQ until ANC &gt; 1,000/mm3</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (226, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Prednisone : various<br>Rituximab : Rituxan<br>Vincristine : Oncovin, VCR', 'R - CHOP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Rituximab:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Rituximab:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Moderate', '<b>R - CHOP</b>', 'Coiffier B, Leapage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. $N Engl J Med. 2002;346(4):235-242.$<br> Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. $J Clin Oncol. 1999; 17(1):268-276$.', null, '<p><strong>Cyclophosphamide:</strong> 750 mg/m2 IV, day 1<br><strong>Doxorubicin:</strong> 50 mg/m2 IV, day 1<br><strong>Vincristine:</strong> 1.4 mg/m2 IV, day 1 up to a maximum dose of 2mg<br><strong>Prednisone:</strong> 40 mg/m2/d PO, days 1-5<br><strong>Rituximab:</strong> 375 mg/m2 IV, day 1<br>Repeat every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (242, 'Rituximab : Rituxan', 'Rituximab Maintenance', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Rituximab:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Rituximab:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Low', '<b>Rituximab Maintenance</b>', 'van Oers NH, Van Glabbeke M, Glurgea L, et al. Rituximab maintenance treatment of relapsed/residual follicular Non Hodgikin''s lymphoma: Long-term outcome or EROTC 20891 phase III randomized intergroup study. $ JClin Oncol. 2010;28(17):2853-2858.$', null, '<p><strong>Rituximab:</strong> 375 mg/m2/day IV, day 1<br>Repeat every 90 days until relapse or maximum of 2 years.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (261, '', 'Arsenic trioxide (acute promyelocytic leukemia only)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Arsenic trioxide:</strong>&nbsp;<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Arsenic trioxide:</strong>&nbsp;<br>If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Use with caution, may require dosage reduction (monitor closely for toxicity)</li></ul>', 'Low', '<b>Arsenic</b>', 'Trisenox [package insert]. $Frazer, PA: Cephalon; 2010.$', null, '<p><strong>Arsenic trioxide:</strong> 0.15 mg/kg IV daily.</p><p>Continue treatment until bone marrow remission up to a maximum of 60 doses.<br>Patients who meet the criteria for clinical CR can receive an additional course<br>of arsenic trioxide as consolidation therapy beginning 3-4 weeks after completion of<br>induction therapy up to a cumulative total of 25 doses.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (482, 'Gemcitabine: Gemzar
Docetaxel: Taxotere', 'Gemcitabine + Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul>', 'Moderate', '', 'Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31.

Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005; 16:602.

Minami, H., Kawada, K., Sasaki, Y., Tahara, M., Igarashi, T., Itoh, K., Fujii, H., Saeki, T., Ozawa, K. and Sato, H. (2009), Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Science, 100: 144-149. doi:10.1111/j.1349-7006.2009.00992.x

Floyd J., Kerr T.A. (2020). Chemotherapy hepatotoxicity and dose modification in patients with liver disease. Retrieved April 2020 from https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease.

Casal J, Amenedo M, Mel JR, Antón LM, Rodríguez-López R, López-López R, González-Ageitos A, Castellanos J, Constenla M, Tisaire JL. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study. Cancer Chemother Pharmacol. 2007 Oct;60(5):725-32. Epub 2007 Feb 2.
', 'METASTATIC', '<p><strong>Docetaxel:</strong> 100 mg/m2 IV, 1 hour infusion, given on day 8<br><strong>Gemcitabine:</strong> 1,100 mg/m2 IV, 30-min infusion, given on day 1, 8</p><p>Repeat cycle every 21 days. G-CSF support is required from day 9 to day 15</p>', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (479, 'Cisplatin: Platinol
Etoposide: Vepesid', 'Cisplatin + Etoposide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', '', 'ECOG E1581: Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol. 1986 Jan;4(1):14-22.

EORTC 07861: Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P, Paesmans M. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organisation for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990 Sep;8(9):1556-62.

Comella P, Frasci G, De Cataldis G, Panza N, Cioffi R, Curcio C, Belli M, Bianco A, Ianniello G, Maiorino L, Della Vittoria M, Perchard J, Comella G; Gruppo Oncologico Campano. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Br J Cancer. 1996 Dec;74(11):1805-11.
Cardenal F, López-Cabrerizo MP, Antón A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, García M, Lianes P, Montalar J, Vadell C, González-Larriba JL, Nguyen B, Artal A, Rosell R. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999 Jan;17(1):12-8.
 Font A, Moyano AJ, Puerto JM, Tres A, Garcia-Giron C, Barneto I, Anton A, Sanchez JJ, Salvador A, Rosell R; Spanish Lung Cancer Group. Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group. Cancer. 1999 Feb 15;85(4):855-63.
 ECOG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.
 Belani CP, Lee JS, Socinski MA, Robert F, Waterhouse D, Rowland K, Ansari R, Lilenbaum R, Natale RB. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol. 2005 Jul;16(7):1069-75. Epub 2005 Apr 28. ', 'METASTATIC', '<p><strong>Cisplatin:</strong>&nbsp;60 mg/m2&nbsp;IV once on day 1<br><strong>Etoposide:</strong> 120 mg/m2&nbsp;IV once per day on days 1 to 3</p><p>Repeat cycle every 21-28 days.</p>', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (251, 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Dexamethasone : various<br>Doxorubicin : Adriamycin, various<br>Prednisone : various<br>Thioguanine : 6-TG<br>Vincristine : Oncovin, VCR', 'CALGB 8811', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL: 75% of usual dosage.&nbsp;<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Daunorubicin:</strong><br>If bilirubin 1.2-3 mg/dL: 75% of usual dosage.<br>If bilirubin 3.1-5 mg/dL: 50% of usual dosage.<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL: 50% of usual dosage.<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL: Do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>L-Asparaginase: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Do not use in patients with severe hepatic impairment.</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 5 mg/dL: Do not use</li><li><strong>6-Mercaptopurine:</strong><br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 3 mg/dL: 50% of usual dosage.</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL: 50% of usual dosage.<br>If bilirubin 3.1-5 mg/dL: 25% of usual dosage.<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>6-Thioguanine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min: 75% of usual dosage.<br>If CrCl &lt; 10 mL/min: 50% of usual dosage.</li><li><strong>Daunorubicin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>L-Asparaginase:</strong><br>No dose reduction</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min: 50% of normal dosage.<br>If CrCl &lt; 30 mL/min: Do not use</li><li><strong>6-Mercaptopurine:</strong><br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>6-Thioguanine:</strong><br>No dose reduction</li></ul>', 'High', '<b>CALGB 8811</b>', 'Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. $Blood. 1995;85(8):2025-2037.$', null, '<p><strong>INDUCTION</strong> (COURSE 1 to 4 WEEKS)<br><strong>Cyclophosphamide:</strong> 1,200 mg/m2 IV, day1 (800 mg/m2 for patients &gt;=60 years)<br><strong>Daunorubicin:</strong> 45 mg/m2 IV, days 1-3 (30 mg/m2 for patients&gt;=60 years)<br><strong>Vincristine:</strong> 2 mg IV, days 1, 8, 15, 22<br><strong>Prednisone:</strong> 60 mg/m2/d PO, days 1-21 (days 1-7 for patients &gt;=60 years)<br><strong>Asparaginase:</strong> 6,000 units/m2 SQ, days 5, 8, 11, 15, 18, 22<br>EARLY INTENSIFICATION (COURSE 2 to 4 WEEKS, REPEAT ONCE)<br><strong>Methotrexate:</strong> 15 mg IT, day 1<br><strong>Cyclophosphamide:</strong> 1,000 mg/m2 IV, day 1<br><strong>Mercaptopurine:</strong> 60 mg/m2/d PO, days 1-14<br><strong>Cytarabine:</strong> 75 mg/m2/d SQ, days 1-4, 8-11<br><strong>Vincristine:</strong> 2 mg IV, days 15, 22<br><strong>Asparaginase:</strong> 6,000 units/m2 SQ, days 15, 18, 22, 25<br>CNS PROPHYLAXIS AND INTERIM MAINTENANCE (COURSE 3 to 12 WEEKS)<br><strong>Cranial RT:</strong> 2,400 cGy, days 1-12<br><strong>Methotrexate:</strong> 15 mg IT, days 1, 8, 15, 22, 29<br><strong>Mercaptopurine:</strong> 60 mg/m2/d PO, days 1-70<br><strong>Methotrexate:</strong> 20 mg/m2 PO, days 36, 43, 50, 57, 64<br>LATE INTENSIFICATION (COURSE 4 to 8 WEEKS)<br><strong>Doxorubicin:</strong> 30 mg/m2 IV, days 1, 8, 15<br><strong>Vincristine:</strong> 2 mg IV, days 1, 8, 15<br><strong>Dexamethasone:</strong> 10 mg/m2/d PO, days 1-14<br><strong>Cyclophosphamide:</strong> 1,000 mg/m2 IV, day 29<br><strong>Thioguanine:</strong> 60 mg/m2/d PO, days 29-42<br><strong>Cytarabine:</strong> 75 mg/m2/d SQ, days 29-32, 36-39<br>MAINTENANCE &nbsp;(FOR 2 YEARS FROM DIAGNOSIS)<br><strong>Vincristine:</strong> 2 mg IV, day 1 of every 4 weeks<br><strong>Prednisone:</strong> 60 mg/m2/d PO, days 1-5 of every 4 weeks<br><strong>Methotrexate:</strong> 20 mg/m2 PO, days 1, 8, 15, 22<br><strong>Mercaptopurine:</strong> 60 mg/m2/d PO, days 1-28</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (463, 'Carboplatin: Paraplatin
Paclitaxel: Taxol', 'Carboplatin + Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Carboplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li></ul>', 'High', '', 'ECOG E4599: Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50.

IPASS: Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57. Epub 2009 Aug 19.

MONET1: Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol. 2012 Aug 10;30(23):2829-36. Epub 2012 Jul 2.

BEYOND: Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015 Jul 1;33(19):2197-204. Epub 2015 May 26.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.

Paclitaxel injection. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Carboplatin:</strong> AUC &nbsp;6, IV on day 1<br><strong>Paclitaxel:</strong>&nbsp;200 mg/m2&nbsp;IV over 3 hours on day 1</p><p>Repeat cycle every 21 days.</p>', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (569, 'Paclitaxel: Taxol<br>Cisplatin: CDDP', 'Paclitaxel/IP Cisplatin/IP Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li></ul>', 'High', '', 'Armstrong DK, Bundy B, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43.', '', '<p><strong>Paclitaxel:</strong>&nbsp;135mg/m2&nbsp;IV over 24 hours on day 1<br><strong>Cisplatin:</strong>&nbsp;100mg/m2&nbsp;IP on day 2<br><strong>Paclitaxel:</strong>&nbsp;60mg/m2&nbsp;IP on day 8</p><p>Repeat cycle every 21 days up to 6 cycles.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (394, '', '5-Fluorouracil + Mitomycin-C + Radiation Therapy (RTOG/ECOG regimen)', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Mitomycin-C:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Renal Impairment:&nbsp;</strong></li><li><strong>5-Fluorouracil</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Mitomycin-C: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;10 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: 75% dosage</li></ul>', 'Low', '', '', '', '<p><strong>5 Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-4 and 29-32</p>

<p><strong>Mitomycin-C:&nbsp;</strong>10 mg/m<sup>2</sup>&nbsp;IV (maximum of 20 mg) on days 1 and 29</p>

<p><strong>Radiation Therapy:</strong>&nbsp;180 cGy/day, 5 days/week for a total of 5 weeks (total dose, 4,500 cGy)</p>

<p>Chemotherapy is given concurrently with radiation therapy.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (299, 'Carboplatin : Paraplatin<br>Cyclophosphamide : Cytoxan<br>Etoposide : VP-16<br>Mesna : Mesnex, various<br>Vincristine : Oncovin, VCR', 'Carbo/VP-16/Vincristine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin:</strong><br>No dose reduction</li><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin:</strong><br>Dosing based on AUC</li><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'High', '<b>Carbo/VP-16/Vincristine</b>', 'Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children''s Cancer Study Group PNET-3 study. $J Clin Oncol. 2003;21(8):1581-1591.$', null, '<p>CYCLES 1 AND 3 (3-WEEK CYCLES)<br><strong>Vincristine:</strong> 1.5 mg/m2 IV, days 1, 7, 14<br><strong>Etoposide:</strong> 100 mg/m2 IV on days 1-3<br><strong>Carboplatin:</strong> 500 mg/m2 IV days 1, 2<br>CYCLES 2 AND 4 (3-WEEK CYCLES)<br><strong>Vincristine:</strong> 1.5 mg/m2 IV days 1, 7, 14<br><strong>Etoposide: </strong>100 mg/m2 IV days 1-3<br><strong>Cyclophosphamide:</strong> 1,500 mg/m2 IV, day 1<br><strong>Mesna: </strong>750 mg/m2 IV 15 minutes before and 4 and 8 hours after cyclophosphamide</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (260, '', 'ATRA', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>All-trans-retinoic acid: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dose reduction not provided by the manufacturer because of insufficient data.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>All-trans-retinoic acid: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dose reduction not provided by the manufacturer because of insufficient data</li></ul>', 'Low', '<b>ATRA</b>', 'Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. $Blood. 1995;85(10):2643-2653.$', null, '<p><strong>All-trans-retinoic acid</strong> (ATRA, tretinoin): 45 mg/m2 PO daily in 1-2 divided doses.</p><p>Continue treatment until documentation of complete remission (CR). Discontinue treatment 30 days after CR or after 90 days, whichever occurs first</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (389, 'Avelumab (Bavencio) ', 'Avelumab Monotherapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Avelumab (Bavencio):</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Avelumab (Bavencio):</strong><br>No dose reduction</li></ul>', 'Low', '', 'Phase 1: Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, phase Ib study. J Clin Oncol. 2017 Jul 1;35(19):2117-2124. Epub 2017 Apr 4.', 'METASTATIC', '<h4><strong>Avelumab (Bavencio):</strong>&nbsp;10 mg/kg IV over 60 minutes once on day 1, every 2 weeks.</h4><p>Continue treatment until disease progression or unacceptable toxicity.</p>', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (474, 'Carboplatin: Platinol
nab-Paclitaxl: Abraxane', 'Carboplatin + nab-Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Nab-Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin 1.2 to ≤1.8 mg/dL:100% dosage<br>If bilirubin &gt;1.8 to ≤3.6 mg/dL: Reduce dose by 75%<br>If bilirubin &gt; 3.6 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Nab-Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: There are no dosage adjustments provided because of insufficient data.</li></ul>', 'High', '', 'KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.

Abraxane for Injectable Suspension. (paclitaxel protein-bound
particles for injectable suspension) (albumin-bound). U.S. Food and Drug Administraton. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021660s037lbl.pdf
', '', '<p><strong>Carboplatin:</strong> AUC 6 IV once on day 1</p><p><strong>nab-Paclitaxel:</strong> 100 mg/m2&nbsp;IV once per day on days 1, 8, 15.</p><p>Repeat cycle every 21 days.</p>', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (584, 'Niraparib: Zejula', 'Niraparib', '<h4><strong>Hepatic impairment</strong></h4><ul><li><strong>Niraparib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><h4><strong>Renal impairment</strong></h4><ul><li><strong>Niraparib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li></ul><h4>&nbsp;</h4>', 'Moderate or High', '', 'Mirza MN, Monk BJ, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154-2164.', '', '<p><strong>Niraparib:</strong>&nbsp;300 mg PO daily</p><p>Repeat cycle every 28 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (836, null, 'Carboplatin + Paclitaxel', '<p>d</p>', 'High', null, null, null, '<p>d</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (483, 'Gemcitabine: Gemxar
Vinorelbine: Navelbine', 'Gemcitabine + Vinorelbine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Vinorelbine</strong>:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Vinorelbine</strong>:<br>No dose reduction</li></ul>', 'Moderate', '', 'National Center for Biotechnology Information. PubChem Database. Vinorelbine, CID=5311497, https://pubchem.ncbi.nlm.nih.gov/compound/Vinorelbine (accessed on May 1, 2020)

National Center for Biotechnology Information. PubChem Database. Gemcitabine, CID=60750, https://pubchem.ncbi.nlm.nih.gov/compound/Gemcitabine (accessed on May 1, 2020)

Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C; Norwegian Lung Cancer Study Group. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC: a phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012 Jul 24;107(3):442-7. Epub 2012 Jul 3.

Greco FA, Spigel DR, Kuzur ME, Shipley D, Gray JR, Thompson DS, Burris HA, Yardley DA, Pati A, Webb CD, Gandhi JG, Hainsworth JD. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer. 2007 Sep;8(8):483-7.

GLOB 2: Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, Wernli M, Reiterer P, Hui R, Pawel JV, Bertetto O, Pouget JC, Burillon JP, Parlier Y, Abratt R; GLOB 2 group. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Aug;49(2):233-40.

Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK; German and Swiss Lung Cancer Study Group. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004 Jun 15;22(12):2348-56.

Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F; Italian GEMVIN Investigators; NCIC CTG. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Aug 15;21(16):3025-34. Epub 2003 Jul 1.

Janus N, Thariat J, Boulanger H, et al, “Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,” Ann Oncol, 2010, 21(7):1395-403.', 'METASTATIC', '<p><strong>Gemcitibine: </strong>1,200 mg/m2 IV once per day on days 1, 8.<br><strong>Vinorelbine:</strong> 30 mg/m2 IV once per day on days 1, 8.</p><p>Repeat cycle every 21 days.</p>', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (465, 'Cisplatin: Platinol
Paclitaxel: Taxol', 'Cisplatin + Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li></ul>', 'High', '', 'COG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.

Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000 Oct 1;18(19):3390-9.

Rosell, R. et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of Oncology, Volume 13, Issue 10, 1539 - 1549', 'METASTATIC', '<p><strong>Cisplatin: </strong>80 mg/m2 IV once on day 1<br><strong>Paclitaxel: </strong>175 mg/m2&nbsp;IV over 3 hours on day 1</p><p>Repeat cycle every 21 days.</p>', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (880, null, 'Lanreotide (Gastroenteropancreatic neuroendocrine tumors)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lanreotide:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Dosage adjustments not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lanreotide:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'N/A', null, null, null, '<p><strong>Lanreotide:</strong> 120 mg SC on day 1</p><p>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (881, null, 'Sunitinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Sunitinib:</strong><br>If Child-Pugh A or B, no dose reduction&nbsp;<br>If Child-Pugh C, reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Sunitinib:</strong><br>If CrCl &gt; 42 mL/min, no dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Sunitinib:</strong> 50 mg PO daily for 4 weeks</p><p>Repeat cycle every 6 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (739, '', 'Panitumumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Panitumumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Panitumumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>Panitumumab:&nbsp;</strong>6 mg/kg IV every 2 weeks</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (489, 'Trastuzumab: Herceptin<br>Gemcitabine: Gemzar', 'Trastuzumab/Gemcitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine</strong>:<br>No dose reduction</li><li><strong>Trastuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine</strong>:<br>No dose reduction.</li><li><strong>Trastuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Cardiac Impairment</strong></li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'Low', '', 'O''Shaughnessy JA, Vukelja S, et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer. 2004;5(2):142-7.', 'METASTATIC', '<p><strong>Trastuzumab:</strong>&nbsp;4 mg/kg IV loading dose, then 2 mg/kg IV weekly<br><strong>Gemcitabine:</strong>&nbsp;1,200 mg/m2&nbsp;IV weekly for 2 weeks</p><p>Repeat cycles every 21 days.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (488, 'Trastuzumab: Herceptin<br>Vinorelbine: Navelbine', 'Trastuzumab/Vinorelbine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vinorelbine</strong>:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Trastuzumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vinorelbine</strong>:<br>No dose reduction</li><li><strong>Trastuzumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Cardiac Impairment</strong></li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul><p>&nbsp;</p>', 'Low', '', 'Burstein HJ, Kuter I, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001;19(10):2722-30.', 'METASTATIC', '<p><strong>Trastuzumab:</strong>&nbsp;4 mg/kg IV loading dose, then 2 mg/kg IV weekly<br><strong>Vinorelbine:</strong>&nbsp;25 mg/m2&nbsp;IV weekly</p><p>Repeat cycle every week until disease progression.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1069, null, 'Cisplatin + Etoposide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:</strong>&nbsp;100 mg/m2&nbsp;IV once on day 1<br><strong>Etoposide:</strong> 100 mg/m2&nbsp;IV once per day on days 1 to 3</p><p>Repeat cycle every 28 days for 4 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (734, '', 'Ramucirumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ramucirumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ramucirumab:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', '', '', '', '<p><strong>Ramucirumab:&nbsp;</strong>8 mg/kg IV on day 1</p>

<p>Repeat cycle every 14 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (468, 'Gemcitabine: Gemzar
Docetaxel: Taxotere', 'Gemcitabine + Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul>', 'Low', '', 'Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31.

Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005; 16:602.

Minami, H., Kawada, K., Sasaki, Y., Tahara, M., Igarashi, T., Itoh, K., Fujii, H., Saeki, T., Ozawa, K. and Sato, H. (2009), Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Science, 100: 144-149. doi:10.1111/j.1349-7006.2009.00992.x

Floyd J., Kerr T.A. (2020). Chemotherapy hepatotoxicity and dose modification in patients with liver disease. Retrieved April 2020 from https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease.

Casal J, Amenedo M, Mel JR, Antón LM, Rodríguez-López R, López-López R, González-Ageitos A, Castellanos J, Constenla M, Tisaire JL. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study. Cancer Chemother Pharmacol. 2007 Oct;60(5):725-32. Epub 2007 Feb 2.', 'METASTATIC', '<p><strong>Docetaxel:</strong>&nbsp;100 mg/m2&nbsp;IV over 1 hour&nbsp;infusion on day 8<br><strong>Gemcitabine:</strong> 1,100 mg/m2&nbsp;IV, 30-min&nbsp;infusion on&nbsp;day 1, 8.</p><p>Repeat cycle every 21 days. G-CSF support is required from day 9 to day 15.</p>', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (916, null, 'CVP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Cyclophosphamide:</strong> 400 mg/m2 PO on days 1-5 ( or 800 mg/m2 IV on day 1)<br><strong>Vincristine:</strong> 1.4 mg/m2 IV on day 1 (maximum dose of 2 mg)<br><strong>Prednisone:</strong> 100 mg/m2 PO, days 1-5<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (491, 'Trastuzumab: Herceptin<br>Lapatinib: Tykerb ', 'Trastuzumab/Lapatinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lapatinib</strong>:<br>If Child-Pugh C, reduce dose to 750 mg/d</li><li><strong>Trastuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lapatinib</strong>:<br>Not studied. Only 2% eliminated by kidneys</li><li><strong>Trastuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Cardiac Impairment</strong></li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'Low', '', 'Blackwell KL, Burstein HJ, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124-30.', 'METASTATIC', '<p><strong>Trastuzumab:</strong>&nbsp;4 mg/kg IV loading dose, then 2 mg/kg IV weekly<br><strong>Lapatinib:</strong>&nbsp;1,000 mg PO daily</p><p>Continue until disease progression.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (467, 'Gemcitabine: Gemzar
Carboplatin: Paraplatin', 'Gemcitabine + Carboplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Carboplatin:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: &nbsp;Reduce dose to 50% of the usual dose. &nbsp; If GFR &lt;10 mL/min: Reduce dose to 75% of the usual dose.</li></ul>', 'High', '', 'Grigorescu AC, Draghici IN, Nitipir C, Gutulescu N, Corlan E. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer. 2002 Jul;37(1):9-14.

Zatloukal P, Petruzelka L, Zemanová M, Kolek V, Skricková J, Pesek M, Fojtů H, Grygárková I, Sixtová D, Roubec J, Horenková E, Havel L, Průsa P, Nováková L, Skácel T, Kůta M. Gemcitabine plus cisplatin vs gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer. 2003 Sep;41(3):321-31.

Sederholm C, Hillerdal G, Lamberg K, Kölbeck K, Dufmats M, Westberg R, Gawande SR; Swedish Lung Cancer Study Group. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005 Nov 20;23(33):8380-8.

Ferry D, Billingham L, Jarrett H, Dunlop D, Woll PJ, Nicolson M, Shah R, Thompson J, Spicer J, Muthukumar D, Skailes G, Leonard P, Chetiyawardana AD, Wells P, Lewanski C, Crosse B, Hill M, Gaunt P, O''Byrne K; British Thoracic Oncology Group. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. Eur J Cancer. 2017 Sep;83:302-312. Epub 2017 Aug 4.

Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S; Norwegian Lung Cancer Study Group. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11.

Grigorescu, Alexandru C. et al. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer, Volume 37, Issue 1, 9 - 14.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Gemcitabine:</strong> 1,000 mg/m2&nbsp;IV over 30 minutes on days 1, 8.</p><p><strong>Carboplatin:</strong> AUC 5, IV once on day 1</p><p>Repeat cycle every 21 days.</p>', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (462, 'Carboplatin: Paraplatin
Etoposide: VP-16', 'Carboplatin + Etoposide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', '', 'EORTC 07861: Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P, Paesmans M. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organisation for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990 Sep;8(9):1556-62.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Carboplatin</strong>:&nbsp;325 mg/m2&nbsp;IV over 60 minutes once on day 1<br><strong>Etoposide</strong>: 100 mg/m2&nbsp;once per day on days 1-3</p><p>Repeat cycle every 21 to 28 days.</p>', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (917, null, 'CHOP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Cyclophosphamide:</strong> 750 mg/m2 IV, day 1<br><strong>Doxorubicin:</strong> 50 mg/m2 IV, day 1<br><strong>Vincristine:</strong> 1.4 mg/m2 IV, day 1 (maximum of 2 mg)<br><strong>Prednisone:</strong> 100 mg/m2 PO, days 1-5<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (470, 'Gemcitabine: Gemxar
Vinorelbine: Navelbine', 'Gemcitabine + Vinorelbine ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Vinorelbine</strong>:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Vinorelbine</strong>:<br>No dose reduction</li></ul>', 'Low', '', 'National Center for Biotechnology Information. PubChem Database. Vinorelbine, CID=5311497, https://pubchem.ncbi.nlm.nih.gov/compound/Vinorelbine (accessed on May 1, 2020)

National Center for Biotechnology Information. PubChem Database. Gemcitabine, CID=60750, https://pubchem.ncbi.nlm.nih.gov/compound/Gemcitabine (accessed on May 1, 2020)

Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C; Norwegian Lung Cancer Study Group. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC: a phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012 Jul 24;107(3):442-7. Epub 2012 Jul 3.

Greco FA, Spigel DR, Kuzur ME, Shipley D, Gray JR, Thompson DS, Burris HA, Yardley DA, Pati A, Webb CD, Gandhi JG, Hainsworth JD. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer. 2007 Sep;8(8):483-7.

GLOB 2: Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, Wernli M, Reiterer P, Hui R, Pawel JV, Bertetto O, Pouget JC, Burillon JP, Parlier Y, Abratt R; GLOB 2 group. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Aug;49(2):233-40.

Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK; German and Swiss Lung Cancer Study Group. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004 Jun 15;22(12):2348-56.

Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F; Italian GEMVIN Investigators; NCIC CTG. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Aug 15;21(16):3025-34. Epub 2003 Jul 1.

Janus N, Thariat J, Boulanger H, et al, “Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,” Ann Oncol, 2010, 21(7):1395-403. ', 'METASTATIC', '<p><strong>Gemcitabine:</strong>&nbsp;1,200 mg/m2&nbsp;IV once per day on days 1 and 8<br><strong>Vinorelbine:</strong>&nbsp;30 mg/m2&nbsp;IV once per day on days 1 and 8</p><p>Repeat cycle every 21 days.</p>', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (427, 'Cisplatin: Platinol.
Etoposide: Vepesid', 'Cisplatin + Etoposide + Durvalumab ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Durvalumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min: Reduce dose by 25%<br>If CrCl &lt; 10 mL/min: Reduce dose by 50%</li><li><strong>Durvalumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li></ul>', 'High', '', 'CASPIAN: Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Oct 4. [Epub ahead of print] ', '', '<p><strong>Cisplatin:</strong> 75-80 mg/m2&nbsp;on day 1<br><strong>Etoposide:</strong> 80-100 mg/m2&nbsp;on days 1, 2, 3&nbsp;<br><strong>Durvalumab:</strong> 1,500 mg on day 1</p><p>Repeat cycle every 21 days for 4 cycles.</p><p>Followed by maintenance durvalumab: 1,500 mg on day 1 and then repeat cycle every 28 days.</p>', 105);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (918, null, 'CNOP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Mitoxantrone:</strong><br>If bilirubin &gt; 3 mg/dL, reduce dose by 25%</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Mitoxantrone:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Cyclophosphamide:</strong> 750 mg/m2 IV on day 1<br><strong>Mitoxantrone: </strong>10 mg/m2 IV on day 1<br><strong>Vincristine:</strong> 1.4 mg/m2 IV on day 1 (maximum, 2 mg)<br><strong>Prednisone:</strong> 50 mg/m2 PO on days 1-5<br>Repeat cycle every 21 days.<br>&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (461, 'Carboplatin: Paraplatin
Nanoparticle albumin bound paclitaxel- Abraxane', 'Carboplatin + nab-Paclitaxel ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Nab-Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin 1.2 to ≤1.8 mg/dL:100% dosage<br>If bilirubin &gt;1.8 to ≤3.6 mg/dL: Reduce dose by 75%<br>If bilirubin &gt; 3.6 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Nab-Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: There are no dosage adjustments provided because of insufficient data.</li></ul>', 'High', '', 'CA031: Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012 Jun 10;30(17):2055-62. Epub 2012 Apr 30.', 'METASTATIC', '<p><strong>Carboplatin:&nbsp;</strong>AUC 6,&nbsp;IV on day 1</p><p><strong>Paclitaxel (Nanoparticle albumin-bound):</strong> 100 mg/m2&nbsp;IV on days 1, 8, 15.</p><p>Repeat cycle every 21 days.</p>', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (512, 'Paclitaxel: Taxol', 'Paclitaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br />
	If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2<br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Holmes FA, Walters RS, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991;83(24):1797-805. --- Perez EA. Paclitaxel in Breast Cancer. Oncologist. 1998;3(6):373-389.', 'METASTATIC', '<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV over 3 hours on day 1</p>

<p>Repeat cycle every 21 days.</p>

<p>OR</p>

<p><strong>Paclitaxel</strong>&nbsp;80-100mg/m<sup>2</sup>&nbsp;IV weekly for 3 weeks</p>

<p>Repeat cycle every 4 weeks.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (513, 'Ixabepilome: Ixempra ', 'Ixabepilone', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Ixabepilone</strong>:<br />
	If AST and ALT &lt; 2.5 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 40 mg/m2<br />
	If AST or ALT &lt; 10 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 32 mg/m2<br />
	If AST and ALT &lt; 10 upper normal limit, and bilirubin 1.5-3 upper normal limit, use 20-30 mg/m2<br />
	If AST or ALT &gt; 10 upper normal limit, or bilirubin &gt; 3 upper normal limit, do not use<br />
	In combination with capecitabine:<br />
	If AST and ALT &lt; 2.5 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 40 mg/m2<br />
	If AST or ALT &gt; 2.5 upper normal limit, or bilirubin &gt; 1 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Ixabepilone</strong>:<br />
	If CrCl &gt; 30 mL/min, no dose reduction</li>
</ul>
', 'Low', '', 'Perez EA, Lerzo G, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25(23):3407-14.', 'METASTATIC', '<p><strong>Ixabepilone</strong>&nbsp;40mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (600, '', 'Irinotecan + 5-Fluorouracil + Leucovorin (FOLFIRI regimen)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (517, 'Doxorubicin liposome: Doxil, various', 'Doxorubicin Liposome', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Al-Batran SE, Meerpohl HG, et al. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology. 2006;70(2):141-6. ', 'METASTATIC', '<p><strong>Doxorubicin liposome</strong>&nbsp;40mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 28 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (519, 'Eribulin: Halaven', 'Eribulin', '', 'Low', '', 'Cortes J, O''Shaughnessy J, et al. Eribulin monotherapy versus treatment of physician''s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914-23. ', 'METASTATIC', '<p><strong>Eribulin</strong>&nbsp;1.4mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p>Repeat cycle every 21 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (518, 'Nab-paclitaxel: Abraxane', 'Nab-Paclitaxel', '', 'Low', '', 'O''Shaughnessy JA, et al. Breast Cancer Res Treat 2003;82:Suppl 1 (abstract 43). --- O''Shaughnessy JA, et al. Breast Cancer Res Treat 2004;88:Suppl 1 (abstract 1070).', 'METASTATIC', '<p><strong>Nab-paclitaxel</strong>&nbsp;260mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>

<p>OR</p>

<p><strong>Nab-paclitaxel</strong>&nbsp;125mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p>Repeat cycle every 28 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (520, 'Abemaciclib: Verzenio', 'Abemaciclib', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Abemaciclib</strong><br />
	Child-Pugh C: Reduce dosing frequency to once daily</li>
</ul>
', 'Minimal', '', 'Dickler MN, Tolaney SM, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017;23(17):5218-5224.', 'METASTATIC', '<p><strong>Abemaciclib</strong>&nbsp;150mg PO BID</p>

<p>Repeat cycle every 28 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (696, '', 'Sunitinib', '', '', '', '', 'METASTATIC', '<p><strong>Sunitinib:&nbsp;</strong>50 mg/day PO for 4 weeks</p>

<p>Repeat cycle every 6 weeks.</p>
', 8);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (263, 'Cytarabine : Ara-C', 'High-dose Cytarabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li></ul>', 'Low', '<b>Cytarabine</b>', 'Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. $Blood. 2001;98(3):548-553.$', null, '<p><strong>Cytarabine:</strong> 1,500-3,000 mg/m2 IV over 3 hours, every 12 hours on day 1, 3, and 5.<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (457, 'Carboplatin: Paraplatin
Atezolizumab: Tecentriq
Paclitaxel: Taxol
Bevacizumab: Avastin', 'Atezolizumab + Carboplatin + Paclitaxel + Bevacizumab ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Atezolizumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Carboplatin</strong>:<br>No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Atezolizumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li></ul><p>&nbsp;</p>', 'High', '', 'Martin Reck, Geetha Shankar, Anthony Lee, Shelley Coleman, Mark McCleland, Vassiliki A. Papadimitrakopoulou, Mark A. Socinski & Alan Sandler (2020) Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations, Expert Review of Respiratory Medicine, 14:2, 125-136, DOI: 10.1080/17476348.2020.1701439

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Atezolizumab:</strong>&nbsp;1,200 mg IV on day 1<br><strong>Bevacizumab:</strong> 15 mg/kg&nbsp;IV on day 1<br><strong>Paclitaxel:</strong>&nbsp;200 mg/m2&nbsp;IV on day 1 OR 175 mg/m2 IV in Asian patients<br><strong>Carboplatin:</strong> AUC 6 IV on day 1&nbsp;</p><p>Repeat cycle every 21-days for a maximum of 4 or 6 cycles followed by atezolizumab and bevacizumab until disease progression or toxicity.</p>', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (526, 'Paclitaxel: Taxol<br>Topotecan: Hycamtin<br>Bevacizumab: Avastin', 'Paclitaxel/Topotecan/Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Topotecan</strong>:<br>No dose reduction</li><li><strong>Bevacizumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel</strong>:<br>No dose reduction</li><li><strong>Topotecan</strong>:<br>If CrCl &gt; 40 mL/min, no dose reduction<br>If CrCl 20-39 mL/min, reduce to 0.75 mg/m2</li><li><strong>Bevacizumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'High', '', 'Tewari KS, et al. J Clin Oncol 2013;31:Suppl (abstract 3).', '', '<p><strong>Paclitaxel:</strong>&nbsp;175 mg/m2&nbsp;IV on day 1<br><strong>Topotecan:</strong>&nbsp;0.75 mg/m2/day IV on days 1-3<br><strong>Bevacizumab:</strong>&nbsp;15 mg/kg IV on day 1</p><p>Repeat cycle every 21 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (248, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR', 'CHOP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Moderate', '<b>CHOP</b>', 'Weiss R, Mitrou P, Arasteh K, et.al. Acquired immunodeficiency syndrome-related lymphoma: Simultaneous treatment with combined cyclophosphamide, doxorubicin, Vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial. $Cancer. 2006; 106(7): 1560-1568.$ ', null, '<p><strong>Cyclophosphamide:</strong> 750 mg/m2 IV, day 1<br><strong>Doxorubicin:</strong> 50 mg/m2 IV, day 1<br><strong>Vincristine:</strong> 1.4 mg/m2 IV, day 1<br><strong>Prednisone:</strong> 100 mg/m2 PO, days 1-5<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (882, null, 'Cisplatin + Ifosfamide + Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Ifosfamide</strong>:<br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Ifosfamide</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥10 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: &nbsp;75% dosage.</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:</strong> 25 mg/m2/day IV over 2 hours on days 1, 2, and 3</p><p><strong>Ifosfamide:</strong> 1,200 mg/m2/day IV over 2 hours on days 1, 2, and 3</p><p><strong>Paclitaxel:</strong> 175 mg/m2 IV over 3 hours day 1</p><p><strong>Mesna:</strong> 400 mg/m2 IV prior to each ifosfamide dose and 200 mg/m2 at 4 and 8 hours after each ifosfamide dose on days 1, 2, and 3</p><p>Repeat cycle every 21 to 28 days for 4 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (464, 'Carboplatin: Paraplatin
Pemetrexed: Alimta', 'Carboplatin + Pemetrexed', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Pemetrexed</strong>:<br>No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Pemetrexed</strong>:<br>If CrCl &gt; 45 mL/min, no dose reduction<br>If CrCl &lt; 45 mL/min, do not use</li></ul>', 'High', '', 'Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O''Brien M, Rao S, Hotta K, Vandormael K, Riccio A, Yang J, Pietanza MC, Brahmer JR. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019 Mar 1;37(7):537-546. Epub 2019 Jan 8.

Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S; Norwegian Lung Cancer Study Group. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Carboplatin:</strong> AUC 5, IV on day 1<br><strong>Pemetrexed:</strong> 500 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days up to 4 cycles.&nbsp;</p><p>Folic acid at 350-1,000 µg PO once daily beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1-2 weeks prior to the first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed therapy.</p>', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (529, 'Bleomycin: Blenoxane<br>Ifosfamide: Ifex<br>Mesna: Mesnex<br>Cisplatin: CDDP', 'BIP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bleomycin</strong>:<br>No dose reduction</li><li><strong>Ifosfamide</strong>:<br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bleomycin</strong><br>If CrCl &gt;50 mL/min: No dose reduction<br>If CrCl 40-50 mL/min: 70% of normal dose<br>If CrCl 30-40 mL/min: 60% of normal dose<br>If CrCl 20-30 mL/min: 55% normal dose<br>If CrCl 10-20 mL/min: 45% normal dose<br>If CrCl 5-10 mL/min: 40% normal dose</li><li><strong>Ifosfamide</strong>:<br>&nbsp;If CrCl ≥10 mL/min: 100% normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: 75% normal dose.</li><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'High', '', 'Buxton EJ, Meanwell CA, et al. Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst. 1989;81(5):359-61.', '', '<p><strong>Bleomycin:</strong>&nbsp;30 U IV over 24 hours on day 1<br><strong>Ifosfamide:</strong>&nbsp;5,000 mg/m2&nbsp;IV over 24 hours on day 2<br><strong>Mesna:</strong>&nbsp;6,000 mg/m2&nbsp;IV over 36 hours on day 2<br><strong>Cisplatin:</strong>&nbsp;50 mg/m2&nbsp;IV on day 2</p><p>Repeat cycle every 21 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (537, 'Docetaxel: Taxotere', 'Docetaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Levy T, et al. Proc Am Soc Clin Oncnol 1996;15:292a.', '', '<p><strong>Docetaxel:</strong>&nbsp;100 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (250, 'Cyclophosphamide : Cytoxan<br>Etoposide : VP-16<br>Prednisone : various<br>Vincristine : Oncovin, VCR', 'EPOCH Dose-adjusted ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Moderate', '<b>EPOCH Dose-adjusted </b>', 'Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. $BLOOD.2003;101(12):4653-4659.$', null, '<p><strong>Etoposide:</strong> 50 mg/m2/d CIVI, days 1-4 (96 hours)<br><strong>Doxorubicin:</strong> 10 mg/m2/d CIVI, days 1-4 (96 hours)<br><strong>Vincristine:</strong> 0.4 mg/m2/d /CIVI, days 1-4 (96 hours)<br><strong>Cyclophosphamide</strong>&nbsp;<br><strong>Cycle1:</strong>&nbsp;<br>375 mg/m2 IV, day 5, if CD4+ cells &gt;= 100/mm3; 187 mg/m2 IV, day 5, if CD4+ cells&lt;100/mm3<br>After cycle 1: increase dose by 187 mg if nadir ANC &gt; 500/mvL or platelets &lt;25,000/mcL<br><strong>Prednisone:</strong> 60 mg/m2/d PO, days 1-5<br><strong>Filgrastim:</strong> 5 mcg/kg/d SQ, day 6, and until ANC &gt;5,000/mcl<br>Repeat every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (234, 'Bendamustine : Treanda', 'Bendamustine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin&nbsp;1.5-3 upper normal limit, or bilirubin &gt; 3 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If CrCl &lt; 40 mL/min, do not use</li></ul>', 'Moderate', '<b>Bendamustine</b>', 'Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgikin lymphoma: results from a multicenter study. $Cancer. 2010,116(1):106-114 $.', null, '<p><strong>Bendamustine:</strong> 120 mg/m2 IV days 1 and 2<br>Repeat every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (538, 'Paclitaxel: Taxol', 'Paclitaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Thigpen T, Vance R, et al. The role of paclitaxel in the management of patients with carcinoma of the cervix. Semin Oncol. 1997;24(1 Suppl 2):S2-41-S2-46.', '', '<p><strong>Paclitaxel:</strong>&nbsp;175 mg/m2&nbsp;IV over 3 hours on day 1</p><p>Repeat cycle every 21 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (540, 'Topotecan: Hycamtin ', 'Topotecan', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Topotecan</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Topotecan</strong>:<br />
	If CrCl &gt; 40 mL/min, no dose reduction<br />
	If CrCl 20-39 mL/min, reduce to 0.75 mg/m<sup>2</sup></li>
</ul>
', 'Low', '', 'Muderspach LI, Blessing JA, et al. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2001;81(2):213-5.', '', '<p><strong>Topotecan:</strong>&nbsp;1.5 mg/m2/day on days 1-5</p><p>Repeat cycle every 21 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (580, 'Bevacizumab: Avastin', 'Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bevacizumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bevacizumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Low', '', 'Burger RA, Sill MW, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-71.', '', '<p><strong>Bevacizumab:</strong>&nbsp;15 mg/kg IV on day 1</p><p>Repeat cycle every 21 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (455, 'Pembrolizumab: Keytruda
Carboplatin: Paraplatin
Pemetrexed: Alimta', 'Pembrolizumab + Carboplatin + Pemetrexed', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (total bilirubin &lt;1 to 1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (total bilirubin &gt;1.5 times ULN): Dosage adjustment not provided by the manufacturer.</li><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Pemetrexed</strong>:<br>No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Pemetrexed</strong>:<br>If CrCl &gt; 45 mL/min, no dose reduction<br>If CrCl &lt; 45 mL/min, do not use</li></ul>', 'High', '', 'KEYNOTE-189: Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078-2092. Epub 2018 Apr 16

KEYNOTE-021: Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov;17(11):1497-1508. Epub 2016 Oct 10.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Pembrolizumab:</strong>&nbsp;200 mg IV on day 1.&nbsp;Administer at least 30 minutes prior to chemotherapy.<br><strong>Carboplatin:</strong> AUC 5, IV on day 1<br><strong>Pemetrexed:</strong> 500 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days up to 4 cycles. Followed by pembrolizumab maintenance therapy up to a total of 35 cycles and pemetrexed maintenance.<br>Folic acid at 350-1,000 µg PO once daily beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1-2 weeks prior to the first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed therapy.</p>', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (561, 'Cisplatin: CDDP<br>Paclitaxel: Taxol', 'CP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li></ul>', 'High', '', 'McGuire WP, Hoskins WJ, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1-6.', '', '<p><strong>Cisplatin:</strong>&nbsp;75 mg/m2&nbsp;IV on day 2<br><strong>Paclitaxel:</strong>&nbsp;135 mg/m2&nbsp;IV over 24 hours on day 1</p><p>Repeat cycle every 21 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (551, 'Paclitaxel: Taxol<br>Ifosfamide: Ifex', 'Paclitaxel/Ifosfamide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ifosfamide</strong>:<br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel</strong>:<br>No dose reduction</li><li><strong>Ifosfamide</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥10 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: &nbsp;75% dosage.</li></ul>', 'Moderate', '', 'Homesley HD, Filiaci V, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(5):526-31.', '', '<p><strong>Paclitaxel:</strong>&nbsp;135 mg/m2&nbsp;IV over 3 hours on day 1<br><strong>Ifosfamide:</strong>&nbsp;1600 mg/m2/day IV on days 1-3</p><p>Repeat cycle every 21 days for up to 8 cycles.&nbsp;</p><p>Mesna to be given as either IV or PO. G-CSF support at 5 μg/kg/day SC to be started on day 4.&nbsp;</p>', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (222, 'Bleomycin : Blenoxane<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Prednisone : various<br>Procarbazine : Matulane<br>Vincristine : Oncovin, VCR', 'BEACOPP (Escalated)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bleomycin:</strong><br>No dose reduction</li><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Procarbazine:</strong><br>If transaminases 1.6 to 6 times ULN: Administer 75% of dose &nbsp; &nbsp; &nbsp; &nbsp; If transaminases &gt;6 times ULN: Use clinical judgment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If serum bilirubin &gt;5 mg/dL or transaminases &gt;3 times ULN: Avoid use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bleomycin:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Procarbazine:</strong><br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li></ul>', 'High', '<b>BEACOPP (Escalated)</b>', 'Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgikin''s disease. $N Engl J Med. 2003;348(24):2386-2395$.', null, '<p><strong>Bleomycin:</strong> 10 mg/m2 IV, day8<br><strong>Etoposide:</strong> 200 mg/m2 IV, days 1-3<br><strong>Doxorubicin:</strong> 35 mg/m2 IV, day 1<br><strong>Cyclophosphamide:</strong> 1,200 mg/m2 IV, day 1<br><strong>Vincristine:</strong> 1.4 mg/m2 IV, day 8<br><strong>Procarbazine:</strong> 100 mg/m2 PO, days 1-7<br><strong>Prednisone:</strong> 40 mg/m2 PO, days 1-14<br>Repeat cycle every 21 days. G-CSF support, at dose of 5 µg/kg/day SC, starting on day 8 and continue until neutrophil recovery.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (550, 'Carboplatin: Paraplatin<br>Doxorubicin liposome: Doxil, various', 'Carboplatin/Doxorubicin Liposome', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Carboplatin</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Carboplatin</strong>:<br />
	Dosing based on AUC</li>
</ul>
', 'High', '', 'Pignata S, Scambia G, et al. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer. 2007;96(11):1639-43.', '', '<p><strong>Carboplatin</strong>&nbsp;AUC of 5, IV on day 1<br><strong>Doxorubicin liposome</strong>&nbsp;40 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 28 days.</p>', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (223, 'Bleomycin : Blenoxane<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Prednisone : various<br>Vinblastine : Velban<br>Vincristine : Oncovin, VCR', 'Stanford V', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bleomycin:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Mechlorethamine:</strong><br>No dose reduction</li><li><strong>Vinblastine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bleomycin:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Mechlorethamine:</strong><br>No dose reduction</li><li><strong>Vinblastine:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li></ul>', 'High', '<b>Stanford V</b>', 'Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ.Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgikin''s disease: a Preliminary report. $J Clin Oncol. 1995; 13(5):1080-1088$.', null, '<p><strong>Doxorubicin:</strong> 25 mg/m2 IV, days 1 and 15<br><strong>Vinblastine:</strong> 6 mg/m2 IV, days 1 and 15<br><strong>Mechlorethamine:</strong> 6 mg/m2 IV, day1<br><strong>Vincristine:</strong> 1.4 mg/m2 IV, days 8 and 22<br><strong>Bleomycin:</strong> 5 U/m2 IV, days 8 and 22<br><strong>Etoposide:</strong> 60mg/m2 IV, days 15 and 16<br><strong>Prednisone:</strong> 40 mg PO every other day</p><p>Repeat cycle every 28 days. In patients &gt;50 years of age, the vinblastine dose<br>&nbsp;must be reduced to 4 mg/m2 and the vincristine dose must be reduced to 1 mg/m2 on weeks 9 and 12. The dose of prednisone should be tapered starting from week 10. The patient should be placed on prophylactic trimethoprim/sulfamethoxazole (Bactrim DS) PO bid and acyclovir 200 mg PO tid.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (235, 'Bexarotene : Targretin', 'Bexarotene', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bexarotene: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bexarotene: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Low', '<b>Bexarotene</b>', 'Targretin [package insert]. $Woodcliff Lake, NJ: Eisai Inc.; 2011.$', null, '<p><strong>Bexarotene:</strong> 300 mg/m2/day PO with a meal</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (563, 'Carboplatin: Paraplatin<br>Paclitaxel: Taxol<br>Bevacizumab: Avastin', 'Carboplatin/Paclitaxel/Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bevacizumab</strong><br>No dose reduction</li><li><strong>Carboplatin</strong><br>No dose reduction</li><li><strong>Paclitaxel</strong><br>Transaminases &lt;10 x ULN and bilirubin ≤1.25 x ULN: 175 mg/m2<br>Transaminases &lt;10 x ULN and bilirubin 1.26 to 2 x ULN: 135 mg/m2<br>Transaminases &lt;10 x ULN and bilirubin 2.01 to 5 x ULN: 90 mg/m2<br>Transaminases ≥10 x ULN or bilirubin &gt;5 x ULN: Use is not recommended</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bevacizumab</strong><br>No dose reduction</li><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose.</li><li><strong>Paclitaxel</strong><br>No dose reduction</li></ul>', 'High', '', 'Burger RA, et al. J Clin Oncol 2010:28:946S (LBA1).', '', '<p><strong>Carboplatin:</strong>&nbsp;AUC of 6, IV on day 1<br><strong>Paclitaxel:</strong>&nbsp;175 mg/m2&nbsp;IV over 3 hours on day 1<br><strong>Bevacizumab:</strong>&nbsp;15 mg/kg IV on day 1</p><p>Repeat cycle every 21 days for 6 cycles, then maintenance bevacizumab for cycles 7-22.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (883, null, 'Sunitinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Sunitinib:</strong><br>If Child-Pugh A or B, no dose reduction&nbsp;<br>If Child-Pugh C, reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Sunitinib:</strong><br>If CrCl &gt; 42 mL/min, no dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Sunitinib:</strong> 50 mg PO daily for 28 days&nbsp;<br>Repeat cycle every 6 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (576, 'Gemcitabine: Gemzar', 'Gemcitabine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Lund B, Hansen OP, et al. Phase II study of gemcitabine (2'',2''-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 1994;86(20):1530-3.', '', '<p><strong>Gemcitabine:</strong>&nbsp;800 mg/m2&nbsp;IV weekly for 3 weeks</p><p>Repeat cycle every 4 weeks.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (574, 'Ixabepilone: Ixempra', 'Ixabepilone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ixabepilone</strong>:<br>If AST or ALT &gt; 10 upper normal limit, or bilirubin &gt; 3 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ixabepilone</strong>:<br>If CrCl &gt; 30 mL/min, no dose reduction</li></ul>', 'Low', '', 'De Geest K, Blessing JA, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2010;28(1):149-53.', '', '<p><strong>Ixabepilone:</strong>&nbsp;20 mg/m2 IV on days 1, 8, and 15</p><p>Repeat cycle every 28 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (575, 'Topotecan: Hycamtin ', 'Topotecan', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Topotecan</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Topotecan</strong>:<br />
	If CrCl &gt; 40 mL/min, no dose reduction<br />
	If CrCl 20-39 mL/min, reduce to 0.75 mg/m<sup>2</sup></li>
</ul>
', 'Low', '', 'Kudelka AP, Tresukosol D, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996;14(5):1552-7.', '', '<p><strong>Topotecan:</strong>&nbsp;1.5 mg/m2&nbsp;IV on days 1-5</p><p>Repeat cycle every 21 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (579, 'Pemetrexed: Alimta', 'Pemetrexed', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Pemetrexed</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Pemetrexed</strong>:<br />
	If CrCl &gt; 45 mL/min, no dose reduction<br />
	If CrCl &lt; 45 mL/min, do not use</li>
</ul>
', 'Low', '', 'Miller DS, et al. J Clin Oncol 2009;27:2686-2691.', '', '<p><strong>Pemetrexed:</strong>&nbsp;900 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p><p>Folic acid 400 to 1,000 mcg PO once daily and vitamin B12 at 1,000 mcg IM to start 7 days prior to the first dose of pemetrexed and repeated every 21 days. Dexamethasone 4 mg PO twice daily on the day before, day of, and day after each dose of pemetrexed to reduce cutaneous reactions.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (578, 'Vinorelbine: Navelbine', 'Vinorelbine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Vinorelbine</strong>:<br />
	If bilirubin 2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Vinorelbine</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Sorensen P, Hoyer M, et al. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol. 2001;81(1):58-62.', '', '<p><strong>Vinorelbine:</strong>&nbsp;30 mg/m2&nbsp;IV on days 1 and 8</p><p>Repeat cycle every 21 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (236, 'Bortezomib : Velcade', 'Bortezomib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If<strong> </strong>bilirubin &gt;1 to 1.5 times ULN: 100% of the dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;1.5 ULN: Reduce initial dose to 0.7 mg/m2.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li></ul>', 'Low', '<b>Bortezomib</b>', 'Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time to event analyses of the multicenter Phase 2. PINNACLE study. $Ann Oncol. 2009;20(3):520-525.$', null, '<p><strong>Bortezomib:</strong> 1.3 mg/m2/day IV bolus, days 1,4, 8, and 11<br>Repeat every 21 days for up to 17 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (521, 'Olaparib: Lynparza ', 'Olaparib', '<h4>Renal impairment</h4>

<ul>
	<li><strong>Olaparib</strong><br />
	CrCl 31-50 mL/min: Reduce dose to 200mg BID</li>
</ul>
', 'Low', '', 'Robson M, Im SA, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523-533.', 'METASTATIC', '<p><strong>Olaparib&nbsp;</strong>300mg PO BID</p>

<p>Repeat cycle every 28 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (596, '', 'LV5FU2 (deGramont regimen)', '', '', '', '', 'ADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p><strong>OR</strong></p>

<p><strong>L-Leucovorin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks for a total of 12 cycles</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (585, 'Bleomycin: Blenoxane<br>Etoposide: VP-16<br>Cisplatin: CDDP', 'BEP (germ cell)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bleomycin</strong>:<br>No dose reduction</li><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bleomycin</strong><br>If CrCl &gt;50 mL/min: No dose reduction<br>If CrCl 40-50 mL/min: 70% of normal dose<br>If CrCl 30-40 mL/min: 60% of normal dose<br>If CrCl 20-30 mL/min: 55% normal dose<br>If CrCl 10-20 mL/min: 45% normal dose<br>If CrCl 5-10 mL/min: 40% normal dose</li><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', '', 'Dimopoulos MA, Papadimitriou C, et al. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol. 2004;95(3):695-700.', '', '<p><strong>Bleomycin:</strong>&nbsp;30 U IV on days 2, 9, and 16<br><strong>Etoposide:</strong>&nbsp;100 mg/m2&nbsp;IV on days 1-5<br><strong>Cisplatin:</strong>&nbsp;20 mg/m2&nbsp;IV on days 1-5</p><p>Repeat cycle every 21 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (581, 'Capecitabine: Xeloda', 'Capecitabine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	If CrCl 30-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
</ul>
', 'Low', '', 'Wolf JK, Bodurka DC, et al. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol. 2006;102(3):468-74.', '', '<p><strong>Capecitabine:</strong>&nbsp;1000 mg/m2&nbsp;PO BID on days 1-14</p><p>Repeat cycle every 21 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (587, 'Erivedge', 'Vismodegib ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vismodegib:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vismodegib:</strong><br>No dose reduction</li></ul>', 'Low', '', 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362529/', '', '<p><strong>Vismodegib:</strong> 150 mg PO daily.</p><p>Continue treatment until disease progression or unacceptable toxicity.</p>', 111);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (599, '', 'Irinotecan + 5-Fluorouracil + Leucovorin (Douillard regimen)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 g/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion prior to 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (595, '', 'Oxaliplatin + Capecitabine (XELOX)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Capecitabine:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'Moderate', '', '', 'ADJUVANT', '<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m2&nbsp;IV on day 1</p><p><strong>Capecitabine:</strong>&nbsp;1,000 mg/m2&nbsp;PO bid on days 1-14</p><p>Repeat every 3 weeks for a total of 8 cycles (6 months total). May decrease the dose to 850 mg/m2&nbsp;PO twice daily on days 1-14 to reduce the risk of toxicity without compromising efficacy.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (583, 'Rucaparib: Rubraca', 'Rucaparib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Rucaparib:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Rucaparib:</strong><br>No dose reduction</li></ul>', 'High', '', 'Swisher EM, Lin KK, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75-87.', '', '<p><strong>Rucaparib:</strong>&nbsp;600 mg PO daily</p><p>Repeat cycle every 28 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (588, 'Odomzo', 'Sonidegib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Sonidegib:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Sonidegib:</strong><br>No dose reduction</li></ul>', 'Low', '', 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970100-2/fulltext', '', '<p><strong>Sonidegib: </strong>200 mg PO daily</p><p>Continue treatment until disease progression or unacceptable toxicity.</p>', 111);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (611, '', 'Capecitabine + Mitomycin-C', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Mitomycin-C: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Mitomycin-C:&nbsp;</strong><br>&nbsp;If CrCl &lt;10 mL/min: 75% of usual dose.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m2&nbsp;PO bid on days 1-14</p><p><strong>Mitomycin-C:&nbsp;</strong>7 mg/m2&nbsp;IV on day 1</p><p>Repeat capecitabine every 3 weeks and mitomycin-C every 6 weeks.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (623, '', 'FOLFIRI + Cetuximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>

<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (619, '', 'Capecitabine + Oxaliplatin (XELOX) + Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Bevacizumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Oxaliplatin:&nbsp;</strong><br>&nbsp;If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Reduce initial dose from 85 mg/m2 to 65 mg/m2.</li><li><strong>Bevacizumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Medium', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>850 mg/m2&nbsp;PO twice daily on days 1-14</p><p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m2&nbsp;IV on day 1</p><p><strong>Bevacizumab:&nbsp;</strong>7.5 mg/kg every 3 weeks</p><p>Repeat every 21 days.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (620, '', 'Cetuximab + Bevacizumab + Irinotecan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> No dose reduction<strong>&nbsp;</strong></li><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Cetuximab:&nbsp;</strong>400 mg/m2&nbsp;IV loading dose, then 250 mg/m2&nbsp;IV weekly</p><p><strong>Bevacizumab:</strong>&nbsp;5 mg/kg IV every 2 weeks</p><p><strong>Irinotecan:&nbsp;</strong>180 mg/m2&nbsp;IV on day 1</p><p>Repeat every 2 weeks.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (617, '', 'FOLFOX4 + Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m2&nbsp;IV on day 1</p><p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m2&nbsp;IV bolus, followed by 600 mg/m2&nbsp;IV continuous infusion on days 1 and 2</p><p><strong>Leucovorin:&nbsp;</strong>200 mg/m2&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p><p><strong>Bevacizumab:&nbsp;</strong>10 mg/kg IV every 2 weeks</p><p>Repeat every 2 weeks.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (625, '', 'FOLFOX6 + Cetuximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Cetuximab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Cetuximab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p>

<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose and then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (622, '', 'Irinotecan + Cetuximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Irinotecan:</strong>&nbsp;125 mg/m<sup>2</sup>&nbsp;IV weekly for 4 weeks</p>

<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p>Repeat cycle every 6 weeks.</p>

<p><strong>OR</strong></p>

<p><strong>Irinotecan:&nbsp;</strong>350 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p>Repeat cycle every 3 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (612, '', 'Oxaliplatin + Irinotecan (IROX regimen)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Irinotecan:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 3 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (644, '', 'Capecitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'Low', '', '', 'ADJUVANT', '<p><strong>Capecitabine:&nbsp;</strong>1,250 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p>Repeat cycles every 21 days for a total of 8 cycles.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (731, '', 'Regorafenib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Regorafenib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Regorafenib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', '', '<p><strong>Regorafenib:&nbsp;</strong>160 mg PO daily for 21 days.</p>

<p>Repeat cycle every 28 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (709, '', 'Gemcitabine + Oxaliplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Oxaliplatin:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li></ul>', 'Medium', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV over 100 minutes on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;over 2 hours on day 2</p>

<p>Repeat cycle every 2 weeks.</p>

<p><strong>OR</strong></p>

<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV over 100 minutes on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;over 2 hours on day 1</p>

<p>Repeat cycle every 2 weeks.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (639, '', '5-Fluorouracil + Cisplatin', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Renal Impairment:&nbsp;</strong></li><li><strong>5-Fluorouracil</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li></ul>', 'High', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5</p>

<p><strong>Cisplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 2</p>

<p>Repeat cycles every 4 weeks.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (641, '', 'mFOLFOX6', '', '', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, then 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycles every 2 weeks.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (640, '', 'Carboplatin + Paclitaxel', '', '', '', '', 'METASTATIC', '<p><strong>Carboplatin:&nbsp;</strong>AUC of 5, IV on day 1</p>

<p><strong>Paclitaxel:&nbsp;</strong>175 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycles every 3 weeks.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (971, null, 'ITP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Ifosfamide</strong>:<br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use<br>&nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Ifosfamide</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥10 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: &nbsp;75% dosage.</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Ifosfamide: </strong>1,500 mg/m2 IV on days 1-3<br><strong>Paclitaxel:</strong> 200 mg/m2 IV over 3 hours on day 1<br><strong>Cisplatin:</strong> 70 mg/m2 IV on day 1<br>Repeat cycle every 21 days. G-CSF support is recommended. Regimen can<br>also, be administered every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (642, '', 'Pembrolizumab', '', '', '', '', 'METASTATIC', '<p><strong>Pembrolizumab:&nbsp;</strong>10 mg/kg IV on day 1 or 200 mg IV on day 1</p>

<p>Repeat cycles every 2 weeks if using 10 mg/kg, or every 3 weeks if using 200 mg dosing.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (643, '', 'Nivolumab', '', '', '', '', 'METASTATIC', '<p><strong>Nivolumab:&nbsp;</strong>480 mg IV on day 1</p>

<p>Repeat cycles every 4 weeks.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (647, '', '5-Fluorouracil + Cisplatin + Radiation Therapy (PRODIGE5/ACCORD17)', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Renal Impairment:&nbsp;</strong></li><li><strong>5-Fluorouracil</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'Low for 5-FU and High for Cisplatin', '', '', 'NEOADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m2/day IV continuous infusion on days 1-4</p><p><strong>Cisplatin:&nbsp;</strong>75 mg/m2&nbsp;IV on day 1</p><p>Repeat every 28 days for a total of 2 cycles given concurrently with radiation therapy. Two additional cycles are given every 21 days after completion of the combined modality therapy.</p><p><strong>Radiation Therapy:&nbsp;</strong>200 cGy/day for 5 days per week to a total dose of 5,000 cGy over 5 weeks</p>', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (648, '', 'FOLFOX + Radiation Therapy (PRODIGE5/ACCORD17)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Moderate', '', '', 'NEOADJUVANT', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m2&nbsp;IV on day 1</p><p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m2&nbsp;IV bolus on day 1, followed by 1,600 mg/m2&nbsp;IV continuous infusion for 46 hours</p><p><strong>Leucovorin:&nbsp;</strong>200 mg/m2&nbsp;IV on day 1 as a 2-hour infusion before the bolus 5-fluorouracil dose</p><p><strong>Radiation Therapy:&nbsp;</strong>200 cGy/day for 5 days per week to a total dose of 5,000 cGy over 5 weeks</p><p>Repeat every 2 weeks for a total of 6 cycles with the first 3 cycles given concurrently with radiation therapy.</p>', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (728, '', 'Sorafenib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Sorafenib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Sorafenib:&nbsp;</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 40 to 59 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 20 to 39 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;20 mL/min: Data inadequate to define dose</li></ul>', 'Low', '', '', '', '<p><strong>Sorafenib:&nbsp;</strong>400 mg PO twice daily</p>

<p>Continue until disease progression. Dose may be reduced to 400 mg once daily or 400 mg every 2 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (663, '', 'Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li>Docetaxel:<br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li>Docetaxel:<br>No dose reduction</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Docetaxel:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (658, '', 'ECF', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li><li><strong>Epirubicin</strong>:<br>If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br>If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction</li><li><strong>Epirubicin</strong><br>If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li></ul>', 'High', '', '', 'METASTATIC', '<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion</p>

<p>Repeat cycle every 21 days.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (660, '', 'ECX', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>Epirubicin</strong>:<br>If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br>If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Capecitabine</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Epirubicin</strong><br>If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'High', '', '', 'METASTATIC', '<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Capecitabine:&nbsp;</strong>625 mg/m<sup>2</sup>&nbsp;PO twice daily continuously</p>

<p>Repeat cycle every 21 days.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (655, '', 'FOLFOX', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1 followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours</p>

<p><strong>Leucovorin:</strong>&nbsp;400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 14 days.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (652, '', 'MAGIC Trial', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li><li><strong>Epirubicin</strong>:<br>If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br>If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction</li><li><strong>Epirubicin</strong><br>If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li></ul>', 'High', '', '', '', '<p><strong>Preoperative ECF Chemotherapy:</strong></p><p><strong>Epirubicin:&nbsp;</strong>50 mg/m2&nbsp;IV on day 1</p><p><strong>Cisplatin:&nbsp;</strong>60 mg/m2&nbsp;IV on day 1</p><p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m2/day IV continuous infusion on days 1-21</p><p>Repeat cycle every 21 days for 3 cycles.</p><p>Followed by esophagectomy and then adjuvant chemotherapy in patients who had total gross removal of disease with negative margins.</p><p><strong>Adjuvant Chemotherapy:</strong></p><p><strong>Epirubicin:&nbsp;</strong>50 mg/m2&nbsp;IV on day 1</p><p><strong>Cisplatin:&nbsp;</strong>60 mg/m2&nbsp;IV on day 1</p><p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m2/day IV continuous infusion on days 1-21</p><p>Repeat cycle every 21 days for 3 cycles.</p>', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (662, '', 'Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel</strong>:<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel</strong>:<br>No dose reduction</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Paclitaxel:&nbsp;</strong>250 mg/m<sup>2</sup>&nbsp;IV over 24 hours on day 1</p>

<p>Repeat cycle every 21 days. G-CSF support is recommended.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (656, '', 'Paclitaxel + Cisplatin', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Paclitaxel</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Renal Impairment:&nbsp;</strong></li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li></ul>', 'High', '', '', 'METASTATIC', '<p><strong>Paclitaxel:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV over 24 hours on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;IV on day 2</p>

<p>Repeat cycle every 21 days. G-CSF support is recommended.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (702, '', 'Gemcitabine (Adjuvant)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'ADJUVANT', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p>Repeat cycle every 28 days for a total of 6 cycles.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (667, '', '5-Fluorouracil + Leucovorin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Low', '', '', 'ADJUVANT', '<p>One cycle of chemotherapy is administered as follows:</p><p><strong>5-Fluorouracil:&nbsp;</strong>&nbsp;425 mg/m2&nbsp;IV on days 1-5</p><p><strong>Leucovorin:&nbsp;</strong>20 mg/m2&nbsp;IV on days 1-5</p><p>Chemoradiotherapy is then started 28 days after the start of the initial cycle of chemotherapy as follows:</p><p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day to a total dose of 4,500 cGy, starting on day 28</p><p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m2&nbsp;IV on days 1-4 and days 23-25 of radiation therapy</p><p><strong>Leucovorin:&nbsp;</strong>20 mg/m2&nbsp;IV on days 1-4 and days 23-25 of radiation therapy</p><p>Chemoradiotherapy is followed by 2 cycles of chemotherapy which are given 1 month apart and include:</p><p><strong>5-Fluorouracil:&nbsp;</strong>425 mg/m2&nbsp;IV on days 1-5</p><p><strong>Leucovorin:&nbsp;</strong>20 mg/m2 IV on days 1-5</p>', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (713, '', 'Liposomal Irinotecan + 5-Fluorouracil + Leucovorin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li></ul>', 'Medium', '', '', 'METASTATIC', '<p><strong>Liposomal Irinotecan:&nbsp;</strong>70 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 2 weeks.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (668, '', 'Capecitabine + Oxaliplatin', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Renal Impairment:&nbsp;</strong></li><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li></ul>', 'Moderate', '', '', 'ADJUVANT', '<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days for 6 months.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (712, '', 'Nab-Paclitaxel + Gemcitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nab-Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin 1.2 to ≤1.8 mg/dL:100% dosage<br>If bilirubin &gt;1.8 to ≤3.6 mg/dL: Reduce dose by 75%<br>If bilirubin &gt; 3.6 mg/dL, do not use</li><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Nab-Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: There are no dosage adjustments provided because of insufficient data.</li><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Nab-Paclitaxel:&nbsp;</strong>125 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p>Repeat cycle every 28 days.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (545, 'Doxorubicin: Adriamycin<br>Cyclophosphamide: Cytoxan', 'AC', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Thigpen JT, Blessing JA, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol. 1994;12(7):1408-14.', '', '<p><strong>Doxorubicin:</strong>&nbsp;60 mg/m2&nbsp;IV on day 1<br><strong>Cyclophosphamide:</strong>&nbsp;500 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p>', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (919, null, 'FND', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Fludarabine:</strong><br>No dose reduction</li><li><strong>Mitoxantrone:</strong><br>If bilirubin &gt; 3 mg/dL, reduce dose by 25%</li><li><strong>Dexamethasone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Fludarabine:</strong><br>If CrCl 10-50 mL/min: Reduce dose by 25%&nbsp;<br>If CrCl &lt;10 mL/min: Reduce dose by 50%</li><li><strong>Mitoxantrone:</strong><br>No dose reduction</li><li><strong>Dexamethasone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Fludarabine:</strong> 25 mg/m2 IV on days 1-3<br><strong>Mitoxantrone:</strong> 10 mg/m2 IV on day 1<br><strong>Dexamethasone:</strong> 20 mg PO on days 1-5<br><strong>Trimethoprim/sulfamethoxazole (Bactrim DS)</strong>: 1 tablet PO bid, 3 times per week<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (684, '', 'FOLFOX', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1 followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours on days 1-3</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 2 weeks.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (685, '', 'Paclitaxel + Ramucirumab', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>Paclitaxel</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li><li><strong>Ramucirumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Renal Impairment:&nbsp;</strong></li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li><li><strong>Ramucirumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Paclitaxel:&nbsp;</strong>80 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p><strong>Ramucirumab:&nbsp;</strong>8 mg/kg IV on days 1 and 15</p>

<p>Repeat cycle every 28 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (681, '', 'XP + Trastuzumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> No dose reduction.</li></ul><p>&nbsp;<strong>Cardiac Impairment</strong></p><ul><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'High', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p><strong>Cisplatin:&nbsp;</strong>80 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Trastuzumab:&nbsp;</strong>8 mg/kg IV loading dose, then 6 mg/kg IV every 3 weeks</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (673, '', 'Enasidenib (AML IDH2 mutated) ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Enasidenib:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Enasidenib:</strong><br>No dose reduction</li></ul>', 'Moderate', '', '', 'FIRST LINE ', '<h4><strong>Enasidenib:</strong> 100 mg PO once per day</h4><p>Repeat cycle every 28 days. Continue treatment for at least 6 months in patients without disease progression or unacceptable toxicity.</p>', 33);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (920, null, 'FC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL: Reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Fludarabine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-29 mL/min: Reduce dose by 25%<br>If CrCl &lt; 10 mL/min: Reduce dose by 50%</li><li><strong>Fludarabine:</strong><br>If CrCl 10-50 mL/min: Reduce dose by 25%&nbsp;<br>If CrCl &lt;10 mL/min: Reduce dose by 50%</li></ul>', 'Moderate', null, null, null, '<p><strong>Fludarabine:</strong> 20 mg/m2 IV on days 1-5<br><strong>Cyclophosphamide:</strong> 1,000 mg/m2 IV on day 1<br><strong>Trimethoprim/sulfamethoxazole (Bactrim DS): </strong>1 tablet PO bid<br>Repeat cycle every 21-28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (674, '', 'CF', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Renal Impairment:&nbsp;</strong></li><li><strong>5-Fluorouracil</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'High', '', '', 'METASTATIC', '<p><strong>Cisplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5</p>

<p>Repeat cycle every 28 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (675, '', 'ECF', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li><li><strong>Epirubicin</strong>:<br>If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br>If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction</li><li><strong>Epirubicin</strong><br>If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li></ul>', 'High', '', '', 'METASTATIC', '<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (683, '', 'FLO', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m<sup>2</sup>&nbsp;IV on day 1 as a continuous infusion over 24 hours</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion</p>

<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 14 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (764, null, 'Cladribine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cladribine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cladribine:</strong><br>If CrCl 10-50 mL/min: Dose reduction by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;10 mL/min: Dose reduction by 50%</li></ul>', 'Low', null, null, null, '<p><strong>Cladribine:&nbsp;</strong>0.09 mg/kg/day IV as continuous infusion on days 1-7&nbsp;</p><p>Administer one cycle.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (247, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16', 'CDE', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'Moderate', '<b>CDE</b>', 'Sparano JA,Lee S, Chen MG, et al. Phase II trial of   infusional, cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkins lymphoma: an Eastern Cooperative Oncology Group Trial (E1491). $J Clin Oncol. 2004; 22(8): 1491-1500.$', null, '<p><strong>Cyclophosphamide:</strong> 200mg/m2/day CIVI for 4 days<br><strong>Doxorubicin:</strong> 12.5 mg/m2/day CIVI for 4 days<br><strong>Etoposide:</strong> 60 mg/m2/day CIVI for 4 days<br>Repeat every 28 days for a maximum of 8 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (746, null, 'Afatinib', '<p><strong>RENAL DOSE ADJUSTMENT</strong></p><p>eGFR &gt;30 mL/minute/1.73 m2: No dosage adjustment is necessary.</p><p>eGFR 15 to-29 mL/minute/1.73 m2: Starting dose reduced to 30 mg once daily.</p><p>eGFR &lt;15 mL/minute/1.73 m2 and hemodialysis: has not been studied</p><p><strong>HEPATIC</strong> <strong>DOSE ADJUSTMENT</strong></p><p><strong>Preexisting mild to moderate impairment (Child-Pugh class A/B): </strong>No dosage adjustment is necessary.</p><p><strong>Preexisting severe impairment (Child-Pugh class C): </strong>has not been studied; closely monitor and adjust dose if necessary.</p><p><strong>Hepatotoxicity during treatment:</strong>&nbsp;</p><ul><li>Withhold therapy for ≥ grade 3 hepatic dysfunction.&nbsp;<ul><li>If improvement to baseline or ≤ grade 1, resume therapy at 10 mg per day less than previous dose.&nbsp;</li><li>Permanently discontinue for severe hepatic impairment.</li></ul></li></ul>', 'Low', null, null, null, '<p>40 mg once daily&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (747, null, 'Afatinib', '<p><strong>Renal</strong>:&nbsp;</p><ul><li>Severe renal impairment (eGFR 15 to-29 mL/min /1.73 m2: Reduce starting dose to 30 mg once daily. (i.e., 10 mg per day less than the dose at which the adverse reaction occurred.)</li><li>eGFR &lt;15 mL/minute/1.73 m2 and hemodialysis: Has not been studied</li></ul><p><strong>Hepatic</strong>:</p><ul><li><strong>Preexisting mild to moderate impairment (Child-Pugh class A/B): </strong>No dosage adjustment is necessary.</li><li><strong>Preexisting severe impairment (Child-Pugh class C): </strong>Has not been studied. Close monitoring</li><li><strong>Hepatotoxicity during treatment:</strong> Withhold treatment</li></ul>', 'Low', null, null, null, '<p>30 mg daily, indefinite duration</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (757, null, 'Ceritinib', '<p><strong>Renal Impairment</strong></p><p>Mild-moderate renal impairment: no dosage adjustment necessary (renal excretion is low)</p><p>Severe renal impairment: has not been studied</p><p><strong>Hepatic Impairment</strong></p><p>Mild hepatic impairment (total bilirubin &lt;ULN and AST &gt; ULN, or total bilirubin &gt; 1.0-1.5x ULN and any AST):</p><p>Severe hepatic impairment: not yet been determined&nbsp;</p>', 'Moderate-High', null, null, null, '<p>450mg once per day by mouth (with food) for indefinite duration</p><p>OR</p><p>750mg once per day by mouth (without food)&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (758, null, 'Crizotinib', '<p>&nbsp;Renal Impairment</p><p>Hepatic Impairment</p>', 'Moderate-High', null, null, null, '<p>250 mg daily by mouth for indefinite duration</p><p><i>(for severe hepatic or renal impairment, see below)</i></p><p>OR</p><p>200 mg twice per day by mouth for indefinite duration</p><p><i>(for moderate hepatic impairment, see below)</i></p><p><i>OR</i></p><p>250 mg twice per day by mouth for indefinite duration</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (750, null, 'Gefitinib', '<p><strong>Renal</strong>:</p><ul><li>CrCl&gt;20mL/min: No dosage adjustments provided in the manufacturer’s labeling ( &lt;4% renal excretion)&nbsp;</li><li>CrCl &nbsp;≤20 mL/minute: Has not been studied</li></ul><p><strong>Hepatic</strong></p><ul><li>Grade 2 or higher hepatic impairment: Withhold treatment for up to 14 days; may resume treatment when fully resolved or improved to grade 1 hepatic impairment.</li><li>Severe hepatic impairment: Permanently discontinue.</li></ul>', 'Low', null, null, null, '<p>250mg PO daily, &nbsp;24 month duration</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (751, null, 'Osimertinib', '<p><strong>Renal</strong></p><ul><li>CrCl 15 to 89 mL/minute: No dosage adjustment necessary.</li><li>CrCl ≤15 mL/minute and ESRD: Has not been studied</li></ul><p><strong>Hepatic</strong></p><ul><li>Mild to moderate impairment : No dosage adjustment necessary<ul><li>Child-Pugh class A /B, OR</li><li>Total bilirubin ≤ ULN and AST &gt; ULN, OR&nbsp;</li><li>Total bilirubin 1 - 3 x ULN and any AST</li></ul></li><li>Severe impairment: Has not been studied<ul><li>Total bilirubin 3 - 10 x ULN and any AST</li></ul></li></ul>', 'Low', null, null, null, '<p><strong>Osimertinib: 80 mg PO daily, indefinite duration</strong></p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (749, null, 'Dacomitinib', '<p>Renal:</p><ul><li>Mild-moderate renal impairment (CrCl 30 to 89 mL/minute): No dosage adjustment is necessary.</li><li>Severe renal impairment (CrCl &lt;30 mL/minute): Has not been studied.</li></ul><p>Hepatic:</p><ul><li>Mild: No dosage adjustment is necessary.<ul><li>AST &gt; ULN and total bilirubin within normal limits, OR</li><li>Total bilirubin 1 - 1.5 x ULN</li></ul></li><li>Moderate: No dosage adjustment is necessary.<ul><li>Total bilirubin 1.5 -3x ULN</li></ul></li><li>Severe: has not been studied<ul><li>Total bilirubin 3 -10 x ULN</li></ul></li></ul>', 'Low', null, null, null, '<p>40 mg daily, indefinite duration</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (745, '', '5-Fluorouracil + Radiation Therapy (German AIO regimen)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li></ul>', 'Low', '', '', 'NEOADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m2/day IV continuous infusion on days 1-5</p><p>Repeat infusional 5-FU on weeks 1 and 5.</p><p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day for 5 days per week (total dose, 5,040 cGy)</p><p>Followed by surgical resection and adjuvant chemotherapy with 5-FU at 500 mg/m2 IV for 5 days every 28 days for a total of 4 cycles.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (748, null, 'Erlotinib', '<p><strong>Renal</strong></p><p><i>Renal impairment at treatment initiation:</i> There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied), although &lt;9% of a single dose is excreted in the urine.</p><p><i>Renal toxicity during treatment:</i></p><ul><li>Renal toxicity, hepatorenal syndrome, dehydration: Withhold treatment</li></ul><p><strong>Hepatic</strong></p><p><i>Hepatic impairment at treatment initiation:</i></p><ul><li>Total bilirubin &gt; ULN or Child-Pugh classes A, B, and C: &nbsp;No dosage adjustments provided; use with caution and monitor closely during treatment.</li><li>Total bilirubin &gt;3 times ULN: Use with extra caution.</li></ul><p><br><i>Hepatic impairment during treatment:</i></p><ul><li>Withhold treatment if severe changes in bilirubin or transaminases</li></ul>', 'Low', null, null, null, '<p>Erlotinib 150 mg daily, indefinite duration</p><p>Erlotinib 25 mg daily, indefinite duration</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (752, null, 'Erlotinib & Ramucirumab', '<p><strong>Renal</strong></p><p><i>Renal impairment at treatment initiation:</i> There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied), although &lt;9% of a single dose is excreted in the urine.</p><p><i>Renal toxicity during treatment:</i></p><ul><li>Renal toxicity, hepatorenal syndrome, dehydration: Withhold treatment</li></ul><p><strong>Hepatic</strong></p><p><i>Hepatic impairment at treatment initiation:</i></p><ul><li>Total bilirubin &gt; ULN or Child-Pugh classes A, B, and C: &nbsp;No dosage adjustments provided; use with caution and monitor closely during treatment.</li><li>Total bilirubin &gt;3 times ULN: Use with extra caution.</li></ul><p><br><i>Hepatic impairment during treatment:</i></p><ul><li>Withhold treatment if severe changes in bilirubin or transaminases</li></ul><p><i><strong>Ramucirumab</strong></i></p><p><strong>Renal</strong></p><ul><li>No dose adjustments provided by manufacturer per studies</li></ul><p><strong>Hepatic</strong></p><ul><li>Use with caution in Child-Pugh class B or C cirrhosis. Monitor for &nbsp;encephalopathy, ascites, or hepatorenal syndrome.<br>&nbsp;</li></ul>', 'Low', null, null, null, '<ul><li>Erlotinib: 150 mg PO daily</li><li>Ramucirumab: 10 mg/kg IV on day 1<ul><li>14 day cycles</li></ul></li></ul>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (755, null, 'Alecitinib', '<p><strong>Renal Impairment</strong></p><ul><li>Prior to initiation:<ul><li>Mild-moderate renal impairment: No dose adjustment provided</li><li>Severe renal impairment (CrCl&lt;30) or ESRD: Not yet studied</li></ul></li><li>During treatment:<ul><li>Grade 3 renal impairment: temporarily withhold until sCr &lt; 1.5, then resume at reduced dose</li><li>Grade 4 renal impairment: permanently discontinue</li></ul></li></ul><p><strong>Hepatic Impairment</strong></p><ul><li>Prior to initiation:<ul><li>Mild Hepatic Impairment(Total bilirubin &lt; ULN and AST &gt; ULN, or total bilirubin &gt; 1.0-1.5x ULN): No dose adjustment recommended&nbsp;</li><li>Moderate to severe hepatic impairment: Not yet studied</li></ul></li></ul>', 'Low', null, null, null, '<p>300mg twice a day by mouth, indefinite duration<br>OR</p><p>600mg twice a day by mouth, indefinite duration</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (279, '', 'Interferon alfa-2a', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Interferon alfa-2a:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Interferon alfa-2a:</strong><br>No dose reduction</li></ul>', 'Low', '<b>Interferon alfa-2a</b>', 'Ratain MJ, et al. $Blood 1985;65:644-648.$', null, '<p><strong>Interferon alfa-2a:</strong> 3 million IU SC or IM, 3 times per week<br>Continue treatment for up to 1 to 1.5 years.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (754, null, 'R - CVP', '<b>Hepatic Impairment</b><ul><li>Rituximab:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate', null, null, null, '<b>Cyclophosphamide</b> 750 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> up to a maximum dose of 2 mg IV, day 1<br> <b>Prednisone</b> 40 mg PO, days 1-5<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for a maximum off 8 cycles ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (756, null, 'Brigatinib', '<p><strong>Renal Impairment</strong></p><p>Mild-moderate renal impairment (CrCl 30-89 mL/min): No dose adjustment is recommended&nbsp;</p><p>Severe renal impairment (CrCl 15-29 mL/min): Reduce daily dose by approximately 50%&nbsp;</p><p><strong>Hepatic impairment</strong></p><p>Mild-moderate hepatic impairment (Child Pugh A/B): No dose adjustment is recommended</p><p>Severe hepatic impairment (Child-Pugh C): Reduce daily dose by approximately 40%&nbsp;</p>', 'Low', null, null, null, '<p>90mg once per day by mouth for 1 week duration</p><p>Followed by</p><p>180mg once per day for indefinite duration</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (760, null, 'Lorlatinib', '<p><strong>Renal Impairment</strong></p><p>Mild/moderate renal impairment (CrCl 30-89 mL/min): No dose adjustment is recommended.&nbsp;</p><p>Severe renal impairment: The recommended dose has not been established&nbsp;</p><p><strong>Hepatic Impairment</strong></p><p>Mild hepatic impairment (Total bilirubin &lt; ULN with AST &gt; ULN or total bilirubin 1-1.5 x ULN with any AST) No dose adjustment is recommended&nbsp;</p><p>Moderate/severe hepatic impairment: The recommended dose has not been established&nbsp;</p>', 'Low', null, null, null, '<p>100mg once daily, indefinite duration</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (761, null, 'Bosutinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bosutinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bosutinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>For first-line treatment: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &gt;50 ml/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 30 to 50 ml/min: Reduce dose to 300 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 ml/min<i>:</i> Reduce dose to 200 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; For resistant treatment: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &gt;50 ml/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 30 to 50 ml/min: Reduce dose to 400 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 ml/min<i>:</i> Reduce dose to 300 mg once daily.&nbsp;</li></ul>', 'Moderate', null, null, null, '<p><strong>First-line treatment:</strong></p><p><strong>Bosutinib:&nbsp;</strong>400 mg PO daily</p><p>Continue until disease progression or unacceptable toxicity</p><p><strong>Resistant:</strong></p><p><strong>Bosutinib:&nbsp;</strong>500 mg PO daily</p><p>Continue until disease progression or unacceptable toxicity</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (762, null, 'Ponatinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ponatinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Mild-to-severe impairment (Child-Pugh class A, B, or C): Reduce initial dose to 30 mg once daily.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ponatinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Ponatinib:&nbsp;</strong>45 mg PO bid</p><p>Continue until loss of response or unacceptable toxicity</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (921, null, 'FCR', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL: Reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Fludarabine:</strong><br>No dose reduction</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-29 mL/min: Reduce dose by 25%<br>If CrCl &lt; 10 mL/min: Reduce dose by 50%</li><li><strong>Fludarabine:</strong><br>If CrCl 10-50 mL/min: Reduce dose by 25%&nbsp;<br>If CrCl &lt;10 mL/min: Reduce dose by 50%</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Fludarabine:</strong> 25 mg/m2 IV on days 1-3<br><strong>Cyclophosphamide:</strong> 300 mg/m2 IV on days 1-3<br><strong>Rituximab:</strong> 375 mg/m2 IV on day 1<br>Repeat every 21 days for a total of 4 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (923, null, 'R-FCM', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL: Reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Fludarabine:</strong><br>No dose reduction</li><li><strong>Rituximab:</strong><br>No dose reduction</li><li><strong>Mitoxantrone:</strong><br>If bilirubin &gt; 3 mg/dL, reduce dose by 25%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-29 mL/min: Reduce dose by 25%<br>If CrCl &lt; 10 mL/min: Reduce dose by 50%</li><li><strong>Fludarabine:</strong><br>If CrCl 10-50 mL/min: Reduce dose by 25%&nbsp;<br>If CrCl &lt;10 mL/min: Reduce dose by 50%</li><li><strong>Rituximab:</strong><br>No dose reduction</li><li><strong>Mitoxantrone:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Rituximab:</strong> 375 mg/m2 IV on day 0<br><strong>Fludarabine: </strong>25 mg/m2 IV on days 1-3<br><strong>Cyclophosphamide:</strong> 200 mg/m2 IV on days 1-3<br><strong>Mitoxantrone:</strong> 8 mg/m2 IV on day 1</p><p><br>Repeat every 4 weeks for a total of 4 cycles. Patients who experience a response can then receive maintenance therapy at 3 and 9 months after completion of therapy with<br><strong>Rituximab: </strong>375 mg/m2 IV weekly for 4 weeks</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1041, null, 'ABV', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Bleomycin</strong>:<br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Doxorubicin</strong>:<br>No dose reduction</li><li><strong>Bleomycin</strong><br>If CrCl &gt;50 mL/min: No dose reduction<br>If CrCl 40-50 mL/min: 70% of normal dose<br>If CrCl 30-40 mL/min: 60% of normal dose<br>If CrCl 20-30 mL/min: 55% normal dose<br>If CrCl 10-20 mL/min: 45% normal dose<br>If CrCl 5-10 mL/min: 40% normal dose</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Doxorubicin: </strong>40 mg/m2 IV on day1<br><strong>Bleomycin:</strong> 15 U/m2 IV on days 1 and 15<br><strong>Vinblastine:</strong> 6 mg/m2 IV on day 1<br>Repeat cycle every 28 days&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (285, 'Dexamethasone : various<br>Lenalidomide : Revlimid', 'Lenalidomide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>If CrCl &gt;60 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 30 to 60 mL/min: 5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min not requiring dialysis: 2.5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min requiring dialysis: 2.5 mg once daily (administer after dialysis on dialysis days).</li></ul>', 'Low', '<b>Lenalidomide/Dexamethasone</b>', 'Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. $N Engl J Med. 2007;357(21):2123-2132.$', null, '<p><strong>Lenalidomide:</strong> 10 mg PO daily</p><p>Continue until disease progression.</p><p><strong>OR</strong><br><strong>Lenalidomide:</strong> 10 mg PO daily for 21 days.<br>Repeat every 28 days until disease progression</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (13, 'Cetuximab : Erbitux', 'Cetuximab', '<p><strong>Hepatic Impairment</strong></p><p>No dose adjustment necessary</p><p><strong>Renal Impairment</strong></p><p>No dose adjustment necessary</p>', 'Low', '<b>Cetuximab</b>', 'Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival datat from a phase 3 randomised trial, and relation between cetuximab-induced rash and surival. $Lancet Oncol.2010;11(1):21-28.$', null, '<b>Cetuximab</b> 400 mg/m<sup>2</sup> loading dose over 120 minutes, <b>THEN</b> 250 mg/m<sup>2</sup> over 60 minutes, every 7 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (8, 'Cisplatin : CDDP', 'PF', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li></ul>', 'High', '<b>CF</b>', 'Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. $J Clin Oncol. 2005;23(15):3562-3567.$', null, '<p><strong>Cisplatin:</strong> 100 mg/m2 IV, day 1<br><strong>5-Fluorouracil:</strong> 1000 mg/m2/day IV continuous infusion, days 1-5<br>Repeat cycle every 21-28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (206, 'Cyclophosphamide : Cytoxan<br>Dactinomycin : Actinomycin<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various<br>Vincristine : Oncovin, VCR', 'CAV-IE', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Dactinomycin:</strong><br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Ifosfamide:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Dactinomycin:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Ifosfamide</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥10 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose by 25%</li></ul>', 'CAV-High: IE-Moderate', '<b>VAC-IE</b>', 'Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing''s sarcoma and primitive neuroectodermal tumor of bone. $N Engl J Med. 2003;348(8):694-701.$', null, '<p><strong>Cyclophosphamide:</strong> 1,200 mg/m2 IV, day 1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Doxorubicin:</strong> 75 mg/m2 IV on day 1<br><strong>Vincristine:</strong> 2 mg IV, day 1<br>Alternating with each cycle<br><strong>Ifosfamide:</strong> 1,800 mg/m2 IV, days 1-5&nbsp;<br><strong>Etoposide:</strong> 100 mg/m2 IV, days 1-5<br>Repeat every 21 days for a total of 17 cycles.</p><p>When the cumulative dose of doxorubicin reaches 375 mg/m2, switch to dactinomycin at 1.25 mg/m2.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (477, 'Carboplatin; Paralatin
Paclitaxal: Taxol ', 'Carboplatin + Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose.</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li></ul>', 'High', '', 'CA184-104: Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, Fadeeva N, Lee KH, Kurata T, Zhang L, Tamura T, Postmus PE, Jassem J, O''Byrne K, Kopit J, Li M, Tschaika M, Reck M. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol. 2017 Oct 20;35(30):3449-3457. Epub 2017 Aug 30.

EYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.

KEYNOTE-042: Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019 May 4;393(10183):1819-1830. Epub 2019 Apr 4.', 'METASTATIC', '<p><strong>Carboplatin:</strong> AUC 6&nbsp;IV over 15 to 60 minutes on day 1<br><strong>Paclitaxel:</strong>&nbsp;175 mg/m2&nbsp;IV over 3 hours on day 1</p><p>Repeat cycle every 21 days.</p><p>&nbsp;</p>', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1140, null, 'Etoposide + Ifosfamide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use.</li><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Ifosfamide:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Ifosfamide</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥10 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose by 25%</li></ul>', 'High', null, null, null, '<p><strong>Etoposide: </strong>100 mg/m2 /day IV on days 1-5<br><strong>lfosfamide: </strong>3,500 mg/m2/day IV on days 1-5<br><strong>Mesna: </strong>700 mg/m2 IV with first ifosfamide dose, then 3, 6, and 9 hours later &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; on days 1-5<br>Repeat cycle every 21 days for 2 cycles. Start G-CSF support at 5 microgram/kg/day<br>SC to start on day 6. Followed by surgical resection of primary tumor and then intensive maintenance chemotherapy.<br><br><strong>Methotrexate:</strong> 1,200 mg/m2 IV on weeks 1, 2, 6, 7, 11, 12, 16, 17, 30, and 31<br><strong>Leucovorin:</strong> 15 mg IV every 6 hours for 10 doses starting 24 hours after start of high-<br>dose methotrexate &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;or<br><strong>L-Leucovorin: </strong>7.5 mg IV every 6 hours for 10 doses starting 24 hours after start of high-dose methotrexate<br><strong>Doxorubicin: </strong>37.5 mg/m2/day IV on days 1-2 on weeks 3, 13, 21, 27, and 32<br><strong>Cisplatin:</strong> 60 mg/m2/day IV on days 1-2 on weeks 3, 13, 21, and 27<br><strong>Ifosfamide:</strong> 2,400 mg/m2/day IV on days 1-5 on weeks 8, 18, and 24<br>Administer G-CSF support at 5 microgram/kg/day SC on weeks 8, 18, and 24.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (225, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Prednisolone : Flo-pred, various<br>Vincristine : Oncovin, VCR', 'CHOP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Moderate', '<b>CHOP</b>', 'Bezwoda W, Ristogi RB, Erazo Valla A, et al. Long-term results of a multicentre randomised, comparitive phase III trial of CHOP versus CNOP regimens in patients with intermediate-and high-grade non-Hodgikin''s lymphomas. $ Eur J Cancer. 1995;31A(6):903-911$.', null, '<p><strong>Cyclophosphamide:</strong> 750 mg/m2 IV, day 1<br><strong>Doxorubicin:</strong> 50 mg/m2 IV, day 1<br><strong>Vincristine:</strong> 1.4 mg/m2 IV, day 1<br><strong>Prednisone:</strong> 100 mg/m2/d PO, days 1-5<br>Repeat every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (770, null, 'TIP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong>&nbsp;</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Mesna:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Paclitaxel:</strong><br>No dose reduction</li><li><strong>Mesna:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:</strong> 60 mg/m2 IV day 1&nbsp;<br><strong>Paclitaxel:</strong> 175 mg/m2 IV over 3 hours on day 1</p><p><strong>Mesna:</strong> 400 mg/m2 IV before ifosfamide and 200 mg/m2 IV, 4 hrs after Ifosfamide</p><p><br>Repeat cycle every 21-28 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (922, null, 'R - CHOP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Rituximab:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Rituximab:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Cyclophosphamide:</strong> 750 mg/m2 IV, day 1<br><strong>Doxorubicin:</strong> 50 mg/m2 IV, day 1<br><strong>Vincristine:</strong> 1.4 mg/m2 IV, day 1 &nbsp;(maximum dose of 2mg)<br><strong>Prednisone:</strong> 100 mg/day PO, days 1-5</p><p>Repeat every 21 days up to 6 cycles. Patients who experience a response to the therapy can then receive maintenance therapy with<br><strong>Rituximab:</strong> 375 mg/m2 IV, day 1<br>Repeat cycle every 3 months up to a maximum of 2 years.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (769, null, 'TPF Induction- followed by Carboplatin and RT', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Carboplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>5-Fluorouracil</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose.</li></ul>', 'High', null, null, null, '<p><strong>Docetaxel:</strong> 75 mg/m2 IV, day 1<br><strong>Cisplatin:</strong> 75-100 mg/m2 IV, day 1<br><strong>5-Fluorouracil:</strong> 1,000 mg/m2/day CIVI, days 1-4<br>Repeat every 21 days for 3 cycles followed by</p><p><strong>Carboplatin:</strong> AUC 1.5, IV every week x 7 along with radiation therapy</p><p><strong>Radiation therapy:</strong> 200 cGy/day to a total dose of 7,400 cGy</p><p>Evaluate for surgical resection after completion of chemoradiotherapy.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (924, null, 'Bendamustine + Rituximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin&nbsp;1.5-3 upper normal limit, or bilirubin &gt; 3 upper normal limit: Do not use</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If CrCl &lt; 30 mL/min: Do not use</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Bendamustine: </strong>90 mg/m2 IV on days 1 and 2<br><strong>Rituximab: </strong>375 mg/m2 IV on day 1<br>Repeat every 28 days for 4 cycles.</p><p><strong>OR</strong></p><p><strong>Rituximab:</strong> 375 mg/m2 IV on day 1<br><strong>Bendamustine: </strong>90 mg/m2 IV on days 2 and 3<br>Repeat every 28 days for 4-6 cycles. An additional dose of rituximab is<br>administered 1 week prior to the first cycle and 4 weeks after the last cycle.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (774, null, 'Cisplatin and Cetuximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Cetuximab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cetuximab:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:</strong> 100 mg/m2, IV on day 1</p><p><strong>Cetuximab:&nbsp;</strong>400 mg/m2&nbsp;IV loading dose followed by 250 mg/m2 IV every week</p><p>Repeat cycles every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (231, 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Dexamethasone : various<br>Vincristine : Oncovin, VCR', 'Hyper-CVAD/MTX-Ara-C', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'High', '<b>Hyper-CVAD/MTX-Ara-C</b>', 'Khouri IF, Romaguera J, Kantrajian H,et al. Hyper-CVAD and high -dose methotrexate/ cytarabine followed by stem-cell tans-plantation: an active regimen for aggressive mantle-cell lymphoma. $J Clin Oncol. 1998; 16(12): 3803-3809$.', null, '<p>COURSE 1<br><strong>Cyclophosphamide:</strong> 300 mg/m2 over 3 hours every 12 hours for 6 doses , days 1-3<br><strong>Doxorubicin:</strong> 50 mg/m2 over 48 hours after cyclophosphamide, days 4-5<br><strong>Vincristine:</strong> 2 mg administered 12 hours after last cyclophosphamide dose, repeated on day 11<br><strong>Dexamethasone:</strong> 40 mg/d IV or PO,days 1-4,11-14<br><strong>Filgrastim:</strong> 5 mcg/kg IV or SQ beginning 24 hours after doxorubicin is complete.<br>COURSE 2&nbsp;<br>(BEGIN AFTER CLINICAL AND HEMATOLOGIC RECOVERY FROM COURSE 1)<br><strong>Methotrexate:</strong> 200 mg/m2 IV bolus, day 1<br><strong>FOLLOWED BY</strong><br><strong>Methotrexate:</strong> 800 mg/m2over 24 hours day1, followed by<br><strong>Cytarabine: </strong>3000 mg/m2 IV every 12 hours for 4 doses, days 2-3 (dose reduced to 1,000 mg/m2 in patients &gt;60 years or with serum creatinine &gt;1.5 mg/dL)<br><strong>Leucovorin calcium:</strong> 50 mg PO 24 hours after end of Methotrexate infusion<br>Followed 6 hours later by<br><strong>Leucovorin calcium:</strong> 15 mg PO every 6 hours for 8 doses (dose adjusted for Methotrexate concentration at 24 and 48 hours after completion of Methotrexate infusion)<br><strong>Filgrastim:</strong> 5 mcg/kg IV or SQ begining 24 hours after cytarabine.<br>Repeat courses every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1141, null, 'Cisplatin+ Doxorubicin + High-Dose Methotrexate', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use.</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Doxorubicin:</strong> 25 mg/m2/day IV on days 1-3 on weeks 0 and 5<br><strong>Cisplatin: </strong>120 mg/m2 IV on day 1 on weeks 0 and 5<br><strong>Methotrexate: </strong>1,200 mg/m2 IV on day 1 on weeks 3, 4, 8, and 9<br><strong>Leucovorin:</strong> 10 mg IV every 6 hours for 10 doses starting 24 hours after start of high-<br>dose methotrexate<br>OR<br><strong>L-Leucovorin: </strong>7.5 mg IV every 6 hours for 10 doses starting 24 hours after start of high-dose methotrexate<br>Induction chemotherapy is followed by surgical resection of primary tumor and<br>then maintenance chemotherapy to begin on week 12 and continuing until week<br>31.<br><strong>Doxorubicin:</strong> 25 mg/m2/day IV on days 1-3 on weeks 12, 17, 22, and 27<br><strong>Cisplatin:</strong> 120 mg/m2 IV on day 1 on weeks 12 and 17<br><strong>Methotrexate:</strong> 1,200 mg/m2 IV on day 1 on weeks 15,16, 20, 21, 25, 26,30, and 31<br><strong>Leucovorin:</strong> 10 mg IV every 6 hours for 10 doses starting 24 hours after start of high-dose methotrexate &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;OR<br><strong>L-Leucovorin:</strong> 7.5 mg IV every 6 hours for 10 doses starting 24 hours after start of high- dose methotrexate</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (779, null, 'Vinorelbine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vinorelbine</strong>:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vinorelbine</strong>:<br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Vinorelbine:&nbsp;</strong>30<strong> </strong>mg/m2&nbsp;IV every week</p><p>Repeat cycle every week.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (780, null, 'VP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Vinorelbine</strong>:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Vinorelbine</strong>:<br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:</strong> 80 mg/m2 IV, day 1&nbsp;</p><p><strong>Vinorelbine:&nbsp;</strong>25<strong> </strong>mg/m2&nbsp;IV on days 1 and 8</p><p>Repeat cycles every 3 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (228, 'Prednisone : various<br>Rituximab : Rituxan<br>Vincristine : Oncovin, VCR', 'R - CVP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Rituximab:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Rituximab:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Moderate', '<b>R - CVP</b>', 'Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. $Blood, 105(4): 1417-1423.$<br> Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine and prednisone alone in patients with previously utreated advanced follicular lymphoma. $J Clin Oncol. 2008;26(28):4578-4589.$', null, '<p><strong>Cyclophosphamide:</strong> 750 mg/m2 IV, day 1<br><strong>Vincristine:</strong> 1.4 mg/m2 up to a maximum dose of 2 mg IV, day 1<br><strong>Prednisone:</strong> 40 mg PO, days 1-5<br><strong>Rituximab:</strong> 375 mg/m2 IV, day 1<br>Repeat every 21 days for a maximum of 8 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (783, null, 'Dacomitinib', '<p>&nbsp;<strong>Hepatic Impairment</strong></p><ul><li><strong>Dacomitinib:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Dacomitinib:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Dacomitinib:</strong> 45 mg PO, once daily.</p><p>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (782, null, 'Erlotinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Erlotinib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Erlotinib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Erlotinib:&nbsp;</strong>150mg PO once a day.</p><p>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (784, null, 'Gefitinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gefitinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gefitinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Gefitinib: </strong>250 mg PO daily.</p><p>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (925, null, 'Polatuzumab vedotin + Bendamustine + Rituximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Polatuzumab vedotin:</strong><br>If mild impairment (AST or ALT &gt;1-2.5 times ULN or total bilirubin &gt;1-1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If moderate to severe impairment (AST or ALT &gt;2.5 times ULN or total bilirubin &gt;1.5 times ULN): Do not use.</li><li><strong>Bendamustine:</strong><br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin&nbsp;1.5-3 upper normal limit, or bilirubin &gt; 3 upper normal limit: Do not use</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Polatuzumab vedotin:</strong><br>No dose reduction</li><li><strong>Bendamustine:</strong><br>If CrCl &lt; 30 mL/min: Do not use</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Polatuzumab vedotin: </strong>1.8 mg/kg IV on day 2 of cycle 1 and on day 1 of subsequent cycles<br><strong>Bendamustine:</strong> 90 mg/m2 IV on days 2 and 3 of cycle 1 and on days 1 and 2 of subsequent cycles<br><strong>Rituximab:</strong> 375 mg/m2 IV on day 1</p><p>Repeat every 21 days for up to 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (788, null, 'Etoposide + Doxorubicin + Cisplatin + Mitotane', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Etoposide: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong> </strong>AST/ALT: 60-180 unit/L: Reduce dose by 50%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If AST/ALT: &gt;180 unit/L: dosing based on clinical decision</li><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Doxorubicin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong> </strong>AST/ALT: 60-180 unit/L: Reduce dose by 50%.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If AST/ALT: &gt;180 unit/L: Reduce dose by 75%.</li><li><strong>Mitotane:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment &nbsp; &nbsp;</strong></p><ul><li><strong>Etoposide: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If CrCl &gt;50 mL/min: No dose reduction &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &nbsp;15-50 mL/min: Reduce dose by 25%.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;15 mL/min: Reduce dose by 50%.&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong></li><li><strong>Cisplatin : &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> &nbsp; &nbsp;If CrCl &gt;60 mL/min: No dose reduction &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &nbsp;45-59 mL/min: Reduce dose by 25%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;45 mL/min: Consider switching to Carboplatin</li><li><strong>Doxorubicin:</strong><br>If CrCl &lt; 20 mL/min: Avoid doxorubicin.</li><li><strong>Mitotane:</strong><br>No dose reduction</li></ul><p>&nbsp;</p>', 'High', null, null, null, '<p><strong>Etoposide:&nbsp;</strong>100 mg/m2&nbsp;IV on days 5-7</p><p><strong>Doxorubicin:</strong>&nbsp;20 mg/m2 on days 1 and 8</p><p><strong>Cisplatin:&nbsp;</strong>40 mg/m2&nbsp;IV on days 1 and 9</p><p><strong>Mitotane: </strong>4 g PO daily</p><p>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (789, null, 'Streptozocin + Mitotane', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Streptozocin:</strong>&nbsp;<br>No dose reduction</li><li><strong>Mitotane:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment &nbsp; &nbsp;</strong></p><ul><li><strong>Streptozocin:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &gt;50 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 10-50 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;10 mL/min: Avoid Streptozosin.</li><li><strong>Mitotane:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Streptozocin:&nbsp; </strong>1,000 mg IV on days 1-5 for cycle 1 and &nbsp;2,000 mg IV on days 1-5 on subsequent cycles</p><p><strong>Mitotane:&nbsp; </strong>4<strong> </strong>g PO daily</p><p>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (790, null, 'Carboplatin+Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%&nbsp;</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Carboplatin:&nbsp;</strong>AUC of 5<strong>,</strong>&nbsp;IV on day 1</p><p><strong>Paclitaxel:&nbsp;</strong>175 mg/m2&nbsp;IV on day 1</p><p>Repeat cycles every 3 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (456, 'Pembrolizumab: Keytruda
Cisplatin: Platinol
Pemetrexed: Alimta', 'Pembrolizumab + Cisplatin + Pemetrexed', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (total bilirubin &lt;1 to 1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (total bilirubin &gt;1.5 times ULN): Dosage adjustment not provided by the manufacturer.</li><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Pemetrexed</strong>:<br>No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Pemetrexed</strong>:<br>If CrCl &gt; 45 mL/min, no dose reduction<br>If CrCl &lt; 45 mL/min, do not use</li></ul>', 'High', '', 'KEYNOTE-189: Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078-2092. Epub 2018 Apr 16', 'METASTATIC', '<p><strong>Pembrolizumab:</strong> 200 mg IV given on day 1&nbsp;at least 30 minutes prior to chemotherapy<br><strong>Pemetrexed:</strong> 500mg/m2 IV on day 1&nbsp;<br><strong>Cisplatin:</strong> 75 mg/m2 IV on day 1</p><p>Repeat cycle every 21 days up to 4 cycles. Followed by pembrolizumab maintenance therapy up to a total of 35 cycles and pemetrexed maintenance.<br>Folic acid at 350-1,000 µg PO once daily beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1-2 weeks prior to the first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed therapy.</p>', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (597, '', 'Capecitabine - Adjuvant.', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'Low', '', '', 'ADJUVANT', '<p><strong>Capecitabine:&nbsp;</strong>1,250 mg/m2&nbsp;PO bid on days 1-14</p><p>Repeat cycle every 21 days for a total of 8 cycles. The dose may be decreased to 850-1,000 mg/m2&nbsp;PO twice daily on days 1-14 to reduce risk of toxicity without compromising clinical efficacy.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (624, '', 'FOLFOX4 + Cetuximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Cetuximab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Cetuximab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion prior to 5-fluorouracil</p>

<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1070, null, 'Cisplatin + Etoposide + Radiation Therapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:</strong> 50 mg/m2 IV on days 1, 8, 29, and 36<br><strong>Etoposide:</strong> 50 mg/m2 IV on days 1-5 and 29-33<br><strong>Radiation therapy:</strong> 180 cGy/day for a total dose of 4,500 cGy<br>Chemotherapy is given concurrently with radiation therapy.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (118, 'Docetaxel : Taxotere<br>Doxorubicin : Adriamycin, various', 'AT - Docetaxel', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Moderate', '<b>AT - Docetaxel</b>', 'Nabholz,JM,Falkson C,Campos D, et al. Docetaxel and doxorubicin comparewd with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer:results of a randomized , multicenter, phase III trial. $J Clin Oncol. 2003;21(6):968-975.$', null, '<p><strong>Doxorubicin:</strong> 50 mg/m2 IV over 15 minutes, day 1<br><strong>FOLLOWED 1 HOUR LATER BY</strong><br><strong>Docetaxel: </strong>75 mg/m2 day 1<br>Repeat every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (404, 'Cyclophosphamide: Cytoxan<br>Docetaxel: Taxotere<br>Doxorubicin: Adriamycin, various', 'AC/Docetaxel (weekly)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt;5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Sparano JA, Zhao F, et al. 2014 San Antonio Breast Cancer Symposium Abstracts S3-03.', 'ADJUVANT', '<p><strong>Doxorubicin:</strong> 60 mg/m2 IV on day 1<br><strong>Cyclophosphamide:</strong> 600 mg/m2 IV on day 1</p><p>Repeat every 21 days for 4 cycles, followed by<br><br><strong>Docetaxel:</strong>&nbsp;35&nbsp;mg/m2 IV on day 1</p><p>Repeat every 7&nbsp;days for 12&nbsp;cycles.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (411, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin, various<br>Paclitaxel: Taxol', 'AC/Paclitaxel (dose-dense)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'High ', '', 'Burstein HJ, Parker LM, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005;23(33):8340-7.', 'ADJUVANT', '<p><strong>Doxorubicin:</strong>&nbsp;60 mg/m2&nbsp;IV on day 1<br><strong>Cyclophosphamide:</strong>&nbsp;600 mg/m2&nbsp;IV on day 1</p><p>Repeat every 14 days for 4 cycles, followed by</p><p><strong>Paclitaxel:</strong>&nbsp;175 mg/m2&nbsp;IV on day 1</p><p>Repeat every 14 days for 4 cycles.</p><p>Add pegfilgrastim 6 mg SC on day 2 of each cycle.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1071, null, 'Weekly Carboplatin + Paclitaxel + Radiation Therapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Carboplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li></ul>', 'High', null, null, null, '<p><strong>Paclitaxel: </strong>45 mg/m2 IV weekly for 7 weeks<br><strong>Carboplatin:</strong> AUC of 2, IV weekly for 7 weeks<br><strong>Radiation therapy:</strong> 200 cGy/day for a total dose of 6,300 cGy over 7 weeks<br><br>Chemotherapy is given concurrently with radiation therapy. Three to 4 weeks<br>after the completion of chemoradiotherapy, two additional cycles of the following<br>chemotherapy are given:<br><strong>Paclitaxel:</strong> 200 mg/m2 IV on day 1<br><strong>Carboplatin: </strong>AUC of 6, IV on day 1<br>Repeat cycle every 21 days for 2 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1074, null, 'Cisplatin + Pemetrexed (Adjuvant)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Pemetrexed</strong>:<br>No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Pemetrexed</strong>:<br>If CrCl &gt; 45 mL/min, no dose reduction<br>If CrCl &lt; 45 mL/min, do not use</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:</strong>&nbsp;80 mg/m2&nbsp;IV once on day 1<br><strong>Pemetrexed:</strong>&nbsp;500 mg/m2&nbsp;IV once on day 1</p><p>Repeat cycle every 21 days for up to 6 cycles.</p><p>Folic acid at 350-1,000 µg PO once daily beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1-2 weeks prior to the first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed therapy.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (439, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin, various<br>Fluorouracil: 5-FU', 'CAF (metastatic)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Budman DR, Berry DA, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205-11.', 'METASTATIC', '<p><strong>Cyclophosphamide:</strong>&nbsp;600 mg/m2&nbsp;IV on day 1<br><strong>Doxorubicin:</strong>&nbsp;60 mg/m2 IV on day 1<br><strong>5-Fluorouracil:</strong>&nbsp;600 mg/m2 IV on day 1</p><p>Repeat cycle every 21 days.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1075, null, 'Gemcitabine + Cisplatin + Bevacizumab ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul>', 'High', null, null, null, '<p><strong>Gemcitabine:</strong> 1,250 mg/m2 IV on days 1 and 8<br><strong>Cisplatin:</strong> 80 mg/m2 IV on day 1<br><strong>Bevacizumab:</strong> 7.5 or 15 mg/kg IV on day 1<br>Repeat cycle every 21 days for a total of 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (139, 'Capecitabine : Xeloda', 'Capecitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine:</strong><br>If CrCl 30-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'Low', '<b>Capecitabine</b>', 'Xeloda [package insert]. $San Francisco, CA: Genentech; 2011.$', null, '<p><strong>Capecitabine:</strong> 1,250 mg/m2 PO bid, days 1-14 with 1 week rest.<br>Repeat every 21 days</p><p>Consider decreasing dose to 850-1,000 mg/m2 PO bid on days 1-14 to decrease the risk of toxicity without compromising clinical efficacy.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (451, 'Carboplatin: Paraplatin<br>Paclitaxel: Taxol', 'Carboplatin/Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on AUC &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% dosage.</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li></ul>', 'High', '', 'Perez EA, Hillman DW, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer. 2000;88(1):124-31.', 'METASTATIC', '<p><strong>Carboplatin:</strong>&nbsp;AUC of 6, IV on day 1<br><strong>Paclitaxel: </strong>200 mg/m2&nbsp;IV over 3 hours on day 1</p><p>Repeat cycle every 21 days.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (119, 'Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol', 'AT - Paclitaxel', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Moderate', '<b>AT - Paclitaxel</b>', 'Jassem J, Pienkowski T, Pluzanska A.et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. $J Clin Oncol. 2001;19(6):1707-1715$', null, '<p><strong>Doxorubicin:</strong> 50 mg/m2 IV over, day 1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<br><strong>FOLLOWED 24 HOUR LATER BY &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong><br><strong>Paclitaxel:</strong> 220 mg/m2,IV over 3 hours ,day 2<br>Repeat every 21 days for up to 8 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1073, null, 'Cisplatin + Vinblastine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vinblastine:</strong><br>If serum bilirubin 1.5 to 3 mg/dL or transaminases 2 to 3 times ULN: Administer 50% of dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If serum bilirubin &gt;3 times ULN: Avoid use.</li><li><strong>Cisplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vinblastine:</strong><br>No dose reduction</li><li><strong>Cisplatin</strong>:<strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:</strong> 100 mg/m2 IV on day 1<br><strong>Vinblastine: </strong>4 mg/m2 IV on days 1,8, 15, 22, and 29, then every 2 weeks after day 43<br>Repeat cycle every 28 days for 4 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (791, null, 'EC Metastatic regimen', '<p><strong>Hepatic Impairment</strong></p><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li>Epirubicin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin 1.2 to 3 mg/dL: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;3 to 5 mg/dL: Reduce dose by 75% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;5 mg/dL: Do not use it.</li></ul><p><strong>Renal Impairment</strong></p><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li>Epirubicin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If creatinine &gt;5 mg/dL: Consider lower doses.</li></ul>', 'High', null, null, null, '<p><strong>Epirubicin:&nbsp;</strong>75 mg/m2&nbsp;IV on day 1</p><p><strong>Cyclophosphamide:&nbsp;</strong>600 mg/m2&nbsp;IV on day 1</p><p>Repeat every 21 days for up to 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (126, 'Cyclophosphamide : Cytoxan<br>Epirubicin : Ellence, various', 'EC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Epirubicin: &nbsp;&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin 1.2 to 3 mg/dL: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;3 to 5 mg/dL: Reduce dose by 75% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;5 mg/dL: Do not use it.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Epirubicin: &nbsp; &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If creatinine &gt;5 mg/dL: Consider lower doses.</li></ul>', 'High', '<b>EC</b>', 'Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. $J Clin Oncol. 2001;19(12):3103-3110.$', null, '<p><strong>Epirubicin:</strong>100 mg/m2 IV, day 1<br><strong>Cyclophosphamide:</strong> 830 mg/m2 IV, day 1<br>Repeat every 21 days for up to 8 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (441, 'Cyclophosphamide: Cytoxan<br>Methotrexate: MTX<br>5-Fluorouracil: 5-FU', 'CMF', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Methotrexate</strong>:<br />
	If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Methotrexate</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Poole CJ, Earl HM, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355(18):1851-62.', 'METASTATIC', '<p><strong>Cyclophosphamide:</strong>&nbsp;600 mg/m2&nbsp;IV on day 1<br><strong>Methotrexate:</strong>&nbsp;40 mg/m2&nbsp;IV on day 1<br><strong>5-Fluorouracil:</strong>&nbsp;600 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (466, '', 'Cisplatin + Pemetrexed', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Pemetrexed</strong>:<br>No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Pemetrexed</strong>:<br>If CrCl &gt; 45 mL/min, no dose reduction<br>If CrCl &lt; 45 mL/min, do not use</li></ul>', 'High', '', 'PARAMOUNT: Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):247-55. Epub 2012 Feb 16.

Park CK, Oh IJ, Kim KS, Choi YD, Jang TW, Kim YS, Lee KH, Shin KC, Jung CY, Yang SH, Ryu JS, Jang SH, Yoo SS, Yong SJ, Lee KY, In KH, Lee MK, Kim YC. Randomized phase III study of docetaxel plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of nonsquamous non-small-cell lung cancer: a TRAIL trial. Clin Lung Cancer. 2017 Jul;18(4):e289-e296. Epub 2017 Jan 11.', 'METASTATIC', '<p><strong>Cisplatin:</strong>&nbsp;75 mg/m2&nbsp;IV once on day 1<br><strong>Pemetrexed:</strong>&nbsp;500 mg/m2&nbsp;IV once on day 1</p><p>Repeat cycle every 21-days.</p><p>Folic acid at 350-1,000 µg PO once daily beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1-2 weeks prior to the first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed therapy.</p>', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1077, null, 'Vinorelbine + Cisplatin + Cetuximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vinorelbine:</strong><br>If bilirubin 2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vinorelbine:</strong><br>No dose reduction</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Vinorelbine:</strong> 25 mg/m2 IV on days 1 and 8<br><strong>Cisplatin:</strong> 80 mg/m2 IV on day 1<br><strong>Cetuximab:</strong> 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly<br>Repeat cycle every 3 weeks up to 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (446, 'Docetaxel: Taxotere<br>Doxorubicin: Adriamycin, various', 'Docetaxel/Doxorubicin', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Dieras V. Review of docetaxel/doxorubicin combination in metastatic breast cancer. Oncology (Williston Park). 1997;11(8 Suppl 8):31-3.', 'METASTATIC', '<p><strong>Docetaxel:</strong>&nbsp;75 mg/m2&nbsp;IV on day 1<br><strong>Doxorubicin:</strong>&nbsp;50 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1081, null, 'Pemetrexed + Carboplatin+ Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Pemetrexed</strong>:<br>No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Pemetrexed</strong>:<br>If CrCl &gt; 45 mL/min, no dose reduction<br>If CrCl &lt; 45 mL/min, do not use</li></ul>', 'High', null, null, null, '<p><strong>Pemetrexed:</strong> 500 mg/m2 IV on day1<br><strong>Carboplatin:</strong> AUC of 6, IV on day 1<br><strong>Bevacizumab:</strong> 15 mg/kg IV on day1<br>Repeat cycle every 21 days up to 6 cycles. Folic acid at 350-1,000 g P0<br>q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM be ginning 1-2 weeks prior to first dose of therapy and repeated every 9 weeks.<br>Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after<br>pemetrexed.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (125, 'Gemcitabine : Gemzar, various<br>Paclitaxel : Taxol', 'Gemcitabine/Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>No dose reduction</li></ul>', 'Low', '<b>Gemcitabine/Paclitaxel</b>', 'Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. $J Clin Oncol. 2008;26(24):3950-3957.$', null, '<p><strong>Gemcitabine: </strong>1,250 mg/m2 IV over 30-60 minutes on days 1 and 8<br><strong>Paclitaxel: </strong>175 mg/m2 IV over 3 hours before gemcitabine, day 1<br>Repeat every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1076, null, 'Vinorelbine + Cisplatin ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vinorelbine:</strong><br>If bilirubin 2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cisplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vinorelbine:</strong><br>No dose reduction</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'High', null, null, null, '<p><strong>Vinorelbine:</strong> 30 mg/m2 IV on days 1, 8, and 15.<br><strong>Cisplatin:</strong> 120 mg/m2 IV on days 1.<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1072, null, 'Vinorelbine + Cisplatin (Adjuvant)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vinorelbine:</strong><br>If bilirubin 2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cisplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vinorelbine:</strong><br>No dose reduction</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'High', null, null, null, '<p><strong>Vinorelbine:</strong> 25 mg/m2 IV weekly for 16 weeks<br><strong>Cisplatin:</strong> 50 mg/m2 IV on days 1 and 8<br>Repeat cycle every 28 days for 4 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1078, null, 'Vinorelbine + Carboplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Vinorelbine</strong>:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: &nbsp;Reduce dose to 50% of the usual dose. &nbsp; If GFR &lt;10 mL/min: Reduce dose to 75% of the usual dose.</li><li><strong>Vinorelbine</strong>:<br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Vinorelbine: </strong>25 mg/m2 IV on days 1 and 8<br><strong>Carboplatin:</strong> AUC of 6, IV on day 1<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (426, 'Ado-trastuzumab emtansine: Kadcyla', 'Ado-Trastuzumab Emtansine', '<p><strong>Renal Impairment</strong><br>&nbsp;<strong>Ado-Trastuzumab Emtansine</strong>: No dose reduction.</p><p><strong>Hepatic Impairment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Ado-Trastuzumab Emtansine</strong>: No dose reduction.</p><p><strong>Cardiac Impairment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> <strong>Ado-Trastuzumab Emtansine</strong>:&nbsp;</p><p>&nbsp; &nbsp;If<strong> </strong>EF ≥50%: 100% dose.</p><p>&nbsp; &nbsp;If EF 45% to &lt;50% and &lt;10% decrease from baseline: 100 % dose and repeat LVEF estimation within 3 weeks.</p><p>&nbsp; &nbsp;If EF 45% to &lt;50% and ≥10% decrease from baseline: Hold treatment and repeat LVEF estimation within 3 weeks; if repeat EF remains &lt;50% and has not recovered to &lt;10% from baseline, stop treatment.</p><p>&nbsp; &nbsp; If EF &lt;45%: Hold treatment and repeat LVEF estimation within 3 weeks; if repeat EF is confirmed &lt;45%, stop treatment.</p><p>&nbsp; &nbsp; If symptomatic heart failure, grade 3 to 4 left ventricular systolic dysfunction, grade 3 to 4 heart failure, or grade 2 heart failure with EF &lt;45%: stop treatment.</p>', 'Low', '', 'von Minckwitz G, Huang CS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617-628.', 'ADJUVANT', '<p><strong>Ado-Trastuzumab Emtansine</strong>: 3.6 mg/kg IV on day 1</p><p>Repeat every 21 days for 14 cycles.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (498, 'Alpelisib: Piqray<br>Fulvestrant: Faslodex', 'Alpelisib/Fulvestrant', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Fulvestrant</strong>:<br>If SGOT, SGPT, bilirubin, and alkaline phosphatase &lt; 2 upper normal limits, no dose reduction<br>If SGOT, SGPT, bilirubin, and alkaline phosphatase &gt; 2 upper normal limits, unknown</li><li><strong>Alpelisib: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Fulvestrant</strong>:<br>No dose reduction</li><li><strong>Alpelisib: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', 'Andre F, Ciruelos E, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929-1940.', 'METASTATIC', '<p><strong>Alpelisib:</strong>&nbsp;3,000 mg PO daily<br><strong>Fulvestrant:</strong>&nbsp;500 mg IM on days 1, 15, and 29 and then once per month</p><p>Repeat cycle every 28 days.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (453, 'Bevacizumab: Avastin<br>Paclitaxel: Taxol', 'Paclitaxel/Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Bevacizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dosage modification. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel</strong>:<br>No dose reduction</li><li><strong>Bevacizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dosage modification. &nbsp;</li></ul>', 'Low', '', 'Miller K, Wang M, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-76.', 'METASTATIC', '<p><strong>Paclitaxel:</strong>&nbsp;90 mg/m2&nbsp;IV on days 1, 8, and 15<br><strong>Bevacizumab:</strong>&nbsp;10 mg/kg on days 1 and 15</p><p>Repeat cycle every 28 days.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1079, null, 'EP + Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Docetaxel:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:</strong> 50 mg/m2 IV on days 1, 8, 29, and 36<br><strong>Etoposide:</strong> 50 mg/m2 IV on days 1-5 and 29-33<br>Administer concurrent thoracic radiotherapy, followed 4-6 weeks after completion of combined modality therapy by<br><strong>Docetaxel:</strong> 75 mg/m2 IV on day 1</p><p><br>Repeat cycle every 21 days for 3 cycles. Dose of docetaxel can be escalated<br>to 100 mg/m2 IV on subsequent cycles in the absence of toxicity.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (131, 'Cyclophosphamide : Cytoxan<br>Docetaxel : Taxotere<br>Doxorubicin : Adriamycin, various', 'TAC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li></ul>', 'High', '<b>TAC</b>', 'Martin M, Pienkowshi T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. $N Engl J Med. 2005;352(22):2303-2313.$', null, '<p><strong>Doxorubicin:</strong> 50 mg/m2 as a 15-minute IV bolus on day 1</p><p>&nbsp;<strong>FOLLOWED BY &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong><br><strong>Cyclophosphamide:</strong> 500 mg/m2 as a 1- to 5-minute IV bolus on day 1<br><strong>Docetaxel:</strong> 75 mg/m2 IV over 1 hour on day 1, 1 hr after IV cyclophosphamide. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Repeat every 21 days for 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1080, null, 'Docetaxel + Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Docetaxel:</strong> 75 mg/m2 IV on day 1<br><strong>Bevacizumab:</strong> 15 mg/kg IV on day 1<br>Repeat cycle every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (152, 'Vinorelbine : Navelbine', 'Vinorelbine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vinorelbine:</strong><br>If bilirubin 2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vinorelbine:</strong><br>No dose reduction</li></ul>', 'Low', '<b>Vinorelbine</b>', 'Weber BL, Vogel C, Jones S, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast  cancer. $J Clin Oncol. 1995;13(11):2722-2730.$', null, '<p><strong>Vinorelbine:</strong> 30 mg/m2 IV on day 1<br>Repeat cycle every 7 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (492, 'Capecitabine: Xeloda<br>Lapatinib: Tykerb ', 'Capecitabine/Lapatinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Lapatinib</strong>:<br>If Child-Pugh C, reduce dose to 750 mg/day</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Lapatinib</strong>:<br>Not studied. Only 2% eliminated by kidneys</li></ul>', 'Low', '', 'Geyer CE, Forster J, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-43.', 'METASTATIC', '<p><strong>Capecitabine:</strong>&nbsp;1,000 mg/m2&nbsp;PO BID on days 1-14<br><strong>Lapatinib:</strong>&nbsp;1,250 mg PO daily</p><p>Repeat cycle every 21 days.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (443, 'Capecitabine: Xeloda<br>Paclitaxel: Taxol', 'XP', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	If CrCl 30-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Biganzoli L, Martin M, et al. Moving forward with capecitabine: a glimpse of the future. Oncologist. 2002;7 Suppl 6:29-35.', 'METASTATIC', '<p><strong>Capecitabine:</strong>&nbsp;825 mg/m2&nbsp;PO BID on days 1-14<br><strong>Paclitaxel: </strong>175 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (497, 'Abemaciclib: Verzenio<br>Fulvestrant: Faslodex', 'Abemaciclib/Fulvestrant', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Abemaciclib</strong><br>Child-Pugh C: Reduce dosing frequency to once daily</li><li><strong>Fulvestrant</strong>:<br>If SGOT, SGPT, bilirubin, and alkaline phosphatase &lt; 2 upper normal limits, no dose reduction<br>If SGOT, SGPT, bilirubin, and alkaline phosphatase &gt; 2 upper normal limits, unknown</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Fulvestrant</strong>:<br>No dose reduction</li><li><strong>Abemaciclib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100 % dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: &nbsp;No dosage adjustments because of insufficient data.</li></ul>', 'Low', '', 'Sledge GW Jr, Toi M, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875-2884.', 'METASTATIC', '<p><strong>Abemaciclib:</strong>&nbsp;150 mg PO BID<br><strong>Fulvestrant:</strong>&nbsp;500 mg IM on days 1 and 15 of the first cycle, then 500mg IM on day 1 for all subsequent cycles</p><p>Repeat cycle every 28 days.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (626, '', 'FOLFOX4 + Panitumumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Panitumumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Panitumumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p><strong>Panitumumab:&nbsp;</strong>6 mg/kg IV on day 1</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (605, '', 'FOLFOXIRI', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>165 mg/m2&nbsp;IV on day 1</p><p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m2&nbsp;IV on day 1</p><p><strong>5-Fluorouracil:&nbsp;</strong>3,200 mg/m2&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p><p><strong>Leucovorin:&nbsp;</strong>200 mg/m2&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p><p>Repeat cycle every 2 weeks for 12 cycles.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (598, '', 'Irinotecan + 5-Fluorouracil + Leucovorin (Modified IFL Saltz regimen)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>125 mg/m<sup>2</sup>&nbsp;IV over 90 minutes weekly for 2 weeks</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 2 weeks</p>

<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV weekly for 2 weeks</p>

<p>Repeat cycle every 3 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (618, '', 'LV5FU2 + Mitomycin-C', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Mitomycin-C: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Mitomycin-C:&nbsp;</strong><br>&nbsp;If CrCl &lt;10 mL/min: 75% of usual dose.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p><strong>Mitomycin-C:&nbsp;</strong>7 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat 5-FU/LV every 2 weeks and mitomycin-C every 4 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1082, null, 'Docetaxel + Ramucirumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li><li><strong>Ramucirumab:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>Ramucirumab:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Docetaxel: </strong>75 mg/m2 IV on day 1<br><strong>Ramucirumab:</strong> 10 mg/kg IV on day 1<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (494, 'Palbociclib: Ibrance<br>Letrozole: Femara', 'Palbociclib/Letrozole', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Palbociclib</strong><br>If Child-Pugh A or B, no dose reduction<br>If Child-Pugh C,&nbsp;reduce dose to 75 mg/day</li><li><strong>Letrozole</strong>:<br>If Child-Pugh A or B, no dose reduction<br>If Child-Pugh C, reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Letrozole</strong>:<br>If CrCl &gt;10 mL/min, no dose reduction</li><li><strong>Palbociclib &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Low', '', 'Finn RS, Crown JP, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35.', 'METASTATIC', '<p><strong>Palbociclib:</strong>&nbsp;125 mg PO daily for 21 days<br><strong>Letrozole:</strong>&nbsp;2.5 mg PO daily</p><p>Repeat cycle every 21 days.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (424, 'Pertuzumab: Perjeta<br>Trastuzumab: Herceptin<br>Docetaxel: Taxotere', 'Pertuzumab/Trastuzumab/Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel</strong>:<br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li><li>&nbsp;<strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction.</li><li><strong>Pertuzumab: &nbsp;&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel</strong>:<br>No dose reduction</li><li>&nbsp;<strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction.</li><li><strong>Pertuzumab: &nbsp;&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Cardiac Impairment</strong></p><ul><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'Moderate', '', 'Baselga J, Cortes J, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-19.', 'ADJUVANT', '<p><strong>Docetaxel:</strong>&nbsp;75 mg/m2&nbsp;IV on day 1<br><strong>Trastuzumab:</strong>&nbsp;8 mg/kg IV loading dose on day 1 and then 6 mg/kg IV every 3 weeks<br><strong>Pertuzumab:</strong>&nbsp;840 mg IV loading dose on day 1 and then 420 mg IV every 3 weeks</p><p>Repeat every 21 days.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1083, null, 'Gemcitabine + Cisplatin + Necitumumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Necitumumab:</strong>&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Necitumumab:</strong>&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li></ul>', 'High', null, null, null, '<p><strong>Gemcitabine:</strong> 1,250 mg/m2 IV on days 1 and 8<br><strong>Cisplatin:</strong> 75 mg/m2 IV on day 1<br><strong>Necitumumab:</strong> 800 mg IV on days 1 and 8<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (135, 'Paclitaxel : Taxol<br>Trastuzumab : Herceptin', 'TP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Trastuzumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel:</strong><br>No dose reduction</li><li><strong>Trastuzumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Cardiac Impairment</strong></li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'Low', '<b>TP</b>', 'Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. $J Clin Oncol. 2006;24(18):2786-2792.$', null, '<p><strong>Trastuzumab:</strong> 4 mg/kg IV loading dose, day 1 Followed by 2 mg/kg IV weekly<br><strong>Paclitaxel:</strong> 175 mg/m2 IV over 3 hours on day 1<br>Repeat every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (425, 'Neratinib: Nerlynx', 'Neratinib', '<p><strong>Hepatic Impairment:</strong><br>&nbsp;<strong>Neratinib: </strong>Severe (Child-Pugh C): reduce starting dose to 80mg.</p><p><strong>Renal Impairment:</strong><br><strong>Neratinib: </strong>No dose reduction necessary.</p>', 'Low', '', 'Chan A, Delaloge S, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367-377.', 'ADJUVANT', '<p><strong>Neratinib:</strong>&nbsp;240 mg PO daily</p><p>Repeat daily for 1 year following trastuzumab-based adjuvant therapy.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (701, '', '5-Fluorouracil + Leucovorin (Adjuvant)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'ADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>425 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p>Repeat cycle every 28 days for a total of 6 cycles.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1084, null, 'Dabrafenib + Trametinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Dabrafenib:</strong><br>If SGOT or SGPT and bilirubin&nbsp;&lt; 1.5 times ULN: 100% &nbsp;dosage &nbsp; &nbsp; &nbsp; &nbsp; If SGOT or SGPT &gt;2.5 times ULN or bilirubin &gt;1.5 times ULN: Dose modification not provided by the manufacturer</li><li><strong>Trametinib:</strong><br>If SGOT or SGPT and bilirubin&nbsp;&lt; 1.5 times ULN: 100% &nbsp;dosage &nbsp; &nbsp; &nbsp; &nbsp; If SGOT or SGPT &gt;2.5 times ULN or bilirubin &gt;1.5 times ULN: Dose modification not provided by the manufacturer</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Dabrafenib:</strong><br>If CrCl ≥ 30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt; 30 mL/min: Dose modification not provided by the manufacturer</li><li><strong>Trametinib:</strong><br>If CrCl ≥ 30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt; 30 mL/min: Dose modification not provided by the manufacturer</li></ul>', 'Low', null, null, null, '<p><strong>Dabrafenib:</strong> 150 mg PO bid<br><strong>Trametinib:</strong> 2 mg PO daily<br>Continue treatment until disease progression</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (493, 'Everolimus: Afinitor<br>Exemestane: Aromasin', 'Everolimus/Exemestane', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Everolimus</strong><br />
	Mild (Child Pugh A): Decrease dose to 7.5 mg daily<br />
	Moderate (Child Pugh B): Decrease dose to 5 mg daily<br />
	Severe (Child Pugh C): Decrease dose to 2.5 mg daily</li>
	<li><strong>Exemestane</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Everolimus</strong>:<br />
	No dose reduction</li>
	<li><strong>Exemestane</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Baselga J, Campone M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.  N Engl J Med. 2012;366(6):520-9.', 'METASTATIC', '<p><strong>Everolimus:</strong>&nbsp;10 mg PO daily<br><strong>Exemestane:&nbsp;</strong> 25 mg PO daily</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (706, '', '5-Fluorouracil + Leucovorin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>425 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p>Repeat cycle every 28 days.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (707, '', 'Gemcitabine + Capecitabine (GEM-CAP)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p><strong>Capecitabine:&nbsp;</strong>650 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p>Repeat cycle every 21 days.</p>

<p><strong>OR</strong></p>

<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p><strong>Capecitabine:&nbsp;</strong>830 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-21</p>

<p>Repeat cycle every 28 days.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (926, null, 'Lenalidomide + Rituximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>No dose reduction.</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>If CrCl &gt;60 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 30 to 60 mL/min: 5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min not requiring dialysis: 2.5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min requiring dialysis: 2.5 mg once daily (administer after dialysis on dialysis days).</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Lenalidomide:</strong> 20 mg/day PO on days 1-21<br><strong>Rituximab: </strong>375 mg/m2 IV on days 1, 8, 15, 22 of cycle 1 and on day 1 of cycles 2-5<br><br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (487, 'Gemcitabine: Gemzar<br>Carboplatin: Paraplatin<br>Trastuzumab: Herceptin', 'Gemcitabine/Carboplatin/Trastuzumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine</strong>:<br>No dose reduction</li><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Trastuzumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine</strong>:<br>No dose reduction</li><li><strong>Carboplatin</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% dosage.</li><li><strong>Trastuzumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Cardiac Impairment</strong></li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'High', '', 'Loesch D, Asmar L, et al. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clin Breast Cancer. 2008;8(2):178-86. ', 'METASTATIC', '<p><strong>Gemcitabine:</strong>&nbsp;1,500 mg/m2&nbsp;IV on day 1<br><strong>Carboplatin:</strong>&nbsp;AUC of 2.5, IV on day 1<br><strong>Trastuzumab:</strong>&nbsp;8 mg/kg IV loading dose on day 1, then 4 mg/kg IV every 2 weeks</p><p>Repeat cycle every 2 weeks.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (485, 'Trastuzumab: Herceptin<br>Docetaxel: Taxotere', 'Trastuzumab/Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel</strong>:<br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li><li><strong>Trastuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel</strong>:<br>No dose reduction</li><li><strong>Trastuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Cardiac Impairment</strong></li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'Low', '', 'Esteva FJ, Valero V, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(7):1800-8.', 'METASTATIC', '<p><strong>Trastuzumab:</strong>&nbsp;4 mg/kg IV loading dose,&nbsp;then 2 mg/kg IV on days 8 and 15<br><strong>Docetaxel:</strong>&nbsp;35 mg/m2&nbsp;IV on days 1, 8, and 15</p><p>The first cycle is administered weekly for 3 weeks, with 1-week off. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; For subsequent cycles:</p><p><strong>Trastuzumab:&nbsp;</strong>2 mg/kg IV weekly<br><strong>Docetaxel:</strong>&nbsp;35 mg/m2&nbsp;IV weekly</p><p>Repeat cycle every 4 weeks.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1085, null, 'Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel</strong>:<br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Paclitaxel:</strong> 225 mg/m2 IV over 3 hours on day 1<br>Repeat cycle every 21 days.</p><p><br>OR</p><p><br><strong>Paclitaxel:</strong> 80-100 mg/m2 IV weekly for 3 weeks<br>Repeat cycle every 28 days after 1-week rest.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (431, 'Anastrozole: Arimidex ', 'Anastrozole', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Anastrozole</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Anastrozole</strong>:<br />
	No dose reduction</li>
</ul>
', 'N/A', '', 'Howell A, Cuzick J, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years'' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-2.', 'ADJUVANT', '<p><strong>Anastrozole:</strong>&nbsp;1 mg PO daily</p><p>Repeat daily for 5 to 10 &nbsp;years in patients with ER+ tumors or ER status unknown.</p>', 17);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (151, 'Trastuzumab : Herceptin', 'Trastuzumab q3wk', '<p><strong>Renal Impairment</strong><br>No dose reduction.</p><p><strong>Hepatic Impairment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Cardiac Impairment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</p>', 'Low', '<b>Trastuzumab q3wk</b>', 'Piccart-Gebhart MJ, Proctor M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. $N Engl J Med. 2005;353(16):1659-1672.$', null, '<p><strong>Trastuzumab:</strong> 8 mg/kg IV over 90 minutes, day 1, then 6 mg/kg IV over 90 minutes<br>Repeat every 21 days for 1 year(adjuvant).</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (150, 'Trastuzumab : Herceptin', 'Trastuzumab qwk', '<p><strong>Renal Impairment</strong><br>No dose reduction.</p><p><strong>Hepatic Impairment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Cardiac Impairment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</p>', 'Low', '<b>Trastuzumab qwk</b>', 'Herception [package insert]. $South San Francisco, CA: Genentech, Inc: 2010.$', null, '<p><strong>Trastuzumab:</strong> 4 mg/kg IV loading dose over 90 minutes, &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>FOLLOWED BY</strong> 2 mg/kg IV over 30 minutes, weekly &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Repeat weekly for a total of 10 weeks. In the absence of disease advancement do a weekly maintenance dose of 2 mg/kg.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (138, 'Anastrozole : Arimidex', 'Anastrozole', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Anastrozole:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Anastrozole:</strong><br>No dose reduction</li></ul>', 'N/A', '<b>Anastrozole</b>', 'Arimidex [package insert]. $Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2011.$', null, '<p><strong>Anastrozole:</strong> 1 mg PO once daily</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (711, '', 'FOLFIRINOX', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.<strong>&nbsp;</strong></li><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours on days 1 and 2</p>

<p>Repeat cycle every 2 weeks.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (630, '', 'FOLFIRI + Ziv-aflibercept', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li><li><strong>Ziv-Aflibercept:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li><li><strong>Ziv-Aflibercept:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Medium', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>

<p><strong>Ziv-aflibercept:&nbsp;</strong>4 mg/kg IV on day 1</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (792, null, 'Alpelisib-Fulvestrant', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Fulvestrant:</strong><br>If SGOT, SGPT, bilirubin and alkaline phosphatase &lt; 2 upper normal limit, no dose reduction<br>If SGOT, SGPT, bilirubin and alkaline phosphatase &gt; 2 upper normal limit, unknown</li><li><strong>Alpelisib: &nbsp; &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Fulvestrant:</strong><br>No dose reduction</li><li><strong>Alpelisib: &nbsp; &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'N/A', null, null, null, '<p><strong>Alpelisib:&nbsp;</strong>300 mg PO daily with food.</p><p><strong>Fulvestrant:&nbsp;</strong>500 mg IM on days 1 and 15.</p><p>The treatment cycle is 28 days.</p><p>Subsequent cycles:</p><p><strong>Alpelisib:</strong>&nbsp;300 mg PO daily with food.</p><p><strong>Fulvestrant:&nbsp;</strong>500 mg IM on day 1</p><p>Repeat every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1086, null, 'Nab-Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nab-Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin 1.2 to ≤1.8 mg/dL:100% dosage<br>If bilirubin &gt;1.8 to ≤3.6 mg/dL: Reduce dose by 75%<br>If bilirubin &gt; 3.6 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nab-Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: There are no dosage adjustments provided because of insufficient data.</li></ul>', 'Low', null, null, null, '<p><strong>Nab-Paclitaxel: </strong>125 mg/m2 IV on days 1,8, and 15<br>Repeat cycle every 28 days&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (740, '', '5-Fluorouracil', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m<sup>2</sup>&nbsp;IV over 24 hours weekly</p>

<p>Repeat cycle weekly for 4 weeks.</p>

<p><strong>OR</strong></p>

<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-4</p>

<p>Repeat cycle every 21-28 days.</p>

<p><strong>OR</strong></p>

<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion on days 1-4</p>

<p><strong>L-Leucovorin:&nbsp;</strong>5 mg/m<sup>2</sup>/day IV on days 1-14</p>

<p>Repeat cycle every 28 days.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (2, 'Lomustine : CCNU<br>Procarbazine : Matulane<br>Vincristine : Oncovin, VCR', 'PCV', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lomustine:</strong><br>No dose reduction</li><li><strong>Procarbazine:</strong><br>If AST, ALT are 1.6 to 6 times ULN: 75% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If AST, ALT are &nbsp;&gt;6 times ULN: Use clinical judgment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin &gt;5 mg/dL or AST, ALT &gt;3 times ULN: Avoid use.</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lomustine:</strong><br>If CrCl &lt; 60 mL/min, do not use</li><li><strong>Procarbazine:</strong><br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'High', '<b>PCV</b>', 'Levin VA, Uhm JH, Jaeckle KA, et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluromethylornithine- procarbazine, N-(2-chloroethyl)-N'' -cyclohexyl- N-nitrosuera, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. $Clin Cancer Res.2000;6(10):3878-3884.$', null, '<p><strong>Procarbazine:</strong> 60 mg/m2 PO, days 8-21<br><strong>Lomustine:</strong> 130 mg/m2 PO, day 1<br><strong>Vincristine:</strong> 1.4 mg/m2 IV, days 8 and 29<br>Repeat cycle every 8 weeks for 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1087, null, 'Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li>Docetaxel:<br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li>Docetaxel:<br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Docetaxel: </strong>75 mg/m2 IV on day 1<br>Repeat cycle every 21 days.</p><p><br>OR</p><p><br><strong>Docetaxel:</strong> 36 mg/m2 IV weekly for 6 weeks<br>Repeat cycle every 8 weeks after 2-week rest. Pre-medicate with dexamethasone 8 mg PO at 12 hours and immediately before docetaxel infusion and 12 hours<br>after each dose.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1088, null, 'Pemetrexed', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pemetrexed</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pemetrexed</strong>:<br>If CrCl &gt; 45 mL/min, no dose reduction<br>If CrCl &lt; 45 mL/min, do not use</li></ul>', 'Low', null, null, null, '<p><strong>Pemetrexed:</strong> 500 mg/m2 IV on day 1<br>Repeat cycle every 21 days. Folic acid at 350-1,000 microgram PO q day beginning 1<br>week prior to therapy and vitamin B12 at 1,000 microgram IM beginning 1-2 weeks prior to first dose of therapy and repeated every 3 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1089, null, 'Gemcitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Gemcitabine: </strong>1,000 mg/m2 IV on days 1, 8, and 15<br>Repeat cycle every 28 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1090, null, 'Vinorelbine', '<p><strong>Hepatic Impairment</strong></p><ul><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li>Vinorelbine:<br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Vinorelbine:</strong> 25 mg/m2 IV on day 1<br>Repeat cycle every 7 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (635, '', '5-Fluorouracil + Mitomycin-C + Radiation Therapy (EORTC regimen)', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Mitomycin-C:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Renal Impairment:&nbsp;</strong></li><li><strong>5-Fluorouracil</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Mitomycin-C: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;10 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: 75% dosage</li></ul>', 'Low', '', '', '', '<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m2/day IV continuous infusion on days 1-26</p><p><strong>Mitomycin-C:</strong>&nbsp;10 mg/m2&nbsp;IV on day 1</p><p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day, 5 days/week for a total of 4 weeks (total dose of 3,600 cGy)</p><p>Chemotherapy and radiation therapy are given concurrently. After a 2-week break following the completion of this first treatment, the second treatment is initiated as following:</p><p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m2/day IV continuous infusion on days 1-17</p><p><strong>Mitomycin-C:&nbsp;</strong>10 mg/m2&nbsp;IV on day 1</p><p><strong>Radiation Therapy:&nbsp;</strong>Total dose of 2,340 cGy over 17 days</p><p>Chemotherapy and radiation are given concurrently</p>', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (637, '', '5-Fluorouracil + Cisplatin + Radiation Therapy', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Renal Impairment:&nbsp;</strong></li><li><strong>5-Fluorouracil</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li></ul>', 'High', '', '', '', '<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-4 of each week of radiation therapy</p>

<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;on days 1, 29, 57, and 85 during radiation therapy</p>

<p><strong>Radiation Therapy:&nbsp;</strong>Total dose, 4,500 cGy over 5 weeks</p>

<p>Chemotherapy is given concurrently with radiation therapy.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (795, null, 'Irinotecan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Irinotecan:</strong><br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>If bilurubin &gt; 2 mg/dL, may not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Irinotecan:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Irinotecan:</strong> 350 mg/m2 IV over 90 min on day 1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Repeat every 3 weeks.<br><strong>OR</strong><br><strong>Irinotecan:</strong> 125 mg/m2 IV weekly for 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<br>Repeat every 6 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (794, null, 'PCV- Advanced', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lomustine:</strong><br>No dose reduction</li><li><strong>Procarbazine:</strong><br>If AST, ALT are 1.6 to 6 times ULN: 75% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If AST, ALT are &nbsp;&gt;6 times ULN: Use clinical judgment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin &gt;5 mg/dL or AST, ALT &gt;3 times ULN: Avoid use.</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lomustine:</strong><br>If CrCl &lt; 60 mL/min, do not use</li><li><strong>Procarbazine:</strong><br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Procarbazine:</strong> 75 mg/m2 PO, days 8-21<br><strong>Lomustine:</strong> 130 mg/m2 PO, day 1<br><strong>Vincristine:</strong> 1.4 mg/m2 IV, days 8 and 29<br>Repeat cycle every 8 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1095, null, 'Ceritinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ceritinib:</strong> &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild to moderate impairment (Child Pugh class A or B): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child Pugh class C): Reduce the dose by approximately one-third (rounded to the nearest multiple of the 150 mg strength).</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ceritinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &gt;30 to 90 mL/min: No dosage adjustment necessary. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: There are no dosage adjustments provided in the manufacturer''s labeling</li></ul>', 'High', null, null, null, '<p><strong>Ceritinib: </strong>750 mg/day P0<br>Continue treatment until disease progression&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (700, '', 'FOLFIRINOX (Adjuvant)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.<strong>&nbsp;</strong></li><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li></ul>', 'Moderate', '', '', 'ADJUVANT', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Irinotecan:&nbsp;</strong>150 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours on days 1 and 2</p>

<p>Repeat cycle every 2 weeks for a total of 12 cycles.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1091, null, 'Sunitinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Sunitinib:</strong><br>If Child-Pugh A or B, no dose reduction&nbsp;<br>If Child-Pugh C, reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Sunitinib:</strong><br>If CrCl &gt; 42 mL/min, no dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Sunitinib:</strong> 50 mg/day PO for 4 weeks<br>Repeat cycle every 6 weeks</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (799, null, 'Procarbazine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Procarbazine:</strong><br>If AST, ALT are 1.6 to 6 times ULN: 75% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If AST, ALT are &nbsp;&gt;6 times ULN: Use clinical judgment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin &gt;5 mg/dL or AST, ALT &gt;3 times ULN: Avoid use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Procarbazine:</strong><br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'High', null, null, null, '<p><strong>Procarbazine:</strong> 150 mg/m2 PO daily divided into 3 doses.<br>Repeat daily.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1092, null, 'Cetuximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Cetuximab: </strong>400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly.<br>Repeat cycle every week.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (800, null, 'Temozolomide ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Temozolomide:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Temozolomide:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Moderate', null, null, null, '<p><strong>Temozolomide:&nbsp;</strong>150<strong> </strong>mg/m2&nbsp;PO on days 1-5.</p><p>Repeat cycle every 28 days. If tolerating can increase the dose to 200 mg/m2.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (614, '', '5-Fluorouracil + Leucovorin + Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> No dose reduction</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks</p>

<p><strong>Leucovorin:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks, administered before 5-fluorouracil</p>

<p><strong>Bevacizumab:&nbsp;</strong>5 mg/kg IV every 2 weeks</p>

<p>Repeat cycle every 8 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (798, null, 'Carboplatin + Irinotecan + Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Irinotecan:</strong><br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>If bilurubin &gt; 2 mg/dL, may not use</li><li><strong>Bevacizumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Carboplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Irinotecan:</strong><br>No dose reduction</li><li><strong>Bevacizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Carboplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% dosage.</li></ul>', 'High', null, null, null, '<p><strong>Carboplatin:&nbsp;</strong>AUC of 4<strong>,</strong>&nbsp;IV on day 1</p><p><strong>Irinotecan:</strong> 340 mg/m2 IV on days 1 and 14</p><p><strong>Bevacizumab:</strong> 10 mg/kg IV on days 1 and 14.<br>&nbsp;</p><p>Repeat cycle every 28 Days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (797, null, 'Temozolomide + Lomustine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Temozolomide:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Lomustine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Temozolomide:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Lomustine:</strong><br>If CrCl 10 to 50 mL/min: 75% dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;10 mL/min: 25 - 50% dose.</li></ul>', 'Moderate', null, null, null, '<p><strong>Temozolomide:&nbsp;</strong>100<strong> </strong>mg/m2&nbsp;PO on days 2-6.</p><p><strong>Lomustine:&nbsp;</strong>100 mg/m2&nbsp;PO on day 1</p><p>Repeat cycle every 28 days for 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1093, null, 'Nivolumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nivolumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nivolumab:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Nivolumab: </strong>240 mg IV on day 1<br>Repeat cycle every 2 weeks. May also administer 480 mg IV on day 1 with<br>cycles every 4 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1094, null, 'Crizotinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Crizotinib:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (AST &gt; ULN and total bilirubin ≤ ULN <strong>or</strong> total bilirubin &gt;1 to ≤1.5 times ULN and any AST): No dose adjustment necessary. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (total bilirubin &gt;1.5 to ≤3 times ULN and any AST): 200 mg twice daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (total bilirubin &gt;3 times ULN and any AST): 250 mg once daily.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Crizotinib:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 30 to 89 mL/min: No dosage adjustment necessary. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min not requiring dialysis: Initial: 250 mg once daily.</li></ul>', 'High', null, null, null, '<p><strong>Crizotinib:</strong> 250 mg PO bid<br>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1096, null, 'Alectinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Alectinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild to moderate impairment (Child Pugh class A or B): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child Pugh class C): Reduce the dose to 450 mg BID</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Alectinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &gt;30 mL/min: No dosage adjustment necessary. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: There are no dosage adjustments provided in the manufacturer''s labeling</li></ul>', 'Low', null, null, null, '<p><strong>Alectinib: </strong>600 mg PO bid<br>Continue treatment until disease progression</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (803, null, 'mFOLFOX6', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m2&nbsp;IV on days 1,</p><p><strong>Fluorouracil:&nbsp;</strong>400 mg/m2&nbsp;IV bolus on day 1, then 2,400 mg/m2 IV continuous infusion over 46 hours.</p><p><strong>Leucovorin: </strong>400 mg/m2 IV on day 1</p><p>Repeat every 2 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (613, '', '5-Fluorouracil + Leucovorin (Roswell Park schedule, high dose)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m2&nbsp;IV weekly for 6 weeks</p><p><strong>Leucovorin:&nbsp;</strong>500 mg/m2&nbsp;IV weekly for 6 weeks, administered before 5-fluorouracil</p><p>Repeat every 8 weeks.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (590, '', '5-Fluorouracil + Leucovorin (weekly schedule, high dose)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Low', '', '', 'ADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m2&nbsp;IV weekly for 6 weeks</p><p><strong>Leucovorin:&nbsp;</strong>500 mg/m2&nbsp;IV over 2 hours weekly for 6 weeks, administered before 5-fluorouracil</p><p>Repeat every 8 weeks for a total of 4 cycles (32 weeks total)</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (591, '', '5-Fluorouracil + Leucovorin (weekly schedule, low dose)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Low', '', '', 'ADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m2&nbsp;IV weekly for 6 weeks</p><p><strong>Leucovorin:&nbsp;</strong>20 mg/m2&nbsp;IV weekly for 6 weeks, administered before 5-fluorouracil</p><p>Repeat every 8 weeks for a total of 4 or 6 cycles (32 or 48 weeks total)</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (802, null, 'Nivolumab', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>Nivolumab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment:</strong></p><ul><li><strong>Nivolumab:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Nivolumab:&nbsp;</strong>480 mg&nbsp;IV on day 1</p><p>Repeat cycle every 4 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (801, null, 'Pembrolizumab', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>Pembrolizumab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment:</strong></p><ul><li><strong>Pembrolizumab:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Pembrolizumab:&nbsp;</strong>10 mg/kg&nbsp;IV on day 1 or 200 mg IV on day 1</p><p>Repeat every 2 weeks if using 10 mg/kg dosing or every 3 weeks if using 200 mg dosing.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (616, '', '5-Fluorouracil + Leucovorin (de Gramont regimen)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV and then 600 mg/m<sup>2</sup>&nbsp;IV for 22 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (615, '', '5-Fluorouracil + Leucovorin (German schedule, low dose)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>600 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks</p>

<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks, administered before 5-fluorouracil</p>

<p>Repeat cycle every 8 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (589, '', '5-Fluorouracil + Leucovorin (Mayo Clinic schedule)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Low', '', '', 'ADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>425 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV on days 1-5, administered before 5-fluorouracil</p>

<p>Repeat cycle every 4-5 weeks for a total of 6 cycles.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (737, '', 'CPT-11 (monthly schedule)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li></ul>', 'Moderate', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>CPT-11:&nbsp;</strong>350 mg/m2&nbsp;IV on day 1</p><p>Repeat every 3 weeks.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (699, '', 'Gemcitabine + Capecitabine (GEM-CAP)- Adjuvant', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'ADJUVANT', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p><strong>Capecitabine:&nbsp;</strong>880 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-21</p>

<p>Repeat cycle every 28 days for a total of 6 cycles.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (633, '', 'Binimetinib + Encorafenib + Cetuximab (BEC)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Binimetinib:</strong><br>If bilirubin &gt;1 to ≤1.5 times ULN: No dose reduction.<br>If bilirubin &gt;1.5 to ≤3 times ULN: 30 mg PO bid, dosage.</li><li><strong>Encorafenib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction.</li><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Binimetinib:</strong><br>No dose reduction.</li><li><strong>Encorafenib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Medium ', '', '', 'METASTATIC', '<p><strong>Binimetinib:&nbsp;</strong>45 mg PO bid</p><p><strong>Encorafenib:&nbsp;</strong>300 mg PO daily</p><p><strong>Cetuximab:&nbsp;</strong>400 mg/m2&nbsp;IV loading dose, then 250 mg/m2&nbsp;IV weekly</p><p>Continue treatment until disease progression. This regimen is only for patients with&nbsp;<i>BRAF</i> V600E-mutant mCRC.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (610, '', 'Capecitabine + Irinotecan (XELIRI)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m2&nbsp;PO bid on days 1-14</p><p><strong>Irinotecan:&nbsp;</strong>250 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days. May decrease the dose of capecitabine to 850 mg/m2&nbsp;PO twice daily and the dose of irinotecan to 200 mg/m2&nbsp;IV to reduce risk of toxicity without compromising clinical efficacy.</p><p><strong>OR</strong></p><p><strong>Capecitabine:&nbsp;</strong>1,500 mg/m2&nbsp;PO bid on days 2-8</p><p><strong>Irinotecan:&nbsp;</strong>150 mg/m2&nbsp;IV on day 1</p><p>Repeat every 14 days.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (738, '', 'Cetuximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cetuximab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>Cetuximab:&nbsp;</strong>400 mg/m2&nbsp;IV loading dose, then 250 mg/m2&nbsp;IV weekly</p><p>Repeat cycle on a weekly basis.</p><p><strong>OR</strong></p><p><strong>Cetuximab:&nbsp;</strong>500 mg/m2&nbsp;IV every 2 weeks (no loading dose is necessary)</p><p>Repeat cycle every 2 weeks.</p><p>&nbsp;</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (621, '', 'Cetuximab + Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> No dose reduction<strong>&nbsp;</strong></li><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p><strong>Bevacizumab:&nbsp;</strong>5 mg/kg IV every 2 weeks</p>

<p>Repeat cycle every 2 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (726, '', 'Floxuridine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Floxuridine: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If bilirubin ≤1.4 mg/dL: 80% dosage.<br>If bilirubin &gt;1.4 to &lt;1.8 mg/dL: 50% dosage.<br>If bilirubin &gt; 2.4 mg/dL: No recommendations available for dosage.<br><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Renal Impairment</strong></li><li><strong>Floxuridine:</strong><br>No dose reduction</li></ul>', 'Low', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>Floxuridine (FUDR):&nbsp;</strong>0.3 mg/kg/day HAI on days 1-14</p>

<p><strong>Dexamethasone:&nbsp;</strong>20 mg HAI on days 1-14</p>

<p><strong>Heparin:&nbsp;</strong>50,000 U HAI on days 1-14</p>

<p>Repeat cycle every 14 days.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (627, '', 'FOLFIRI + Panitumumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li><li><strong>Panitumumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li><li><strong>Panitumumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>180 mg/m2&nbsp;IV on day 1</p><p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m2&nbsp;IV bolus on day 1, followed by 2,400 mg/m2&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p><p><strong>Leucovorin:&nbsp;</strong>400 mg/m2&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p><p><strong>Panitumumab:&nbsp;</strong>6 mg/kg IV on day 1</p><p>Repeat cycle every 2 weeks.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1142, null, 'Aminoglutethimide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Aminoglutethimide:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Aminoglutethimide:</strong><br>No dose reduction</li></ul>', 'N/A', null, null, null, '<p><strong>Aminoglutethimide: </strong>250 mg PO qid, if tolerated may increase to 500 mg PO qid.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (744, '', 'Nivolumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nivolumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nivolumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>Nivolumab:&nbsp;</strong>3 mg/kg IV on day 1</p><p>Repeat cycle every 2 weeks. May also consider administering using a fixed dose of 240 mg IV on day 1 every 2 weeks or 480 mg IV on day 1 every 4 weeks.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1097, null, 'Brigatinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Brigatinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If mild to moderate impairment (Child Pugh class A or B): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child Pugh class C): Reduce dose by ~40% (eg, from 180 mg once daily to 120 mg once daily, from 120 mg once daily to 90 mg once daily, from 90 mg once daily to 60 mg once daily).</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Brigatinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &gt;30 to 89 mL/min: No dosage adjustment necessary. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 15 to 29 mL/min: Reduce dose by ~50% (eg, from 180 mg once daily to 90 mg once daily, from 90 mg once daily to 60 mg once daily).</li></ul>', 'Low', null, null, null, '<p><strong>Brigatinib: </strong>90 mg PO daily for 7 days and then 180 mg PO daily<br>Continue treatment until disease progression</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (677, '', 'ECX', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>Epirubicin</strong>:<br>If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br>If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Capecitabine</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction</li><li><strong>Epirubicin</strong><br>If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'High', '', '', 'METASTATIC', '<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Capecitabine:&nbsp;</strong>625 mg/m<sup>2</sup>&nbsp;PO twice daily continuously</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (649, '', 'CAPOX + Radiation Therapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Oxaliplatin:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li></ul>', 'Moderate', '', '', 'NEOADJUVANT', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on days 1, 15, and 29</p>

<p><strong>Capecitabine:&nbsp;</strong>625 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-5 for 5 weeks</p>

<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day for 5 days per week to a total dose of 5,400 cGy</p>

<p>Chemotherapy is given concurrently with radiation therapy, followed by surgical resection</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (705, '', 'Capecitabine-based Chemoradiotherapy (SCALOP Regimen)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'LOCALLY ADVANCED', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m2&nbsp;IV on days 1, 8, and 15</p><p><strong>Capecitabine:&nbsp;</strong>830 mg/m2&nbsp;PO twice daily on days 1-21</p><p>Repeat every 28 days for 3 cycles. Patients with stable or responding disease can receive one additional cycle, followed by concurrent chemoradiation.</p><p><strong>Capecitabine:&nbsp;</strong>830 mg/m2&nbsp;PO twice daily Monday-Friday for 6 weeks</p><p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day to a total dose of 5,040 cGy</p><p>Chemotherapy and radiation therapy started on the same day and given concurrently.</p>', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (634, '', 'Nivolumab + Ipilimumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nivolumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Ipilimumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nivolumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Ipilimumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Nivolumab:&nbsp;</strong>3 mg/kg IV on day 1</p><p><strong>Ipilimumab:&nbsp;</strong>1 mg/kg IV on day 1</p><p>Repeat every 21 days for 4 cycles and then treat with nivolumab at 3 mg/kg or 240 mg IV every 14 days until disease progression or toxicity.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (601, '', 'Oxaliplatin + 5-Fluorouracil + Leucovorin (FOLFOX4)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p><strong>OR</strong></p>

<p><strong>L-Leucovorin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (804, null, 'LV5FU2 (de Gramont regimen)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m2&nbsp;IV and then 600 mg/m2&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p><p><strong>Leucovorin:&nbsp;</strong>200 mg/m2&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p><p><strong>OR</strong></p><p><strong>Leucovorin:&nbsp;</strong>100 mg/m2&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p><p>Repeat every 2 weeks for a total of 12 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (741, '', 'Regorafenib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Regorafenib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Regorafenib:&nbsp;</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>Regorafenib:&nbsp;</strong>160 mg PO daily on days 1-21</p>

<p>Repeat cycle every 28 days.</p>

<p><strong>OR</strong></p>

<p><strong>Regorafenib:&nbsp;</strong>80 mg PO daily on days 1-7. Increase by 40 mg PO daily every week until target dosing of 160 mg is reached depending on tolerability.</p>

<p>Repeat cycle every 28 days.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (715, '', 'Gemcitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV weekly for 7 weeks, then 1-week rest; subsequent cycles 1,000 mg/m<sup>2</sup>&nbsp;IV weekly for 3 weeks with 1-week rest</p>

<p>Repeat 3-week cycle every 28 days.</p>

<p><strong>OR</strong></p>

<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV over 100 min at 10 mg/m<sup>2</sup>/min on days 1, 8, and 15</p>

<p>Repeat cycle every 28 days.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (244, '', 'Temsirolimus', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Temsirolimus:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Temsirolimus:</strong><br>No dose reduction</li></ul>', 'Low', '<b>Temsirolimus</b>', 'Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evalute temsirolimus compared with investigator''s choice therapy for the treatment or relapsed or refractory mantle cell lymphoma. $J Clin Oncol.2009; 27(23):3822-3829.$', null, '<p><strong>Temsirolimus:</strong> 175 mg IV per week for 3 weeks<br>Followed by<br><strong>Temsirolimus:</strong> 75 mg IV weekly</p><p>Continue until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (742, '', 'TAS-102', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>TAS-102:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &lt;1.2 to 1.8 mg/dL: 100 % dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin &gt;1.8 to 3.6 mg/dL: Do not initiate therapy.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>TAS-102:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100% dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 15 to 29 mL/min: Decrease dosage from 35 mg/m2 to 20 mg/m2</li></ul><p>If unable to tolerate the 20 mg/m2 dose: Decrease the dose to 15 mg/m2. If unable to tolerate the 15 mg/m2 dose: Permanently stop the treatment with trifluridine/tipiracil.</p>', 'Moderate', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>TAS-102:&nbsp;</strong>35 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-5 and 8-12</p>

<p>Repeat cycle every 28 days.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (632, '', 'Vemurafenib + Irinotecan + Cetuximab (VIC)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vemurafenib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vemurafenib:&nbsp;&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Vemurafenib:&nbsp;</strong>960 mg PO twice daily</p><p><strong>Irinotecan:&nbsp;</strong>180 mg/m2&nbsp;IV on day 1</p><p><strong>Cetuximab:&nbsp;</strong>500 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 2 weeks. This regimen is only for patients with <i>BRAF</i> V600E-mutant mCRC.</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1098, null, 'Pembrolizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (total bilirubin &lt;1 to 1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (total bilirubin &gt;1.5 times ULN): Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><br><strong>Pembrolizumab:</strong> 200 mg IV on day 1<br>Repeat cycle every 3 weeks</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (657, '', 'Capecitabine + Oxaliplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Oxaliplatin:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (646, '', 'Paclitaxel + Carboplatin + Radiation Therapy (CROSS regimen)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel</strong>:<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Carboplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel</strong>:<br>No dose reduction</li><li><strong>Carboplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% dosage.</li></ul>', 'Moderate', '', '', 'NEOADJUVANT', '<p><strong>Paclitaxel:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, 15, 22 and 29</p>

<p><strong>Carboplatin:&nbsp;</strong>AUC of 2, IV on days 1, 8, 15, 22 and 29</p>

<p>Chemotherapy concurrently with radiation therapy of 1.8 Gy in 23 fractions for total dose of 41.4 Gy over 5 weeks.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (659, '', 'EOF', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li><li><strong>Epirubicin</strong>:<br>If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br>If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction</li><li><strong>Epirubicin</strong><br>If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion</p>

<p>Repeat cycle every 21 days.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (661, '', 'EOX', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Epirubicin</strong>:<br>If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br>If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%</li><li><strong>Oxaliplatin:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Capecitabine</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Epirubicin</strong><br>If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Capecitabine:&nbsp;</strong>625 mg/m<sup>2</sup>&nbsp;PO twice daily continuously</p>

<p>Repeat cycle every 21 days.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (653, '', 'FLOT4 Trial', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li></ul>', 'Moderate', '', '', '', '<p><strong>Preoperative FLOT chemotherapy:</strong></p><p><strong>Docetaxel:&nbsp;</strong>50 mg/m2&nbsp;IV on day 1</p><p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m2&nbsp;IV on day 1</p><p><strong>Leucovorin:&nbsp;</strong>200 mg/m2&nbsp;IV on day 1</p><p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m2&nbsp;IV continuous infusion over 24 hours on day 1</p><p>Repeat every 2 weeks for 4 cycles. &nbsp;It is followed by esophagectomy and then adjuvant chemotherapy in patients who had total gross removal of disease with negative margins.</p><p><strong>Adjuvant Chemotherapy:</strong></p><p><strong>Docetaxel:&nbsp;</strong>50 mg/m2&nbsp;IV on day 1</p><p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m2&nbsp;IV on day 1</p><p><strong>Leucovorin:&nbsp;</strong>200 mg/m2&nbsp;IV on day 1</p><p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m2&nbsp;IV continuous infusion over 24 hours on day 1</p><p>Repeat every 2 weeks for 4 cycles. Only patients with resectable gastric or gastroesophageal junction tumors were included in this trial.</p>', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (688, '', 'Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Docetaxel:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>

<p><strong>OR</strong></p>

<p><strong>Docetaxel:&nbsp;</strong>36 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks.</p>

<p>Repeat cycle every 8 weeks.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (679, '', 'Docetaxel + Cisplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'High', '', '', 'METASTATIC', '<p><strong>Docetaxel:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (664, '', 'TAS-102', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>TAS-102:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &lt;1.2 to 1.8 mg/dL: 100 % dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin &gt;1.8 to 3.6 mg/dL: Do not initiate therapy.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>TAS-102:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100% dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 15 to 29 mL/min: Decrease dosage from 35 mg/m2 to 20 mg/m2</li></ul><p>If unable to tolerate the 20 mg/m2 dose: Decrease the dose to 15 mg/m2. If unable to tolerate the 15 mg/m2 dose: Permanently stop the treatment with trifluridine/tipiracil.</p>', 'Moderate', '', '', 'METASTATIC', '<p><strong>TAS-102:&nbsp;</strong>35 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-5 and 8-12</p>

<p>Repeat cycle every 28 days.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (686, '', '5-Fluorouracil', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p>Repeat cycle every 28 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (687, '', '5-Fluorouracil + Leucovorin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>370 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (680, '', 'Capecitabine + Cisplatin', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Renal Impairment:&nbsp;</strong></li><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'High', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p><strong>Cisplatin:&nbsp;</strong>80 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (669, '', 'DCF', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>5-Fluorouracil</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'High', '', '', 'METASTATIC', '<p><strong>Docetaxel:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>750 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (710, '', 'Gemcitabine + Erlotinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Erlotinib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Erlotinib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV weekly for 7 weeks, then 1-week rest; subsequent cycles 1,000 mg/m<sup>2</sup>&nbsp;IV weekly for 3 weeks with 1-week rest</p>

<p><strong>Erlotinib:&nbsp;</strong>100 mg PO daily</p>

<p>Repeat 3-week cycles every 28 days.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (245, '', 'Tositumomab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Tositumomab:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Tositumomab:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '<b>Tositumomab</b>', 'Bexxar [package insert]. $Seattle, WA, and Philadelphia, PA: Corixa Corp and GlaxoSmithKline;2011.$', null, '<p>Dosimetric step:&nbsp;</p><p><strong>Tositumomab:</strong> 450 mg IV over 60 minutes<br><strong>I-131 tositumomab</strong> (35 mg tositumomab containing 5.0 mCi I-131) IV over 20 minutes<br>Therapeutic step:&nbsp;</p><p><strong>Tositumomab:</strong> 450 mg infused over 60minutes<br><strong>I-131 tositumomab</strong> (dose individualized for each patient based on results of dosimetric step)</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (676, '', 'EOF', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Epirubicin</strong>:<br>If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br>If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%</li><li><strong>Oxaliplatin:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Epirubicin</strong><br>If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>5-Fluorouracil</strong>:<br>No dose reduction</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (678, '', 'EOX', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Epirubicin</strong>:<br>If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br>If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%</li><li><strong>Oxaliplatin:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Capecitabine</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Epirubicin</strong><br>If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Capecitabine:&nbsp;</strong>625 mg/m<sup>2</sup>&nbsp;PO twice daily continuously</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (666, '', 'FLOT4 Trial', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>5-Fluorouracil</strong>:<br>No dose reduction.</li></ul>', 'Moderate', '', '', '', '<p><strong>Preoperative FLOT chemotherapy:</strong></p><p><strong>Docetaxel:&nbsp;</strong>50 mg/m2&nbsp;IV on day 1</p><p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m2&nbsp;IV on day 1</p><p><strong>Leucovorin:&nbsp;</strong>200 mg/m2&nbsp;IV on day 1</p><p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m2&nbsp;IV continuous infusion over 24 hours on day 1</p><p>Repeat every 2 weeks for 4 cycles. Followed by gastrectomy and then adjuvant chemotherapy in patients who had total gross removal of disease with negative margins.</p><p><strong>Adjuvant Chemotherapy:</strong></p><p><strong>Docetaxel:&nbsp;</strong>50 mg/m2&nbsp;IV on day 1</p><p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m2&nbsp;IV on day 1</p><p><strong>Leucovorin:&nbsp;</strong>200 mg/m2&nbsp;IV on day 1</p><p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m2&nbsp;IV continuous infusion over 24 hours on day 1</p><p>Repeat every 2 weeks for 4 cycles. Only patients with resectable gastric and gastroesophageal junction tumors were included in this trial.</p>', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (708, '', 'Gemcitabine + Docetaxel + Capecitabine (GTX)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li><li><strong>Capecitabine</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>750 mg/m<sup>2</sup>&nbsp;IV over 75 minutes on days 4 and 11</p>

<p><strong>Docetaxel:&nbsp;</strong>30 mg/m<sup>2</sup>&nbsp;IV on days 4 and 11</p>

<p><strong>Capecitabine:&nbsp;</strong>750 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p>Repeat cycle every 3 weeks.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1099, null, 'Durvalumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Durvalumab:</strong><br>Dose modification not provided by the manufacturer</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Durvalumab:</strong><br>Dose modification not provided by the manufacturer</li></ul>', 'Low', null, null, null, '<p><strong>Durvalumab: </strong>10 mg/kg IV on day 1<br>Repeat cycle every 14 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (714, '', 'Olaparib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Olaparib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Olaparib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 51 to 80 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 50 mL/min: Reduce dose to 200 mg twice daily. &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≤30 mL/min: There are no dosage adjustments because &nbsp; &nbsp; of inadequate study.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Olaparib:&nbsp;</strong>300 mg PO twice daily</p><p>Continue therapy until evidence of disease progression. This regimen is for patients who have germline <i>BRCA1/2&nbsp;</i>mutation and have received at least 16 weeks of platinum-based chemotherapy.</p>', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (703, '', 'RTOG Chemoradiation Regimen', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>5-Fluorouracil</strong>:<br>No dose reduction</li></ul>', 'Low', '', '', 'LOCALLY ADVANCED', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m2&nbsp;IV on days 1, 8, and 15</p><p><strong>Followed by concurrent chemoradiation:</strong></p><p><strong>5-Fluorouracil:&nbsp;</strong>250 mg/m2/day IV continuous infusion during radiation therapy</p><p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day to a total dose of 5,040 cGy</p><p>Chemotherapy and radiation therapy started on the same day and given concurrently.</p><p><strong>After chemoradiation:</strong></p><p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m2&nbsp;IV on days 1, 8, and 15</p><p>Repeat every 4 weeks for a total of 3 cycles. Adjuvant chemotherapy is given to patients with complete gross total resection of pancreatic adenocarcinoma.</p><p>&nbsp;</p>', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (805, null, 'Capecitabine + Erlotinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Erlotinib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Erlotinib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m2&nbsp;PO twice daily on days 1-14</p><p><strong>Erlotinib:&nbsp;</strong>150 mg PO daily.</p><p>Repeat cycles every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (530, 'Bleomycin: Blenoxane<br>Ifosfamide: Ifex<br>Mesna: Mesnex<br>Carboplatin: Paraplatin', 'BIC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bleomycin</strong>:<br>No dose reduction</li><li><strong>Ifosfamide</strong>:<br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Carboplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bleomycin</strong><br>If CrCl &gt;50 mL/min: No dose reduction<br>If CrCl 40-50 mL/min: 70% of normal dose<br>If CrCl 30-40 mL/min: 60% of normal dose<br>If CrCl 20-30 mL/min: 55% normal dose<br>If CrCl 10-20 mL/min: 45% normal dose<br>If CrCl 5-10 mL/min: 40% normal dose</li><li><strong>Ifosfamide</strong>:<br>&nbsp;If CrCl ≥10 mL/min: 100% normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: 75% normal dose.</li><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Carboplatin</strong>:<br>Dosing based on AUC</li></ul>', 'High', '', 'Murad AM, Triginelli SA, et al. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol. 1994;12(1):55-9.', '', '<p><strong>Bleomycin:</strong>&nbsp;30 U IV on day 1<br><strong>Ifosfamide:</strong>&nbsp;2000 mg/m2&nbsp;IV on days 1-3<br><strong>Mesna:</strong>&nbsp;400 mg/m2&nbsp;IV, 15min before ifosfamide dose, then 400 mg/m2&nbsp;IV at 4 and 8 hours following ifosfamide<br><strong>Carboplatin:&nbsp;</strong>200 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (291, 'Bortezomib : Velcade', 'Bortezomib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin&nbsp;1-1.5 times upper normal limit: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin&nbsp;&gt;1.5 times upper normal limit: Reduce the initial dose to 0.7 mg/m2. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li></ul>', 'Low', '<b>Bortezomib</b>', 'Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. $N Engl J Med. 2003;348(26):2609-2617.$', null, '<p><strong>Bortezomib:</strong> 1.3 mg/m2 IV or SC on days 1, 4, 8 and 11.<br>Repeat cycle every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (172, 'Cisplatin : CDDP', 'Cisplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'High', '<b>Cisplatin</b>', 'Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. $N Engl J Med. 1999;340(15):1154-1161.$', null, '<b>Cisplatin</b> 40 mg/m<sup>2</sup> IV once per week during RT for up to 6', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (7, 'Carboplatin : Paraplatin<br>Cetuximab : Erbitux<br>Fluorouracil : 5-FU', 'Carboplatin/Fluorouracil/Cetuximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin:</strong><br>No dose reduction</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose.</li><li><strong>Fluorouracil:</strong><br>No dose reduction</li><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'High', '<b>Carboplatin/Fluorouracil/Cetuximab</b>', 'Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. $N Engl J Med. 2008;359(11):1116-1127.$', null, '<p><strong>Carboplatin:</strong> AUC of 5, IV on day 1<br><strong>5-Fluorouracil:</strong> 1,000 mg/m2/day IV continuous infusion, days 1-4<br><strong>Cetuximab:</strong> 400 mg/m2 IV loading dose over 4 hours, day 1, cycle 1 <strong>THEN</strong> 250 mg/m2 IV over 1 hour, every week.</p><p>Repeat every 21 days for a maximum of 6 cycles. If no evidence of disease progression at the end of 6 cycles, can continue with weekly cetuximab.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (523, 'Cisplatin: CDDP', 'Cisplatin/Radiation', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'High', '', 'Rose PG, Bundy BN, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144-53.', '', '<p><strong>Radiation therapy:&nbsp;</strong>1.8 to 2 Gy per fraction (total dose, 45 Gy)<br><strong>Cisplatin:</strong>&nbsp;40 mg/m2&nbsp;IV weekly (maximal dose, 70mg per week)</p><p>Cisplatin is given 4 hours before radiation therapy on weeks 1-6.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (927, null, 'Bortezomib (Mantle cell lymphoma)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If<strong> </strong>bilirubin &gt;1 to 1.5 times ULN: 100% of the dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;1.5 ULN: Reduce initial dose to 0.7 mg/m2.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li></ul>', 'low', null, null, null, '<p><strong>Bortezomib:</strong> 1.3 mg/m2 IV or SC on days 1, 4, 8, and 11<br>Repeat cycle every 21 days for up to 17 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (534, 'Cisplatin: CDDP<br>Gemcitabine: Gemzar', 'Cisplatin + Gemcitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine</strong>:<br>No dose reduction</li><li><strong>Cisplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine</strong>:<br>No dose reduction</li><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'High', '', 'Monk BJ, et al. Proc Am Soc Clin Oncol 2008;26:(LBA5504). --- Brewer CA, Blessing JA, et al. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;100(2):385-8.', '', '<p><strong>Cisplatin:</strong>&nbsp;50 mg/m2&nbsp;IV on day 1<br><strong>Gemcitabine:</strong>&nbsp;1000 mg/m2&nbsp;IV on days 1 and 8</p><p>Repeat cycle every 21 days for up to 6 cycles.</p><p><strong>OR</strong></p><p><strong>Cisplatin:</strong>&nbsp;30 mg/m2&nbsp;IV on day 1<br><strong>Gemcitabine:</strong>&nbsp;800 mg/m2&nbsp;IV on days 1 and 8</p><p>Repeat cycle every 28 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (533, 'Cisplatin: CDDP<br>Irinotecan: Camptosar', 'Cisplatin + Irinotecan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong><br>No dose reduction</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Irinotecan</strong>:<br>No dose reduction</li></ul>', 'High', '', 'Chitapanarux I, Tonusin A, et al. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol. 2003;89(3):402-7.', '', '<p><strong>Cisplatin:</strong>&nbsp;60 mg/m2&nbsp;IV on day 1<br><strong>Irinotecan:</strong>&nbsp;60 mg/m2&nbsp;IV on days 1, 8, and 15</p><p>Repeat cycle every 28 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (169, 'Cisplatin : CDDP<br>Fluorouracil : 5-FU', 'Cisplatin + Fluorouracil', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Fluorouracil:</strong><br>If bilirubin &lt; 5 mg/dL, no dose reduction&nbsp;<br>If bilirubin &gt; 5 mg/dL, do not use&nbsp;<br>No dose reduction for infusional administration</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br><strong>&nbsp; </strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Fluorouracil:</strong><br>No dose reduction</li></ul>', 'High', '<b>Cisplatin/Fluorouracil</b>', 'Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemoterapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. $N Engl J Med. 1999;340(15):1137-1143.$<br> Whitney CW, Sausse W, Bundy BN, et al. Randomized commparison of fluorouuracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study. $J Clin Oncol. 1999;17(5):1339-1348.$', null, '<p><strong>Cisplatin:</strong> 75 mg/m2 IV over 4 hours, day 1, given within 16 hours of the first dose of RT<br><strong>Fluorouracil:</strong> 4,000 mg/m2 IV over 96 hours, days 2-5<br>Repeat every 21 days for 3 cycles<br><strong>OR</strong><br><strong>Cisplatin:</strong> 50 mg/m2/d IV, days 1, 29, given 4 hours before the first dose of RT<br><strong>Fluorouracil:</strong> 1,000 mg/m2/d IV, days 2-5, 30-33</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (527, 'Cisplatin: CDDP<br>Paclitaxel: Taxol<br>Bevacizumab: Avastin', 'Cisplatin + Paclitaxel + Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Bevacizumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li><li><strong>Bevacizumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'High', '', 'Tewari KS, et al. J Clin Oncol 2013;31:Suppl (abstract 3).', '', '<p><strong>Cisplatin:&nbsp;</strong>50 mg/m2&nbsp;IV on day 1<br><strong>Paclitaxel:</strong>&nbsp;135-175 mg/m2&nbsp;IV on day 1<br><strong>Bevacizumab:</strong>&nbsp;15 mg/kg IV on day 1</p><p>Repeat cycle every 21 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (211, '', 'Liposomal Daunorubicin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Liposomal daunorubicin:</strong><br>If bilirubin 1.2 to 3 mg/dL: 75% of normal dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;3 mg/dL: 50% of normal dose.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Liposomal daunorubicin:</strong><br>&nbsp;If serum creatinine &gt;3 mg/dL: 50% of normal dose.</li></ul>', 'Low', '<b>Liposomal daunorubicin</b>', 'Rosenthal E, Poizot-Martin I, Saint Marc T, et al. Phase Ivstudy of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. $AM J Clin Oncol.2002;25(1): 57-59$', null, '<p><strong>Liposomal daunorubicin:</strong> 40 mg/m2 IV over 60 min on day 1.<br>Repeat every 14 days. Continue until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (265, 'Cyclophosphamide : Cytoxan<br>Fludarabine : Fludara', 'CF', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL: Reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Fludarabine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-29 mL/min: Reduce dose by 25%<br>If CrCl &lt; 10 mL/min: Reduce dose by 50%</li><li><strong>Fludarabine:</strong><br>If CrCl 10-50 mL/min: Reduce dose by 25%&nbsp;<br>If CrCl &lt;10 mL/min: Reduce dose by 50%</li></ul>', 'Moderate', '<b>FC</b>', 'Catovsky D, Richards S, Oscier D, et al. Assesmentof fludarabine plus cyclo-phosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 trial): a randomized ocntrolled trial. $Lancet. 2007; 370(9583):230-239.$', null, '<p><strong>Cyclophosphamide:</strong> 1,000 mg/m2 IV on day 1.</p><p><strong>Fludarabine:</strong> 20 mg/m2 IV on days 1-5</p><p>Trimethoprim/sulfamethoxazole (Bactrim DS) 1 tablet PO bid<br>Repeat every 21-28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (525, 'Cisplatin: CDDP<br>Topotecan: Hycamtin ', 'Cisplatin/Topotecan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Topotecan</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Topotecan</strong>:<br>If CrCl &gt; 40 mL/min, no dose reduction<br>If CrCl 20-39 mL/min, reduce to 0.75 mg/m2/dose</li></ul>', 'High', '', 'Fiorica J, Holloway R, et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol. 2002;85(1):89-94.', '', '<p><strong>Cisplatin:</strong>&nbsp;50 mg/m2&nbsp;IV on day 1<br><strong>Topotecan:</strong>&nbsp;0.75 mg/m2/day IV on days 1-3</p><p>Repeat cycle every 21 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (281, 'Bortezomib : Velcade<br>Dexamethasone : various<br>Doxorubicin : Adriamycin, various', 'Bortezomib/Doxorubicin/Dexamethasone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin&nbsp;1-1.5 times upper normal limit: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin&nbsp;&gt;1.5 times upper normal limit: Reduce the initial dose to 0.7 mg/m2.</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'Moderate', '<b>Bortezomib/Doxorubicin/Dexamethasone</b>', 'Sonneveld P, van der Holt B, Schmidt-Wolf IGH, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycin, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). $Blood. 2008;112(11):Abstract 653.$', null, '<p><strong>Bortezomib:</strong> 1.3 mg/m2 IV, bolus days 1, 4, 8, 11<br><strong>Doxorubicin:</strong> 9 mg/m2 IV, bolus days 1-4<br><strong>Dexamethasone:</strong> 40 mg PO days 1-4, 9-12, 17-20</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (928, null, 'Ibrutinib (Mantle cell lymphoma)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ibrutinib:</strong> &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (Child-Pugh class A): Decrease dose to 140 mg PO daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If moderate impairment (Child-Pugh class B): Decrease dose to 70 mg PO daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (Child-Pugh class C): Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ibrutinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Dosage adjustment not provided by the manufacturer.</li></ul>', 'Low', null, null, null, '<p><strong>Ibrutinib:</strong> 560 mg/day PO<br>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (929, null, 'Acalabrutinib (Mantle cell lymphoma)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Acalabrutinib:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If mild to moderate impairment (Child-Pugh class A and B): &nbsp; 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (Child-Pugh class C): Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Acalabrutinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Dosage adjustment not provided by the manufacturer.</li></ul>', 'Low', null, null, null, '<p><strong>Acalabrutinib: </strong>100 mg PO bid<br>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (532, 'Cisplatin: CDDP<br>Vinorelbine: Navelbine', 'Cisplatin/Vinorelbine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Vinorelbine</strong>:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br><strong>&nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Vinorelbine</strong>:<br>No dose reduction</li></ul>', 'High', '', 'Pignata S, Silvestro G, et al. Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. J Clin Oncol. 1999;17(3):756-60.', '', '<p><strong>Cisplatin:</strong>&nbsp;80 mg/m2&nbsp;IV on day 1<br><strong>Vinorelbine:</strong>&nbsp;25 mg/m2&nbsp;IV on days 1 and 8</p><p>Repeat cycle every 21 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (542, 'Gemcitabine: Gemzar, various', 'Gemcitabine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Schilder RJ, Blessing J, et al. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2005;96(1):103-7.', '', '<p><strong>Gemcitabine:</strong>&nbsp;800 mg/m2&nbsp;IV on days 1, 8, and 15</p><p>Repeat cycle every 28 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (539, 'Irinotecan: Camptosar', 'Irinotecan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Irinotecan</strong>:<br>No dose reduction</li></ul>', 'Moderate', '', 'Verschraegen CF, Levy T, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol. 1997;15(2):625-31.', '', '<p><strong>Irinotecan:</strong>&nbsp;125 mg/m2&nbsp;IV weekly for 4 weeks</p><p>Repeat cycle every 6 weeks.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (543, 'Pembrolizumab: Keytruda', 'Pembrolizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', 'Schellens JHM, et al. J Clin Oncol 2017;35 (Suppl: abstr 5514).', '', '<p><strong>Pembrolizumab:</strong>&nbsp;200 mg IV on day 1</p><p>Repeat cycle every 3 weeks.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (546, 'Doxorubicin: Adriamycin<br>Cisplatin: CDDP', 'AP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li></ul>', 'High', '', 'Deppe G, Malviya VK, et al. Treatment of recurrent and metastatic endometrial carcinoma with cisplatin and doxorubicin. Eur J Gynaecol Oncol. 1994;15(4):263-6.', '', '<p><strong>Doxorubicin:</strong>&nbsp;50 mg/m2&nbsp;IV on day 1<br><strong>Cisplatin:</strong>&nbsp;50 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p>', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (549, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin<br>Cisplatin: CDDP', 'CAP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Cyclophosphamide</strong>:<br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Cyclophosphamide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li></ul>', 'High', '', 'Burke TW, Gershenson DM, et al. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. Gynecol Oncol. 1994;55(1):47-50.', '', '<p><strong>Cyclophosphamide:</strong>&nbsp;500 mg/m2&nbsp;IV on day 1<br><strong>Doxorubicin:</strong>&nbsp;50 mg/m2&nbsp;IV on day 1<br><strong>Cisplatin:</strong>&nbsp;50 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p>', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (547, 'Doxorubicin: Adriamycin<br>Paclitaxel: Taxol', 'Doxorubicin/Paclitaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Fiorica JV. Update on the treatment of cervical and uterine carcinoma: focus on topotecan. Oncologist. 2002;7 Suppl 5:36-45. ', '', '<p><strong>Doxorubicin:</strong>&nbsp;50 mg/m2&nbsp;IV on day 1<br><strong>Paclitaxel:</strong>&nbsp;150 mg/m2&nbsp;on day 1</p><p>Repeat cycle every 21 days.</p>', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (556, 'Paclitaxel: Taxol', 'Paclitaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Ball HG, Blessing JA, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;62(2):278-81.', '', '<p><strong>Paclitaxel:</strong>&nbsp;200 mg/m2&nbsp;IV over 3 hours on day 1</p><p>Repeat cycle every 21 days. Reduce dose to 175 mg/m2 IV for patients with prior pelvic radiation therapy.</p>', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (544, 'Paclitaxel: Taxol<br>Carboplatin: Paraplatin', 'Paclitaxel/Carboplatin', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	Dosing based on AUC</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Hoskins PJ, Swenerton KD, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol. 2001;19(20):4048-53.', '', '<p><strong>Paclitaxel:</strong>&nbsp;175 mg/m2&nbsp;IV over 3 hours on day 1<br><strong>Carboplatin:</strong>&nbsp;AUC of 5-7, IV on day 1</p><p>Repeat cycle every 28 days.</p>', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (557, 'Topotecan: Hycamtin', 'Topotecan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Topotecan</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Topotecan</strong>:<br>If CrCl &gt; 40 mL/min: No dose reduction<br>If CrCl 20-39 mL/min: Reduce to 0.75 mg/m2</li></ul>', 'Low', '', 'Wadler S, Levy DE, et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. J Clin Oncol. 2003;21(11):2110-4.', '', '<p><strong>Topotecan:</strong>&nbsp;1.0 mg/m2/day IV on days 1-5</p><p>Repeat cycle every 21 days. Reduce dose to 0.8mg/m2/day IV on days 1-3 in patients with prior pelvic radiation therapy.</p>', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (564, 'Carboplatin: Paraplatin<br>Docetaxel: Taxotere', 'Carboplatin/Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Docetaxel</strong>:<br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose.</li><li><strong>Docetaxel</strong>:<br>No dose reduction</li></ul>', 'High', '', 'Markman M, Kennedy A, et al. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol. 2001;19(7):1901-5.', '', '<p><strong>Carboplatin:</strong>&nbsp;AUC of 6, IV on day 1<br><strong>Docetaxel:</strong>&nbsp;60 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (565, 'Carboplatin: Paraplatin<br>Doxorubicin liposome: Doxil, various', 'Carboplatin/Doxorubicin Liposome', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong><br>No dose reduction</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose.</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li></ul>', 'High', '', 'Pignant S, et al. J Clin Oncol 2009;27:18S (LBA5509).', '', '<p><strong>Carboplatin:</strong>&nbsp;AUC of 5, IV on day 1<br><strong>Doxorubicin liposome:</strong>&nbsp;30 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 28 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (560, 'Cisplatin: CDDP<br>Cyclophosphamide: Cytoxan', 'CC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Cyclophosphamide</strong>:<br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Cyclophosphamide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', '', 'Alberts DS, Green S, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 1992;10(5):706-17.', '', '<p><strong>Cisplatin:</strong>&nbsp;100 mg/m2&nbsp;IV on day 1<br><strong>Cyclophosphamide:</strong>&nbsp;600 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 28 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (559, 'Carboplatin: Paraplatin<br>Cyclophosphamide: Cytoxan', 'CC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Cyclophosphamide</strong>:<br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose.</li><li><strong>Cyclophosphamide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', '', 'Swenerton K, Jeffrey J, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1992;10(5):718-26.', '', '<p><strong>Carboplatin:</strong>&nbsp;300 mg/m2&nbsp;IV on day 1<br><strong>Cyclophosphamide:</strong>&nbsp;600 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 28 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (572, 'Doxorubicin liposome: Doxil, various', 'Doxorubicin Liposome', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Rose PG, Maxson JH, et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol. 2001;82(2):323-8.', '', '<p><strong>Doxorubicin liposome:</strong>&nbsp;40-50 mg/m2&nbsp;IV over 1 hour on day 1</p><p>Repeat cycle every 28 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (948, null, 'CODOX-M/IVAC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Ifosfamide:</strong><br>No dose reduction</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Ifosfamide</strong>:<br>&nbsp;If CrCl ≥10 mL/min: 100% normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: 75% normal dose.</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><i><strong>CODOX-M</strong></i> (Cycles 1 and 3; cycles begin when ANC &gt;1,000/mm3)</p><p><strong>Cyclophosphamide:</strong> 800 mg/m2 IV on day 1, followed by 200 mg/m2/day IV on days 2 to 5</p><p><strong>Vincristine:</strong> 1.5 mg/m2/day IV (no maximum dose) days 1 and 8 (cycle 1) and days 1, 8, and 15 (cycle 3; day 15 in cycle 3 only if no neuropathy)</p><p><strong>Doxorubicin: </strong>40 mg/m2 IV on day 1</p><p><strong>Methotrexate:</strong> 1,200 mg/m2 IV (loading dose) over 1 hour day 10, followed by 240 mg/m2/hour IV for 23 hours (total of 5,520 mg/m2 over 23 hours) day 10</p><p><strong>Leucovorin Calcium:</strong> 192 mg/m2 &nbsp;IV on day 11 (begin 36 hours after the start of methotrexate infusion), followed by 12 mg/m2 IV every 6 hours until methotrexate level &lt;5 x 10-8 micromolar</p><p><strong>CNS Prophylaxis:</strong></p><p><strong>Cytarabine: </strong>Intrathecal: 70 mg/day (adjust to age-appropriate dose if ≤3 years of age) days 1 and 3</p><p><strong>Methotrexate:</strong> Intrathecal: 12 mg (adjust to age-appropriate dose if ≤3 years of age) day 15</p><p><strong>Sargramostim:</strong> 7.5 mcg/kg/day SC beginning day 13, continue until ANC &gt;1,000/mm3</p><p><strong>Note:</strong> If CNS involvement is present, administer additional intrathecal treatment in cycle 1: Cytarabine 70 mg (adjust to age-appropriate dose if ≤3 years of age) day 5 and methotrexate 12 mg (adjust to age-appropriate dose if ≤3 years of age) day 17</p><p><i><strong>IVAC</strong></i> (Cycles 2 and 4; cycles begin when ANC &gt;1,000/mm3)</p><p><strong>Ifosfamide:</strong> 1,500 mg/m2/day IV on days 1 to 5</p><p><strong>Mesna:</strong> 360 mg/m2 IV every 3 hours days 1 to 5</p><p><strong>Etoposide:</strong> 60 mg/m2/day IV on days 1 to 5</p><p><strong>Cytarabine:</strong> 2,000 mg/m2 &nbsp;IV every 12 hours, for 4 doses, days 1 and 2</p><p><strong>Methotrexate:</strong> Intrathecal: 12 mg day 5</p><p><strong>Sargramostim:</strong> 7.5 mcg/kg/day SC beginning day 7, continue until ANC &gt;1000/mm3</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (568, 'Gemcitabine: Gemzar<br>Carboplatin: Paraplatin', 'Gemcitabine/Carboplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Gemcitabine</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose.</li><li><strong>Gemcitabine</strong>:<br>No dose reduction</li></ul>', 'High', '', 'Thigpen T. The role of gemcitabine in first-line treatment of advanced ovarian carcinoma. Semin Oncol. 2006;33(2 Suppl 6):S26-32.', '', '<p><strong>Gemcitabine:</strong>&nbsp;1000 mg/m2&nbsp;IV on days 1 and 8<br><strong>Carboplatin:</strong>&nbsp;AUC of 4, IV on day 1</p><p>Repeat cycle every 21 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (567, 'Gemcitabine: Gemzar<br>Cisplatin: CDDP', 'Gemcitabine/Cisplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Gemcitabine</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Gemcitabine</strong>:<br>No dose reduction</li></ul>', 'High', '', 'Nagourney RA, Brewer CA, et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol. 2003;88(1):35-9.', '', '<p><strong>Gemcitabine:</strong>&nbsp;800-1000 mg/m2&nbsp;IV on days 1 and 8<br><strong>Cisplatin:</strong>&nbsp;30 mg/m2&nbsp;IV on days 1 and 8</p><p>Repeat cycle every 21 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (566, 'Gemcitabine: Gemzar<br>Doxorubicin liposome: Doxil, various', 'Gemcitabine/Doxorubicin liposome', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong><br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong><br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'D''Agostino G, Ferrandina G, et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer. 2003;89(7):1180-4.', '', '<p><strong>Gemcitabine:</strong>&nbsp;1000 mg/m2&nbsp;IV on days 1 and 8<br><strong>Doxorubicin liposome:</strong>&nbsp;30 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (582, 'Olaparib: Lynparza', 'Olaparib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Olaparib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Olaparib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 51 to 80 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 50 mL/min: Reduce dose to 200 mg twice daily. &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≤30 mL/min: There are no dosage adjustments because &nbsp; &nbsp; &nbsp;of inadequate study.</li></ul>', 'Low', '', 'Ledermann J, Harter P, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852-61. --- Moore K, Colombo N, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495-2505.', '', '<p><strong>Olaparib:</strong>&nbsp;400 mg PO BID</p><p>Repeat cycle every 28 days.</p><p><strong>OR&nbsp;</strong></p><p><strong>Olaparib:&nbsp;</strong>(maintenance after 1st-line chemo) 300mg PO BID</p><p>Repeat cycle every 28 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (573, 'Paclitaxel: Taxol', 'Paclitaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'McGuire WP, Rowinsky EK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111(4):273-9.', '', '<p><strong>Paclitaxel:</strong>&nbsp;135 mg/m2&nbsp;IV over 3 hours on day 1</p><p>Repeat cycle every 21 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (570, 'Pemetrexed: Alimta<br>Carboplatin: Paraplatin', 'Pemetrexed/Carboplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pemetrexed</strong>:<br>No dose reduction</li><li><strong>Carboplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pemetrexed</strong>:<br>If CrCl &gt; 45 mL/min, no dose reduction<br>If CrCl &lt; 45 mL/min, do not use</li><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose.</li></ul>', 'High', '', 'Matulonis UA, Horowitz NS, et al. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008;26(35):5761-6.', '', '<p><strong>Pemetrexed:</strong>&nbsp;500 mg/m2&nbsp;IV on day 1<br><strong>Carboplatin:</strong>&nbsp;AUC of 5, IV on day 1</p><p>Repeat cycle every 21 days.</p><p>Folic acid 400 to 1,000 mcg PO once daily and vitamin B12 at 1,000 mcg IM to start 7 days prior to the first dose of pemetrexed and repeated every 21 days. Dexamethasone 4 mg PO twice daily on the day before, day of, and day after each dose of pemetrexed to reduce cutaneous reactions.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1100, null, 'Dacarbazine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Dacarbazine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Dacarbazine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 20%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 45 mL/min: Reduce dose to 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≤30 mL/min: Reduce dose to 30%.</li></ul>', 'High', null, null, null, '<p><strong>Dacarbazine: </strong>250 mg/m2 IV on days 1-5<br>Repeat cycle every 21 days.</p><p>OR</p><p><strong>Dacarbazine: </strong>850 mg/m2 IV on day 1<br>Repeat cycle every 3-6 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (778, null, 'Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><p>&nbsp;</p><ul><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Paclitaxel:</strong> 137-175 mg/m2 IV over 3 hours on day 1</p><p>Repeat cycle every 21 days.</p><p>OR</p><p><strong>Paclitaxel:</strong> 250 mg/m2 IV over 24 hours on day 1<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (776, null, 'Nivolumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nivolumab:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nivolumab:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Nivolumab:&nbsp;</strong>240 mg<strong> </strong>IV on day 1</p><p>Repeat every 2 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (771, null, 'TIC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Ifosfamide:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li><li><strong>Mesna:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose.</li><li><strong>Paclitaxel:</strong><br>No dose reduction</li><li><strong>Ifosfamide: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If CrCl 46-59 mL/min, reduce dose by 20% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31-45 mL/min, reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30mL/min, reduce dose by 30%</li><li><strong>Mesna:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Paclitaxel:</strong> 175 mg/m2 IV over 3 hours on day 1</p><p><strong>Ifosfamide:</strong> 1000 mg/m2 IV over 2 hours on days 1-3</p><p><strong>Mesna: </strong>400 mg/m2 IV before ifosfamide and 200 mg/m2 IV, 4 hrs after Ifosfamide</p><p><strong>Carboplatin: </strong>AUC of 6, IV on day 1&nbsp;</p><p><br>Repeat cycle every 21-28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (210, '', 'Interferon alfa', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Interferon alfa</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Interferon alfa</strong>:<br>No dose reduction</li></ul>', 'Moderate', '<b>Interferon alfa-2b</b>', 'Groopman JE, et al. Recombinant alpha-2 interferon therapy for Kaposi''s sarcoma associated with the acquired immunodeficiency syndrome.$Ann Intern Med. 1984 May;100(5):671-6$', null, '<p><strong>Interferon alfa-2a:</strong> 36 million IU/m2 IM or SC, daily for 8-12 weeks.</p><p><strong>Interferon alfa-2b:</strong> 30 million IU/m2 IM or SC, 3 times per week<br>Repeat until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (10, 'Cisplatin : CDDP', 'Cisplatin + radiation (Laryngeal Preservation) ', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li></ul>', 'High', '<b>Cisplatin + radiation</b>', 'Franchin G, Minatel E, Politi D, et al. Postoperative reduced dose of cisplatin concomitant with radiatoin therapy in high-risk head and neck squamous cell carcinoma. $Cancer. 2009;115(11):2464-2471.$', null, '<p><strong>Cisplatin:</strong> 100 mg/m2 IV on days 1,22 and 43.</p><p><strong>Radiation therapy:</strong> 7,000 cGy in 200 cGy fractions (For Laryngeal Preservation).</p><p>Administer cisplatin concurrently with radiation therapy.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (12, 'Cisplatin : CDDP<br>Docetaxel : Taxotere', 'TPF', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>5-Fluorouracil</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'High', '<b>TPF</b>', 'Vermorken JB, Remenar E, Van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. $N Engl J Med. 2007;357(17):1695-1704.$<br> Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. $N Engl J Med. 2007;357(17):1705-1715.$', null, '<p><strong>Docetaxelb:</strong> 75 mg/m2 IV over 1 hour, day1<br><strong>Cisplatin:</strong> 75-100 mg/m2 IV over 24 hours, day 1<br><strong>5-Fluorouracil:</strong> 1,000 mg/m2 over 24 hrs on days 1-4.</p><p><br>Repeat cycle every 21 days<br><br>&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (283, 'Bortezomib : Velcade<br>Cyclophosphamide : Cytoxan<br>Dexamethasone : various', 'CyBorD', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide</strong>:<br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin&nbsp;1-1.5 times upper normal limit: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin&nbsp;&gt;1.5 times upper normal limit: Reduce the initial dose to 0.7 mg/m2.</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'Moderate-High', '<b>CyBorD</b>', 'Khan ML, Reeder CB, Kumar SK, et al. A comparison af lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethansone in newly diagnosed multiple myeloma. $Br J Haematol. 2011 [Epub ahead of print].$', null, '<p><strong>Cyclophosphamide:</strong> 300 mg/m2 PO days 1, 8, 15, 22<br><strong>Bortezomib:</strong> 1.3 mg/m2 IV on days 1, 4, 8, and 11<br><strong>Dexamethasone:</strong> 40 mg PO days 1-4, 9-12, and 17-20<br>Repeat every 28 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (204, 'Dacarbazine : DTIC<br>Doxorubicin : Adriamycin, various', 'AD', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Dacarbazine:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Dacarbazine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 20%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 45 mL/min: Reduce dose to 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≤30 mL/min: Reduce dose to 30%.</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li></ul>', 'High', '<b>AD</b>', 'Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. $J Clin Oncol. 1993;11(7):1276-1285.$', null, '<p><strong>Doxorubicin:</strong> 15 mg/m2/day IV continuous infusion, days 1-4<br><strong>Dacarbazine:</strong> 250 mg/m2/day IV continuous infusion, days 1-4<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (768, null, 'AI', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Ifosfamide</strong>:<br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Doxorubicin</strong>:<br>No dose reduction</li><li><strong>Ifosfamide</strong>:<br>&nbsp;If CrCl ≥10 mL/min: 100% normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: 75% normal dose.</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Doxorubicin:&nbsp;</strong>20 mg/m2/day IV continuous infusion on days 1-3</p><p><strong>Ifosfamide:&nbsp;</strong>1,500 mg/m2/day IV continuous infusion on days 1-4</p><p><strong>Mesna: </strong>225 mg/m2 IV over 1 hour before ifosfamide and at 4 and 8 hours after ifosfamide.</p><p>Repeat cycles every 3 weeks.</p><p>Consider G-CSF support at 5 μg/kg/day for 10 days starting on day 5.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (212, 'Paclitaxel : Taxol', 'Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel:</strong><br>No dose reduction</li></ul>', 'Low', '<b>Paclitaxel</b>', 'Parkash S. Gill, et al. Paclitaxel Is Safe and Effective in the Treatment of Advanced AIDS-Related Kaposi''s Sarcoma.$http://jco.ascopubs.org/content/17/6/1876.full$', null, '<p><strong>Paclitaxel:</strong> 135 mg/m2 IV over 3 hours on day 1.<br>Repeat every 21 days.<br><strong>OR</strong><br>&nbsp;<strong>Paclitaxel: </strong>100 mg/m2 IV over 3 hours on day 1.<br>Repeat every 14 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (825, null, 'Lenalidomide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>If CrCl &gt;60 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 30 to 60 mL/min: 5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min not requiring dialysis: 2.5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min requiring dialysis: 2.5 mg once daily (administer after dialysis on dialysis days).</li></ul>', 'Low', null, null, null, '<p><strong>Lenalidomide: </strong>30 mg PO daily on days 1-21<br>Repeat cycle every 28 days until disease progression or undue toxicity.<br><strong>or</strong><br><strong>Lenalidomide: </strong>10 mg PO daily on days 1-21<br>For maintenance therapy after autologous stem-cell transplantation, repeat the cycle<br>every 28 days until disease progression or unacceptable toxicity.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1101, null, 'Interferon Alpha- 2b', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Interferon alfa- 2b</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Interferon alfa-2b</strong>:<br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Interferon alfa- 2b</strong>: 20 million U/m2 IM, 3 times weekly for 12 weeks</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (806, null, 'Blinatumomab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Blinatumomab:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Blinatumomab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Blinatumomab:</strong> 9 μg IV on days 1-7 and 28 μg IV on days 8-28 on cycle 1, 28 μg on days&nbsp;1-28 for all subsequent cycles.</p><p>Repeat cycle every 42 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (807, null, 'Inotuzumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Inotuzumab:</strong>&nbsp;<strong>&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Inotuzumab:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Inotuzumab:</strong> 0.8 mg/m2 IV on days 1, 8, and 15. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Repeat cycle every 21 days.</p><p>For patients who achieve CR or CRi: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Inotuzumab:</strong> 0.5 mg/m2 IV on days 1, 8, and 15. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Repeat cycle every 28 days.</p><p>For patients who do not achieve CR or CRi: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Inotuzumab:</strong> &nbsp;0.8 mg/m2 IV on day 1 and 0.5 mg/m2 IV on days 8, and 15. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1102, null, 'Aldesleukin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Aldesleukin (IL-2):</strong><br>Dose modification not provided by the manufacturer</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Aldesleukin (IL-2):</strong><br>If Cr ≤1.5: Dose modification not provided by the manufacturer &nbsp; &nbsp; If Cr &gt;1.5: Do not initiate therapy&nbsp;</li></ul>', 'Low', null, null, null, '<p><strong>Aldesleukin (IL-2):</strong> 720,000 IU/kg IV every 8 hours on days 1-5 and 15-19<br>Repeat cycle in 6- to 12-week intervals.</p><p><br>OR</p><p><strong>Aldesleukin (IL-2): </strong>100,000 IU/kg IV every 4 hours on days 1-5 and 15-19<br>Repeat cycle in 12-week intervals up to a total of 3 cycles.</p><p><br>OR</p><p><br><strong>Aldesleukin (IL-2):</strong> 720,000 IU/kg IV at 8 am and 6 pm on days 1-5 and 15-19 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Treat up to a maximum of 8 total doses on days 1-5 and repeat on days 15-19. Repeat cycle in 8- to 12-week intervals.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (275, 'Imatinib : Gleevec', 'Imatinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Imatinib</strong>:<br>&nbsp;If bilirubin &lt; 3 upper normal limit, no dose reduction<br>If bilirubin &gt; 3 upper normal limit, use with caution</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Imatinib</strong>:<br>If CrCl 40 to 59 mL/min: Maximum dose recommended-600 mg. &nbsp; If CrCl 20 to 39 mL/min: Reduce dose by 50%; dose may be increased as tolerated; maximum recommended dose: 400 mg. &nbsp; If CrCl &lt;20 mL/minute: Use caution; 100 mg daily dose has been tolerated in a limited number of patients with severe impairment.</li></ul>', 'Low', '<b>Imatinib</b>', 'Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.$N Engl J Med. 2001 Apr 5;344(14):1031-7.$', null, '<p><strong>Imatinib mesylate:</strong> 400 mg PO daily (chronic phase); 600 mg PO daily (accelerated blast phase crisis)</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1103, null, 'Ipilimumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ipilimumab:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ipilimumab:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Ipilimumab:</strong> 3 mg/kq IV on day 1<br>Repeat cycle every 3 weeks for a total of 4 doses.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (753, null, 'Nelarabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nelarabine:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nelarabine:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Nelarabine:</strong> 1,500 mg/m2/day IV, days 1, 3 and 5</p><p>Repeat every 28 days for 4 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (808, null, 'Clofarabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Clofarabine:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Clofarabine:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &gt;60 mL/min: 100 % dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 30 to 60 mL/min: 50% of the usual dose</li></ul>', 'Moderate', null, null, null, '<p><strong>Clofarabine:&nbsp;</strong>52 mg/m2&nbsp;IV for 5 days</p><p>Repeat cycles every 2-6 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (759, null, 'Dasatinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Dasatinib:</strong>&nbsp; <strong>&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Dasatinib:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Dasatinib:</strong> 70 mg PO twice daily.</p><p>OR</p><p><strong>Dasatinib:</strong> 100 mg PO daily.</p><p>Continue until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (286, 'Melphalan : Alkeran<br>Prednisone : various', 'Melphalan/Prednisone (MP)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Melphalan:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Melphalan:</strong><br>&nbsp;If CrCl 10 to 50 mL/min: Reduce dose to 75%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose to 50%.</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Low', '<b>Melphalan/Prednisone (MP)</b>', ' $Southwest Oncology Group Study. Arch Intern Med 1975;135:147-152$', null, '<p><strong>Melphalan:</strong> 8 - 10 mg/m2 PO on days 1 - 4<br><strong>Prednisone:</strong> 60 mg/m2 on days 1 - 4<br>Repeat cycle every 42 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (996, null, 'EVA                                                                                    ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Vinblastine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Vinblastine:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Etoposide:</strong> 100 mg/m2 IV on days 1-3<br><strong>Vinblastine: </strong>6 mg/m2 IV on day 1<br><strong>Doxorubicin:</strong> 50 mg/m2 IV on day 1<br>Repeat cycle every 28 days for up to 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1104, null, 'Pembrolizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (total bilirubin &lt;1 to 1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (total bilirubin &gt;1.5 times ULN): Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Pembrolizumab:</strong> 200 mg IV on day 1<br>Repeat cycle every 3 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1015, null, 'Pembrolizumab (Adjuvant)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (total bilirubin &lt;1 to 1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (total bilirubin &gt;1.5 times ULN): Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Pembrolizumab:</strong> 200 mg IV on day 1<br>Repeat cycle every 3 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (586, 'Calquence', 'Acalabrutinib', '<p><strong>Hepatic impairment</strong></p><ul><li><strong>Acalabrutinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Avoid use in severe hepatic impairment.</li></ul><p><strong>Renal impairment</strong></p><ul><li><strong>Acalabrutinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Low', '', 'Sharman et al. 2020 https://doi.org/10.1016/s0140-6736(20)30262-2', '', '<p><strong>Acalabrutinib:</strong> 100 mg P.O twice daily.</p><p>Continue until disease progression or unacceptable toxicity.</p>', 34);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (269, 'Alemtuzumab : Campath', 'Alemtuzumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Alemtuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Alemtuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li></ul>', 'Moderate', '<b>Alemtuzumab</b>', 'Campath [package insert]. $Wayne, NJ: Bayer HealthCare Pharmaceuticals: 2009.$', null, '<p><strong>Alemtuzumab:</strong> 30 mg/day IV, 3 times per week.</p><p>Repeat weekly for up to a maximum of 23 weeks.</p><p>&nbsp;Premedicate with diphenhydramine 50 mg PO and acetaminophen 625 mg PO 30 minutes before drug infusion. Patients should be placed on trimethoprim/sulfamethoxazole (Bactrim DS) PO bid and famciclovir 250 mg PO bid from day 8 through 2 months following completion of therapy.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (270, 'Bendamustine : Treanda', 'BR- First line treatment', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin&nbsp;1.5-3 upper normal limit, or bilirubin &gt; 3 upper normal limit: Do not use</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If CrCl &lt; 30 mL/min: Do not use</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul>', 'Moderate', '<b>Bendamustine</b>', 'Knauf WU, Lissichov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously treated patients with chronic lyphocytic leukemia. $J Clin Oncol. 2009;27(26):4378-4348.$', null, '<p><strong>Bendamustine:</strong> 90 mg/m2 IV over 30 min, days 1, 2</p><p><strong>Rituximab:&nbsp;</strong>375<strong> </strong>mg/m2&nbsp;IV on day 0 of cycle 1, then 500 mg/m2 IV on day 1 of cycles 2-6.</p><p>Repeat cycle every 4 weeks for up to 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (811, null, 'BR- Refractory treatment', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin&nbsp;1.5-3 upper normal limit, or bilirubin &gt; 3 upper normal limit: Do not use</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If CrCl &lt; 30 mL/min: Do not use</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Bendamustine:</strong> 70 mg/m2 IV over 30 min, days 1, 2</p><p><strong>Rituximab:&nbsp;</strong>375<strong> </strong>mg/m2&nbsp;IV on day 0 of cycle 1, then 500 mg/m2 IV on day 1 of cycles 2-6.</p><p>Repeat cycle every 4 weeks for up to 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (266, 'Cyclophosphamide : Cytoxan<br>Fludarabine : Fludara<br>Rituximab : Rituxan', 'FCR', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL: Reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Fludarabine:</strong><br>No dose reduction</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-29 mL/min: Reduce dose by 25%<br>If CrCl &lt; 10 mL/min: Reduce dose by 50%</li><li><strong>Fludarabine:</strong><br>If CrCl 10-50 mL/min: Reduce dose by 25%&nbsp;<br>If CrCl &lt;10 mL/min: Reduce dose by 50%</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul>', 'Moderate', '<b>FCR</b>', 'Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. $J Clin Oncol. 2010;28(10):1756-1765.$', null, '<p><strong>Fludarabine:</strong> 25 mg/m2 IV, days 1-3<br><strong>Cyclophosphamide:</strong> 250 mg/m2 IV, days 1-3<br><strong>Rituximab:</strong> 375 mg/m2 IV, day 1&nbsp;<br><strong>FOLLOWED BY</strong><br><strong>Rituximab:</strong> 500 mg/m2 IV, day 1 on cycles 2-6.<br>Repeat every 28 days for 6 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (469, 'Carboplatin: Paraplatin
Docetaxel: Taxotere', 'Carboplatin + Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%&nbsp;</li><li><strong>Docetaxel:</strong><br>No dose reduction</li></ul><p>&nbsp;</p>', 'High', '', '1. Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011 Nov 10;29(32):4320-6. Epub 2011 Oct 11.
2. Fossella F, et al. J Clin Oncol 2003; 21:3016.
3. Docetaxel injection. United States Prescribing Information. US National Library of Medicine.
4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Carboplatin:</strong>&nbsp;AUC 6, IV on day 1<br><strong>Docetaxel:</strong>&nbsp;75 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p>', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1013, null, 'Nivolumab (Adjuvant)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Dose modification not provided by the manufacturer</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Dose modification not provided by the manufacturer</li></ul>', 'Low', null, null, null, '<p><strong>Nivolumab: </strong>240 mg IV on day 1<br>Repeat cycle every 2 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (205, 'Doxorubicin : Adriamycin, various<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various', 'DI', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Ifosfamide:</strong><br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Ifosfamide</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥10 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose by 25%</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul>', 'Moderate', '<b>DI</b>', 'Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. $J Clin Oncol. 1995;13(7):1537-1545.$', null, '<p><strong>Doxorubicin:</strong> 50 mg/m2 IV bolus, day 1,<br>Followed by<br><strong>Ifosfamide:</strong> 5,000 mg/m2 IV continuous infusion, day 1<br><strong>Mesna:</strong> 600 mg/m2 IV bolus, before ifosfamide, followed by 2,500 mg/m2 &nbsp;IV continuous infusion with ifosfamide, and 1,250 mg/m2 IV over 12 hours following ifosfamide.<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (460, 'Carboplatin: Paraplatin
Paclitaxel: Taxol
Bevacizumab: Avastin', 'Bevacizumab + Carboplatin + Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Carboplatin</strong>:<br>No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li></ul>', 'High', '', 'Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004 Jun 1;22(11):2184-91

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Carboplatin:</strong> AUC 6 IV over 15 to 30 minutes on day 1</p><p><strong>Paclitaxel:</strong>&nbsp;200 mg/m2&nbsp;IV over 3 hours on day 1<br><strong>Bevacizumab:</strong> 15 mg/kg IV on day 1.</p><p>Repeat cycle every 21 days.</p>', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (812, null, 'Fludarabine + Prednisone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Fludarabine:</strong><br>No dose reduction</li><li><strong>Prednisone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Fludarabine:</strong><br>If CrCl 10-50 mL/min: Reduce dose by 25%&nbsp;<br>If CrCl &lt;10 mL/min: Reduce dose by 50%</li><li><strong>Prednisone:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Fludarabine:</strong> 30 mg/m2 IV over 30 minutes , days 1-5</p><p><strong>Prednisone:&nbsp;</strong>30 mg/m2&nbsp;IV on days 1-5</p><p>Repeat every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (271, 'Chlorambucil : Leukeran', 'Chlorambucil', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Chlorambucil:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Chlorambucil:</strong><br>If CrCl &gt;50 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 10 to 50 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;10 mL/min: Reduce dose by 50%</li></ul>', 'Low', '<b>Chlorambucil</b>', 'Eichhorst BF, Busch R, Stilgenbauer S, et al. First line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. $Blood. 2009;114:3382-3391.$', null, '<p><strong>Chlorambucil:</strong> 6-14 mg/day PO as induction therapy and then 0.7 mg/kg PO for 2-4 days.<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (813, null, 'Chlorambucil + Prednisone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Chlorambucil:</strong><br>No dose reduction</li><li><strong>Prednisone:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Chlorambucil:</strong><br>If CrCl &gt;50 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 10 to 50 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;10 mL/min: Reduce dose by 50%</li><li><strong>Prednisone:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Chlorambucil:</strong> 30 mg/m2 PO on day 1</p><p><strong>Prednisone:&nbsp;</strong>80 mg PO on days 1-5.</p><p>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (815, null, 'Imatinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Imatinib</strong>:<br>&nbsp;If bilirubin &lt; 3 upper normal limit, no dose reduction<br>If bilirubin &gt; 3 upper normal limit, use with caution</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Imatinib</strong>:<br>If CrCl 40 to 59 mL/min: Maximum dose recommended-600 mg. &nbsp; If CrCl 20 to 39 mL/min: Reduce dose by 50%; dose may be increased as tolerated; maximum recommended dose: 400 mg. &nbsp; If CrCl &lt;20 mL/minute: Use caution; 100 mg daily dose has been tolerated in a limited number of patients with severe impairment.</li></ul>', 'Moderate', null, null, null, '<p><strong>Imatinib:&nbsp;</strong>600 mg PO daily.</p><p>Continue until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (276, 'Nilotinib : Tasigna', 'Nilotinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nilotinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Newly diagnosed:</strong><br>Mild, moderate, or severe impairment (Child-Pugh class A, B, or C): Initial: 200 mg twice daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Resistant: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Mild to moderate impairment (Child-Pugh class A or B): Initial: 300 mg twice daily;&nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nilotinib:</strong><br>No dose reduction.</li></ul>', 'Low', '<b>Nilotinib</b>', 'Kantarjian HM, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.$Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17$', null, '<p><strong>Nilotinib:</strong> 300 mg PO bid (newly diagnosed)<br><strong>OR</strong><br><strong>Nilotinib:</strong> 400 mg PO bid (resistant or intolerant chronic or accelerated phase)</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (763, null, 'Omacetaxine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Omacetaxine: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Omacetaxine: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Omacetaxine:&nbsp;</strong>1.25<strong> </strong>mg/m2&nbsp;subcutaneous bid on days 1-14, cycle 1 (induction) followed by 1.25 mg/m2 subcutaneous bid on days 1-7 as maintenance.</p><p>Repeat cycles every 28 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (816, null, 'Busulfan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Busulfan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Busulfan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Busulfan:</strong> 1.8 mg/m2/day PO</p><p>Continue until loss of response or unacceptable toxicity</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (207, 'Dacarbazine : DTIC<br>Doxorubicin : Adriamycin, various<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various', 'MAID', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Ifosfamide</strong>:<br>No dose reduction</li><li><strong>Dacarbazine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Ifosfamide</strong>:<br>&nbsp;If CrCl ≥10 mL/min: 100% normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose to 25%&nbsp;</li><li><strong>Dacarbazine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 20%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 45 mL/min: Reduce dose to 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≤30 mL/min: Reduce dose to 30%.</li></ul>', 'High', '<b>MAID</b>', 'Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. $J Clin Oncol. 1993;11(7):1276-1285.$', null, '<p><strong>Mesna:</strong> 2,500 mg/m2/day continuous IV, days 1-4<br><strong>Doxorubicin:</strong> 20 mg/m2/day continuous IV, days 1-3<br><strong>Ifosfamide:</strong> 2,500 mg/m2/day continuous IV, days 1-3<br><strong>Dacarbazine:</strong> 300 mg/m2/day continuous IV, days 1-3<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (826, null, 'Cemiplimab-rwlc', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cemiplimab-rwlc:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cemiplimab-rwlc:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Cemiplimab-rwlc:</strong> 350 mg IV on day 1.</p><p>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (827, null, 'EP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', null, null, null, '<p><strong>Etoposide:&nbsp;</strong>80 mg/m2&nbsp;IV on days 1-3.</p><p><strong>Cisplatin:&nbsp;</strong>80<strong> </strong>mg/m2&nbsp;IV on day 1</p><p>Repeat cycles every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (828, null, 'EC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Carboplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose.</li></ul>', 'High', null, null, null, '<p><strong>Etoposide:&nbsp;</strong>100 mg/m2&nbsp;IV on days 1-3.</p><p><strong>Carboplatin:&nbsp;</strong>AUC of 6&nbsp;IV on day 1.</p><p>Repeat cycles every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (137, '', 'Abraxane', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Abraxane:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If bilirubin<strong> </strong>&gt;1.2 to ≤1.8 &nbsp;mg/dl : 100 % dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin<strong> </strong>&gt;1.8 to ≤6 &nbsp;mg/dl : Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin<strong> </strong>&gt;6 mg/dl : Not recommended.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Abraxane: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong> </strong>CrCl ≥30 mL/min: 100 % dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Insufficient data for dosage adjustment.</li></ul>', 'Low', '<b>Abraxane</b>', 'Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. $J Clin Oncol. 2005;23(31):7794-7803.$', null, '<p><strong>Abraxane:</strong> 260 mg/m2 IV over 30 minutes day 1.<br>Repeat every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (835, null, 'Carboplatin + Paclitaxel (Adjuvant)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Carboplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li></ul>', 'High', null, null, null, '<p><strong>Carboplatin:</strong> AUC &nbsp;6, IV on day 1<br><strong>Paclitaxel:</strong>&nbsp;175 mg/m2&nbsp;IV over 3 hours on day 1</p><p>Repeat cycle every 21 days for 4 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (458, 'Carboplatin: Paraplatin
Albumin-Bound Paclitaxel: Abraxane
Atezolizumab: Tecentriq', 'Atezolizumab + Carboplatin + nab-Paclitaxel ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Atezolizumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li><li><strong>Nab-Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin 1.2 to ≤1.8 mg/dL:100% dosage<br>If bilirubin &gt;1.8 to ≤3.6 mg/dL: Reduce dose by 75%<br>If bilirubin &gt; 3.6 mg/dL, do not use</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%&nbsp;</li><li><strong>Atezolizumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li><li><strong>Nab-Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: There are no dosage adjustments provided because of insufficient data.</li></ul><p>&nbsp;</p>', 'High', '', 'Power130: West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):924-937. Epub 2019 May 20.
4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Carboplatin:</strong> AUC 6 IV on day 1<br><strong>Paclitaxel</strong>&nbsp;(<strong>nanoparticle albumin-bound):</strong> 100 mg/m2&nbsp;IV on days 1, 8, 15<br><strong>Atezolizumab:</strong> 1,200 mg IV on day 1&nbsp;</p><p>Repeat cycle every 21 days for up to 4-6 cycles<strong>.</strong></p>', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (997, null, 'EVAP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Vinblastine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Vinblastine:</strong><br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li></ul>', 'High', null, null, null, '<p><strong>Etoposide:</strong> 120 mg/m2 IV on days 1,8, and 15<br><strong>Vinblastine:</strong> 4 mg/m2 IV on days 1,8, and 15<br><strong>Cytarabine: </strong>30 mg/m2 IV on days 1, 8, and 15<br><strong>Cisplatin:</strong> 40 mg/m2 IV on days 1, 8, and 15<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (785, null, 'Osimertinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Osimertinib:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Osimertinib:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Osimertinib: </strong>80 mg PO daily.</p><p>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (459, 'Ipilimumab: Yervoy
Nivolumab: Opdivo', 'Ipilimumab + Nivolumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ipilimumab:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ipilimumab:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', '', 'Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O''Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031. Epub 2019 Sep 28.

Opdivo (Nivolumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf

Yervoy (Ipilimumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf', 'METASTATIC', '<p><strong>Ipilimumab:</strong> 1 mg/kg IV on day 1</p><p><strong>Nivolumab:</strong> 3 mg/kg IV on day 1, 15, 29</p><p>Repeat cycle every 42-days (6 weeks) for up to 4 cycles.</p>', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (781, null, 'Afatinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Afatinib:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Afatinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> If<strong> </strong>eGFR &gt;30 mL/min: 100% dosage.<br>&nbsp;If eGFR 15 - 29 mL/min: Reduce dose to 30 mg/day PO.</li></ul>', 'Low', null, null, null, '<p><strong>Afatinib:</strong> 40 mg/day PO.</p><p>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (786, null, 'Erlotinib + Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Erlotinib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Erlotinib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Erlotinib:</strong> 150 mg PO once daily</p><p><strong>Bevacizumab:</strong> 15 mg/kg IV once on day 1</p><p>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (787, null, 'Erlotinib + Ramucirumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Erlotinib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Ramucirumab:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Erlotinib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Ramucirumab:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Erlotinib:&nbsp;</strong> 150mg PO daily</p><p><strong>Ramucirumab: </strong>10 mg/kg IV once on day 1</p><p>Repeat cycle every 14 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (417, 'Carboplatin: Paraplatin
Etoposide: Vepesid
Durvalumab: Imfinzi', 'Carboplatin + Etoposide + Durvalumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Durvalumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Durvalumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li></ul>', 'High', '', 'CASPIAN: Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Oct 4. ', '', '<p><strong>Carboplatin:</strong> AUC 5-6, IV on day 1 OR 75-80 mg/m2 IV on day 1.<br><strong>Etoposide:</strong> 80-100 mg/m2 days 1, 2, 3<br><strong>Durvalumab:</strong> 1,500 mg day 1&nbsp;</p><p>Repeat cycle every 21 days for a maximum of 4 cycles, followed by maintenance durvalumab: 1,500 mg on day 1.</p>', 105);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (428, 'Carboplatin: Paraplatin
Irinotecan: Camptosar', 'Carboplatin + Irinotecan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li></ul>', 'High', '', 'Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C, Hortig P, Fischer JR, Link H, Binder D, Fischer B, Caca K, Eberhardt WE, Keilholz U; Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol. 2011 Aug;22(8):1798-804. Epub 2011 Jan 25.

Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, Sundstrøm S, Thaning L, Vilsvik J, Aasebø U, Sörenson S. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008 Sep 10;26(26):4261-7.', '', '<p><strong>Carboplatin:</strong> AUC 5 on day 1&nbsp;<br><strong>Irinotecan:</strong> 50mg/m2&nbsp;on days 1, 8, 15.</p><p>Repeat every 28 days for a maximum of&nbsp;4-6 cycles.</p>', 105);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (473, 'Ipilimumab: Yervoy
Nivolumab: Opdivo', 'Nivolumab + Ipilimumab ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ipilimumab:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ipilimumab:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Moderate', '', 'Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O''Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031. Epub 2019 Sep 28.

Opdivo (Nivolumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf

Yervoy (Ipilimumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf
', 'METASTATIC', '<p><strong>Ipilimumab:</strong> 1 mg/kg IV on day 1<br><strong>Nivolumab:</strong> 3 mg/kg IV on day 1, 15, 29.</p><p>Repeat cycle every 42-days (6 weeks).</p>', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (397, 'Cisplatin: Platinol
Etoposide: Vepesid', 'Cisplatin + Etoposide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: &nbsp;Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min: Reduce dose by 25%<br>If CrCl &lt; 10 mL/min: Reduce dose by 50%</li></ul>', 'High', '', 'Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116–1125. doi:10.1016/S1470-2045(17)30318-2

Seckl MJ, Ottensmeier CH, Cullen M, et al. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). J Clin Oncol. 2017;35(14):1506–1514. doi:10.1200/JCO.2016.69.7391

T. Marcello, Boni L., Ambrosio F. et al. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. Journal of Clinical Oncology 2017 35:12, 1281-1287.

Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 99, 171.

Hendrayana T, Wilmer A, Kurth V, Schmidt-Wolf IG, Jaehde U. Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application. Sci Pharm. 2017;85(1):8. Published 2017 Feb 27. doi:10.3390/scipharm85010008
', '', '<p><strong>Cisplatin:</strong> 75 mg/m2&nbsp;on day 1&nbsp;<br><strong>Etoposide:</strong> 100&nbsp;mg/m2&nbsp;on days 1, 2, 3&nbsp;<br>21 day cycle for 4-6 cycles</p><p>OR</p><p><strong>Cisplatin:</strong> 60&nbsp;mg/m2&nbsp;on day 1&nbsp;<br><strong>Etoposide:</strong> 120&nbsp;mg/m2&nbsp;on days 1, 2, 3<br>21 day cycle for 4-6 cycles</p><p>OR</p><p><strong>Cisplatin:</strong> 25 mg/m2&nbsp;on days 1, 2, 3<br><strong>Etoposide:</strong> 100&nbsp;mg/m2&nbsp;on days 1, 2, 3&nbsp;<br>21 day cycle for 4-6 cycles</p><p>Recommended for use with concominant RT (category I)</p>', 104);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (415, 'Carboplatin: Paraplatin
Etoposide: Vepesid', 'Carboplatin + Etoposide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', '', 'Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol. 1999 Nov;17(11):3540-5. link to original article contains verified protocol PubMed Skarlos DV, Samantas E, Briassoulis E, Panoussaki E, Pavlidis N, Kalofonos HP, Kardamakis D, Tsiakopoulos E, Kosmidis P, Tsavdaridis D, Tzitzikas J, Tsekeris P, Kouvatseas G, Zamboglou N, Fountzilas G; Hellenic Cooperative Oncology Group. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2001 Sep;12(9):1231-8. link to original article contains verified protocol PubMed', '', '<p><i>&nbsp;</i><strong>Carboplatin:</strong> AUC 5-6 IV over 60 minutes, day 1-&nbsp;<i>given first</i><br><strong>Etoposide:</strong> 100 mg/m2&nbsp;IV over 1-2 hours,&nbsp;days 1, 2, 3-&nbsp;<i>given second</i></p><p>Repeat cycle every 21 days.</p><p>Recommended for use with concomitant RT&nbsp;if Cisplatin + Etoposide is contraindicated or not tolerated.</p>', 104);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (109, 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR', 'ADOC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'High', '<b>ADOC</b>', 'Fornasiero A, et al.$Cancer 1991;68:30-33.$', null, '<p><strong>Cisplatin:</strong> 50 mg/m2 IV on day 1<br><strong>Doxorubicin:</strong> 40 mg/m2 IV on day 1<br><strong>Vincristine:</strong> 0.6 mg/m2 IV on day 3<br><strong>Cyclophosphamide:</strong> 700 mg/m2 IV on day 4<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (998, null, 'Mini-BEAM', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carmustine: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Melphalan:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carmustine: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If CrCl 46 to 60 mL/min: Reduce dose by 20% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl ≤30 mL/min: Consider use of alternative drug.</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 40% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 45 mL/minute: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Melphalan:</strong><br>&nbsp;If CrCl 10 to 50 mL/min: Reduce dose to 75%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose to 50%.</li></ul>', 'High', null, null, null, '<p><strong>Carmustine:</strong> 60 mg/m2 IV on day 1<br><strong>Etoposide:</strong> 75 mg/m2 IV on days 2-5<br><strong>Ara-C:</strong> 100 mg/m2 IV every 12 hours on days 2-5<br><strong>Melphalan:</strong> 30 mg/m2 IV on day 6<br>Repeat cycle every 4-6 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (108, 'Cisplatin : CDDP<br>Etoposide : VP-16', 'Cisplatin + Etoposide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', '<b>Cisplatin + Etoposide</b>', 'Giaccone G, et al.$J Clin Oncol 1996;14:814-820.$', null, '<p><strong>Cisplatin:</strong> 60 mg/m2 IV on day 1<br><strong>Etoposide:</strong> 120 mg/m2 IV on day 1 - 3<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1105, null, 'Nivolumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Dose modification not provided by the manufacturer</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Dose modification not provided by the manufacturer</li></ul>', 'Low', null, null, null, '<p><strong>Nivolumab: </strong>240 mg IV on day 1<br>Repeat cycle every 2 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (930, null, 'Copanlisib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Copanlisib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (Child-Pugh class A): 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (Child-Pugh class B): Decrease dose to 45 mg. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (Child-Pugh class C): Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Copanlisib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Dosage adjustment not provided by the manufacturer.</li></ul>', 'Low', null, null, null, '<p><strong>Copanlisib:</strong> 60 mg IV on days 1, 8, and 15<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (931, null, 'Bendamustine + Obinutuzumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin&nbsp;1.5-3 upper normal limit, or bilirubin &gt; 3 upper normal limit: Do not use</li><li><strong>Obinutuzumab:</strong><br>Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If CrCl &lt; 30 mL/min: Do not use</li><li><strong>Obinutuzumab:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Bendamustine: </strong>90 mg/m2 IV on days 1 and 2<br><strong>Obinutuzumab:</strong> 1,000 mg IV on days 1, 8, and 15<br>The first cycle is administered over 28 days followed by<br><strong>Bendamustine:</strong> 90 mg/m2 IV on days 1 and 2<br><strong>Obinutuzumab:</strong> 1,000 mg IV on day 1<br>Repeat every 28 days for a total of 5 cycles.<br>&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (937, null, 'MACOP-B', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Bleomycin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Bleomycin</strong><br>If CrCl &gt;50 mL/min: No dose reduction<br>If CrCl 40-50 mL/min: 70% of normal dose<br>If CrCl 30-40 mL/min: 60% of normal dose<br>If CrCl 20-30 mL/min: 55% normal dose<br>If CrCl 10-20 mL/min: 45% normal dose<br>If CrCl 5-10 mL/min: 40% normal dose</li></ul>', 'High', null, null, null, '<p><strong>Methotrexate:</strong> 400 mg/m2 IV on weeks 2, 6, and 10<br><strong>Leucovorin:</strong> 15 mg/m2 PO every 6 hours for 6 doses, beginning 24 hours after methotrexate<br><strong>Doxorubicin: </strong>50 mg/m2 IV on weeks 1, 3, 5, 7, 9, and 11<br><strong>Cyclophosphamide:</strong> 350 mg/m2 IV on weeks 1, 3, 5, 7, 9, and 11<br><strong>Vincristine:</strong> 1.4 mg/m2 IV on weeks 2, &nbsp;4, &nbsp;6, &nbsp;8, 10, and 12<br><strong>Prednisone:</strong> 75 mg/day PO for 12 weeks with taper over the last 2 weeks<br><strong>Bleomycin:</strong> 10 U/m2 IV on weeks 4, 8, and 12<br><strong>Bactrim DS: </strong>1 tablet PO bid<br><strong>Ketoconazole:</strong> 200 mg/day PO<br>Administer one cycle.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (381, 'Atezolizumab (Tecentriq)', 'Atezolizumab monotherapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Atezolizumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Atezolizumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li></ul>', 'Low', '', 'Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 Jan 7;389(10064):67-76. Epub 2016 Dec 8.', 'METASTATIC', '<h4><strong>Atezolizumab</strong> (Tecentriq):&nbsp;1,200 mg IV once on day 1</h4><p>Repeat cycle every 21 days.</p>', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (392, 'Carboplatin (Paraplatin), Gemcitabine (Gemzar)', 'Carboplatin + Gemcitabine (AUC 5/1250)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Carboplatin:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Carboplatin</strong>:<br>Dosing based on&nbsp;<strong>mg/m2</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: &nbsp;Reduce dose to 50% of the usual dose. &nbsp; If GFR &lt;10 mL/min: Reduce dose to 75% of the usual dose.</li></ul>', 'High', '', 'Dogliotti L, Cartenì G, Siena S, Bertetto O, Martoni A, Bono A, Amadori D, Onat H, Marini L. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007 Jul;52(1):134-41. Epub 2006 Dec 26', 'METASTATIC', '<h4>&nbsp;</h4><p><strong>Carboplatin (Paraplatin):</strong>&nbsp;AUC 5 IV over 30 to 60 minutes once on day 2</p><p><strong>Gemcitabine (Gemzar):</strong>&nbsp;1250 mg/m2&nbsp;IV over 30 to 60 minutes once per day on days 1 &amp; 8</p><p><strong>Repeat cycle every 21-days for up to 6 cycles.</strong></p>', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (378, 'Methotrexate (Otrexup; Rasuvo; Rheumatrex [DSC]; Trexall; Xatmep). Vinblastine (Vinblastine), Doxorubicin (Adriamycin), (Cisplatin (Platinum)', 'Dose-Dense MVAC (DDMVAC)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use.</li><li><strong>Vinblastine:</strong><br>If serum bilirubin 1.5 to 3 mg/dL or transaminases 2 to 3 times ULN: Administer 50% of dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If serum bilirubin &gt;3 times ULN: Avoid use.</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Cisplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Vinblastine:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'High', '', 'Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20;32(18):1889-94. Epub 2014 May 12.', 'NEOADJUVANT', '<p>&nbsp;</p><p><strong>Methotrexate (MTX):</strong>&nbsp;30 mg/m2&nbsp;IV over 30 minutes on days 1, 15, and 22.</p><p><strong>Vinblastine (Velban):</strong>&nbsp;3 mg/m2&nbsp;IV on days 2, 15, and 22.</p><p><strong>Doxorubicin (Adriamycin):</strong>&nbsp;30 mg/m2&nbsp;IV on day 2</p><p><strong>Cisplatin (Platinol):</strong>&nbsp;70 mg/m2&nbsp;IV on day 2</p><h4><strong>Supportive medications</strong></h4><ul><li><strong>Pegfilgrastim (Neulasta):</strong>&nbsp;6 mg SC once, 24 to 48 hours after completion of chemotherapy</li><li>Antiemetics used often included&nbsp;Aprepitant (Emend),&nbsp;Ondansetron (Zofran), and&nbsp;Dexamethasone (Decadron)&nbsp;but were not specified by the trial.</li></ul><p>Repeat cycle every 28 days.</p>', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1106, null, 'Temozolomide ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Temozolomide:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If mild to moderate impairment (Child-Pugh classes A and B): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): There are no dosage adjustments provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Temozolomide:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥36 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;36 mL/min: There are no dosage adjustments provided by the manufacturer</li></ul>', 'High', null, null, null, '<p><strong>Temozolomide:</strong> 150 mg/m2 PO on days 1 to 5.</p><p>Repeat cycle every 28 days. If tolerated, can increase dose to 200 mg/m2 PO<br>on days 1-5.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1110, null, 'Gemcitabine + Vinorelbine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vinorelbine:</strong><br>If bilirubin 2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Gemcitabine:&nbsp;</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vinorelbine:</strong><br>No dose reduction</li><li><strong>Gemcitabine:&nbsp;</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Gemcitabine: </strong>1,000 mg/m2 IV on days 1 and 8<br><strong>Vinorelbine:</strong> 25 mg/m2 IV on days 1 and 8<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1107, null, 'Vemurafenib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vemurafenib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild to moderate impairment (Child-Pugh classes A and B): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (Child-Pugh class C): Dose modification not provided by the manufacturer</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vemurafenib:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If mild to moderate impairment (preexisting): 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If Severe impairment (preexisting): Dose modification not provided by the manufacturer.</li></ul>', 'Low', null, null, null, '<p><strong>Vemurafenib: </strong>960 mg PO bid.<br>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (382, 'Pembrolizumab (Keytruda)', 'Pembrolizumab monotherapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', '', 'KEYNOTE-052: Balar AV, Castellano D, O''Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Nov;18(11):1483-1492. Epub 2017 Sep 26.', 'METASTATIC', '<h4>&nbsp;</h4><p><strong>Pembrolizumab (Keytruda):</strong>&nbsp;200 mg IV on day 1</p><p>Repeat cycle every 21 days.</p>', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (386, 'Paclitaxel (Taxol)', 'Paclitaxel monotherapy (21 day cycle)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li></ul>', 'Low', '', 'Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017 Mar 16;376(11):1015-1026. Epub 2017 Feb 17', 'METASTATIC', '<p>&nbsp;</p><p><strong>Paclitaxel (Taxol)</strong>: 250 mg/m2&nbsp;IV over 24 hours on day 1</p><p>Repeat cycle every 21 days.</p>', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (932, null, 'CHOP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Cyclophosphamide:</strong> 750 mg/m2 IV, day 1<br><strong>Doxorubicin:</strong> 50 mg/m2 IV, day 1<br><strong>Vincristine:</strong> 1.4 mg/m2 IV, day 1 (Maximum of 2 mg)<br><strong>Prednisone:</strong> 100 mg PO, days 1-5<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (933, null, 'CHOP+R', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Rituximab:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Rituximab:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Cyclophosphamide:</strong> 750 mg/m2 IV, day 1<br><strong>Doxorubicin:</strong> 50 mg/m2 IV, day 1<br><strong>Vincristine:</strong> 1.4 mg/m2 IV, day 1 &nbsp;(maximum dose of 2mg)<br><strong>Prednisone:</strong> 40 mg/m2 PO, days 1-5<br><strong>Rituximab:</strong> 375 mg/m2 IV, day 1<br>Repeat cycle every 21 days. Rituximab is to be administered first followed by cyclophosphamide, doxorubicin, and vincristine.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (177, 'Sorafenib : Nexavar', 'Sorafenib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Sorafenib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Sorafenib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 40 to 59 mL/min: 400 mg twice daily &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 20 to 39 mL/min: 200 mg twice daily &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;20 mL/min: Inadequate data&nbsp;to define dose.</li></ul>', 'Low', '<b>Sorafenib</b>', 'Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. $N Engl J Med. 2007;356(2):125-134.$', null, '<p><strong>Sorafenib:</strong> 400 mg PO bid.</p><p>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1108, null, 'Dabrafenib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Dabrafenib:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Dabrafenib:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Dabrafenib:</strong> 150 mg PO bid</p><p>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (838, null, 'Flutamide + Leuprolide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Flutamide:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If mild or moderate impairment (Child-Pugh class A and B): Dosage adjustments not provided by the manufacturer. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): Do not use.</li><li><strong>Leuprolide:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Flutamide:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Leuprolide:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'N/A', null, null, null, '<p><strong>Flutamide:</strong> 250 mg PO tid.<br><strong>Leuprolide: </strong>7.5 mg IM every 28 days or 22.5 mg IM every 12 weeks.<br>&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (840, null, 'Estramustine + Etoposide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Estramustine:</strong>&nbsp;<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Estramustine:</strong>&nbsp;<br>No dose reduction<br>&nbsp;</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'Moderate', null, null, null, '<p><strong>Estramustine:</strong> 15 mg/kg/day PO in 4 divided doses on days 1-21<br><strong>Etoposide: </strong>50 mg/m2/day PO in 2 divided doses on days 1-21</p><p><br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (837, null, 'Olaparib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Olaparib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Olaparib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 51 to 80 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 50 mL/min: Reduce dose to 200 mg twice daily. &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≤30 mL/min: There are no dosage adjustments because of inadequate study.</li></ul>', 'Low', null, null, null, '<p><strong>Olaparib:&nbsp;</strong>300 mg&nbsp;PO bid, daily.</p><p>Continue treatment until disease progression or unacceptable toxicity.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1109, null, 'Trametinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Trametinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Trametinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Trametinib:</strong> 2 mg PO daily</p><p>Continue treatment until disease progression</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (841, null, 'PEB', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Bleomycin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Bleomycin</strong><br>If CrCl &gt;50 mL/min: No dose reduction<br>If CrCl 40-50 mL/min: 70% of normal dose<br>If CrCl 30-40 mL/min: 60% of normal dose<br>If CrCl 20-30 mL/min: 55% normal dose<br>If CrCl 10-20 mL/min: 45% normal dose<br>If CrCl 5-10 mL/min: 40% normal dose</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:</strong> 20 mg/m2/day IV on days 1-5<br><strong>Etoposide: </strong>100 mg/m2/day IV on days 1-5<br><strong>Bleomycin:</strong> 30 U IV on days 2, 9, and 16<br><br>Repeat cycle every 28 days for a total of 2 cycles. Adjuvant therapy of stage<br>II testicular cancer treated with orchiectomy and retroperitoneal lymph node<br>dissection.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (842, null, 'Carboplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on mg/m2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%&nbsp;</li></ul>', 'High', null, null, null, '<p><strong>Carboplatin:</strong> AUC of 7, IV on day 1<br><br>Administer one dose for adjuvant therapy of stage I seminoma.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (843, null, 'BEP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bleomycin</strong>:<br>No dose reduction</li><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bleomycin</strong><br>If CrCl &gt;50 mL/min: No dose reduction<br>If CrCl 40-50 mL/min: 70% of normal dose<br>If CrCl 30-40 mL/min: 60% of normal dose<br>If CrCl 20-30 mL/min: 55% normal dose<br>If CrCl 10-20 mL/min: 45% normal dose<br>If CrCl 5-10 mL/min: 40% normal dose</li><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', null, null, null, '<p><strong>Bleomycin:</strong> 30 U IV on days 1, 8, and 15.</p><p><strong>Etoposide: </strong>100 mg/m2/day IV on days 1-5</p><p><strong>Cisplatin:</strong> 20 mg/m2/day IV on days 1-5<br><br>Repeat cycle every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (301, 'Carboplatin : Paraplatin', 'Carboplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%&nbsp;</li></ul>', 'High', '<b>Carboplatin</b>', 'Friedman HS, Krischer JP, Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. $J Clin Oncol. 2000;18(22):3819-3828.$', null, '<p><strong>Carboplatin:</strong> 560 mg/m2 IV over 1 hour on day 1<br>Repeat every 28 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (999, null, 'BEACOPP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bleomycin:</strong><br>No dose reduction</li><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Procarbazine:</strong><br>If transaminases 1.6 to 6 times ULN: Administer 75% of dose &nbsp; &nbsp; &nbsp; &nbsp; If transaminases &gt;6 times ULN: Use clinical judgment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If serum bilirubin &gt;5 mg/dL or transaminases &gt;3 times ULN: Avoid use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bleomycin:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Procarbazine:</strong><br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li></ul>', 'High', null, null, null, '<p><strong>Bleomycin:</strong> 10 mg/m2 IV, day8<br><strong>Etoposide:</strong> 100 mg/m2 IV, days 1-3<br><strong>Doxorubicin:</strong> 25 mg/m2 IV, day 1<br><strong>Cyclophosphamide:</strong> 650 mg/m2 IV, day 1<br><strong>Vincristine:</strong> 1.4 mg/m2 IV, day 8 (maximum, 2 mg)<br><strong>Procarbazine:</strong> 100 mg/m2 PO, days 1-7<br><strong>Prednisone:</strong> 40 mg/m2 PO, days 1-14<br>Repeat cycle every 21 days.&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (845, null, 'Carboplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on mg/m2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%&nbsp;</li></ul>', 'High', null, null, null, '<p><strong>Carboplatin: </strong>AUC of 7, IV on day 1<br>Administer one dose for adjuvant therapy of stage I seminoma.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (331, 'Cytarabine : Ara-C', 'DA', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Daunorubicin:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Daunorubicin:</strong><br>If Cr &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 40% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Consider use of alternative drug.</li></ul>', 'Moderate', '<b>DA</b>', 'Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia. $Cancer. 2006;66(6):1106-1113.$', null, '<p><strong>Daunorubicin:&nbsp;</strong> 45 mg/m2/day IV, days 1-3<br><strong>Cytarabine:</strong> 100 mg/m2/day continuous infusion IV, days 1-7</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (846, null, 'BEP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bleomycin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Cisplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bleomycin</strong><br>If CrCl &gt;50 mL/min: No dose reduction<br>If CrCl 40-50 mL/min: 70% of normal dose<br>If CrCl 30-40 mL/min: 60% of normal dose<br>If CrCl 20-30 mL/min: 55% normal dose<br>If CrCl 10-20 mL/min: 45% normal dose<br>If CrCl 5-10 mL/min: 40% normal dose</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'High', null, null, null, '<p><strong>Bleomycin: </strong>30 U IV on days 1, 8, and 15.</p><p><strong>Etoposide:</strong> 100 mg/m2/day IV on days 1-5</p><p><strong>Cisplatin: </strong>20 mg/m2/day IV on days 1-5<br><br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (327, '', 'IDMTX', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 5 mg/dL: Do not use</li><li><strong>6-Mercaptopurine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min: 50% of normal dosage.<br>If CrCl &lt; 30 mL/min: Do not use</li><li><strong>6-Mercaptopurine:</strong><br>No dose reduction</li></ul>', 'High', '<b>IDMTX</b>', 'Mahoney DH, Shuster JJ, Nitschke R, et al. Intensification with intermediate-dose intravenous methotrexate is effectie therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study. $J Clin Oncol. 2000;18(6):1285-1294.$', null, '<p><strong>WEEK 1</strong></p><p><strong>Methotrexate:</strong> 1,000 mg/m2 IV over 24 hours<br>Followed by<br><strong>Mercaptopurine:</strong> 1,000 mg/m2 IV over 6 hours<br>Then (48 hours after the start of Methotrexate)<br><strong>Leucovorin calcium:</strong> 5 mg/m2 IV every 6 hours for at least 5 doses</p><p><br><strong>WEEK 2</strong><br><strong>Methotrexate:</strong> 20 mg/m2 IM, day 1<br><strong>Mercaptopurine:</strong> 50 mg/m2/d PO, days 1-7</p><p><br>Repeat cycle every 14 days for a total of 12 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (323, '', 'Nelarabine', '<p><strong>Hepatic impairment</strong></p><ul><li><strong>Nelarabine: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li></ul><p><strong>Renal impairment</strong></p><ul><li><strong>Nelarabine: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Low', '<b>Nelarabine</b>', 'Arranon [package insert]. $Research Triangle Park, NC: GlaxoSmithKline; 2011.$', null, '<p><strong>Nelarabine:</strong> 650 mg/m2/day IV, over 1 hour for 5 consecutive days<br>Repeat every 21 days until disease progression or unacceptable toxicity.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (298, 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Vincristine : Oncovin, VCR', 'Vincristine + Cyclophosphamide + Cisplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'High', 'Vincristine/Cyclophosphamide/Cisplatin', 'Douglas JG, Barker JL, Ellenbogen RG, et al. Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure. $Int J Radiat Oncol Biol Phys. 2004;58(4):1161-1164.$<br> National Cancer Institute. Phase III randomized study of adjuvant lomustine/cisplatin/vincristine vs cyclophosphamide/cisplatin/vincristine following craniospinal radiotherapy in children with newly diagnosed, average-risk medulloblastoma. $http://cancer.gov.clinicaltrials.CCG-A9961. Accessed January 27, 2012.$', null, '<p><strong>Vincristine:</strong> 1.5 mg/m2 IV, day 1<br><strong>Cisplatin:</strong> 75 mg/m2 IV, day 1<br><strong>Cyclophosphamide:</strong> 1,000 mg/m2 IV, day 1<br>Repeat every 6 weeks for 8 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (308, 'Dactinomycin : Actinomycin<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR', 'VAD', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Dactinomycin:</strong><br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Dactinomycin:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li></ul>', 'High', '<b>VAD</b>', 'Pritchard J, Imeson J , Barnes J, et al. Results of the United Kingdom Children''s Cancer Study Group first Wilms'' tumor study. $J Clin Oncol. 1995; 13(1):124-133.$<br>  de Camargo B, Franco EL. A randomized clinical trial of single-dose versus fractionated-dose dactinomycin in the treatment of Wilms'' tumor. $Cancer. 1994;73(12):3081-3086.$', null, '<p><strong>Vincristine:</strong> 1.5 mg/m2 IV weekly for 10 weeks, then every 3 weeks for 15 weeks<br><strong>Dactinomycin:</strong> 1.5 mg/m2 IV every 6 weeks for 26 weeks<br><strong>Doxorubicin:</strong> 40 mg/m2 IV every 6 weeks for 1 year (stage III)<br><strong>OR</strong><br><strong>Vincristine:</strong> 1.5 mg/m2 IV, day 1<br><strong>Dactinomycin:</strong> 15 mcg/kg/d IV, days 1-5 or 60 mcg/kg IV, day 1<br>Repeat every 6 weeks. If stage III or IV add:<br><strong>Doxorubicin:</strong> 20 mg/m2 IV, day 1, and RT</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (330, 'Cytarabine : Ara-C', 'CA', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>L-Asparaginase: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Do not use in patients with severe hepatic impairment.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>L-Asparaginase:</strong><br>No dose reduction</li></ul>', 'High', '<b>CA</b>', 'Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia. $Cancer. 2006;66(6):1106-1113.$', null, '<p><strong>Cytarabine:</strong> 3,000 mg/m2 IV over 3 hours every 12 hours for 4 doses<br><strong>Asparaginase:</strong> 6,000 units/m2 IM 3 hours after the last dose of cytarabine<br>Repeat every 28 days after the initial cycle or after recovery of blood counts, whichever is later</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1006, null, 'Bendamustine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin&nbsp;1.5-3 upper normal limit, or bilirubin &gt; 3 upper normal limit: Do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If CrCl &lt; 30 mL/min: Do not use</li></ul>', 'Moderate', null, null, null, '<p><strong>Bendamustine: </strong>70-120 mg/m IV on days 1 and 2<br>Repeat weekly for 4 weeks</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (333, 'Cytarabine : Ara-C<br>Dexamethasone : various<br>Etoposide : VP-16<br>Thioguanine : 6-TG', 'DCTER', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Dexamethasone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li><li><strong>6-Thioguanine:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Daunorubicin:</strong><br>If bilirubin 1.2-3 mg/dL: &nbsp;Reduce dose by 25%&nbsp;<br>If bilirubin 3.1-5 mg/dL: Reduce dose by 50%<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL: &nbsp;Reduce dose by 25%&nbsp;<br>If bilirubin &gt; 3 mg/dL: Reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Dexamethasone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li><li><strong>6-Thioguanine:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Daunorubicin:</strong><br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 40% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li></ul>', 'Moderate', '<b>DCTER</b>', 'Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children''s Cancer Group. $Blood. 1996;87(12):4979-4989.$', null, '<p><strong>Dexamethasone:</strong> 6 mg/m2/d (if age &lt; 3 years 0.2mg/kg/d) PO tid, days 0-4<br><strong>Cytarabine:</strong> 200 mg/m2/d (if age &lt; 3 years 6.7 mg/kg/d) CIVI, days 0-4<br><strong>Thioguanine:</strong> 100 mg/m2/d (if age &lt; 3 years 3.3 mg/kg/d) PO bid, days 0-4<br><strong>Etoposide:</strong> 100 mg/m2/d (if age &lt; 3 years 3.3 mg/kg/d) CIVI, days 0-4<br><strong>Daunorubicin:</strong> 20 mg/m2/d (if age &lt; 3 years 0.67 mg/kg/d) CIVI, days 0-4<br><strong>Cytarabine:</strong> IT (age-based doses)<br>Doses in parentheses used for children &lt;3 years of age</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (318, 'Bleomycin : Blenoxane<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Prednisone : various<br>Procarbazine : Matulane<br>Vincristine : Oncovin, VCR', 'BEACOPP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bleomycin:</strong><br>No dose reduction</li><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Procarbazine:</strong><br>If AST, ALT are 1.6 to 6 times ULN: 75% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If AST, ALT are &nbsp;&gt;6 times ULN: Use clinical judgment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin &gt;5 mg/dL or AST, ALT &gt;3 times ULN: Avoid use.</li><li><strong>Prednisone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bleomycin:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Procarbazine:</strong><br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone:</strong><br>No dose reduction</li></ul>', 'High', '<b>BEACOPP</b>', 'Kelly KM, Hutchinson RJ, Sposto R, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin''s lymphoma: preliminary results from the Children''s Cancer Group Study Ccg-59704. $Ann Oncol. 2002;13(suppl 1):107-111.', null, '<p><strong>Bleomycin:</strong> 10 units/m2 IV, day 7<br><strong>Etoposide:</strong> 200 mg/m2/day IV, days 0-2<br><strong>Doxorubicin:</strong> 35 mg/m2 IV, day 0<br><strong>Cyclophosphamide:</strong> 1,200 mg/m2 IV, day 0<br><strong>Vincristine:</strong> 2 mg/m2 IV, day 7<br><strong>Procarbazine:</strong> 100 mg/m2/d PO, days 0-6<br><strong>Prednisone:</strong> 40 mg/m2/d PO, days 0-13<br>Repeat every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (855, null, 'Doxorubicin + Cisplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Doxorubicin:</strong> 60 mg/m2 IV on day 1<br><strong>Cisplatin: </strong>40 mg/m2 IV on day 1<br>Repeat cycle every 21 days.<br><br>&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (857, null, 'Sorafenib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Sorafenib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Sorafenib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 40 to 59 mL/min: 400 mg twice daily &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 20 to 39 mL/min: 200 mg twice daily &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;20 mL/min: Inadequate data&nbsp;to define dose.</li></ul>', 'Low', null, null, null, '<p><strong>Sorafenib:&nbsp;</strong>400 mg/day PO twice daily</p><p>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (320, 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR', 'SNCCL/B-ALL', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL: 75% of usual dosage.&nbsp;<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL: 50% of usual dosage.<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL: Do not use</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 5 mg/dL: Do not use</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 3 mg/dL: 50% of usual dosage.</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL: 50% of usual dosage.<br>If bilirubin 3.1-5 mg/dL: 25% of usual dosage.<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min: 75% of usual dosage.<br>If CrCl &lt; 10 mL/min: 50% of usual dosage.</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min: 50% of normal dosage.<br>If CrCl &lt; 30 mL/min: Do not use</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'High', '<b>SNCCL/B-ALL</b>', 'Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a Pediatric Oncology Group study. $J Clin Oncol. 1996;14(4):1252-1261.$', null, '<p>INITIAL PHASE<br><strong>Cytarabine:</strong> 50 mg/m2/day (maximum, 50 mg/d) IT, days 1, 2, 3, 11<br><strong>Methotrexate:</strong> 12 mg/m2/day (maximum, 12 mg/d) IT, days 4, 11<br><strong>Cyclophosphamide:</strong> 300 mg/m2 IV push every 12 hours for 6 doses, days 1-3<br><strong>Doxorubicin:</strong> 50 mg/m2 IV, day 4<br><strong>Vincristine:</strong> 1.5 mg/m2/day IV, days 4, 11<br>Alternating with:<br><br>SECONDARY PHASE<br><strong>Cytarabine:</strong> 50 mg/m2 (maximum, 50 mg) IT, day 1<br><strong>Methotrexate:</strong> 12 mg/m2 (maximum, 12 mg) IT, day 1<br><strong>Methotrexate:</strong> 200 mg/m2 IV bolus, then 800 mg/m2 IV continuous infusion<br><strong>Cytarabine:</strong> 3,000 mg/m2 IV over 3 hours every 12 hours for 4 doses, days 2, 3<br><strong>Leucovorin calcium:</strong> 30 mg/m2 IV at hour 42, then 3 mg/m2 IV at hours 54, 66, 78</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (304, 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Vincristine : Oncovin, VCR', 'CAV + P/VP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'High', '<b>CAV + P/VP</b>', 'Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. $J Clin Oncol. 1994;12(12):2607-2613.$', null, '<p>CAV (COURSES 1, 2, 4, 6)<br><strong>Cyclophosphamide:</strong> 70 mg/kg/day IV over 6 hours, days 1, 2<br><strong>Doxorubicin:</strong> 25 mg/m2/day IV continuous infusion for 72 hours<br><strong>Vincristine: </strong>0.033mg/kg/day continuous infusion for 72 hours<br><strong>Vincristine:</strong> 1.5 mg/m2 IV bolus, day 9<br><br>P/VP (COURSES 3, 5, 7)<br><strong>Etoposide:</strong> 200 mg/m2/d IV over 2 hours, days 1-3<br><strong>Cisplatin:</strong> 50 mg/m2/d IV over 1 hour, days 1-4</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1111, null, 'Pemetrexed + Gemcitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong>&nbsp;<br>No dose reduction</li><li><strong>Pemetrexed</strong>:<br>No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong>&nbsp;<br>No dose reduction</li><li><strong>Pemetrexed</strong>:<br>If CrCl &gt; 45 mL/min, no dose reduction<br>If CrCl &lt; 45 mL/min, do not use</li></ul>', 'Low', null, null, null, '<p><strong>Pemetrexed:</strong> 500 mg/m2 IV on day 8<br><strong>Gemcitabine:</strong> 1,250 mg/m2 IV on days 1 and 8.</p><p><br>Repeat cycle every 21 days.</p><p>Folic acid at 350 -1,000 μg &nbsp;PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 μg IM to start 1-2 weeks prior to the first dose of therapy and repeated every 3 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1112, null, 'Vinorelbine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vinorelbine:</strong><br>If bilirubin 2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vinorelbine:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Vinorelbine:</strong> 30 mg/m2 IV weekly<br>One cycle consists of 6 weekly injections. Continue until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (848, null, 'CD', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:</strong> 80 mg/m2 IV continuous infusion over 24 hours (&gt;1 year of age) <strong>OR</strong> 3 mg/kg (&lt;1 year of age) IV over 6 hours with post-hydration fluid<br><br><strong>Doxorubicin:</strong> 30 mg/m2/day IV continuous infusion over 48 hours, days 2, 3</p><p><br>Administer 4 cycles before surgery, 2 cycles after surgery</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1113, null, 'Gemcitabine ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Gemcitabine: </strong>1,250 mg/m2 IV on days 1, 8, and 15.</p><p>Repeat cycle every 28 days up to a total of 10 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1114, null, 'Pembrolizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (total bilirubin &lt;1 to 1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (total bilirubin &gt;1.5 times ULN): Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Pembrolizumab:</strong> 10 mg/kg IV on day 1<br>Repeat cycle every 2 weeks</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (852, null, 'CHOP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Cyclophosphamide:</strong> 750 mg/m2/day IV, days 1, 22<br><strong>Doxorubicin:</strong> 40 mg/m2/day IV, days 1, 22<br><strong>Vincristine:</strong> 1.5 mg/m2 IV weekly for 6 doses<br><strong>Prednisone:</strong> 40 mg/m2/day PO for 28 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (853, null, 'SNCCL/B-ALL', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL: 75% of usual dosage.&nbsp;<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL: 50% of usual dosage.<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL: Do not use</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 5 mg/dL: Do not use</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 3 mg/dL: 50% of usual dosage.</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL: 50% of usual dosage.<br>If bilirubin 3.1-5 mg/dL: 25% of usual dosage.<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min: 75% of usual dosage.<br>If CrCl &lt; 10 mL/min: 50% of usual dosage.</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min: 50% of normal dosage.<br>If CrCl &lt; 30 mL/min: Do not use</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><h3>&nbsp;</h3>', 'High', null, null, null, '<p>INITIAL PHASE<br><strong>Cytarabine:</strong> 50 mg/m2/day (maximum, 50 mg/d) IT, days 1, 2, 3, 11<br><strong>Methotrexate:</strong> 12 mg/m2/day (maximum, 12 mg/d) IT, days 4, 11<br><strong>Cyclophosphamide:</strong> 300 mg/m2 IV push every 12 hours for 6 doses, days 1-3<br><strong>Doxorubicin:</strong> 50 mg/m2 IV, day 4<br><strong>Vincristine:</strong> 1.5 mg/m2/day IV, days 4, 11<br>Alternating with:<br><br>SECONDARY PHASE<br><strong>Cytarabine:</strong> 50 mg/m2 (maximum, 50 mg) IT, day 1<br><strong>Methotrexate:</strong> 12 mg/m2 (maximum, 12 mg) IT, day 1<br><strong>Methotrexate:</strong> 200 mg/m2 IV bolus, then 800 mg/m2 IV continuous infusion<br><strong>Cytarabine:</strong> 3,000 mg/m2 IV over 3 hours every 12 hours for 4 doses, days 2, 3<br><strong>Leucovorin calcium:</strong> 30 mg/m2 IV at hour 42, then 3 mg/m2 IV at hours 54, 66, 78</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (854, null, 'Vincristine + Asparaginase + Dexamethasone + MTX', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Asparaginase:</strong>&nbsp;<br>Use contraindicated in patients with severe hepatic impairment.</li><li><strong>Dexamethasone:</strong>&nbsp;<br>No dose reduction</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Prednisone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Asparaginase:</strong>&nbsp;<br>No dose reduction</li><li><strong>Dexamethasone:</strong>&nbsp;<br>No dose reduction</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Prednisone:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Vincristine:</strong> 1.5 mg/m2 IV, days 0,7, 14, 21<br><strong>Asparaginase:</strong> 6,000 units/m2 IM, 3 times weekly for 9 doses, starting on days 2-4<br><strong>Dexamethasone:</strong> 6 mg/m2/day PO in 3 equal doses (was substituted for prednisone)<br><strong>Methotrexate:</strong> 8, 10, or 12 mg IT, age-adjusted, days 0, 14 (also days 7, 21 for patients with CNS disease at diagnosis)<br><strong>Prednisone:</strong> 40 mg/m2/day PO</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (312, 'Carboplatin : Paraplatin<br>Etoposide : VP-16<br>Ifosfamide : Ifex', 'ICE', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ifosfamide</strong>:<br>No dose reduction</li><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Ifosfamide</strong>:<br>&nbsp;If CrCl ≥10 mL/min: 100% normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose by 25%</li><li><strong>Carboplatin</strong>:<br>Dosing based on&nbsp;<strong>mg/m2</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', '<b>ICE</b>', 'Cairo MS. The use of ifosfamide, carboplatin, and etoposide in children with solid tumors. $Semin Oncol. 1995;22(3 suppl 7):23-27.$', null, '<p><strong>Ifosfamide:</strong> 1,800 mg/m2/day IV over 1 hour, days 1 to 5<br><strong>Carboplatin:</strong> 400 mg/m2/day IV over 1 hour, days 1 and 2<br><strong>Etoposide: </strong>100 mg/m2/day IV over 1 hour, days 1 to 5</p><p><strong>Filgrastim:</strong> 5 to 10 mcg/kg/day SC, days 6 to 18 if ANC ≥1,000/mm3 or until post nadir ANC ≥1,000/mm3</p><p>Repeat cycle every 21 days for up to 12 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (314, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Vincristine : Oncovin, VCR', 'P6', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Ifosfamide:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Ifosfamide</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥10 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose by 25%</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'High', '<b>P6</b>', 'Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing''s family of tumors in children and young adults. $J Clin Oncol. 2003;21(18):3423-3430.$', null, '<p>CYCLES 1, 2, 3 AND 6<br><strong>Cyclophosphamide:</strong> 2,100 mg/m2/day IV, days 1, 2<br><strong>Doxorubicin:</strong> 25 mg/m2 IV continuous infusion, days 1-3<br><strong>Vincristine:</strong> 0.67 mg/m2 (maximum, 2 mg/cycle) continuous infusion, days 1-3<br><br>CYCLES 4, 5 AND 7<br><strong>Ifosfamide:</strong> 1,800 mg/m2/day IV, days 1-5<br><strong>Etoposide:</strong> 100 mg/m2/day IV, days 1-5</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (856, null, 'Doxorubicin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Doxorubicin</strong>:<br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Doxorubicin:</strong> 60 mg/m2 IV on day 1<br>Repeat cycle every 21 days.<br>&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (863, null, 'Bortezomib + Dexamethasone + Rituximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin&nbsp;1-1.5 times upper normal limit: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin&nbsp;&gt;1.5 times upper normal limit: Reduce the initial dose to 0.7 mg/m2. &nbsp; &nbsp;</li><li><strong>Dexamethasone:</strong><br>No dose reduction &nbsp; &nbsp; &nbsp;&nbsp;</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Bortezomib:</strong> 1.3 mg/m2 IV on days 1, 4, 8, and 11<br><strong>Dexamethasone:</strong> 40 mg IV on days 1, 4, 8, and 11<br><strong>Rituximab:</strong> 375 mg/m2 IV on day 11<br>Repeat for 4 cycles as induction therapy followed by a 12-week break and then 4<br>additional cycles, each given 12 weeks apart.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (869, null, 'CAP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide</strong>:<br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cisplatin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li></ul>', 'High', null, null, null, '<p><strong>Cyclophosphamide: </strong>500 mg/m2 IV on day 1<br><strong>Doxorubicin:</strong> 50 mg/m2 IV on day 1<br><strong>Cisplatin: </strong>80 mg/m2 IV on day&nbsp;1<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (870, null, 'Gemcitabine + Cisplatin', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Renal Impairment:&nbsp;</strong> &nbsp; &nbsp;</li><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li></ul>', 'High', null, null, null, '<p><strong>Gemcitabine:</strong> 1,000 mg/m2 IV on days 1, 8, and 15<br><strong>Cisplatin:</strong> 100 mg/m2 IV on day 1</p><p>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (934, null, 'CNOP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Mitoxantrone:</strong><br>If bilirubin &gt; 3 mg/dL, reduce dose by 25%</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Mitoxantrone:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Cyclophosphamide:</strong> 750 mg/m2 IV on day 1<br><strong>Mitoxantrone: </strong>10 mg/m2 IV on day 1<br><strong>Vincristine:</strong> 1.4 mg/m2 IV on day 1 (maximum, 2 mg)<br><strong>Prednisone:</strong> 100 mg PO on days 1-5<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (935, null, 'EPOCH', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Etoposide:</strong> 50 mg/m2/day CIVI, days 1-4 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Prednisone:</strong> 60 mg/m2 PO, days 1-5<br><strong>Vincristine:</strong> 0.4 mg/m2/day CIVI, days 1-4<br><strong>Cyclophosphamide:</strong> 750 mg/m2 IV on day 5, begin after the infusion &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Doxorubicin:</strong> 10 mg/m2/day CIVI, days 1-4 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Trimethoprim/sulfamethoxazole (Bactrim DS)</strong>: 1 tablet PO bid, 3 times per week<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (868, null, 'Doxorubicin + Cisplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Doxorubicin: </strong>60 mg/m2 IV on day 1<br><strong>Cisplatin:</strong> 60 mg/m2 IV on day 1<br>Repeat cycle every 21-28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (936, null, 'EPOCH + R', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Rituximab:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Rituximab:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Etoposide:</strong> 50 mg/m2/day CIVI, days 1-4 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Prednisone:</strong> 60 mg/m2 PO, days 1-5<br><strong>Vincristine:</strong> 0.4 mg/m2/day CIVI, days 1-4<br><strong>Cyclophosphamide:</strong> 750 mg/m2 IV on day 5, begin after the infusion &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Doxorubicin:</strong> 10 mg/m2/day CIVI, days 1-4 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Rituximab:</strong> 375 mg/m2 IV, day 1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Trimethoprim/sulfamethoxazole (Bactrim DS)</strong>: 1 tablet PO bid, 3 times per week<br>Repeat cycle every 21 days. Rituximab to be administered first followed by infusions of etoposide, doxorubicin, and vincristine.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (946, null, 'Axicabtagene ciloceucel (Yescarta)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL: Reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Fludarabine:</strong><br>No dose reduction</li><li><strong>Axicabtagene ciloceucel:</strong><br>Dosage adjustments have not been studied yet.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-29 mL/min: Reduce dose by 25%<br>If CrCl &lt; 10 mL/min: Reduce dose by 50%</li><li><strong>Fludarabine:</strong><br>If CrCl 10-50 mL/min: Reduce dose by 25%&nbsp;<br>If CrCl &lt;10 mL/min: Reduce dose by 50%</li><li><strong>Axicabtagene ciloceucel:</strong><br>Dosage adjustments have not been studied yet.</li></ul>', 'Moderate', null, null, null, '<p><strong>Cyclophosphamide:</strong> 500 mg/m2 IV on days -5, -4, and -3<br><strong>Fludarabine:</strong> 30 mg/m2 IV on days -5, -4, and -3<br><strong>Axicabtagene ciloceucel:</strong> 2 x10^6 CAR-positive T cells/kg body weight IV on day 1</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (949, null, 'Stanford Regimen (Small noncleaved cell and Burkitt''s lymphoma)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'High', null, null, null, '<p><strong>Cyclophosphamide:</strong> 1,200 mg/m2 IV on day 1<br><strong>Doxorubicin:</strong> 40 mg/m2 IV on day 1<br><strong>Vincristine: </strong>1.4 mg/m2 IV on day 1 (maximum of 2 mg)<br><strong>Prednisone:</strong> 40 mg/m2 PO on days 1-5<br><strong>Methotrexate: </strong>3 g/m2 IV over 6 hours on day 10</p><p><strong>Leucovorin rescue: </strong>25 mg/m2 IV or PO every 6 hours for 12 doses, beginning 24 hours after methotrexate&nbsp;<br><strong>Intrathecal methotrexate:</strong> 12 mg IT on days 1 and 10<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (950, null, 'Hyper-CVAD/MTX-Ara-C', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Cyclophosphamide:</strong> 300 mg/m2 over 3 hours every 12 hours for 6 doses , days 1-3 &nbsp; &nbsp; &nbsp;&nbsp;<strong> Mesna:</strong> 600 mg/m2/day continuous infusion on days 1 to 3 to start 1 hour before cyclophosphamide until 12 hours after completion of cyclophosphamide.<br><strong>Doxorubicin:</strong> 50 mg/m2 over 24 hours on day 4.<br><strong>Vincristine:</strong> 2 mg IV on days 4 and 11<br><strong>Dexamethasone:</strong> 40 mg IV or PO on days 1-4 and 11-14<br>Administer every 3 to 4 weeks on cycles 1, 3, 5, and 7.<br><strong>Methotrexate:</strong> 200 mg/m2 IV over 2 hours followed by 800 mg/m2 IV continuous infusion over 22 hours on day1<br><strong>Cytarabine: </strong>3,000 mg/m2 IV over 2 hours every 12 hours for 4 doses, days 2-3 (dose reduced to 1,000 mg/m2 in patients &gt;60 years or with serum creatinine &gt;1.5 mg/dL)<br><strong>Leucovorin calcium:</strong> 50 mg IV every 6 hours starting 12 hours after completion of methotrexate until methotrexate level &lt;50nM.<br>Administer every 3 to 4 weeks on cycles 2, 4, 6, and 8.</p><p><strong>Intrathecal Chemotherapy Prophylaxis</strong><br><strong>Methotrexate:</strong> 12 mg IT on day 2 of each cycle for a total of 3-4 treatments<br><strong>Cytarabine: </strong>100 mg IT on day 8 of each cycle for a total of 3-4 treatments<br><strong>Intrathecal Chemotherapy:</strong> Administer intrathecal chemotherapy twice a week with methotrexate 12 mg and cytarabine 100 mg, respectively, until no more cancer cells in CSF, then decrease intrathecal chemotherapy to once a week for 4 weeks, followed<br>by methotrexate 12 mg on day 2 and cytarabine 100 mg on day 8 for the remaining chemotherapy cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (872, null, 'Pemetrexed + Cisplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Pemetrexed</strong>:<br>No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Pemetrexed</strong>:<br>If CrCl &gt; 45 mL/min, no dose reduction<br>If CrCl &lt; 45 mL/min, do not use</li></ul>', 'High', null, null, null, '<p><strong>Pemetrexed:</strong> 500 mg/m2 IV on day 1<br><strong>Cisplatin:</strong> 75 mg/m2 IV on day 1</p><p><br>Repeat cycle every 21 days.</p><p>Folic acid at 350 -1,000 μg &nbsp;PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 μg IM to start 1-2 weeks prior to the first dose of therapy and repeated every 3 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (873, null, 'Pemetrexed', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pemetrexed</strong>:<br>No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Pemetrexed</strong>:<br>If CrCl &gt; 45 mL/min, no dose reduction<br>If CrCl &lt; 45 mL/min, do not use</li></ul>', 'Low', null, null, null, '<p><strong>Pemetrexed:</strong> 500 mg/m2 IV on day 1<br><br>Repeat cycle every 21 days.</p><p>&nbsp;Folic acid at 350-1,000 μg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 &nbsp;μg&nbsp; IM to start 1-2 weeks prior to the first dose of therapy and repeated every 3 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (876, null, 'Cisplatin + Etoposide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:</strong> 45 mg/m2/day IV continuous infusion on days 2 and 3<br><strong>Etoposide: </strong>130 mg/m2/day IV continuous infusion on days 1-3<br>Repeat cycle every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (874, null, '5-Fluorouracil + Streptozocin (Advanced Islet-Cell Carcinoma)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li><li><strong>Streptozocin:</strong>&nbsp;<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction</li><li><strong>Streptozocin:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &gt;50 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 10-50 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;10 mL/min: Avoid Streptozosin.</li></ul>', 'High', null, null, null, '<p><strong>5-Fluorouracil:</strong> 400 mg/m2/day IV on days 1-5<br><strong>Streptozocin: </strong>500 mg/m2/day IV on days 1-5</p><p>Repeat cycle every 6 weeks</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (875, null, 'Doxorubicin + Streptozocin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Streptozocin:</strong>&nbsp;<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Doxorubicin</strong>:<br>No dose reduction</li><li><strong>Streptozocin:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &gt;50 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 10-50 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;10 mL/min: Avoid Streptozosin.</li></ul>', 'High', null, null, null, '<p><strong>Doxorubicin: </strong>50 mg/m2 IV on days 1 and 22<br><strong>Streptozocin:</strong> 500 mg/m2/day IV on days 1-5</p><p>Repeat cycle every 6 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (877, null, 'Everolimus + Octreotide LAR', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Everolimus:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (Child-Pugh class A): Reduce dose to 7.5 mg once daily &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (Child-Pugh class B): Reduce dose to 5 mg once daily &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (Child-Pugh class C): Reduce dose to 2.5 mg once daily</li><li><strong>Octreotide LAR:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If patients has established liver cirrhosis: Initiate dose at 10 mg IM every 4 weeks then titrate based upon response.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Everolimus:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Octreotide LAR:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild to moderate impairment: No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment requiring dialysis: Initiate dose at 10 mg IM every 4 weeks then titrate based upon response (clearance is reduced by 50%).</li></ul>', 'Low', null, null, null, '<p><strong>Everolimus:</strong> 10 mg PO daily<br><strong>Octreotide LAR: </strong>30 mg IM on day 1</p><p>Repeat cycle every 28 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (884, null, 'Bevacizumab + Interferon alpha-2a', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Interferon alfa-2a</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Interferon alfa-2a</strong>:<br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Bevacizumab:</strong> 10 mg/kg IV every 2 weeks<br><strong>Interferon alpha-2a:</strong> 9 million units SC, 3 times per week, for 1year<br>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (885, null, 'Interferon-alpha + IL-2', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Interferon alfa-2a</strong>:<br>No dose reduction</li><li><strong>Interleukin-2: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dosage adjustments not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Interferon alfa-2a</strong>:<br>No dose reduction</li><li><strong>Interleukin-2: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If serum creatinine ≤1.5 mg/dL: Dosage adjustments not provided by the manufacturer. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If serum creatinine &gt;1.5 mg/dL: Do not initiate treatment.</li></ul>', 'Low', null, null, null, '<p><strong>Interferon alpha-2a:</strong> 9 million units SC on days 1-4, weeks 1-4<br><strong>Interleukin-2:</strong> 12 million units SC on days 1-4, weeks 1-4</p><p>Repeat cycle every 6 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (886, null, 'Lenvatinib + Everolimus', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Everolimus:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (Child-Pugh class A): Reduce initial dose by ~33%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (Child-Pugh class B): &nbsp;Reduce initial dose by ~50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (Child-Pugh class C): Reduce initial dose by ~50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ( Further dosing should be individualized based on therapeutic drug monitoring - target trough concentration: 3 to 8 ng/mL) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</li><li><strong>Lenvatinib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (Child-Pugh class A): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (Child-Pugh class B): &nbsp;100% dosage. &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (Child-Pugh class C): Reduce initial dose to&nbsp;10 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Everolimus:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Lenvatinib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Reduce dose to 10 mg once daily.</li></ul>', 'High', null, null, null, '<p><strong>Lenvatinib:</strong> 18 mg/day PO daily<br><strong>Everolimus:</strong> 5 mg/day PO daily<br>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (887, null, 'Nivolumab + Ipilimumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ipilimumab:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ipilimumab:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Ipilimumab: </strong>1 mg/kg IV on day 1<br><strong>Nivolumab:</strong> 3 mg/kg IV on day 1<br>Repeat cycle every 21 days for 4 cycles followed by<br><strong>Nivolumab:</strong> 240 mg IV on day 1<br>Repeat cycle every 14 days until disease progression. May also consider administering<br>480 mg IV on day 1 with cycles repeated every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (938, null, 'm-BACOD', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Dexamethasone:</strong>&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li><li><strong>Bleomycin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Dexamethasone:</strong>&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Bleomycin</strong><br>If CrCl &gt;50 mL/min: No dose reduction<br>If CrCl 40-50 mL/min: 70% of normal dose<br>If CrCl 30-40 mL/min: 60% of normal dose<br>If CrCl 20-30 mL/min: 55% normal dose<br>If CrCl 10-20 mL/min: 45% normal dose<br>If CrCl 5-10 mL/min: 40% normal dose</li></ul>', 'High', null, null, null, '<p><strong>Methotrexate: </strong>200 mg/m2 IV on days 8 and 15<br><strong>Leucovorin: </strong>10 mg/m2 PO every 6 hours for 8 doses, beginning 24 hours after methotrexate<br><strong>Bleomycin: </strong>4 U/m2 IV on day 1<br><strong>Doxorubicin:</strong> 45 mg/m2 IV on day 1<br><strong>Cyclophosphamide:</strong> 600 mg/m2 IV on day 1<br><strong>Vincristine: </strong>1 mg/m2 IV on day 1 (maximum, 2 mg)<br><strong>Dexamethasone:</strong> 6 mg/m2 PO on days 1-5<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (888, null, 'Bevacizumab + Everolimus', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Everolimus:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (Child-Pugh class A): Reduce initial dose by ~33%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (Child-Pugh class B): &nbsp;Reduce initial dose by ~50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (Child-Pugh class C): Reduce initial dose by ~50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ( Further dosing should be individualized based on therapeutic drug monitoring - target trough concentration: 3 to 8 ng/mL)</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Everolimus:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Bevacizumab: </strong>10 mg/kg IV on day 1<br><strong>Everolimus:</strong> 10 mg/day PO daily</p><p>Repeat cycle every 14 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (939, null, 'ProMACE/CytaBOM', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Bleomycin</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 40%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 45 mL/minute: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Bleomycin</strong><br>If CrCl &gt;50 mL/min: No dose reduction<br>If CrCl 40-50 mL/min: 70% of normal dose<br>If CrCl 30-40 mL/min: 60% of normal dose<br>If CrCl 20-30 mL/min: 55% normal dose<br>If CrCl 10-20 mL/min: 45% normal dose<br>If CrCl 5-10 mL/min: 40% normal dose</li></ul>', 'High', null, null, null, '<p><strong>Prednisone:</strong> 60 mg/m2 PO on days 1-14<br><strong>Doxorubicin:</strong> 25 mg/m2 IV on day 1<br><strong>Cyclophosphamide:</strong> 650 mg/m2 IV on day 1<br><strong>Etoposide: </strong>120 mg/m2 IV on day 1<br><strong>Cytarabine:</strong> 300 mg/m2 IV on day 8<br><strong>Bleomycin:</strong> 5 U/m2 IV on day 8<br><strong>Vincristine:</strong> 1.4 mg/m2 IV on day 8<br><strong>Methotrexate:</strong> 120 mg/m2 IV on day 8<br><strong>Leucovorin rescue:</strong> 25 mg/m2 PO every 6 hours for 6 doses, beginning 24 hours after methotrexate<br><strong>Trimethoprim/sulfamethoxazole: </strong>1 tablet PO bid on days 1-21<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (944, null, 'MINE', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Ifosfamide:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Mitoxantrone:</strong><br>If bilirubin &gt; 3 mg/dL, reduce dose by 25%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Ifosfamide</strong>:<br>&nbsp;If CrCl ≥10 mL/min: 100% normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: 75% normal dose.</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Mitoxantrone:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Mesna:</strong> 1,330 mg/m2 IV administered at same time as ifosfamide on days 1-3, then<br>500 mg IV 4 hours after ifosfamide on days 1-3<br><strong>Ifosfamide:</strong> 1,330 mg/m2 IV on days 1-3<br><strong>Mitoxantrone:</strong> 8 mg/m2 IV on day 1<br><strong>Etoposide:</strong> 65 mg/m2 IV on days 1-3<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1115, null, 'Nivolumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nivolumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nivolumab:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Nivolumab: </strong>3 mg/kg IV on day 1<br>Repeat cycle every 2 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (889, null, 'Pembrolizumab + Axitinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Axitinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If mild impairment (Child-Pugh class A): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (Child-Pugh class B): Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C):&nbsp;<strong> </strong>Dosage adjustments not provided by the manufacturer.</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Axitinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> If<strong> </strong>CrCl 15 to &lt;89 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;15 mL/min:&nbsp;<strong> </strong>Dosage adjustments not provided by the manufacturer.</li></ul>', 'Low', null, null, null, '<p><strong>Pembrolizumab:</strong> 200 mg IV on day 1<br><strong>Axitinib:</strong> 5 mg PO BID</p><p>Repeat cycle every 3 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (940, null, 'ESHAP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Methylprednisolone:</strong>&nbsp;<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Cisplatin:</strong><br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Methylprednisolone:</strong>&nbsp;<br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Etoposide:</strong> 40 mg/m2 IV, days 1-4<br><strong>Methylprednisolone:</strong> 500 mg IV, days 1-4<br><strong>Cisplatin:</strong> 25 mg/m2/day IV continuous infusion, days 1-4<br><strong>Cytarabine:</strong> 2,000 mg/m2 IV over 2 hours on day 5, immediately following completion of cisplatin and etoposide.<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (941, null, 'DHAP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Dexamethasone:</strong><br>No dose reduction</li><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Dexamethasone:</strong><br>No dose reduction</li><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:</strong> 100 mg/m2 IV continuous infusion over 24 hours, day 1<br><strong>Cytarabine:</strong> 2,000 mg/m2 IV over 3 hours every 12 hours for 2 doses on day 2 after completion of cisplatin infusion. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Dexamethasone:</strong> 40 mg/day PO or IV on days 1-4<br>Repeat cycle every 21-28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (942, null, 'ICE', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ifosfamide:</strong><br>No dose reduction</li><li><strong>Carboplatin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ifosfamide</strong>:<br>&nbsp;If CrCl ≥10 mL/min: 100% normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: 75% normal dose.</li><li><strong>Carboplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% dosage.</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Ifosfamide:</strong> 5,000 mg/m2 IV continuous infusion over 24 hours on day 2<br><strong>Etoposide:</strong> 100 mg/m2 IV on days 1-3</p><p><strong>Carboplatin:</strong> AUC of 5 (maximum 800 mg) IV on day 2<br><strong>Mesna:</strong> 5,000 mg/m2 IV in combination with ifosfamide dose.<br>Repeat every 14 days. G-CSF support is administered at 5 μg/kg/day on days 5-12.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (943, null, 'RICE', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Rituximab:</strong><br>No dose reduction</li><li><strong>Carboplatin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Ifosfamide:</strong><br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Rituximab:</strong><br>No dose reduction</li><li><strong>Carboplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% dosage.</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Ifosfamide</strong>:<br>&nbsp;If CrCl ≥10 mL/min: 100% normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: 75% normal dose.</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Rituximab:</strong> 375 mg/m2 IV on day 1<br><strong>Ifosfamide:</strong> 5,000 mg/m2 IV continuous infusions for 24 hours, day 4<br><strong>Carboplatin:</strong> AUC of 5 (maximum 800 mg) IV, day 4<br><strong>Etoposide:</strong> 100 mg/m2 IV, days 3-5</p><p><strong>Mesna:</strong> 5,000 mg/m2 IV in combination with ifosfamide dose.<br>Repeat every 14 days.&nbsp;<br>Repeat cycle every 14 days. Rituximab is also given at 48 hours before the<br>start of the first cycle. G-CSF is administered at 5 μg/kg/day SC on days 7-14 after<br>the first 2 cycles and at 10 μg/kg/day SC after the third cycle.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (954, null, 'Ibritumomab Tiuxetan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ibritumomab tiuxetan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustments not provided by the manufacturer</li><li><strong>Rituximab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ibritumomab tiuxetan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustments not provided by the manufacturer</li><li><strong>Rituximab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Rituximab:</strong> 250 mg/m2 IV on days 1 and 8<br><strong>111 In-Ibritumomab tiuxetan:</strong> 5 mCi of 111 In, 1.6 mg of ibritumomab tiuxetan IV on day 1<br><strong>90 Y-Ibritumomab tiuxetan: </strong>0.4 mCi/kg IV over 10 min on day 8 after the day 8 rituximab dose<br>The dose of 90 Y-ibritumomab tiuxetan is capped at 32 mCi.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (955, null, 'Fludarabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Fludarabine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Fludarabine:</strong><br>If CrCl 10-50 mL/min: Reduce dose by 25%&nbsp;<br>If CrCl &lt;10 mL/min: Reduce dose by 50%</li></ul>', 'Low', null, null, null, '<p><strong>Fludarabine:</strong> 25 mg/m2 IV on days 1-5<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (956, null, 'Cladribine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cladribine: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> Dosage adjustments not provided by the manufacturer&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong></li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cladribine:</strong><br>If CrCl 10-50 mL/min: Dose reduction by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;10 mL/min: Dose reduction by 50%</li></ul>', 'Low', null, null, null, '<p><strong>Cladribine:</strong> 0.5-0.7 mg/kg SC on days 1-5 or 0.1 mg/kg IV on days 1-7<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (957, null, 'Bendamustine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin&nbsp;1.5-3 upper normal limit, or bilirubin &gt; 3 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bendamustine:</strong><br>If CrCl &lt; 40 mL/min, do not use</li></ul>', 'Moderate', null, null, null, '<p><strong>Bendamustine:</strong> 120 mg/m2 IV days 1 and 2<br>Repeat every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (958, null, 'Pralatrexate', '<p>d</p>', 'Low', null, null, null, '<p><strong>Pralatrexate: </strong>30 mg/m2 IV weekly for 6 weeks<br>Repeat cycle every 7 weeks. Folic acid at 1-1.25 mg PO q day beginning<br>10 days prior to therapy and vitamin B12 at 1 mg IM beginning no more than 10<br>weeks prior to the first dose of therapy and should be repeated every 8-10 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (959, null, 'Brentuximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Brentuximab:</strong><br>If Child-Pugh A: Reduce dose to 1.2 mg/kg every 3 weeks.<br>If Child-Pugh B or C: Avoid use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Brentuximab:</strong><br>If CrCl ≥30 mL/min, no dose reduction &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/minute: Avoid use.</li></ul>', 'Low', null, null, null, '<p><strong>Brentuximab:</strong> 1.8 mg/kg IV on day 1<br>Repeat cycle every 3 weeks for up to 16 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (636, '', 'Capecitabine + Mitomycin-C + Radiation Therapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Mitomycin-C: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Mitomycin-C: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;10 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: 75% dosage</li></ul>', 'Low', '', '', '', '<p><strong>Capecitabine:&nbsp;</strong>825 mg/m<sup>2</sup>&nbsp;PO twice daily on Monday-Friday</p>

<p><strong>Mitomycin-C:&nbsp;</strong>10 mg/m<sup>2</sup>&nbsp;IV on days 1 and 29</p>

<p><strong>Radiation Therapy:&nbsp;</strong>Total dose, 5,500 cGy over 6 weeks</p>

<p>Chemotherapy is given concurrently with radiation therapy.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (964, null, 'MPV', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Procarbazine:</strong><br>If AST, ALT are 1.6 to 6 times ULN: 75% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If AST, ALT are &nbsp;&gt;6 times ULN: Use clinical judgment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin &gt;5 mg/dL or AST, ALT &gt;3 times ULN: Avoid use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Procarbazine:</strong><br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'High', null, null, null, '<p><strong>Methotrexate:</strong> 3,500 mg/m2 IV over 2 hours every other week for 5 doses</p><p><strong>Intrathecal methotrexate: </strong>12 mg IT weekly every other week after IV methotrexate<br><strong>Leucovorin: </strong>10 mg IV every 6 hours for 12 doses starting 24 hours after IV methotrexate; 10 mg IV every 12 hours for 8 doses starting 24 hours after IT methotrexate<br><strong>Vincristine:</strong> 1.4 mg/m2 IV every other week along with IV methotrexate<br><strong>Procarbazine:</strong> 100 mg/m2/day PO for 7 days on first, third, and fifth cycle of IV methotrexate.<br>Once chemotherapy is completed, whole-brain radiation therapy is administered<br>to a total dose of 45 cGy.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (965, null, 'R-MPV+ Radiation Therapy + Cytarabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Procarbazine:</strong><br>If AST, ALT are 1.6 to 6 times ULN: 75% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If AST, ALT are &nbsp;&gt;6 times ULN: Use clinical judgment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin &gt;5 mg/dL or AST, ALT &gt;3 times ULN: Avoid use.</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Procarbazine:</strong><br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 40%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 45 mL/minute: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Consider use of alternative drug.</li></ul>', 'High', null, null, null, '<p><strong>Rituximab:</strong> 500 mg/m2 on day 1<br><strong>Methotrexate: </strong>3,500 mg/m2 IV on day 2<br><strong>Leucovorin: </strong>20-25 mg every 6 hours starting 24 hours after methotrexate infusion<br>for 72 hours or until serum methotrexate level, 1 x 10^-8 mg/dL.<br>Increase leucovorn to 40 mg every 4 hours IV, if methotrexate level &gt; 1 x 10^-8 mg/dL<br>at 48 hours or &gt;1 x 10^-8 mg/dL at 72 hours<br><strong>Vincristine:</strong> 1.4 mg/m2 (maximum, 2.8 mg) IV on day 2<br><strong>Procarbazine:</strong> 100 mg/m2 PO on days 1-7 of odd-numbered cycles only<br>If positive CSF cytology, administer 12 mg methotrexate IT between days 5 and 12<br>of each cycle<br>Repeat every 2 weeks for a total of 5 cycles.<br>After 5 cycles of R-MPV:<br>If CR, whole-brain radiotherapy (WBRT) 180 cGy/day for 13 days to a total of<br>2340 cGy beginning 3-5 weeks after the completion of R-MPV.<br>IF PR, administer 2 additional cycles of R-MPV. If CR is achieved after 7 cycles of<br>R-MPV, administer WBRT 180 cGy/day x 13 days to a total of 2,340 cGy beginning<br>3-5 weeks after the completion of R-MPV.<br>If persistent disease exists even after 7 cycles of R-MPV, administer WBRT<br>180 cGy/day x 25 days to a total of 4,500 cGy beginning 3-5 weeks after the<br>completion of R-MPV.<br>If stable or progressive disease after 5 cycles of R-MPV, then administer WBRT<br>180 cGy/day for 25 days to a total of 4,500 cGy beginning 3-5 weeks after the completion of R-MPV. Three weeks after the completion of WBRT, consolidation therapy is given with:&nbsp;</p><p>&nbsp;<strong>Cytarabine:</strong> 3 g/m2/day (maximum, 6 g) IV over 3 hours for 2 days.<br>The second cycle of cytarabine is given 1 month later.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (966, null, 'High-Dose Methotrexate', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'Moderate', null, null, null, '<p><strong>Methotrexate:</strong> 8,000 mg/m2 IV on day 1<br>Repeat cycle every 2 weeks up to 8 cycles, followed by 8,000 mg/m2 IV on day 1 every month up to 100 months.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (967, null, 'Temozolomide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Temozolomide:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If mild to moderate impairment (Child-Pugh classes A and B): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): There are no dosage adjustments provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Temozolomide:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥36 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;36 mL/min: There are no dosage adjustments provided by the manufacturer</li></ul>', 'Moderate', null, null, null, '<p><strong>Temozolomide:</strong> 150 mg/m2/day PO on days 1-5<br>Repeat cycle every 4 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (968, null, 'Topotecan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Topotecan</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Topotecan</strong>:<br>If CrCl &gt; 40 mL/min, no dose reduction<br>If CrCl 20-39 mL/min, reduce to 0.75 mg/m2/dose</li></ul>', 'Low', null, null, null, '<p><strong>Topotecan:</strong> 1.5 mg/m2 IV on days 1-5<br>Repeat cycle every 3 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (724, '', 'Pembrolizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Pembrolizumab:&nbsp;</strong>200 mg IV on day 1</p><p>Repeat cycle every 3 weeks. Consider this therapy only in the setting of MSI/dMMR tumors.</p>', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (638, '', 'XELOX + Radiation Therapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: &nbsp;Reduce dose by 25%</li></ul>', 'Moderate', '', '', '', '<p><strong>Capecitabine:&nbsp;</strong>825 mg/m<sup>2</sup>&nbsp;PO twice daily on Monday-Friday for 6 weeks</p>

<p><strong>Oxaliplatin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, 22, 29</p>

<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day, 5 days/week for a total of 6 weeks</p>

<p>Chemotherapy is given concurrently with radiation therapy.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (721, '', 'Capecitabine + Oxaliplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Oxaliplatin:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Capecitabine</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Reduce dose by 25%</li><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'Moderate', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (379, 'Gemcitabine (Gemzar), CIsplatin (Platinum) ', 'Gemcitabine and Cisplatin (split dosing)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul>', 'High', '', 'Dash A, Pettus JA 4th, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008 Nov 1;113(9):2471-7.', 'NEOADJUVANT', '<h4><strong>Cisplatin (Platinol):</strong>&nbsp;35 mg/m2&nbsp;IV once per day on days 1 and <strong>Gemcitabine (Gemzar):</strong>&nbsp;2,500 mg/m2&nbsp;IV on day 1.</h4><p>Repeat cycle every 14 days for 6 cycles.</p>', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (383, 'Gemcitabine (Gemzar), Paclitaxel (Taxol)', 'Gemcitabine and Paclitaxel (14 day cycle)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>No dose reduction</li></ul>', 'Moderate', '', 'Calabrò F, Lorusso V, Rosati G, Manzione L, Frassineti L, Sava T, Di Paula ED, Alonso S, Sternberg CN. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer. 2009 Jun 15;115(12):2652-9', 'METASTATIC', '<h4>&nbsp;</h4><p><strong>Paclitaxel (Taxol): </strong>150 mg/m2&nbsp;IV over 3 hours once on day 1,&nbsp;given first.</p><p><strong>Gemcitabine (Gemzar):&nbsp;</strong>2,500 mg/m2&nbsp;IV over 30 minutes once on day 1,&nbsp;given second.</p><p>&nbsp;</p><p>Repeat cycle every 14 days.</p>', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (384, 'Gemcitabine (Gemzar), Paclitaxel (Taxol)', 'Gemcitabine and Paclitaxel (21 day cycle)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>No dose reduction</li></ul>', 'Moderate', '', 'Meluch AA, Greco FA, Burris HA 3rd, O''Rourke T, Ortega G, Steis RG, Morrissey LH, Johnson V, Hainsworth JD. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001 Jun 15;19(12):3018-24.', 'METASTATIC', '<h4>&nbsp;</h4><p><strong>Gemcitabine (Gemzar): </strong>1,000 mg/m2&nbsp;IV once per day on days 1, 8, 15.</p><p><strong>Paclitaxel (Taxol):</strong>&nbsp;200 mg/m2&nbsp;IV over 3 hours once on day 1.</p><p>Repeat cycle every 21-days.</p>', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (829, null, 'Pembrolizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (total bilirubin &lt;1 to 1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (total bilirubin &gt;1.5 times ULN): Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Pembrolizumab:&nbsp;</strong>200 mg&nbsp;IV on day 1.</p><p>Repeat cycles every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1116, null, 'Avelumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Avelumab:</strong><br>Dose modification not provided by the manufacturer</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Avelumab:</strong><br>Dose modification not provided by the manufacturer</li></ul>', 'Low', null, null, null, '<p><strong>Avelumab:</strong> 10 mg/kg IV on day 1.</p><p>Repeat cycle every 2 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (295, 'Pomalidamide : Pomalyst', 'Pomalidomide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pomalidomide:</strong><br>Avoid POMALYST in patients with serum bilirubin greater than 2.0 mg/dL and AST/ALT greater than 3.0 x ULN.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pomalidomide:</strong><br>Avoid Pomalidamide in patients with serum creatinine greater than 3.0 mg/dL.</li></ul>', 'Low', '<b>Pomalidamide</b>', 'Leleu X, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.$Blood. 2013 Mar 14;121(11):1968-75. doi: 10.1182/blood-2012-09-452375. Epub 2013 Jan 14$', null, '<p><strong>Pomalidomide: </strong>4 mg PO daily on days 1-21&nbsp;<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (289, 'Dexamethasone : various<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR', 'VAD', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'Moderate', '<b>VAD</b>', 'Segeren CM, Sonneveld P, Holt V, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. $Br J Haematol. 1999;105(1):127-130.$', null, '<p><strong>Vincristine:</strong> 0.4 mg/day IV continuous infusion, days 1-4<br><strong>Doxorubicin:</strong> 9 mg/m2/day IV continuous infusion, days 1-4<br><strong>Dexamethasone:</strong> 40 mg/day PO, days 1-4, 9-12, 17-20<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (562, 'Carboplatin: Paraplatin<br>Paclitaxel: Taxol', 'Carboplatin/Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose.</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li></ul>', 'High', '', 'Ozols RF. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Semin Oncol. 1995;22(6 Suppl 15):1-6. --- Pignata S, Breda E, et al. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol. 2008;66(3):229-36.', '', '<p><strong>Carboplatin:</strong>&nbsp;AUC of 6-7.5, IV on day 1<br><strong>Paclitaxel:</strong>&nbsp;175 mg/m2&nbsp;IV over 3 hours on day 1</p><p>Repeat cycle every 21 days.</p><p>OR</p><p><strong>Carboplatin:</strong>&nbsp;AUC of 2, IV on days 1, 8, and 15<br><strong>Paclitaxel:</strong>&nbsp;60 mg/m2&nbsp;IV on days 1, 8, and 15</p><p>Repeat cycle every 28 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (388, 'Durvalumab (Imfinzi)', 'Durvalumab Monotherapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Durvalumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Durvalumab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction</li></ul>', 'Low', '', 'Study 1108: Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O''Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016 Sep 10;34(26):3119-25. Epub 2016 Jun 6.', 'METASTATIC', '<h4>&nbsp;</h4><p>&nbsp; <strong>Durvalumab: </strong>10 mg/kg IV over 60 minutes once on day 1</p><p>Repeat cycle every 14 days for up to 26 cycles (1 year). Patients could receive another 12 months of treatment if they experienced disease progression, had not received other anticancer treatment and did not meet the criteria for discontinuation.</p>', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (393, 'Enfortumab vedotin (Padcev) ', 'Enfortumab vedotin monotherapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Enfortumab vedotin (Padcev):</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Enfortumab vedotin (Padcev):</strong><br>No dose reduction</li></ul>', 'Moderate', '', 'Rosenberg JE, O''Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019 Oct 10;37(29): 2592-2600. Epub 2019 Jul 29. ', 'METASTATIC', '<h4>&nbsp;</h4><p><strong>Enfortumab vedotin (Padcev):</strong>&nbsp;1.25 mg/kg (maximum dose of 125 mg) IV over 30 minutes once per day on days 1, 8, 15</p><p>Repeat cycle every 28 days.</p>', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (969, null, 'Gemcitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Gemcitabine:</strong> 1,200 mg/m2 IV on days 1,8, and 15.<br>Repeat cycle every 28 days.<br>&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (970, null, 'Pemetrexed', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pemetrexed</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pemetrexed</strong>:<br>If CrCl &gt; 45 mL/min, no dose reduction<br>If CrCl &lt; 45 mL/min, do not use</li></ul>', 'Low', null, null, null, '<p><strong>Pemetrexed: </strong>500 mg/m2 IV on day 1<br>Repeat cycle every 21 days. Folic acid at 350-1,000 ug PO daily beginning<br>1-2 weeks prior to therapy and vitamin B12 at 1,000 ug IM to start 1-2 weeks prior<br>to the first dose of therapy and repeated every 3 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (972, null, 'CMV', '<p><strong>Hepatic Impairment</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><ul><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Vinblastine:</strong><br>If serum bilirubin 1.5 to 3 mg/dL or transaminases 2 to 3 times ULN: Administer 50% of dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If serum bilirubin &gt;3 times ULN: Avoid use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Vinblastine:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:</strong> 100 mg/m2 IV on day 2 (give 12 hours after methotrexate)<br><strong>Methotrexate:</strong> 30 mg/m2 IV on days 1 and 8<br><strong>Vinblastine:</strong> 4 mg/m2 V on days 1 and 8<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (973, null, 'MCV', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use.</li><li><strong>Vinblastine:</strong><br>If serum bilirubin 1.5 to 3 mg/dL or transaminases 2 to 3 times ULN: Administer 50% of dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If serum bilirubin &gt;3 times ULN: Avoid use.</li><li><strong>Carboplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Vinblastine:</strong><br>No dose reduction</li><li><strong>Carboplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% dosage.</li></ul>', 'High', null, null, null, '<p><strong>Methotrexate: </strong>30 mg/m2 IV on days 1, 15, and 22<br><strong>Carboplatin:</strong> AUC of 4.5, IV on day 1<br><strong>Vinblastine:</strong> 3 mg/m2 IV on days 1, 15, and 22<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (403, 'Cyclophosphamide: Cytoxan<br>Docetaxel: Taxotere<br>Doxorubicin: Adriamycin, various', 'AC/Docetaxel (q3weekly)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt;5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Sparano JA, Zhao F, et al. 2014 San Antonio Breast Cancer Symposium Abstracts S3-03.', 'ADJUVANT', '<p><strong>Doxorubicin:</strong> 60 mg/m2 IV on day 1<br><strong>Cyclophosphamide:&nbsp;</strong> 600 mg/m2 IV on day 1</p><p>Repeat every 21 days for 4 cycles, followed by<br><br><strong>Docetaxel:</strong> 100 mg/m2 IV on day 1</p><p>Repeat every 21 days for 4 cycles.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (974, null, 'Docetaxel + Cisplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li></ul>', 'High', null, null, null, '<p><strong>Docetaxel: </strong>75 mg/m2 IV on day 1<br><strong>Cisplatin:</strong> 75 mg/m2 IV on day 1<br>Repeat cycle every 21 days up to 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (975, null, 'Paclitaxel + Carboplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Carboplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel</strong>:<br>No dose reduction</li><li><strong>Carboplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% dosage.</li></ul>', 'High', null, null, null, '<p><strong>Paclitaxel:</strong> 225 mg/m2 IV over 3 hours on day 1<br><strong>Carboplatin:</strong> AUC of 6, IV on day 1, given 15 minutes after paclitaxel<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (976, null, 'CAP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Cyclophosphamide</strong>:<br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Cyclophosphamide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Cyclophosphamide:</strong> 400 mg/m2 IV on day 1<br><strong>Doxorubicin:</strong> 40 mg/m2 IV on day 1<br><strong>Cisplatin: </strong>75 mg/m2 IV on day 2<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (977, null, '5-Fluorouracil + Mitomycin-C + Radiation Therapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use.</li><li><strong>Mitomycin-C: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Mitomycin-C:&nbsp;</strong><br>&nbsp;If CrCl &lt;10 mL/min: 75% of usual dose.</li></ul>', 'Low', null, null, null, '<p><strong>5-Fluorouracil:</strong> 500 mg/m2/day IV continuous infusion on days 1-5 and 16-20 of radiotherapy<br><strong>Mitomycin-C:</strong> 12 mg/m2 IV on day 1<br><strong>Radiation therapy:</strong> 275 cGy/day, 5 days/week for a total of 4 weeks (total dose, 5,500 cGy) or 200 cGy/day for 6.5 weeks (total dose, 6,400 cGy)<br>Chemotherapy is given concurrently with radiation therapy.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (793, null, 'Carmustine- Adjuvant.', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carmustine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carmustine: &nbsp;&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &gt; 60 mL/min: 100 % dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 46-60 mL/min: 80% dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31-45 mL/min: 75% dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Use another drug.</li></ul>', 'High', null, null, null, '<p><strong>Carmustine:</strong> 220 mg/m2 IV &nbsp;on day 1.<br>Repeat every 6-8 weeks for 1 year.</p><p><strong>OR</strong></p><p><strong>Carmustine:</strong> 75-100 mg/m2 IV &nbsp;on days 1 and 2.<br>Repeat every 6-8 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (4, 'Carmustine : BCNU', 'BCNU (Carmustine)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carmustine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carmustine: &nbsp;&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &gt; 60 mL/min: 100 % dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 46-60 mL/min: 80% dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31-45 mL/min: 75% dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Use another drug.</li></ul>', 'High', '<b>BCNU (Carmustine)</b>', 'Selker RG, Sharipo WR, Burger p, et al. The Brain tumor cooperative group NIH Trial 87-01: a randomized comparision of surgery, external radiotherapy, and carmustine versus surgery, interstital radiotherapy, and carmustine. $Neurosurgery.2002;51(2):343-355; discussion 355-357.$', null, '<p><strong>Carmustine:</strong> 200 mg/m2 IV over 30-60 minutes on day 1.<br>Repeat cycle every 8 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1, 'Bevacizumab : Avastin', 'Bevacizumab + Irinotecan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Irinotecan:</strong><br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>If bilurubin &gt; 2 mg/dL, may not use</li><li><strong>Bevacizumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Irinotecan:</strong><br>No dose reduction</li><li><strong>Bevacizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Moderate', '<b>Bevacizumab/Irinotecan</b>', 'Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. $J Clin Oncol. 2007;25(30):4722-4279.$', null, '<p><strong>Irinotecan:</strong> 125 mg/m2 IV on day 1.</p><p><strong>Bevacizumab:</strong> 10 mg/kg IV on day 1.<br>Repeat cycle every 2 weeks for 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (796, null, 'Temozolomide +Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bevacizumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Temozolomide:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bevacizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Temozolomide:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Moderate', null, null, null, '<p><strong>Temozolomide:&nbsp;</strong>150<strong> </strong>mg/m2&nbsp;PO on days 1-5.</p><p><strong>Bevacizumab:</strong> 10 mg/kg IV on days 1 and 14.</p><p>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (413, 'Cyclophosphamide: Cytoxan<br>Docetaxel: Taxotere<br>Doxorubicin: Adriamycin, various', 'AC + Docetaxel (dose-dense)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt;5 mg/dL, do not use</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
</ul>
', 'High', '', 'Puhalla S, Mrozek E, et al. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol. 2008;26(10):1691-7.', 'ADJUVANT', '<p><strong>Doxorubicin:</strong>&nbsp;60 mg/m2&nbsp;IV on day1<br><strong>Cyclophosphamide:</strong>&nbsp;600 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 14 days for 4 cycles, followed by</p><p><strong>Docetaxel:</strong>&nbsp;75 mg/m2&nbsp;IV on day 1</p><p>Repeat every 14 days for a total of 4 cycles. Administer pegfilgrastim 6 mg SC on day 2 of each treatment cycle.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1117, null, 'CAV', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Cyclophosphamide:</strong> 1,000 mg/m2 IV on day 1<br><strong>Doxorubicin:</strong> 40 mg/m2 IV on day 1<br><strong>Vincristine:</strong> 1mg/m2 IV on day 1 (maximum, 2 mg)<br>Repeat cycle every 21 days&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (670, 'Temodar', 'Temozolamide + RT (Glioblastoma)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Temozolomide:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Temozolomide:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Moderate', '', '', 'ADJUVANT', '<p><strong>Radiation therapy:</strong> 200 cGy/day for 5 days per week for 6 weeks.</p><p><strong>Temozolomide: </strong>75 mg/m2 PO daily for 6 weeks with radiation therapy. After a 4 weeks break, 150 mg/m2 PO on days 1-5.</p><p>Repeat temozolomide monotherapy every 28 days for 6 cycles. If the patient tolerated well can increase the dose to 200 mg/m2 on subsequent cycles.</p><p><strong>Supportive medications</strong></p><ul><li>PCP prophylaxis with one of the following:<ul><li>Trimethoprim/sulfamethoxazole</li><li>Pentamidine 300 mg nebulized inhaled</li></ul></li><li>Metoclopramide( Reglan) or 5 HT-3 antagonist recommended before the initial doses of radiation therapy &amp; temozolomide</li></ul><h4>&nbsp;</h4>', 1);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (400, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin', 'AC', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Fisher B, Brown AM, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8(9):1483-96.', 'ADJUVANT', '<p><strong>Doxorubicin</strong>: 60 mg/m2&nbsp;IV on day 1<br><strong>Cyclophosphamide</strong>: 600 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days for 4 cycles.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (114, 'Cyclophosphamide: Cytoxan<br>Docetaxel: Taxotere<br>Doxorubicin: Adriamycin, various', 'AC/Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li></ul>', 'High', '<b>AC/Docetaxel</b>', 'Swain SM, Jeong JH, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053-2065.', null, '<p><strong>Doxorubicin:</strong> 60 mg/m2 IV, day 1<br><strong>Cyclophosphamide:</strong> 600 mg/m2 IV, day 1<br>Repeat every 21 days for 4 cycles, followed by<br><strong>Docetaxel:</strong> 100 mg/m2 IV, day 1<br>Repeat every 21 days for 4 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (402, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin, various<br>Paclitaxel: Taxol', 'AC/Paclitaxel (weekly) ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide</strong>:<br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>No dose reduction</li></ul>', 'High', '', 'Sparano JA, Wang M, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663-71.', 'ADJUVANT', '<p><strong>Doxorubicin</strong>: 60 mg/m2&nbsp;IV on day 1<br><strong>Cyclophosphamide</strong>: 600 mg/m2&nbsp;IV on day 1</p><p>Repeat every 21 days for 4 cycles, followed by</p><p><strong>Paclitaxel</strong>: 80 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 7&nbsp;days for 12&nbsp;cycles.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1017, null, 'Dabrafenib + Trametinib', '<p>d</p>', 'd', null, null, null, '<p><strong>Dabrafenib: </strong>150 mg PO bid<br><strong>Trametinib: </strong>2 mg PO daily<br>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1014, null, 'Ipilimumab (Adjuvant)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ipilimumab:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ipilimumab:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Ipilimumab: </strong>10 mg/kg IV on day 1<br>Repeat cycle every 3 weeks for 4 doses followed by 10 mg/kg on day 1 every 12<br>weeks for up to 3 years.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (116, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol', 'AC  T (dose-dense)               ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>No dose reduction</li></ul>', 'High   ', '<b>AC  T (dose-dense)</b>               ', 'Citron ML, berry DA, Cirrincione C,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combinational chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer : first report of intergroup trial C9741/cancer and leukemia Group B trial 9741. $J Clin Oncol. 2003;21(8): 1431-1439$', null, '<p><strong>Doxorubicin</strong>: 60 mg/m2 IV, day 1<br><strong>Cyclophosphamide:</strong> 600 mg/m2 IV, day 1<br>Repeat every 21 days for 4 cycles<br><strong>Filgrastim</strong> (prophylactic) given on days 3-10 of each cycle<br><strong>OR</strong> <strong>PEG-Filgastrim</strong> 6 mg SQ on day 2</p><p><strong>FOLLOWED BY</strong></p><p><strong>Paclitaxel :</strong> 175 mg/m2 IV over 3 hours every 14 days for 4 cycles<br><strong>Filgrastim</strong> (prophylactic) given on days 3-10 of each cycle &nbsp; OR &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>PEG-Filgastrim</strong> 6 mg SQ on day 2.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (438, 'Doxorubicin: Adriamycin, various<br>Paclitaxel: Taxol', 'AT', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Sledge GW, Neuberg D, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21(4):588-92.', 'METASTATIC', '<p><strong>Doxorubicin:&nbsp;</strong>50 mg/m2&nbsp;IV on day 1<br><strong>Paclitaxel:</strong>&nbsp;150 mg/m2&nbsp;IV over 24 hours on day 1</p><p>Repeat cycle every 21 days.<br>&nbsp;</p><p><strong>OR</strong></p><p><br><strong>Doxorubicin:</strong>&nbsp;60mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days up to a maximum of 8 cycles, followed by</p><p><strong>Paclitaxel:</strong>&nbsp;175 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days until disease progression.</p><p><br><strong>OR</strong></p><p><br><strong>Paclitaxel:</strong>&nbsp;175 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days until disease progression, followed by</p><p><strong>Doxorubicin:</strong>&nbsp;60 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days up to a maximum of 8 cycles.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (120, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol', 'A - T - C (dose-dense)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>No dose reduction</li></ul>', 'High', '<b>A - T - C (dose-dense)</b>', 'Citron ML, Berry DA, Cirrincione C,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer : first report of intergroup trial C9741/cancer and leukemia Groüp B Trial 9741. $J Clin Oncol. 2003;21(8):1431-1439$', null, '<p><strong>Doxorubicin:</strong> 60 mg/m2 IV on day 1. Repeat every 14 days for 4 cycles, followed by<br><strong>Paclitaxel:</strong> 175 mg/m2 IV on day 1. Repeat every 14 days for 4 cycles, followed by<br><strong>Cyclophosphamide:</strong> 600 mg/m2 IV on day 1. Repeat every 14 days for 4 cycles.<br><strong>Filgrastim</strong> (prophylactic): 5 µg/kg SC given on days 3-10 of each cycle.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (407, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin, various<br>Fluorouracil: 5-FU', 'CAF', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Budman DR, Berry DA, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205-11.', 'ADJUVANT', '<p><strong>Cyclophosphamide:</strong>&nbsp;600 mg/m2&nbsp;IV on day 1<br><strong>Doxorubicin:</strong>&nbsp;60 mg/m2 IV on day 1<br><strong>5-Fluorouracil:</strong>&nbsp;600 mg/m2 IV on day 1</p><p>Repeat every 28 days for a total of 4 cycles.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (122, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Fluorouracil : 5-FU', 'CAF(oral)', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'High', '<b>CAF(oral)</b>', 'Hutchins LF, Green SJ, Favolin PM, et al. Randomized controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high risk, node-negative breast cancer:treatment results of Intergroup Protocol INT-0102. $J Clin Oncol. 2005;23(33):8313-8321.$', null, '<p><strong>Cyclophosphamide:</strong> 100 mg/m2 PO, days 1-14<br><strong>Doxorubicin:</strong> 30 mg/m2 IV ,days 1, and 8<br><strong>Fluorouracil:</strong> 500 mg/m2 IV, days 1, and 8<br>Repeat every 28 days for 6 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (452, 'Carboplatin: Paraplatin<br>Docetaxel: Taxotere', 'Carboplatin/Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Docetaxel</strong>:<br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on AUC &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% dosage.</li><li><strong>Docetaxel</strong>:<br>No dose reduction</li></ul>', 'High', '', 'Fitch V, et al. Proc Am Soc Clin Oncol 2003;22:23 (abstract 90).', 'METASTATIC', '<p><strong>Carboplatin:</strong>&nbsp;AUC of 6, IV on day 1<br><strong>Docetaxel:</strong>&nbsp;75 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (440, 'Cyclophosphamide: Cytoxan<br>Epirubicin: Ellence, various<br>5-Fluorouracil: 5-FU', 'CEF', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
	<li><strong>Epirubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />
	If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
	<li><strong>Epirubicin</strong><br />
	If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
</ul>
', 'High', '', 'Levine MN, Bramwell VH, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16(8):2651-8.', 'METASTATIC', '<p><strong>Cyclophosphamide:</strong>&nbsp;75 mg/m2&nbsp;PO on days 1-14<br><strong>Epirubicin:</strong>&nbsp;60 mg/m2&nbsp;IV on days 1 and 8<br><strong>5-Fluorouracil:</strong>&nbsp;500 mg/m2&nbsp;IV on days 1 and 8</p><p>Repeat cycle every 28 days.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (140, 'Docetaxel : Taxotere', 'Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel:</strong><br>No dose reduction</li></ul>', 'Low', '<b>Docetaxel</b>', 'Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. $J Clin Oncol. 1999;17(8):2341-2354.$<br> Nabholtz JM, Senn Hj, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. $J Clin Oncol. 1999;17(5):1413-1424.$<br> Taxotere [package insert]. $New York, NY: Sanofi-Aventis; 2010.$', null, '<p><strong>Docetaxel:</strong> 100 mg/m2 IV over 1 hour on day 1.<br>Repeat every 21 days. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>OR</strong><br><strong>Docetaxel: </strong>35-40 mg/m 2 IV weekly for 6 weeks &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Repeat every 8 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (409, 'Cyclophosphamide: Cytoxan<br>Epirubicin: Ellence, various<br>5-Fluorouracil: 5-FU', 'FEC-100', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
	<li><strong>Epirubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />
	If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
	<li><strong>Epirubicin</strong><br />
	If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
</ul>
', 'High', '', 'Levine MN, Bramwell VH, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16(8):2651-8.', 'ADJUVANT', '<p><strong>5-Fluorouracil:</strong> 500 mg/m2 IV on day 1<br><strong>Epirubicin:</strong> 100 mg/m2 IV on&nbsp;day 1<br><strong>Cyclophosphamide:</strong> 500 mg/m2 IV on day 1</p><p>Repeat every 21 days.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (988, null, 'Clofarabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Clofarabine:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Clofarabine:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &gt;60 mL/min: 100 % dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 30 to 60 mL/min: 50% of the usual dose</li></ul>', 'Moderate', null, null, null, '<p><strong>Clofarabine: </strong>40 mg/m2 IV on days 1-5</p><p>Repeat cycle every 3-6 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (414, 'Cyclophosphamide: Cytoxan<br>Docetaxel: Taxotere<br>Doxorubicin: Adriamycin, various', 'Docetaxel/AC (dose-dense)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt;5 mg/dL, do not use</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
</ul>
', 'High', '', 'Puhalla S, Mrozek E, et al. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol. 2008;26(10):1691-7.', 'ADJUVANT', '<p><strong>Docetaxel:</strong>&nbsp;75 mg/m2&nbsp;IV on day 1</p><p>Repeat every 14 days for 4 cycles, followed by</p><p><strong>Doxorubicin:</strong>&nbsp;60 mg/m2&nbsp;IV on day 1<br><strong>Cyclophosphamide:</strong>&nbsp;600 mg/m2&nbsp;IV on day 1</p><p>Repeat every 14 days for 4 cycles. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Treatment with pegfilgrastim 6 mg SC on day 2 of each cycle.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (408, 'Epirubicin: Ellence<br>Cyclophosphamide: Cytoxan<br>Methotrexate: MTX<br>5-Fluorouracil: 5-FU', 'Epirubicin/CMF', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Epirubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />
	If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Methotrexate</strong>:<br />
	If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Epirubicin</strong><br />
	If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Methotrexate</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Poole CJ, Earl HM, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355(18):1851-62.', 'ADJUVANT', '<p><strong>Epirubicin:</strong>&nbsp;100 mg/m2&nbsp;IV on day 1</p><p>Repeat every 21 days for 4 cycles, followed by</p><p><strong>Cyclophosphamide:</strong> 600 mg/m2 IV on&nbsp;day 1<br><strong>Methotrexate:</strong> 40 mg/m2 IV on&nbsp;day 1<br><strong>5-Fluorouracil:</strong> 600 mg/m2 IV on&nbsp;day 1</p><p>Repeat every 21 days for 4 cycles.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (141, 'Eribulin : Halaven', 'Eribulin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Eribulin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If<strong> </strong>mild impairment (Child-Pugh class A): Reduce dose to 1.1 mg/m2. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (Child-Pugh class B): Reduce dose to 0.7 mg/m2. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): Do not use.</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Eribulin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If CrCl ≥50 mL/min: 100 % dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 15 to 49 mL/min: Reduce dose to 1.1 mg/m2. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;15 mL/min: Do not use.</li></ul>', 'Low', '<b>Eribulin</b>', 'Cortes J, O''Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician''s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. $Lancet. 2011;377(9769):914-923.$', null, '<p><strong>Eribulin:</strong> 1.4 mg/m2 IV over 2-5 minutes, days 1 and 8<br>Repeat cycle every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (410, 'Cyclophosphamide: Cytoxan<br>Epirubicin: Ellence, various<br>5-Fluorouracil: 5-FU<br>Docetaxel: Taxotere', 'FEC/Docetaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
	<li><strong>Epirubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />
	If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
	<li><strong>Epirubicin</strong><br />
	If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'High ', '', 'Roche H, Fumoleau P, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24(36):5664-71.', 'ADJUVANT', '<p><strong>5-Fluorouracil:</strong> 500 mg/m2 IV on day 1<br><strong>Epirubicin:</strong> 100 mg/m2 IV on&nbsp;day 1<br><strong>Cyclophosphamide:</strong> 500 mg/m2 IV on day 1</p><p>Repeat every 21 days for 6&nbsp;cycles, followed by</p><p><strong>Docetaxel:</strong>&nbsp;100 mg/m2&nbsp;IV on day 1</p><p>Repeat every 21 days for 3 cycles.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (132, 'Cyclophosphamide : Cytoxan<br>Docetaxel : Taxotere', 'TC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Docetaxel:</strong><br>No dose reduction</li></ul>', 'High', '<b>TC</b>', 'Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. $J Clin Oncol. 2006:24(34):5381-5387.$', null, '<p><strong>Docetaxel:</strong> 75 mg/m2 IV over 30-60 minutes, day 1<br><strong>Cyclophosphamide:</strong> 600 mg/m2 IV over 30-60 minutes, day 1<br>Repeat every 21 days for 4 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (449, 'Cyclophosphamide: Cytoxan<br>Epirubicin: Ellence, various<br>5-Fluorouracil: 5-FU', 'FEC-50', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
	<li><strong>Epirubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />
	If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
	<li><strong>Epirubicin</strong><br />
	If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
</ul>
', 'High', '', 'A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. J Clin Oncol. 1991;9(2):305-12.', 'METASTATIC', '<p><strong>5-Fluorouracil:</strong> 500 mg/m2 IV on day 1<br><strong>Epirubicin:</strong> 50 mg/m2 IV on&nbsp;day 1<br><strong>Cyclophosphamide:</strong> 500 mg/m2 IV on day 1</p><p>Repeat cycle every 21 days.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (257, 'Cytarabine : Ara-C<br>Idarubicin : Idamycin<br>Mitoxantrone : Novantrone', '7 + 3', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Daunorubicin:</strong><br>If bilurubin 1.5-3 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Idarubicin:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 25%<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Mitoxantrone:</strong><br>If bilirubin &gt; 3 mg/dL, reduce dose by 25%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Daunorubicin:</strong><br>If Cr &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Idarubicin:</strong><br>If CrCl &lt; 10 mL/min, reduce dose by 25%</li><li><strong>Mitoxantrone:</strong><br>No dose reduction</li></ul>', 'Moderate', '<b>7 + 3</b>', 'Presler H, Davis RB, Kirshener J, et al. Comparison of three remission induction regimens and two post-induction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. $Blood. 1987;69(5):1441-1449.$<br> Wiernik PH, BAnks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated patients with acute myeloid leukemia. $Blood. 1992;79(2):313-319.$<br> Wahlin A, Hornsten P, Hedenus M, Malm C. Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia. $Cancer Chemother Pharmacol. 1991;28(6):480-483.$', null, '<p><strong>Cytarabine:</strong> 100 mg/m2/day IV continuous infusion on days 1-7<br><strong>Daunorubicin:</strong> 45 mg/m2 IV on days 1-3<br><strong>OR</strong><br><strong>Idarubicin:</strong> 13 mg/m2/day IV, days 1-3<br><strong>OR</strong><br><strong>Mitoxantrone:</strong> 12 mg/m2/day &nbsp;IV, days 1-3</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (258, 'Cytarabine : Ara-C', '7 + 3 with hi-dose Daunorubicin (<60 years)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Daunorubicin:</strong><br>If bilurubin 1.5-3 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Daunorubicin:</strong><br>If Cr &gt; 3 mg/dL, reduce dose by 50%</li></ul>', 'Moderate', '<b>7 + 3 with hi-dose daunorubicin <br>(<60 years)</b>', 'Fernandez HF, Sun Z, Pao X, et al. Anthracycline dose intensification in acute myeloid leukemia. $N Engl J Med. 2009;361(13):1249-1259.$', null, '<p><strong>Cytarabine:</strong> 100 mg/m2/day CIVI, days 1-7<br><strong>Daunorubicin:</strong> 90 mg/m2/day IV, days 1-3</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (672, '', 'Ivosidenib (AML IDH1 mutated) ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ivosidenib:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ivosidenib:</strong><br>No dose reduction</li></ul>', 'Low', '', '', 'FIRST LINE ', '<h4><strong>Ivosidenib:</strong> 500 mg PO once per day</h4><p>Continue for at least 6 months ( to allow time for clinical response) and then until disease progression or unacceptable toxicity occurs.</p>', 33);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (294, 'Carfilzomib : Kyprolis', 'Carfilzomib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carfilzomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If total&nbsp;bilirubin&nbsp;1-3 times upper normal limit: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If total bilirubin&nbsp;&gt;3 times upper normal limit: No dosage recommendation. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carfilzomib:</strong><br>No dose reduction.</li></ul>', 'Low', '<b>Carfilzomib</b>', 'Siegel DS, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.$Blood. 2012 Oct 4;120(14):2817-25. doi: 10.1182/blood-2012-05-425934. Epub 2012 Jul 25$', null, '<p><strong>Carfilzomib:</strong> 20 mg/m2 IV on days 1,2,8,9,15, and 16. After cycle 1, increase dose to 27 mg/m2 IV.<br>&nbsp;</p><p>Repeat cycle every 28 days for up to 12 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1020, null, 'Nivolumab + Ipilimumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ipilimumab:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Dose modification not provided by the manufacturer</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ipilimumab:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Dose modification not provided by the manufacturer</li></ul>', 'Low', null, null, null, '<p><strong>Ipilimumab:</strong> 1 mg/kg IV on day 1<br><strong>Nivolumab:</strong> 1 mg/kg IV on day 1<br>Repeat cycle every 21 days for 4 cycles followed by<br><strong>Nivolumab:</strong> 240 mg IV on day 1<br>Repeat cycle every 14 days until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1018, null, 'Cobimetinib + Vemurafenib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cobimetinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Vemurafenib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild to moderate impairment (Child-Pugh classes A and B): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (Child-Pugh class C): Dose modification not provided by the manufacturer</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cobimetinib:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Dose modification not provided by the manufacturer</li><li><strong>Vemurafenib:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If mild to moderate impairment (preexisting): 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If Severe impairment (preexisting): Dose modification not provided by the manufacturer.</li></ul>', 'Low', null, null, null, '<p><strong>Cobimetinib: </strong>60 mg/day PO on days 1-21<br><strong>Vemurafenib: </strong>960 mg PO bid daily<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (255, 'Idarubicin : Idamycin', 'ATRA/Idarubicin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>All-trans-retinoic acid: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dose reduction not provided by the manufacturer because of insufficient data</li><li><strong>Idarubicin:</strong>&nbsp;<br>If bilirubin 2.6-5 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>All-trans-retinoic acid: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dose reduction not provided by the manufacturer because of insufficient data</li><li><strong>Idarubicin:</strong><br>If CrCl &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 10 to 50 mL/minute: reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: &nbsp;reduce dose by 50%</li></ul>', 'Moderate', '<b>ATRA/Idarubicin</b>', 'Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcomeon the LPA99 multicenter study by the PETHEMA Group. $Blood. 2008;112(8):3130-3134.$', null, '<p><strong>All-trans-retinoic acid</strong> (ATRA): 45 mg/m2 PO, daily.<br><strong>Idarubicin:</strong> 12 mg/m2 IV, on days 2, 4, 6, and 8.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (981, null, 'FLAG', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Fludarabine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 40%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Fludarabine:</strong><br>If CrCl 10-50 mL/min: Reduce dose by 25%&nbsp;<br>If CrCl &lt;10 mL/min: Reduce dose by 50%</li></ul>', 'Low', null, null, null, '<p><strong>Fludarabine:</strong> 30 mg/m2 IV on days 1-5<br><strong>Cytarabine:</strong> 2,000 mg/m2/day IV over 4 hours on days 1-5 starting 3.5 hours after<br>fludarabine<br><strong>G-CSF: </strong>5 µg/kg/day SC starting 24 hours before chemotherapy.<br>An additional cycle may be given in the setting of a partial response.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (982, null, 'Ara-C + Daunorubicin (5 + 2)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Daunorubicin:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Daunorubicin:</strong><br>If Cr &gt; 3 mg/dL, reduce dose by 50%</li></ul>', 'Moderate', null, null, null, '<p><strong>Cytarabine:</strong> 100 mg/m2/day IV continuous infusion on days 1-5<br><strong>Daunorubicin:</strong> 45 mg/m2 IV on days 1 and 2</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (983, null, 'Liposomal Daunorubicin and Cytarabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Liposomal Daunorubicin:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Liposomal Daunorubicin:</strong><br>If Cr &gt; 3 mg/dL, reduce dose by 50%</li></ul>', 'Low', null, null, null, '<p><strong>Liposomal Daunorubicin and Cytarabine:</strong> 29 mg/m2 daunorubicin and 65 mg/m2<br>cytarabine on days 1 and 3</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (822, null, ' Ara-C+ Idarubicin (Induction Regimen)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Idarubicin:</strong>&nbsp;<br>If bilirubin 2.6-5 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Idarubicin:</strong>&nbsp;<br>If CrCl &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 10 to 50 mL/minute: reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: &nbsp;reduce dose by 50%</li></ul>', 'Moderate', null, null, null, '<p><strong>Cytarabine:</strong> 100 mg/m2/day IV continuous infusion on days 1-7<br><strong>Idarubicin:</strong> 12 mg/m2 IV on days 1-3.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (978, null, 'Tretinoin + Daunorubicin + Cytarabine (Acute promyelocytic leukemia)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>All-trans-retinoic acid: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dose reduction not provided by the manufacturer because of insufficient data</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Daunorubicin:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>All-trans-retinoic acid: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dose reduction not provided by the manufacturer because of insufficient data</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Daunorubicin:</strong><br>If Cr &gt; 3 mg/dL, reduce dose by 50%</li></ul>', 'Moderate', null, null, null, '<p><strong>ATRA:</strong> 45 mg/m2 PO daily<br><strong>Daunorubicin:</strong> 60 mg/m2 IV on days 1-3<br><strong>Cytarabine:</strong> 200 mg/m2 IV on days 1-7</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (979, null, 'Tretinoin + Arsenic trioxide (Acute promyelocytic leukemia)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Arsenic trioxide:</strong>&nbsp;<br>No dose reduction</li><li><strong>All-trans-retinoic acid: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dose reduction not provided by the manufacturer because of insufficient data</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Arsenic trioxide:</strong>&nbsp;<br>If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Use with caution, may require dosage reduction (monitor closely for toxicity)</li><li><strong>All-trans-retinoic acid: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dose reduction not provided by the manufacturer because of insufficient data</li></ul>', 'Low', null, null, null, '<p><strong>ATRA:</strong> 45 mg/m2 PO daily<br><strong>Arsenic trioxide:</strong> 0.15 mg/kg/day IV starting on day 10<br>Continue treatment until CR. Once in CR, patients should receive the following:<br><strong>ATRA:</strong> 45 mg/m2 PO daily on weeks 1-2, 5-6, 9-10, 13-14, 17-18, 21-22, and 25-26<br><strong>Arsenic trioxide:</strong> 0.15 mg/kg/day IV on Monday-Friday on weeks 1-4, 9-12, 17-20, and 25-28<br>Therapy should be terminated 28 weeks after the CR date.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (980, null, 'Mitoxantrone + Etoposide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Mitoxantrone:</strong><br>If bilirubin &gt; 3 mg/dL, reduce dose by 25%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Mitoxantrone:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Mitoxantrone: </strong>10 mg/m2/day IV on days 1-5<br><strong>Etoposide:</strong> 100 mg/m2/day IV on days 1-5</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (984, null, 'Ara-C + Idarubicin (Consolidation Regimen)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Idarubicin:</strong>&nbsp;<br>If bilirubin 2.6-5 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Idarubicin:</strong>&nbsp;<br>If CrCl &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 10 to 50 mL/minute: reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: &nbsp;reduce dose by 50%</li></ul>', 'Moderate', null, null, null, '<p><strong>Cytarabine:</strong> 100 mg/m2 IV continuous infusion on days 1-5<br><strong>Idarubicin:</strong> 13 mg/m2 IV on days 1 and 2<br>Repeat cycle every 21-28 days.<br>&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (992, null, 'Gilteritinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gilteritinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustment not provided because of insufficient data. &nbsp;&nbsp;<strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong></li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gilteritinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustment not provided because of insufficient data.</li></ul>', 'Low', null, null, null, '<p><strong>Gilteritinib:</strong> 120 mg PO daily<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (985, null, 'Glasdegib + Cytarabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Glasdegib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Glasdegib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong> </strong>eGFR &gt;15 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If<strong> </strong>eGFR &lt;15 mL/min: Dosage adjustment not provided by the manufacturer. &nbsp;</li></ul>', 'Low', null, null, null, '<p><strong>Glasdegib:</strong> 100 mg PO daily<br><strong>Cytarabine:</strong> 20 mg SC BID on days 1-10<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (986, null, 'Venetoclax + Azacytidine (Decitabine)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Azacytidine:</strong><br>If mild impairment (Child-Pugh classes A): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (Child-Pugh class B and C): Dosage adjustment not provided by the manufacturer.</li><li><strong>Venetoclax:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If mild to moderate impairment (Child-Pugh classes A and B): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): Reduce dose by 50%.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Azacytidine:</strong><br>No dose reduction.</li><li><strong>Venetoclax: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If<strong>&nbsp;</strong>CrCl ≥15 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If<strong>&nbsp;</strong>CrCl &lt;15 mL/min: Dosage adjustment not provided by the manufacturer.</li></ul>', 'Moderate', null, null, null, '<p><strong>Venetoclax:</strong> 20 mg, increase up to 400 mg PO daily<br><strong>Azacytidine: </strong>75 mg/m2 IV on days 1-7<br>Repeat cycle every 28 days.<br><strong>OR</strong><br><strong>Venetoclax:</strong> 20 mg,increase up to 400 mg PO daily<br><strong>Decitabine:</strong> 20 mg/m2 IV on days 1-5<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (989, null, 'Sorafenib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Sorafenib:&nbsp;</strong><br>If mild to moderate impairment (Child-Pugh classes A): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class B and C): Dosage adjustment not provided by the manufacturer. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Sorafenib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 40 to 59 mL/min: 400 mg twice daily &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 20 to 39 mL/min: 200 mg twice daily &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;20 mL/min: Inadequate data&nbsp;to define dose.</li></ul>', 'Low', null, null, null, '<p><strong>Sorafenib:</strong> 200-400 mg PO bid<br>Continue until disease progression or stem cell transplant.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (990, null, 'Azacitidine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Azacitidine: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustment not provided because of insufficient data. &nbsp;&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong></li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Azacitidine:</strong><br>No dose reduction.</li></ul>', 'Moderate', null, null, null, '<p><strong>Azacitidine: </strong>75 mg/m2 SC daily for 7 days<br>Repeat the cycle every 28 days for at least 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (991, null, 'Decitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Decitabine: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dosage adjustment not provided because of insufficient data. &nbsp;&nbsp;<strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong></li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Decitabine: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dosage adjustment not provided because of insufficient data.&nbsp;</li></ul>', 'Low', null, null, null, '<p><strong>Decitabine:</strong> 20 mg/m2 IV on days 1-5<br>Repeat cycle every 4 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (221, 'Bleomycin : Blenoxane<br>Dacarbazine : DTIC<br>Doxorubicin : Adriamycin, various<br>Vinblastine : Velban', 'ABVD', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bleomycin:</strong><br>No dose reduction</li><li><strong>Dacarbazine:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vinblastine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bleomycin:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Dacarbazine:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Vinblastine:</strong><br>No dose reduction</li></ul>', 'High', '<b>ABVD</b>', 'Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin''s disease after failure of MOPP: ABVD and B-CAVe. $Ann Intern Med. 1984;  101(4):440-446$.<br> Longo DL, Glastein E, Duffey PL,et al. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgikin''s disease. $J Clin Oncol. 1997; 15(11): 3338-3346$.     ', null, '<p><strong>Doxorubicin:</strong> 25 mg/m2 IV on days 1 and 15<br><strong>Bleomycin:</strong> 10 U/m2 IV on days 1 and 15<br><strong>Vinblastine:</strong> 6 mg/m2 IV on &nbsp;days 1 and 15<br><strong>Dacarbazine:</strong> 375 mg/m2 IV on days 1 and 15<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (993, null, 'A + AVD', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Brentuximab:</strong><br>If mild impairment (Child-Pugh class A): Initial dose 0.9 mg/kg (maximum dose: 90 mg) every 2 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If moderate to severe impairment (Child-Pugh class B or C): Avoid use.</li><li><strong>Dacarbazine:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vinblastine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Brentuximab:</strong><br>If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/minute: Avoid use.</li><li><strong>Dacarbazine:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Vinblastine:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Brentuximab:</strong> 1.2 mg/kg IV on days 1 and 15<br><strong>Doxorubicin: </strong>25 mg/m2 IV on days 1 and 15<br><strong>Vinblastine: </strong>6 mg/m2 IV on days 1 and 15<br><strong>Dacarbazine:</strong> 375 mg/m2 IV on days 1 and 15</p><p>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (994, null, 'MOPP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nitrogen mustard: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Procarbazine:</strong><br>If AST, ALT are 1.6 to 6 times ULN: 75% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If AST, ALT are &nbsp;&gt;6 times ULN: Use clinical judgment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin &gt;5 mg/dL or AST, ALT &gt;3 times ULN: Avoid use.</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nitrogen mustard: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Procarbazine:</strong><br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li></ul>', 'High', null, null, null, '<p><strong>Nitrogen mustard:</strong> 6 mg/m2 IV on days 1 and 8<br><strong>Vincristine:</strong> 1.4 mg/m2 IV on days 1 and 8<br><strong>Procarbazine:</strong> 100 mg/m2 PO on days 1-14<br><strong>Prednisone:</strong> 40 mg/m2 PO on days 1-14<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (290, 'Bortezomib : Velcade<br>Melphalan : Alkeran<br>Prednisone : various', 'BMP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin&nbsp;1-1.5 times upper normal limit: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin&nbsp;&gt;1.5 times upper normal limit: Reduce the initial dose to 0.7 mg/m2.</li><li><strong>Melphalan:</strong><br>No dose reduction</li><li><strong>Prednisone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li><li><strong>Melphalan:</strong><br>&nbsp;If CrCl 10 to 50 mL/min: Reduce dose to 75%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose to 50%.</li><li><strong>Prednisone:</strong><br>No dose reduction</li></ul>', 'Low', '<b>VMP</b>', 'San Miguel JF, Schalg R, Khuageva NK, et al. MMY-3002 a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. $Blood. 2007;110(11 pt 1): Abstract 78.$<br> San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. $N Engl J Med. 2008;359(9):906-917.$', null, '<p><strong>Bortezomib:</strong> 1.3 mg/m2 IV or SC on days 1, 4, 8,11, 22, 25, 29, and 32<br><strong>Melphalan:</strong> 9 mg/m² PO on days 1-4<br><strong>Prednisone: </strong>60 mg/m2 PO on days 1-4<br>Repeat cycle every 6 weeks for 4 cycles, followed by<br><strong>Bortezomib:</strong> 1.3 mg/m2 IV on days 1, 8, 22, and 29<br><strong>Melphalan: </strong>9 mg/m2 PO on days 1-4<br><strong>Prednisone:</strong> 60 mg/m2 PO on days 1-4<br>Repeat cycle every 6 weeks for 5 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1121, null, 'Melphalan/Prednisone/Lenalidomide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Melphalan:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Lenalidomide:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Melphalan:</strong><br>&nbsp;If CrCl 10 to 50 mL/min: Reduce dose to 75%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose to 50%.</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Lenalidomide:</strong><br>If CrCl &gt;60 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 30 to 60 mL/min: 5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min not requiring dialysis: 2.5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min requiring dialysis: 2.5 mg once daily (administer after dialysis on dialysis days).</li></ul>', 'Low', null, null, null, '<p><strong>Melphalan:</strong> 0.18 mg/kg PO, days 1-4<br><strong>Prednisone:</strong> 2 mg/kg PO, days 1-4<br><strong>Lenalidomide: </strong>10 mg/day PO on days 1 to 21</p><p>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (995, null, 'MOPP/ABVD Hybrid', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nitrogen mustard: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Procarbazine:</strong><br>If AST, ALT are 1.6 to 6 times ULN: 75% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If AST, ALT are &nbsp;&gt;6 times ULN: Use clinical judgment &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin &gt;5 mg/dL or AST, ALT &gt;3 times ULN: Avoid use.</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Bleomycin:</strong><br>No dose reduction</li><li><strong>Hydrocortisone:</strong>&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li><li><strong>Vinblastine:</strong><br>If serum bilirubin 1.5 to 3 mg/dL or transaminases 2 to 3 times ULN: Administer 50% of dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If serum bilirubin &gt;3 times ULN: Avoid use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nitrogen mustard: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Procarbazine:</strong><br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Bleomycin:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Hydrocortisone:</strong>&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Dosage adjustment not provided by the manufacturer.</li><li><strong>Vinblastine:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Nitrogen mustard:</strong> 6 mg/m2 IV on days 1 and 8<br><strong>Vincristine:</strong> 1.4 mg/m2 IV on day 1 (maximum dose, 2 mg)<br><strong>Procarbazine:</strong> 100 mg/m2 PO on days 1-14<br><strong>Prednisone:</strong> 40 mg/m2 PO on days 1-14<br><strong>Doxorubicin:</strong> 35 mg/m2 IV on day 8<br><strong>Bleomycin: </strong>10 U/m2 IV on day 8<br><strong>Hydrocortisone:</strong> 100 mg IV given before bleomycin<br><strong>Vinblastine:</strong> 6 mg/m2 IV on day 8<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1118, null, 'Imatinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Imatinib</strong>:<br>&nbsp;If bilirubin &lt; 3 upper normal limit, no dose reduction<br>If bilirubin &gt; 3 upper normal limit, use with caution</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Imatinib</strong>:<br>If CrCl 40 to 59 mL/min: Maximum dose recommended-600 mg. &nbsp; If CrCl 20 to 39 mL/min: Reduce dose by 50%; dose may be increased as tolerated; maximum recommended dose: 400 mg. &nbsp; If CrCl &lt;20 mL/minute: Use caution; 100 mg daily dose has been tolerated in a limited number of patients with severe impairment.</li></ul>', 'High', null, null, null, '<p><strong>Imatinib: </strong>400 mg PO daily<br><br>Continue until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1119, null, 'Antithymocyte globulin (ATG) + Cyclosporine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>ATG:&nbsp;</strong><br>Dose modification not provided by the manufacturer</li><li><strong>Cyclosporine:</strong><br>Dose modification not provided by the manufacturer</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>ATG:&nbsp;</strong><br>Dose modification not provided by the manufacturer</li><li><strong>Cyclosporine:</strong><br>Dose modification not provided by the manufacturer</li></ul>', 'Low', null, null, null, '<p><strong>ATG: </strong>15 mg/kg IV on days 1-5<br><strong>Cyclosporine: </strong>5-6 mg/kg PO bid<br>Adjust cyclosporine dose to maintain blood levels between 100 and 300 ng/mL</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1120, null, 'Cemiplimab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cemiplimab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild to moderate impairment (Child Pugh class A or B): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child Pugh class C): There are no dosage adjustments provided in the manufacturer''s labeling</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cemiplimab:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥21 mL/min: No dosage adjustment necessary. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;21 mL/min: There are no dosage adjustments provided in the manufacturer''s labeling</li></ul>', 'Low', null, null, null, '<p><strong>Cemiplimab: </strong>350 mg once every 3 weeks.</p><p>Continue treatment until disease progression or unacceptable toxicity. Note- Select the patients for treatment based on PD-L1 expression (on ≥50% of tumor cells).</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1122, null, 'Thalidomide + Dexamethasone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Thalidomide:</strong>&nbsp;<br>No dose reduction</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Thalidomide:</strong>&nbsp;<br>No dose reduction</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Thalidomide:</strong> 200 mg/day PO<br><strong>Dexamethasone:</strong> 40 mg/day PO on days 1-4,9-12, and 17-20 for first 4 cycles and then 40 mg/day PO on days 1-4<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1123, null, 'Lenalidomide + Dexamethasone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>No dose reduction.</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>If CrCl &gt;60 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 30 to 60 mL/min: 5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min not requiring dialysis: 2.5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min requiring dialysis: 2.5 mg once daily (administer after dialysis on dialysis days).</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Lenalidomide: </strong>25 mg/day PO on days 1-21<br><strong>Dexamethasone:</strong> 40 mg/day PO on days 1-4,9-12, and 17-20 (first 4 cycles) and then 40 mg/day PO on days 1-4 with future cycles<br>Repeat cycles every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1124, null, 'Panobinostat + Bortezomib + Dexamethasone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin&nbsp;1-1.5 times upper normal limit: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin&nbsp;&gt;1.5 times upper normal limit: Reduce the initial dose to 0.7 mg/m2.</li><li><strong>Panobinostat:</strong><br>If mild impairment (AST &gt; ULN and total bilirubin ≤ ULN <strong>or</strong> total bilirubin &gt;1 to ≤1.5 times ULN and any AST): Reduce initial dose to 15 mg; monitor frequently for adverse events and adjust dose as needed for toxicity. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (total bilirubin &gt;1.5 to ≤3 times ULN and any AST):Reduce initial dose to 10 mg; monitor frequently for adverse events and adjust dose as needed for toxicity. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (total bilirubin &gt;3 times ULN and any AST): Avoid use.</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li><li><strong>Panobinostat:</strong><br>There are no dosage adjustments provided in the manufacturer''s labeling</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Panobinostat:</strong> 20 mg/day PO on days 1,3,5, 8, 10, and 12<br><strong>Bortezomib: </strong>1.3 mg/m2 IV on days 1, 4, 8, and 11<br><strong>Dexamethasone: </strong>20 mg/day PO on days 1, 2, 4, 5, 8,9, 11, and 12<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1000, null, 'GVD', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If AST, ALT elevated (with normal bilirubin): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin &gt;1.6 mg/dL: Reduce initial dose to 800 mg/m2</li><li><strong>Vinorelbine</strong>:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Doxil:</strong><br>If bilirubin ≥1.2 mg/dL: Consider decreasing the dose of the drug.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li><li><strong>Vinorelbine</strong>:<br>No dose reduction</li><li><strong>Doxil:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p>For transplant-naïve patients:<br><strong>Gemcitabine:</strong> 1,000 mg/m2 IV on days 1 and 8<br><strong>Vinorelbine:</strong> 20 mg/m2 IV on days 1 and 8<br><strong>Doxil:</strong> 15 mg/m2 IV on days 1 and 8<br>Repeat cycle every 21 days.<br>&nbsp;</p><p><strong>OR</strong></p><p><br>For post-transplant patients:<br><strong>Gemcitabine:</strong> 800 mg/m2 IV on days 1 and 8<br><strong>Vinorelbine:</strong> 15 mg/m2 IV on days 1 and 8<br><strong>Doxil:</strong> 10 mg/m2 IV on days 1 and 8<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1001, null, 'Gemcitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If AST, ALT elevated (with normal bilirubin): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin &gt;1.6 mg/dL: Reduce initial dose to 800 mg/m2</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Gemcitabine:</strong> 1,250 mg/m2 IV on days 1,8, and 15<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1002, null, 'Rituximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Rituximab:</strong><br>Dose modification not provided by the manufacturer</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Rituximab:</strong><br>Dose modification not provided by the manufacturer</li></ul>', 'Low', null, null, null, '<p><strong>Rituximab:</strong> 375 mg/m2 IV on day 1<br>Repeat weekly for 4 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1003, null, 'Brentuximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Brentuximab:</strong><br>If mild impairment (Child-Pugh class A): Initial dose 0.9 mg/kg (maximum dose: 90 mg) every 2 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If moderate to severe impairment (Child-Pugh class B or C): Avoid use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Brentuximab:</strong><br>If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/minute: Avoid use.</li></ul>', 'Low', null, null, null, '<p><strong>Brentuximab:</strong> 1.8 mg/kg IV on day 1<br>Repeat cycle every 3 weeks for up to 16 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1004, null, 'Nivolumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Dose modification not provided by the manufacturer</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Dose modification not provided by the manufacturer</li></ul>', 'Low', null, null, null, '<p><strong>Nivolumab:</strong> 240 mg IV on day 1<br>Repeat cycle every 2 weeks. May also administer 480 mg IV with cycles repeated every 4 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1005, null, 'Pembrolizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment: No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment: Dosage adjustment not provided by the manufacturer.</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Pembrolizumab:</strong> 200 mg IV on day 1<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (145, 'Letrozole : Femara', 'Letrozole', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Letrozole:</strong><br>If Child-Pugh A or B, no dose reduction&nbsp;<br>If Child-Pugh C, reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Letrozole:</strong><br>If CrCl &gt; 10 mL/min, no dose reduction</li></ul>', 'NA', '<b>Letrozole</b>', 'Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol aectate. $J Clin Oncol. 1998;16(2):453-461.$<br> Ingle JN, et al. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. $Cancer. 1997;80(2):218-224.$<br> Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. $N Engl J Med. 2003;349(19): 1793-1802.$', null, '<p><strong>Letrozole:</strong> 2.5 mg PO once daily</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1007, null, 'Everolimus', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Everolimus:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (Child-Pugh class A): Reduce dose to 7.5 mg once daily &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (Child-Pugh class B): Reduce dose to 5 mg once daily &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (Child-Pugh class C): Reduce dose to 2.5 mg once daily</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Everolimus:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Everolimus:</strong> 10 mg PO daily<br>Continue until disease progression</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1008, null, 'Lenalidomide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>If CrCl &gt;60 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 30 to 60 mL/min: 5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min not requiring dialysis: 2.5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min requiring dialysis: 2.5 mg once daily (administer after dialysis on dialysis days).</li></ul>', 'Low', null, null, null, '<p><strong>Lenalidomide: </strong>25 mg PO daily<br>Continue until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1009, null, 'Mogamulizumab-kpkc', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Mogamulizumab-kpkc:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild to moderate impairment (total bilirubin &lt; 3 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (total bilirubin &gt; 3 times ULN): Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Mogamulizumab-kpkc:</strong><br>No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Mogamulizumab-kpkc:</strong> 1 mg/kg IV on days 1, 8, 15, and 22 of cycle 1 and then on days 1 and 15 of all subsequent cycles<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1016, null, 'Temozolomide + Thalidomide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Temozolomide:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If mild to moderate impairment (Child-Pugh classes A and B): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): There are no dosage adjustments provided by the manufacturer.</li><li><strong>Thalidomide:</strong>&nbsp;<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Temozolomide:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥36 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;36 mL/min: There are no dosage adjustments provided by the manufacturer</li><li><strong>Thalidomide:</strong>&nbsp;<br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Temozolomide:</strong> 75 mg/m2/day PO for 6 weeks<br><strong>Thalidomide:</strong> 200 mg/day PO for 6 weeks<br>Repeat cycle every 8 weeks. Consider dose escalation to 400 mg/day for patients &lt;70 years and starting at a lower dose of 100 mg/day with dose escalation to 250 mg/day for patients &gt;70 years.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1019, null, 'Binimetinib + Encorafenib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Binimetinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If mild impairment (Child-Pugh classes A): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (Child-Pugh class B and C): Reduce dose to 30 mg PO bid.</li><li><strong>Encorafenib:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If mild impairment (Child-Pugh classes A): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (Child-Pugh class B and C): Dose modification not provided by the manufacturer &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Binimetinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li><li><strong>Encorafenib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If CrCl ≥30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Dose modification not provided by the manufacturer &nbsp;</li></ul>', 'High', null, null, null, '<p><strong>Binimetinib:</strong> 45 mg PO bid<br><strong>Encorafenib:</strong> 300 mg PO daily<br>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (963, null, 'Pembrolizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (total bilirubin &gt;1 to 1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (total bilirubin &gt;1.5 times ULN): Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Pembrolizumab:</strong> 200 mg IV on day 1<br>Repeat cycle every 21 days.<br>&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1010, null, 'Vorinostat', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vorinostat: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If mild to moderate impairment (total bilirubin &lt; 3 times ULN): Reduce dose to 300 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (total bilirubin &gt; 3 times ULN): Dosage adjustment not provided by the manufacturer <strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong></li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vorinostat:</strong><br>No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Vorinostat: </strong>400 mg PO daily<br>Continue therapy until disease progression</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1011, null, 'Romidepsin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Romidepsin: &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If mild impairment (total bilirubin &gt;1 to 1.5 times ULN): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (total bilirubin &gt;1.5 to 3 times ULN): Reduce initial dose to 7 mg/m2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (total bilirubin &gt; 3 times ULN): Reduce initial dose to 5 mg/m2.&nbsp;<strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong></li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Romidepsin:</strong><br>No dose reduction.</li></ul>', 'Moderate', null, null, null, '<p><strong>Romidepsin: </strong>14 mg/m2 IV on days 1, 8, and 15<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1012, null, 'Belinostat', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Belinostat: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (total bilirubin &lt; 1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (total bilirubin &gt; 1.5 times ULN): Dosage adjustment not provided by the manufacturer.&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong></li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Belinostat:</strong><br>If CrCl &gt;39 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≤39 mL/min: Dosage adjustment not provided because of insufficient data</li></ul>', 'Low', null, null, null, '<p><strong>Belinostat: </strong>1,000 mg/m2 IV on days 1-5<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (287, 'Melphalan : Alkeran<br>Prednisone : various', 'Melphalan/Prednisone/Thalidomide (MPT)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Melphalan:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Thalidomide:</strong>&nbsp;<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Melphalan:</strong><br>&nbsp;If CrCl 10 to 50 mL/min: Reduce dose to 75%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose to 50%.</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Thalidomide:</strong>&nbsp;<br>No dose reduction</li></ul>', 'Low', '<b>Melphalan/Prednisone/Talidomide (MPT)</b>', ' $Palumbo A, et al. Lancet 2006;28:367-835.$', null, '<p><strong>Melphalan:</strong> 0.25 mg/kg PO, days 1-4<br><strong>Prednisone:</strong> 1.5 mg/kg PO, days 1-4<br><strong>Thalidomide: </strong>50 - 100 mg/day PO, &nbsp;q daily.</p><p>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (144, 'Gemcitabine : Gemzar, various', 'Gemcitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '<b>Gemcitabine</b>', 'Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. $J Clin Oncol. 1995;13(11):2731-2736.$', null, '<p><strong>Gemcitabine:</strong> 725 mg/m2 IV weekly for 3 weeks.<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (127, 'Capecitabine : Xeloda<br>Ixabepilone : Ixempra', 'Ixabepilone/Capecitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine:</strong><br>No dose reduction</li><li><strong>Ixabepilone:</strong><br>Monotherapy:&nbsp;<br>If AST and ALT &lt; 2.5 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 40 mg/m2<br>If AST or ALT &lt; 10 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 32 mg/m2&nbsp;<br>If AST and ALT &lt; 10 upper normal limit, and bilirubin 1.5-3 upper normal limit, use 20-30 mg/m2&nbsp;<br>If AST or ALT &gt; 10 upper normal limit, or bilirubin &gt; 3 upper normal limit, do not use&nbsp;<br>In combination with capecitabine:&nbsp;<br>If AST and ALT &lt; 2.5 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 40 mg/m2&nbsp;<br>If AST or ALT &gt; 2.5 upper normal limit, or bilirubin &gt; 1 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine:</strong><br>If CrCl 30-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Ixabepilone:</strong><br>If CrCl &gt; 30 mL/min, no dose reduction</li></ul>', 'Low', '<b>Ixabepilone/Capecitabine</b>', 'Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. $J Clin Oncol. 2007;25(33):5210-5217.$', null, '<p><strong>Ixabepilone:</strong> 40 mg/m2 IV over 3 hours, day 1<br><strong>Capecitabine:</strong> 1,000 mg/m2 PO bid, days 1-14<br>Repeat every 21 days for up to 8 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (147, 'Paclitaxel : Taxol', 'Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel:</strong><br>No dose reduction</li></ul>', 'Low', '<b>Paclitaxel</b>', 'Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. $J Clin Oncol. 1995;13(10):2575-2581.$<br> Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. $J Clin Oncol. 1999;17(11):3403-3411.$', null, '<p><strong>Paclitaxel:</strong> 175 mg/m2 IV over 3 hours on day 1<br>Repeat every 21 days</p><p><strong>OR</strong></p><p><strong>Paclitaxel:</strong> 80-100 mg/m2 IV weekly for 3 weeks<br>Repeat every 4 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (130, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol', 'Sequential AC --> T (Weekly)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>No dose reduction</li></ul>', 'High ', '<b>Sequential AC --> T</b>', 'Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. $N Engl J Med. 2008;238(16):1663-1671.$', null, '<p><strong>Doxorubicin:</strong> 60 mg/m2 over 5-15 minutes, day 1<br><strong>Cyclophosphamide:</strong> 600 mg/m2 IV 30-60 minutes, day 1<br>Repeat every 21 days for 4 cycles &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br><strong>FOLLOWED BY &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong><br><strong>Paclitaxel:</strong> 80 mg/m2 IV over 1 hour<br>Repeat every 7 days for 12 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (444, 'Capecitabine: Xeloda<br>Vinorelbine: Navelbine', 'XN', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	No dose reduction</li>
	<li><strong>Vinorelbine</strong>:<br />
	If bilirubin 2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	If CrCl 30-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Vinorelbine</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Biganzoli L, Martin M, et al. Moving forward with capecitabine: a glimpse of the future. Oncologist. 2002;7 Suppl 6:29-35.', 'METASTATIC', '<p><strong>Capecitabine:</strong>&nbsp;1000 mg/m2&nbsp;PO BID on days 1-14<br><strong>Navelbine/ Vinorelbine:</strong>&nbsp;25 mg/m2&nbsp;IV on days 1 and 8</p><p>Repeat cycle every 21 days.</p>', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (133, 'Capecitabine : Xeloda<br>Docetaxel : Taxotere', 'X+T', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine:</strong><br>No dose reduction</li><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine:</strong><br>If CrCl 30-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Docetaxel:</strong><br>No dose reduction</li></ul>', 'Low', '<b>X+T</b>', 'O''Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthraccline-pretreated patients with advanced breast cancer: phase III trial results. $J Clin Oncol. 2002;20(12):2812-2823.$', null, '<p><strong>Capecitabine:</strong> 1,250 mg/m2 PO bid, days 1-14<br><strong>Docetaxel:</strong> 75 mg/m2 as a 1-hour IV infusion, day 1<br>Repeat every 21 days. May decrease dose of capecitabine to 825-1,000 mg/m2 PO bid on days 1-14 to reduce the risk of toxicity without compromising clinical efficacy.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (496, 'Palbociclib: Ibrance<br>Fulvestrant: Faslodex', 'Palbociclib/Fulvestrant', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Palbociclib</strong><br>If Child-Pugh A or B, no dose reduction<br>If Child-Pugh C,&nbsp;reduce dose to 75 mg/day</li><li><strong>Fulvestrant</strong>:<br>If SGOT, SGPT, bilirubin, and alkaline phosphatase &lt; 2 upper normal limits, no dose reduction<br>If SGOT, SGPT, bilirubin, and alkaline phosphatase &gt; 2 upper normal limits, unknown</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Fulvestrant</strong>:<br>No dose reduction</li><li><strong>Palbociclib &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul>', 'Low', '', 'Turner NC, Ro J, et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015;373(3):209-19.', 'METASTATIC', '<p><strong>Palbociclib:</strong>&nbsp;125 mg PO daily for 21 days<br><strong>Fulvestrant:</strong>&nbsp;500 mg IM on days 1 and 15 of the first cycle, then 500 mg IM on day 1 for all subsequent cycles</p><p>Repeat cycle every 28 days.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (422, 'Carboplatin: Paraplatin<br>Docetaxel: Taxotere<br>Trastuzumab: Herceptin', 'TCH', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Docetaxel</strong>:<br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li><li><strong>Trastuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on AUC</li><li><strong>Docetaxel</strong>:<br>No dose reduction</li><li><strong>Trastuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p>&nbsp;</p><p>&nbsp;<strong>Cardiac Impairment</strong></p><ul><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'Moderate', '', 'Slamon D, Eiermann W, et all. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Breast Cancer Res Treat. 2006; 100 (Abstract #52).', 'ADJUVANT', '<p><strong>Docetaxel:</strong> 75 mg/m2 IV on&nbsp;day 1<br><strong>Carboplatin:</strong> AUC of 6, IV on&nbsp;day 1<br><strong>Trastuzumab:&nbsp;</strong>4 mg/kg IV loading dose and then 2 mg/kg IV weekly during chemotherapy</p><p>Repeat every 21 days for 6 cycles, followed by</p><p><strong>Trastuzumab:</strong>&nbsp;6 mg/kg IV on day 1</p><p>Repeat every 21 days for 1 year.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1021, null, 'Abraxane', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Abraxane:&nbsp;</strong><br>If mild impairment (Child-Pugh class A): Dose at 260 mg/m2. &nbsp; &nbsp; &nbsp; If moderate impairment (Child-Pugh class B): Dose at 200 mg/m2. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): Use is not recommended&nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Abraxane:&nbsp;</strong><br>If CrCl ≥30 mL/minute: No dosage adjustment necessary. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer''s labeling (insufficient data).</li></ul>', 'Low', null, null, null, '<p><strong>Abraxane: </strong>260 mg/m2 IV on day 1.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1125, null, 'PD', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pomalidomide:</strong><br>Avoid POMALYST in patients with serum bilirubin greater than 2.0 mg/dL and AST/ALT greater than 3.0 x ULN.</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pomalidomide:</strong><br>Avoid Pomalidamide in patients with serum creatinine greater than 3.0 mg/dL</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Pomalidomide:</strong> 4 mg/day PO on days 1-21<br><strong>Dexamethasone:</strong> 40 mg/day PO on day 1<br>Repeat cycle every 28 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1130, null, 'RMPT', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>No dose reduction</li><li><strong>Melphalan:</strong><br>No dose reduction</li><li><strong>Prednisone:</strong><br>No dose reduction</li><li><strong>Thalidomide:</strong>&nbsp;<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>If CrCl &gt;60 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 30 to 60 mL/min: 5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min not requiring dialysis: 2.5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min requiring dialysis: 2.5 mg once daily (administer after dialysis on dialysis days).</li><li><strong>Melphalan:</strong><br>&nbsp;If CrCl 10 to 50 mL/min: Reduce dose to 75%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose to 50%.</li><li><strong>Prednisone:</strong><br>No dose reduction</li><li><strong>Thalidomide:</strong>&nbsp;<br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Lenalidomide:</strong> 10 mg PO on days 1-21<br><strong>Melphalan:</strong> 0.18 mg/kg PO on days 1-4<br><strong>Prednisone:</strong> 2 mg/kg PO on days 1-4<br><strong>Thalidomide: </strong>50 mg PO daily on days 1-28</p><p>Repeat cycle every 28 days for 6 cycles followed by maintenance lenalidomide<br>10 mg PO on days 1-21 until progression or toxicity.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (420, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin, various<br>Paclitaxel: Taxol<br>Trastuzumab: Herceptin', 'AC/Paclitaxel/Trastuzumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide</strong>:<br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Trastuzumab: &nbsp; &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dosage modification.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li><li><strong>Trastuzumab: &nbsp; &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dosage modification. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Cardiac Impairment</strong></li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong> </strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'High', '', 'Romond EH, Perez EA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.', 'ADJUVANT', '<p><strong>Doxorubicin:</strong>&nbsp;60 mg/m2&nbsp;IV on day 1<br><strong>Cyclophosphamide:</strong>&nbsp;600 mg/m2&nbsp;IV on day 1</p><p>Repeat every 21 days for 4 cycles, followed by</p><p><strong>Paclitaxel:</strong>&nbsp;80 mg/m2&nbsp;IV over 1 hour on day 1<br><strong>Trastuzumab:</strong>&nbsp;4 mg/kg IV loading dose, then 2mg/kg IV weekly</p><p>Repeat every 7 days for 12 cycles, followed by</p><p><strong>Trastuzumab:</strong>&nbsp;2 mg/kg IV weekly</p><p>Repeat every 7 days for 40 cycles.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (421, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin, various<br>Paclitaxel: Taxol<br>Trastuzumab: Herceptin', 'AC/Paclitaxel/Trastuzumab (dose-dense)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide</strong>:<br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Trastuzumab: &nbsp; &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>No dose reduction &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Trastuzumab: &nbsp; &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Cardiac Impairment</strong></li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong> </strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.<br>&nbsp;</li></ul><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p>', 'High', '', 'Romond EH, Perez EA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.', 'ADJUVANT', '<p><strong>Doxorubicin:</strong>&nbsp;60 mg/m2&nbsp;IV on day 1<br><strong>Cyclophosphamide:</strong>&nbsp;600 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 14&nbsp;days for 4 cycles, followed by</p><p><strong>Paclitaxel:</strong>&nbsp;175 mg/m2&nbsp;IV on day 1</p><p>Repeat every 14 days for 4 cycles.</p><p><strong>Trastuzumab:</strong>&nbsp;4 mg/kg IV loading dose along with paclitaxel and&nbsp;then 2 mg/kg IV weekly</p><p>Repeat every 7 days for 52 cycles.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (117, 'Cyclophosphamide : Cytoxan<br>Docetaxel : Taxotere<br>Doxorubicin : Adriamycin, various<br>Trastuzumab : Herceptin', 'AC - TH                                                  ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Docetaxel:</strong><br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Docetaxel:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Cardiac Impairment</strong></li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'High', '<b>AC  TH</b>                                                  ', 'Neyt M, Albrecht J, Cocquyt V.An economic evaluation of herceptinR  in adjuvant setting: the Breast Cancer International Research Group 006 trial. $Ann Oncol. 2006; 17(3):381-390$', null, '<p><strong>Doxorubicin:</strong> 60 mg/m2 IV,day 1<br><strong>Cyclophosphamide:</strong> 600 mg/m2 IV,day 1<br>Repeat every 21 days for 4 cycles, followed by<br><strong>Docetaxel:</strong> 100 mg/m2 IV, day1<br>Repeat every 21 days for 4 cycles<br><strong>Trastuzumab:</strong> 4 mg/kg IV, day 1, followed by<br>2 mg/kg IV weekly during docetaxel, followed by<br>6 mg/kg IV every 21 days for 1 year</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1022, null, 'Abemaciclib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Abemaciclib &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> If mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.<br>&nbsp; If severe impairment (Child-Pugh C): Reduce dosing frequency to once daily</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Abemaciclib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100 % dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: &nbsp;No dosage adjustments because of insufficient data.</li></ul>', 'High', null, null, null, '<p><strong>Abemaciclib: </strong>150 mg PO BID.</p><p>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1023, null, 'Olaparib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Olaparib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Olaparib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 51 to 80 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 50 mL/min: Reduce dose to 200 mg twice daily. &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≤30 mL/min: There are no dosage adjustments because of inadequate study.</li></ul>', 'Low', null, null, null, '<p><strong>Olaparib:</strong> 300 mg PO BID.</p><p>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (423, 'Cyclophosphamide: Cytoxan<br>Epirubicin: Ellence, various<br>5-Fluorouracil: 5-FU<br>Docetaxel: Taxotere<br>Trastuzumab: Herceptin', 'DH/FEC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li><li><strong>Epirubicin</strong>:<br>If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br>If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%</li><li><strong>Cyclophosphamide</strong>:<br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Docetaxel</strong>:<br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use.</li><li><strong>Trastuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction</li><li><strong>Epirubicin</strong><br>If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li><li><strong>Cyclophosphamide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Docetaxel</strong>:<br>No dose reduction</li><li><strong>Trastuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Cardiac Impairment</strong></li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'High', '', 'Joensuu H, Kellokumpu-Lehtinen PL, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809-20.', 'ADJUVANT', '<p><strong>Docetaxel:</strong>&nbsp;100 mg/m2&nbsp;IV on day 1<br><strong>Trastuzumab:</strong>&nbsp;4 mg/kg IV loading dose on day 1 and then 2 mg/kg IV weekly</p><p>Repeat every 21 days for 3 cycles, followed by</p><p><strong>5-Fluorouracil:</strong>&nbsp;600 mg/m2&nbsp;IV on day 1<br><strong>Epirubicin:</strong>&nbsp;60 mg/m2&nbsp;IV on day 1<br><strong>Cyclophosphamide:&nbsp;</strong>600 mg/m2&nbsp;IV on day 1</p><p>Repeat every 21 days for 3 cycles.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (486, 'Carboplatin: Paraplatin<br>Docetaxel: Taxotere<br>Trastuzumab: Herceptin', 'TCH (metastatic)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Docetaxel</strong>:<br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li><li><strong>Trastuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on AUC</li><li><strong>Docetaxel</strong>:<br>No dose reduction</li><li><strong>Trastuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p>&nbsp;</p><p>&nbsp;<strong>Cardiac Impairment</strong></p><ul><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'Moderate', '', 'Pegram M, Forbes J, et al. BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 2007; 25: (Abstr LBA1008).', 'METASTATIC', '<p><strong>Carboplatin:</strong>&nbsp;AUC of 6, IV on day 1<br><strong>Docetaxel:</strong>&nbsp;75 mg/m2&nbsp;IV on day 1<br><strong>Trastuzumab:</strong>&nbsp;4 mg/kg IV loading dose on day 1, then 2 mg/kg IV on days 8 and 15, then 2 mg/kg IV weekly thereafter</p><p>Repeat cycle every 21 days.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (490, 'Trastuzumab: Herceptin<br>Capecitabine: Xeloda', 'Trastuzumab/Capecitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Trastuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Trastuzumab: &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Cardiac Impairment</strong></li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'Low', '', 'Schaller G, Fuchs I, et al. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol. 2007;25(22):3246-50. --- Bartsch R, Wenzel C, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007;25(25):3853-8.', 'METASTATIC', '<p><strong>Trastuzumab:</strong>&nbsp;4 mg/kg IV loading dose, then 2mg/kg IV weekly<br><strong>Capecitabine:</strong>&nbsp;1,250 mg/m2&nbsp;PO bid on days 1-14</p><p>Repeat cycle every 21 days.</p><p><strong>OR</strong></p><p><strong>Trastuzumab:</strong>&nbsp;8 mg/kg IV loading dose, then 6 mg/kg IV on day 1 of all subsequent cycles<br><strong>Capecitabine:</strong>&nbsp;1,250 mg/m2&nbsp;PO bid on days 1-14</p><p>Repeat cycle every 21 days.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (484, 'Trastuzumab: Herceptin<br>Paclitaxel: Taxol', 'Trastuzumab/Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Trastuzumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Paclitaxel:</strong><br>No dose reduction</li><li><strong>Trastuzumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Cardiac Impairment</strong></li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'Low', '', 'Slamon DJ, Leyland-Jones B, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92. --- Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999;21(2):309-18.', 'METASTATIC', '<p><strong>Trastuzumab:</strong>&nbsp;4 mg/kg IV loading dose and then 2 mg/kg weekly<br><strong>Paclitaxel:</strong>&nbsp;175 mg/m2&nbsp;IV over 3 hours on day 1</p><p>Repeat cycle every 21 days.</p><p><strong>OR</strong></p><p><strong>Trastuzumab:</strong>&nbsp;4 mg/kg IV loading dose and then 2 mg/kg weekly<br><strong>Paclitaxel:</strong>&nbsp;80 mg/m2&nbsp;IV weekly</p><p>Repeat cycle every 4 weeks.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (136, 'Carboplatin : Paraplatin<br>Paclitaxel : Taxol<br>Trastuzumab : Herceptin', 'Trastuzumab/Paclitaxel/Carboplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Trastuzumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin:</strong><br>Dosing based on AUC</li><li><strong>Paclitaxel:</strong><br>No dose reduction</li><li><strong>Trastuzumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Cardiac Impairment</strong></li><li><strong>Trastuzumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If<strong>&nbsp;</strong>EF decreases ≥16% &nbsp;from baseline &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> &nbsp; OR &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EF below normal limits and ≥10% decrease from baseline &nbsp; &nbsp; &nbsp;Hold treatment for 4 weeks and repeat LVEF every 4 weeks. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Resume treatment if EF returns to normal limits within 4 to 8 weeks and remains at ≤15% decrease from the baseline value. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stop treatment permanently if EF declines persistently for &gt; 8 weeks or for &gt;3 incidents of interruptions in treatment for cardiomyopathy.</li></ul>', 'Moderate ', '<b>Trastuzumab/Paclitaxel/Carboplatin</b>', 'Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. $J Clin Oncol. 2006;24(18):2786-2792.$', null, '<p><strong>Trastuzumab</strong> 4 mg/kg loading dose, day 1 of cycle 1, <strong>THEN</strong> 2 mg/kg weekly thereafter<br><strong>Paclitaxel</strong> 175 mg/m2 IV, day 2<br><strong>Carboplatin</strong> AUC of 6, day 2<br>Repeat every 21 days for at least 6 cycles, followed by</p><p><strong>&nbsp;Trastuzumab</strong> 2 mg/kg weekly until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1024, null, 'Talazoparib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Talazoparib:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Talazoparib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> If CrCl ≥60 mL/minute: No dosage adjustment necessary. &nbsp;&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If CrCl 30 to 59 mL/min: Reduce dose to 0.75 mg OD &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 15 to 29 mL/min: Reduce dose to 0.5 mg OD &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≤15 mL/min: There are no dosage adjustments because of inadequate study.</li></ul>', 'Low', null, null, null, '<p><strong>Talazoparib: </strong>1 mg PO daily.</p><p>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (216, 'Carboplatin : Paraplatin<br>Gemcitabine : Gemzar, various<br>paclitaxel : Taxol', 'Gemcitabine/Carboplatin/paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin:</strong><br>No dose reduction</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose.</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>No dose reduction</li></ul>', 'High', '<b>Gemcitabine/Carboplatin/paclitaxel</b>', 'Greco FA, Burris HA III, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie pearl cancer center research Network study. J Clin Oncol.2002;20(6):1651-1656.                ', null, '<p><strong>Gemcitabine:</strong> 1,000 mg/m2 1V, days 1,8<br><strong>Carboplatin:</strong> AUC of 5 IV, day 1<br><strong>Paclitaxel:</strong> 200 mg/m2 IV over 1 hour, day 1<br>Repeat cycle every 21 days for 4 cycles. This is followed by paclitaxel at 70 mg/m2 IV every week for 6 weeks with a 2 weeks rest. Repeat for a total of 3 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (217, 'Cisplatin : CDDP<br>Gemcitabine : Gemzar, various', 'Gemcitabine/Cisplatin/ Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Gemcitabine:</strong><br>No dose reduction&nbsp;</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li></ul>', 'High', '<b>Gemcitabine/Cisplatin</b>', 'Culine S, Lortholary A, Voigt JJ, et al. Gemcitabine, carboplatin combintion with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study- trial for the French study Group on Carcinomas of Unknown Primary (GEFCAPI 01). $JClin Oncol. 2003;21(18):3479-3482.$', null, '<p><strong>Gemcitabine:</strong> 1,250 mg/m2 IV, days 1 and 8<br><strong>Cisplatin:</strong> 100 mg/m2 IV, day 1</p><p><strong>Paclitaxel</strong>: 175 mg/m2 IV on days 1 and 8.<br>Repeat every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1027, null, 'Gemcitabine + Irinotecan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>&nbsp;If AST, ALT elevated (with normal bilirubin): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin &gt;1.6 mg/dL: Reduce initial dose to 800 mg/m2</li><li><strong>Irinotecan: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin &gt;1.2 to ≤2 mg/dL: &nbsp;Reduce initial dose by one dose level &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin &gt;2 mg/dL: Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Irinotecan:&nbsp;</strong><br>No dose reduction.</li></ul>', 'Moderate', null, null, null, '<p><strong>Gemcitabine:</strong> 1000 mg/m2 IV on days 1 and 8<br><strong>Irinotecan:</strong> 100 mg/m2 IV on days 1 and 8</p><p>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (170, 'Cisplatin : CDDP<br>Paclitaxel : Taxol', 'C-P', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br><strong>&nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Paclitaxel:</strong><br>No dose reduction</li></ul>', 'High', '<b>C-P</b>', 'Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet commbinations in stage IVB recurrent or persistent cervical carcinoma: A Gynecologic Group Study. $J Clin Oncol. 2009;27(28):4649-4655.$', null, '<p><strong>Paclitaxel:</strong> 135 mg/m2 IV over 24 hours on day 1.</p><p><strong>Cisplatin:</strong> 75 mg/m2 IV on day 2<br>Repeat every 21 days for 6 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (528, 'Paclitaxel: Taxol<br>Topotecan: Hycamtin', 'Paclitaxel/Topotecan', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br />
	If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2<br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
	<li><strong>Topotecan</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Topotecan</strong>:<br />
	If CrCl &gt; 40 mL/min, no dose reduction<br />
	If CrCl 20-39 mL/min, reduce to 0.75 mg/m<sup>2</sup></li>
</ul>
', 'High', '', '', '', '<p><strong>Paclitaxel</strong>&nbsp;175 mg/m2&nbsp;IV on day 1<br><strong>Topotecan</strong>&nbsp;0.75 mg/m2&nbsp;IV on days 1-3&nbsp;</p><p>Repeat cycle every 21 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1025, null, 'EP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', null, null, null, '<p><strong>Etoposide: </strong>100 mg/m2 IV on days 1-5<br><strong>Cisplatin: </strong>100 mg/m2 IV on day 1<br>Repeat cycle every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1026, null, 'РЕВ', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bleomycin</strong>:<br>No dose reduction</li><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bleomycin</strong><br>If CrCl &gt;50 mL/min: No dose reduction<br>If CrCl 40-50 mL/min: 70% of normal dose<br>If CrCl 30-40 mL/min: 60% of normal dose<br>If CrCl 20-30 mL/min: 55% normal dose<br>If CrCl 10-20 mL/min: 45% normal dose<br>If CrCl 5-10 mL/min: 40% normal dose</li><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:</strong> 20 mg/m2 IV on days 1-5<br><strong>Etoposide: </strong>100 mg/m2 IV on days 1-5<br><strong>Bleomycin:</strong> 30 units IV on days 1, 8, and 15</p><p>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1126, null, 'DVD', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Doxorubicin Liposome:</strong><br>There are no dosage adjustments provided in the manufacturer''s labeling. But since, doxorubicin is predominantly hepatically eliminated and consider decreasing the dose of doxorubicin (liposomal) in patients with serum bilirubin ≥1.2 mg/dL.</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Doxorubicin Liposome:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Doxorubicin liposome:</strong> 40 mg/m2 IV on day 1<br><strong>Vincristine:</strong> 2 mg V on day 1<br><strong>Dexamethasone: </strong>40 mg PO on days 1-4<br>Repeat cycles every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1127, null, 'Bortezomib + Doxorubicin liposome', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin&nbsp;1-1.5 times upper normal limit: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin&nbsp;&gt;1.5 times upper normal limit: Reduce the initial dose to 0.7 mg/m2.</li><li><strong>Doxorubicin Liposome:</strong><br>There are no dosage adjustments provided in the manufacturer''s labeling. But since, doxorubicin is predominantly hepatically eliminated and consider decreasing the dose of doxorubicin (liposomal) in patients with serum bilirubin ≥1.2 mg/dL.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li><li><strong>Doxorubicin Liposome:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Bortezomib:</strong> 1.3 mg/m2 IV or SC on days 1, 4, 8, and 11<br><strong>Doxorubicin liposome:</strong> 30 mg/m2 IV infusion on day 4<br>Repeat cycle every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1128, null, 'Bortezomib + Melphalan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin&nbsp;1-1.5 times upper normal limit: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin&nbsp;&gt;1.5 times upper normal limit: Reduce the initial dose to 0.7 mg/m2.</li><li><strong>Melphalan:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li><li><strong>Melphalan:</strong><br>&nbsp;If CrCl 10 to 50 mL/min: Reduce dose to 75%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose to 50%.</li></ul>', 'Low', null, null, null, '<p><strong>Bortezomib:</strong> 1.0 mg/m2 IV or SC on days 1, 4, 8, and 11<br><strong>Melphalan:</strong> 0.10 mg/kg PO on days 1-4<br>Repeat cycle every 28 days up to 8 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1028, null, 'Bevacizumab + Erlotinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Erlotinib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>Erlotinib:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Bevacizumab: </strong>10 mg/kg IV on day 1<br><strong>Erlotinib: </strong>150 mg PO daily<br>Continue until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1029, null, 'Everolimus', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Everolimus:</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (Child-Pugh class A): Reduce dose to 7.5 mg once daily &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (Child-Pugh class B): Reduce dose to 5 mg once daily &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (Child-Pugh class C): Reduce dose to 2.5 mg once daily</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Everolimus:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Everolimus: </strong>10 mg PO daily.</p><p>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1030, null, 'Lutetium Lu 177 dotatate', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lutetium Lu 177 dotatate:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild to moderate impairment (Child-Pugh classes A and B): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): There are no dosage adjustments provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lutetium Lu 177 dotatate:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: There are no dosage adjustments provided by the manufacturer</li></ul>', 'Moderate', null, null, null, '<p><strong>Lutetium Lu 177 dotatate:</strong> 120 mg SC on day 1<br>Repeat every 8 weeks for a total of 4 doses. Long-acting octreotide<br>30 mg IM should be administered at 4 to 24 hours after each dose of lutetium<br>Lu 177 dotatate.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (535, 'Carboplatin: Paraplatin<br>Docetaxel: Taxotere', 'Carboplatin + Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Docetaxel</strong>:<br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% dosage.</li><li><strong>Docetaxel</strong>:<br>No dose reduction</li></ul>', 'High', '', 'Nagao S, Fujiwara K, et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol. 2005;96(3):805-9.', '', '<p><strong>Carboplatin:</strong>&nbsp;AUC of 6, IV on day 1<br><strong>Docetaxel:</strong>&nbsp;60 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (531, 'Cisplatin: CDDP<br>Fluorouracil: 5-FU', 'Cisplatin + 5-Fluorouracil', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>5-Fluorouracil</strong>:<br>No dose reduction</li></ul>', 'High', '', 'Whitney CW, Sause W, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339-48.', '', '<p><strong>Cisplatin:</strong>&nbsp;75 mg/m2&nbsp;IV on day 1<br><strong>5-Fluorouracil:</strong>&nbsp;1000 mg/m2/day IV continuous infusion on days 2-5</p><p>Repeat cycle every 21 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (536, 'Cisplatin: CDDP<br>Pemetrexed: Alimta', 'Cisplatin/Pemetrexed', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Pemetrexed</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Pemetrexed</strong>:<br>If CrCl &gt; 45 mL/min, no dose reduction<br>If CrCl &lt; 45 mL/min, do not use</li></ul>', 'High', '', 'Miller DS, Blessing JA, et al. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol. 2014;32(25):2744-9.', '', '<p><strong>Cisplatin:</strong>&nbsp;50 mg/m2&nbsp;IV on day 1<br><strong>Pemetrexed:</strong>&nbsp;500 mg/m2&nbsp;IV on day 1</p><p>Repeat cycle every 21 days.</p><p>Folic acid 350 to 1,000 μg PO once daily and vitamin B12 at 1,000 μg IM to start 7 days prior to the first dose of pemetrexed and repeated every 21 days.</p>', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1033, null, '5-FU/LV Oxaliplatin+ Radiation Therapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl &gt;30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: 75% dosage</li><li><strong>5-Fluorouracil</strong>:<br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>5-Fluorouracil:</strong> 200 mg/m2/day IV continuous infusion throughout the entire course of radiation therapy<br><br><strong>Oxaliplatin:</strong> 60 mg/m2 IV on days 1, 8, 15, 22, 29, and 36<br><br><strong>Radiation therapy: </strong>180 cGy/day for 5 days each week (total dose, 5,040 cGy)<br>Followed by surgical resection 4-6 weeks after completion of chemoradiotherapy<br>and then adjuvant chemotherapy.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1034, null, 'XELOX + Radiation Therapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>No dose reduction</li><li><strong>Oxaliplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Capecitabine</strong>:<br>If CrCl 30-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Oxaliplatin:&nbsp;</strong><br>&nbsp;If CrCl ≥30 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Reduce initial dose from 85 mg/m2 to 65 mg/m2.</li></ul>', 'Moderate', null, null, null, '<p><strong>Capecitabine:</strong> 825 mg/m2 PO bid on days 1-14 and 22-35.<br><strong>Oxaliplatin:</strong> 50 mg/m2 IV on days 1,8, 22, and 29<br><strong>Radiation therapy:</strong> 180 cGy/day for 5 days per week [total dose, 5,040 cGy)<br>Followed by surgical resection and then adjuvant chemotherapy with<br><br><strong>Capecitabine:</strong> 1,000 mg/m2 PO bid on days 1-14<br><strong>Oxaliplatin:</strong> 130 mg/m2 IV on day 1<br>Repeat cycle every 3 weeks for 4 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (548, 'Cisplatin: CDDP<br>Doxorubicin: Adriamycin<br>Paclitaxel: Taxol', 'Cisplatin/Doxorubicin/Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Doxorubicin</strong>:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Doxorubicin</strong>:<br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li></ul>
<ul><li>Fludarabine:<br>No dose reduction</li></ul>', 'High', '', 'Fleming GF, Brunetto VL, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22(11):2159-66.', '', '<p><strong>Cisplatin:</strong>&nbsp;50 mg/m2&nbsp;IV on day 1<br><strong>Doxorubicin:</strong>&nbsp;45 mg/m2&nbsp;IV on day 1<br><strong>Paclitaxel:</strong>&nbsp;160 mg/m2&nbsp;over 3 hours on day 2</p><p><strong>Filgrastim:&nbsp;</strong>5 μg/kg SC on days 3-12</p><p>Repeat cycle every 21 days.</p>', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (665, '', 'Pembrolizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (total bilirubin &lt;1 to 1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (total bilirubin &gt;1.5 times ULN): Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Pembrolizumab:&nbsp;</strong>200 mg IV on day 1</p>

<p>Repeat cycle every 3 weeks.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (107, 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various', 'CAP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li></ul>', 'High', '<b>CAP</b>', 'Loehrer PJ, et al.$J Clin Oncol 1994;12:1164-1168.$', null, '<p><strong>Cyclophosphamide:</strong> 500 mg/m2 IV on day 1<br><strong>Doxorubicin:</strong> 50 mg/m2 IV on day 1<br><strong>Cisplatin:</strong> 50 mg/m2 IV on day 1<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (79, 'Sunitinib : Sutent', 'Sunitinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Sunitinib:</strong><br>If Child-Pugh A or B, no dose reduction&nbsp;<br>If Child-Pugh C, reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Sunitinib:</strong><br>If CrCl &gt; 42 mL/min, no dose reduction</li></ul>', 'Low', '<b>Sunitinib</b>', 'Demetri GD, van Oossterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour afer failure of imatinib: a randomised controlled trial. $Lancet. 2006;368(9544):1329-1338.$', null, '<p><strong>Sunitinib malate:</strong> 50 mg/day PO for 28 days.</p><p>Repeat cycle every 6 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (9, 'Cetuximab : Erbitux<br>Cisplatin : CDDP<br>Fluorouracil : 5-FU', 'Cisplatin/Fluorouracil/Cetuximab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Fluorouracil:</strong><br>No dose reduction</li><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'High', '<b>Cisplatin/Fluorouracil/Cetuximab</b>', 'Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. $N Engl J Med. 2008;359(11):1116-1127.$', null, '<p><strong>Cisplatin:</strong> 100 mg/m2 IV, day 1<br><strong>Fluorouracil:</strong> 1,000 mg/m2/day continuous infusion IV, days 1-4<br><strong>Cetuximab:</strong> 400 mg/m2 IV loading dose over 4 hours, day 1, cycle 1. Then<strong>, </strong>250 mg/m2 IV over 1 hour, every week</p><p>Repeat every 21 days for up to 6 cycles. If no evidence of disease progression at the end of 6 cycles, can continue with weekly cetuximab.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (11, 'Cisplatin : CDDP<br>Paclitaxel : Taxol', 'Paclitaxel + Cisplatin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Paclitaxel:</strong><br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Paclitaxel:</strong><br>No dose reduction</li></ul>', 'High', '<b>CP</b>', 'Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. $J Clin Oncol. 2005;23(15):3562-3567.$', null, '<p><strong>Paclitaxel:</strong> 175 mg/m2 over 3 hours on day 1</p><p><strong>Cisplatin:</strong> 75 mg/m2 IV on day 2.</p><p><strong>G-CSF:&nbsp;</strong>5 μg/kg/day SC on days 4-10.<br>Repeat cycle every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (775, null, 'Pembrolizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (total bilirubin &lt;1 to 1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (total bilirubin &gt;1.5 times ULN): Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Pembrolizumab:&nbsp;</strong>200 mg<strong> </strong>IV on day 1</p><p>Repeat cycles every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1035, null, 'Methotrexate', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'Low', null, null, null, '<p><strong>Methotrexate:</strong> 40 mg/m2 IV or IM weekly</p><p>Repeat cycle every week.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (862, null, 'Lenvatinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lenvatinib:&nbsp;</strong><br>If mild impairment (Child-Pugh class A): 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If moderate impairment (Child-Pugh class B): 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; If Severe impairment (Child-Pugh class C): Reduce dose to 14 mg once daily.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lenvatinib:&nbsp;</strong><br>If CrCl ≥30 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Reduce dose to 14 mg once daily.</li></ul>', 'High', null, null, null, '<p><strong>Lenvatinib: </strong>24 mg PO daily<br>Continue treatment until disease progression</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (695, '', 'Nilotinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nilotinib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nilotinib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', '', '', 'METASTATIC', '<p><strong>Nilotinib:&nbsp;</strong>400-600 mg PO twice daily</p><p>Continue treatment until disease progression.</p>', 8);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (773, null, 'Carboplatin + Fluorouracil', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin:</strong><br>No dose reduction</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose.</li><li><strong>Fluorouracil:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Carboplatin:</strong> AUC of 5, IV on day 1<br><strong>Fluorouracil:</strong> 1,000 mg/m2/day IV continuous infusion on days 1-4</p><p><br>Repeat cycle every 21 days.<br>&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (772, null, 'Cisplatin + radiation (Nasopharyngeal)', '<p><strong>Hepatic Impairment:</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>5-Fluorouracil</strong>:<br>No dose reduction</li><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:</strong> 100 mg/m2 IV on days 1, 22 and 43.&nbsp;</p><p><strong>Radiation therapy:</strong> 7,000 cGy in 180-200 cGy fractions</p><p>After the completion of chemoradiotherapy, it should be followed by</p><p><strong>Cisplatin</strong>: 80 mg/m2 IV on day 1</p><p><strong>5-Fluorouracil:</strong> 1000 mg/m2/day as IV continuous infusion on days 1-4</p><p>Repeat every 28 days for 3 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1040, null, 'BV', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bleomycin</strong>:<br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bleomycin</strong><br>If CrCl &gt;50 mL/min: No dose reduction<br>If CrCl 40-50 mL/min: 70% of normal dose<br>If CrCl 30-40 mL/min: 60% of normal dose<br>If CrCl 20-30 mL/min: 55% normal dose<br>If CrCl 10-20 mL/min: 45% normal dose<br>If CrCl 5-10 mL/min: 40% normal dose</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Bleomycin:</strong> 10 U/m2 IV on days 1 and 15<br><strong>Vincristine:</strong> 1.4 mg/m2 IV on days 1 and 15 (maximum, 2 mg)<br>Repeat cycle every 2 weeks</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1037, null, 'Pembrolizumab + Cisplatin + 5-FU', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (total bilirubin &lt;1 to 1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (total bilirubin &gt;1.5 times ULN): Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Fluorouracil:</strong><br>No dose reduction</li><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'High', null, null, null, '<p><strong>Pembrolizumab:</strong> 200 mg IV on day 1<br><strong>Cisplatin:</strong> 100 mg IV on day 1<br><strong>5-Fluorouracil: </strong>1,000 mg/m2/day IV continuous infusion on days 1-4<br>Repeat cycle every 21 days for 4 cycles followed by pembrolizumab monotherapy<br>at 200 mg IV on day 1 every 3 weeks for up to 35 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1038, null, 'Pembrolizumab + Carboplatin + 5-FU', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li><li><strong>Pembrolizumab:&nbsp;</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (total bilirubin &lt;1 to 1.5 times ULN): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (total bilirubin &gt;1.5 times ULN): Dosage adjustment not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% of the usual dose. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% of the usual dose</li><li><strong>Fluorouracil:</strong><br>No dose reduction</li><li><strong>Pembrolizumab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'High', null, null, null, '<p><strong>Pembrolizumab:</strong> 200 mg IV on day 1<br><strong>Carboplatin:</strong> AUC of 5, IV on day 1<br><strong>5-Fluorouracil: </strong>1,000 mg/m2/day IV continuous infusion on days 1-4<br>Repeat cycle every 21 days for 4 cycles followed by pembrolizumab monotherapy<br>at 200 mg IV on day 1 every 3 weeks for up to 35 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1039, null, 'Cetuximab + Radiation Therapy', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cetuximab:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Cetuximab: </strong>400 mg/m2 IV loading dose, 1 week before radiation therapy, then 250 mg/m2 IV weekly.</p><p><strong>Radiation Therapy:</strong> 200 cGy/day for 5 days per week ( total dose, 7000 cGy).</p><p>Cetuximab is given concurrently with radiation therapy.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (577, 'Etoposide: VP-16', 'Etoposide', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Etoposide</strong>:<br />
	If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br />
	If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Etoposide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
</ul>
', 'Low', '', 'Ozols RF. Oral etoposide for the treatment of recurrent ovarian cancer. Drugs. 1999;58 Suppl 3:43-9.', '', '<p><strong>Etoposide:</strong>&nbsp;50 mg/m2/day PO daily on days 1-21</p><p>Repeat cycle every 28 days.</p>', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1036, null, 'PF-Larynx Preservation', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li><li><strong>5-Fluorouracil</strong>:<br>If bilirubin &lt; 5 mg/dL, no dose reduction<br>If bilirubin &gt; 5 mg/dL, do not use<br>No dose reduction for infusional administration</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Fluorouracil:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:</strong> 100 mg/m2 IV on day 1<br><strong>5-Fluorouracil:</strong> 1,000 mg/m2/day IV continuous infusion on days 1-5<br><strong>Radiation therapy: </strong>6,600-7,600 cGy in 180-200 cGy fractions<br>Repeat cycle every 21-28 days for 3 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (987, null, 'Cladribine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cladribine: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dosage adjustment not provided because of insufficient data. &nbsp;&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong></li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cladribine:</strong><br>If CrCl 10-50 mL/min: Dose reduction by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;10 mL/min: Dose reduction by 50%</li></ul>', 'Low', null, null, null, '<p><strong>Cladribine:</strong> 0.1 mg/kg/day IV continuous infusion on days 1-7</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1129, null, 'BMPT', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If bilirubin&nbsp;1-1.5 times upper normal limit: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If bilirubin&nbsp;&gt;1.5 times upper normal limit: Reduce the initial dose to 0.7 mg/m2.</li><li><strong>Melphalan:</strong><br>No dose reduction</li><li><strong>Prednisone:</strong><br>No dose reduction</li><li><strong>Thalidomide:</strong>&nbsp;<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bortezomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li><li><strong>Melphalan:</strong><br>&nbsp;If CrCl 10 to 50 mL/min: Reduce dose to 75%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose to 50%.</li><li><strong>Prednisone:</strong><br>No dose reduction</li><li><strong>Thalidomide:</strong>&nbsp;<br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Bortezomib:</strong> 1-1.3 mg/m2 IV or SC on days 1, 4, 15, and 22.<br><strong>Melphalan:</strong> 6 mg/m2 PO on days 1-5<br><strong>Prednisone: </strong>60 mg/m2 PO on days 1-5<br><strong>Thalidomide:</strong> 50 mg PO daily<br>Repeat cycle every 5 weeks for 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1131, null, 'Carfilzomib + Lenalidomide + Dexamethasone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carfilzomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If total&nbsp;bilirubin&nbsp;1-3 times upper normal limit: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If total bilirubin&nbsp;&gt;3 times upper normal limit: No dosage recommendation.</li><li><strong>Lenalidomide:</strong><br>No dose reduction.</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carfilzomib:</strong><br>No dose reduction</li><li><strong>Lenalidomide:</strong><br>If CrCl &gt;60 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 30 to 60 mL/min: 5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min not requiring dialysis: 2.5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min requiring dialysis: 2.5 mg once daily (administer after dialysis on dialysis days).</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Carfilzomib: </strong>20 mg/m2 IV on days 1 and 2 of cycle 1, and if tolerated, then 27 mg/m2 IV on days 8, 9, 15, and 16 during cycles 1 through 12 and 27 mg/m2 IV on days 1, 2, 15, and 16 during cycles 13 through 18 after which carfilzomib is discontinued&nbsp;<br><strong>Lenalidomide:</strong> 25 mg PO on days 1-21<br><strong>Dexamethasone:</strong> 40 mg PO on days 1, 8, 15, and 22<br>Repeat cycle every 28 days for up to 9 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1132, null, 'Carfilzomib + Dexamethasone', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carfilzomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>If total&nbsp;bilirubin&nbsp;1-3 times upper normal limit: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If total bilirubin&nbsp;&gt;3 times upper normal limit: No dosage recommendation.</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carfilzomib:</strong><br>No dose reduction.</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Carfilzomib:</strong> 20 mg/m2 IV on days 1, 8, and 15 of cycle 1, and then 70 mg/m2 IV on days 1,8, and 15 for all subsequent cycles<br><br><strong>Dexamethasone:</strong> 40 mg PO on days 1, 8, and 15 for all cycles &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 40 mg PO on days 1, 8, 15, and 22 (cycles 1-9 only)<br>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (810, null, 'Larson Regimen', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL: 75% of usual dosage.&nbsp;<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Daunorubicin:</strong><br>If bilirubin 1.2-3 mg/dL: 75% of usual dosage.<br>If bilirubin 3.1-5 mg/dL: 50% of usual dosage.<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL: 50% of usual dosage.<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL: Do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>L-Asparaginase: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Do not use in patients with severe hepatic impairment.</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 5 mg/dL: Do not use</li><li><strong>6-Mercaptopurine:</strong><br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 3 mg/dL: 50% of usual dosage.</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL: 50% of usual dosage.<br>If bilirubin 3.1-5 mg/dL: 25% of usual dosage.<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>6-Thioguanine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min: 75% of usual dosage.<br>If CrCl &lt; 10 mL/min: 50% of usual dosage.</li><li><strong>Daunorubicin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>L-Asparaginase:</strong><br>No dose reduction</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min: 50% of normal dosage.<br>If CrCl &lt; 30 mL/min: Do not use</li><li><strong>6-Mercaptopurine:</strong><br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>6-Thioguanine:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><i><strong>Induction </strong></i>(weeks 1-4):</p><p><strong>Cyclophosphamide:</strong> &nbsp;1,200 mg/m2 IV on day 1</p><p><strong>Daunorubicin:</strong> 45 mg/m2 IV on &nbsp;days 1 to 3</p><p><strong>Vincristine:</strong> 2 mg IV on days 1, 8, 15, and 22</p><p><strong>Prednisone:</strong> 60 mg/m2/day PO on days 1 to 21</p><p><strong>L-Asparaginase:</strong> 6,000 units/m2 SC on days 5, 8, 11, 15, 18, and 22</p><p><strong>Filgrastim:</strong> &nbsp;5 mcg/kg SC starting on day 4, continue for at least 7 days and until ANC ≥1000/mm3 on two draws, 24 hours apart</p><p><i><strong>Early intensification</strong></i> (Weeks 5 - 12):</p><p><strong>Methotrexate:</strong> 15 mg IT on day 1</p><p><strong>Cyclophosphamide:</strong> 1,000 mg/m2 IV on day 1</p><p><strong>6-Mercaptopurine: </strong>60 mg/m2/day PO on days 1 to 14</p><p><strong>Cytarabine:</strong> 75 mg/m2 IV on days 1 to 4 and 8 to 11</p><p><strong>Vincristine:</strong> 2 mg IV on days 15 and 22</p><p><strong>L-Asparaginase:</strong> 6000 units/m2 SC on days 15, 18, 22, and 25</p><p><strong>Filgrastim:</strong> &nbsp;5 mcg/kg SC starting on day 2; continue at least 14 days and until ANC ≥5000/mm3 on two draws, 24 hours apart.</p><p>Repeat the early intensification cycle once.</p><p><i><strong>CNS prophylaxis and interim maintenance</strong></i> (Weeks 13 to 25):</p><p><strong>Cranial irradiation:</strong> 2,400 cGy on days 1 to 12.</p><p><strong>Methotrexate:</strong> 15 mg IT on days 1, 8, 15, 22, and 29</p><p><strong>6-Mercaptopurine:</strong> 60 mg/m2/ day PO on days 1 to 70</p><p><strong>Methotrexate: </strong>20 mg/m2 PO on days 36, 43, 50, 57, and 64</p><p><i><strong>Late intensification</strong></i> (Weeks 26-33):</p><p><strong>Doxorubicin:</strong> 30 mg/m2 IV on days 1, 8, and 15</p><p><strong>Vincristine: </strong>2 mg IV on days 1, 8, and 15</p><p><strong>Dexamethasone:</strong> 10 mg/m2/day PO on days 1 to 14</p><p><strong>Cyclophosphamide:</strong> 1,000 mg/m2 IV on day 29</p><p><strong>6-Thioguanine:</strong> 60 mg/m2/day PO on days 29 to 42</p><p><strong>Cytarabine:</strong> 75 mg/m2 on days 29, 32, and 36 to 39</p><p><i><strong>Prolonged Maintenance</strong> </i>(continue until 24 months after diagnosis):</p><p><strong>Vincristine:</strong> 2 mg IV on day 1</p><p><strong>Prednisone:</strong> 60 mg/m2/day PO on days 1 to 5&nbsp;</p><p><strong>6-Mercaptopurine:</strong> 80 mg/m2/day PO on days 1 to 28</p><p><strong>Methotrexate:</strong> 20 mg/m2 PO on days 1, 8, 15, and 22</p><p>Repeat maintenance cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (252, 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Dexamethasone : various<br>Doxorubicin : Adriamycin, various<br>Mesna : Mesnex, various<br>Methylprednisolone : Depo-Medrol, Solu-Medrol, various<br>Vincristine : Oncovin, VCR', 'Hyper-CVAD', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Leucovorin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li></ul>', 'High', '<b>Hyper-CVAD</b>', 'Kantarjian HM, O''Brien S, Smith TL, et al. Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. $J Clin Oncol. 2000;18(3):547-561.$', null, '<p><strong>ODD CYCLES (1, 3, 5, 7)</strong><br><strong>Cyclophosphamide:</strong> 300 mg/m2 IV over 3 hours every 12 hours for 6 doses, days 1-3<br><strong>Mesna:</strong> 600 mg/m2 IV over 24 hours on days 1-3, ending 6 hours after cyclophosphamide completion<br><strong>Vincristine:</strong> 2 mg IV, days 4, 11<br><strong>Doxorubicin:</strong> 50 mg/m2 IV, day 4<br><strong>Dexamethasone:</strong> 40 mg PO or IV on days 1-4 and11-14<br>Alternate cycles every 21 days with the following:<br><strong>EVEN CYCLES (2, 4, 6, 8)</strong><br><strong>Methotrexate:</strong> 200 mg/m2 IV over 2 hours, followed by 800 mg/m2 IV over 24 hours on day 1.<br><strong>Leucovorin calcium:</strong> 15 mg IV every 6 hours for 8 doses, beginning 24 hours after Methotrexate completion; adjust per Methotrexate level<br><strong>Cytarabine:</strong> 3,000 mg/m2 IV over 2 hours every 12 hours for 4 doses, days 2-3<br><strong>Methylprednisolone:</strong> 50 mg IV bid, days 1-3.<br>Alternate 4 cycles of hyper-CVAD with 4 cycles of high-dose methotrexate and cytarabine combination therapy.<br><strong>CNS PROPHYLAXIS</strong><br><strong>Methotrexate:</strong> 12 mg IT, day 2 of each cycle<br><strong>Cytarabine:</strong> 100 mg IT, day 8 of each cycle<br>Repeat with each cycle of chemotherapy, depending on the risk of CNS disease.</p><p><strong>Supportive Care: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Ciprofloxacin: </strong>500 mg PO twice daily &nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Fluconazole: </strong>200 mg/day PO &nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Acyclovir: </strong>200 mg PO twice daily &nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;G-CSF: </strong>10 μg/kg/day starting 24 hours after the completion of chemotherapy( on day 5 of hyper-CVAD therapy and on day 4 of high-dose methotrexate and cytarabine therapy)</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1042, null, 'Liposomal Daunorubicin and Cytarabine( Induction Regimen)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Liposomal Daunorubicin:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Liposomal Daunorubicin:</strong><br>If Cr &gt; 3 mg/dL, reduce dose by 50%</li></ul>', 'Low', null, null, null, '<p><strong>Liposomal Daunorubicin and Cytarabine:</strong> 100 U/m2 (44 mg/m2 daunorubicin and 100 mg/m2 cytarabine) IV on days 1, 3 and 5.</p><p>A second induction course and up to 2 cycles of consolidation therapy can be given.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (814, null, 'CVP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL: Reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-29 mL/min: Reduce dose by 25%<br>If CrCl &lt; 10 mL/min: Reduce dose by 50%</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Moderate', null, null, null, '<p><strong>Cyclophosphamide:</strong> 400 mg/m2 PO on day 1-5 (or 800 mg/m2 IV on day 1)</p><p><strong>Vincristine:</strong> 1.4 mg/m2 IV on day 1(maximum dose, 2 mg)</p><p><strong>Prednisone:</strong> 100 mg/m2 PO on days 1-5.<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1133, null, 'Lenalidomide + Dexamethasone + Ixazomib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>No dose reduction.</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li><li><strong>Ixazomib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (Child Pugh class A): No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate to severe impairment (Child Pugh class B and C): Reduce initial dose to 3 mg once weekly on days 1, 8, and 15 of a 28-day treatment cycle</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lenalidomide:</strong><br>If CrCl &gt;60 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 30 to 60 mL/min: 5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min not requiring dialysis: 2.5 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min requiring dialysis: 2.5 mg once daily (administer after dialysis on dialysis days).</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li><li><strong>Ixazomib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &gt;30 mL/min: No dosage reduction &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Reduce initial dose to 3 mg once weekly on days 1, 8, and 15 of a 28-day treatment cycle</li></ul>', 'Low', null, null, null, '<p><strong>Lenalidomide:</strong> 25 mg/day PO on days 1-21<br><strong>Dexamethasone: </strong>40 mg/day PO on days 1,8, 15, and 22<br><strong>Ixazomib:</strong> 4 mg/day PO on days 1,8, and 15<br>Repeat cycle every 28 days until disease progression</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1138, null, 'lbrutinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ibrutinib:</strong> &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (Child-Pugh class A): Decrease dose to 140 mg PO daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If moderate impairment (Child-Pugh class B): Decrease dose to 70 mg PO daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (Child-Pugh class C): Do not use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ibrutinib:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Dosage adjustment not provided by the manufacturer.</li></ul>', 'Low', null, null, null, '<p><strong>Ibrutinib:</strong> 420 mg/day PO daily<br><br>Continue treatment until disease progression</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1139, null, 'Melphalan', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Melphalan:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Melphalan:</strong><br>&nbsp;If CrCl 10 to 50 mL/min: Reduce dose to 75%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose to 50%.</li></ul>', 'Low', null, null, null, '<p><strong>Melphalan:</strong> 90-140 mg/m2 IV on day 1.<br>Repeat cycle every 28-42 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (861, null, 'Cabozantinib (Medullary carcinoma of the thyroid)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cabozantinib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If mild impairment (Child-Pugh class A): Reduce the initial dose to 80 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If moderate impairment (Child-Pugh class B): Reduce the initial dose to 80 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): Use is not recommended</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cabozantinib:&nbsp;</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'High', null, null, null, '<p><strong>Cabozantinib: </strong>140 mg PO daily<br>Continue treatment until disease progression</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (865, null, 'Carfilzomib + Dexamethasone + Rituximab ( Neuropathy sparing approach)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carfilzomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If bilirubin&nbsp;1.5 to 3 times upper normal limit: Reduce the initial dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If bilirubin&nbsp;&gt;3 times upper normal limit: No dosage adjustment as per manufacturer.</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carfilzomib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>No dose reduction</li><li><strong>Dexamethasone:</strong><br>No dose reduction</li><li><strong>Rituximab:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Carfilzomib:</strong> 20 mg/m2 IV on days 1, 2, 8, and 9 in cycle 1 and then 36 mg/m2 IV on days 1, 2, 8, and 9 in cycles 2-6<br><strong>Dexamethasone:</strong> 20 mg IV on days 1, 2, 8, and 9<br><strong>Rituximab: </strong>375 mg/m2 IV on days 2 and 9<br>Repeat cycle every 21 days for up to 6 induction cycles, followed by 8-week<br>break, and then 8 additional cycles for maintenance therapy as follows:<br><strong>Carfilzomib:</strong> 36 mg/m2 IV on days 1 and 2 in cycle 1 and then 36 mg/m2 IV on days 1, 2, 8, and 9 in cycles 2-6<br><strong>Dexamethasone: </strong>20 mg IV on days and 1 and 2<br><strong>Rituximab:</strong> 375 mg/m2 IV on day 2<br>Repeat cycle every 8 weeks for up to 8 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (844, null, 'PEB', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Bleomycin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Bleomycin</strong><br>If CrCl &gt;50 mL/min: No dose reduction<br>If CrCl 40-50 mL/min: 70% of normal dose<br>If CrCl 30-40 mL/min: 60% of normal dose<br>If CrCl 20-30 mL/min: 55% normal dose<br>If CrCl 10-20 mL/min: 45% normal dose<br>If CrCl 5-10 mL/min: 40% normal dose</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin: </strong>20 mg/m2/day IV on days 1-5<br><strong>Etoposide:</strong> 100 mg/m2/day IV on days 1-5<br><strong>Bleomycin: </strong>30 U IV on days 2, 9, and 16</p><p><br>Repeat cycle every 28 days for a total of 2 cycles. Adjuvant therapy of stage II testicular cancer treated with orchiectomy and retroperitoneal lymph node<br>dissection.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1143, null, 'Bevacizumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bevacizumab: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Bevacizumab: </strong>10 mg/kg lV on day 1<br>Repeat cycle every 2 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1144, null, 'Pazopanib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Pazopanib:</strong><br>If mild impairment (AST &gt; ULN and total bilirubin ≤ ULN <strong>or</strong> total bilirubin &gt;1 to ≤1.5 times ULN and any AST): 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If moderate impairment (total bilirubin &gt;1.5 to ≤3 times ULN and any AST): Reduce initial dose to 200 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (total bilirubin &gt;3 times ULN and any AST): Avoid use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Pazopanib:</strong><br>No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Pazopanib:</strong> 800 mg PO daily</p><p>Continue treatment until disease progression</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1145, null, 'Axitinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Axitinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If mild impairment (Child-Pugh class A): 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (Child-Pugh class B): Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C):&nbsp;<strong> </strong>Dosage adjustments not provided by the manufacturer.</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Axitinib: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> If<strong> </strong>CrCl 15 to &lt;89 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;15 mL/min:&nbsp;<strong> </strong>Dosage adjustments not provided by the manufacturer.</li></ul>', 'Low', null, null, null, '<p><strong>Axitinib:</strong> 5 mg PO bid; 2 weeks later may increase the dose to 7 mg PO bid; after 2 weeks may increase the dose to 10 mg P0 bid<br>Continue cycle every 6 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1146, null, 'Everolimus', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Everolimus:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (Child-Pugh class A): Reduce initial dose by ~33%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (Child-Pugh class B): &nbsp;Reduce initial dose by ~50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (Child-Pugh class C): Reduce initial dose by ~50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ( Further dosing should be individualized based on therapeutic drug monitoring - target trough concentration: 3 to 8 ng/mL)</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Everolimus:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Everolimus:</strong> 10 mg PO daily<br>Continue treatment until disease progression.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1147, null, 'Aldesleukin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Interleukin-2: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Dosage adjustments not provided by the manufacturer.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Interleukin-2: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> If serum creatinine ≤1.5 mg/dL: Dosage adjustments not provided by the manufacturer. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If serum creatinine &gt;1.5 mg/dL: Do not initiate treatment.</li></ul>', 'Low', null, null, null, '<p><strong>Interleukin-2:</strong> 720,000 IU/kg IV every 8 hours on days 1-5 and 15-19<br>Repeat cycles in 6 to 12-week intervals for a total of 3 cycles.<br>OR<br><br><strong>Interleukin-2:</strong> 720,000 IU/kg IV at 8 am and 6 pm on days 1-5 and 15-19 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Treat for a total of 8 &nbsp;doses on days 1-5 and repeat on days 15-19.<br>Repeat cycles in 8- to 12-week intervals.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1148, null, 'Interferon alpha-2a', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Interferon alfa-2a</strong>:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Interferon alfa-2a</strong>:<br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Interferon alpha-2a:</strong> 5-15 million U SC daily or 3-5 times per week.</p><p>&nbsp;Continue treatment until disease progression</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1149, null, 'Cabozantinib', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cabozantinib:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (Child-Pugh class A): 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If moderate impairment (Child-Pugh class B): Reduce the initial dose to 40 mg once daily. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If severe impairment (Child-Pugh class C): Use is not recommended&nbsp;</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cabozantinib:&nbsp;</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'High', null, null, null, '<p><strong>Cabozantinib:</strong> 60 mg P0 daily<br>Continue treatment until disease progression&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1150, null, 'Nivolumab', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nivolumab:</strong>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; No dose reduction.</li></ul>', 'Low', null, null, null, '<p><strong>Nivolumab:</strong> 240 mg IV on day 1<br>Repeat cycle every 2 weeks. May also administer 480 mg IV on day 1 with cycles repeated every 4 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1151, null, 'CYVADIC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Dacarbazine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Dacarbazine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 20%. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 45 mL/min: Reduce dose to 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≤30 mL/min: Reduce dose to 30%.</li></ul>', 'High', null, null, null, '<p><strong>Cyclophosphamide: </strong>500 mg/m2 IV on day 1<br><strong>Vincristine:</strong> 1.5 mg/m2 IV on day 1 (maximum, 2 mg)<br><strong>Doxorubicin: </strong>50 mg/m2 IV on day<br><strong>Dacarbazine:</strong> 750 mg/m2 IV on day 1<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1152, null, 'Gemcitabine + Docetaxel', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Docetaxel</strong>:<br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Docetaxel</strong>:<br>No dose reduction</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Gemcitabine:</strong> 900 mg/m2 IV over 90 minutes on days 1 and 8<br><strong>Docetaxel: </strong>100 mg/m2 IV on day 8<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1153, null, 'Gemcitabine + Navelbine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vinorelbine:</strong><br>If bilirubin 2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vinorelbine:</strong><br>No dose reduction</li><li><strong>Gemcitabine:</strong><br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Gemcitabine:</strong> 800 mg/m2 IV over 90 minutes on days 1 and 8<br><strong>Vinorelbine:</strong> 25 mg/m2 IV on days 1 and 8<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1159, null, 'Trabectedin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Trabectedin:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (AST &gt; ULN and total bilirubin ≤ ULN <strong>or</strong> total bilirubin &gt;1 to ≤1.5 times ULN and any AST): 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If moderate impairment (total bilirubin &gt;1.5 to ≤3 times ULN and any AST): Reduce dose from 1.5 mg/m2 to 0.9 mg/m2. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (total bilirubin &gt;3 times ULN and any AST): Avoid use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Trabectedin:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl ≥30 &nbsp;mL/min: No dosage adjustment necessary. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: There is no dosage adjustment provided in the manufacturer''s labeling</li></ul>', 'Moderate', null, null, null, '<p><strong>Trabectedin:</strong> 1.5 mg/m2 IV on day 1<br>Repeat cycles every 21 days. Continue treatment until disease progression or unacceptable toxicity</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1160, null, 'Eribulin', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Eribulin:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If mild impairment (AST &gt; ULN and total bilirubin ≤ ULN <strong>or</strong> total bilirubin &gt;1 to ≤1.5 times ULN and any AST): Reduce initial dose to &nbsp;1.1 mg/m2. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If moderate impairment (total bilirubin &gt;1.5 to ≤3 times ULN and any AST): Reduce initial dose to &nbsp;0.7 mg/m2.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If severe impairment (total bilirubin &gt;3 times ULN and any AST): Avoid use.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Eribulin:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl ≥50 &nbsp;mL/min: No dosage adjustment necessary. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 15 to 49 mL/min: Reduce initial dose to &nbsp;1.1 mg/m2.&nbsp;</li></ul>', 'Low', null, null, null, '<p><strong>Eribulin: </strong>1.4 mg/m2 IV on days 1 and 8<br>Repeat cycles every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1173, null, 'Nivolumab (Resected Esophageal or GE junction CA)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Nivolumab:</strong><br>Dose modification not provided by the manufacturer</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Nivolumab:</strong><br>Dose modification not provided by the manufacturer</li></ul>', 'Low', null, null, null, '<p><strong>Nivolumab: </strong>240 mg IV once every 2 weeks for 16 weeks followed by 480 mg IV once every 4 weeks.</p><p>Continue treatment for up to 1 year.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (300, 'Lomustine : CCNU<br>Prednisone : various<br>Vincristine : Oncovin, VCR', 'POC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Lomustine:</strong><br>No dose reduction</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Lomustine:</strong><br>If CrCl 10 to 50 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;10 mL/min: Reduce dose by 25% to 50%</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li></ul>', 'Severe', '<b>POC</b>', 'Finlay JL, Bayett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. $J Clin Oncol. 1995;13(1):112-123.$', null, '<p><strong>Prednisone:</strong> 40 mg/m2/d PO, days 1-14<br><strong>Lomustine:</strong> 100 mg/m2 PO, day 1<br><strong>Vincristine:</strong> 1.5 mg/m2/d IV, days 1, 8, 15</p><p>Repeat cycle every 6 weeks for 8 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1165, null, 'PVB', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vinblastine:</strong><br>If serum bilirubin 1.5 to 3 mg/dL or transaminases 2 to 3 times ULN: Administer 50% of dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If serum bilirubin &gt;3 times ULN: Avoid use.</li><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Bleomycin:&nbsp;</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vinblastine:</strong><br>No dose reduction</li><li><strong>Cisplatin</strong>:<strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Bleomycin</strong><br>If CrCl &gt;50 mL/min: No dose reduction<br>If CrCl 40-50 mL/min: 70% of normal dose<br>If CrCl 30-40 mL/min: 60% of normal dose<br>If CrCl 20-30 mL/min: 55% normal dose<br>If CrCl 10-20 mL/min: 45% normal dose<br>If CrCl 5-10 mL/min: 40% normal dose</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin: </strong>20 mg/m2/day IV on days 1-5<br><strong>Vinblastine:</strong> 0.15 mg/kg IV on days 1 and 2<br><strong>Bleomycin: </strong>30 U IV on days 2, 9, and 16<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1166, null, 'VAB-6', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vinblastine:</strong><br>If serum bilirubin 1.5 to 3 mg/dL or transaminases 2 to 3 times ULN: Administer 50% of dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If serum bilirubin &gt;3 times ULN: Avoid use.</li><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Bleomycin:&nbsp;</strong><br>No dose reduction</li><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Dactinomycin:</strong><br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Vinblastine:</strong><br>No dose reduction</li><li><strong>Cisplatin</strong>:<strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Bleomycin</strong><br>If CrCl &gt;50 mL/min: No dose reduction<br>If CrCl 40-50 mL/min: 70% of normal dose<br>If CrCl 30-40 mL/min: 60% of normal dose<br>If CrCl 20-30 mL/min: 55% normal dose<br>If CrCl 10-20 mL/min: 45% normal dose<br>If CrCl 5-10 mL/min: 40% normal dose</li><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Dactinomycin:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Vinblastine:</strong> 4 mg/m2 IV on day 1<br><strong>Dactinomycin: </strong>1 mg/m2 IV on day 1<br><strong>Bleomycin:</strong> 30 U IV on day 1, then 20 U/m2 continuous infusion on days 1-3</p><p><strong>Cisplatin: </strong>20 mg/m2 IV on day 4<br><strong>Cyclophosphamide: </strong>600 mg/m2 IV on day 1<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1167, null, 'VelP (salvage regimen)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Ifosfamide</strong>:<br>No dose reduction</li><li><strong>Vinblastine:</strong><br>If serum bilirubin 1.5 to 3 mg/dL or transaminases 2 to 3 times ULN: Administer 50% of dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If serum bilirubin &gt;3 times ULN: Avoid use.</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Ifosfamide</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥10 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: &nbsp;75% dosage.</li><li><strong>Vinblastine:</strong><br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Vinblastine:</strong> 0.11 mg/kg IV on days 1 and 2<br><strong>Ifosfamide:</strong> 1,200 mg/m2/day IV on days 1-5<br><strong>Cisplatin: </strong>20 mg/m2/day IV on days 1-5<br><strong>Mesna:</strong> 400 mg/m2 IV, given 15 minutes before first ifosfamide dose, then<br>1,200 mg/m2/day IV continuous infusionfor 5 days<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1168, null, 'VIP (salvage regimen)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Ifosfamide</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Ifosfamide</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥10 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: &nbsp;75% dosage.</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Etoposide (VP-16):</strong> 75 mg/m2/day IV on days 1-5<br><strong>lfosfamide:</strong> 1,200 mg/m2/day IV on days 1-5<br><strong>Cisplatin: </strong>20 mg/m2/day IV on days 2-5<br><strong>Mesna:</strong> 400 mg/m2 IV, given 15 minutes before first ifosfamide dose, then<br>1,200 mg/m2/day IV continuous infusion for 5 days<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1170, null, 'Paclitaxel + Gemcitabine', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>For 3-hour infusion:<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Gemcitabine:</strong><br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Paclitaxel:</strong> 100 mg/m2 IV on days 1,8, and 15<br><strong>Gemcitabine: </strong>1,000 mg/m2 IV on days 1,8, and 15<br>Repeat cycle every 28 days for a total of 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1169, null, 'TIP (salvage regimen)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</li><li><strong>Ifosfamide</strong>:<br>No dose reduction</li><li><strong>Paclitaxel</strong>:<br>For 24-hour infusion:<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: 75% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: 50% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug.</li><li><strong>Ifosfamide</strong>: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl ≥10 mL/min: 100% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: &nbsp;75% dosage.</li><li><strong>Paclitaxel</strong>:<br>No dose reduction</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Paclitaxel: </strong>250 mg/m2 IV over 24 hours on day 1<br><strong>Ifosfamide:</strong> 1,500 mg/m2/day IV on days 2-5<br><strong>Cisplatin:</strong> 25 mg/m2/day IV on days 2-5<br><strong>Mesna:</strong> 500 mg/m2 IV, given before ifosfamide dose, and at 4 and 8 hours after ifosfamide on days 2-5<br>Repeat cycle every 21 days for a total of 4 cycles. G-CSF support at<br>5 µg/kg/day SC should be given on days 7-18.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1175, null, 'CA', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>L-Asparaginase: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Do not use in patients with severe hepatic impairment.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>L-Asparaginase:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Cytarabine:</strong> 3,000 mg/m2 IV over 3 hours every 12 hours for 4 doses<br><strong>Asparaginase:</strong> 6,000 units/m2 IM 3 hours after the last dose of cytarabine<br>Repeat every 28 days after the initial cycle or after recovery of blood counts, whichever is later</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1176, null, 'DA', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Daunorubicin:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Daunorubicin:</strong><br>If Cr &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 40% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Consider use of alternative drug.</li></ul>', 'Moderate', null, null, null, '<p><strong>Daunorubicin:&nbsp;</strong> 45 mg/m2/day IV, days 1-3<br><strong>Cytarabine:</strong> 100 mg/m2/day continuous infusion IV, days 1-7</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1177, null, 'Augmented BFM', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL: 75% of usual dosage.&nbsp;<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL: 50% of usual dosage.<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL: Do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Dexamethasone:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>L-Asparaginase: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Do not use in patients with severe hepatic impairment.</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 5 mg/dL: Do not use</li><li><strong>6-Mercaptopurine:</strong><br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 3 mg/dL: 50% of usual dosage.</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL: 50% of usual dosage.<br>If bilirubin 3.1-5 mg/dL: 25% of usual dosage.<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>6-Thioguanine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min: 75% of usual dosage.<br>If CrCl &lt; 10 mL/min: 50% of usual dosage.</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Dexamethasone:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>L-Asparaginase:</strong><br>No dose reduction</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min: 50% of normal dosage.<br>If CrCl &lt; 30 mL/min: Do not use</li><li><strong>6-Mercaptopurine:</strong><br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>6-Thioguanine:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>&nbsp;</strong><i><strong>CONSOLIDATION</strong></i></p><p><strong>Cyclophosphamide:</strong> 1000 mg/m2/ day IV on days 0, 28 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Cytarabine:</strong> 75 mg/m2/day SC or IV on days 1-4, 8-11, 29-32, 36-39. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Mercaptopurine:</strong> 60 mg/m2/ day PO on days 0-13, 28-41. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong> Vincristine:</strong> 1.5 mg/m2/day IV on days 14, 21, 42, 49. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong> Asparaginase:</strong> 6000 units/m2/day IM on days 14, 16, 18, 21, 23, 25, 42, 44, 46, 49, 51, 53. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong> &nbsp;Methotrexate</strong>: IT on days 1, 8, 15, and 22. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Radiotherapy:</strong> Cranial at 1800 cGy (CNS 1); cranial at 2400 cGy and spinal 600 cGy (CNS 2 and 3); testicular at 2400 cGy for clinical involvement.</p><p><i><strong>INTERIM MAINTENANCE (I)</strong></i></p><p><strong>Vincristine:</strong> 1.5 mg/m2/day IV on days 0, 10, 20, 30, 40 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Methotrexate</strong>: 100 mg/m2/day IV on days 0, 10, 20, 30, 40 &nbsp; &nbsp;( Can increase dose by 50 mg/m2/dose)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>Asparaginase:</strong> 15000 units/m2/day IM on days 1, 11, 21, 31, and 41.</p><p><i><strong>DELAYED INTENSIFICATION (I) &nbsp;</strong></i><strong> &nbsp;&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Reinduction</strong></p><p><strong>Dexamethasone: </strong>10 mg/m2/day PO, days 0-20, then taper for 7 days &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Doxorubicin:</strong> 25 mg/m2 day IV on days 0, 7, and 14. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Vincristine:</strong> 1.5 mg/m2/day IV on days 0, 14, 21. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Asparaginase:</strong> 6000 units/m2/day IM on days 3, 5, 7, 10, 12, 14.</p><p><strong>Reconsolidation. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Vincristine:</strong> 1.5 mg/m2/day IV on days 42, 49. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Cyclophosphamide:</strong> 1000 mg/m2/ day IV on day 28 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Thioguanine: </strong>60 mg/m2/day PO on days 28 to 41. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Cytarabine:</strong> 75 mg/m2/day SC or IV on days 29-32, 36-39. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Methotrexate</strong>: IT on days 29, 36 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Asparaginase:</strong> 6000 units/m2/day IM on days 42, 44, 46, 49, 51, 53.</p><p>&nbsp;<i><strong>INTERIM MAINTENANCE (II)</strong></i></p><p><strong>Vincristine:</strong> 1.5 mg/m2/day IV on days 0, 10, 20, 30, 40 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Methotrexate</strong>: 100 mg/m2/day IV on days 0, 10, 20, 30, 40 &nbsp;( Can increase dose by 50 mg/m2/dose)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Asparaginase:</strong> 15000 units/m2/day IM on days 1, 11, 21, 31, and 41. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> Methotrexate</strong>: IT on days&nbsp;0, 20 and 40.</p><p>&nbsp; <i><strong>DELAYED INTENSIFICATION (II) &nbsp;</strong></i><strong> &nbsp;&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Reinduction</strong></p><p><strong>Dexamethasone: </strong>10 mg/m2/day PO, days 0-20, then taper for 7 days &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Doxorubicin:</strong> 25 mg/m2 day IV on days 0, 7, and 14. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Vincristine:</strong> 1.5 mg/m2/day IV on days 0, 14, 21. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Asparaginase:</strong> 6000 units/m2/day IM on days 3, 5, 7, 10, 12, 14.</p><p><strong>Reconsolidation. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Vincristine:</strong> 1.5 mg/m2/day IV on days 42, 49. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Cyclophosphamide:</strong> 1000 mg/m2/ day IV on day 28 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Thioguanine: </strong>60 mg/m2/day PO on days 28 to 41. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Cytarabine:</strong> 75 mg/m2/day SC or IV on days 29-32, 36-39. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Methotrexate</strong>: IT on days 29, 36 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Asparaginase:</strong> 6000 units/m2/day IM on days 42, 44, 46, 49, 51, 53.</p><p><i><strong>MAINTENANCE</strong></i></p><p><strong>Vincristine:</strong> 1.5 mg/m2/day IV on days 0, 28, and 56. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Prednisone:</strong> 60 mg/m2/day PO on days 0-4, 28-32, 56-60. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Methotrexate</strong>: 20 mg/m2/day PO on days 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Mercaptopurine:</strong> 75 mg/m2/ day IM on days 0-83. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong> Methotrexate</strong>: IT on days&nbsp;0&nbsp;</p><p>Repeat cycles for 2 years from first interim maintenance for girls, 3 years for boys.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (322, 'Cytarabine : Ara-C<br>Prednisone : various<br>Vincristine : Oncovin, VCR', 'VCR + Prednisone + Pegaspargase + Cytarabine + MTX', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Prednisone:</strong><br>No dose reduction</li><li><strong>Pegaspargase:</strong><br>No dose reduction</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><p>&nbsp;</p><ul><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone:</strong><br>No dose reduction</li><li><strong>Pegaspargase:</strong><br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 40%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 45 mL/minute: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li></ul>', 'Moderate', '<b>VCR/Prednisone/Pegaspargase/Cytarabine/MTX</b>', 'Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children''s Cancer Group Study. $Blood. 2002;99(6):1986-1994.$ $Erratum in: Blood. 2002; 100(6):1531.$', null, '<p><strong>Vincristine:</strong> 1.5 mg/m2 IV, days 0, 7, 14, 21<br><strong>Prednisone:</strong> 40 mg/m2 PO, days 0-28, then 10-day taper<br><strong>Pegaspargase:</strong> 2,500 units/m2 IM, day 3<br><strong>Cytarabine:</strong> 30, 50, or 70 mg IT, age-adjusted, day 0<br><strong>Methotrexate:</strong> 8, 10, or 12 mg IT, age-adjusted, days 7, 28</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (326, 'Cytarabine : Ara-C<br>Hydrocortisone : various', 'TIT (CNS Prophylaxis)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Hydrocortisone:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 40%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 45 mL/minute: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Hydrocortisone:</strong><br>No dose reduction</li></ul>', 'Moderate', '<b>TIT (CNS Prophylaxis)</b>', 'Lauer SJ, Camitta BM, Leventhal BG, et al. Intensive alternating drug pairs for treatment of hgh-risk chidhood acute lymphoblastic leukemia. Apediatric Oncology Group pilot study. $Cancer. 1993;71(9):2854-2861.$', null, '<p><strong>Regimen: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Age 1 year &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Age 2 year &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Age ≥ 3 years</strong><br><strong>Methotrexate: &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong> 10 mg &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.5 mg &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 15 mg<br><strong>Cytarabine:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 20 mg &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 25 mg &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;30 mg<br><strong>Hydrocortisone:</strong> &nbsp; &nbsp; &nbsp; 10 mg &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.5 mg &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;15 mg<br>Administer IT on day 1, then at weeks 1, 2, 3, 6, 11, 16, 21, 26, 31, then every 12 weeks</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1178, null, 'SNCCL/B-ALL', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL: 75% of usual dosage.&nbsp;<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL: 50% of usual dosage.<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL: Do not use</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 5 mg/dL: Do not use</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 3 mg/dL: 50% of usual dosage.</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL: 50% of usual dosage.<br>If bilirubin 3.1-5 mg/dL: 25% of usual dosage.<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min: 75% of usual dosage.<br>If CrCl &lt; 10 mL/min: 50% of usual dosage.</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min: 50% of normal dosage.<br>If CrCl &lt; 30 mL/min: Do not use</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Leucovorin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No dose reduction.</li></ul>', 'High', null, null, null, '<p>INITIAL PHASE<br><strong>Cytarabine:</strong> 50 mg/m2/day (maximum, 50 mg/d) IT, days 1, 2, 3, 11<br><strong>Methotrexate:</strong> 12 mg/m2/day (maximum, 12 mg/d) IT, days 4, 11<br><strong>Cyclophosphamide:</strong> 300 mg/m2 IV push every 12 hours for 6 doses, days 1-3<br><strong>Doxorubicin:</strong> 50 mg/m2 IV, day 4<br><strong>Vincristine:</strong> 1.5 mg/m2/day IV, days 4, 11<br>Alternating with:<br><br>SECONDARY PHASE<br><strong>Cytarabine:</strong> 50 mg/m2 (maximum, 50 mg) IT, day 1<br><strong>Methotrexate:</strong> 12 mg/m2 (maximum, 12 mg) IT, day 1<br><strong>Methotrexate:</strong> 200 mg/m2 IV bolus, then 800 mg/m2 IV continuous infusion for 24 hours.<br><strong>Cytarabine:</strong> 3,000 mg/m2 IV over 3 hours every 12 hours for 4 doses, days 2, 3<br><strong>Leucovorin calcium:</strong> 30 mg/m2 IV at hour 42, then 3 mg/m2 IV at hours 54, 66, 78</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (303, 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16', 'A3', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', '<b>A<sub>3</sub></b>', 'Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. $J Pediatr Hematol Oncol. 2002;24(8):613-621.$', null, '<b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup>/d IV, days 1, 2<br> <b>Doxorubicin</b> 40 mg/m<sup>2</sup> IV, day 3<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Cisplatin</b> 25 mg/m<sup>2</sup>/d CIVI, days 1-5', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1181, null, 'IFoVP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ifosfamide</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Ifosfamide</strong>:<br>&nbsp;If CrCl ≥10 mL/min: 100% normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: 75% normal dose.</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Mesna:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Ifosfamide:</strong> 1,800 mg/m2/day IV, days 1-5<br><strong>Etoposide:</strong> 100 mg/m2/d IV over 1 hour, days 1-5<br><strong>Mesna:</strong> 2,880 mg/m2/day IV, days 1-5<br>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (315, 'Cyclophosphamide : Cytoxan<br>Topotecan : Hycamtin', 'Topo + CTX', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Topotecan:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Topotecan:</strong><br>If CrCl &gt; 40 mL/min, no dose reduction&nbsp;<br>If CrCl 20-39 mL/min, reduce to 0.75 mg/m2</li></ul>', 'High', '<b>Topo/CTX</b>', 'Saylors RL, Stewart CF, Zamboni WC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncolgy Group study. $J Clin Oncol. 1998;16(3):945-952.$', null, '<p><strong>Cyclophosphamide:</strong> 250 mg/m2/day IV, days 1 to 5.<br>Followed by<br><strong>Topotecan:</strong> 0.6-0.75 mg/m2/day IV as an escalating dose, days 1-5</p><p><strong>Filgrastim:</strong> 5 mcg/kg SC daily beginning on day 6 until ANC ≥1,500/mm3 after the time of expected nadir</p><p>Repeat cycle every 21 days until disease progression and unacceptable toxicity.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1182, null, '6-MP orally MTX', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL: 75% of usual dosage.<br>If bilirubin &gt; 5 mg/dL: Do not use</li><li><strong>6-Mercaptopurine:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min: 50% of normal dosage.<br>If CrCl &lt; 30 mL/min: Do not use</li><li><strong>6-Mercaptopurine:</strong><br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Mercaptopurine:</strong> 25 mg/m2/day PO, days 1-56</p><p><strong>Methotrexate:</strong> 5000 mg/m2 IV over 24 hours on days 8,22, 36, 50.&nbsp;</p><p><strong>Methotrexate:</strong> 12 mg/day IT (adjust dose for children less than 3 years)days 8,22, 36, 50.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (336, '', 'MidAC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Mitoxantrone</strong><br>There are no pediatric-specific recommendations</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 40%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 45 mL/minute: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Mitoxantrone</strong><br>There are no pediatric-specific recommendations</li></ul>', 'Moderate', '<b>MidAC</b>', 'Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council''s 10th AML trial. $Br J Haematol. 1998;101(1):130-140.$', null, '<p><strong>Mitoxantrone:</strong> 10 mg/m2 IV (short infusion), days 1-5<br><strong>Cytarabine:</strong> 1,000 mg/m2 IV (2-hour infusion), every 12 hours, days 1-3</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (305, 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16', 'Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide( High risk Neuroblastoma)', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', '<b>High-risk neuroblastoma</b>', 'Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid. $N Engl J Med. 1999;341(16):1165-1173.$', null, '<p><strong>Cisplatin:</strong> 60 mg/m2 IV over 6 hours, day 0<br><strong>Doxorubicin:</strong> 30 mg/m2 IV, day 2<br><strong>Etoposide:</strong> 100 mg/m2/day IV, days 2, 5<br><strong>Cyclophosphamide:</strong> 1,000 mg/m2/day IV, days 3, 4<br>Repeat every 28 days for a total of 5 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1183, null, 'MAE 3+10+5', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>Mitoxantrone</strong><br>There are no pediatric-specific recommendations</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 40%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl 31 to 45 mL/minute: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>Mitoxantrone</strong><br>There are no pediatric-specific recommendations</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'Moderate', null, null, null, '<p><strong>Mitoxantrone:</strong> 12 mg/m2 IV days 1, 3, 5.<br><strong>Cytarabine:</strong> 100 mg/m2 IV every 12 hours, days 1-10</p><p><strong>Etoposide:</strong> 100 mg/m2 IV, days 1 to 5.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1184, null, 'CLASP', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 3 mg/dL, reduce dose by 50%</li><li><strong>L-Asparaginase: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Do not use in patients with severe hepatic impairment.</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: 60% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: 50% of normal dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li><li><strong>L-Asparaginase:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Cytarabine:</strong> 3,000 mg/m2 every 12 hours IV, days 1, 2, 8, 9.<br><strong>Asparaginase:</strong> 6,000 units/m2 SC, day 2, 9.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1185, null, 'ADE 10+3+5', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Daunorubicin:</strong><br>If bilirubin 1.2-3 mg/dL: &nbsp;Reduce dose by 25%&nbsp;<br>If bilirubin 3.1-5 mg/dL: Reduce dose by 50%<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Cytarabine:</strong><br>If bilirubin 1.5-3 mg/dL: &nbsp;Reduce dose by 25%&nbsp;<br>If bilirubin &gt; 3 mg/dL: Reduce dose by 50%</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Daunorubicin:</strong><br>No dose reduction</li><li><strong>Cytarabine:</strong><br>If CrCl 46 to 60 mL/min: Reduce dose by 40% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/minute: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Consider use of alternative drug.</li></ul>', 'Moderate', null, null, null, '<p><strong>Cytarabine:</strong> 100 mg/m2 every 12 hours IV, days 1-10</p><p><strong>Daunorubicin:&nbsp;</strong> 50 mg/m2/day IV, days 1, 3, 5</p><p><strong>Etoposide:</strong> 100 mg/m2 IV, days 1- 5.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (310, 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various', 'MTX-CDDP/Adr', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Leucovorin:</strong><br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cisplatin:</strong><br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Leucovorin:</strong><br>No dose reduction</li></ul>', 'High', '<b>MTX-CDDP/Adr</b>', 'Weiner MA, Harris MB, Lewis M, et al. Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma. $Cancer Treat Rep. 1986;70(12):1431-1432.$', null, '<p><strong>Methotrexate:</strong> 12,000 mg/m2 IV weekly for 2 weeks; escalate dose by 1,000 mg/m2 in subsequent courses until peak level of 10 to the power -8 M is reached (reduce dose to 8,000 mg/m2 IV for patients &gt;12 years)<br><strong>Leucovorin calcium:</strong> 20 mg/m2 IV every 3 hours for 8 doses beginning 16 hours after completion of methotrexate, then every 6 hours PO for 8 doses<br><strong>ALTERNATING WITH:</strong><br><strong>Cisplatin:</strong> 75 mg/m2 IV, day 15 of cycles 1-7, then 120 mg/m2 for cycles 8-10<br><strong>Doxorubicin:</strong> 25 mg/m2/day IV, days 15-17 of cycles 1-7</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (847, null, 'Vincristine/ Carboplatin/ Etoposide', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Carboplatin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Carboplatin</strong>:<br>Dosing based on <strong>mg/m2</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Vincristine:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Vincristine:</strong> 0.05 mg/kg (for age &lt;12 months) <strong>OR</strong> 1.5-2 mg/m2 (for age &gt;12 months) on day 0<br><strong>Carboplatin:</strong> 20 mg/kg (for age &lt;12 months) &nbsp;<strong>OR </strong>550-600 mg/m2<strong> </strong>(for age &gt;12 months) on day 0<br><strong>Etoposide phosphate: </strong>5 mg/kg (for age &lt;12 months) or 150 mg/m2 (for age &gt;12 months) on day 0 and 1.</p><p>Repeat cycle every 28 days for 6 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1180, null, 'ICE', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Ifosfamide</strong>:<br>No dose reduction</li><li><strong>Carboplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><ul><li><strong>Ifosfamide</strong>:<br>&nbsp;If CrCl ≥10 mL/min: 100% normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;10 mL/min: Reduce dose by 25%</li><li><strong>Carboplatin</strong>:<br>Dosing based on&nbsp;<strong>mg/m2</strong>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100 % dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min:&nbsp;Reduce dose by 50%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min:&nbsp;Reduce dose by 75%</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', null, null, null, '<p><strong>Ifosfamide:</strong> 1,800 mg/m2/day IV over 1 hour, days 0 to 4<br><strong>Carboplatin:</strong> 400 mg/m2/day IV over 1 hour, days 0 and 1<br><strong>Etoposide: </strong>100 mg/m2/day IV over 1 hour, days 0 to 4</p><p><strong>Filgrastim:</strong> 5 to 10 mcg/kg/day SC, days 6 to 18 if ANC ≥1,000/mm3 or until post nadir ANC ≥1,000/mm3</p><p>Repeat cycle every 21 days for up to 12 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1174, null, 'CDDP/VP-16', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<br>No dose reduction</li><li><strong>Etoposide</strong>:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin</strong>:<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>If CrCl 46 to 60 mL/min: Reduce dose by 25% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl 31 to 45 mL/min: Reduce dose by 50% &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If CrCl &lt;30 mL/min: Use alternative drug</li><li><strong>Etoposide</strong>:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin:&nbsp;</strong>90 mg/m2&nbsp;IV on day 1</p><p><strong>Etoposide:&nbsp;</strong>150 mg/m2/day&nbsp;IV on day 3, 4</p><p>Repeat cycles every 21 days for a total of 4 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1186, null, 'HIT-SKK', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Methotrexate</strong>:<br>If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br>If bilirubin &gt; 5 mg/dL, do not use</li><li><strong>Cyclophosphamide</strong>:<br>No pediatric-specific dosing.</li><li><strong>Carboplatin:</strong><br>No pediatric-specific dosing.</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><p>&nbsp;</p><ul><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Methotrexate</strong>:<br>If CrCl 30-60 mL/min, reduce dose by 50%<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cyclophosphamide</strong>:<br>No pediatric-specific dosing.</li><li><strong>Carboplatin:&nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &gt;50 mL/min: 100% dosage &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR 10 to 50 mL/min: 50% dosage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If GFR &lt;10 mL/min: 25% dosage.</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', null, null, null, '<p><i>WEEK 1</i></p><p><strong>Methotrexate: </strong>2 mg/day intraventricular, days 1-4<br><strong>Cyclophosphamide:</strong> 800 mg/m2/day IV, days 1-3<br><strong>Vincristine:</strong> 1.5 mg/m2 IV, day 1<br><i>WEEKS 3 AND 5</i><br><strong>Methotrexate: </strong>2 mg/day intraventricular, days 1-2<br><strong>Methotrexate: </strong>5 g/m2 CIVI<br><strong>Vincristine: </strong>1.5 mg/m2, day1<br><i>WEEK 7</i><br><strong>Methotrexate: </strong>2 mg/day intraventricular, days 1-4<br><strong>Carboplatin:</strong> 200 mg/m2 IV, days 1-3<br><strong>Etoposide: </strong>150 mg/m2 IV, days 1-3<br>Repeat for 3 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (851, null, 'ABVD', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Bleomycin:</strong><br>No dose reduction</li><li><strong>Dacarbazine:</strong><br>No dose reduction</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Vinblastine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Bleomycin:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Dacarbazine:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Vinblastine:</strong><br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Doxorubicin:</strong> 25 mg/m2/day IV, days 1, 15<br><strong>Bleomycin:</strong> 10 units/m2/day IV, days 1, 15<br><strong>Vinblastine:</strong> 6 mg/m2/day IV, days 1, 15<br><strong>Dacarbazine:</strong> 375 mg/m2/day IV, days 1, 15<br>Repeat cycle every 14 days for a total of 12 cycles.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1179, null, 'A1', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>No dose reduction</li><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%&nbsp;<br>If bilirubin 3.1-5 mg/dL, reduce dose by 75%&nbsp;<br>If bilirubin &gt;5 mg/dL, do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cisplatin:</strong><br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li></ul>', 'High', null, null, null, '<p><strong>Cyclophosphamide</strong> 1,200 mg/m2 IV, days 1.<br><strong>Doxorubicin</strong> 40 mg/m2 IV, day 3<br><strong>Etoposide</strong> 100 mg/m2/day IV, days 1-5<br><strong>Cisplatin</strong> 90 mg/m2 IV on day 5.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1187, null, 'ABVE-PC', '<p><strong>Hepatic Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL: 75% of usual dosage.&nbsp;<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Vincristine:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL: 50% of usual dosage.<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL: Do not use</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Doxorubicin:</strong><br>If bilirubin 1.2-3 mg/dL: 50% of usual dosage.<br>If bilirubin 3.1-5 mg/dL: 25% of usual dosage.<br>If bilirubin &gt;5 mg/dL: Do not use</li><li><strong>Etoposide:</strong><br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li><li><strong>Bleomycin:</strong><br>There are no pediatric-specific recommendations</li></ul><p><strong>Renal Impairment</strong></p><ul><li><strong>Cyclophosphamide:</strong><br>If CrCl 10-50 mL/min: 75% of usual dosage.<br>If CrCl &lt; 10 mL/min: 50% of usual dosage.</li><li><strong>Vincristine:</strong><br>No dose reduction</li><li><strong>Prednisone: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>No dose reduction</li><li><strong>Doxorubicin:</strong><br>No dose reduction</li><li><strong>Etoposide:</strong><br>If CrCl 10-50 mL/min, reduce dose by 25%&nbsp;<br>If CrCl &lt; 10 mL/min, reduce dose by 50%</li><li><strong>Bleomycin:</strong><br>There are no pediatric-specific recommendations</li></ul>', 'High', null, null, null, '<p><strong>Doxorubicin:</strong> 30 mg/m2 IV, days 0,1<br><strong>Bleomycin:</strong> 5 units/m2 IV/SQ, day 0<br><strong>Bleomycin:</strong> 10 units/m2 IV/SQ, day 7<br><strong>Vincristine:</strong> 1.4 mg/m2 IV days 0, 7 (maximum 2.8 mg)<br><strong>Etoposide:</strong> 75 mg/m2 IV, days 0-4<br><strong>Prednisone:</strong> 40 mg/m2 PO, days 0-7<br><strong>Cyclophosphamide:</strong> 800 mg/m2 IV, day 0<br><strong>Filgrastim: </strong>5 mcg/kg IV OR SQ (day 5 until neutrophil recovery; held day 7)</p>', null);


insert into public.regimen_reference (id, reference, regimen_detail_id) values (1, 'Hayes DF, Van Zyl JA, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 1995;13(10):2556-66.', 502);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2, 'Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.', 347);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3, 'Br J Haematol. 2015 Mar;168(6):811-9.', 347);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (4, 'Lonning PE, Bajetta E, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol. 2000;18(11):2234-4.', 503);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2854, 'Smith TJ, et al. J Clin Oncol 1995;13:2166-2173.', 1076);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2375, 'Coiffier B, Leapage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma.', 226);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2855, 'Winton T. et al. N Engl J Med 2005;352:2589-2597.', 1072);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1733, 'Miller DS, et al. J Clin Oncol 2009;27:2686-2691.', 579);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (9, 'Stupp R, et al.  Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma.', 3);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (10, 'N Engl J Med 2005; 352:987-996', 3);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1734, 'Matulonis UA, Horowitz NS, et al. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008;26(35):5761-6.', 570);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2613, 'Johnston PB, et al. Am J Hematol 2010;85:320-324', 1007);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2857, 'Cremonesi M, et al. Oncology 2003;64:97-101.', 1078);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1853, 'Cassileth PA, et al. J Clin Oncol. 1991;9:243-246.', 278);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1854, '', 278);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (17, 'Gállego Pérez-Larraya J, et al.Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.', 6);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (18, 'J Clin Oncol. 2011 Aug 1;29(22):3050-5. doi: 10.1200/JCO.2011.34.8086. Epub 2011 Jun 27', 6);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1855, 'Dhillon S, et al. Drugs 2018;78:1-5.', 820);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1856, 'Silverman LR, et al. J Clin Oncol 2006;24:3895-3903', 766);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2858, 'Gandara D, et al. J Clin Oncol 2003,21:2004-2010', 1079);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2859, 'Herbst RS, et al. J Clin Oncol 2007;25:4734-4750', 1080);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2861, 'Garon EB, et al. Lancet 2014:384 665-673.', 1082);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (37, 'Kies MS, et al. Cancer 1987;60:2156-2160.', 14);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (38, 'Ilson DH, et al. J Clin Oncol 1999;17:3270-3275.', 15);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (39, 'Ilson DH, et al. J Clin Oncol 1998;16:1826-1834.', 16);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (40, 'Van Meerten E, et al. Br J Cancer 2007;96:1348-1352.', 17);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (41, 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 18);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (42, 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 19);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (43, 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 20);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (44, 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 21);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (45, 'Ajani JA, et al. Semin Oncol 1995;22 (Suppl 6):35-40.', 22);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (46, 'Taieb J, et al. Cancer 2003;98:2664-2670.', 31);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (47, 'Moscowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin''s lymphoma at risk of relapse or progression: a randomised, double-blind, placebo-controlled, phase 3 trial.', 348);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (48, 'Lancet. 2015 May 9;385(9980):1853-62.', 348);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (49, 'Van Custem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus florouracil compared with cisplatin and flouorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.', 23);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (50, 'J Clin Oncol. 2006;24(31):4991-4997', 23);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (51, 'Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma.', 24);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (52, 'Ann Oncol. 2000;11(3):301-306', 24);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (53, 'Waters JS, Norman A, Cunningham D, et al. Long-term survival afer epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.', 25);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (54, 'Br J Cancer. 1999;80(1-2):269-272.', 25);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (55, 'Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional flurorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gasttrointestinal Tract Cancer Cooperative Group.', 26);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (56, 'J Clin Oncol. 2000;18(41):2648-2657', 26);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (57, 'Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy afer surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.', 27);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (58, 'N Engl J Med. 2001;345(10):725-730.', 27);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (59, 'Bang YJ, Van Cutsem E, Feyereislava A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 open-label, randomised controlled trial.', 28);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (60, 'Lancet. 2010;376(99742):687-697.', 28);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (61, 'Qin S, et al. J Clin Oncol 2010;28:303S (abstract 408).', 32);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (62, 'Thomas MB, et al. J Clin Oncol 2009;27:843-850.', 33);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (63, 'Llovet J, et al. N Engl J Med 2008;359:378-390.', 34);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (64, 'Venook AP. J Clin Oncol 1994;12:1323-1334.', 35);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (65, 'Okada S, et al. Oncology 1993;50:22-26.', 36);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (66, 'Patt YZ, et al. Cancer 2004;101:578-586.', 37);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (67, 'Siegel AB, et al. J Clin Oncol 2008;26:2992-2998.', 38);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (68, 'Thongprasert S, et al. Ann Oncol 2005;16:279-281', 39);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (69, 'Knox JJ, et al. J Clin Oncol 2005;23:2332-2338.', 40);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (70, 'Andre T, et al. Ann Oncol 2004;15:1339-1343.', 41);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (71, 'Taieb J, et al. Ann Oncol 2002;13:1192-1196.', 42);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (72, 'Hong YS, et al. Cancer Chemother Pharmacol 2007;60:321-328.', 43);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (73, 'Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.', 349);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (74, 'N Engl J Med. 2014 Mar 13;370(11):997-1007.', 349);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (75, 'Nehis O, et al. Br J Cancer 2008;98:309-315.', 44);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (76, 'Patt YZ, et al. Cancer 2004;101:578-586.', 45);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1857, 'Kantarjian HM, et al. Cancer 2006;106:1794-1803.', 767);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1858, 'Kantarjian HM, et al. Semin Hematology 2005;32 (Suppl 2): S17-522.', 767);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1860, 'Stone RM, et al. N Engl J Med 2017; doi: 10.1056/NEJMoa 1614359.', 671);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1866, 'Faderi S, et al. Blood 2006;108:45-51.', 824);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (77, 'Papakostas P, et al. Eur J Cancer 2001;37:1833-1838.', 46);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (78, 'Park JS, et al. Jpn J Clin Oncol 2005;35:68-73.', 47);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2155, 'Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma.', 179);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (83, 'Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.', 48);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (84, 'N Engl J Med. 2011;364(19):1817-1825.', 48);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (85, 'Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.', 49);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (86, 'J Clin Oncol. 2007;25(16):221-2217.', 49);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (87, 'Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer institute of Canada Clinical Trials Group.', 50);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (88, 'J Clin Oncol. 2007;25(15):1960-1966.', 50);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (89, 'Louvet C, Labianca R, Hammel P, at al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.', 51);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (90, 'J Clin Oncol. 2005;23(15):3509-3516.', 51);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (91, 'Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survivial and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.', 52);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (92, 'J Clin Oncol. 1997;15(6):2403-2413.', 52);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (93, 'Cunningham D, Humblet Z, Siena S,et al. Cetuximab monothherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.', 53);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (94, 'N Engl J Med. 2004;351(4):337-345.', 53);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (95, 'Poon MA, O''Connell MJ, Moertel CG. Biochemical modulation of fluorouracil: evidence of significant improvement of surival and quality of life in patients with advanced colorectal carcinoma.', 54);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (96, 'J Clin Oncol. 1989;7(10):1407-1418', 54);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (97, 'Petreli N, Douglass HO Jr, Herrera L, et al. The modulation of fluroouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial.', 55);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (98, 'J Clin Oncol. 1989;7(10):1419-1426', 55);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (99, '<br> Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previoulsy untreated patients with advanced colorectal carcinoma.', 55);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (100, 'J Clin Oncol. 1987;5(10):1559-1565.', 55);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (101, 'Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumb to flurouracil/leucovorin improves survival for patients with metastatic colorectal cancer.', 56);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (102, 'J Clin Oncol. 2005;23(16):3706-3712.', 56);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (103, '<br> Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin; an active regimen for firstline metastatic colorectal cancer.', 56);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (104, 'J Clin Oncol. 2005;23(15):3502-3508', 56);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (105, 'Kuebler JP, Wieand HS, O''Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.', 57);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (106, 'J Clin Oncol. 2007;25(16):2198-2204.', 57);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (107, 'Tournigand C, Andre T, Achille E, et al. FOLFIRI  followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.', 58);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (108, 'J Clin Oncol. 2004;22(2):229-237', 58);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (109, 'Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin); active first-line therapy for patients with metastatic colorectal cancer.', 67);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (110, 'J Clin Oncol. 2004;22(11):2084-2091', 67);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (111, 'Byrd JC, Brown JR, O''Brien S .Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.', 350);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (112, 'N Engl J Med. 2014 Jul 17;371(3):213-23.', 350);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (113, 'Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.', 59);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (114, 'J Clin Oncol. 2007;25(30):4779-4786.', 59);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (115, 'Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial.', 60);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (116, 'J Clin Oncol. 2007;25:4000 (abstract).', 60);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (117, 'Richard M. Goldberg, et al.Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer.', 61);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (118, 'http://jco.ascopubs.org/content/24/25/4085.abstract', 61);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (349, 'N Engl J Med. 2015 Nov 5;373(19):1803-13.', 355);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (119, 'Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.', 62);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (120, 'J Clin Oncol. 2008;26(18)2013-2019.', 62);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (121, 'Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.', 63);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (122, 'J Clin Oncol. 2010;28(31):4697-4705.', 63);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (123, 'Patt YZ, Lee F, Liebman JE, et al. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer.', 66);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (124, 'Am J Clin Oncol. 2007;30(4):350-357', 66);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (125, 'Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.', 68);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (126, 'J Clin Oncol. 2008;26(18)2013-2019.', 68);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (127, 'Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III Study.', 69);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (128, 'J Clin Oncol. 2001;19(21):4097-4106', 69);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (129, 'Erbitux [package insert].', 70);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (130, 'Branchburg, NJ, and Princeton, NJ: ImClone Systems/ Bristol-Myers Squibb; 2011.', 70);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (187, 'Lancet Oncol.2006:7(9):719-727.', 90);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1989, 'Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.', 288);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1990, 'Blood. 2010;116(5):679-686.', 288);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (131, 'Kemeny N, Israel K, Niedzwieki D, et al. Randomized study of continuous-infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer.', 71);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (132, 'J Clin Oncol. 1990;8(2):313-318.', 71);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (133, '<br> Schmoll HJ. Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents.', 71);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (134, 'lEur J Cancer. 1996;32A(suppl 5):S18-S22.', 71);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1736, 'Kudelka AP, Tresukosol D, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996;14(5):1552-7.', 575);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1737, 'Sorensen P, Hoyer M, et al. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol. 2001;81(1):58-62.', 578);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (137, 'Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy.', 72);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (138, 'J Clin Oncol. 1997;15(1):251-260', 72);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (139, '<br> Camptosar [package insert]. New York, NY: Pfizer; 2010.<br> Conti JA, Kemeny NE, jSaltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.', 72);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (140, 'J Clin Oncol. 1996;14(3):709-715.', 72);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (141, '<br> Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.', 72);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (142, 'Lancet. 1998;352(9138):1413-1418.', 72);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (143, 'Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase: S0033.', 77);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (144, 'J Clin Oncol. 2008;26(4):626-632', 77);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (145, 'Montemurro M, Schoffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.', 78);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (146, 'Eur J Cancer. 2009;45:2293-2297.', 78);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2376, 'N Engl J Med. 2002;346(4):235-242.', 226);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (149, 'Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.', 80);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (150, 'N Engl J Med. 2002;346(2):92-98.', 80);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2614, 'Fehniger TA, et al. Blood 2011;118:5119-5125.', 1008);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (152, 'Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer.', 81);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (153, 'J Clin Oncol. 2008;26(21):3543-3551.', 81);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (154, 'Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.', 82);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (155, 'Lancet. 2009;373(9674):1525-1531.', 82);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (156, 'Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.', 83);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (157, 'N Engl J Med. 2002;346(2):92-98.', 83);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2856, 'Pirker R, et al. Proc Am Soc Clin Oncol 2008,26 (abstract 3).', 1077);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2860, 'Patel JD, et al. J Clin Oncol 2009;27:3284-3289.', 1081);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (160, 'Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.', 84);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (161, 'N Engl J Med. 2002;346(2):92-98.', 84);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (162, '<b> Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.', 84);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (163, 'J Clin Oncol. 1999;17(1):12-18.', 84);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (164, 'Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomized multicentre trial.', 85);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (165, 'Lancet. 2001;357(9267):1478-1484.', 85);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (166, 'Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.', 86);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (167, 'J Clin Oncol. 2002;20(17):3578-3585.', 86);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (168, 'Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non small cell  lung cancer Institute of Canada Clinical trials group study BR 21.', 93);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (169, 'J Clin Oncol. 2008;26(14):2350-2357.', 93);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (170, '<br> Tarceva [packaga insert].', 93);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (171, 'Melville, NY south San Fransisco, CA:OSI Pharmaceuticals Inc & Genentich Inc;2010.', 93);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (172, 'Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer.', 87);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (173, 'J Clin Oncol. 2000;18(13):2529-2536.', 87);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (174, '<br> Chen YM, Perng, RP, Yang KY, et al. A multi-gemcitabine in previously untreated inoperable (stageIIIB/IV) non-small-cell lung cancer.', 87);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (175, 'Chest. 2000;117(6):1583-1589.', 87);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (176, '<br> Hainsworth JD, Burris HA 3rd, Litchy S, et al. Gemcitabine and vinorelbine in the second-line treatment of non-small-celll lung carcinoma patients: a Minnie Pearl Cancer Research Network phase II trial.', 87);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (177, 'Cancer. 2000;88(6):1353-1358.', 87);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (178, 'Schiller JH, Hamington D, Belani CP, et al. Comparison of four chemotherapy regiments for advanced non-small-cell lung cancer.', 88);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (179, 'N Eng/J Med.2002;346(2);92-98.', 88);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (180, '<br> Smit EF., van Meerbeeck JP,lianes P,et al.Three-arm randomaized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advance m=non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of cancer Lung Group-EORTC 08975.', 88);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (181, 'J Clin Oncol.2003;21(21):3909-3917.', 88);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (182, 'Sandler A, Gray R, Perry MC,et al. Paclitaxel-carboplatin alone or with bevacizumab for non small-cell lung cancer.', 89);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (183, 'N Engl J Med. 2006;355(24):2542-2550.', 89);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (184, 'Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.', 189);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (185, 'N Engl J Med. 2004;351(15):1502-1512.', 189);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (186, 'Douillard JY, Rosell R, De Lena M,et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-III A non small-cell lung cancer  (Adjuvant Naverlbine International Trialist Association [ANITA): a randomised controlled trial.', 90);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2616, 'Kim YH, et al. Lancet Oncol 2018;19:1192-1204', 1009);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1410, 'Gnant M, Mlineritsch B, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-91.', 436);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (188, 'Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic Lymphoma Kinase inhabitation in non-small-cell lung cancer.', 91);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (189, 'N engl J Med.2010;363(18):1693-1703.', 91);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (190, '<br> Xalkori [packages insert].', 91);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (191, 'New York, NY: Pfizer labs;2011.', 91);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (192, 'Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.', 92);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (193, 'J Clin Oncol. 2000;18(10):2095-2103.', 92);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (194, '<br> Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-lung cancer previously treated with platinum-containing chemotherapy regimens.', 92);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (195, 'J Clin Oncol. 2000;18(12):2354-2362.', 92);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (196, 'Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukemia  (Complimet1 (: A rondomised, multicentre, open-label phase 3 trial.', 351);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (197, 'Lancet. 2015 May 9;385(9980):1873-83.', 351);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (198, 'Crino L, Mosconi AM, Scaglotti G, et al.              Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial.', 94);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (199, 'J Clin Oncol. 1999;17(7):2081-2085.', 94);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (200, '<br> Ricci S, Anonuzzo A, Galli L, et al. Gemcitabine monotherapy in elderly paients with advanced non-smell-cell lung cancer: a multicenter phase II study.', 94);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (201, 'Lung Cancer.2000;27(2):75-80.', 94);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (202, 'Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III study of premtrexed versus docetaxel in patients with non-smell-cell lung cancer previously treated with chemotherapy.', 95);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (203, 'J Clin Oncol. 2004;22(9):1589-1597.', 95);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (204, 'Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesin and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.', 96);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (205, 'J Clin Oncol.1994;12(2):360-367.', 96);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (206, 'Hermes A, Bergman B, Bremnes R, et al           Irinotecan plus carboplatin in extensive versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.', 97);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (207, 'J Clin Oncol. 2008:26(26):4261-4267.', 97);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (208, 'Noda K, Nishiwaki Y, Kawahara M, et al.                     Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.', 98);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (209, 'N Engl J Med. 2002;346(2):85-91.', 98);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (210, 'Sarosdy MF, Schellhammer PF, Johnson R, Carroll K, Kolvenbag GJCM. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?', 190);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (211, 'Urology. 2000;55(3):391-396.', 190);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (212, 'Roth  BJ, et al. J Clin Oncol 1992;10:282-291.', 99);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (213, 'Neubauer M, et al. J Clin Oncol2004;22:1872-1877', 100);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (214, 'Viren M, Liippo K, Ojala a, et al. Carboplatin and etoposide in extensive small-cell lung cancer.', 101);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (215, 'Acta Oncal. 1994;33(8):921-924.', 101);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (216, 'Ihde DC, Mulshine JL, Kramer BS, et al.  Prospective randomized comparision of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.', 102);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (217, 'J Clin Oncol.1994; 12(10):2022-2034.', 102);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (218, 'Johnson DH. Recent developments in chemotherapy treatment of small-cell lung cancer.', 103);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (219, 'Semin Oncol. 1993;20(4):315-325.', 103);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (220, 'Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.', 104);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (221, 'J Clin Oncol. 1995;13(6):1430-1435.', 104);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (222, '<br> Kirschling RJ, Grill JP, Marks RS, et al. Paclitaxel and G-CSF in previously untreated patients with extensive-stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group.', 104);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (223, 'Am J Clin Oncol. 1999;22(5):517-522', 104);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (224, '<br>', 104);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (225, 'Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease.', 105);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (226, 'J Clin Oncol.1997;15(5):2090-2096.', 105);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (227, '<br> von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.', 105);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (228, 'J Clin Oncol. 1999;17(2):658-667.', 105);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (229, 'Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.', 106);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (230, 'J Clin Oncol. 2007;25(15):2086-2092.', 106);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (231, 'Erratum in: J Clin Oncol. 2007;25(22):3387.', 106);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2156, 'N Engl J Med. 2007;356(22):2271-2281.', 179);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2615, 'Zinzani PL, et al. Blood 2017;130:267-270.', 963);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2377, '<br> Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.', 226);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2862, 'Thatcher N, et al. Lancet Oncol 2015:16.763-774', 1083);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2863, 'Planchard D. et al. Lancet Oncol 2016:17:642-650', 1084);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2160, 'Pienta KJ, et al. J Clin Oncol 1994;12:2005-2012', 840);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2161, 'Einhorn LH, et al. J Clin Oncol 1989;7:387-391.', 841);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2162, 'Oliver RT. et al. Lancet 2005;366:293-300.', 842);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2617, 'Argnani L, et al. Cancer Treat Rev 2017;61:61-69.', 1010);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2872, 'Socinski MA, et al. J Clin Oncol 2008;26:650-656.', 1091);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2873, 'Hanna N, et al. J Clin Oncol 2006;24:5253-5258.', 1092);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2874, 'Brahmer J. et al. N Engl J Med 2015;373:123-135.', 1093);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2875, 'Kwak EL, et al. N Engl J Med 2010;363:1693-1703.', 1094);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2885, 'Kirkwood JM, et al. Semin Oncol 1997:24 (Suppl 4)1:1-48.', 1101);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2886, 'Kirkwood JM, et al. J Clin Oncol 1996;14:7-17', 831);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2887, 'Atkins MB, et al. J Clin Oncol 1999;17:2105-2116', 1102);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (250, 'Fisher B,Brown AM,Dimitor NV,et al.Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide,methotrexade,and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors:results from the National Surgical Adjuvant Breast and Bowel Project B-15.', 113);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1745, ' Fountzilas G, et al. Semin Oncol 1997;24 (Suppl 2):65-67.', 477);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (251, 'J Clin Oncol. 1990;8(9):1483-1496', 113);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2378, 'J Clin Oncol. 1999; 17(1):268-276', 226);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2379, 'Kewalramani T, Zelenetz AD, Nimer SD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.', 233);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1406, 'Burstein HJ, Kuter I, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001;19(10):2722-30.', 488);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2864, 'Lilenbaum RC, et al. J Clin Oncol 2005;23:190-196.', 1085);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2865, 'Tester WJ, et al. Cancer 1997;79:724-729', 1085);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2866, 'Rizvi NA, et al. J Clin Oncol 2008;26:639-643.', 1086);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2867, ' Miller VA, et al. Semin Oncol 2000;27 (Suppl 3):3-10 ', 1087);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2868, 'Hainsworth JD, et al. Cancer 2000:89:328-333', 1087);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2869, 'Hanna N, et al. J Clin Oncol 2004;22:1589-1597.', 1088);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2380, 'Blood. 2004; 103(10):3684-3688.', 233);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2870, 'Manegold C, et al. Ann Oncol 1997;8:525-529.', 1089);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2618, 'Foss F. et al. Clin Lymphoma Myeloma Leuk 2016;16:637-643', 1011);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (264, 'Kumar SK, Berdeja JG, Niesvizky, R. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously unreated multiple myeloma .', 353);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (265, 'Lancet Oncol. 2014 Dec;15(13):1503-12.', 353);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2871, 'Furuse K, et al. Ann Oncol 1996;7:815-820', 1090);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2876, 'Shaw AT, et al. N Engl J Med 2014;370:1189-1197.', 1095);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2877, 'Shaw AT, et al. Lancet Oncol 2016;17:234-242', 1096);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2878, 'Kim DW. et al. J Clin Oncol 2017. doi: 10.1200/JC0.2016.71.5904.', 1097);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2879, 'Mok T. et al. J Thorac Oncol 2016:11:S142.', 1098);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2619, 'Foss F, et al. Br J Hematol 2015;168:811-819.', 1012);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2880, 'Antonia SJ, et al. N Engl J Med 2017;377:1919-1929.', 1099);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1435, 'Gnant M, Mlineritsch B, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-91.', 435);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2881, 'Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt''s lymphoma: results of United Kingdom Lymphoma Group LY06 Study.Ann Oncol. 2002;13(8): 1254-1274.', 948);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1441, 'André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929-1940', 792);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2625, 'Hwu WJ, et al. J Clin Oncol 2003;21:3351-3356.', 1016);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (280, 'Lokhorst HM, Plesner T, Laubach JP, et al Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.', 354);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (281, 'N Engl J Med. 2015 Sep 24;373(13):1207-19.', 354);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (282, 'Amadori D, Nanni O, Marangolo M, et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapdly proliferating breast cancer: a randomized multicenter study.', 124);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (283, 'J Clin Oncol. 2000:18(17):3125-3134.', 124);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (284, '<br> Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results.', 124);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (285, 'JAMA. 1995:273(7):542-547.', 124);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2882, 'Khouri IF, Romaguera J, Kantrajian H,et al. Hyper-CVAD and high -dose methotrexate/ cytarabine followed by stem-cell tans-plantation: an active regimen for aggressive mantle-cell lymphoma.J Clin Oncol. 1998; 16(12): 3803-3809.', 950);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1619, 'Schmid P, Rugo HS, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44-59.', 454);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1631, 'Cartwright TH, et al. J Clin Oncol 2002;20:160-164.', 716);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1632, 'Mukherjee S, et al. Lancet Oncol 2013;14:317-326', 705);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2883, ' Luce JK, et al. Cancer Chemother Rep 1970:54:119-124.', 1100);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2884, ' Pritchard Kl, et al. Cancer Treat Rep 1980:64:1123-1126', 1100);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2893, 'Weber J, et al. N Engl J Med 2017;377:1824-1835.', 1013);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2897, 'Sosman JA, et al. N Engl J Med 2012;366:707-714', 1107);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2898, 'Falchook GS, et al. Lancet 2012;379:1893-1901', 1108);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2899, 'Kim KB, et al. J Clin Oncol 2013:31:482-489.', 1109);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2906, 'Nqhiem P, et al. J Clin Oncol 2019;37:693-702', 829);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2907, 'Kaufman HL, et al. Lancet Oncol 2016, 10:1374-1385', 1116);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1665, 'Chitapanarux I, Tonusin A, et al. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol. 2003;89(3):402-7.', 533);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1672, 'Tewari KS, et al. J Clin Oncol 2013;31:Suppl (abstract 3).', 527);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (366, '<br> Doxil [package insert].', 163);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (367, 'Raritan, NJ: Centocor Ortho Biotech Products, LP;2010.', 163);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1680, 'Pignata S, Silvestro G, et al. Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. J Clin Oncol. 1999;17(3):756-60.', 532);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1681, 'Levy T, et al. Proc Am Soc Clin Oncnol 1996;15:292a.', 537);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1682, 'Schilder RJ, Blessing J, et al. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2005;96(1):103-7.', 542);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1690, 'Thigpen JT, Blessing JA, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol. 1994;12(7):1408-14.', 545);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1715, 'Alberts DS, Green S, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 1992;10(5):706-17.', 560);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1720, 'Lund B, Hansen OP, et al. Phase II study of gemcitabine (2'',2''-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 1994;86(20):1530-3.', 576);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1721, 'Thigpen T. The role of gemcitabine in first-line treatment of advanced ovarian carcinoma. Semin Oncol. 2006;33(2 Suppl 6):S26-32.', 568);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1722, 'Nagourney RA, Brewer CA, et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol. 2003;88(1):35-9.', 567);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2888, 'Parkinson DR, et al. J Clin Oncol 1990,8:1650-1656. ', 1102);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2889, ' Acquavella N, et al. J Immunother 2008,31:569-576.', 1102);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2890, 'Wolchok JD, et al. Lancet Oncology 2010:11:155-164', 1103);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2891, 'Robert C, et al. N Engl J Med 2015,372:2521-2532', 1104);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2892, 'Eggermont AM, et al. N Engl J Med 2018;378:1789-1801.', 1015);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2894, 'Weber JS, et al. Lancet Oncol 2015:16:375-384', 1105);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2895, 'Middleton MR, et al. J Clin Oncol 2000;18:158-166.', 1106);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2896, 'Eggermont AM, et al. Lancet Oncol 2015;16:522-530', 1014);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2624, 'Creagen ET, et al. J Clin Oncol 1999;17:1884-1890.', 833);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1437, 'Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.', 149);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1438, 'J Clin Oncol. 1995;13(10):2556-2566.', 149);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1439, '<br> Fareston [package insert].', 149);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1440, 'Memphis, TN: GTx, Inc,:2011.', 149);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2900, ' Zucali PA, et al. Cancer 2008:112:1555-1561.', 1110);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2901, 'Simon GR, et al. J Clin Oncol 2008;21:3567-3572', 1111);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2902, 'Steele JPC, et al. J Clin Oncol 2000:18:3912-3917.', 1112);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2626, 'Larkin J, et al. N Engl J Med 2015;373:23-34', 1020);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2627, 'Dummer R, et al. Lancet Oncol 2018;19:603-615.', 1019);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2903, 'van Meerbeeck JP, et al. Cancer 1999:85:2577-2582', 1113);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2628, 'Larkin J, et al. N Engl J Med 2014;371:1867-1876.', 1018);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2827, 'JOG5208L: Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N; West Japan Oncology Group. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1630-8. Epub 2015 Oct 28.

5501068: Lu S, Chen Z, Hu C, Zhang J, Chen Y, Song Y, Zhao Q, Fan Y, Wu G, Ma Z, Fang J, Yu Q, Liu Z. Nedaplatin plus docetaxel versus cisplatin plus docetaxel as first-line chemotherapy for advanced squamous cell carcinoma of the lung - a multicenter, open-label, randomized, phase III trial. J Thorac Oncol. 2018 Nov;13(11):1743-1749. Epub 2018 Jul 11.', 478);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2904, 'Alley EW, et al. Lancet Oncol 2017:18:623-630', 1114);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2905, 'Quispel-Janssen J, et al. J Thorac Oncol 2018. doi: 10.1016/j.jtho.2018.038', 1115);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2387, 'Urba WJ, et al. J Natl Cancer Inst Monogr 1990;10:29-37.', 917);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (338, 'Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.', 153);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (339, 'J Natl Cancer Inst. 2004;96(22):1682-1691.', 153);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (340, 'Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.', 154);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (341, 'J Clin Oncol. 2000;18(17):3084-3092.', 154);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (342, 'Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relppase.', 155);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (343, 'J Clin Oncol. 2010;28:3323-3329.', 155);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (344, 'McGuire WP, Hoskins WJ, Brady MF, et al. Cyclo-phosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.', 156);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (345, 'N Engl J Med. 1996;334(1):1-6.', 156);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (346, '<br> Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.', 156);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (347, 'J Clin Oncol. 2000;18(17):3084-3092.', 156);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (348, 'Motzer RJ, Escudier B, McDermott DF, et al.  Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma.', 355);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (350, 'Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.', 157);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (351, 'J Clin Oncol. 2006;24(29):4699-4707.', 157);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (352, 'Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.', 158);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (353, 'N Engl J Med. 2006;354(1):34-43.', 158);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (354, 'Markman M, Blessing JA, Moore D, Ball H, Lentz SS. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.', 159);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (355, 'Gynecol Oncol. 1998;69(3):226-229.', 159);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (356, 'Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistant or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.', 160);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (357, 'J Clin Oncol. 2007;25(33):5165-5171.', 160);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (358, 'Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2'', 2'' difluorodeoxycytidine) in previously treated ovarian cancer patients.', 161);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (359, 'J Natl Cancer Inst. 1994;86(20):1530-1533.', 161);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (360, 'Zoladex 3.6 mg, Zoladex 10.8 mg [package inserts]. Wilmington, DE: AstraZeneca; 2010. Roach M, Bae K, Speight J, et al. Short-term androgen deprivation therapy and external beam radiotherapy for locally advanced prostate cancer: Long-term results of RJOG 8610.', 191);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (361, 'J Clin Oncol. 2009;26(4):585-591.', 191);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (362, 'ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.', 162);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (363, 'J Clin Oncol. 1997;15(6):2183-2193.', 162);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (364, 'Gordon AN, Granai CO, Rose CG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.', 163);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (365, 'J Clin Oncol. 2000;18(17):3093-3100.', 163);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1620, 'Sahai V, et al. JAMA Oncol 2018;4:1707-1712', 722);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1621, ' Andre T, et al. Ann Oncol 2004;15:1339-1343.', 718);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1622, 'Kudo M, et al. Lancet 2018;391:1163-1173.', 729);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1623, 'El-Khoueiry AB, et al. Lancet 2017;389:2492-2502.', 732);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1624, 'Zhu AX, et al, Lancet Oncol 2018. doi: 10.1016/S1470-2045(18)30351-6.', 733);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1626, 'Zhu AX, et al. Lancet Oncol 2019;20:282-296.', 734);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1627, 'Bruix J, et al. Lancet 2017;389:56-66.', 731);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1628, 'Llovet J, et al. N Engl J Med 2008;359:378-390.', 728);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1629, 'DeCaprio JA, et al. J Clin Oncol 1991;9.2128-2133', 706);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1635, 'Burris HA, et al. J Clin Oncol 1997;15:2403-2413.', 715);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (368, 'ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.', 164);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (369, 'J Clin Oncol. 1997;15(6):2183-2193.', 164);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (370, 'Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus Sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial.', 356);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (371, 'Lancet Oncol. 2013 May;14(6):552-62.', 356);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (372, 'Sosman JA, Kim KB, Schuchter L, Survival in BRAF V600-Mutant advanced Melanoma treated with Vemurafenib.', 357);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (373, 'N Engl J Med. 2012 Feb 23; 366(8): 707–714 .', 357);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (374, 'Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.', 165);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (375, 'J Clin Oncol. 2006;24(1):36-44.', 165);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (376, 'Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastimin advanced endometrial carcinoma: a Gynecologic Oncology Group Study.', 166);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (377, 'J Clin Oncol. 2004;22(11):2159-2166.', 166);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (378, 'Thigpen JT, Brady MF, Homesly HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A Gynecologic Oncology Group Study.', 167);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (379, 'J Clin Oncol. 2004;22(19):3902-3908.', 167);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (380, 'Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecological Oncology Group.', 168);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (381, 'J Clin Oncol. 1999;17(6):1736-1744.', 168);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (382, 'Petrylak DP, Tangen CM, Hussain MA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.', 188);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (383, 'N Engl J Med. 2004;351(15):1513-1520.', 188);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2000, 'Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.', 204);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2001, 'J Clin Oncol. 1993;11(7):1276-1285.', 204);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2163, 'Nichols CR, et al. J Clin Oncol 1998;16:1287-1295', 843);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2629, 'Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine.', 144);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2908, 'Roth BJ, et al. J Clin Oncol 1992:10:282-291.', 1117);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2909, 'Siegel DS, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.', 294);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2002, 'Worden FP, et al. J clin Oncol 2005;23:105-112', 768);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2165, 'Oliver RT. et al. Lancet 2005;366:293-300.', 845);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (392, 'Hodi FS, O''Day SJ, McDermott DF, et al. Improved survival with Ipilumimab in patients with Metastatic Melanoma.', 358);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (393, 'N Engl J Med 2010; 363:711-723.', 358);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (394, 'Long HJ, Bundy BN, Grendys EC, et al. Randomized Phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study.', 171);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (395, 'J Clin Oncol. 2005;23(21):4626-4633.', 171);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1749, 'Franchin G, Minatel E, Politi D, et al. Postoperative reduced dose of cisplatin concomitant with radiatoin therapy in high-risk head and neck squamous cell carcinoma.', 10);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1750, 'Cancer. 2009;115(11):2464-2471.', 10);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2166, 'Nichols CR, et al. J Clin Oncol 1998;16:1287-1295', 846);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2630, 'J Clin Oncol. 1995;13(11):2731-2736.', 144);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2631, 'Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.', 125);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2632, 'J Clin Oncol. 2008;26(24):3950-3957.', 125);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2910, 'Blood. 2012 Oct 4;120(14):2817-25. doi: 10.1182/blood-2012-05-425934. Epub 2012 Jul 25', 294);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (404, 'Bamias A, Moulopoulos LA, Koutras A, et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma.', 180);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (405, 'Cancer. 2006;106(2):297-303.', 180);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (406, 'von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and ciplatin in advanced or metastatic bladder cancer: results of a large, randomized, mulinational, multicenter, phase III study.', 181);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (407, 'J Clin Oncol. 2000;18(17):3068-3077.', 181);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (410, 'von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and ciplatin in advanced or metastatic bladder cancer: results of a large, randomized, mulinational, multicenter, phase III study.', 182);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (411, 'J Clin Oncol. 2000;18(17):3068-3077.', 182);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (412, 'Schellhammer P, Sharifi R, Block N, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.', 193);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (413, 'Urology. 1995;45(5):745:752.', 193);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (414, 'Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.', 194);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (415, 'BJU Int. 2008;102(11):1531-1538.', 194);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (416, 'Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, jSouthwest Oncology Group, and Cancer and Leukemia Group B Study.', 183);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (417, 'J Clin Oncol. 1998;16(4):1287-1293.', 183);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (418, 'Motzer RJ, Sheinfeld J, Mazumdar M, et al. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.', 184);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (419, 'J Clin Oncol. 1995;13(11):2700-2704.', 184);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (420, 'Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.', 185);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (421, 'J Oncol. 2005;23(27):6549-6555.', 185);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1761, 'Vermorken JB, Remenar E, Van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.', 12);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1762, 'N Engl J Med. 2007;357(17):1695-1704.', 12);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1763, 'Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.', 12);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1764, 'N Engl J Med. 2007;357(17):1705-1715.', 12);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1765, 'Posner M, et al. N Engl J Med. 2007 Oct 25;357(17):1705-15. doi: 10.1056/NEJMoa070956.', 769);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (422, 'Loehrer PJ, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ-cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide.', 186);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (423, 'Ann Intern Med. 1988;109(7):540-546.', 186);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (424, 'de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.', 187);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (425, 'Lancet. 2010;376(9747):1147-1154.', 187);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2384, 'van Oers NH, Van Glabbeke M, Glurgea L, et al. Rituximab maintenance treatment of relapsed/residual follicular Non Hodgikin''s lymphoma: Long-term outcome or EROTC 20891 phase III randomized intergroup study.', 242);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (428, 'Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisonealone for symptptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints.', 192);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (429, 'J Clin Oncol. 1996;14(6)1756-1764.', 192);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (430, 'Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid deukemia. Cancer and Leukemia Group B.', 262);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (431, 'N Engl J Med. 1994;331(14):896-903.', 262);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (433, 'N. Engl. J. Med. 368 (2): 138–48.', 195);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (434, 'Zoladex 3.6 mg, Zoladex 10.8 mg [package inserts].', 198);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (435, 'Wilmington, DE: AstraZeneca; 2010.', 198);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (436, 'Lupron Depot 7.5 mg, 22.5 mg, 30 mg [package insers].', 199);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (437, 'North Chicago, IL: Abbot Laboratories; 2011.', 199);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (438, 'Dijkman GA, Janknegt RA, et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate speific antigen normalization. International Anadron Study Group.', 200);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (439, 'J Urol. 1997;158(1):160-163.', 200);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (440, 'Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisonealone for symptptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints.', 201);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (441, 'J Clin Oncol. 1996;14(6)1756-1764.', 201);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (442, 'Provenge [package insert].', 202);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (443, 'Parsippany, NJ: Watson Pharma, Inc.; 2011.', 202);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (444, 'Trelstar [package insert].', 203);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (445, 'Parsippany, NJ: Watson Pharma, Inc.; 2011.', 203);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2003, 'Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing''s sarcoma and primitive neuroectodermal tumor of bone.', 206);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1886, 'Weiss R, Mitrou P, Arasteh K, et.al. Acquired immunodeficiency syndrome-related lymphoma: Simultaneous treatment with combined cyclophosphamide, doxorubicin, Vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.', 248);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1887, 'Cancer. 2006; 106(7): 1560-1568.', 248);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1888, 'Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin''s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001;19(8):2171-2178', 248);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (452, 'Postow, MA, Chesney J, Pavlick AC, et al. Nivolumab and Ipilumimab versus Ipilumimab in untreated melanoma.', 359);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (453, 'N Engl J Med. 2015 May 21;372(21):2006-17.', 359);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2004, 'N Engl J Med. 2003;348(8):694-701.', 206);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2385, 'JClin Oncol. 2010;28(17):2853-2858.', 242);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2386, 'Bagley CM Jr, et al. Ann Intern Med 1972;76:227-234', 916);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2633, 'O''Shaughnessy J. Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience. Oncology (Williston Park). 2003;17(12 Suppl 14):15-21.', 125);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2388, 'Sonnevald P. et al. J Clin Oncol 1995;13:2530-2539.', 918);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2634, 'Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.', 127);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1891, 'Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.', 250);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1892, 'BLOOD.2003;101(12):4653-4659.', 250);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2635, 'J Clin Oncol. 2007;25(33):5210-5217.', 127);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2636, 'Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.', 147);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2637, 'J Clin Oncol. 1995;13(10):2575-2581.', 147);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2638, '<br> Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26.', 147);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2639, 'J Clin Oncol. 1999;17(11):3403-3411.', 147);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2005, 'Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.', 205);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2006, 'J Clin Oncol. 1995;13(7):1537-1545.', 205);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (472, 'Robert c, Karaszewska B, Schachter J, et al. Improved overall Survival in Melanoma with combines Dabrafenib and Trametinib.', 360);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (473, 'N Engl J Med. 2015 Jan 1;372(1):30-9.', 360);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2007, 'Nielsen OS, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas: a study of the EORTC soft tissue and bone sarcoma group.', 209);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2008, 'Br J Cancer. 1998;78(12):1634-1639.', 209);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2025, 'Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary Carcinoma: a Phase II Hellenic Cooperative Oncology Group Study.', 214);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2026, 'J Clin Oncol. 2000; 18(17):3101-3107.', 214);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2085, 'Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul;5(7):1048-53.', 782);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2086, 'Tarceva (erlotinib) [package insert]: OSI Pharmaceuticals, LLC, 2016. Northbrook, IL', 782);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2151, 'Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma.', 177);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2152, 'N Engl J Med. 2007;356(2):125-134.', 177);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2172, 'Duffner id, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than 3 years of age with malignant brain tumors.', 297);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2640, 'Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer.', 130);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2641, 'N Engl J Med. 2008;238(16):1663-1671.', 130);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2911, 'Leleu X, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.', 295);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2009, 'Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.', 207);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2010, 'J Clin Oncol. 1993;11(7):1276-1285.', 207);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2912, 'Blood. 2013 Mar 14;121(11):1968-75. doi: 10.1182/blood-2012-09-452375. Epub 2013 Jan 14', 295);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2913, 'Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma.', 293);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (489, 'Larkin J, Ascierto PA, Dreno B. Combined Vemurafenib and Cobimetinib in BRAF-mutated Melanoma.', 361);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (490, 'N Engl J Med. 2014 Nov 13;371(20):1867-76.', 361);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2011, 'Ferrrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.', 208);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2012, 'J Clin Oncol. 2005;23(34):8845-8852.', 208);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2914, 'N Engl J Med. 1999;341(21):1565-1571.', 293);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2016, 'Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341-351.', 826);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2017, 'Ihde DC, et al. J Clin Oncol 1994;12:2022-2034.', 827);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2018, 'Viren M, et al. Acta Oncol 1994;33:921-924.', 828);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2020, 'Hauschild LA, et al. N Engl J Med 2017;377:1813-1823', 830);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2022, 'Eggermont AM, et al. Lancet 2008;372:117-126', 832);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2915, 'Erratum in N Engl J Med. 2000;342(5):364.', 293);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (502, 'Rummel MK, Niederle N, Mascmeyere G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared too CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and matle cell lymphomas: Final results of a randomized phase III study of StiL (Study Group of Indolent Lymphomas, Germany).', 224);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (503, 'Presented at :51st American Society of Hematology Annual Meeting; December 5-8, 2009; New Orleans, LA. Abstract 405.', 224);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2024, 'Falkson CI, et al. J Clin Oncol 1998;16:1743-1751', 834);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2916, 'Segeren CM, Sonneveld P, Holt V, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.', 289);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2917, 'Br J Haematol. 1999;105(1):127-130.', 289);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2087, 'JO25567: Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014 Oct;15(11):1236-44. Epub 2014 Aug 27. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475.', 786);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2088, 'NEJ026: Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019 May;20(5):625-635. Epub 2019 Apr 8. ', 786);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2089, 'AVASTIN (Bevacizumab) [package insert]: Genitech Inc. 2013. San Francisco, CA.', 786);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2090, 'Tarceva (erlotinib) [package insert]: OSI Pharmaceuticals, LLC. 2016. Northbrook, IL', 786);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2091, 'RELAY: Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Dec;20(12):1655-1669. Epub 2019 Oct 4.', 787);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2092, 'Tarceva (erlotinib) [package insert]: OSI Pharmaceuticals, LLC, 2016. Northbrook, IL', 787);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2093, 'CYRAMZA (ramucirumab) [package insert]: Eli Lilly and Company, 2014. Indianapolis, IN', 787);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2098, 'NEJ002 Update: Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013 Jan;24(1):54-9. Epub 2012 Sep 11. ', 784);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2099, 'IRESSA (gefitinib) [product label]: AstraZeneca Pharmaceuticals LP Wilmington, DE ', 784);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2100, 'FLAURA: Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18.', 785);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2101, 'FLAURA Subgroup analysis: Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018 Nov 20;36(33):3290-7. Epub 2018 Aug 28.', 785);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2102, 'FLAURA Update: Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50. Epub 2019 Nov 21.', 785);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2103, 'Osimertinib (TAGRISSO) [product label]: AstraZeneca Pharmaceuticals LP, Wilmington, DE ', 785);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1636, 'Brand R, et al. Invest New Drugs 1997;15:331-341.', 715);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2027, 'Pentheroudakis G, Briasoulis E, Kalofonos HP, et al. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group Phase II study.', 215);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2028, 'Acta Oncol. 2008;47(6): 1148-1155.', 215);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2642, 'Weber BL, Vogel C, Jones S, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast  cancer.', 152);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2389, 'McLaughlin P, et al. J Clin Oncol 1996;14:1262-1268.', 919);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2643, 'J Clin Oncol. 1995;13(11):2722-2730.', 152);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2644, 'Biganzoli L, Martin M, et al. Moving forward with capecitabine: a glimpse of the future. Oncologist. 2002;7 Suppl 6:29-35.', 444);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2645, 'O''Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthraccline-pretreated patients with advanced breast cancer: phase III trial results.', 133);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2918, 'San Miguel JF, Schalg R, Khuageva NK, et al. MMY-3002 a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma.', 290);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2919, 'Blood. 2007;110(11 pt 1): Abstract 78.', 290);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2920, '<br> San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.', 290);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2035, 'Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.', 218);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2036, 'Cancer. 2004; 100(6): 1257-1261.', 218);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2041, 'Power130: West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):924-937. Epub 2019 May 20.
4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 458);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2132, 'William WN, et al. Am J Clin Oncol 2009;32:15-19.', 111);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2133, 'Loehrer PJ, et al. Cancer 2001;91:2010-2015.', 110);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2390, 'Hochster H, et al. Blood 1994;84 (Suppl 1):383a.', 920);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2391, 'Sacchi S, et al. Cancer 2007;110:121-128.', 921);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2646, 'J Clin Oncol. 2002;20(12):2812-2823.', 133);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2393, 'Forstpointer R, et al. Blood 2006;108.4003-4008', 923);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1889, 'Wang ES, Strauss DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphosphamide, doxorucibicin, high-dose methotrecate/ ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC)for human immunodeficiency virus-associated Burkitt lymphoma.', 249);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (564, 'Trisenox [package insert].', 259);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (565, 'Frazer, PA: Cephalon; 2010.', 259);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1890, 'Cancer. 2003;98(6): 1196-1205.', 249);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2921, 'N Engl J Med. 2008;359(9):906-917.', 290);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2922, 'Markman M, Blessing JA, et al. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 1998;69(3):226-9.', 571);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2660, 'Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.', 129);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (570, 'Arranon [package insert].', 253);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (571, 'Research Triangle Park, NC: GlaxoSmithKline;2011.', 253);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (572, 'Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans-retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.', 254);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (573, 'Blood. 2006;107(9):3469-3473.', 254);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2661, 'J Clin Oncol. 200927(33):5538-5546.', 129);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2662, 'Chan A, Delaloge S, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367-377.', 425);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2663, 'Turner NC, Ro J, et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015;373(3):209-19.', 496);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2923, 'Wolf JK, Bodurka DC, et al. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol. 2006;102(3):468-74.', 581);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (584, 'Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG).', 264);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (585, 'J Clin Oncol. 2011;29(26)3559-3566.', 264);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1960, 'Istodax [package insert].', 243);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1961, 'Summit , NJ: Celgene Corporation; 2011.', 243);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1962, 'Piekarz RL, Frye R, Prince HM, et al, “Phase 2 Trial of Romidepsin in Patients With Peripheral T-Cell Lymphoma,” Blood, 2011, 117(22):5827-34.', 243);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1963, 'Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evalute temsirolimus compared with investigator''s choice therapy for the treatment or relapsed or refractory mantle cell lymphoma.', 244);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1964, 'J Clin Oncol.2009; 27(23):3822-3829.', 244);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1965, 'Bexxar [package insert].', 245);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (834, 'Jaiyesimi IA, Buzdar AU, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995;13(2):513-29.', 501);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1966, 'Seattle, WA, and Philadelphia, PA: Corixa Corp and GlaxoSmithKline;2011.', 245);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1967, 'Zolinza [package insert].', 246);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1968, 'Mann BS, et al. Oncologist 2007;12:1247-1252.', 246);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1979, 'Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma.', 292);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1980, 'Blood. 1992;80(4):887-890.', 292);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1907, 'Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time to event analyses of the multicenter Phase 2. PINNACLE study.', 236);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1908, 'Ann Oncol. 2009;20(3):520-525.', 236);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1909, 'Advani RH, Shustov AR, Brice P, et al.                                     Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: A Phase 2 study update.', 237);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1910, 'Blood (ASH Annula Meeting Abstracts). 2011; 118:443.', 237);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (602, 'Robert C, Schachter J, Long GV, et al.  Pembrolizumab versus Ipilumimab in Advanced Melanoma.', 362);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (603, 'N Engl J Med 2015; 372:2521-2532.', 362);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2924, 'Ozols RF. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Semin Oncol. 1995;22(6 Suppl 15):1-6. --- Pignata S, Breda E, et al. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol. 2008;66(3):229-36.', 562);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (606, 'Kantarijan H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid deukemia.', 274);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (607, 'N Engl J Med. 2010;362(24):2260-2270.', 274);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1911, '<br> Adcetris [package insert].', 237);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2392, ' van Oers MHJ, et al. Blood 2006;108:3295-3301', 922);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (612, 'Saven A, et al.', 277);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (613, 'Blood 1992;79:1111-1120.', 277);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1912, 'Bothell, WA: Seattle Genetics; 2011.', 237);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2037, 'Hainsworth JD, Spigel DR, Burris HA, et al. Oxaliplatin and capecitabine inn the treatment of patients with recurrent or refractory carcinoma of unknown primary site: A phase 2 trial of the Sarah Cannon Oncology Research Consortium.', 219);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (618, 'Doxil [package insert].', 280);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (619, 'Raritan, NJ: Centocor Ortho Biotech Products, LP; 2010.', 280);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (620, '<br> Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.', 280);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (621, 'J clin Oncol. 2007;25(25):3892.', 280);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2038, 'Cancer. 2010; 116(10):2448-2454.', 219);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2925, 'Evans SR, et al. J Clin Oncol 2002;20:3236-3241.', 577);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2926, 'D''Agostino G, Ferrandina G, et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer. 2003;89(7):1180-4.', 566);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2039, 'Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neutroendocrine carcinoma: a Minnie Pearl Cancer Network Study.', 220);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2040, 'J Clin Oncol. 2006;24(22):3548-3554.', 220);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2394, 'Rummel MJ, et al. J Clin Oncol 2005;23:3383-3389.', 924);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (628, 'Mitsudomi T, Tsai C, Shepherd F, et al. AZD9291 in pre-treated T790M positive advanced non-small cell lung carcinoma:AURA 2 phase II study. Presented at 16th world conference on lung cancer:September 6-9; Denverm CO. Abstract 1406.', 342);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2395, 'Robinson KS, et al. J Clin Oncol 2008;26:4473-4479.', 924);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2927, 'Swisher EM, Lin KK, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75-87.', 583);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2396, 'Sehn LH, et al. J Clin Oncol 2018;36: (Suppl 15) abstract 7507.', 925);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2397, 'Leonard J et al. J Clin Oncol 2019;37:1188-1199.', 926);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2398, 'Fisher RI. et al. J Clin Oncol 2006;24:4867-4874.', 927);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2094, 'WJTOG3405: Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Thoracic Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010 Feb;11(2):121-8. Epub 2009 Dec 18. ', 784);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2095, 'WJTOG3405 Update: Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann Oncol. 2019 Dec 1;30(12):1978-1984.', 784);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2096, 'NEJ002: Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8. ', 784);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2097, 'NEJ002, HRQoL analysis: Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist. 2012;17(6):863-70. Epub 2012 May 11.', 784);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (654, 'Kovnar EH, Kellie SJ, Horowitz ME, et al. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study.', 296);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (655, 'J Clin Oncol. 1990;8(2):330-336.', 296);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2399, 'Wang ML, et al. N Engl J Med 2013;369:507-516.', 928);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2400, 'Wang ML, et al. Lancet 2018;391:659-667.', 929);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (662, 'Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.', 328);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (663, 'Blood. 2000;95(11):3310-3322.', 328);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (664, 'Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small cell lung cancer.', 343);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (665, 'N Engl J Med 2015; 372:2018-2028.', 343);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (666, 'Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.', 344);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (667, 'N Engl J Med. 2013 Aug 8;369(6):507-16.', 344);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (668, 'Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.', 345);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (669, 'J Clin Oncol. 2013 Sep 20;31(27):3327-34.', 345);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2401, ' Dreyling M. et al. Ann Oncol 2017;28:2169-2178.', 930);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2402, 'Sehn LH, et al. J Clin Oncol 2015;33:LBA8502.', 931);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2410, 'Klimo P, et al. Ann Intern Med 1985;102:596-602.', 937);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2411, 'Shipp MA, et al. Ann Intern Med 1986;104:757-765.', 938);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2412, ' Longo DL, et al. J Clin Oncol 1991;9:25-38.', 939);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2413, 'Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP- an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.J Clin Oncol. 1994; 12(6): 1169-1176.', 940);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2414, 'Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).Blood. 1988;71(1):117-122.', 941);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2647, 'Romond EH,perez EA,Bryant J.et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.', 115);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2415, 'Moskowitz C, et al. J Clin Oncol 1999;17:3776-3785.', 942);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2416, 'Kewairamani T. et al. Blood 2004;103; 3684-3688', 943);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2417, 'Rodriguez MA, et al. Ann Oncol 1995;6:609-611', 944);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2648, 'N Engl J Med. 2005;353(16):1673-1684.', 115);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2928, 'David M, et al. Blood 2007:109:61-64.', 1118);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2418, 'El Gnaoui T. et al. Ann Oncol 2007;18:1363-1368.', 945);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2419, 'Shen QD, et al. Lancet Hematol 2018. doi:10.1016/S2352-3026 (18)30054-1', 945);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2421, 'Schuster SJ, et al. N Engl J Med 2017;377:2545-2554', 947);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (686, 'Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach- results of the first prospective study of the International Society of Pediatric Oncology.', 307);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (687, 'J Clin Oncol. 2000;18(22):3819-3828.', 307);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2434, 'O''Connor OA, et al. J Clin Oncol 2015;33:2492-2499.', 960);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2435, 'Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time to event analyses of the multicenter Phase 2. PINNACLE study. Ann Oncol. 2009;20(3):520-525.', 961);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2436, 'Habermann TM, et al. Br J Haematol 2009;145:344-349.', 962);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2438, 'Abrey LE, et al. J Clin Oncol 2002;18:3144-3150.', 964);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (692, 'Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.', 309);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (693, 'J Clin Oncol. 1987;5(8):1191-1198.', 309);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2439, 'Shah GD, et al. J Clin Oncol 2007;25:4730-4735', 965);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2440, 'Batchelor T. et al. J Clin Oncol 2003;21:1044-1049.', 966);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (696, 'Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR.', 346);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (697, 'N Engl J Med. 2010 Jun 24;362(25):2380-8.', 346);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2441, 'Reni M, et al. Br J Cancer 2007;96:864-867', 967);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2649, 'Romond EH, Perez EA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.', 420);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2442, 'Fischer L. et al. Ann Oncol 2006;17:1141-1145.', 968);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2650, 'Romond EH, Perez EA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.', 421);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2445, 'Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal Canal: A Randomized Controlled Trial. JAMA. 2008;299(16):1914–1921. doi:10.1001/jama.299.16.1914', 637);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2457, 'Le DT, et al. NEJM 2015;372:2509-2520.', 724);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2458, 'Qin S, et al. J Clin Oncol 2010:28; 303S (abstract 408).', 727);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2461, 'Meluch AA, Greco FA, Burris HA 3rd, O''Rourke T, Ortega G, Steis RG, Morrissey LH, Johnson V, Hainsworth JD. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001 Jun 15;19(12):3018-24.', 384);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2651, 'Neyt M, Albrecht J, Cocquyt V.An economic evaluation of herceptinR  in adjuvant setting: the Breast Cancer International Research Group 006 trial.', 117);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2652, 'Ann Oncol. 2006; 17(3):381-390', 117);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2653, 'von Minckwitz G, Huang CS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617-628.', 426);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2654, 'Andre F, Ciruelos E, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929-1940.', 498);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2655, 'Geyer CE, Forster J, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-43.', 492);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2929, 'Passweg JR, et al. J Clin Oncol 2011:29:303-309.', 1119);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2656, 'Joensuu H, Kellokumpu-Lehtinen PL, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809-20.', 423);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2657, 'Loesch D, Asmar L, et al. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clin Breast Cancer. 2008;8(2):178-86.', 487);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (714, 'Fryer CJ, Hutchinson RJ, Krailo M, et al. Efficacy and toxicity of 12 courses of ABVD therapy followed by low-dose regional radiation in advanced Hodgkin''s disease in children: a report from the Children''s Cancer Study Group.', 317);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (715, 'J Clin Oncol. 1990;8(12):1971-1980.', 317);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2658, 'Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.', 128);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2659, 'N Engl J Med. 2006;355(26):2733-2743.', 128);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2403, ' Klimo P. et al. J Clin Oncol 1985;3:1174-1182.', 932);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2404, 'Coiffier B, et al. N Engl J Med 2002;346:235-242.', 933);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2405, 'Vose JM, et al. Leuk Lymphoma 2002;43:799-804.', 934);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2406, 'Wilson WH, et al. J Clin Oncol 1993;11:1573-1582.', 935);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2407, 'Wilson WH. Semin Oncol 2000;27 (Suppl 12):30-36.', 936);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2408, 'Jermann M, jost M, Taverna C, et al. Rituximab EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.', 232);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2409, 'Ann Oncol. 2004; 15(3):511-516', 232);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2420, 'Neelapu SS, et al. N Engl J Med 2017;377:2531-2544', 946);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (724, 'Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children''s Cancer Group.', 321);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (725, 'Blood 2003;101(10):3809-3817.', 321);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2423, 'Berstein Jl, et al. J Clin Oncol 1986;4:847-858.', 949);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2425, 'Mann BS, et al. Oncologist 2007;12:1247-1252.', 951);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2426, 'Piekarz RL, Frye R, Prince HM, et al, “Phase 2 Trial of Romidepsin in Patients With Peripheral T-Cell Lymphoma,” Blood, 2011;17(22):5827-34.', 952);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2427, 'McLaughlin P, et al. J Clin Oncol 1998;16:2825-2833.', 953);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2428, 'Ghielmini M, et al. Blood 2004;103:4416-4423.', 953);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2429, 'Witzig TE, et al. J Clin Oncol 2002;20:2453-2463.', 954);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2430, 'Falkson Cl. Am J Clin Oncol 1996;19:268-270', 955);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2431, ' Betticher DC, et al. J Clin Oncol 1998;16:850-858.', 956);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2432, 'Friedberg JW, et al. J Clin Oncol 2008;26:204-210.', 957);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2433, 'Pro B, et al. J Clin Oncol 2012;30:2190-2196.', 959);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2443, 'Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189-2197. doi:10.1056/NEJMoa1200966', 788);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2444, 'Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14(9):2527-2539. doi:10.1200/JCO.1996.14.9.2527', 639);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2446, 'Goodman KA et al. Int J Radiat Oncol Biol Phys 2017: 98:1087-1095', 636);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2447, 'Bosset JF, et al. Eur J Cancer 2003;39:45-51', 635);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2448, 'Flam M. et al. J Clin Oncol 1996;14:2527-2539', 394);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2449, 'Eng C, et al. J Clin Oncol 2009;27:15S (abstract 4116)', 638);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2450, 'Eng C, et al. Oncotarget 2014;5:11133-11142.', 790);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2451, 'Morris VK, et al. Lancet Oncol 2017:18:446-453', 802);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2452, 'Ott PA, et al. Ann Oncol 2017:28:1036-1041', 801);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (749, 'Rizvi, NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.', 337);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (750, 'Lancet Oncol. 2015 Mar;16(3):257-65.', 337);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (751, 'Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.', 338);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (752, 'Lancet. 2014 Aug 23;384(9944):665-73.', 338);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (753, 'Ou SI, Ahn Js, Petris LD, et al. Alectinib in Crizotinib refractory ALK-rearranged non-small cell lung cancer: A phase II global study.', 339);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (754, 'J Clin Oncol. 2015 Nov 23. pii: JCO639443.', 339);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (755, 'Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer.', 340);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (756, 'N Engl J Med. 2014 Mar 27;370(13):1189-97.', 340);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (757, 'Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first line therapy in patients with stage IV sqaumous non-small cell lung cancer (SQUIRE): an open label, randomised, controlled phase 3 trial.', 341);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (758, 'Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1.', 341);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (759, 'Lonial S, Dimopoulous M, Palumbo A, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma .', 363);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (760, 'N Engl J Med. 2015 Aug 13;373(7):621-31.', 363);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (761, 'Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer.', 364);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (762, 'N Engl J Med. 2015 May 14;372(20):1909-19..', 364);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (763, 'Lancet Oncol. 2014 Oct;15(11):1195-206.', 364);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (764, 'Tabernero J, Yoshino T, Cohn Al, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.', 365);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (765, 'Lancet Oncol. 2015 May;16(5):499-508.', 365);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (766, 'Wilke H, Muro K, Van Custem E, et al. Ramucirumab plus paclitaxel versus placebo plus palcitaxel in patients with previously treated advanced gastric or gastro-esophageal junction adenocarcinoma I RAINBOW): a double-blind, randomised phase 3 trial.', 366);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (767, 'Lancet Oncol. 2014 Oct;15(11):1224-35.', 366);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1639, 'Hess V, et al. J Clin Oncol 2003;21:66-68', 707);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2453, 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970100-2/fulltext', 588);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2454, 'Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicenter, randomized, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716-728', 588);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2455, 'Sekulic A, Migden M, Oro AE, et al, “Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma,” New Engl J Med, 2012, 366(23):2171-9', 587);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2456, 'Nehls O, et al. Br J Cancer 2008;98:309-315.', 721);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2459, 'lyer G, et al. J Clin Oncol 2018. doi: 10.1200/JCO.2017.75.0158.', 379);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (768, 'Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-esophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.', 367);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (769, 'Lancet. 2014 Jan 4;383(9911):31-9.', 367);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (770, 'Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open label, phase 3 trial.', 368);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (771, 'Lancet. 2015 Nov 20. pii: S0140-6736(15)00986-1.', 368);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (772, 'Von Hoff DD, Ervin T, Arena FP, et al. Incrased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.', 369);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (773, 'N Engl J Med. 2013 Oct 31;369(18):1691-703.', 369);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (774, 'Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/Trio-18): a randomised phase 2 study.', 370);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (775, 'Lancet Oncol. 2015 Jan;16(1):25-35.', 370);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (776, 'Beck JT, Hortobogyi GN, Campone M, et al. Everolimus plus exemestane as first-line therapy in HR +, HER2 - advanced breast cancer in BOLERO-2.', 371);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (777, 'Breast Cancer Res Treat. 2014 Feb;143(3):459-67.', 371);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (778, 'Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.', 372);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (779, 'N Engl J Med. 2012 Jan 12;366(2):109-19. S', 372);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (780, 'Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer.', 373);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (781, 'N Engl J Med. 2012 Nov 8;367(19):1783-91.', 373);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (782, 'Cortes JE, et al. Bosutinib versus Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.', 374);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (783, 'J Clin Oncol.2012  October 30;(28):3486-3492.', 374);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (784, 'Cortes JE, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemia.', 375);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (785, 'N Engl J Med.2013 Nov 7;369(19):1783-96.', 375);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (786, 'Cortes JE, et al. phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phaseCML with T315I mutation.', 376);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (787, 'Blood.2012 Sep;120(13):2573-2580.', 376);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (788, 'Goede V, et. al. Obinutuzumab plus chlorambulcil in patients with CLL and coexisting conditions.', 377);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (789, 'N Engl J Med. 2014 Mar 20;370(12):1101-10.', 377);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2173, 'N Engl J Med. 1993;328(24):1725-1731.', 297);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2460, 'Calabrò F, Lorusso V, Rosati G, Manzione L, Frassineti L, Sava T, Di Paula ED, Alonso S, Sternberg CN. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer. 2009 Jun 15;115(12):2652-9', 383);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2462, 'Phase 1: Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, phase Ib study. J Clin Oncol. 2017 Jul 1;35(19):2117-2124. Epub 2017 Apr 4.', 389);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2463, 'Study 1108: Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O''Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016 Sep 10;34(26):3119-25. Epub 2016 Jun 6.', 388);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2464, 'CheckMate 275: Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar;18(3):312-322. Epub 2017 Jan 25.', 385);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2465, 'KEYNOTE-052: Balar AV, Castellano D, O''Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Nov;18(11):1483-1492. Epub 2017 Sep 26.', 382);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2930, 'Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592-604. doi:10.1016/S0140-6736(21)00228-2', 1120);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2690, 'Fisher B, Dignam J, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89(22):1673-82.', 430);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1640, 'Hubner RA, et al. Pancreas 2013;42:511-515', 707);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2691, 'Hackshaw A, Roughton M, et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer.', 148);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (800, 'McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997 May;15(5):1853-7', 387);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2692, 'J Clin Oncol. 2011;29(13):1657-1663.', 148);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1969, 'Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma.', 291);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2693, 'Di Leo A, et al.Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.', 143);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1641, 'Fine RL, et al. Cancer Chemother Pharmacol 2008;61:167-175', 708);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2932, 'Rajkumar SV, et al. J Clin Oncol 2002 20:4319-4323', 1122);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2933, 'Richardson PG, et al. Blood 2006;108:3458-3464', 1123);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2694, 'J Clin Oncol. 2010 Oct 20;28(30):4594-600', 143);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2695, 'Coombes RC, Hall E, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081-92.', 434);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2934, 'San-Miguel JF. et al. Lancet Oncol 2014:15:1195-1206.', 1124);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2696, 'O''Shaughnessy JA, et al. Breast Cancer Res Treat 2003;82:Suppl 1 (abstract 43).', 1021);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2935, 'Leleu X, et al. Blood 2013;121:1968-1975.', 1125);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2940, 'Palumbo A, et al. Leukemia 2010;24:1037-1042.', 1130);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2947, 'Lonial S, et al. Lancet 2016,387:1551-1560', 1137);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2948, 'Treon SP, et al. N Engl J Med 2015,372:1430-1400.', 1138);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2949, 'Cunningham D, et al. J Clin Oncol 1994:12:764-768.', 1139);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2951, 'Meyers PA, et al. J Clin Oncol 2005;23:2004-2011', 1141);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2176, 'Int J Radiat Oncol Biol Phys. 2004;58(4):1161-1164.', 298);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2177, 'Douglas JG, Barker JL, Ellenbogen RG, et al. Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure.', 298);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2178, '<br> National Cancer Institute. Phase III randomized study of adjuvant lomustine/cisplatin/vincristine vs cyclophosphamide/cisplatin/vincristine following craniospinal radiotherapy in children with newly diagnosed, average-risk medulloblastoma.', 298);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2179, 'http://cancer.gov.clinicaltrials.CCG-A9961. Accessed January 27, 2012.', 298);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1970, 'N Engl J Med. 2003;348(26):2609-2617.', 291);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (808, 'Swain SM, Jeong JH, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053-2065.', 398);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2931, 'Palumbo A, et al. Lancet 2006;28:367-835.', 287);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2936, 'Hussein MA, et al. Cancer 2002:95:2160-2168.', 1126);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2937, 'Orlowski RZ, et al. Proc Am Soc Hematol 2006 (abstract 404).', 1127);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2466, 'Rosenberg JE, O''Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019 Oct 10;37(29): 2592-2600. Epub 2019 Jul 29.', 393);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2938, 'Berenson JR, et al. J Clin Oncol 2006:24937-944.', 1128);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2467, 'Moore MJ, et al. J Clin Oncol 1997;15:3441-3445.', 969);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (823, 'Jones SE, Savin MA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24(34):5381-7.', 405);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (824, 'Martin M, Pienkowski T, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302-13.', 406);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1755, 'Dreyfuss A, et al. Proc Am Soc Clin Oncol 1995;14:875a.', 777);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2468, 'Sweeney CJ, et al. J Clin Oncol 2006;24:3451-3457.', 970);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (829, 'Citron ML, Berry DA, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-9.', 412);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1756, 'Ferris RL, et al. N Engl J Med 2016;375:1856-1867', 776);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1476, 'Matsunaga M, et al. Case Rep Oncol 2016;9:249-254', 803);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1483, 'Petrelli N. et al. J Clin Oncol 1989:7-1419-1426', 613);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1484, 'Wolmark N, et al. J Clin Oncol 1993;11:1879-1887', 590);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1485, 'Benson AB, et al. Oncology 2000;14:203-212', 591);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1486, 'Sauer R, et al. N Engl J Med 2004;351:1731-1740', 745);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2470, 'Harker WG, et al. J Clin Oncol 1985;3:1463-1470.', 972);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1489, 'Twelves C, et al. N Engl J Med 2005;352:2696-2704', 597);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1490, 'Hoff P, et al. J Clin Oncol 2001:15:2282-2292', 735);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1491, 'Kerr D. Oncology 2002;16 (Suppl 14):12-15', 610);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1492, ' Borner MM, et al. Ann Oncol 2005;16:282-288', 610);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1493, 'Lim DH, et al. Cancer Chemother Pharmacol 2005.56:10-14', 611);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1494, 'Scheithauer W. et al. J Clin Oncol 2003 21:1307-1312', 609);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1495, ' Hochster HS, et al. J Clin Oncol 2008:26:3523-3529', 619);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1496, 'Saltz LB, et al. J Clin Oncol 2004:22:1201-1208', 738);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1497, 'Tabernero J, et al. J Clin Oncol 2006;24:18S (abstract 3085).', 738);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1498, 'Saltz L, et al. J Clin Oncol 2007:22:4557-4561', 621);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2471, 'Santis MD, et al. J Clin Oncol 2009;27:5634-5638.', 973);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2472, 'Garcia del Muro X, et al. Br J Cancer 2002;86:326-330.', 974);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2473, 'Vaughn D, et al. Cancer 2002;95:1022-1027.', 975);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2474, 'Dreicer R, et al. J Clin Oncol 2000;18:1058-1061.', 976);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2486, 'Reardon DA, et al. Cancer 2011;26:188-193', 798);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2487, 'DeAngelis LM, et al. Ann Neurol 1998;44:691-695', 793);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2488, 'Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. doi:10.1056/NEJMoa043330', 670);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2495, 'Glas M, et al. J Clin Oncol, 2009;27:1257-1261', 797);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2496, 'Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523-533. doi: 10.1056/NEJMoa1706450.', 837);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2497, 'Gradishar WJ, Tjulandin S, Davidson N, et al, “Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil-Based Paclitaxel in Women With Breast Cancer,” J Clin Oncol, 2005, 23(31):7794-803', 137);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2498, 'Fisher B, Brown AM, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8(9):1483-96.', 400);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2499, 'Swain SM, Jeong JH, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053-2065.', 114);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2505, 'Sparano JA, Wang M, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663-71.', 402);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2506, 'Citron ML, berry DA, Cirrincione C,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combinational chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer : first report of intergroup trial C9741/cancer and leukemia Group B trial 9741.', 116);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2507, 'J Clin Oncol. 2003;21(8): 1431-1439', 116);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2508, 'Sledge GW, Neuberg D, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21(4):588-92.', 438);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2509, 'Citron ML, Berry DA, Cirrincione C,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer : first report of intergroup trial C9741/cancer and leukemia Groüp B Trial 9741.', 120);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2510, 'J Clin Oncol. 2003;21(8):1431-1439', 120);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2511, 'Miller KD. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer.', 121);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2512, 'J Clin Oncol. 2003;3(6):421-422', 121);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2513, 'Budman DR, Berry DA, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205-11.', 407);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2939, 'Palumbo A, et al. Blood 2007, 109:2757-2762', 1129);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1913, 'Sparano JA,Lee S, Chen MG, et al. Phase II trial of   infusional, cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkins lymphoma: an Eastern Cooperative Oncology Group Trial (E1491).', 247);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2664, 'Slamon D, Eiermann W, et all. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Breast Cancer Res Treat. 2006; 100 (Abstract #52).', 422);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2941, 'Stewart AK, et al. N Engl J Med 2015,372:142-152', 1131);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2942, 'Moreau P, et al. Lancet Oncol 2018;19.953-964.', 1132);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (842, 'Buzdar A, Jonat W, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol. 1996;14(7):2000-11.', 504);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (843, 'Dombernowsky P, Smith I, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16(2):453-61.', 505);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1466, 'Yung A, et al. Proc Am Soc Clin Oncol 1999:18:139a', 799);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (845, 'Howell A. Future use of selective estrogen receptor modulators and aromatase inhibitors. Clin Cancer Res. 2001;7(12 Suppl):4402s-4410s --- Di Leo A, Jerusalem G, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594-600.', 506);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2180, 'Pritchard J, Imeson J , Barnes J, et al. Results of the United Kingdom Children''s Cancer Study Group first Wilms'' tumor study.', 308);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (847, 'Kimmick GG, Muss HB. Endocrine therapy in metastatic breast cancer. Cancer Treat Res. 1998;94:231-54.', 507);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2943, 'Moreau P, et al. Blood 2015;126:727', 1133);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2944, 'Lokhorst HM, et al. N Engl J Med 2015,373:1207-1219', 1134);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2181, 'J Clin Oncol. 1995; 13(1):124-133.', 308);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2182, '<br>  de Camargo B, Franco EL. A randomized clinical trial of single-dose versus fractionated-dose dactinomycin in the treatment of Wilms'' tumor.', 308);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (850, 'Baselga J, Tripathy D, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999;26(4 Suppl 12):78-83. --- Baselga J, Carbonell X, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 2005;23(10):2162-71.', 508);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (851, 'Verma S, Miles D, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-91.', 509);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2945, 'Lonial S, et al. N Engl J Med 2015,373:621-631.', 1135);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2946, 'Chen C, et al. Blood 2018;131:855-863', 1136);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2950, 'Goorin A, et al. Med Pediatr Oncol 1995,24:362-367.', 1140);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1477, 'Leichman CG. Oncology 1999;13 (Suppl 3):26-32 ', 740);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2183, 'Cancer. 1994;73(12):3081-3086.', 308);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1914, 'J Clin Oncol. 2004; 22(8): 1491-1500.', 247);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1478, ' Falcone A, et al. Cancer Chemother Pharmacol 1999,44:159-163', 740);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2952, 'Neoptolemos J, et al. J Clin Oncol 2009;27:18S (abstract LBA4505)', 701);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1480, 'de Gramont A, et al. J Clin Oncol 1997:15:808-815.', 616);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1481, 'Jager E, et al. J Clin Oncol 1996:14 2274-2279.', 615);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1482, 'O''Connell MJ, et al. J Clin Oncol 1997:15:246-250', 589);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2956, 'Oettle H, et al. JAMA 2007;297:267-277.', 702);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1500, 'Saltz L, et al. J Clin Oncol 2007:22:4557-4561', 620);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2958, 'Loehrer PJ, et al. J Clin Oncol 1994;12:1164-1168.', 107);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2959, 'Kurzrock R, et al. J Clin Oncol 2011:29:2660-2666.', 861);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2961, 'Treon SP, et al. Blood 2014;124:503-510.', 865);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1504, 'Rougier P. et al. J Clin Oncol 1997:15:251-260.', 737);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1505, 'Pitot HC, et al. J Clin Oncol 1997;15:2910-2919. ', 736);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1506, 'Ulrich-Pur H, et al. Ann Oncol 2001:12:1269-1272', 736);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1517, 'Scott J, et al. J Clin Oncol 2005;23:16S (abstract 3705).', 625);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1518, 'Falcone A, et al. J Clin Oncol 2007:25:1670-1676.', 605);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1519, ' Loupakis F, et al. N Engl J Med 2014,371:1609-1618', 606);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1520, 'Fornaro L, et al. Ann Oncol 2013,24:2062-2067', 607);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2962, 'Einhorn LH, et al. J Clin Oncol 1989;7:387-391.', 844);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2963, 'Yang JC, et al. N Engl J Med 2003;349:427-434', 1143);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2964, 'Sternberg CN, et al. J Clin Oncol 2010:28:1061-1068.', 1144);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2965, 'Rini Bl, et al., et al. Lancet 2011378:1931-1939.', 1145);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2184, 'Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia.', 330);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2185, 'Cancer. 2006;66(6):1106-1113.', 330);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2186, 'Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia.', 331);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2187, 'Cancer. 2006;66(6):1106-1113.', 331);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2190, 'Camitta B, Leventhal B, Lauer S, et al. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of chldhood: a Pediatric Oncology Group study.', 329);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2191, 'J Clin Oncol. 1989;7(10):1539-1544.', 329);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2211, 'Bezwoda W, Ristogi RB, Erazo Valla A, et al. Long-term results of a multicentre randomised, comparitive phase III trial of CHOP versus CNOP regimens in patients with intermediate-and high-grade non-Hodgikin''s lymphomas.', 225);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2212, 'Eur J Cancer. 1995;31A(6):903-911', 225);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2213, 'Link MP, Donaldson SS, Berard CW, Shuster JJ, Murphy JB. Results of treatment of childhood localized non-Hodgkin''s lymphoma with combination chemotherapy with or without radiotherapy.', 319);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2665, 'Pegram M, Forbes J, et al. BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 2007; 25: (Abstr LBA1008).', 486);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2469, 'Bajorin DF, et al. Cancer 2000;88:1671-1678.', 971);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (861, 'Blum JL, Jones SE, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17(2):485-93.', 510);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1772, 'Parkash S. Gill, et al. Paclitaxel Is Safe and Effective in the Treatment of Advanced AIDS-Related Kaposi''s Sarcoma.', 212);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1773, 'http://jco.ascopubs.org/content/17/6/1876.full', 212);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2042, 'Martin Reck, Geetha Shankar, Anthony Lee, Shelley Coleman, Mark McCleland, Vassiliki A. Papadimitrakopoulou, Mark A. Socinski & Alan Sandler (2020) Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations, Expert Review of Respiratory Medicine, 14:2, 125-136, DOI: 10.1080/17476348.2020.1701439

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 457);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (866, 'Litton JK, Rugo HS, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379(8):753-763.', 522);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2666, 'Schneeweiss A, Chia S, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278-84.', 399);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1869, 'Trisenox [package insert].', 261);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1870, 'Frazer, PA: Cephalon; 2010.', 261);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1871, 'Soignet SL, et al. J Clin Oncol 2001;19:3852-3860', 261);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1872, 'Dombret H, et al. Semin Hematol 2002;39 (2 Suppl 1):8-13', 261);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2953, 'Conroy T. et al. J Clin Oncol 2010;28:302S (abstract 4010).', 711);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2954, 'Conroy T, et al. J Clin Oncol 2018;36:18S (abstract LBA4001).', 700);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1499, 'Kabbinavar F, et al. J Clin Oncol 2005:23 3697-3705', 614);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (952, 'Carmichael J, Walling J, et al. Phase II activity of gemcitabine in advanced breast cancer. Semin Oncol. 1996;23(5 Suppl 10):77-81.', 516);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1507, 'Kuebler JP, et al. J Clin Oncol 2007;25:2198-2204.', 594);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1508, 'Kemeny N, et al. J Clin Oncol 1994;12:2288-2295', 726);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1509, 'Kopetz S, et al. J Clin Oncol 2007;25:18S (abstract 4027)', 628);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1510, 'van Cutsem EV, et al. N Engl J Med 2009;360:1408-1417', 623);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2475, 'James ND, et al. N Engl J Med 2012;366:1477-1488.', 977);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1511, 'Peeters M. et al. J Clin Oncol 2010;28:4706-4713', 627);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1512, 'Tabernero J, et al. Lancet Oncol 2015:16:499-508', 631);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1513, 'van Cutsem EE, et al. J Clin Oncol 2012:30:3499-3506.', 630);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1514, 'Giantonio BJ, et al. J Clin Oncol 2007:25:1539-1544', 617);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1515, 'Bokemeyer C, et al. J Clin Oncol 2009:27:663-671', 624);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1516, 'Doullard JY, et al. J Clin Oncol 2010;28:4697-4705.', 626);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1521, 'Douillard JY, et al. Lancet 2000;355:1041-1047.', 599);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1522, 'Andre T, et al. Eur J Cancer 1999:35:1343-1347', 600);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1523, 'Hwang JJ, et al. Am J Oncol Rev 2003;2 (Suppl 5):15-25', 598);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1524, 'Cunningham D. et al. N Engl J Med 2004:351.337-345', 622);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1525, 'Dimou A, et al. Expert Opin Investing Drugs 2010:19:723-735.', 618);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1642, 'Moore MJ, et al. J Clin Oncol 2005;23:16S (abstract 1).', 710);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1643, 'Louvet C, et al. J Clin Oncol 2007;25:18S (abstract 4592).', 709);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1644, 'Loehrer PJ, et al. J Clin Oncol 2008;26 (abstract 4506).', 704);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1645, ' Wang-Gilam A, et al. Lancet 2016;387:545-557', 713);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2476, 'Yung A, et al. J Clin Oncol 1999;17:2762-2771', 800);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2477, 'Selker RG, Sharipo WR, Burger p, et al. The Brain tumor cooperative group NIH Trial 87-01: a randomized comparision of surgery, external radiotherapy, and carmustine versus surgery, interstital radiotherapy, and carmustine.', 4);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2478, 'Neurosurgery.2002;51(2):343-355; discussion 355-357.', 4);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2479, 'Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab plus irinotecan at tumor progression in recuurent glioblastoma.', 5);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2480, 'J Clin Oncol. 2009;27(5):740-745.', 5);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2481, 'Raizer JJ, Grimm S, et al. Aphase 2 trial of single-agent bevacizumab plus irinotecan at tumor progression in recurrent high- grade schedule for patients with recurrent high- grade gliomas.', 5);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2482, 'Cancer.2010;116(22):597-5305.', 5);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2483, 'Beal K, et al. Radiat Oncol 2011;6:2-15.', 5);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2205, 'Ravindranath Y, Steuber CP, Krischer J, et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study.', 332);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2206, 'J Clin Oncol. 1991;9(4):572-580.', 332);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2207, 'Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children''s Cancer Group.', 333);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2208, 'Blood. 1996;87(12):4979-4989.', 333);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2484, 'Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.', 1);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2485, 'J Clin Oncol. 2007;25(30):4722-4279.', 1);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2209, 'Kelly KM, Hutchinson RJ, Sposto R, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin''s lymphoma: preliminary results from the Children''s Cancer Group Study Ccg-59704.', 318);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2210, 'Ann Oncol. 2002;13(suppl 1):107-111.', 318);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2489, 'Raymond E. et al. Ann Oncol 2003;14:603-614', 795);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2490, 'Friedman H, et al. J Clin Oncol 1999;17:1516-1525', 795);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1526, 'Overman MJ, et al. Lancet Oncol 2017:18:1182-1191', 744);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1527, 'Overman MJ, et al. J Clin Oncol 2018:36:773-779', 634);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1528, 'de Gramont A, et al. J Clin Oncol 2000,18:2938-2947.', 601);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1529, 'Andre, T et al. N Engl J Med 2004:350:2343-2351.', 592);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1530, 'Tournigand C, et al. J Clin Oncol 2004;22:229-237', 602);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1531, 'Andre T. et al. Proc Am Soc Clin Oncol 2003;22:253 (abstract 1016).', 603);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1532, 'Maindrault-Goebel F. et al. J Clin Oncol 2006;24 (June 20 Supplement):3504.', 604);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2955, 'Neoptolemos JP, et al. Lancet 2017;389:1011-1024.', 699);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1534, 'Schmoll HJ, et al. J Clin Oncol 2007;25:102-109.', 595);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1535, 'Andre, T et al. N Engl J Med 2004:350:2343-2351.', 804);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1536, 'Goldberg RM, et al. J Clin Oncol 2004:22:23-30', 612);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2667, 'Schaller G, Fuchs I, et al. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol. 2007;25(22):3246-50. --- Bartsch R, Wenzel C, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007;25(25):3853-8.', 490);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2668, 'Esteva FJ, Valero V, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(7):1800-8.', 485);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1537, 'van Cutsem EV, et al. J Clin Oncol 2007:25:1658-1664.', 739);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2957, 'Havlin KA, et al. Cancer Treat Res 1988;39:83-96.', 1142);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1539, 'Grothey A, et al. Lancet 2013,381:303-312', 741);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1540, 'Bekaii-Saab TS, et al. Lancet Oncol 2019,20:1070-1082.', 741);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1541, 'Mayer RJ, et al. N Engl J Med 2015,20:1909-1919.', 742);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1774, 'Udhrain A, et al.Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma.', 213);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2214, 'N Engl J Med. 1990;322(17):1169-1174.', 319);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2215, 'Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a Pediatric Oncology Group study.', 320);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2216, 'J Clin Oncol. 1996;14(4):1252-1261.', 320);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2217, 'Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.', 304);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1542, 'Xu RH, et al. Lancet Oncol 2019:25:660-671.', 629);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1646, 'Von Hoff DD, et al. N Engl J Med 2013,369:1691-1703', 712);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1647, 'Golan T, et al. N Engl J Med 2019;381:317-327.', 714);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1648, 'Regine WF, et al. J Clin Oncol 2006;25 (abstract 4007).', 703);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1649, 'Kulke MH, et al. J Clin Oncol 2007;25:4787-4792', 805);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1650, 'Murad AM, Triginelli SA, et al. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol. 1994;12(1):55-9.', 530);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1651, 'Buxton EJ, Meanwell CA, et al. Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst. 1989;81(5):359-61.', 529);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2960, 'Schlumberger M, et al. N Engl J Med 2015;372:621-630.', 862);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1775, 'Int J Nanomedicine. 2007 September; 2(3): 345–352.', 213);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2218, 'J Clin Oncol. 1994;12(12):2607-2613.', 304);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2491, 'Levin VA, Uhm JH, Jaeckle KA, et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluromethylornithine- procarbazine, N-(2-chloroethyl)-N'' -cyclohexyl- N-nitrosuera, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.', 2);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2492, 'Clin Cancer Res.2000;6(10):3878-3884.', 2);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1653, 'Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.', 172);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1654, 'N Engl J Med. 1999;340(15):1154-1161. ', 172);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2221, 'Sussman DA, Escalona-Benz E, Benz MS, et al. Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy.', 306);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2974, 'Tap WD, et al. Lancet 2016;388:488-497.', 1154);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1667, 'Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemoterapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.', 169);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1668, 'N Engl J Med. 1999;340(15):1137-1143.', 169);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1669, '<br> Whitney CW, Sausse W, Bundy BN, et al. Randomized commparison of fluorouuracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study.', 169);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2222, 'Arch Ophthalmol. 2003;121(7):979-984.', 306);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2493, 'Buckner JC, Gesme D Jr, O''Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol. 2003;21(2):251-255. doi:10.1200/JCO.2003.06.023', 794);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2494, 'Nicholas MK, et al. J Clin Oncol 2009:27:15S (abstract 2016)', 796);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2225, 'Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach- results of the first prospective study of the International Society of Pediatric Oncology', 848);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2226, 'J Clin Oncol. 2000;18(22):3819-3828.', 848);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2500, 'Puhalla S, Mrozek E, et al. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol. 2008;26(10):1691-7.', 413);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2501, 'Sparano JA, Zhao F, et al. 2014 San Antonio Breast Cancer Symposium Abstracts S3-03.', 403);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2502, 'Sparano JA, Zhao F, et al. 2014 San Antonio Breast Cancer Symposium Abstracts S3-03.', 404);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2503, 'Burstein HJ, Parker LM, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005;23(33):8340-7.', 411);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2504, 'Citron ML, Berry DA, et al. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-9.', 401);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2975, 'Maki RG, et al. J Clin Oncol 2007;25:2755-2763.', 1155);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2976, ' van Oosterom AT, et al. Eur J Cancer 2002:38:2397-2406', 1156);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2977, 'Judson I, et al. Eur J Cancer 2001:37:870-877.', 1157);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2978, 'van Der Graaf, et al. J Clin Oncol 2011:29:18S (LBA 10002).', 1158);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2981, 'Schlumberger M, et al. N Engl J Med 2015;372:621-630.', 1161);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2982, 'Treon SP, Hanzis C, Tripsas C, et al, “Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström''s Macroglobulinemia,” Clin Lymphoma Myeloma Leuk, 2011, 11(1):133-5.', 1162);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2227, 'Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.', 849);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2966, 'Motzer RJ, et al. Lancet 2008;372:449-456.', 1146);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2967, 'Fyfe G, et al. J Clin Oncol 1995:13:688-696.', 1147);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2228, 'J Clin Oncol. 1987;5(8):1191-1198.', 849);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2514, 'Budman DR, Berry DA, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205-11.', 439);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2515, 'Hutchins LF, Green SJ, Favolin PM, et al. Randomized controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high risk, node-negative breast cancer:treatment results of Intergroup Protocol INT-0102.', 122);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1778, 'Lim ST, et al. Cancer 2005;103:417-421.', 511);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2516, 'J Clin Oncol. 2005;23(33):8313-8321.', 122);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2234, 'Link MP, Donaldson SS, Berard CW, Shuster JJ, Murphy JB. Results of treatment of childhood localized non-Hodgkin''s lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med. 1990;322(17):1169-1174.', 852);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (953, 'Al-Batran SE, Meerpohl HG, et al. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology. 2006;70(2):141-6.', 517);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2235, 'Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a Pediatric Oncology Group study. J Clin Oncol. 1996;14(4):1252-1261.', 853);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2968, 'Minasian LM, et al. J Clin Oncol 1993:11:1368-1375.', 1148);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2969, 'Choueiri TK, et al. N Engl J Med 2015:373:1814-1822.', 1149);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1939, 'Zevalin [package insert].', 240);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1940, 'San Deigo, CA: IDEC Pharmaceutical Coorporation; 2010.', 240);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2236, 'Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children''s Cancer Group. Blood 2003;101(10):3809-3817.', 854);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2970, 'Motzer RJ et al. Lancet Oncol 2015;16:1473-1482.', 1150);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2971, 'Santoro A, et al. J Clin Oncol 1995;13:1537-1545.', 1151);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1781, 'DeAngelo DJ, et al. Blood 2007;109.5136-5142', 753);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1787, 'Kantarjian H, et al. N Engl J Med 2016;375:740-753.', 807);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1788, 'Faderl S, et al. Cancer 2005;103:1985-1995', 808);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2240, 'Van Winkle P, Angiolillo A, Krailo M, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children''s Cancer Group (CCG) experience. Pediatr Blood Cancer. 2005;44(4):338-347.', 312);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2972, 'Maki RG, et al. J Clin Oncol 2007;25:2755-2763.', 1152);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2973, 'Dileo P, et al. Cancer 2007;109:1863-1869.', 1153);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2245, 'Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing''s family of tumors in children and young adults.', 314);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2246, 'J Clin Oncol. 2003;21(18):3423-3430.', 314);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2255, 'Shimaoka K, et al. Cancer 1985,56:2155-2160.', 856);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2517, 'Xeloda [package insert].', 139);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2257, 'Ravaud A, et al. Eur J Cancer 2017;76:110-117.', 858);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2258, 'Bible KC, et al. Lancet Oncol 2010:11:962-972.', 859);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2518, 'San Francisco, CA: Genentech; 2011.', 139);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2259, 'Wells SA, et al. J Clin Oncol 2010;28:767-772.', 860);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2519, 'Blum JL, et al. J Clin Oncol 1999;17:485-493.', 139);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2979, 'Demetri GD, et al. J Clin Oncol 2016;34:786-793.', 1159);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2980, 'Schoffski P, et al. Lancet 2016,387:1629-1637.', 1160);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2263, 'Dimopoulos MA, et al. J Clin Oncol 2007;25:3344-3349.', 864);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2993, 'Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021;384(13):1191-1203. doi:10.1056/NEJMoa2032125', 1173);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2996, 'Finlay JL, Bayett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen.', 300);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2997, 'J Clin Oncol. 1995;13(1):112-123.', 300);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2266, 'Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189-2197. doi:10.1056/NEJMoa1200966', 789);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2267, 'Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731-739', 866);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2268, 'Drilon A, et al. Cancer Discov 2017;7:400-409.', 867);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2269, 'Ardizzoni A, et al. Cancer 1991;67:2984-2987.', 868);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2279, 'Strosberg JR, et al. Cancer 2011;117:268-275.', 878);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2250, 'Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing''s sarcoma and primitive neuroectodermal tumor of bone.', 313);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2251, 'N Engl J Med. 2003;348(8):694-701.', 313);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2983, 'Alexanian R, et al. Ann Intern Med 1986;105:8-11.', 1163);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2053, ' Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol. 2012 Aug 10;30(23):2829-36. Epub 2012 Jul 2.BEYOND: Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015 Jul 1;33(19):2197-204. Epub 2015 May 26.Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.Paclitaxel injection. United States Prescribing Information. US National Library of Medicine.', 463);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2254, 'Shimaoka K, et al. Cancer 1985,56:2155-2160.', 855);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2256, 'Gupta-Abramson V, et al. J Clin Oncol 2008;26:2010-2015', 857);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2669, 'Slamon DJ, Leyland-Jones B, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92. --- Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999;21(2):309-18.', 484);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2984, 'Bosl G, et al. J Clin Oncol 1988;6:1231-1238.', 1164);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1786, 'Topp MS, et al. Lancet Oncol 2015;16:57-66.', 806);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2054, 'ECOG E4599: Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50.', 463);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (954, 'Cortes J, O''Shaughnessy J, et al. Eribulin monotherapy versus treatment of physician''s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914-23.', 519);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2985, 'Einhorn LH, et al. Ann Intern Med 1977:87293-298.', 1165);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1003, 'https://hemonc.org/wiki/Afatinib_(Gilotrif)', 746);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2986, 'Vugrin D, et al. Ann Intern Med 1981:95:59-61.', 1166);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2055, ' Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57. Epub 2009 Aug 19', 463);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2670, 'Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.', 484);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2671, 'Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.', 136);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2520, 'Fitch V, et al. Proc Am Soc Clin Oncol 2003;22:23 (abstract 90).', 452);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2262, 'Treon SP, et al. J Clin Oncol 2009;27:3830-3835.', 863);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2672, 'J Clin Oncol. 2006;24(18):2786-2792.', 136);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2270, 'Shin DM, et al. Cancer 1995;76:2230-2236.', 869);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2271, 'Nowak AK, et al. Br J Cancer 2002;87:491-496.', 870);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2272, 'Favaretto AG, et al. Cancer 2003;97:2791-2797.', 871);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2521, 'Perez EA, Hillman DW, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer. 2000;88(1):124-31.', 451);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2273, 'Vogelzang NJ, et al. J Clin Oncol 2003;21:2636-2644.', 872);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2274, 'Jassem J, et al. J Clin Oncol 2008;26:1698-1704.', 873);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2522, 'Levine MN, Bramwell VH, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16(8):2651-8.', 440);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2275, 'Moertel CG, et al. N Engl J Med 1992;326:519-526', 874);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2523, 'Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.', 140);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2276, 'Moertel CG, et al. N Engl J Med 1992;326:519-526', 875);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2524, 'J Clin Oncol. 1999;17(8):2341-2354.', 140);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2277, 'Moertel CG, et al. Cancer 1991;68:227-232.', 876);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2525, '<br> Nabholtz JM, Senn Hj, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy.', 140);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2673, 'Howell A, Cuzick J, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years'' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-2.', 431);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2526, 'J Clin Oncol. 1999;17(5):1413-1424.', 140);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2527, '<br> Taxotere [package insert].', 140);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2528, 'New York, NY: Sanofi-Aventis; 2010.', 140);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2542, 'Levine MN, Bramwell VH, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16(8):2651-8.', 409);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2987, 'Loehrer PJ, et al. Ann Intern Med 1988:109:540-546.', 1167);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2988, 'Loehrer PJ, et al. Ann Intern Med 1988:109:540-546.', 1168);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2567, 'Sanz MA, et al. Blood 2010;115:5137-5146.', 978);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2568, 'Estey E, et al. Blood 2006;107:3469-3473.', 979);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2674, 'Arimidex [package insert].', 138);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2569, 'Ho AD, et al. J Clin Oncol 1988;6:213-217', 980);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2574, 'Tallman MS, et al Blood 2005;106:1154-1163', 984);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2575, 'Cortes JE, et al. Leukemia 2019;33:379-389.', 985);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2989, 'Kondagunat GV, et al. J Clin Oncol 2005;23:6549-6555.', 1169);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2576, 'DiNardo CD. et al Blood 2019;133:7-17.', 986);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2579, 'Man CH, et al. Blood 2012;119:5133-5143.', 989);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2580, 'Fenaux P. et al. J Clin Oncol 2010;28:562-569.', 990);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2581, 'Kantarjian HM, et al. J Clin Oncol 2012;30 2670-2677.', 991);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2582, 'Perl AE, et al. J Clin Oncol 2017;35: (Suppl 15) abstract 7067', 992);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2280, 'Saltz L, et al. Cancer 1993;72:244.', 879);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2529, 'Puhalla S, Mrozek E, et al. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol. 2008;26(10):1691-7.', 414);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1543, 'Hong DS, et al. Cancer Discov 2016;6:1352-1365.', 632);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2530, 'Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.', 126);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2990, ' Einhorn LH, et al. J Clin Oncol 2007:25:513-516.', 1170);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2281, 'aplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224-233. doi: 10.1056/NEJMoa1316158.', 880);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2675, 'Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2011.', 138);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2282, 'Kulke MH, et al. J Clin Oncol 2008;26:3403-3410.', 881);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2991, 'Bokemeyer C, et al. Ann Oncol 2008;19:448-453.', 1171);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2283, 'Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010;28(24):3851-3857.', 882);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1552, 'Jassem J, Pienkowski T, Pluzanska A.et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.', 119);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2284, 'Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.', 178);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (955, 'O''Shaughnessy JA, et al. Breast Cancer Res Treat 2003;82:Suppl 1 (abstract 43). --- O''Shaughnessy JA, et al. Breast Cancer Res Treat 2004;88:Suppl 1 (abstract 1070).', 518);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1553, 'J Clin Oncol. 2001;19(6):1707-1715', 119);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1555, 'Conroy T, et al. Lancet Oncol 2014;15:305-314.', 647);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1556, 'van Meerten E, et al. Br J Cancer 2007,96:1348-1352', 657);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1566, 'Cunningham D. et al. N Engl J Med 2006;355 11-20', 652);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1567, 'Ajani JA, et al. Semin Oncol 1995;22 (Suppl 6):35-40', 662);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1571, 'Shitara K, et al. Lancet Oncol 2018;19:1437-1448.', 664);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2285, 'N Engl J Med. 2007;356(2):115-124', 178);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2286, 'Ravaud A. et al. N Engl J Med 2016;375:2246-2254.', 883);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2287, 'Escudier B, et al. Lancet 2007;370:2103-2111.', 884);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2531, 'J Clin Oncol. 2001;19(12):3103-3110.', 126);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2288, 'Atzpodien J, et al. Semin Oncol 1993;20 (Suppl 9):22.', 885);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2289, 'Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473-1482.', 886);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2290, 'Motzer RJ, et al. N Engl J Med 2018;378:1277-1290.', 887);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2291, 'Voss MH, et al. J Clin Oncol 2016;34:3846-3853.', 888);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2292, 'Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116-1127.', 889);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2532, 'Poole CJ, Earl HM, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355(18):1851-62.', 408);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2293, 'Motzer RJ, et al. N Engl J Med 2019;380:1103-1115.', 890);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2297, 'Copur MS, et al. Semin Oncol 2001;28:16-21.', 894);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2298, 'Petrylak DP, et al. N Engl J Med 2004;351:1513-1520', 894);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2299, 'Tannock IF, et al. N Engl J Med 2004;351:1502-1512', 895);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2300, 'Halabi S, et al. J Clin Oncol 2010;28:951S (LBA 4511).', 896);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2308, 'Petrylak DP. Semin Oncol 2000;27 (Suppl 3):24-29.', 901);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2309, 'Dreicer R. Hematol Oncol Clin North Am 2006;20:935-946.', 901);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2310, 'Hudes G. Semin Urol Oncol 1997;15:13-9.', 902);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2533, 'Cortes J, O''Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician''s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.', 141);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2534, 'Lancet. 2011;377(9769):914-923.', 141);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2311, 'Murphy GP, et al. Urology 1984;23:54-63.', 903);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2312, 'Dijkman GA, et al. Eur Urol 1995;27:43-46.', 903);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2313, 'Hanks GE, et al. J Clin Oncol 2003;21:3972-3978.', 904);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2535, 'Levine MN, Bramwell VH, Pritchard KI, et al. Randomized tiral of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer.', 123);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2330, 'Kantoff PW, et al. N Engl J Med 2010;363:411-422.', 914);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2331, 'Scher Hl. et al. N Engl J Med 2012:367:1187-1197.', 915);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2342, 'Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP- an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.', 230);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2343, 'J Clin Oncol. 1994; 12(6): 1169-1176.', 230);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2344, '<br> Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.', 230);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2345, 'J Clin Oncol. 1995; 13(7): 1734-1741.', 230);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2346, 'Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.', 302);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2347, 'J Pediatr Hematol Oncol. 2002;24(8):613-621.', 302);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2536, 'J Clin Oncol. 1998;16(8):2651:2658.', 123);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2537, '<br> French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose intensity and duration of treatment.', 123);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2538, 'J Clin Oncol. 2000;18(7):3115-3124.', 123);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2539, 'Roche H, Fumoleau P, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24(36):5664-71.', 410);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2540, 'Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.', 132);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2541, 'J Clin Oncol. 2006:24(34):5381-5387.', 132);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2543, 'A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. J Clin Oncol. 1991;9(2):305-12.', 449);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2546, 'Presler H, Davis RB, Kirshener J, et al. Comparison of three remission induction regimens and two post-induction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study.', 257);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2547, 'Blood. 1987;69(5):1441-1449.', 257);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2294, 'Hudes GR, et al. J Clin Oncol 1992;11:1754-1761.', 891);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2295, 'Hudes GR, et al. J Clin Oncol 1997;15:3156-3163.', 892);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2296, 'Tannock IF, et al. J Clin Oncol 1996;14:1756-1764.', 893);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2548, '<br> Wiernik PH, BAnks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated patients with acute myeloid leukemia.', 257);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2549, 'Blood. 1992;79(2):313-319.', 257);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2992, 'Miller JC, et al. Semin Oncol 1990;17(1 Suppl 2):36-39.', 1172);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2550, '<br> Wahlin A, Hornsten P, Hedenus M, Malm C. Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia.', 257);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2551, 'Cancer Chemother Pharmacol. 1991;28(6):480-483.', 257);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2301, 'De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-1154.', 897);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2552, 'Fernandez HF, Sun Z, Pao X, et al. Anthracycline dose intensification in acute myeloid leukemia.', 258);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (948, 'Holmes FA, Walters RS, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991;83(24):1797-805. --- Perez EA. Paclitaxel in Breast Cancer. Oncologist. 1998;3(6):373-389.', 512);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (949, 'Perez EA, Lerzo G, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25(23):3407-14.', 513);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2302, 'Eisenberger M, Hardy-Bessard AC, Kim CS, et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in post Docetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol. 2017;35(28):3198-3206.', 897);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (951, 'Torti FM, Bristow MR, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983;99(6):745-9.', 515);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2303, 'Climent MA, et al. Eur J Cancer 2017;878:30-37.', 897);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2553, 'N Engl J Med. 2009;361(13):1249-1259.', 258);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1670, 'J Clin Oncol. 1999;17(5):1339-1348.', 169);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1724, 'De Geest K, Blessing JA, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2010;28(1):149-53.', 574);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1725, 'Mirza MN, Monk BJ, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154-2164.', 584);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2304, 'DeBono JS, et al. N Engl J Med 2011;364:1995-2005.', 898);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2305, 'Sweeney C, et al. J Clin Oncol 2014;32:5S (LBA2).', 899);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2306, 'Roth BJ, et al. Cancer 1993;72:2457-2460.', 900);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2307, 'Ahmed S, et al. Proc Am Soc Clin Oncol 1998;17:325a.', 900);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2554, 'Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135(7):463-471. doi:10.1182/blood.2019002140', 672);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2314, 'Klotz L, et al. BJU Int 2008;10:1531-1538.', 905);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2315, 'The Leuprolide Study Group. N Engl J Med 1984;311:1281-1286.', 906);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2316, 'Sharifi R. et al. Clin Ther 1996;18:647-657.', 906);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2317, 'Sartor 0, et al. Urology 2003;62:319-323', 906);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2318, 'Schellhammer PF, et al. Urology 1997;50:330-336.', 907);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3000, 'Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of pre-radiation chemotherapy versus radiotherapy alone for non metastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children''s Cancer Study Group PNET-3 study.', 299);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2319, 'McLeod DG, et al. Cancer 1993;72:3870-3873.', 908);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2320, 'Jurincic CD, et al. Semin Oncol 1991;18 (Suppl 6):21-25.', 839);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2321, 'Eisenberger MA, et al. Semin Oncol 1994;21:613-619.', 838);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3001, 'J Clin Oncol. 2003;21(8):1581-1591.', 299);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2557, 'Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia.', 260);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2323, 'Smith MR, et al. N Engl J Med 2018;378:1408-1418.', 910);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2558, 'Blood. 1995;85(10):2643-2653.', 260);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2325, 'Janknegt RA, et al. J Urol 1993;149:77-82', 909);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2326, 'Fizazi K, Shore N, Tammela TL, et al; ARAMIS Investigators. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13):1235-1246. doi: 10.1056/NEJMoa1815671.', 911);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2327, 'Tannock IF, et al. J Clin Oncol 1989;7:590-597.', 912);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2328, 'Fossa SD, et al. J Clin Oncol 2001;19:62-71.', 912);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2329, 'Johnson DE, et al. Urology 1988;31:132-134.', 913);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2561, 'Gardin C, et al. Blood 2007;109:5129-5132', 263);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2562, 'Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid deukemia. Cancer and Leukemia Group B.', 263);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2563, 'Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA group study AML-10.', 256);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2564, 'J Clin Oncol. 2009;32(10):5397-5403.', 256);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2565, 'Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcomeon the LPA99 multicenter study by the PETHEMA Group.', 255);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2566, 'Blood. 2008;112(8):3130-3134.', 255);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2570, 'Montillo M, et al. Am J Hematol 1998;58:105-109.', 981);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2571, 'Wiernik PH, et al. Blood 1992;79:313-319', 982);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2572, 'Lancet JE, et al. Blood 2014;123:3239-3246.', 983);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2573, 'Preisler H, et al. Blood 1987;69:1441-1449.', 822);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2578, 'Kantarjian HM, et al. Blood 2003;102:2379-2386', 988);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2583, 'Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin''s disease after failure of MOPP: ABVD and B-CAVe.', 221);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2584, 'Ann Intern Med. 1984;  101(4):440-446', 221);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2585, '.<br> Longo DL, Glastein E, Duffey PL,et al. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgikin''s disease.', 221);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2586, 'J Clin Oncol. 1997; 15(11): 3338-3346', 221);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (956, 'Dickler MN, Tolaney SM, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017;23(17):5218-5224.', 520);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2587, 'Bonadonna G, et al. Cancer 1975;36:252-259.', 221);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1927, 'Olsen E, Duvic M Frankel A, et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.', 238);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1928, 'J Clin Oncol. 2001; 19(2):376-388.', 238);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2676, 'Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase in hibitors: a phase II trial.', 142);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2677, 'J Clin Oncol. 2000;18(11):2234-2244.', 142);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2678, '<br> Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.', 142);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2679, 'J Clin Oncol. 2000;18(7):1399-1411.', 142);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2680, '<br> Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.', 142);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2681, 'N Engl J Med. 2004;350(11):1081-1092.', 142);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1820, 'Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.', 266);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1821, 'J Clin Oncol. 2010;28(10):1756-1765.', 266);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2682, '<br> Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.', 145);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2683, 'N Engl J Med. 2003;349(19): 1793-1802.', 145);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1884, 'Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811.', 251);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1885, 'Blood. 1995;85(8):2025-2037.', 251);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1935, 'Klasa RJ,Meyer RM, Shustic C, et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisione in patients with recurrent low-grade Non-Hodgikin''s lymphoma previously treated with an alkylating agent or alkylatic containing regimen.', 239);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1936, 'J Clin Oncol. 2002;20(24):4649-4654.', 239);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1937, 'Khouri IF, Romaguera J, Kantrajian H,et al. Hyper-CVAD and high -dose methotrexate/ cytarabine followed by stem-cell tans-plantation: an active regimen for aggressive mantle-cell lymphoma.', 231);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1938, 'J Clin Oncol. 1998; 16(12): 3803-3809', 231);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1950, 'Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.', 228);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1951, 'Blood, 105(4): 1417-1423.', 228);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (989, 'Robson M, Im SA, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523-533.', 521);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1952, '<br> Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine and prednisone alone in patients with previously utreated advanced follicular lymphoma.', 228);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1953, 'J Clin Oncol. 2008;26(28):4578-4589.', 228);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1671, 'Monk BJ, et al. Proc Am Soc Clin Oncol 2008;26:(LBA5504). --- Brewer CA, Blessing JA, et al. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;100(2):385-8.', 534);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2350, 'Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council''s 10th AML trial.', 335);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2351, 'Br J Haematol. 1998;101(1):130-140.', 335);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1971, 'Sonneveld P, van der Holt B, Schmidt-Wolf IGH, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycin, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM).', 281);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1674, 'Rose PG, Bundy BN, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144-53.', 523);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1972, 'Blood. 2008;112(11):Abstract 653.', 281);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1675, 'Fiorica J, Holloway R, et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol. 2002;85(1):89-94.', 525);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1676, 'Long HJ, Bundy BN, Grendys EC, et al. Randomized Phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study.', 525);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1716, 'Swenerton K, Jeffrey J, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1992;10(5):718-26.', 559);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1717, 'McGuire WP, Hoskins WJ, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1-6.', 561);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1718, 'Rose PG, Maxson JH, et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol. 2001;82(2):323-8.', 572);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1973, 'Cazo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.', 282);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1974, 'Lancet. 2010;18;376(9758):2075-2085.', 282);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1977, 'Khan ML, Reeder CB, Kumar SK, et al. A comparison af lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethansone in newly diagnosed multiple myeloma.', 283);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1978, 'Br J Haematol. 2011 [Epub ahead of print].', 283);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1981, 'Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.', 284);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1004, 'LUX-Lung 6: Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):213-22.', 746);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1005, 'LUX-Lung 2: Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012 May;13(5):539-48. Epub 2012 Mar 26.', 746);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1006, 'LUX-Lung 7: Park K, Tan EH, O''Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 May;17(5):577-89. Epub 2016 Apr 12.', 746);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1007, 'LUX-Lung 3: Sequist LV, Yang JC, Yamamoto N, O''Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. Epub 2013 Jul 1.', 746);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2684, 'Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol aectate.', 145);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2588, 'Connors JM, et al. N Engl J Med 2018;378:331-344.', 993);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2685, 'J Clin Oncol. 1998;16(2):453-461.', 145);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2686, '<br> Ingle JN, et al. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma.', 145);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2687, 'Cancer. 1997;80(2):218-224.', 145);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2688, 'Buzdar A, Douma J, et al. Phase III, multicenter, double-blind, randomized study of letrozole, and aromatiase inhibitor, for advanced breast cancer versus megestrol acetate.', 146);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2596, 'Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ.Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgikin''s disease: a Preliminary report.', 223);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1060, 'Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18. ', 751);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2597, 'J Clin Oncol. 1995; 13(5):1080-1088', 223);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2598, ' Klimo P, et al. J Clin Oncol 1985;3:1174-1182.', 995);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2689, 'J Clin Oncol. 2001;19(14):3357-3366.', 146);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2599, 'Canellos GP, et al. Ann Oncol 2003;14:268-272.', 996);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2600, 'Longo DL. Semin Oncol 1990;17:716-735.', 997);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2697, 'Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218-5224. doi:10.1158/1078-0432.CCR-17-0754', 1022);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2605, 'Bartlett NL, et al. Ann Oncol 2007;18:1071-1079', 1000);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2698, 'Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523-533. doi: 10.1056/NEJMoa1706450.', 1023);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2606, 'Santoro A, et al. J Clin Oncol 2000;18.2615-2619', 1001);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2828, 'ECOG E1581: Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol. 1986 Jan;4(1):14-22.

EORTC 07861: Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P, Paesmans M. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organisation for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990 Sep;8(9):1556-62.

Comella P, Frasci G, De Cataldis G, Panza N, Cioffi R, Curcio C, Belli M, Bianco A, Ianniello G, Maiorino L, Della Vittoria M, Perchard J, Comella G; Gruppo Oncologico Campano. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Br J Cancer. 1996 Dec;74(11):1805-11.
Cardenal F, López-Cabrerizo MP, Antón A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, García M, Lianes P, Montalar J, Vadell C, González-Larriba JL, Nguyen B, Artal A, Rosell R. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999 Jan;17(1):12-8.
 Font A, Moyano AJ, Puerto JM, Tres A, Garcia-Giron C, Barneto I, Anton A, Sanchez JJ, Salvador A, Rosell R; Spanish Lung Cancer Group. Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group. Cancer. 1999 Feb 15;85(4):855-63.
 ECOG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.
 Belani CP, Lee JS, Socinski MA, Robert F, Waterhouse D, Rowland K, Ansari R, Lilenbaum R, Natale RB. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol. 2005 Jul;16(7):1069-75. Epub 2005 Apr 28.', 479);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2607, 'Schulz H, et al. Blood 2008;111:109-111', 1002);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2832, 'Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O''Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031. Epub 2019 Sep 28.

Opdivo (Nivolumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf

Yervoy (Ipilimumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf', 473);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2608, 'Younes A, et al. J Clin Oncol 2012;30:2183-2189', 1003);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2609, 'Ansell SM, et al. N Engl J Med 2015;372:311-318', 1004);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2833, 'Solomon BJ, et al. Lancet Oncol 2018;19:1654-1667.', 1067);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2834, 'Al-Salama ZT, et al. Drugs 2019. doi: 10.1007/s40265-019-01177-y.', 1068);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1061, 'National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2020 – April 23, 2020. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. ', 751);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1062, 'Uptodate.com', 751);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1063, 'Zhong WZ, Wang Q, Mao WM, et al; ADJUVANT investigators. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Jan;19(1):139-148. Epub 2017 Nov 21.', 750);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1064, 'Uptodate.com', 750);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1065, 'National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2020 – April 23, 2020. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.', 750);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1086, 'Uptodate.com ', 747);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1087, 'UX-Lung 2: Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012 May;13(5):539-48. Epub 2012 Mar 26.', 747);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1088, 'LUX-Lung 3: Sequist LV, Yang JC, Yamamoto N, O''Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. Epub 2013 Jul 1.', 747);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1089, 'LUX-Lung 6: Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):213-22. ', 747);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1090, 'LUX-Lung 7: Park K, Tan EH, O''Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 May;17(5):577-89. Epub 2016 Apr 12.', 747);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1091, 'National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2020 – April 23, 2020. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.', 747);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1092, 'Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O''Connell J, Boyer M. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20;30(27):3337-44. Epub 2012 Jul 2', 749);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1093, 'Ramalingam SS, Jänne PA, Mok T, O''Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, Goldberg Z, O''Connell J, Paz-Ares L. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1369-78. Epub 2014 Oct 15.', 749);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1094, 'Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Onol. 2017 Nov;18(11):1454-1466. Epub 2017 Sep 25..', 749);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1095, 'UPDATE: Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018 Aug 1;36(22):2244-2250. Epub 2018 Jun 4.', 749);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1096, 'Uptodate.com', 749);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1097, 'National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2020 – April 23, 2020. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.', 749);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1098, 'Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. Epub 2011 Jul 23.', 748);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1099, 'Rosell R, Carcereny E, Gervais R,  et al; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. ', 748);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1100, 'Yeo WL, Riely GJ, Yeap BY, et al. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul;5(7):1048-53. ', 748);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1101, 'O''Bryant CL, Haluska P, Rosen L, et al, “An Open-Label Study to Describe Pharmacokinetic Parameters of Erlotinib in Patients With Advanced Solid Tumors With Adequate and Moderately Impaired Hepatic Function,” Cancer Chemother Pharmacol, 2012, 69(3):605-12.', 748);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1102, 'Miller AA, Murry DJ, Owzar K, et al, “Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or Renal Dysfunction: CALGB 60101,” J Clin Oncol, 2007, 25(21):3055-60.', 748);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1103, 'Uptodate.com', 748);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1104, 'National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2020 – April 23, 2020. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.', 748);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1105, 'Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Dec;20(12):1655-1669. Epub 2019 Oct 4.', 752);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1982, 'J Clin Oncol. 2003;21(14):2732-2739.', 284);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1109, 'Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.', 754);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1110, 'Blood, 105(4): 1417-1423.', 754);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1111, '<br> Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine and prednisone alone in patients with previously utreated advanced follicular lymphoma.', 754);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1112, 'J Clin Oncol. 2008;26(28):4578-4589.', 754);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2998, 'Friedman HS, Krischer JP, Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study.', 301);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1983, 'Richardson PG, et al. Blood 2006;108:3458-3464.', 825);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1115, 'Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, Ohe Y, Nogami N, Takeuchi K, Shimada T, Tanaka T, Tamura T. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 2013 Jun;14(7):590-8. Epub 2013 Apr 30.', 755);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1116, 'Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017 Jul 1;390(10089):29-39. Epub 2017 May 10.', 755);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1117, 'Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017 Aug 31;377(9):829-838. Epub 2017 Jun 6.', 755);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1118, 'Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019 May;7(5):437-446. Epub 2019 Apr 10.', 755);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1119, 'Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2027-2039. Epub 2018 Sep 25.', 756);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1120, 'Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Mar 27;370(13):1189-97.', 757);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1121, 'Soria JC, Tan DS, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017 Mar 4;389(10072):917-929. Epub 2017 Jan 24.', 757);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1122, ' Cho BC, Kim DW, Bearz A, Laurie SA, McKeage M, Borra G, Park K, Kim SW, Ghosn M, Ardizzoni A, Maiello E, Greystoke A, Yu R, Osborne K, Gu W, Scott JW, Passos VQ, Lau YY, Wrona A. ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol. 2017 Sep;12(9):1357-1367. Epub 2017 Jul 17.', 757);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1123, 'Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28;363(18):1693-703.', 758);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1124, 'Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011 Oct;12(11):1004-12. Epub 2011 Sep 18.', 758);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1125, 'Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O''Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013 Jun 20;368(25):2385-94. Epub 2013 Jun 1.', 758);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1126, 'Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014 Dec 4;371(23):2167-77. Erratum in: N Engl J Med. 2015 Oct 15;373(16):1582.', 758);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1127, 'Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017 Jul 1;390(10089):29-39. Epub 2017 May 10.', 758);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1128, 'Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017 Aug 31;377(9):829-838. Epub 2017 Jun 6. ', 758);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1129, 'Blackhall F, Ross Camidge D, Shaw AT, Soria JC, Solomon BJ, Mok T, Hirsh V, Jänne PA, Shi Y, Yang PC, Pas T, Hida T, Carpeño JC, Lanzalone S, Polli A, Iyer S, Reisman A, Wilner KD, Kim DW. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO Open. 2017 Aug 17;2(3):e000219. eCollection 2017.', 758);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1130, 'Wu YL, Lu S, Lu Y, Zhou J, Shi YK, Sriuranpong V, Ho JCM, Ong CK, Tsai CM, Chung CH, Wilner KD, Tang Y, Masters ET, Selaru P, Mok TS. Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer. J Thorac Oncol. 2018 Oct;13(10):1539-1548. Epub 2018 Aug 14.', 758);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2999, 'J Clin Oncol. 2000;18(22):3819-3828.', 301);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1984, 'Palumbo A, et al. N Engl J Med 2014;371:895-905.', 825);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1131, 'Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2027-2039. Epub 2018 Sep 25. ', 758);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1132, 'hou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019 May;7(5):437-446. Epub 2019 Apr 10.', 758);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1941, '<br> Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevali radiommunotherapy for low-grade, follicular, or transofrmed B-cell non-Hodgikin''s lymphoma.', 240);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1942, 'Crit Rev Oncol Hematol. 2001;39(1-2):181-194.', 240);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1943, 'Folotyn [package insert].', 241);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1944, 'Westminster, CO: Allos Therapeutics Inc.; 2012.', 241);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1945, 'O’Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies. J Clin Oncol. 2009; 27(26):4357-4364.', 241);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2699, 'Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753-763.', 1024);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2700, 'Greco FA, Burris HA III, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie pearl cancer center research Network study. J Clin Oncol.2002;20(6):1651-1656.', 216);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2361, 'Baselga J, Campone M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.  N Engl J Med. 2012;366(6):520-9.', 437);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1141, 'Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017 Dec;18(12):1590-1599. Epub 2017 Oct 23.', 760);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2363, 'BIG 1-98 Collaborative Group, Mouridsen H, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766-76.', 432);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2365, 'Goss PE, Ingle JN, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262-71.', 433);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2701, 'Culine S, Lortholary A, Voigt JJ, et al. Gemcitabine, carboplatin combintion with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study- trial for the French study Group on Carcinomas of Unknown Primary (GEFCAPI 01).', 217);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2593, 'DeVita VT Jr, et al. Ann Intern Med 1970;73:881-895.', 994);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2366, 'Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgikin lymphoma: results from a multicenter study.', 234);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2367, 'Cancer. 2010,116(1):106-114', 234);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2702, 'JClin Oncol. 2003;21(18):3479-3482.', 217);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2601, 'Colwill R, et al. J Clin Oncol 1995;13:396-402.', 998);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2602, 'Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgikin''s disease.', 222);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2603, 'N Engl J Med. 2003;348(24):2386-2395', 222);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2604, 'Diehl V. et al. J Clin Oncol 1998;16:3810-3821.', 999);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2705, 'Hainsworth JD, et al. Cancer J 2010;16:70-75.', 1027);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2610, 'Armand P, et al. J Clin Oncol 2016;34:3733-3739', 1005);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2611, 'Pavel ME, et al. Lancet 2011;378:2005-2012', 877);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2706, 'Hainsworth JD, et al. J Clin Oncol 2007;25:1747-1752.', 1028);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1808, 'Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278-1291. doi:10.1016/S0140-6736(20)30262-2', 586);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1163, 'Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival datat from a phase 3 randomised trial, and relation between cetuximab-induced rash and surival.', 13);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1164, 'Lancet Oncol.2010;11(1):21-28.', 13);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2612, 'Moskowitz AJ, et al. J Clin Oncol 2013;31:456-460', 1006);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2707, 'Yao JC, et al. N Engl J Med 2011;364:514-523.', 1029);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2708, 'Strosberg J, et al. N Engl J Med 2017,376:125-135.', 1030);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2715, 'Nagao S, Fujiwara K, et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol. 2005;96(3):805-9.', 535);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1809, 'Campath [package insert].', 269);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1810, 'Wayne, NJ: Bayer HealthCare Pharmaceuticals: 2009.', 269);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1811, 'Osterborg A, et al. J Clin Oncol 1997;15:1567-1574', 269);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1812, 'Knauf WU, Lissichov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously treated patients with chronic lymphocytic leukemia.', 270);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1813, 'J Clin Oncol. 2009;27(26):4378-4348.', 270);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1818, 'Catovsky D, Richards S, Oscier D, et al. Assesment of fludarabine plus cyclo-phosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 trial): a randomized ocntrolled trial.', 265);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1819, 'Lancet. 2007; 370(9583):230-239.', 265);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2368, 'Targretin [package insert].', 235);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2369, 'Woodcliff Lake, NJ: Eisai Inc.; 2011.', 235);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2370, 'Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19(9):2456-2471', 235);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2371, 'Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt''s lymphoma: results of United Kingdom Lymphoma Group LY06 Study.', 227);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2372, 'Ann Oncol. 2002, 13(8): 1254-1274.', 227);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2703, 'Longeval E, et al. Cancer 1982:50;2751-2756.', 1025);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3006, 'Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children''s Cancer Group.', 324);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2373, 'Blood. 1988;71(1):117-122.', 229);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2374, 'Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).', 229);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2704, 'Hainsworth JD, et al. J Clin Oncol 1992;10:912-922.', 1026);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2831, 'Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31.

Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005; 16:602.

Minami, H., Kawada, K., Sasaki, Y., Tahara, M., Igarashi, T., Itoh, K., Fujii, H., Saeki, T., Ozawa, K. and Sato, H. (2009), Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Science, 100: 144-149. doi:10.1111/j.1349-7006.2009.00992.x

Floyd J., Kerr T.A. (2020). Chemotherapy hepatotoxicity and dose modification in patients with liver disease. Retrieved April 2020 from https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease.

Casal J, Amenedo M, Mel JR, Antón LM, Rodríguez-López R, López-López R, González-Ageitos A, Castellanos J, Constenla M, Tisaire JL. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study. Cancer Chemother Pharmacol. 2007 Oct;60(5):725-32. Epub 2007 Feb 2.', 482);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2836, '1. Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011 Nov 10;29(32):4320-6. Epub 2011 Oct 11.
2. Fossella F, et al. J Clin Oncol 2003; 21:3016.
3. Docetaxel injection. United States Prescribing Information. US National Library of Medicine.
4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 469);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1822, 'Eichhorst BF, Busch R, Stilgenbauer S, et al. First line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.', 272);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1823, 'Blood. 2009;114:3382-3391.', 272);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1824, 'Keating MJ, et al. Blood 1988;92:1165-1171.', 272);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2838, 'Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O''Brien M, Rao S, Hotta K, Vandormael K, Riccio A, Yang J, Pietanza MC, Brahmer JR. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019 Mar 1;37(7):537-546. Epub 2019 Jan 8.

Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S; Norwegian Lung Cancer Study Group. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 464);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2839, 'COG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.

Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000 Oct 1;18(19):3390-9.

Rosell, R. et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of Oncology, Volume 13, Issue 10, 1539 - 1549', 465);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3007, 'Blood 2003;101(10):3809-3817.', 324);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1846, 'Hehlmann R, et al. Blood 1994;84:4064-4077', 817);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1847, 'The Italian Cooperative Study Group on Chronic Myelogenous Leukemia. N Engl J Med 1994;330:820-825.', 818);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3015, 'Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338(23):1663-1671. doi:10.1056/NEJM199806043382304', 1177);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1848, 'Guilhot F, et al. N Engl J Med 1997;337:223-229.', 819);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1849, 'Hematol Oncol Clin North Am 2006 Oct;20(5):1109-23.  doi: 10.1016/j.hoc.2006.06.008.', 764);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1850, 'Saven A, et al. Blood 1992;79:111-1120', 764);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1851, 'Ravandi F, O''Brien S, Jorgensen J, et al, "Phase 2 Study of Cladribine Followed by Rituximab in Patients With Hairy Cell Leukemia," Blood, 2011, 118(14):3818-23', 765);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1280, 'Nabholz,JM,Falkson C,Campos D, et al. Docetaxel and doxorubicin comparewd with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer:results of a randomized , multicenter, phase III trial.', 118);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1281, 'J Clin Oncol. 2003;21(6):968-975.', 118);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2716, 'Whitney CW, Sause W, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339-48.', 531);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2717, 'Miller DS, Blessing JA, et al. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol. 2014;32(25):2744-9.', 536);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2718, 'Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet commbinations in stage IVB recurrent or persistent cervical carcinoma: A Gynecologic Group Study.', 170);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2719, 'J Clin Oncol. 2009;27(28):4649-4655.', 170);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2722, 'Buziad AC, et al. Clin Colorectal Cancer 2010:9-282-289. ', 608);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2723, 'Cunningham D. et al. N Engl J Med 2004351-537-545.', 608);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2724, 'Sobrero AF, et al. J Clin Oncol 2008:26:2311-2319.', 608);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3008, 'Lauer SJ, Camitta BM, Leventhal BG, et al. Intensive alternating drug pairs for treatment of hgh-risk chidhood acute lymphoblastic leukemia. Apediatric Oncology Group pilot study.', 325);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2725, 'Chung KY and Saltz LB. Cancer J 2007;13:192-197', 593);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1296, 'Poole CJ, Earl HM, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355(18):1851-62.', 441);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2733, 'Kies MS, et al. Cancer 1987;60:2156-2160', 654);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2734, 'Bedenne L, et al. J Clin Oncol 2007,25:1160-1168', 650);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2735, 'Heath El, et al. J Clin Oncol 2000:18:868-876.', 651);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2742, ' Vokes EE, et al. Cancer 1989;63 (Suppl 6):1048-1053', 773);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2743, 'Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer.', 7);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2744, 'N Engl J Med. 2008;359(11):1116-1127.', 7);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2745, 'Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.', 8);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2746, 'J Clin Oncol. 2005;23(15):3562-3567.', 8);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1557, 'Javle MM, et al. Cancer Invest 2009;27:193-200', 649);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1558, 'Ford HER, et al. Lancet Oncol 2013;15:78-86', 663);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1559, 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 658);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1560, 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 660);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1561, 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 659);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2747, 'J Clin Oncol. 2005 Dec 1;23(34):8646-54. doi: 10.1200/JCO.2005.02.4646.', 774);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2750, 'J Clin Oncol 1998 Apr;16(4):1310-7 doi: 10.1200/JCO.1998.16.4.1310.', 772);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1562, 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 661);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1563, 'Al-Batran SE, et al. Lancet 2019;393.1948-1957.', 653);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1564, 'Al-Batran SE, et al. J Clin Oncol 2008;26:1435-1442.', 655);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1565, 'Conroy T, et al. Lancet Oncol 2014;15:305-314.', 648);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1568, 'Van Hagen P, et al. N Engl J Med 2012;366:2074-2084', 646);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1569, 'Ilson DH, et al. J Clin Oncol 1998;16:1826-1834', 656);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2751, 'Al-Sarraf M, et al. J Clin Oncol 1998;16:1310-1317.', 772);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1578, 'Ajani JA, et al. J Clin Oncol 2007;25:3205-3209.', 669);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2761, 'Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324:1685-1690.', 1036);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2835, 'Arriagada R, et al. N Engl J Med 2004;350:351-360', 1069);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2837, 'CA031: Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012 Jun 10;30(17):2055-62. Epub 2012 Apr 30.', 461);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1579, 'O''Connell MJ. J Clin Oncol 1985;3:1032-1039.', 688);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1580, 'Ajani JA. Oncology 2002;16 (suppl 6):89-96.', 688);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1581, 'Ajani JA, et al. Proc Am Soc Clin Oncol 2000;20:165a (abstract 657)', 679);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1582, 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 675);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1583, 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 677);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1584, 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 676);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1585, 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 678);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1586, 'Al-Batran SE, et al. J Clin Oncol 2008;26:1435-1442', 683);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1587, 'Al-Batran SE, et al. Lancet 2019,393:1948-1957.', 666);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1588, 'Enzinger PC, et al. J Clin Oncol 2017;34:2736-2742.', 684);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1589, 'van Cutsem EV, et al. J Clin Oncol 2009;27:18s (LBA4509) ', 682);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1590, 'Thuss-Patience PC, et al. Eur J Cancer 2011;47:23-6-2314', 689);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1591, 'Wilke H, et al. Lancet Oncol 2014;11;1224-1235.', 685);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1592, 'Fuchs CS, et al. JAMA Oncol 2018;4:e180013.', 691);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1593, 'Fuchs CS, et al. Lancet 2014;383:31-39.', 690);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1594, 'Shitara K, et al. Lancet Oncol 2018;19:1437-1448', 692);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1595, 'van Cutsem EV, et al. J Clin Oncol 2009;27:18s (LBA4509) ', 681);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3009, 'Cancer. 1993;71(9):2854-2861.', 325);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1600, 'Demetri GD, et al. N Engl J Med 2002;347:472-480.', 694);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1601, 'Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase: S0033', 694);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1604, 'Demetri GD, et al. Lancet 2013;381.295-302', 698);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1605, ' Italiano A, et al. Ann Surg Oncol 2012;19:1551-1559', 697);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1608, 'Taieb J, et al. Ann Oncol 2002;13:1192-1196.', 719);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1683, 'Verschraegen CF, Levy T, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol. 1997;15(2):625-31.', 539);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1684, 'Thigpen T, Vance R, et al. The role of paclitaxel in the management of patients with carcinoma of the cervix. Semin Oncol. 1997;24(1 Suppl 2):S2-41-S2-46.', 538);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1685, 'Morris M, Eifel PJ, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137-43.', 524);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1686, 'Tewari KS, et al. J Clin Oncol 2013;31:Suppl (abstract 3).', 526);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1687, 'Schellens JHM, et al. J Clin Oncol 2017;35 (Suppl: abstr 5514).', 543);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2720, 'Lorusso D, Ferrandina G, et al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol. 2010;21(1):61-6.', 541);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2721, 'Van Cutsem E, et al. J Clin Oncol 2019,37:1460-1469', 633);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3011, 'Mahoney DH, Shuster JJ, Nitschke R, et al. Intensification with intermediate-dose intravenous methotrexate is effectie therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study.', 327);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3012, 'J Clin Oncol. 2000;18(6):1285-1294.', 327);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2726, 'Le D, et al. N Engl J Med 2015,372.2509-2520', 743);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2727, 'Minsky BD. Oncology 1994;6:53-58.', 1031);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2728, 'Minsky BD. Clin Colorectal Cancer 2004:4 (Suppl 1):S29-36.', 1032);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1304, 'Dieras V. Review of docetaxel/doxorubicin combination in metastatic breast cancer. Oncology (Williston Park). 1997;11(8 Suppl 8):31-3.', 446);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1305, 'Dieras V. Review of docetaxel/doxorubicin combination in metastatic breast cancer. Oncology (Williston Park). 1997;11(8 Suppl 8):31-3.', 447);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2729, 'Ryan DP, et al. J Clin Oncol 2006;24:2557-2562.', 1033);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2730, 'Rodel C, et al. J Clin Oncol 2007;25:110-117.', 1034);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2731, 'Pignata S, Scambia G, et al. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer. 2007;96(11):1639-43.', 550);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2732, 'Fleming GF, Brunetto VL, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22(11):2159-66.', 548);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1308, 'Langley RE, Carmichael J, Jones AL, et al. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol. 2005;23(33):8322-8330. doi:10.1200/JCO.2005.01.1817', 791);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2736, 'Shah M, et al. JAMA Oncol 2019;5:546-550', 665);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2737, 'Joensu H, et al. J Clin Oncol 2011;29:18S (LBA1).', 693);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3013, 'Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia. Cancer. 2006;66(6):1106-1113.', 1175);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3014, 'Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia. Cancer. 2006;66(6):1106-1113.', 1176);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3016, 'Hurwitz CA, Mounce KG, Grier HE. Treatment of patients with acute myelogenous leukemia: review of clinical trials of the past decade.', 334);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3017, 'J Pediatr Hematol Oncol. 1995;17(3):185-197.', 334);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2740, 'Demetri GD, van Oossterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour afer failure of imatinib: a randomised controlled trial.', 79);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2741, 'Lancet. 2006;368(9544):1329-1338.', 79);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2748, 'Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer.', 9);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2749, 'N Engl J Med. 2008;359(11):1116-1127.', 9);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1317, 'A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. J Clin Oncol. 1991;9(2):305-12.', 448);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2752, 'Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.', 11);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2753, 'J Clin Oncol. 2005;23(15):3562-3567.', 11);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2754, 'Forastiere AA, Urba SG. Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Semin Oncol. 1995;22(3 Suppl 6):24-27.', 778);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2755, 'Bauml J, et al. J Clin Oncol 2016;34:abstract 6011', 775);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2756, 'Shin DM, et al. Cancer 1999;91:1316-1323.', 771);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1323, 'O''Shaughnessy J. Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience. Oncology (Williston Park). 2003;17(12 Suppl 14):15-21.', 450);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1333, 'Miller K, Wang M, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-76.', 453);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1336, 'Martin M, Pienkowshi T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer.', 131);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1337, 'N Engl J Med. 2005;352(22):2303-2313.', 131);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2757, 'Shin DS, et al. J Clin Oncol 1998;16:1325-1330.', 770);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2758, 'Degardin M, et al. Ann Oncol 1998;9:1103-1107.', 779);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1342, 'Thomas ES, Gomez HL, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210-7.', 445);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1344, 'Biganzoli L, Martin M, et al. Moving forward with capecitabine: a glimpse of the future. Oncologist. 2002;7 Suppl 6:29-35.', 443);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1345, 'O''Shaughnessy J, Miles D, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812-23.', 442);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2759, 'Gebbia V, et al. Am J Clin Oncol 1995;18:293-296.', 780);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2760, 'Hong WK, et al. N Engl J Med 1983;308:75-79.', 1035);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2841, 'Zatloukal P, Petruzelka L, Zemanová M, Kolek V, Skricková J, Pesek M, Fojtů H, Grygárková I, Sixtová D, Roubec J, Horenková E, Havel L, Průsa P, Nováková L, Skácel T, Kůta M. Gemcitabine plus cisplatin vs gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer. 2003 Sep;41(3):321-31', 467);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1572, 'Cullinan SA, et al. J Clin Oncol 1994;12:412-416.', 686);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1573, 'Cascinu S, et al. J Chemother 1992;4:185-188', 687);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1350, 'Goetz MP, Toi M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-3646.', 499);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1351, 'Sledge GW Jr, Toi M, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875-2884.', 497);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1352, 'Goetz MP, Toi M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-3646.', 500);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3019, 'Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a Pediatric Oncology Group study. J Clin Oncol. 1996;14(4):1252-1261.', 1178);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1366, 'Baselga J, Campone M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.  N Engl J Med. 2012;366(6):520-9.', 493);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1374, 'Finn RS, Crown JP, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35.', 494);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1375, 'Baselga J, Cortes J, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-19.', 424);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1376, 'Hortobagyi GN, Stemmer SN, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738-1748.', 495);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1378, 'Pegram M, Forbes J, Pienkowski T, et al. BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC).', 134);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1379, 'J Clin Oncol. 2007;25:LBA 1008 (abstract).', 134);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1389, 'O''Shaughnessy JA, Vukelja S, et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer. 2004;5(2):142-7.', 489);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1390, 'Blackwell KL, Burstein HJ, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124-30.', 491);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1391, 'Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.', 135);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1392, 'J Clin Oncol. 2006;24(18):2786-2792.', 135);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1574, 'MacDonald JS, et al. N Engl J Med 2001;345:725-730', 667);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1575, 'Kang Y, et al. J Clin Oncol 2006;24:18S (LBA4018) ', 680);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1576, 'Bang Y, et al. J Clin Oncol 2011;29:185 (LBA4002).', 668);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1401, 'Piccart-Gebhart MJ, Proctor M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.', 151);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1402, 'N Engl J Med. 2005;353(16):1659-1672.', 151);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1403, 'Herception [package insert].', 150);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1404, 'South San Francisco, CA: Genentech, Inc: 2010.', 150);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1405, 'Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14(3):737-744. doi:10.1200/JCO.1996.14.3.737', 150);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1577, 'Wilke M, et al. J Clin Oncol 1989;7:1318-1326', 674);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1609, 'Abou-Alfa GK, et al. N Engl J Med 2018;379:54-63.', 730);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1610, 'Primrose JN, et al. Lancet Oncol 2019;20:663-673', 644);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1611, 'Patt YZ, et al. Cancer 2004;101:578-586.', 723);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1612, 'Hong YS, et al. Cancer Chemother Pharmacol 2007;60:321-328.', 720);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2762, 'Rischin D, et al. J Clin Oncol 2019:37 (Suppl 15): abstract 6000', 1037);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2763, 'Rischin D, et al. J Clin Oncol 2019:37 (Suppl 15): abstract 6000', 1038);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1615, 'Park JS, et al. Jpn J Clin Oncol 2005;35:68-73.', 725);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1616, 'Knox JJ, et al. J Clin Oncol 2005;23:2332-2338', 717);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1617, 'Thongprasert S, et al. Ann Oncol 2005;16:279-281', 645);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1618, 'Valle JW, et al. N Engl J Med 2010;362:1273-1281', 645);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2764, ' Bonner JA, et al. N Engl J Med 2006;354:567-578.', 1039);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1689, 'Muderspach LI, Blessing JA, et al. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2001;81(2):213-5.', 540);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1691, 'Deppe G, Malviya VK, et al. Treatment of recurrent and metastatic endometrial carcinoma with cisplatin and doxorubicin. Eur J Gynaecol Oncol. 1994;15(4):263-6.', 546);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1692, 'Burke TW, Gershenson DM, et al. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. Gynecol Oncol. 1994;55(1):47-50.', 549);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1694, 'Wolfson AH, et al. J Clin Oncol 2006;24(18S):5001.', 552);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1695, 'Muss HB. Chemotherapy of metastatic endometrial cancer. Semin Oncol. 1994;21(1):107-13.', 554);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1696, 'Fiorica JV. Update on the treatment of cervical and uterine carcinoma: focus on topotecan. Oncologist. 2002;7 Suppl 5:36-45.', 547);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1697, 'Hensley ML, Blessing JA, et al. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109(3):329-34.', 553);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1698, 'Thigpen JT, Brady MF, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17(6):1736-44.', 555);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1699, 'Ball HG, Blessing JA, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;62(2):278-81.', 556);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1700, 'Hoskins PJ, Swenerton KD, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol. 2001;19(20):4048-53.', 544);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1701, 'Homesley HD, Filiaci V, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(5):526-31.', 551);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1702, 'Oza AM, Elit L, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011;29(24):3278-85.', 558);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1703, 'Wadler S, Levy DE, et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. J Clin Oncol. 2003;21(11):2110-4.', 557);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1705, 'Dimopoulos MA, Papadimitriou C, et al. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol. 2004;95(3):695-700.', 585);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1706, 'Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol. 1994;12(4):701-706', 585);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2766, 'Real FX, et al. J Clin Oncol 1986;4:544-551.', 210);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1707, 'Burger RA, Sill MW, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-71.', 580);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1709, 'Markman M, Kennedy A, et al. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol. 2001;19(7):1901-5.', 564);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1710, 'Pignant S, et al. J Clin Oncol 2009;27:18S (LBA5509).', 565);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1712, 'Burger RA, et al. J Clin Oncol 2010:28:946S (LBA1).', 563);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1985, 'Southwest Oncology Group Study. Arch Intern Med 1975;135:147-152', 286);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2767, 'Groopman JE, et al. Recombinant alpha-2 interferon therapy for Kaposi''s sarcoma associated with the acquired immunodeficiency syndrome.', 210);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2768, ' Nasti G, et al. J Clin Oncol 2000;18:1550-1557', 514);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2769, 'Ireland-Gill A, et al. Semin Oncol 1992;19 (Suppl 5):32-37', 1040);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2770, 'Rosenthal E, Poizot-Martin I, Saint Marc T, et al. Phase Ivstudy of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma.', 211);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2043, 'Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004 Jun 1;22(11):2184-91

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 460);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1726, 'Ledermann J, Harter P, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852-61. --- Moore K, Colombo N, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495-2505.', 582);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1727, 'McGuire WP, Rowinsky EK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111(4):273-9.', 573);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1728, 'Armstrong DK, Bundy B, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43.', 569);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2771, 'AM J Clin Oncol.2002;25(1): 57-59', 211);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2045, 'EORTC 07861: Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P, Paesmans M. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organisation for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990 Sep;8(9):1556-62.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 462);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1831, 'O''Brien S, et al. Blood 1993;82:1695-1700', 812);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1832, 'Dighiero G, et al. N Engl J Med 1998;338:1506-1514.', 271);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1833, 'Raphael B, Anderson JW, Silber R, et al, “Comparison of Chlorambucil and Prednisone Versus Cyclophosphamide, Vincristine, and Prednisone as Initial Treatment for Chronic Lymphocytic Leukemia: Long-Term Follow-up of an Eastern Cooperative Oncology Group Randomized Clinical Trial,” J Clin Oncol, 1991, 9(5):770-6', 813);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1835, 'Isfort S, Brümmendorf TH. Bosutinib in chronic myeloid leukemia: patient selection and perspectives. J Blood Med. 2018;9:43-50. Published 2018 Apr 10. doi:10.2147/JBM.S129821', 761);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3025, 'Weiner MA, Harris MB, Lewis M, et al. Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma.', 310);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3026, 'Cancer Treat Rep. 1986;70(12):1431-1432.', 310);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1838, 'Druker BJ, et al. N Engl J Med 2001;344:1031-1037', 275);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1839, 'Ottman OG, et al. Blood 2002;100:1965-1971.', 815);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1840, 'Kantarjian HM, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.', 276);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1841, 'Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17', 276);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1842, 'Saglio G, et al. N Engl J Med 2010;362:2251-2259.', 276);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1843, 'Gandhi V, Plunkett W, Cortes JE. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014;20(7):1735-1740. doi:10.1158/1078-0432.CCR-13-1283', 763);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1844, 'Kantarjian HM, et al. Blood 2012;120 (abstract 915)', 762);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3027, 'Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.', 311);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1845, 'Hehlmann R, et al. Blood 1993;82:398-407.', 816);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1859, 'Galili N, et al. Expert Opin Investig Drugs 2006;15:805-813', 285);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (1861, 'Goodwin CD, et al. Leukemia 2017;31:1855-1868.', 821);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2076, 'ARCHER 1009: Ramalingam SS, Jänne PA, Mok T, O''Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, Goldberg Z, O''Connell J, Paz-Ares L. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1369-78. Epub 2014 Oct 15.', 783);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3028, 'J Clin Oncol. 2002;20(2):426-433.', 311);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2772, 'Laubenstein LL, et al. J Clin Oncol 1984:2:1115-1120.', 1041);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2773, 'Linker CA, Levitt LJ, O''Donnell M, et al, “Treatment of Adult Acute Lymphoblastic Leukemia With Intensive Cyclical Chemotherapy: A Follow-up Report,” Blood, 1991 78(11):2814-22.', 809);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2774, 'Linker CA, et al. Blood 1987;69:1242-1248.', 809);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3032, 'Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.', 316);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3033, 'J Clin Oncol. 2001;19(12):3091-3102.', 316);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3034, 'Pritchard J, Imeson J , Barnes J, et al. Results of the United Kingdom Children''s Cancer Study Group first Wilms'' tumor study. J Clin Oncol. 1995; 13(1):124-133.', 850);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3035, 'de Camargo B, Franco EL. A randomized clinical trial of single-dose versus fractionated-dose dactinomycin in the treatment of Wilms'' tumor. Cancer. 1994;73(12):3081-3086.', 850);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3036, 'Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol. 2000;18(1):12-17. doi:10.1200/JCO.2000.18.1.12', 847);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3057, 'Erratum: Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114(10):2051-2059. (2016). Blood, 128(4), 605. https://doi.org/10.1182/blood-2016-06-723056', 1187);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3022, 'Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.', 303);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3023, 'J Pediatr Hematol Oncol. 2002;24(8):613-621.', 303);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3030, 'Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987;5(8):1191-1198.', 1181);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3031, 'Saylors RL 3rd, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19(15):3463-3469', 315);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3037, 'Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children''s Cancer Group Study.', 322);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3038, 'Blood. 2002;99(6):1986-1994.', 322);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3039, 'Erratum in: Blood. 2002; 100(6):1531.', 322);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2065, 'Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31.

Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005; 16:602.

Minami, H., Kawada, K., Sasaki, Y., Tahara, M., Igarashi, T., Itoh, K., Fujii, H., Saeki, T., Ozawa, K. and Sato, H. (2009), Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Science, 100: 144-149. doi:10.1111/j.1349-7006.2009.00992.x

Floyd J., Kerr T.A. (2020). Chemotherapy hepatotoxicity and dose modification in patients with liver disease. Retrieved April 2020 from https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease.

Casal J, Amenedo M, Mel JR, Antón LM, Rodríguez-López R, López-López R, González-Ageitos A, Castellanos J, Constenla M, Tisaire JL. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study. Cancer Chemother Pharmacol. 2007 Oct;60(5):725-32. Epub 2007 Feb 2.', 468);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3040, 'Arranon [package insert].', 323);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3041, 'Research Triangle Park, NC: GlaxoSmithKline; 2011.', 323);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2077, 'ARCHER 1050: Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1454-1466. Epub 2017 Sep 25.', 783);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2078, 'ARCHER 1050 UPDATE: Update: Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018 Aug 1;36(22):2244-2250. Epub 2018 Jun 4.', 783);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2079, 'A7471028: Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O''Connell J, Boyer M. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20;30(27):3337-44. Epub 2012 Jul 2.', 783);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2080, 'VIZIMPRO (Dacomitinib) [package insert]: Pfizer Inc. NY, NY.', 783);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2081, 'Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul;5(7):1048-53. ', 782);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2082, 'OPTIMAL: Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. Epub 2011 Jul 23.', 782);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2083, 'EURTAC: Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26', 782);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2084, 'JO25567: Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014 Oct;15(11):1236-44. Epub 2014 Aug 27. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475.', 782);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3042, 'Berg SL, Blaney SM, Devidas M, et al, “Phase II Study of Nelarabine (Compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report from the Children’s Oncology Group,” J Clin Oncol, 2005, 23(15):3376-82.', 323);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3043, 'Kerr JZ, Berg S, Blaney SM. Intrathecal chemotherapy. Crit Rev Oncol Hematol. 2001;37(3):227-236.', 326);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3044, 'Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95(11):3310-3322', 1182);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2068, 'National Center for Biotechnology Information. PubChem Database. Vinorelbine, CID=5311497, https://pubchem.ncbi.nlm.nih.gov/compound/Vinorelbine (accessed on May 1, 2020)

National Center for Biotechnology Information. PubChem Database. Gemcitabine, CID=60750, https://pubchem.ncbi.nlm.nih.gov/compound/Gemcitabine (accessed on May 1, 2020)

Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C; Norwegian Lung Cancer Study Group. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC: a phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012 Jul 24;107(3):442-7. Epub 2012 Jul 3.

Greco FA, Spigel DR, Kuzur ME, Shipley D, Gray JR, Thompson DS, Burris HA, Yardley DA, Pati A, Webb CD, Gandhi JG, Hainsworth JD. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer. 2007 Sep;8(8):483-7.

GLOB 2: Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, Wernli M, Reiterer P, Hui R, Pawel JV, Bertetto O, Pouget JC, Burillon JP, Parlier Y, Abratt R; GLOB 2 group. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Aug;49(2):233-40.

Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK; German and Swiss Lung Cancer Study Group. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004 Jun 15;22(12):2348-56.

Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F; Italian GEMVIN Investigators; NCIC CTG. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Aug 15;21(16):3025-34. Epub 2003 Jul 1.

Janus N, Thariat J, Boulanger H, et al, “Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,” Ann Oncol, 2010, 21(7):1395-403.', 470);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2069, 'Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O''Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031. Epub 2019 Sep 28.

Opdivo (Nivolumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf

Yervoy (Ipilimumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf', 459);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2775, 'Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood. 1995;85(8):2025-2037', 810);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3045, 'Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council''s 10th AML trial.', 336);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3046, 'Br J Haematol. 1998;101(1):130-140.', 336);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2072, 'Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013 Sep 20;31(27):3335-41. doi: 10.1200/JCO.2012.45.0981. Epub 2013 Jul 1. PMID: 23816963.', 781);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2073, 'GILOTRIF (afatinib) [package insert]: Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.  2018. ', 781);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2074, 'Afatinib: Drug Information. UpToDate, Copyright 1978-2020 Lexicomp, Inc: Accessed Nov 29, 2020. ', 781);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2075, 'Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O''Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. doi: 10.1016/S1470-2045(14)71173-8. Epub 2015 Jan 12. PMID: 25589191.', 781);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2776, 'Kantarjian HM, O''Brien S, Smith TL, et al. Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.', 252);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2777, 'J Clin Oncol. 2000;18(3):547-561.', 252);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2778, 'Kantarjian HM, et al. Blood 2007;110 3540-3546.', 759);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2779, 'Kantarjian HM, et al. N Engl J Med 2010;362:2260-2270', 759);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2780, 'Kantarjian HM, et al. N Engl J Med 2006;354.2542-2551', 695);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2781, 'Ottmann OG, Larson RA, Kantarjian HM, et al. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2013;27(6):1411-1413. doi: 10.1038/leu.2012.324.', 695);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2785, 'Nasti G, et al. J Clin Oncol 2000:18:1550-1557', 1042);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2788, 'Raphael B, et al. J Clin Oncol 1991;9:770-776.', 814);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2789, 'Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lympocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).', 267);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2790, 'Blood. 2003;101(1):6-14', 267);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2793, 'Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.', 268);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2794, 'Blood. 2007;109(2):405-411.', 268);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2798, 'Fischer K, et al. N Engl J Med 2019;380:2225-2236.', 1046);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2803, 'Alvado M, et al. Semin Oncol 2002;2914 (Suppl 13):19-22.', 1051);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2804, 'Kath R, et al. J Cancer Res Clin Oncol 2001;127:48-54.', 1051);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2805, 'Ferrajoli A, et al. Blood 2008;111:5291-5297', 1052);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3047, 'Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005;19(12):2130-2138. doi:10.1038/sj.leu.2403924', 1183);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3048, 'Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005;19(12):2130-2138. doi:10.1038/sj.leu.2403924', 1184);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3049, 'Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005;19(12):2130-2138. doi:10.1038/sj.leu.2403924', 1185);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3050, 'Kovnar EH, Kellie SJ, Horowitz ME, et al. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study. J Clin Oncol. 1990;8(2):330-336. doi:10.1200/JCO.1990.8.2.330', 1174);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3051, 'Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005;352(10):978-986. doi:10.1056/NEJMoa042176', 1186);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2782, 'Preisler H, et al. Cancer Treat Rep 1977;61:89-92', 823);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2783, 'Santana VM, et al. J Clin Oncol 1992;10:364-369.', 987);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2784, 'Stein EM, DiNardo CD, et al. Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia [published online ahead of print June 6, 2017]. Blood. 2017. pii: blood-2017-04-779405. doi: 10.1182/blood-2017-04-779405.', 673);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2786, 'Knauf WU, Lissichov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously treated patients with chronic lymphocytic leukemia.', 811);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2787, 'J Clin Oncol. 2009;27(26):4378-4348.', 811);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2791, 'Arzerra [package insert]. <br> Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.', 273);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2792, 'J Clin Oncol. 2010;28:1749-1755.', 273);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2795, 'Seymour JF, et al. N Engl J Med 2018;378:1107-1120', 1043);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2796, ' Furman RR, et al. N Engl J Med 2014;370:997-1007', 1044);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2797, 'Goede V, et al. N Engl J Med 2014;370:1101-1110.', 1045);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2799, 'Saven A, et al. J Clin Oncol 1995;13:570-574', 1047);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2800, 'Sawitsky A, et al. Blood 1977;50:1049', 1048);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2801, 'Hainsworth JD. et al. J Clin Oncol 2003;21:1746-1751.', 1049);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2802, 'Grever MR. et al. J Clin Oncol 1985;3:1196-1201.', 1050);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2809, 'Ratain MJ, et al. Blood 1985;65:644-648.', 279);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2812, 'Eckardt JR, et al. J Clin Oncol 2006;24:2044-2051.', 1057);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2813, 'Neubauer M, et al. J Clin Oncol 2004:22:1872-1877.', 1058);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2814, 'Roth BJ, et al. J Clin Oncol 1992;10:282-291.', 1059);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2816, 'Johnson DH. Semin Oncol 1993,20:315-325 ', 1061);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2817, 'Johnson DH, et al. J Clin Oncol 1990;8:1013-1017.', 1061);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2818, 'Hainsworth JD, et al. Semin Oncol 1999;26 (Suppl 2):60-66.', 1062);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2819, 'Ardizzoni A, et al. J Clin Oncol 1997;15:2090-2096.', 1063);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2823, '1. Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011 Nov 10;29(32):4320-6. Epub 2011 Oct 11.
2. Fossella F, et al. J Clin Oncol 2003; 21:3016.
3. Docetaxel injection. United States Prescribing Information. US National Library of Medicine.
4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 475);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2824, 'Patil V, Noronha V, Joshi A, Chougule A, Kannan S, Bhattacharjee A, Goud S, More S, Chandrasekharan A, Menon N, Srinivas S, Vallathol DH, Dsouza H, Majumdar S, Das S, Zawar A, Khaddar S, Kumar A, Singh G, Kumar KAP, Ravind R, Trivedi V, Behel V, Mahajan A, Janu A, Purandare N, Prabhash K. Phase III non-inferiority study evaluating efficacy and safety of low dose gemcitabine compared to standard dose gemcitabine with platinum in advanced squamous lung cancer. EClinicalMedicine. 2019 Apr 9;9:19-25.

Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S; Norwegian Lung Cancer Study Group. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11.', 476);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2825, 'KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.

Abraxane for Injectable Suspension. (paclitaxel protein-bound
particles for injectable suspension) (albumin-bound). U.S. Food and Drug Administraton. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021660s037lbl.pdf', 474);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2826, 'KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 471);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2843, 'KEYNOTE-189: Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078-2092. Epub 2018 Apr 16

KEYNOTE-021: Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov;17(11):1497-1508. Epub 2016 Oct 10.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 455);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2845, 'Gandara DR, et al. J Clin Oncol 2003;21:2004-2010', 1070);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2848, 'Arriagada R, et al. N Engl J Med 2004:350:351-360', 1073);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2850, 'PARAMOUNT: Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):247-55. Epub 2012 Feb 16.

Park CK, Oh IJ, Kim KS, Choi YD, Jang TW, Kim YS, Lee KH, Shin KC, Jung CY, Yang SH, Ryu JS, Jang SH, Yoo SS, Yong SJ, Lee KY, In KH, Lee MK, Kim YC. Randomized phase III study of docetaxel plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of nonsquamous non-small-cell lung cancer: a TRAIL trial. Clin Lung Cancer. 2017 Jul;18(4):e289-e296. Epub 2017 Jan 11.', 466);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2107, 'KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 472);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3052, 'Fryer CJ, Hutchinson RJ, Krailo M, et al. Efficacy and toxicity of 12 courses of ABVD therapy followed by low-dose regional radiation in advanced Hodgkin''s disease in children: a report from the Children''s Cancer Study Group. J Clin Oncol. 990;8(12):1971-1980.', 851);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3053, 'Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol. 2002;24(8):613-621.', 1179);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3054, 'Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid.', 305);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3055, 'N Engl J Med. 1999;341(16):1165-1173.', 305);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (3056, 'Van Winkle P, Angiolillo A, Krailo M, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children''s Cancer Group (CCG) experience. Pediatr Blood Cancer. 2005;44(4):338-347.', 1180);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2134, 'Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 Jan 7;389(10064):67-76. Epub 2016 Dec 8.', 381);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2114, 'National Center for Biotechnology Information. PubChem Database. Vinorelbine, CID=5311497, https://pubchem.ncbi.nlm.nih.gov/compound/Vinorelbine (accessed on May 1, 2020)

National Center for Biotechnology Information. PubChem Database. Gemcitabine, CID=60750, https://pubchem.ncbi.nlm.nih.gov/compound/Gemcitabine (accessed on May 1, 2020)

Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C; Norwegian Lung Cancer Study Group. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC: a phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012 Jul 24;107(3):442-7. Epub 2012 Jul 3.

Greco FA, Spigel DR, Kuzur ME, Shipley D, Gray JR, Thompson DS, Burris HA, Yardley DA, Pati A, Webb CD, Gandhi JG, Hainsworth JD. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer. 2007 Sep;8(8):483-7.

GLOB 2: Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, Wernli M, Reiterer P, Hui R, Pawel JV, Bertetto O, Pouget JC, Burillon JP, Parlier Y, Abratt R; GLOB 2 group. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Aug;49(2):233-40.

Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK; German and Swiss Lung Cancer Study Group. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004 Jun 15;22(12):2348-56.

Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F; Italian GEMVIN Investigators; NCIC CTG. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Aug 15;21(16):3025-34. Epub 2003 Jul 1.

Janus N, Thariat J, Boulanger H, et al, “Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,” Ann Oncol, 2010, 21(7):1395-403.', 483);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2806, 'Byrd JC, et al. N Engl J Med 2014;369:32-42.', 1053);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2116, 'IMpower133: Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018 Dec 6;379(23):2220-2229. Epub 2018 Sep 25. link to original article contains verified protocol PubMed', 416);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2807, 'Stilgenbauer S, et al. Lancet Oncol 2016;17:768-778.', 1054);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2117, 'CASPIAN: Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Oct 4.', 417);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2808, 'Flinn IW. et al. Blood 2018;131:877-887.', 1055);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2118, 'Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007;97(2):162–169. doi:10.1038/sj.bjc.6603810', 418);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2810, 'Marcello I., Boni L., Ambrosio F. et al. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. Journal of Clinical Oncology 2017 35:12, 1281-1287.

Sundstrom, S., Bremnes RM., Kaasa, S., et al. Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up. Journal of Clinical Oncology 2002 20:24, 4665-4672.

Niell, H.B., Herndon II, J.E, Miller, A.A., et al. Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732. Journal of Clinical Oncology 2005 23:16, 3752-3759.

Ihde D.C., Mulshine J.L., Kramer, B.S., et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.Journal of Clinical Oncology 1994 12:10, 2022-2034.', 419);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2119, 'Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C, Hortig P, Fischer JR, Link H, Binder D, Fischer B, Caca K, Eberhardt WE, Keilholz U; Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol. 2011 Aug;22(8):1798-804. Epub 2011 Jan 25.

Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, Sundstrøm S, Thaning L, Vilsvik J, Aasebø U, Sörenson S. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008 Sep 10;26(26):4261-7.', 428);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2811, 'Eckardt JR, et al. J Clin Oncol 2006;24:2044-2051.', 1056);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2136, 'Linardou H, et al. Urology 2004;64:479-484.', 391);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2137, 'Dogliotti L, Cartenì G, Siena S, Bertetto O, Martoni A, Bono A, Amadori D, Onat H, Marini L. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007 Jul;52(1):134-41. Epub 2006 Dec 26', 392);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2138, 'Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20;32(18):1889-94. Epub 2014 May 12.', 378);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2815, 'Aisner J, et al. Semin Oncol 1986 (Suppl 3):54-62.', 1060);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2820, 'Masters GA, et al. J Clin Oncol 2003;21:1550-1555', 1064);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2141, 'BLC2001: Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O''Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019 Jul 25;381(4):338-348.', 390);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2821, 'Ready N, et al. J Thor Oncol 2018;4:237-244', 1065);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2121, 'CASPIAN: Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Oct 4. [Epub ahead of print]', 427);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2122, 'JCOG 9511: Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; JCOG. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):85-91.
SWOG S0124: Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20;27(15):2530-5. Epub 2009 Apr 6.
JCOG 0509: Satouchi M, Kotani Y, Shibata T, Ando M, Nakagawa K, Yamamoto N, Ichinose Y, Ohe Y, Nishio M, Hida T, Takeda K, Kimura T, Minato K, Yokoyama A, Atagi S, Fukuda H, Tamura T, Saijo N. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol. 2014 Apr 20;32(12):1262-8. Epub 2014 Mar 17.', 429);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2822, 'Chung HC, et al. Proc Am Assoc Cancer Res. 2019; abstract CT073', 1066);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2124, 'Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116–1125. doi:10.1016/S1470-2045(17)30318-2Seckl MJ, Ottensmeier CH, Cullen M, et al. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). J Clin Oncol. 2017;35(14):1506–1514. doi:10.1200/JCO.2016.69.7391T. Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 99, 171.Hendrayana T, Wilmer A, Kurth V, Schmidt-Wolf IG, Jaehde U. Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application. Sci Pharm. 2017;85(1):8. Published 2017 Feb 27. doi:10.3390/scipharm85010008', 397);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2125, 'Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol. 1999 Nov;17(11):3540-5. link to original article contains verified protocol PubMed Skarlos DV, Samantas E, Briassoulis E, Panoussaki E, Pavlidis N, Kalofonos HP, Kardamakis D, Tsiakopoulos E, Kosmidis P, Tsavdaridis D, Tzitzikas J, Tsekeris P, Kouvatseas G, Zamboglou N, Fountzilas G; Hellenic Cooperative Oncology Group. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2001 Sep;12(9):1231-8. link to original article contains verified protocol PubMed', 415);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2126, 'Fornasiero A, et al. Cancer 1991;68:30-33.', 109);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2829, 'SQUIRE: Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015 Jul;16(7):763-74. Epub 2015 Jun 1.', 480);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2830, 'COG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.

Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000 Oct 1;18(19):3390-9.

Rosell, R. et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of Oncology, Volume 13, Issue 10, 1539 – 1549

EORTC 08975: Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G; EORTC Lung Cancer Group. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organisation for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol. 2003 Nov 1;21(21):3909-17.', 481);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2130, 'Lemma GL, et al. J Clin Oncol 2011;29:2060-2065.', 112);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2844, 'KEYNOTE-189: Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078-2092. Epub 2018 Apr 16', 456);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2131, 'Giaccone G, et al. J Clin Oncol 1996;14:814-820.', 108);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2144, 'Kaufman D, et al. J Clin Oncol 2000;18:1921-1927.', 380);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2846, 'Belani CP, et al. J Clin Oncol 2005;23:5883-5891.', 1071);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2851, 'Kreuter M. et al. Ann Oncol 2012;24-986-992', 1074);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2852, 'Reck M, et al. J Clin Oncol 2009;27:1227-1234', 1075);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2853, 'Strauss GM, et al. J Clin Oncol 2004; 621S (abstract 7019).', 835);
insert into public.regimen_reference (id, reference, regimen_detail_id) values (2149, 'Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017 Mar 16;376(11):1015-1026. Epub 2017 Feb 17', 386);



insert into public.level_type (id, level) values (1, 'ADJUVANT');
insert into public.level_type (id, level) values (2, 'NEOADJUVANT');
insert into public.level_type (id, level) values (3, 'METASTATIC');
insert into public.level_type (id, level) values (6, 'LOCALLY ADVANCED');
insert into public.level_type (id, level) values (7, 'HEPATIC ARTERY INFUSION');
insert into public.level_type (id, level) values (8, 'First Line');
insert into public.level_type (id, level) values (11, '5 q Deletion Syndrome');
insert into public.level_type (id, level) values (15, 'Definitive');
insert into public.level_type (id, level) values (16, 'Nasopharyngeal');
insert into public.level_type (id, level) values (17, 'ADVANCED');
insert into public.level_type (id, level) values (18, 'RECURRENT');
insert into public.level_type (id, level) values (19, 'PERSISTENT');
insert into public.level_type (id, level) values (20, 'RECOMBINANT');
insert into public.level_type (id, level) values (22, 'RESISTANT');
insert into public.level_type (id, level) values (23, 'INDUCTION');
insert into public.level_type (id, level) values (26, 'RELAPSED');
insert into public.level_type (id, level) values (27, 'CONSOLIDATION');
insert into public.level_type (id, level) values (29, 'NOVEL');
insert into public.level_type (id, level) values (30, 'NEWLY DIAGNOSED');
insert into public.level_type (id, level) values (31, 'REFRACTORY');
insert into public.drug (id, generic_name) values (78, 'Necitumumab');
insert into public.drug (id, generic_name) values (3, 'Ribociclib');
insert into public.drug (id, generic_name) values (81, 'Megestrol');
insert into public.drug (id, generic_name) values (28, 'Methylprednisolone');
insert into public.drug (id, generic_name) values (41, 'Thioguanine');
insert into public.drug (id, generic_name) values (4, 'Enfortumab vedotin (Padcev) ');
insert into public.drug (id, generic_name) values (5, 'Synribo');
insert into public.drug (id, generic_name) values (84, 'Iclusig');
insert into public.drug (id, generic_name) values (156, 'Dacarbazine');
insert into public.drug (id, generic_name) values (66, 'Sunitinib');
insert into public.drug (id, generic_name) values (85, 'Pembrolizumab');
insert into public.drug (id, generic_name) values (7, 'Docetaxel (Taxotere)');
insert into public.drug (id, generic_name) values (2, 'Lomustine');
insert into public.drug (id, generic_name) values (10, 'Altretamine');
insert into public.drug (id, generic_name) values (11, 'Zykadia');
insert into public.drug (id, generic_name) values (86, 'Methotrexate');
insert into public.drug (id, generic_name) values (133, 'Sipuleucel-T');
insert into public.drug (id, generic_name) values (154, 'Thalidomide');
insert into public.drug (id, generic_name) values (65, 'Vinblastine');
insert into public.drug (id, generic_name) values (82, 'Obinutuzumab');
insert into public.drug (id, generic_name) values (13, 'Lenalidomide');
insert into public.drug (id, generic_name) values (87, 'Nivolumab (Opdivo)');
insert into public.drug (id, generic_name) values (71, 'Prednisone');
insert into public.drug (id, generic_name) values (90, 'Zelboraf');
insert into public.drug (id, generic_name) values (37, 'Trametinib');
insert into public.drug (id, generic_name) values (61, 'Pentostatin');
insert into public.drug (id, generic_name) values (93, 'Ipilumimab');
insert into public.drug (id, generic_name) values (50, 'Nivolumab');
insert into public.drug (id, generic_name) values (95, 'Pembrolizumab (Keytruda)');
insert into public.drug (id, generic_name) values (97, 'Toremifene');
insert into public.drug (id, generic_name) values (99, 'Darzalex');
insert into public.drug (id, generic_name) values (100, 'Atezolizumab (Tecentriq)');
insert into public.drug (id, generic_name) values (101, 'Alpelisib');
insert into public.drug (id, generic_name) values (91, 'Ramicurimab');
insert into public.drug (id, generic_name) values (102, 'Iressa');
insert into public.drug (id, generic_name) values (40, 'Capecitabine');
insert into public.drug (id, generic_name) values (104, 'Durvalumab (Imfinzi)');
insert into public.drug (id, generic_name) values (18, 'Ofatumumab');
insert into public.drug (id, generic_name) values (120, 'Cabazitaxel');
insert into public.drug (id, generic_name) values (63, 'Oxaliplatin');
insert into public.drug (id, generic_name) values (19, 'Paclitaxel');
insert into public.drug (id, generic_name) values (20, 'Opdivo');
insert into public.drug (id, generic_name) values (21, 'Zoledronic acid');
insert into public.drug (id, generic_name) values (74, 'Ixabepilone');
insert into public.drug (id, generic_name) values (23, 'Idelalisib');
insert into public.drug (id, generic_name) values (34, 'Prednisolone');
insert into public.drug (id, generic_name) values (22, 'paclitaxel');
insert into public.drug (id, generic_name) values (108, 'Cotellic');
insert into public.drug (id, generic_name) values (59, 'Dexamethasone');
insert into public.drug (id, generic_name) values (25, 'Tagrisso');
insert into public.drug (id, generic_name) values (26, 'Anastrozole');
insert into public.drug (id, generic_name) values (109, 'Erivedge');
insert into public.drug (id, generic_name) values (27, 'Dabrafenib');
insert into public.drug (id, generic_name) values (16, 'Gemcitabine (Gemzar), Cisplatin (Platinum)');
insert into public.drug (id, generic_name) values (29, 'Pablociclib');
insert into public.drug (id, generic_name) values (119, 'Alemtuzumab');
insert into public.drug (id, generic_name) values (125, 'Estramustine');
insert into public.drug (id, generic_name) values (30, 'Tamoxifen');
insert into public.drug (id, generic_name) values (31, 'Cisplatin');
insert into public.drug (id, generic_name) values (112, 'Nab-paclitaxel');
insert into public.drug (id, generic_name) values (143, 'Flutamide');
insert into public.drug (id, generic_name) values (113, 'Keytruda');
insert into public.drug (id, generic_name) values (35, 'Doxorubicin liposome');
insert into public.drug (id, generic_name) values (98, 'Vorinostat');
insert into public.drug (id, generic_name) values (38, 'Methotrexate');
insert into public.drug (id, generic_name) values (114, 'Ixabepilome');
insert into public.drug (id, generic_name) values (161, 'Bicalutamide');
insert into public.drug (id, generic_name) values (57, 'Procarbazine');
insert into public.drug (id, generic_name) values (132, 'Abaraterone');
insert into public.drug (id, generic_name) values (42, 'Liposomal Irinotecan');
insert into public.drug (id, generic_name) values (117, 'Imbruvica');
insert into public.drug (id, generic_name) values (118, '5-Fluorouracil');
insert into public.drug (id, generic_name) values (157, 'Carboplatin; Paralatin Paclitaxal');
insert into public.drug (id, generic_name) values (126, 'Nilutamide');
insert into public.drug (id, generic_name) values (43, 'Temsirolimus');
insert into public.drug (id, generic_name) values (44, 'Olaparib');
insert into public.drug (id, generic_name) values (121, 'Odomzo');
insert into public.drug (id, generic_name) values (45, 'Doxorubicin');
insert into public.drug (id, generic_name) values (24, 'Pralatrexate');
insert into public.drug (id, generic_name) values (94, 'Degarelix');
insert into public.drug (id, generic_name) values (96, 'Fulvestrant');
insert into public.drug (id, generic_name) values (123, 'Bevacizumab');
insert into public.drug (id, generic_name) values (46, 'Bleomycin');
insert into public.drug (id, generic_name) values (127, 'Pertuzumab');
insert into public.drug (id, generic_name) values (159, 'Azacitidine');
insert into public.drug (id, generic_name) values (128, 'Blincyto');
insert into public.drug (id, generic_name) values (130, 'Lapatinib');
insert into public.drug (id, generic_name) values (115, 'Cetuximab');
insert into public.drug (id, generic_name) values (162, 'Mitoxantrone');
insert into public.drug (id, generic_name) values (131, 'Everolimus');
insert into public.drug (id, generic_name) values (48, 'Various');
insert into public.drug (id, generic_name) values (136, 'Crizotinib');
insert into public.drug (id, generic_name) values (47, 'Dasatinib');
insert into public.drug (id, generic_name) values (49, 'Eribulin');
insert into public.drug (id, generic_name) values (103, 'Imatinib');
insert into public.drug (id, generic_name) values (150, 'Bexarotene');
insert into public.drug (id, generic_name) values (79, 'Bortezomib');
insert into public.drug (id, generic_name) values (1, 'Ifosfamide');
insert into public.drug (id, generic_name) values (51, 'Rucaparib');
insert into public.drug (id, generic_name) values (32, 'Carmustine');
insert into public.drug (id, generic_name) values (56, 'Docetaxel');
insert into public.drug (id, generic_name) values (134, 'Palbociclib');
insert into public.drug (id, generic_name) values (116, 'Rituximab');
insert into public.drug (id, generic_name) values (53, 'Paclitaxel (Taxol)');
insert into public.drug (id, generic_name) values (8, 'Exemestane');
insert into public.drug (id, generic_name) values (137, 'Carboplatin (Paraplatin), Gemcitabine (Gemzar)');
insert into public.drug (id, generic_name) values (54, 'Ixazomib');
insert into public.drug (id, generic_name) values (55, 'Pemetrexed');
insert into public.drug (id, generic_name) values (138, 'Inlyta');
insert into public.drug (id, generic_name) values (139, 'Kadcyla');
insert into public.drug (id, generic_name) values (140, 'Abemaciclib');
insert into public.drug (id, generic_name) values (12, 'Cyclophosphamide');
insert into public.drug (id, generic_name) values (72, 'Erlotinib');
insert into public.drug (id, generic_name) values (110, 'Sorafenib');
insert into public.drug (id, generic_name) values (129, 'Pomalidamide');
insert into public.drug (id, generic_name) values (151, 'Cladribine');
insert into public.drug (id, generic_name) values (39, 'Carfilzomib');
insert into public.drug (id, generic_name) values (135, 'Carboplatin');
insert into public.drug (id, generic_name) values (92, 'Idarubicin');
insert into public.drug (id, generic_name) values (141, 'Ramucirumab');
insert into public.drug (id, generic_name) values (58, 'Ado-trastuzumab emtansine');
insert into public.drug (id, generic_name) values (62, 'Temozolomide');
insert into public.drug (id, generic_name) values (111, 'Goserelin');
insert into public.drug (id, generic_name) values (142, 'Neratinib');
insert into public.drug (id, generic_name) values (6, 'Trastuzumab');
insert into public.drug (id, generic_name) values (17, 'Letrozole');
insert into public.drug (id, generic_name) values (15, 'Nilotinib');
insert into public.drug (id, generic_name) values (9, 'Mesna');
insert into public.drug (id, generic_name) values (68, 'Gemcitabine');
insert into public.drug (id, generic_name) values (145, 'Lonsurf');
insert into public.drug (id, generic_name) values (146, 'Ipilimumab');
insert into public.drug (id, generic_name) values (60, 'nab-paclitaxel');
insert into public.drug (id, generic_name) values (163, 'Hydrocortisone');
insert into public.drug (id, generic_name) values (124, 'Chlorambucil');
insert into public.drug (id, generic_name) values (64, 'Calquence');
insert into public.drug (id, generic_name) values (36, 'Cytarabine');
insert into public.drug (id, generic_name) values (106, 'Bendamustine');
insert into public.drug (id, generic_name) values (122, 'Melphalan');
insert into public.drug (id, generic_name) values (67, 'Temodar');
insert into public.drug (id, generic_name) values (52, 'Epirubicin');
insert into public.drug (id, generic_name) values (88, 'Fluorouracil');
insert into public.drug (id, generic_name) values (152, 'Gilotrif');
insert into public.drug (id, generic_name) values (153, 'Cyramza');
insert into public.drug (id, generic_name) values (69, 'Etoposide');
insert into public.drug (id, generic_name) values (70, 'Niraparib');
insert into public.drug (id, generic_name) values (105, 'Topotecan');
insert into public.drug (id, generic_name) values (158, 'Talazoparib');
insert into public.drug (id, generic_name) values (14, 'Dactinomycin');
insert into public.drug (id, generic_name) values (155, 'Vincristine');
insert into public.drug (id, generic_name) values (160, 'Irinotecan');
insert into public.drug (id, generic_name) values (33, 'Lenalidamide');
insert into public.drug (id, generic_name) values (80, 'Fludarabine');
insert into public.drug (id, generic_name) values (144, 'Gemcitabine (Gemzar), CIsplatin (Platinum)');
insert into public.drug (id, generic_name) values (73, 'Gemcitabine (Gemzar), Paclitaxel (Taxol)');
insert into public.drug (id, generic_name) values (75, 'Elotuzumab');
insert into public.drug (id, generic_name) values (76, 'Erdafitinib (Balversa)');
insert into public.drug (id, generic_name) values (148, 'Vinorelbine');
insert into public.drug (id, generic_name) values (164, 'Yervoy');
insert into public.drug (id, generic_name) values (77, 'Atezolizumab');
insert into public.drug (id, generic_name) values (107, 'Brentuximab');
insert into public.drug (id, generic_name) values (89, 'Alectinib');
insert into public.drug (id, generic_name) values (149, 'Avelumab');
insert into public.drug (id, generic_name) values (83, 'Belenostat');
insert into public.drug (id, generic_name) values (147, 'Bosutinib');
insert into public.drug (id, generic_name) values (165, 'Ponatinib');
insert into public.drug (id, generic_name) values (166, 'Omacetaxine');
insert into public.drug (id, generic_name) values (167, 'Cladribine');
insert into public.drug (id, generic_name) values (168, 'Cladribine');
insert into public.drug (id, generic_name) values (169, 'Azacitidine');
insert into public.drug (id, generic_name) values (170, 'Decitabine');
insert into public.drug (id, generic_name) values (171, 'Mitotane');
insert into public.drug (id, generic_name) values (172, 'Streptozocin');
insert into public.drug (id, generic_name) values (173, 'Clofarabine');


insert into public.brand (id, brand_name, generic_name, manufacturer) values (2, 'Ifex', 'Ifosfamide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (3, 'CCNU', 'Lomustine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (4, 'Kisqali', 'Ribociclib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (5, '', 'Enfortumab vedotin (Padcev) ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (6, '', 'Synribo', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (7, 'Herceptin', ' Trastuzumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (8, '', 'Docetaxel (Taxotere)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (9, 'Aromasin', ' Exemestane', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (10, 'Mesnex, various', 'Mesna ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (11, 'Hexalen', 'Altretamine', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (12, '', 'Zykadia', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (13, 'Cytoxan', 'Cyclophosphamide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (14, 'Revlimid', ' Lenalidomide', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (15, 'Actinomycin', 'Dactinomycin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (16, 'Tasigna', 'Nilotinib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (17, '', 'Gemcitabine (Gemzar), Cisplatin (Platinum) ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (18, 'Femara', ' Letrozole', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (19, 'Arzerra', 'Ofatumumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (20, 'Femara', 'Letrozole ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (21, 'Taxol', 'Paclitaxel ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (22, '', 'Opdivo', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (23, 'Taxol', 'Paclitaxel', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (24, 'Zometa, various', 'Zoledronic acid', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (25, 'Taxol', 'paclitaxel ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (26, 'Zydelig', 'Idelalisib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (27, 'Folotyn', 'Pralatrexate ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (28, '', 'Tagrisso', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (29, 'Arimidex', 'Anastrozole', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (30, 'Tafilnar', 'Dabrafenib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (31, 'Depo-Medrol, Solu-Medrol, various', 'Methylprednisolone ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (32, 'Ibrance', 'Pablociclib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (33, 'Nolvadex', 'Tamoxifen', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (34, 'CDDP', 'Cisplatin', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (35, 'BCNU', 'Carmustine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (36, 'Revlimid', ' Lenalidamide', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (37, 'Arimidex', 'Anastrozole ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (38, 'Flo-pred, various', 'Prednisolone ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (39, 'Doxil, various', 'Doxorubicin liposome', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (40, 'Ara-C', 'Cytarabine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (41, 'Mekinist', ' Trametinib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (42, '', 'Methotrexate (Otrexup; Rasuvo; Rheumatrex [DSC]; Trexall; Xatmep). Vinblastine (Vinblastine), Doxorubicin (Adriamycin), (Cisplatin (Platinum)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (43, '', ' Cisplatin', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (44, 'Kyprolis', 'Carfilzomib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (45, 'Xeloda', 'Capecitabine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (46, '6-TG', 'Thioguanine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (47, 'Onivyde', 'Liposomal Irinotecan', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (48, 'Torisel', 'Temsirolimus', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (49, 'Lynparza', 'Olaparib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (50, 'Adriamycin', 'Doxorubicin', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (51, 'Blenoxane', 'Bleomycin', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (52, 'Revlimid', 'Lenalidomide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (53, 'Sprycel', 'Dasatinib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (54, '', 'Various', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (55, 'Halaven', 'Eribulin', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (56, 'Opdivo', ' Nivolumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (57, 'Ifex', 'Ifosfamide', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (58, 'Rubraca', 'Rucaparib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (59, 'Ellence, various', 'Epirubicin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (60, '', 'Paclitaxel (Taxol)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (61, 'Ninlaro', 'Ixazomib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (62, 'Alimta', 'Pemetrexed', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (63, 'Cytoxan', 'Cyclophosphamide', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (64, 'Taxotere', ' Docetaxel', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (65, 'Matulane', 'Procarbazine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (66, 'Kadcyla', 'Ado-trastuzumab emtansine', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (67, 'CDDP', 'Cisplatin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (68, 'Taxotere', 'Docetaxel ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (69, 'Mesnex', 'Mesna', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (70, 'Decadron, various', ' Dexamethasone', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (71, 'Abraxane', 'nab-paclitaxel', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (72, 'Nipent', 'Pentostatin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (73, 'Temodar', 'Temozolomide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (74, 'Eloxatin, Oxaliplatin, various', 'Oxaliplatin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (75, '', 'Calquence', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (76, 'Velban', 'Vinblastine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (77, 'Sutent', 'Sunitinib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (78, '', 'Temodar', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (79, 'Ellence, various', 'Epirubicin', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (80, 'Hexalen', 'Altretamine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (81, 'Gemzar, various', 'Gemcitabine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (82, 'VP-16', 'Etoposide', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (83, 'Zejula', 'Niraparib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (84, 'Arzerra', 'Ofatumumab ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (85, 'various', 'Prednisone ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (86, 'Tarceva', 'Erlotinib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (87, '', 'Gemcitabine (Gemzar), Paclitaxel (Taxol)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (88, 'Ixempra', 'Ixabepilone ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (89, 'Empliciti', 'Elotuzumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (90, '', 'Erdafitinib (Balversa)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (91, 'Tecentriq', 'Atezolizumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (92, 'Portrazza', 'Necitumumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (93, 'Velcade', 'Bortezomib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (94, 'Fludara', 'Fludarabine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (95, 'Megace', 'Megestrol', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (96, 'Gazyva', 'Obinutuzumab ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (97, 'Alimta', 'Pemetrexed ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (98, '', 'Beleodaq', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (99, '', 'Iclusig', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (100, 'Keytruda
nab-Paclitaxal', 'Pembrolizumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (101, 'MTX', 'Methotrexate', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (102, '', 'Nivolumab (Opdivo)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (103, 'Adriamycin, various', 'Doxorubicin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (104, '5-FU', 'Fluorouracil ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (105, 'Aromasin, various', 'Exemestane ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (106, '', 'Alecensa', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (107, '', 'Zelboraf', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (108, 'Cyramza', ' Ramicurimab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (109, 'Idamycin', 'Idarubicin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (110, 'Yeroy', 'Ipilumimab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (111, 'Firmagon', 'Degarelix ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (112, '', 'Pembrolizumab (Keytruda)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (113, 'Faslodex', 'Fulvestrant ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (114, 'Fareston', 'Toremifene', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (115, 'Zolinza', 'Vorinostat ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (116, '', 'Darzalex', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (117, '', 'Atezolizumab (Tecentriq)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (118, 'Piqray', 'Alpelisib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (119, '', 'Iressa', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (120, 'Xeloda', 'Capecitabine', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (121, 'Gleevec', 'Imatinib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (122, '', 'Durvalumab (Imfinzi)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (123, 'Hycamtin', 'Topotecan ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (124, 'Treanda', 'Bendamustine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (125, 'Ixempra', 'Ixabepilone', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (126, '', 'Adcetris', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (127, '', 'Cotellic', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (128, '', 'Erivedge', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (129, 'Nexavar', 'Sorafenib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (130, 'Zoladex', 'Goserelin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (131, 'Abraxane', 'Nab-paclitaxel', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (132, '', 'Keytruda', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (133, 'Ixempra', 'Ixabepilome', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (134, 'Erbitux', 'Cetuximab ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (135, 'Rituxan', 'Rituximab ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (136, '', 'Imbruvica', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (137, '5-FU', '5-Fluorouracil', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (138, 'Campath', 'Alemtuzumab ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (139, 'Jevtana', 'Cabazitaxel ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (140, '', 'Odomzo', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (141, 'Alkeran', 'Melphalan ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (142, 'Faslodex', 'Fulvestrant', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (143, 'Avastin', 'Bevacizumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (144, 'Various', ' Chlorambucil', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (145, 'Estracyte', 'Estramustine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (146, 'Nilandron', 'Nilutamide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (147, 'VP-16', 'Etoposide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (148, 'Perjeta', 'Pertuzumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (149, '', 'Blincyto', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (150, 'Herceptin', 'Trastuzumab ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (151, 'Gemzar', ' Gemcitabine', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (152, 'Pomalyst', 'Pomalidamide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (153, 'Tykerb', 'Lapatinib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (154, 'Afinitor', 'Everolimus', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (155, 'Zytiga', 'Abaraterone ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (156, 'Avastin', 'Bevacizumab ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (157, 'Provenge', 'Sipuleucel-T ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (158, 'Taxotere', 'Docetaxel', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (159, 'Ibrance', 'Palbociclib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (160, 'Paraplatin', 'Carboplatin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (161, 'Aromasin', 'Exemestane', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (162, 'Xalkori', 'Crizotinib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (163, '', 'Carboplatin (Paraplatin), Gemcitabine (Gemzar)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (164, '', 'Inlyta', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (165, '', 'Kadcyla', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (166, 'Verzenio', 'Abemaciclib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (167, 'Leukeran', 'Chlorambucil ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (168, 'Paraplatin', 'Carboplatin', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (169, 'Halaven', 'Eribulin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (170, 'Cyramza', 'Ramucirumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (171, 'Nerlynx', 'Neratinib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (172, 'Zoladex', 'Goserelin', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (173, 'Rituxan', ' Rituximab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (174, 'Herceptin', 'Trastuzumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (175, 'Femara', 'Letrozole', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (176, 'various', 'Flutamide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (177, '', 'Gemcitabine (Gemzar), CIsplatin (Platinum) ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (178, 'Gemzar', 'Gemcitabine', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (179, '', 'Lonsurf', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (180, 'Yervoy
Nivolumab', 'Ipilimumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (181, 'Blenoxane', 'Bleomycin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (182, 'Taxol', ' Paclitaxel', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (183, '', 'Bosulif', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (184, 'Navelbine', 'Vinorelbine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (185, '', 'Avelumab (Bavencio) ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (186, 'Targretin', 'Bexarotene ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (187, '2-CdA', 'Cladribine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (188, 'Tykerb', 'Lapatinib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (189, '', 'Gilotrif', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (190, '', 'Cyramza', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (191, '5-FU', 'Fluorouracil', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (192, 'Thalomid', 'Thalidomide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (193, 'Oncovin, VCR', 'Vincristine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (194, 'DTIC', 'Dacarbazine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (195, 'Nolvadex', 'Tamoxifen ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (196, 'Hycamtin', 'Topotecan', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (197, 'Taxol', 'Carboplatin; Paralatin
Paclitaxal', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (198, 'Talzenna', 'Talazoparib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (199, 'various', 'Dexamethasone ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (200, 'Vidaza', 'Azacitidine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (201, 'Camptosar', 'Irinotecan', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (202, 'Casodex', 'Bicalutamide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (203, 'Novantrone', 'Mitoxantrone ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (204, 'various', 'Hydrocortisone ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (205, '', 'Yervoy', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (206, 'Navelbine', 'Vinorelbine', '');


insert into public.drug_brand (id, brand_name, manufacturer) values (115, 'Vidaza', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (10, 'Actinomycin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (37, 'Sprycel', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (93, 'Estracyte', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (25, 'Flo-pred, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (87, 'Rituxan', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (5, 'Aromasin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (72, 'Aromasin, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (32, 'Onivyde', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (110, '2-CdA', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (59, 'Tarceva', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (12, 'Femara', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (98, 'Tykerb', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (36, 'Blenoxane', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (30, 'Xeloda', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (75, 'Yeroy', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (8, 'Cytoxan', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (60, 'Ixempra', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (114, 'Talzenna', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (26, 'Doxil, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (47, 'Mesnex', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (99, 'Afinitor', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (45, 'Matulane', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (117, 'Casodex', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (27, 'Ara-C', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (54, 'Sutent', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (80, 'Piqray', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (62, 'Tecentriq', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (74, 'Idamycin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (102, 'Paraplatin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (85, 'Zoladex', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (2, 'CCNU', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (20, 'Depo-Medrol, Solu-Medrol, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (79, 'Zolinza', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (11, 'Tasigna', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (89, 'Jevtana', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (61, 'Empliciti', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (66, 'Megace', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (103, 'Xalkori', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (43, 'Alimta', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (78, 'Fareston', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (112, 'Oncovin, VCR', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (28, 'Mekinist', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (76, 'Firmagon', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (39, 'Opdivo', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (17, 'Folotyn', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (105, 'Leukeran', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (63, 'Portrazza', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (19, 'Tafilnar', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (14, 'Taxol', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (33, 'Torisel', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (7, 'Hexalen', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (84, 'Nexavar', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (16, 'Zydelig', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (31, '6-TG', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (42, 'Ninlaro', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (96, 'Gemzar', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (82, 'Hycamtin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (9, 'Revlimid', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (21, 'Ibrance', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (68, 'Keytruda nab-Paclitaxal', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (34, 'Lynparza', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (71, '5-FU', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (116, 'Camptosar', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (13, 'Arzerra', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (113, 'DTIC', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (64, 'Velcade', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (77, 'Faslodex', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (104, 'Verzenio', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (4, 'Herceptin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (69, 'MTX', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (1, 'Ifex', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (52, 'Eloxatin, Oxaliplatin, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (97, 'Pomalyst', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (67, 'Gazyva', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (100, 'Zytiga', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (57, 'Zejula', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (92, 'Various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (44, 'Taxotere', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (83, 'Treanda', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (95, 'Perjeta', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (22, 'Nolvadex', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (118, 'Novantrone', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (40, 'Rubraca', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (101, 'Provenge', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (111, 'Thalomid', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (88, 'Campath', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (91, 'Avastin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (46, 'Kadcyla', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (23, 'CDDP', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (29, 'Kyprolis', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (107, 'Yervoy Nivolumab', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (50, 'Nipent', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (109, 'Targretin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (35, 'Adriamycin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (90, 'Alkeran', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (41, 'Ellence, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (70, 'Adriamycin, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (94, 'Nilandron', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (18, 'Arimidex', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (24, 'BCNU', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (51, 'Temodar', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (48, 'Decadron, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (73, 'Cyramza', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (65, 'Fludara', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (106, 'Nerlynx', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (3, 'Kisqali', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (81, 'Gleevec', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (6, 'Mesnex, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (108, 'Navelbine', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (86, 'Erbitux', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (53, 'Velban', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (55, 'Gemzar, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (15, 'Zometa, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (49, 'Abraxane', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (58, 'various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (38, 'Halaven', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (56, 'VP-16', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (119, 'Adcetris', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (120, 'Alecensa', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (121, 'Bavencio', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (122, 'Beleodaq', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (123, 'Bosulif', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (124, 'Bendeka', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (125, 'Mvasi', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (126, 'Iclusig', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (127, 'Synribo', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (128, 'Leustatin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (129, 'Vidaza', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (130, 'Dacogen', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (131, '', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (132, '', '');


insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (102, 102, 135);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (90, 90, 122);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (17, 17, 24);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (43, 43, 55);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (22, 22, 30);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (13, 13, 18);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (59, 59, 72);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (70, 70, 45);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (78, 78, 97);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (39, 39, 50);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (54, 54, 66);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (88, 88, 119);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (38, 38, 49);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (31, 31, 41);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (85, 85, 111);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (99, 99, 131);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (21, 21, 29);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (69, 69, 86);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (50, 50, 61);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (95, 95, 127);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (62, 62, 77);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (26, 26, 35);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (71, 71, 88);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (82, 82, 105);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (76, 76, 94);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (46, 46, 58);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (19, 19, 27);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (2, 2, 2);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (9, 9, 13);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (36, 36, 46);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (110, 110, 151);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (56, 56, 69);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (87, 87, 116);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (4, 4, 6);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (92, 92, 124);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (57, 57, 70);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (24, 24, 32);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (63, 63, 78);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (114, 114, 158);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (96, 96, 68);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (18, 18, 26);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (61, 61, 75);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (33, 33, 43);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (11, 11, 15);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (116, 116, 160);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (15, 15, 21);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (28, 28, 37);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (74, 74, 92);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (97, 97, 129);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (44, 44, 56);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (1, 1, 1);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (113, 113, 156);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (8, 8, 12);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (30, 30, 40);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (84, 84, 110);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (66, 66, 81);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (10, 10, 14);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (6, 6, 9);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (94, 94, 126);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (111, 111, 154);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (25, 25, 34);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (48, 48, 59);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (75, 75, 93);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (40, 40, 51);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (118, 118, 162);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (35, 35, 45);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (106, 106, 142);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (51, 51, 62);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (86, 86, 115);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (67, 67, 82);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (29, 29, 39);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (16, 16, 23);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (42, 42, 54);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (58, 58, 71);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (105, 105, 124);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (23, 23, 31);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (12, 12, 17);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (104, 104, 140);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (79, 79, 98);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (108, 108, 148);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (49, 49, 60);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (32, 32, 42);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (53, 53, 65);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (103, 103, 136);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (20, 20, 28);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (98, 98, 130);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (5, 5, 8);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (27, 27, 36);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (73, 73, 91);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (47, 47, 9);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (45, 45, 57);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (72, 72, 8);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (65, 65, 80);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (55, 55, 68);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (37, 37, 47);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (109, 109, 150);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (93, 93, 125);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (107, 107, 146);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (81, 81, 103);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (64, 64, 79);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (117, 117, 161);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (14, 14, 19);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (89, 89, 120);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (101, 101, 133);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (41, 41, 52);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (77, 77, 96);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (60, 60, 74);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (112, 112, 155);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (34, 34, 44);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (3, 3, 3);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (7, 7, 10);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (52, 52, 63);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (68, 68, 85);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (120, 119, 107);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (121, 100, 132);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (122, 120, 89);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (123, 80, 101);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (124, 121, 149);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (125, 122, 83);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (126, 123, 147);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (127, 83, 106);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (128, 124, 106);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (129, 91, 123);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (130, 125, 123);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (131, 126, 165);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (132, 127, 166);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (133, 128, 168);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (134, 129, 169);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (135, 115, 159);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (136, 130, 170);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (137, 131, 170);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (138, 132, 171);


insert into public.brand_regimen_link (id, brand_id, regimen_id) values (0, 114, 502);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1, 98, 347);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (2, 161, 503);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (3, 156, 1);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (4, 3, 2);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (5, 65, 2);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (6, 193, 2);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (7, 73, 3);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (8, 35, 4);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (9, 156, 5);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (10, 73, 6);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (11, 168, 7);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (12, 134, 7);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (13, 191, 7);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (14, 67, 8);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (15, 134, 9);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (16, 67, 9);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (17, 191, 9);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (18, 37, 138);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (19, 67, 10);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (20, 67, 11);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (21, 182, 11);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (22, 67, 12);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (23, 158, 12);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (24, 134, 13);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (25, 67, 14);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (26, 191, 14);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (27, 67, 15);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (28, 67, 16);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (29, 182, 16);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (30, 120, 17);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (31, 74, 17);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (32, 67, 18);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (33, 79, 18);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (34, 79, 19);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (35, 74, 19);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (36, 120, 20);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (37, 67, 20);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (38, 79, 20);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (39, 120, 21);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (40, 79, 21);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (41, 74, 21);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (42, 182, 22);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (43, 178, 31);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (44, 74, 31);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (45, 126, 348);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (46, 67, 23);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (47, 158, 23);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (48, 191, 23);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (49, 67, 24);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (50, 158, 24);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (51, 67, 25);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (52, 79, 25);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (53, 147, 26);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (54, 191, 26);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (55, 191, 27);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (56, 120, 28);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (57, 67, 28);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (58, 191, 28);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (59, 174, 28);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (60, 74, 32);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (61, 156, 33);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (62, 86, 33);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (63, 129, 34);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (64, 103, 35);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (65, 67, 36);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (66, 120, 37);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (67, 156, 38);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (68, 67, 39);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (69, 178, 39);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (70, 120, 40);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (71, 178, 40);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (72, 178, 41);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (73, 74, 41);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (74, 67, 42);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (75, 120, 43);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (76, 67, 43);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (77, 26, 349);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (78, 173, 349);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (79, 120, 44);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (80, 74, 44);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (81, 120, 45);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (82, 158, 46);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (83, 178, 47);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (84, 120, 139);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (85, 191, 48);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (86, 74, 48);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (87, 120, 49);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (88, 178, 49);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (89, 86, 50);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (90, 178, 50);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (91, 178, 51);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (92, 74, 51);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (93, 178, 52);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (94, 134, 53);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (95, 191, 55);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (96, 156, 56);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (97, 191, 56);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (98, 191, 57);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (99, 74, 57);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (100, 191, 58);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (101, 74, 67);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (102, 136, 350);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (103, 156, 59);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (104, 191, 59);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (105, 134, 60);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (106, 191, 60);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (107, 191, 61);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (108, 74, 61);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (109, 156, 62);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (110, 191, 62);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (111, 74, 62);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (112, 191, 63);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (113, 74, 63);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (114, 156, 68);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (115, 74, 68);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (116, 120, 69);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (117, 134, 70);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (118, 191, 71);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (119, 174, 151);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (120, 121, 77);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (121, 16, 78);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (122, 77, 79);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (123, 168, 80);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (124, 182, 80);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (125, 66, 426);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (126, 67, 81);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (127, 97, 81);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (128, 134, 82);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (129, 67, 82);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (130, 206, 82);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (131, 67, 83);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (132, 158, 83);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (133, 206, 152);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (134, 67, 84);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (135, 178, 84);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (136, 158, 85);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (137, 178, 85);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (138, 178, 86);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (139, 182, 86);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (140, 86, 93);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (141, 178, 87);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (142, 206, 87);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (143, 67, 88);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (144, 182, 88);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (145, 156, 89);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (146, 168, 89);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (147, 182, 89);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (148, 158, 189);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (149, 85, 189);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (150, 67, 90);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (151, 206, 90);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (152, 162, 91);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (153, 158, 92);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (154, 84, 351);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (155, 167, 351);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (156, 178, 94);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (157, 97, 95);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (158, 206, 96);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (159, 168, 97);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (160, 67, 98);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (161, 176, 190);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (162, 63, 99);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (163, 103, 99);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (164, 193, 99);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (165, 168, 100);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (166, 182, 100);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (167, 168, 101);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (168, 147, 101);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (169, 149, 352);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (170, 67, 102);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (171, 147, 102);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (172, 147, 103);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (173, 182, 104);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (174, 196, 105);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (175, 196, 106);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (176, 67, 107);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (177, 63, 107);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (178, 103, 107);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (179, 67, 108);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (180, 147, 108);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (181, 161, 142);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (182, 67, 109);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (183, 63, 109);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (184, 103, 109);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (185, 193, 109);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (186, 67, 110);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (187, 147, 110);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (188, 57, 110);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (189, 69, 110);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (190, 178, 111);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (191, 196, 111);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (192, 168, 112);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (193, 182, 112);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (194, 63, 113);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (195, 103, 113);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (196, 142, 143);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (197, 63, 115);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (198, 103, 115);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (199, 182, 115);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (200, 174, 115);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (201, 63, 116);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (202, 103, 116);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (203, 182, 116);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (204, 63, 122);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (205, 103, 122);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (206, 191, 122);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (207, 63, 117);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (208, 158, 117);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (209, 103, 117);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (210, 174, 117);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (211, 178, 144);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (212, 61, 353);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (213, 36, 353);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (214, 199, 353);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (215, 158, 118);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (216, 103, 118);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (217, 103, 119);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (218, 182, 119);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (219, 63, 120);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (220, 103, 120);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (221, 182, 120);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (222, 156, 121);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (223, 182, 121);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (224, 63, 130);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (225, 103, 130);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (226, 182, 130);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (227, 63, 123);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (228, 79, 123);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (229, 191, 123);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (230, 116, 354);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (231, 63, 124);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (232, 191, 124);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (233, 178, 125);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (234, 182, 125);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (235, 63, 126);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (236, 79, 126);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (237, 120, 127);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (238, 125, 127);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (239, 120, 128);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (240, 188, 128);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (241, 188, 129);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (242, 175, 129);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (243, 63, 131);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (244, 158, 131);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (245, 103, 131);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (246, 63, 132);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (247, 158, 132);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (248, 120, 133);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (249, 158, 133);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (250, 168, 134);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (251, 158, 134);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (252, 174, 134);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (253, 182, 135);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (254, 174, 135);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (255, 168, 136);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (256, 182, 136);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (257, 174, 136);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (258, 158, 140);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (259, 169, 141);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (260, 175, 145);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (261, 182, 147);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (262, 195, 148);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (263, 174, 150);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (264, 168, 153);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (265, 158, 153);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (266, 168, 154);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (267, 182, 154);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (268, 168, 155);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (269, 67, 156);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (270, 182, 156);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (271, 22, 355);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (272, 168, 157);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (273, 178, 157);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (274, 67, 158);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (275, 182, 158);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (276, 80, 159);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (277, 156, 160);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (278, 178, 161);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (279, 176, 191);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (280, 172, 191);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (281, 182, 162);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (282, 196, 164);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (283, 164, 356);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (284, 107, 357);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (285, 67, 165);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (286, 103, 165);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (287, 67, 166);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (288, 103, 166);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (289, 182, 166);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (290, 103, 167);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (291, 158, 188);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (292, 145, 188);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (293, 67, 169);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (294, 191, 169);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (295, 67, 170);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (296, 182, 170);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (297, 205, 358);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (298, 67, 171);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (299, 196, 171);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (300, 67, 172);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (301, 129, 177);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (302, 77, 178);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (303, 168, 180);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (304, 178, 180);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (305, 67, 181);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (306, 178, 181);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (307, 67, 182);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (308, 103, 182);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (309, 76, 182);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (310, 202, 193);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (311, 172, 193);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (312, 111, 194);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (313, 181, 183);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (314, 67, 183);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (315, 147, 183);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (316, 67, 184);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (317, 147, 184);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (318, 67, 185);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (319, 57, 185);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (320, 69, 185);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (321, 182, 185);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (322, 67, 186);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (323, 147, 186);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (324, 69, 186);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (325, 76, 186);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (326, 139, 187);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (327, 85, 187);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (328, 203, 192);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (329, 85, 192);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (330, 40, 262);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (331, 155, 195);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (332, 172, 198);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (333, 146, 200);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (334, 85, 201);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (335, 157, 202);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (336, 194, 204);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (337, 103, 204);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (338, 103, 205);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (339, 57, 205);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (340, 69, 205);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (341, 63, 206);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (342, 15, 206);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (343, 103, 206);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (344, 147, 206);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (345, 57, 206);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (346, 69, 206);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (347, 193, 206);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (348, 110, 359);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (349, 56, 359);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (350, 194, 207);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (351, 103, 207);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (352, 57, 207);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (353, 69, 207);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (354, 67, 208);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (355, 103, 208);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (356, 57, 208);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (357, 103, 209);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (358, 182, 212);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (359, 173, 242);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (360, 168, 214);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (361, 182, 214);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (362, 30, 360);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (363, 41, 360);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (364, 168, 215);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (365, 158, 215);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (366, 168, 216);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (367, 178, 216);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (368, 182, 216);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (369, 67, 217);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (370, 178, 217);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (371, 158, 218);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (372, 178, 218);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (373, 120, 219);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (374, 74, 219);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (375, 168, 220);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (376, 147, 220);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (377, 182, 220);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (378, 40, 263);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (379, 127, 361);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (380, 181, 221);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (381, 194, 221);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (382, 103, 221);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (383, 76, 221);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (384, 181, 222);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (385, 63, 222);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (386, 103, 222);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (387, 147, 222);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (388, 85, 222);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (389, 65, 222);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (390, 193, 222);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (391, 181, 223);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (392, 103, 223);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (393, 147, 223);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (394, 85, 223);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (395, 76, 223);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (396, 193, 223);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (397, 124, 224);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (398, 173, 224);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (399, 63, 225);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (400, 103, 225);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (401, 38, 225);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (402, 193, 225);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (403, 63, 226);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (404, 103, 226);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (405, 85, 226);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (406, 173, 226);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (407, 193, 226);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (408, 63, 227);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (409, 40, 227);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (410, 147, 227);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (411, 57, 227);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (412, 69, 227);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (413, 193, 227);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (414, 85, 228);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (415, 173, 228);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (416, 193, 228);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (417, 67, 229);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (418, 40, 229);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (419, 199, 229);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (420, 67, 230);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (421, 40, 230);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (422, 147, 230);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (423, 31, 230);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (424, 27, 241);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (425, 115, 246);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (426, 63, 231);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (427, 40, 231);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (428, 199, 231);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (429, 193, 231);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (430, 63, 232);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (431, 103, 232);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (432, 147, 232);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (433, 85, 232);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (434, 173, 232);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (435, 193, 232);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (436, 168, 233);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (437, 147, 233);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (438, 57, 233);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (439, 69, 233);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (440, 173, 233);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (441, 124, 234);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (442, 186, 235);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (443, 93, 236);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (444, 94, 239);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (445, 63, 247);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (446, 103, 247);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (447, 147, 247);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (448, 63, 248);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (449, 103, 248);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (450, 193, 248);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (451, 63, 249);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (452, 40, 249);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (453, 147, 249);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (454, 57, 249);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (455, 69, 249);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (456, 193, 249);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (457, 63, 250);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (458, 147, 250);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (459, 85, 250);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (460, 193, 250);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (461, 40, 258);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (462, 63, 251);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (463, 40, 251);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (464, 199, 251);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (465, 103, 251);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (466, 85, 251);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (467, 46, 251);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (468, 193, 251);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (469, 63, 252);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (470, 40, 252);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (471, 199, 252);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (472, 103, 252);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (473, 69, 252);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (474, 31, 252);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (475, 193, 252);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (476, 109, 255);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (477, 40, 256);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (478, 147, 256);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (479, 109, 256);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (480, 203, 256);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (481, 40, 257);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (482, 109, 257);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (483, 203, 257);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (484, 124, 264);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (485, 173, 264);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (486, 63, 265);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (487, 94, 265);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (488, 63, 266);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (489, 94, 266);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (490, 173, 266);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (491, 94, 267);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (492, 173, 267);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (493, 63, 268);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (494, 72, 268);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (495, 173, 268);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (496, 138, 269);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (497, 124, 270);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (498, 167, 271);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (499, 94, 272);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (500, 132, 362);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (501, 84, 273);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (502, 53, 274);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (503, 121, 275);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (504, 16, 276);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (505, 187, 277);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (506, 72, 278);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (507, 93, 280);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (508, 93, 281);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (509, 199, 281);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (510, 103, 281);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (511, 93, 282);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (512, 192, 282);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (513, 93, 283);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (514, 63, 283);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (515, 199, 283);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (516, 28, 342);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (517, 67, 284);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (518, 199, 284);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (519, 103, 284);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (520, 147, 284);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (521, 192, 284);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (522, 199, 285);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (523, 52, 285);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (524, 141, 286);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (525, 85, 286);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (526, 141, 287);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (527, 85, 287);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (528, 93, 288);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (529, 199, 288);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (530, 52, 288);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (531, 199, 289);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (532, 103, 289);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (533, 193, 289);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (534, 93, 290);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (535, 141, 290);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (536, 85, 290);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (537, 93, 291);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (538, 199, 292);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (539, 192, 293);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (540, 44, 294);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (541, 152, 295);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (542, 67, 296);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (543, 147, 296);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (544, 67, 297);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (545, 63, 297);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (546, 147, 297);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (547, 193, 297);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (548, 67, 298);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (549, 63, 298);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (550, 193, 298);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (551, 132, 343);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (552, 136, 344);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (553, 189, 345);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (554, 168, 299);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (555, 63, 299);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (556, 147, 299);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (557, 69, 299);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (558, 193, 299);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (559, 3, 300);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (560, 85, 300);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (561, 193, 300);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (562, 168, 301);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (563, 67, 302);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (564, 63, 302);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (565, 103, 302);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (566, 147, 302);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (567, 67, 303);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (568, 63, 303);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (569, 103, 303);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (570, 147, 303);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (571, 67, 304);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (572, 63, 304);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (573, 103, 304);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (574, 147, 304);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (575, 193, 304);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (576, 67, 305);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (577, 63, 305);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (578, 103, 305);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (579, 147, 305);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (580, 168, 306);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (581, 147, 306);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (582, 193, 306);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (583, 67, 307);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (584, 103, 307);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (585, 15, 308);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (586, 103, 308);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (587, 193, 308);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (588, 147, 309);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (589, 57, 309);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (590, 69, 309);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (591, 119, 346);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (592, 67, 310);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (593, 103, 310);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (594, 147, 311);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (595, 57, 311);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (596, 69, 311);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (597, 168, 312);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (598, 147, 312);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (599, 57, 312);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (600, 63, 313);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (601, 103, 313);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (602, 193, 313);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (603, 63, 314);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (604, 103, 314);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (605, 147, 314);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (606, 57, 314);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (607, 193, 314);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (608, 40, 330);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (609, 63, 315);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (610, 196, 315);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (611, 63, 316);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (612, 15, 316);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (613, 193, 316);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (614, 181, 317);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (615, 194, 317);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (616, 103, 317);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (617, 76, 317);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (618, 181, 318);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (619, 63, 318);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (620, 103, 318);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (621, 147, 318);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (622, 85, 318);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (623, 65, 318);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (624, 193, 318);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (625, 63, 319);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (626, 103, 319);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (627, 85, 319);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (628, 193, 319);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (629, 40, 331);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (630, 63, 320);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (631, 40, 320);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (632, 103, 320);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (633, 193, 320);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (634, 199, 321);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (635, 85, 321);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (636, 193, 321);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (637, 40, 322);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (638, 85, 322);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (639, 193, 322);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (640, 199, 324);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (641, 193, 324);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (642, 40, 326);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (643, 204, 326);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (644, 40, 332);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (645, 46, 332);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (646, 40, 333);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (647, 199, 333);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (648, 147, 333);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (649, 46, 333);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (650, 200, 334);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (651, 40, 334);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (652, 147, 334);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (653, 22, 337);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (654, 158, 338);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (655, 108, 338);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (656, 106, 339);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (657, 12, 340);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (658, 92, 341);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (659, 178, 341);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (660, 67, 341);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (661, 54, 341);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (662, 89, 363);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (663, 52, 363);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (664, 199, 363);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (665, 179, 364);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (666, 170, 365);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (667, 170, 366);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (668, 182, 366);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (669, 190, 367);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (670, 47, 368);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (671, 131, 369);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (672, 178, 369);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (673, 32, 370);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (674, 175, 370);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (675, 154, 371);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (676, 161, 371);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (677, 148, 372);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (678, 174, 372);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (679, 158, 372);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (680, 165, 373);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (681, 183, 374);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (682, 99, 375);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (683, 6, 376);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (684, 96, 377);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (685, 177, 379);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (686, 117, 381);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (687, 42, 378);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (688, 17, 380);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (689, 112, 382);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (690, 87, 383);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (691, 87, 384);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (692, 102, 385);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (693, 154, 493);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (694, 161, 493);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (695, 60, 386);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (696, 8, 387);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (697, 122, 388);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (698, 185, 389);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (699, 90, 390);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (700, 163, 391);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (701, 5, 393);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (702, 163, 392);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (703, 63, 114);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (704, 158, 114);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (705, 103, 114);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (706, 63, 398);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (707, 158, 398);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (708, 103, 398);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (709, 168, 399);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (710, 158, 399);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (711, 148, 399);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (712, 174, 399);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (713, 63, 410);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (714, 79, 410);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (715, 137, 410);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (716, 158, 410);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (717, 154, 437);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (718, 161, 437);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (719, 63, 411);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (720, 103, 411);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (721, 182, 411);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (722, 159, 494);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (723, 175, 494);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (724, 166, 500);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (725, 175, 500);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (726, 63, 400);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (727, 103, 400);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (728, 63, 402);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (729, 103, 402);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (730, 182, 402);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (731, 63, 404);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (732, 158, 404);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (733, 103, 404);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (734, 100, 456);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (735, 4, 495);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (736, 175, 495);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (737, 178, 567);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (738, 67, 567);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (739, 118, 498);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (740, 142, 498);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (741, 67, 533);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (742, 201, 533);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (743, 63, 405);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (744, 158, 405);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (745, 63, 406);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (746, 158, 406);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (747, 103, 406);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (748, 63, 407);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (749, 103, 407);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (750, 191, 407);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (751, 79, 408);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (752, 63, 408);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (753, 101, 408);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (754, 137, 408);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (755, 168, 415);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (756, 63, 403);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (757, 158, 403);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (758, 103, 403);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (759, 63, 412);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (760, 103, 412);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (761, 182, 412);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (762, 63, 413);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (763, 158, 413);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (764, 103, 413);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (765, 63, 414);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (766, 158, 414);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (767, 103, 414);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (768, 178, 542);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (769, 100, 543);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (770, 195, 501);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (771, 182, 544);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (772, 168, 544);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (773, 103, 545);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (774, 63, 545);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (775, 103, 546);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (776, 67, 546);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (777, 178, 566);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (778, 39, 566);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (779, 166, 497);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (780, 142, 497);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (781, 159, 496);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (782, 142, 496);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (783, 166, 499);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (784, 37, 499);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (785, 37, 504);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (786, 175, 505);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (787, 63, 420);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (788, 103, 420);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (789, 182, 420);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (790, 174, 420);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (791, 142, 506);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (792, 67, 397);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (793, 95, 507);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (794, 168, 417);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (795, 168, 418);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (796, 174, 508);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (797, 66, 509);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (798, 63, 421);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (799, 103, 421);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (800, 182, 421);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (801, 174, 421);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (802, 168, 422);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (803, 158, 422);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (804, 174, 422);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (805, 63, 423);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (806, 79, 423);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (807, 137, 423);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (808, 158, 423);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (809, 174, 423);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (810, 148, 424);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (811, 174, 424);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (812, 158, 424);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (813, 171, 425);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (814, 168, 416);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (815, 158, 511);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (816, 67, 427);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (817, 67, 419);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (818, 120, 510);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (819, 67, 552);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (820, 57, 552);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (821, 196, 557);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (822, 178, 553);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (823, 158, 553);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (824, 198, 522);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (825, 103, 554);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (826, 67, 523);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (827, 67, 524);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (828, 182, 524);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (829, 67, 525);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (830, 196, 525);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (831, 95, 555);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (832, 182, 556);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (833, 168, 428);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (834, 37, 431);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (835, 195, 430);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (836, 175, 432);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (837, 195, 433);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (838, 175, 433);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (839, 195, 434);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (840, 161, 434);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (841, 195, 435);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (842, 172, 435);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (843, 24, 435);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (844, 37, 436);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (845, 172, 436);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (846, 24, 436);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (847, 103, 438);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (848, 182, 438);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (849, 63, 439);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (850, 103, 439);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (851, 191, 439);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (852, 63, 440);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (853, 79, 440);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (854, 137, 440);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (855, 63, 441);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (856, 101, 441);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (857, 137, 441);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (858, 120, 442);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (859, 158, 442);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (860, 120, 443);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (861, 182, 443);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (862, 120, 444);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (863, 206, 444);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (864, 120, 445);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (865, 125, 445);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (866, 174, 491);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (867, 188, 491);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (868, 158, 446);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (869, 103, 446);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (870, 158, 447);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (871, 39, 447);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (872, 63, 409);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (873, 79, 409);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (874, 137, 409);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (875, 63, 448);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (876, 79, 448);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (877, 137, 448);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (878, 63, 449);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (879, 79, 449);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (880, 137, 449);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (881, 63, 401);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (882, 103, 401);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (883, 182, 401);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (884, 178, 450);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (885, 182, 450);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (886, 168, 451);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (887, 182, 451);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (888, 168, 452);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (889, 158, 452);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (890, 156, 453);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (891, 182, 453);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (892, 91, 454);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (893, 131, 454);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (894, 100, 455);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (895, 180, 473);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (896, 168, 457);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (897, 168, 474);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (898, 100, 472);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (899, 48, 558);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (900, 168, 559);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (901, 63, 559);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (902, 67, 480);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (903, 178, 482);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (904, 168, 460);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (905, 168, 458);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (906, 67, 478);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (907, 67, 481);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (908, 80, 571);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (909, 39, 572);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (910, 182, 573);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (911, 168, 463);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (912, 178, 568);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (913, 168, 568);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (914, 182, 569);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (915, 67, 569);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (916, 97, 570);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (917, 168, 570);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (918, 67, 479);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (919, 67, 465);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (920, 178, 483);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (921, 67, 531);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (922, 191, 531);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (923, 67, 532);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (924, 206, 532);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (925, 83, 584);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (926, 168, 464);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (927, 168, 461);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (928, 168, 486);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (929, 158, 486);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (930, 174, 486);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (931, 174, 488);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (932, 206, 488);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (933, 174, 489);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (934, 178, 489);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (935, 174, 490);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (936, 120, 490);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (937, 178, 467);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (938, 120, 492);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (939, 188, 492);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (940, 178, 468);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (941, 178, 487);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (942, 168, 487);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (943, 174, 487);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (944, 168, 469);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (945, 168, 462);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (946, 178, 470);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (947, 168, 471);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (948, 180, 459);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (949, 168, 475);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (950, 168, 476);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (951, 174, 484);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (952, 182, 484);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (953, 197, 477);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (954, 174, 485);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (955, 158, 485);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (956, 182, 512);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (957, 133, 513);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (958, 206, 514);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (959, 103, 515);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (960, 178, 516);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (961, 39, 517);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (962, 169, 519);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (963, 131, 518);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (964, 166, 520);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (965, 67, 527);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (966, 182, 527);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (967, 156, 527);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (968, 168, 535);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (969, 158, 535);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (970, 182, 528);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (971, 196, 528);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (972, 182, 526);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (973, 196, 526);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (974, 156, 526);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (975, 181, 529);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (976, 57, 529);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (977, 69, 529);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (978, 67, 529);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (979, 181, 530);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (980, 57, 530);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (981, 69, 530);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (982, 168, 530);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (983, 67, 534);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (984, 178, 534);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (985, 67, 536);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (986, 97, 536);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (987, 158, 537);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (988, 182, 538);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (989, 201, 539);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (990, 196, 540);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (991, 97, 541);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (992, 103, 547);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (993, 182, 547);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (994, 67, 548);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (995, 103, 548);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (996, 182, 548);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (997, 63, 549);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (998, 103, 549);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (999, 67, 549);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1000, 168, 550);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1001, 39, 550);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1002, 182, 551);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1003, 57, 551);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1004, 67, 560);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1005, 63, 560);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1006, 67, 561);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1007, 182, 561);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1008, 168, 562);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1009, 182, 562);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1010, 168, 563);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1011, 182, 563);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1012, 156, 563);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1013, 168, 564);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1014, 158, 564);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1015, 168, 565);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1016, 39, 565);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1017, 196, 575);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1018, 125, 574);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1019, 178, 576);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1020, 147, 577);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1021, 206, 578);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1022, 97, 579);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1023, 156, 580);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1024, 120, 581);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1025, 49, 582);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1026, 49, 521);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1027, 58, 583);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1028, 181, 585);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1029, 147, 585);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1030, 67, 585);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1031, 75, 586);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1032, 128, 587);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1033, 140, 588);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1034, 78, 670);



insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1, 1, 1);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (2, 1, 2);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (4, 1, 4);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (5, 1, 5);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (6, 2, 7);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (7, 2, 8);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (8, 2, 9);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (9, 2, 10);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (10, 2, 11);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (11, 2, 12);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (56, 8, 79);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (57, 9, 39);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (58, 9, 40);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (59, 9, 41);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (60, 9, 42);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (61, 9, 43);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (62, 9, 44);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (63, 9, 45);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (64, 9, 46);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (65, 9, 47);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (66, 10, 31);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (67, 10, 32);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (68, 10, 33);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (69, 10, 34);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (70, 10, 35);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (71, 10, 36);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (72, 10, 37);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (73, 10, 38);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (106, 14, 107);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (107, 14, 108);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (108, 14, 109);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (109, 14, 110);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (110, 14, 111);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (111, 14, 112);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (112, 15, 152);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (114, 15, 114);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (119, 15, 120);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (120, 15, 121);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (121, 15, 122);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (122, 15, 131);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (123, 15, 123);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (124, 15, 124);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (125, 15, 125);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (126, 15, 126);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (128, 15, 132);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (129, 15, 133);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (130, 15, 137);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (131, 15, 139);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (132, 15, 140);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (133, 15, 141);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (134, 15, 144);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (135, 15, 147);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (137, 16, 117);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (138, 16, 128);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (139, 16, 129);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (142, 16, 136);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (143, 16, 151);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (144, 16, 150);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (145, 17, 138);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (146, 17, 142);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (147, 17, 143);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (148, 17, 145);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (149, 17, 146);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (150, 17, 148);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (151, 17, 149);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (155, 18, 172);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (160, 20, 153);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (161, 20, 154);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (162, 20, 155);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (163, 20, 156);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (164, 20, 157);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (165, 20, 158);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (166, 20, 159);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (167, 20, 160);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (168, 20, 161);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (169, 20, 162);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (170, 20, 163);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (171, 20, 164);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (179, 22, 177);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (180, 22, 178);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (181, 22, 179);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (182, 23, 193);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (183, 23, 187);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (184, 23, 188);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (185, 23, 189);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (186, 23, 190);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (187, 23, 191);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (188, 23, 192);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (189, 23, 195);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (192, 23, 201);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (193, 23, 202);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (194, 24, 194);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (195, 24, 198);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (196, 24, 199);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (197, 24, 200);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (198, 24, 203);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (199, 26, 204);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (200, 26, 205);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (201, 26, 206);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (202, 26, 207);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (204, 26, 209);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (205, 27, 210);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (206, 27, 211);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (207, 27, 212);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (208, 27, 213);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (209, 28, 214);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (210, 28, 215);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (211, 28, 216);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (212, 28, 217);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (213, 28, 218);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (214, 28, 219);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (215, 28, 220);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (216, 29, 248);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (217, 29, 249);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (218, 29, 250);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (219, 29, 251);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (220, 30, 221);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (221, 30, 222);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (222, 30, 223);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (223, 31, 225);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (224, 31, 226);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (225, 31, 227);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (226, 31, 228);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (227, 31, 229);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (228, 31, 230);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (229, 31, 231);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (230, 31, 232);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (231, 31, 233);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (232, 31, 234);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (233, 31, 235);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (234, 31, 236);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (235, 31, 237);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (236, 31, 238);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (237, 31, 239);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (238, 31, 240);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (239, 31, 241);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (241, 31, 243);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (243, 31, 245);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (245, 31, 247);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (246, 32, 252);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (249, 33, 256);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (250, 33, 255);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (251, 33, 257);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (252, 33, 258);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (254, 33, 260);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (255, 33, 261);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (257, 33, 263);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (259, 34, 266);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (260, 34, 265);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (261, 34, 267);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (262, 34, 268);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (263, 34, 269);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (264, 34, 270);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (265, 34, 271);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (266, 34, 272);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (267, 34, 273);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (271, 35, 276);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (272, 35, 275);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (273, 36, 278);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (274, 36, 279);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (276, 37, 281);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (277, 37, 282);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (278, 37, 283);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (279, 37, 284);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (281, 37, 286);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (282, 37, 287);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (283, 37, 288);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (284, 37, 289);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (285, 37, 290);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (286, 37, 291);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (287, 37, 292);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (288, 37, 293);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (289, 37, 294);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (290, 37, 295);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (292, 38, 297);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (293, 38, 298);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (294, 38, 299);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (295, 38, 300);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (296, 38, 301);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (298, 39, 303);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (299, 39, 304);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (300, 39, 305);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (305, 43, 310);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (306, 43, 311);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (308, 44, 313);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (309, 44, 314);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (310, 44, 315);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (311, 44, 316);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (313, 45, 318);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (317, 47, 322);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (318, 47, 323);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (319, 47, 324);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (320, 47, 325);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (321, 47, 326);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (322, 47, 327);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (323, 47, 329);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (326, 48, 332);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (327, 48, 333);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (328, 48, 334);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (329, 48, 335);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (330, 48, 336);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (332, 96, 714);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (333, 95, 720);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (334, 95, 721);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (335, 5, 509);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (336, 95, 722);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (337, 95, 723);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (338, 95, 724);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (339, 95, 725);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (340, 96, 716);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (341, 93, 602);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (342, 100, 379);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (343, 100, 381);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (344, 93, 633);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (345, 100, 378);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (346, 100, 380);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (347, 100, 382);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (348, 100, 383);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (349, 100, 384);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (350, 100, 385);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (351, 100, 386);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (352, 100, 392);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (353, 93, 634);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (355, 100, 388);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (356, 100, 389);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (357, 100, 390);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (358, 100, 391);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (359, 96, 708);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (360, 100, 393);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (361, 93, 628);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (362, 5, 398);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (363, 16, 399);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (364, 93, 603);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (365, 16, 493);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (366, 15, 410);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (367, 16, 499);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (368, 17, 437);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (369, 15, 411);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (370, 16, 494);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (371, 93, 604);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (372, 93, 605);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (373, 93, 606);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (374, 93, 607);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (375, 95, 733);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (376, 95, 734);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (377, 15, 400);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (378, 16, 500);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (379, 15, 402);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (380, 15, 404);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (381, 106, 456);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (382, 16, 495);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (383, 99, 567);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (384, 18, 533);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (387, 15, 407);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (388, 15, 408);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (389, 15, 403);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (391, 5, 501);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (392, 15, 413);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (393, 15, 414);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (394, 18, 542);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (395, 18, 543);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (397, 5, 502);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (398, 5, 503);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (399, 5, 504);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (400, 95, 717);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (401, 98, 544);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (402, 98, 545);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (403, 98, 546);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (404, 99, 566);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (405, 16, 497);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (406, 16, 496);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (407, 16, 498);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (408, 5, 505);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (409, 16, 420);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (410, 5, 506);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (411, 104, 397);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (412, 5, 507);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (413, 105, 417);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (414, 105, 418);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (415, 5, 508);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (416, 16, 421);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (417, 16, 422);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (418, 16, 423);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (419, 16, 424);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (420, 16, 425);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (421, 16, 426);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (422, 105, 429);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (423, 5, 522);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (424, 105, 416);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (425, 5, 511);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (426, 105, 427);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (427, 105, 419);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (428, 5, 510);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (429, 98, 552);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (430, 98, 553);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (431, 98, 554);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (432, 18, 523);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (433, 18, 524);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (434, 18, 525);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (435, 98, 555);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (436, 98, 556);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (437, 15, 438);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (438, 105, 428);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (439, 17, 431);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (440, 17, 430);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (441, 17, 432);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (442, 17, 433);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (443, 17, 434);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (444, 17, 435);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (445, 17, 436);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (446, 15, 439);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (447, 15, 440);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (448, 15, 441);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (450, 93, 629);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (451, 15, 448);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (452, 15, 443);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (453, 15, 444);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (454, 15, 445);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (455, 15, 446);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (456, 15, 447);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (457, 15, 409);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (458, 15, 449);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (459, 15, 401);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (461, 93, 735);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (462, 93, 736);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (463, 93, 737);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (464, 93, 738);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (465, 107, 473);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (466, 93, 631);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (467, 15, 451);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (468, 15, 452);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (470, 15, 454);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (471, 106, 455);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (472, 93, 608);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (473, 93, 609);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (474, 106, 457);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (475, 98, 557);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (476, 107, 474);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (477, 107, 472);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (478, 98, 558);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (479, 99, 559);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (480, 91, 394);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (481, 99, 571);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (482, 93, 632);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (483, 107, 480);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (484, 106, 460);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (485, 106, 458);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (486, 107, 478);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (487, 107, 481);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (488, 93, 626);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (489, 99, 572);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (490, 99, 573);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (491, 93, 627);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (492, 106, 463);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (493, 99, 568);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (494, 99, 569);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (495, 99, 570);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (496, 93, 630);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (497, 107, 479);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (498, 107, 482);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (499, 106, 465);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (500, 107, 483);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (501, 18, 531);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (502, 18, 532);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (503, 99, 584);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (504, 106, 464);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (505, 106, 461);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (506, 16, 486);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (507, 16, 488);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (508, 16, 489);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (509, 94, 664);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (510, 94, 665);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (511, 93, 739);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (512, 93, 740);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (513, 95, 718);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (514, 106, 466);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (515, 16, 490);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (516, 16, 491);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (517, 106, 467);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (518, 16, 492);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (519, 106, 468);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (520, 16, 487);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (521, 106, 469);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (522, 106, 462);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (523, 92, 689);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (524, 106, 470);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (525, 107, 471);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (526, 92, 690);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (527, 106, 459);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (528, 92, 691);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (529, 92, 692);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (530, 8, 693);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (531, 8, 694);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (532, 107, 475);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (533, 107, 476);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (534, 16, 484);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (536, 16, 485);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (537, 93, 600);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (538, 8, 695);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (539, 5, 512);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (540, 5, 513);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (541, 5, 514);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (543, 5, 516);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (544, 5, 517);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (545, 5, 519);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (546, 5, 518);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (547, 5, 520);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (549, 8, 697);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (550, 8, 698);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (551, 18, 527);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (552, 18, 528);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (553, 18, 526);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (554, 18, 529);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (555, 18, 530);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (556, 18, 534);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (557, 18, 535);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (558, 18, 536);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (559, 18, 537);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (560, 18, 538);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (561, 18, 539);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (562, 18, 540);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (563, 18, 541);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (564, 96, 699);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (565, 98, 547);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (566, 98, 548);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (567, 98, 549);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (568, 98, 550);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (569, 98, 551);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (570, 93, 601);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (571, 99, 560);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (572, 99, 561);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (573, 99, 562);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (574, 99, 563);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (575, 99, 564);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (576, 99, 565);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (577, 99, 575);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (578, 99, 574);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (579, 99, 576);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (580, 99, 577);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (581, 99, 578);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (582, 99, 579);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (583, 99, 580);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (584, 99, 581);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (585, 99, 582);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (586, 5, 521);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (587, 99, 583);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (588, 99, 585);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (589, 93, 595);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (591, 93, 597);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (592, 93, 598);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (593, 34, 586);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (594, 93, 599);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (595, 111, 587);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (596, 111, 588);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (597, 93, 589);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (598, 93, 590);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (599, 93, 591);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (600, 93, 592);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (601, 93, 593);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (602, 93, 594);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (603, 95, 719);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (604, 93, 610);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (605, 93, 611);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (606, 93, 612);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (607, 93, 613);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (608, 93, 614);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (609, 93, 615);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (610, 93, 616);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (611, 93, 617);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (612, 93, 618);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (613, 93, 619);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (614, 93, 620);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (615, 93, 621);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (617, 93, 623);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (618, 93, 624);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (619, 93, 625);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (620, 96, 700);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (621, 91, 635);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (622, 91, 636);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (623, 91, 637);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (624, 91, 638);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (627, 91, 639);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (628, 95, 644);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (629, 95, 645);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (632, 94, 646);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (633, 94, 647);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (634, 94, 648);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (635, 94, 649);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (636, 94, 650);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (637, 96, 709);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (638, 94, 651);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (639, 94, 652);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (640, 94, 653);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (641, 94, 654);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (642, 94, 655);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (643, 94, 656);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (644, 94, 657);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (645, 94, 658);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (646, 94, 659);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (647, 94, 660);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (648, 94, 661);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (649, 94, 662);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (650, 94, 663);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (651, 92, 666);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (652, 96, 710);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (653, 92, 667);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (654, 92, 668);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (655, 92, 669);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (656, 96, 706);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (657, 1, 670);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (658, 96, 701);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (659, 96, 702);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (660, 96, 704);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (661, 96, 703);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (662, 96, 705);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (663, 96, 707);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (664, 96, 711);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (665, 96, 712);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (666, 96, 713);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (667, 33, 671);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (668, 92, 679);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (669, 33, 672);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (670, 33, 673);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (671, 92, 674);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (672, 92, 675);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (673, 92, 676);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (674, 92, 677);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (675, 92, 678);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (676, 92, 680);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (677, 92, 681);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (678, 92, 682);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (679, 92, 683);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (680, 92, 684);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (681, 92, 685);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (682, 92, 686);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (683, 92, 687);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (684, 92, 688);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (685, 93, 726);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (686, 95, 727);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (687, 95, 728);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (688, 95, 729);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (689, 95, 730);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (690, 95, 731);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (691, 95, 732);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (692, 93, 741);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (693, 93, 742);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (694, 93, 743);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (695, 93, 744);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (696, 93, 745);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (697, 96, 715);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (704, 32, 753);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (712, 35, 759);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (713, 35, 761);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (714, 35, 762);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (715, 35, 763);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (716, 36, 764);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (717, 36, 765);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (718, 117, 766);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (719, 117, 767);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (720, 117, 285);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (721, 26, 768);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (722, 2, 769);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (723, 2, 770);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (724, 2, 477);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (737, 2, 738);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (739, 2, 771);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (740, 2, 772);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (741, 2, 773);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (742, 2, 774);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (743, 2, 775);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (744, 2, 776);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (745, 2, 777);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (746, 2, 778);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (747, 2, 779);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (748, 2, 780);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (749, 115, 781);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (750, 115, 782);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (751, 115, 783);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (752, 115, 784);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (753, 115, 785);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (754, 115, 786);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (755, 115, 787);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (756, 119, 788);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (757, 119, 789);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (758, 91, 790);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (760, 114, 792);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (761, 1, 793);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (762, 1, 794);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (763, 1, 795);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (764, 1, 796);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (765, 1, 797);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (766, 1, 798);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (767, 1, 799);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (768, 1, 800);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (769, 91, 801);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (770, 91, 802);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (771, 91, 803);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (772, 93, 804);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (773, 96, 805);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (774, 27, 514);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (775, 27, 577);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (776, 27, 511);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (778, 32, 695);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (779, 32, 759);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (780, 32, 806);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (781, 32, 807);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (782, 32, 808);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (783, 32, 809);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (784, 32, 810);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (785, 34, 811);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (786, 34, 812);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (787, 34, 813);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (788, 34, 814);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (789, 32, 815);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (790, 35, 816);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (791, 35, 817);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (792, 35, 818);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (793, 35, 819);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (794, 36, 820);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (795, 33, 821);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (796, 33, 822);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (797, 33, 823);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (798, 33, 824);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (799, 37, 825);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (800, 110, 826);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (801, 112, 827);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (802, 112, 828);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (803, 112, 829);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (804, 109, 830);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (805, 109, 831);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (806, 109, 832);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (807, 109, 833);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (808, 109, 834);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (809, 106, 835);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (810, 113, 837);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (811, 101, 838);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (812, 101, 839);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (813, 101, 840);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (814, 103, 844);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (815, 103, 845);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (816, 103, 846);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (817, 40, 847);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (818, 41, 848);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (820, 42, 850);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (821, 45, 851);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (822, 46, 852);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (824, 47, 854);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (825, 120, 855);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (826, 120, 856);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (827, 120, 857);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (828, 120, 858);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (829, 120, 859);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (830, 120, 860);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (831, 120, 861);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (832, 120, 862);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (834, 121, 864);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (835, 121, 865);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (836, 122, 866);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (837, 122, 867);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (833, 121, 863);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (838, 123, 868);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (839, 123, 869);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (840, 123, 870);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (841, 123, 871);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (842, 123, 872);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (843, 123, 873);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (844, 124, 874);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (845, 124, 875);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (846, 124, 876);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (847, 124, 877);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (848, 124, 878);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (849, 124, 879);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (850, 124, 880);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (851, 124, 881);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (852, 102, 882);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (853, 22, 883);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (854, 22, 884);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (855, 22, 885);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (856, 22, 886);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (857, 22, 887);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (858, 22, 888);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (859, 22, 889);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (860, 22, 890);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (861, 101, 891);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (862, 101, 892);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (863, 101, 893);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (864, 101, 894);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (865, 101, 895);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (866, 101, 896);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (867, 101, 897);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (868, 101, 898);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (869, 101, 899);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (870, 101, 900);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (871, 101, 901);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (872, 101, 902);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (873, 101, 903);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (874, 101, 904);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (875, 101, 905);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (876, 101, 906);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (877, 101, 907);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (878, 101, 908);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (879, 101, 909);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (880, 101, 910);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (881, 101, 911);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (882, 101, 912);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (883, 101, 913);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (884, 101, 914);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (885, 101, 915);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (886, 125, 916);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (887, 125, 917);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (888, 125, 918);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (889, 125, 919);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (890, 125, 920);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (891, 125, 921);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (892, 125, 922);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (893, 125, 923);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (894, 125, 924);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (895, 125, 925);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (896, 125, 926);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (897, 125, 927);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (898, 125, 928);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (899, 125, 929);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (900, 125, 930);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (901, 125, 931);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (902, 126, 932);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (903, 126, 933);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (904, 126, 934);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (905, 126, 935);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (906, 126, 936);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (907, 126, 937);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (908, 126, 938);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (909, 126, 939);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (910, 126, 940);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (911, 126, 941);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (912, 126, 942);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (913, 126, 943);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (914, 126, 944);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (915, 126, 945);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (916, 127, 946);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (917, 127, 947);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (918, 127, 948);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (919, 127, 949);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (920, 127, 950);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (921, 127, 951);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (922, 127, 952);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (923, 127, 953);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (924, 127, 954);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (925, 127, 955);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (926, 127, 956);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (927, 127, 957);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (928, 127, 958);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (929, 127, 959);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (930, 127, 960);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (931, 127, 961);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (932, 127, 962);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (933, 127, 963);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (934, 128, 964);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (935, 128, 965);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (936, 128, 966);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (937, 128, 967);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (938, 128, 968);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (939, 100, 969);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (940, 100, 970);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (941, 100, 971);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (942, 100, 972);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (943, 100, 973);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (944, 100, 974);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (945, 100, 975);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (946, 100, 976);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (947, 100, 977);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (948, 33, 978);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (949, 33, 979);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (950, 33, 980);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (951, 33, 981);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (952, 33, 982);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (953, 33, 983);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (954, 33, 984);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (955, 33, 985);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (956, 33, 986);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (957, 33, 987);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (958, 33, 988);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (959, 33, 989);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (960, 33, 990);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (961, 33, 991);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (962, 33, 992);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (963, 30, 993);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (964, 30, 994);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (965, 30, 995);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (966, 30, 996);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (967, 30, 997);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (968, 30, 998);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (969, 30, 999);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (970, 30, 1000);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (971, 30, 1001);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (972, 30, 1002);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (973, 30, 1003);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (974, 30, 1004);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (975, 30, 1005);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (976, 30, 1006);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (977, 30, 1007);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (978, 30, 1008);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (979, 129, 1009);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (980, 129, 1010);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (981, 129, 1011);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (982, 129, 1012);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (983, 109, 1013);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (984, 109, 1014);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (985, 109, 1015);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (986, 109, 1016);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (987, 109, 1018);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (988, 109, 1019);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (989, 109, 1020);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (990, 17, 1021);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (991, 17, 1022);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (992, 17, 1023);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (993, 17, 1024);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (994, 28, 1025);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (995, 28, 1026);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (996, 28, 1027);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (997, 28, 1028);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (998, 124, 1029);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (999, 124, 1030);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1000, 93, 1031);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1001, 93, 1032);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1002, 93, 1033);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1003, 93, 1034);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1004, 2, 1035);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1005, 2, 1036);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1006, 2, 1037);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1007, 2, 1038);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1008, 2, 1039);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1009, 27, 1040);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1010, 27, 1041);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1011, 33, 1042);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1012, 34, 1043);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1013, 34, 1044);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1014, 34, 1045);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1015, 34, 1046);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1016, 34, 1047);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1017, 34, 1048);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1018, 34, 1049);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1019, 34, 1050);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1020, 34, 1051);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1021, 34, 1052);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1022, 34, 1053);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1023, 34, 1054);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1024, 34, 1055);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1025, 105, 1056);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1029, 105, 1060);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1033, 105, 1064);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1034, 105, 1065);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1035, 105, 1066);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1040, 106, 1071);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1044, 106, 1075);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1045, 106, 1076);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1047, 106, 1078);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1048, 106, 1079);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1049, 106, 1080);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1051, 106, 1082);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1052, 106, 1083);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1053, 106, 1084);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1060, 106, 1091);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1061, 106, 1092);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1062, 106, 1093);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1063, 106, 1094);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1070, 109, 1101);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1071, 109, 1102);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1072, 109, 1103);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1073, 109, 1104);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1074, 109, 1105);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1075, 109, 1106);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1079, 123, 1110);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1080, 123, 1111);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1081, 123, 1112);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1082, 123, 1113);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1083, 123, 1114);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1084, 123, 1115);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1086, 112, 1117);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1026, 105, 1057);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1027, 104, 1058);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1028, 105, 1059);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1030, 105, 1061);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1031, 105, 1062);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1032, 105, 1063);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1036, 116, 1067);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1037, 118, 1068);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1038, 107, 1069);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1039, 106, 1070);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1041, 106, 1072);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1042, 106, 1073);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1043, 106, 1074);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1046, 106, 1077);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1050, 106, 1081);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1054, 106, 1085);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1055, 106, 1086);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1056, 106, 1087);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1057, 106, 1088);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1058, 106, 1089);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1059, 106, 1090);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1064, 106, 1095);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1065, 106, 1096);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1066, 106, 1097);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1067, 106, 1098);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1068, 106, 1099);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1069, 109, 1100);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1076, 109, 1107);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1077, 109, 1108);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1078, 109, 1109);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1085, 112, 1116);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1087, 117, 1118);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1088, 117, 1119);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1089, 106, 1120);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1090, 37, 1121);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1091, 37, 1122);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1092, 37, 1123);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1093, 37, 1124);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1094, 37, 1125);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1095, 37, 1126);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1096, 37, 1127);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1097, 37, 1128);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1098, 37, 1129);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1099, 37, 1130);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1100, 37, 1131);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1101, 37, 1132);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1102, 37, 1133);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1103, 37, 1134);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1104, 37, 1135);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1105, 37, 1136);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1106, 37, 1137);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1107, 37, 1138);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1108, 37, 1139);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1109, 130, 1140);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1110, 130, 1141);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1111, 101, 1142);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1112, 22, 1143);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1113, 22, 1144);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1114, 22, 1145);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1115, 22, 1146);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1116, 22, 1147);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1117, 22, 1148);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1118, 22, 1149);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1119, 22, 1150);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1120, 26, 1151);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1121, 26, 1152);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1122, 26, 1153);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1123, 26, 1154);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1124, 26, 1155);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1125, 26, 1156);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1126, 26, 1157);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1127, 26, 1158);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1128, 26, 1159);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1129, 26, 1160);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1130, 121, 1161);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1131, 121, 1162);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1132, 121, 1163);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1133, 103, 1164);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1134, 103, 1165);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1135, 103, 1166);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1136, 103, 1167);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1137, 103, 1168);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1138, 103, 1169);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1139, 103, 1170);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1140, 103, 1171);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1141, 103, 1172);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1142, 94, 1173);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1143, 38, 1174);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1144, 48, 1175);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1145, 48, 1176);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1146, 47, 1177);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1147, 46, 1178);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1148, 39, 1179);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1149, 44, 1180);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1150, 43, 1181);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1151, 47, 1182);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1152, 48, 1183);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1153, 48, 1184);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1154, 48, 1185);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1155, 38, 1186);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1156, 45, 1187);


insert into public.regimen_level_link (id, level_id, regimen_id) values (1, 3, 502);
insert into public.regimen_level_link (id, level_id, regimen_id) values (2, 3, 503);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1267, 3, 802);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1268, 3, 801);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1269, 6, 588);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1270, 3, 587);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1271, 6, 587);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1272, 3, 721);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1275, 2, 379);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1276, 3, 383);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1278, 3, 389);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1279, 3, 388);
insert into public.regimen_level_link (id, level_id, regimen_id) values (568, 7, 742);
insert into public.regimen_level_link (id, level_id, regimen_id) values (643, 3, 454);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1280, 3, 385);
insert into public.regimen_level_link (id, level_id, regimen_id) values (16, 3, 387);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1281, 3, 382);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1282, 3, 393);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1283, 17, 969);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1284, 17, 970);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1286, 3, 972);
insert into public.regimen_level_link (id, level_id, regimen_id) values (569, 3, 629);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1287, 17, 973);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1288, 17, 974);
insert into public.regimen_level_link (id, level_id, regimen_id) values (25, 2, 398);
insert into public.regimen_level_link (id, level_id, regimen_id) values (570, 3, 632);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1763, 1, 1186);
insert into public.regimen_level_link (id, level_id, regimen_id) values (476, 17, 792);
insert into public.regimen_level_link (id, level_id, regimen_id) values (477, 3, 792);
insert into public.regimen_level_link (id, level_id, regimen_id) values (794, 18, 12);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1457, 8, 1027);
insert into public.regimen_level_link (id, level_id, regimen_id) values (579, 3, 119);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1764, 17, 851);
insert into public.regimen_level_link (id, level_id, regimen_id) values (581, 2, 647);
insert into public.regimen_level_link (id, level_id, regimen_id) values (582, 3, 657);
insert into public.regimen_level_link (id, level_id, regimen_id) values (607, 3, 675);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1765, 17, 1179);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1458, 3, 1028);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1289, 17, 975);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1459, 17, 1029);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1460, 17, 1030);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1766, 17, 305);
insert into public.regimen_level_link (id, level_id, regimen_id) values (43, 1, 405);
insert into public.regimen_level_link (id, level_id, regimen_id) values (44, 1, 406);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1767, 18, 1180);
insert into public.regimen_level_link (id, level_id, regimen_id) values (493, 17, 799);
insert into public.regimen_level_link (id, level_id, regimen_id) values (608, 3, 677);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1521, 23, 823);
insert into public.regimen_level_link (id, level_id, regimen_id) values (49, 1, 412);
insert into public.regimen_level_link (id, level_id, regimen_id) values (609, 3, 676);
insert into public.regimen_level_link (id, level_id, regimen_id) values (610, 3, 678);
insert into public.regimen_level_link (id, level_id, regimen_id) values (52, 3, 501);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1522, 8, 673);
insert into public.regimen_level_link (id, level_id, regimen_id) values (611, 3, 683);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1523, 26, 673);
insert into public.regimen_level_link (id, level_id, regimen_id) values (56, 3, 504);
insert into public.regimen_level_link (id, level_id, regimen_id) values (57, 3, 505);
insert into public.regimen_level_link (id, level_id, regimen_id) values (612, 2, 666);
insert into public.regimen_level_link (id, level_id, regimen_id) values (59, 3, 506);
insert into public.regimen_level_link (id, level_id, regimen_id) values (60, 3, 507);
insert into public.regimen_level_link (id, level_id, regimen_id) values (61, 3, 508);
insert into public.regimen_level_link (id, level_id, regimen_id) values (62, 3, 509);
insert into public.regimen_level_link (id, level_id, regimen_id) values (613, 3, 684);
insert into public.regimen_level_link (id, level_id, regimen_id) values (504, 7, 740);
insert into public.regimen_level_link (id, level_id, regimen_id) values (655, 3, 716);
insert into public.regimen_level_link (id, level_id, regimen_id) values (614, 3, 682);
insert into public.regimen_level_link (id, level_id, regimen_id) values (506, 3, 616);
insert into public.regimen_level_link (id, level_id, regimen_id) values (507, 3, 615);
insert into public.regimen_level_link (id, level_id, regimen_id) values (70, 3, 510);
insert into public.regimen_level_link (id, level_id, regimen_id) values (71, 3, 522);
insert into public.regimen_level_link (id, level_id, regimen_id) values (795, 3, 12);
insert into public.regimen_level_link (id, level_id, regimen_id) values (508, 1, 589);
insert into public.regimen_level_link (id, level_id, regimen_id) values (615, 3, 689);
insert into public.regimen_level_link (id, level_id, regimen_id) values (616, 3, 685);
insert into public.regimen_level_link (id, level_id, regimen_id) values (656, 6, 705);
insert into public.regimen_level_link (id, level_id, regimen_id) values (968, 3, 468);
insert into public.regimen_level_link (id, level_id, regimen_id) values (796, 2, 769);
insert into public.regimen_level_link (id, level_id, regimen_id) values (619, 3, 691);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1525, 31, 811);
insert into public.regimen_level_link (id, level_id, regimen_id) values (620, 3, 690);
insert into public.regimen_level_link (id, level_id, regimen_id) values (621, 3, 692);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1528, 8, 273);
insert into public.regimen_level_link (id, level_id, regimen_id) values (622, 3, 681);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1529, 19, 273);
insert into public.regimen_level_link (id, level_id, regimen_id) values (699, 8, 532);
insert into public.regimen_level_link (id, level_id, regimen_id) values (700, 19, 537);
insert into public.regimen_level_link (id, level_id, regimen_id) values (701, 18, 537);
insert into public.regimen_level_link (id, level_id, regimen_id) values (627, 3, 694);
insert into public.regimen_level_link (id, level_id, regimen_id) values (702, 18, 542);
insert into public.regimen_level_link (id, level_id, regimen_id) values (971, 3, 470);
insert into public.regimen_level_link (id, level_id, regimen_id) values (629, 3, 698);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1531, 26, 1043);
insert into public.regimen_level_link (id, level_id, regimen_id) values (972, 3, 459);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1532, 31, 1043);
insert into public.regimen_level_link (id, level_id, regimen_id) values (703, 19, 542);
insert into public.regimen_level_link (id, level_id, regimen_id) values (630, 3, 697);
insert into public.regimen_level_link (id, level_id, regimen_id) values (632, 3, 719);
insert into public.regimen_level_link (id, level_id, regimen_id) values (704, 18, 539);
insert into public.regimen_level_link (id, level_id, regimen_id) values (705, 3, 539);
insert into public.regimen_level_link (id, level_id, regimen_id) values (706, 17, 538);
insert into public.regimen_level_link (id, level_id, regimen_id) values (707, 17, 524);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1533, 26, 1044);
insert into public.regimen_level_link (id, level_id, regimen_id) values (708, 17, 526);
insert into public.regimen_level_link (id, level_id, regimen_id) values (810, 18, 806);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1534, 8, 1045);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1536, 17, 1049);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1540, 8, 279);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1543, 17, 1057);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1544, 1, 1058);
insert into public.regimen_level_link (id, level_id, regimen_id) values (975, 8, 781);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1545, 17, 1059);
insert into public.regimen_level_link (id, level_id, regimen_id) values (976, 17, 781);
insert into public.regimen_level_link (id, level_id, regimen_id) values (709, 3, 543);
insert into public.regimen_level_link (id, level_id, regimen_id) values (977, 8, 783);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1547, 17, 1061);
insert into public.regimen_level_link (id, level_id, regimen_id) values (978, 17, 783);
insert into public.regimen_level_link (id, level_id, regimen_id) values (979, 8, 782);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1548, 17, 1062);
insert into public.regimen_level_link (id, level_id, regimen_id) values (980, 17, 782);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1549, 3, 1063);
insert into public.regimen_level_link (id, level_id, regimen_id) values (710, 18, 543);
insert into public.regimen_level_link (id, level_id, regimen_id) values (981, 8, 786);
insert into public.regimen_level_link (id, level_id, regimen_id) values (982, 17, 786);
insert into public.regimen_level_link (id, level_id, regimen_id) values (713, 18, 540);
insert into public.regimen_level_link (id, level_id, regimen_id) values (714, 3, 540);
insert into public.regimen_level_link (id, level_id, regimen_id) values (717, 18, 546);
insert into public.regimen_level_link (id, level_id, regimen_id) values (718, 3, 546);
insert into public.regimen_level_link (id, level_id, regimen_id) values (719, 1, 549);
insert into public.regimen_level_link (id, level_id, regimen_id) values (983, 17, 787);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1004, 8, 428);
insert into public.regimen_level_link (id, level_id, regimen_id) values (721, 17, 552);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1006, 3, 427);
insert into public.regimen_level_link (id, level_id, regimen_id) values (722, 3, 554);
insert into public.regimen_level_link (id, level_id, regimen_id) values (723, 17, 547);
insert into public.regimen_level_link (id, level_id, regimen_id) values (724, 18, 547);
insert into public.regimen_level_link (id, level_id, regimen_id) values (725, 3, 553);
insert into public.regimen_level_link (id, level_id, regimen_id) values (726, 17, 555);
insert into public.regimen_level_link (id, level_id, regimen_id) values (727, 18, 555);
insert into public.regimen_level_link (id, level_id, regimen_id) values (728, 17, 556);
insert into public.regimen_level_link (id, level_id, regimen_id) values (729, 18, 556);
insert into public.regimen_level_link (id, level_id, regimen_id) values (730, 17, 544);
insert into public.regimen_level_link (id, level_id, regimen_id) values (731, 18, 544);
insert into public.regimen_level_link (id, level_id, regimen_id) values (162, 3, 512);
insert into public.regimen_level_link (id, level_id, regimen_id) values (163, 3, 513);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1007, 17, 429);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1008, 1, 397);
insert into public.regimen_level_link (id, level_id, regimen_id) values (166, 3, 515);
insert into public.regimen_level_link (id, level_id, regimen_id) values (167, 3, 516);
insert into public.regimen_level_link (id, level_id, regimen_id) values (168, 3, 517);
insert into public.regimen_level_link (id, level_id, regimen_id) values (169, 3, 519);
insert into public.regimen_level_link (id, level_id, regimen_id) values (170, 3, 518);
insert into public.regimen_level_link (id, level_id, regimen_id) values (171, 3, 520);
insert into public.regimen_level_link (id, level_id, regimen_id) values (172, 3, 696);
insert into public.regimen_level_link (id, level_id, regimen_id) values (732, 17, 551);
insert into public.regimen_level_link (id, level_id, regimen_id) values (733, 18, 558);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1009, 3, 109);
insert into public.regimen_level_link (id, level_id, regimen_id) values (817, 26, 269);
insert into public.regimen_level_link (id, level_id, regimen_id) values (734, 3, 558);
insert into public.regimen_level_link (id, level_id, regimen_id) values (735, 3, 557);
insert into public.regimen_level_link (id, level_id, regimen_id) values (736, 18, 557);
insert into public.regimen_level_link (id, level_id, regimen_id) values (180, 3, 521);
insert into public.regimen_level_link (id, level_id, regimen_id) values (183, 1, 596);
insert into public.regimen_level_link (id, level_id, regimen_id) values (739, 1, 585);
insert into public.regimen_level_link (id, level_id, regimen_id) values (740, 19, 580);
insert into public.regimen_level_link (id, level_id, regimen_id) values (741, 18, 580);
insert into public.regimen_level_link (id, level_id, regimen_id) values (742, 17, 564);
insert into public.regimen_level_link (id, level_id, regimen_id) values (743, 17, 565);
insert into public.regimen_level_link (id, level_id, regimen_id) values (746, 17, 563);
insert into public.regimen_level_link (id, level_id, regimen_id) values (748, 17, 559);
insert into public.regimen_level_link (id, level_id, regimen_id) values (749, 17, 561);
insert into public.regimen_level_link (id, level_id, regimen_id) values (750, 17, 572);
insert into public.regimen_level_link (id, level_id, regimen_id) values (861, 23, 824);
insert into public.regimen_level_link (id, level_id, regimen_id) values (865, 23, 261);
insert into public.regimen_level_link (id, level_id, regimen_id) values (866, 27, 261);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1012, 17, 112);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1013, 6, 108);
insert into public.regimen_level_link (id, level_id, regimen_id) values (644, 3, 722);
insert into public.regimen_level_link (id, level_id, regimen_id) values (645, 3, 718);
insert into public.regimen_level_link (id, level_id, regimen_id) values (646, 17, 729);
insert into public.regimen_level_link (id, level_id, regimen_id) values (647, 17, 732);
insert into public.regimen_level_link (id, level_id, regimen_id) values (648, 17, 733);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1273, 3, 724);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1550, 3, 1064);
insert into public.regimen_level_link (id, level_id, regimen_id) values (633, 17, 730);
insert into public.regimen_level_link (id, level_id, regimen_id) values (634, 1, 644);
insert into public.regimen_level_link (id, level_id, regimen_id) values (635, 3, 723);
insert into public.regimen_level_link (id, level_id, regimen_id) values (636, 3, 720);
insert into public.regimen_level_link (id, level_id, regimen_id) values (650, 17, 734);
insert into public.regimen_level_link (id, level_id, regimen_id) values (651, 17, 731);
insert into public.regimen_level_link (id, level_id, regimen_id) values (652, 17, 728);
insert into public.regimen_level_link (id, level_id, regimen_id) values (653, 3, 706);
insert into public.regimen_level_link (id, level_id, regimen_id) values (800, 17, 212);
insert into public.regimen_level_link (id, level_id, regimen_id) values (801, 17, 213);
insert into public.regimen_level_link (id, level_id, regimen_id) values (211, 3, 641);
insert into public.regimen_level_link (id, level_id, regimen_id) values (212, 3, 640);
insert into public.regimen_level_link (id, level_id, regimen_id) values (664, 3, 715);
insert into public.regimen_level_link (id, level_id, regimen_id) values (216, 3, 642);
insert into public.regimen_level_link (id, level_id, regimen_id) values (217, 3, 643);
insert into public.regimen_level_link (id, level_id, regimen_id) values (667, 3, 707);
insert into public.regimen_level_link (id, level_id, regimen_id) values (715, 17, 545);
insert into public.regimen_level_link (id, level_id, regimen_id) values (716, 18, 545);
insert into public.regimen_level_link (id, level_id, regimen_id) values (747, 17, 560);
insert into public.regimen_level_link (id, level_id, regimen_id) values (752, 17, 576);
insert into public.regimen_level_link (id, level_id, regimen_id) values (753, 17, 568);
insert into public.regimen_level_link (id, level_id, regimen_id) values (754, 18, 567);
insert into public.regimen_level_link (id, level_id, regimen_id) values (755, 19, 567);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1014, 3, 108);
insert into public.regimen_level_link (id, level_id, regimen_id) values (804, 17, 511);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1027, 2, 380);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1551, 17, 1065);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1552, 3, 1066);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1559, 3, 480);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1560, 8, 480);
insert into public.regimen_level_link (id, level_id, regimen_id) values (806, 18, 753);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1034, 3, 177);
insert into public.regimen_level_link (id, level_id, regimen_id) values (811, 18, 807);
insert into public.regimen_level_link (id, level_id, regimen_id) values (812, 18, 808);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1035, 17, 177);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1561, 17, 481);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1562, 3, 482);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1274, 17, 727);
insert into public.regimen_level_link (id, level_id, regimen_id) values (875, 23, 251);
insert into public.regimen_level_link (id, level_id, regimen_id) values (876, 27, 251);
insert into public.regimen_level_link (id, level_id, regimen_id) values (877, 15, 248);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1037, 3, 179);
insert into public.regimen_level_link (id, level_id, regimen_id) values (879, 15, 250);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1277, 3, 384);
insert into public.regimen_level_link (id, level_id, regimen_id) values (884, 22, 235);
insert into public.regimen_level_link (id, level_id, regimen_id) values (885, 17, 235);
insert into public.regimen_level_link (id, level_id, regimen_id) values (886, 26, 236);
insert into public.regimen_level_link (id, level_id, regimen_id) values (887, 26, 237);
insert into public.regimen_level_link (id, level_id, regimen_id) values (891, 17, 240);
insert into public.regimen_level_link (id, level_id, regimen_id) values (892, 26, 241);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1038, 17, 179);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1567, 17, 469);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1285, 17, 971);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1291, 6, 977);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1292, 17, 800);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1293, 17, 4);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1294, 18, 5);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1295, 17, 1);
insert into public.regimen_level_link (id, level_id, regimen_id) values (899, 26, 244);
insert into public.regimen_level_link (id, level_id, regimen_id) values (900, 26, 245);
insert into public.regimen_level_link (id, level_id, regimen_id) values (901, 22, 246);
insert into public.regimen_level_link (id, level_id, regimen_id) values (907, 23, 292);
insert into public.regimen_level_link (id, level_id, regimen_id) values (475, 3, 149);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1042, 17, 840);
insert into public.regimen_level_link (id, level_id, regimen_id) values (271, 1, 746);
insert into public.regimen_level_link (id, level_id, regimen_id) values (272, 3, 747);
insert into public.regimen_level_link (id, level_id, regimen_id) values (273, 6, 747);
insert into public.regimen_level_link (id, level_id, regimen_id) values (274, 3, 749);
insert into public.regimen_level_link (id, level_id, regimen_id) values (275, 6, 749);
insert into public.regimen_level_link (id, level_id, regimen_id) values (276, 3, 748);
insert into public.regimen_level_link (id, level_id, regimen_id) values (277, 6, 748);
insert into public.regimen_level_link (id, level_id, regimen_id) values (278, 1, 750);
insert into public.regimen_level_link (id, level_id, regimen_id) values (279, 3, 751);
insert into public.regimen_level_link (id, level_id, regimen_id) values (280, 6, 751);
insert into public.regimen_level_link (id, level_id, regimen_id) values (281, 3, 752);
insert into public.regimen_level_link (id, level_id, regimen_id) values (282, 6, 752);
insert into public.regimen_level_link (id, level_id, regimen_id) values (283, 3, 755);
insert into public.regimen_level_link (id, level_id, regimen_id) values (284, 6, 755);
insert into public.regimen_level_link (id, level_id, regimen_id) values (285, 3, 756);
insert into public.regimen_level_link (id, level_id, regimen_id) values (286, 6, 756);
insert into public.regimen_level_link (id, level_id, regimen_id) values (287, 6, 757);
insert into public.regimen_level_link (id, level_id, regimen_id) values (288, 3, 757);
insert into public.regimen_level_link (id, level_id, regimen_id) values (289, 3, 758);
insert into public.regimen_level_link (id, level_id, regimen_id) values (290, 6, 758);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1043, 1, 841);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1044, 1, 842);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1299, 17, 795);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1300, 1, 2);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1045, 3, 843);
insert into public.regimen_level_link (id, level_id, regimen_id) values (296, 3, 760);
insert into public.regimen_level_link (id, level_id, regimen_id) values (297, 6, 760);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1301, 17, 794);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1047, 1, 845);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1302, 17, 796);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1351, 23, 981);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1048, 3, 846);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1352, 27, 982);
insert into public.regimen_level_link (id, level_id, regimen_id) values (305, 3, 13);
insert into public.regimen_level_link (id, level_id, regimen_id) values (916, 17, 204);
insert into public.regimen_level_link (id, level_id, regimen_id) values (917, 17, 768);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1053, 1, 298);
insert into public.regimen_level_link (id, level_id, regimen_id) values (918, 15, 206);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1054, 1, 308);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1353, 27, 983);
insert into public.regimen_level_link (id, level_id, regimen_id) values (919, 8, 205);
insert into public.regimen_level_link (id, level_id, regimen_id) values (920, 17, 205);
insert into public.regimen_level_link (id, level_id, regimen_id) values (921, 17, 209);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1055, 23, 330);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1056, 23, 331);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1058, 26, 329);
insert into public.regimen_level_link (id, level_id, regimen_id) values (938, 3, 214);
insert into public.regimen_level_link (id, level_id, regimen_id) values (939, 3, 215);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1066, 15, 225);
insert into public.regimen_level_link (id, level_id, regimen_id) values (944, 8, 218);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1067, 15, 319);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1068, 17, 320);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1069, 3, 320);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1070, 17, 304);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1354, 23, 822);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1358, 26, 988);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1073, 2, 848);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1074, 18, 849);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1359, 31, 988);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1361, 17, 221);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1078, 1, 852);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1079, 17, 853);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1362, 26, 993);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1363, 31, 993);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1369, 17, 223);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1370, 17, 995);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1371, 17, 996);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1372, 17, 997);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1377, 26, 1000);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1378, 31, 1001);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1080, 3, 853);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1081, 1, 854);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1083, 18, 312);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1086, 1, 314);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1379, 26, 1002);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1092, 17, 856);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1094, 6, 858);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1095, 3, 858);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1380, 26, 1003);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1096, 17, 859);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1381, 31, 1003);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1382, 26, 1004);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1097, 6, 860);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1098, 3, 860);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1383, 31, 1004);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1102, 8, 864);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1389, 26, 1007);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1390, 26, 1008);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1391, 31, 1008);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1105, 17, 789);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1106, 15, 866);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1394, 26, 1009);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1395, 31, 1009);
insert into public.regimen_level_link (id, level_id, regimen_id) values (385, 3, 441);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1464, 3, 535);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1465, 6, 531);
insert into public.regimen_level_link (id, level_id, regimen_id) values (388, 3, 446);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1466, 19, 536);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1290, 17, 976);
insert into public.regimen_level_link (id, level_id, regimen_id) values (400, 3, 450);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1467, 18, 536);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1468, 18, 170);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1469, 19, 170);
insert into public.regimen_level_link (id, level_id, regimen_id) values (404, 3, 453);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1473, 3, 608);
insert into public.regimen_level_link (id, level_id, regimen_id) values (406, 1, 131);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1474, 1, 593);
insert into public.regimen_level_link (id, level_id, regimen_id) values (409, 3, 445);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1482, 3, 654);
insert into public.regimen_level_link (id, level_id, regimen_id) values (411, 3, 443);
insert into public.regimen_level_link (id, level_id, regimen_id) values (412, 3, 442);
insert into public.regimen_level_link (id, level_id, regimen_id) values (818, 8, 270);
insert into public.regimen_level_link (id, level_id, regimen_id) values (519, 3, 609);
insert into public.regimen_level_link (id, level_id, regimen_id) values (583, 2, 649);
insert into public.regimen_level_link (id, level_id, regimen_id) values (520, 3, 619);
insert into public.regimen_level_link (id, level_id, regimen_id) values (521, 3, 738);
insert into public.regimen_level_link (id, level_id, regimen_id) values (523, 3, 621);
insert into public.regimen_level_link (id, level_id, regimen_id) values (524, 3, 614);
insert into public.regimen_level_link (id, level_id, regimen_id) values (584, 3, 663);
insert into public.regimen_level_link (id, level_id, regimen_id) values (585, 3, 658);
insert into public.regimen_level_link (id, level_id, regimen_id) values (529, 1, 594);
insert into public.regimen_level_link (id, level_id, regimen_id) values (530, 7, 726);
insert into public.regimen_level_link (id, level_id, regimen_id) values (531, 3, 628);
insert into public.regimen_level_link (id, level_id, regimen_id) values (532, 3, 623);
insert into public.regimen_level_link (id, level_id, regimen_id) values (586, 3, 660);
insert into public.regimen_level_link (id, level_id, regimen_id) values (533, 3, 627);
insert into public.regimen_level_link (id, level_id, regimen_id) values (534, 3, 631);
insert into public.regimen_level_link (id, level_id, regimen_id) values (535, 3, 630);
insert into public.regimen_level_link (id, level_id, regimen_id) values (536, 3, 617);
insert into public.regimen_level_link (id, level_id, regimen_id) values (537, 3, 624);
insert into public.regimen_level_link (id, level_id, regimen_id) values (587, 3, 659);
insert into public.regimen_level_link (id, level_id, regimen_id) values (539, 3, 626);
insert into public.regimen_level_link (id, level_id, regimen_id) values (668, 3, 708);
insert into public.regimen_level_link (id, level_id, regimen_id) values (547, 3, 599);
insert into public.regimen_level_link (id, level_id, regimen_id) values (548, 3, 600);
insert into public.regimen_level_link (id, level_id, regimen_id) values (549, 3, 598);
insert into public.regimen_level_link (id, level_id, regimen_id) values (550, 3, 622);
insert into public.regimen_level_link (id, level_id, regimen_id) values (551, 3, 618);
insert into public.regimen_level_link (id, level_id, regimen_id) values (984, 8, 784);
insert into public.regimen_level_link (id, level_id, regimen_id) values (588, 3, 661);
insert into public.regimen_level_link (id, level_id, regimen_id) values (589, 2, 653);
insert into public.regimen_level_link (id, level_id, regimen_id) values (590, 3, 655);
insert into public.regimen_level_link (id, level_id, regimen_id) values (591, 2, 648);
insert into public.regimen_level_link (id, level_id, regimen_id) values (594, 2, 646);
insert into public.regimen_level_link (id, level_id, regimen_id) values (595, 3, 656);
insert into public.regimen_level_link (id, level_id, regimen_id) values (669, 3, 710);
insert into public.regimen_level_link (id, level_id, regimen_id) values (670, 3, 709);
insert into public.regimen_level_link (id, level_id, regimen_id) values (604, 3, 669);
insert into public.regimen_level_link (id, level_id, regimen_id) values (671, 6, 704);
insert into public.regimen_level_link (id, level_id, regimen_id) values (672, 3, 713);
insert into public.regimen_level_link (id, level_id, regimen_id) values (605, 3, 688);
insert into public.regimen_level_link (id, level_id, regimen_id) values (606, 3, 679);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1483, 2, 650);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1484, 2, 651);
insert into public.regimen_level_link (id, level_id, regimen_id) values (639, 3, 725);
insert into public.regimen_level_link (id, level_id, regimen_id) values (673, 3, 712);
insert into public.regimen_level_link (id, level_id, regimen_id) values (640, 3, 717);
insert into public.regimen_level_link (id, level_id, regimen_id) values (985, 18, 784);
insert into public.regimen_level_link (id, level_id, regimen_id) values (641, 3, 645);
insert into public.regimen_level_link (id, level_id, regimen_id) values (674, 3, 714);
insert into public.regimen_level_link (id, level_id, regimen_id) values (675, 6, 703);
insert into public.regimen_level_link (id, level_id, regimen_id) values (676, 3, 805);
insert into public.regimen_level_link (id, level_id, regimen_id) values (677, 3, 530);
insert into public.regimen_level_link (id, level_id, regimen_id) values (678, 3, 529);
insert into public.regimen_level_link (id, level_id, regimen_id) values (821, 19, 265);
insert into public.regimen_level_link (id, level_id, regimen_id) values (986, 8, 785);
insert into public.regimen_level_link (id, level_id, regimen_id) values (680, 1, 172);
insert into public.regimen_level_link (id, level_id, regimen_id) values (687, 6, 169);
insert into public.regimen_level_link (id, level_id, regimen_id) values (688, 18, 534);
insert into public.regimen_level_link (id, level_id, regimen_id) values (693, 6, 523);
insert into public.regimen_level_link (id, level_id, regimen_id) values (694, 19, 525);
insert into public.regimen_level_link (id, level_id, regimen_id) values (695, 18, 525);
insert into public.regimen_level_link (id, level_id, regimen_id) values (757, 18, 574);
insert into public.regimen_level_link (id, level_id, regimen_id) values (758, 19, 574);
insert into public.regimen_level_link (id, level_id, regimen_id) values (759, 18, 584);
insert into public.regimen_level_link (id, level_id, regimen_id) values (760, 17, 582);
insert into public.regimen_level_link (id, level_id, regimen_id) values (761, 17, 573);
insert into public.regimen_level_link (id, level_id, regimen_id) values (762, 17, 569);
insert into public.regimen_level_link (id, level_id, regimen_id) values (768, 18, 579);
insert into public.regimen_level_link (id, level_id, regimen_id) values (769, 18, 570);
insert into public.regimen_level_link (id, level_id, regimen_id) values (772, 3, 575);
insert into public.regimen_level_link (id, level_id, regimen_id) values (773, 18, 578);
insert into public.regimen_level_link (id, level_id, regimen_id) values (829, 8, 812);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1015, 17, 111);
insert into public.regimen_level_link (id, level_id, regimen_id) values (831, 17, 271);
insert into public.regimen_level_link (id, level_id, regimen_id) values (786, 3, 777);
insert into public.regimen_level_link (id, level_id, regimen_id) values (787, 3, 776);
insert into public.regimen_level_link (id, level_id, regimen_id) values (788, 18, 776);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1016, 17, 110);
insert into public.regimen_level_link (id, level_id, regimen_id) values (832, 8, 813);
insert into public.regimen_level_link (id, level_id, regimen_id) values (834, 8, 761);
insert into public.regimen_level_link (id, level_id, regimen_id) values (835, 22, 761);
insert into public.regimen_level_link (id, level_id, regimen_id) values (837, 18, 275);
insert into public.regimen_level_link (id, level_id, regimen_id) values (838, 26, 815);
insert into public.regimen_level_link (id, level_id, regimen_id) values (839, 8, 276);
insert into public.regimen_level_link (id, level_id, regimen_id) values (840, 22, 276);
insert into public.regimen_level_link (id, level_id, regimen_id) values (841, 22, 763);
insert into public.regimen_level_link (id, level_id, regimen_id) values (842, 22, 762);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1296, 17, 798);
insert into public.regimen_level_link (id, level_id, regimen_id) values (843, 22, 816);
insert into public.regimen_level_link (id, level_id, regimen_id) values (854, 11, 285);
insert into public.regimen_level_link (id, level_id, regimen_id) values (856, 23, 821);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1489, 3, 773);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1017, 3, 381);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1490, 3, 7);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1491, 17, 8);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1492, 3, 774);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1019, 3, 391);
insert into public.regimen_level_link (id, level_id, regimen_id) values (878, 15, 249);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1020, 3, 392);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1495, 15, 772);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1021, 2, 378);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1496, 16, 772);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1506, 17, 1036);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1507, 3, 1037);
insert into public.regimen_level_link (id, level_id, regimen_id) values (890, 18, 239);
insert into public.regimen_level_link (id, level_id, regimen_id) values (893, 8, 228);
insert into public.regimen_level_link (id, level_id, regimen_id) values (894, 17, 228);
insert into public.regimen_level_link (id, level_id, regimen_id) values (902, 26, 291);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1024, 3, 390);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1297, 1, 793);
insert into public.regimen_level_link (id, level_id, regimen_id) values (903, 23, 281);
insert into public.regimen_level_link (id, level_id, regimen_id) values (904, 23, 282);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1508, 3, 1038);
insert into public.regimen_level_link (id, level_id, regimen_id) values (906, 23, 283);
insert into public.regimen_level_link (id, level_id, regimen_id) values (948, 3, 458);
insert into public.regimen_level_link (id, level_id, regimen_id) values (949, 8, 458);
insert into public.regimen_level_link (id, level_id, regimen_id) values (950, 3, 457);
insert into public.regimen_level_link (id, level_id, regimen_id) values (951, 3, 460);
insert into public.regimen_level_link (id, level_id, regimen_id) values (952, 6, 460);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1032, 3, 386);
insert into public.regimen_level_link (id, level_id, regimen_id) values (955, 3, 462);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1509, 6, 1039);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1051, 1, 297);
insert into public.regimen_level_link (id, level_id, regimen_id) values (960, 3, 463);
insert into public.regimen_level_link (id, level_id, regimen_id) values (961, 17, 463);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1298, 1, 670);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1303, 17, 797);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1304, 3, 837);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1063, 23, 332);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1064, 23, 333);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1065, 17, 318);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1089, 15, 313);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1091, 17, 855);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1093, 17, 857);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1305, 3, 137);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1101, 8, 863);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1107, 17, 867);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1108, 3, 867);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1109, 17, 868);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1110, 3, 869);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1111, 17, 870);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1406, 3, 833);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1408, 3, 1020);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1409, 3, 1019);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1410, 3, 1018);
insert into public.regimen_level_link (id, level_id, regimen_id) values (389, 3, 447);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1470, 19, 541);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1471, 18, 541);
insert into public.regimen_level_link (id, level_id, regimen_id) values (391, 3, 791);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1472, 3, 633);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1475, 7, 743);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1476, 2, 1031);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1477, 2, 1032);
insert into public.regimen_level_link (id, level_id, regimen_id) values (396, 3, 448);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1478, 2, 1033);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1479, 2, 1034);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1480, 3, 550);
insert into public.regimen_level_link (id, level_id, regimen_id) values (822, 26, 266);
insert into public.regimen_level_link (id, level_id, regimen_id) values (416, 3, 499);
insert into public.regimen_level_link (id, level_id, regimen_id) values (417, 3, 497);
insert into public.regimen_level_link (id, level_id, regimen_id) values (418, 3, 500);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1481, 17, 548);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1306, 1, 400);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1485, 3, 665);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1486, 1, 693);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1488, 3, 79);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1493, 3, 9);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1494, 8, 9);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1497, 17, 11);
insert into public.regimen_level_link (id, level_id, regimen_id) values (429, 3, 493);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1498, 17, 778);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1499, 3, 775);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1500, 18, 775);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1501, 3, 771);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1502, 3, 770);
insert into public.regimen_level_link (id, level_id, regimen_id) values (435, 3, 494);
insert into public.regimen_level_link (id, level_id, regimen_id) values (436, 1, 424);
insert into public.regimen_level_link (id, level_id, regimen_id) values (437, 3, 495);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1503, 3, 779);
insert into public.regimen_level_link (id, level_id, regimen_id) values (439, 3, 134);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1504, 3, 780);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1505, 3, 1035);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1553, 3, 475);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1307, 1, 114);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1554, 17, 476);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1313, 1, 402);
insert into public.regimen_level_link (id, level_id, regimen_id) values (592, 2, 652);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1555, 17, 474);
insert into public.regimen_level_link (id, level_id, regimen_id) values (448, 3, 489);
insert into public.regimen_level_link (id, level_id, regimen_id) values (449, 3, 491);
insert into public.regimen_level_link (id, level_id, regimen_id) values (450, 3, 135);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1314, 1, 116);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1556, 3, 471);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1557, 3, 478);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1558, 3, 479);
insert into public.regimen_level_link (id, level_id, regimen_id) values (593, 3, 662);
insert into public.regimen_level_link (id, level_id, regimen_id) values (455, 1, 151);
insert into public.regimen_level_link (id, level_id, regimen_id) values (456, 1, 150);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1563, 3, 473);
insert into public.regimen_level_link (id, level_id, regimen_id) values (457, 3, 488);
insert into public.regimen_level_link (id, level_id, regimen_id) values (990, 3, 472);
insert into public.regimen_level_link (id, level_id, regimen_id) values (503, 3, 803);
insert into public.regimen_level_link (id, level_id, regimen_id) values (509, 3, 613);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1564, 3, 1067);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1315, 3, 438);
insert into public.regimen_level_link (id, level_id, regimen_id) values (460, 1, 436);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1316, 1, 120);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1317, 3, 121);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1565, 3, 1068);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1566, 1, 1069);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1569, 3, 461);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1318, 1, 407);
insert into public.regimen_level_link (id, level_id, regimen_id) values (510, 1, 590);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1319, 3, 439);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1576, 3, 455);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1578, 3, 1070);
insert into public.regimen_level_link (id, level_id, regimen_id) values (473, 1, 435);
insert into public.regimen_level_link (id, level_id, regimen_id) values (511, 1, 591);
insert into public.regimen_level_link (id, level_id, regimen_id) values (512, 2, 745);
insert into public.regimen_level_link (id, level_id, regimen_id) values (515, 1, 597);
insert into public.regimen_level_link (id, level_id, regimen_id) values (516, 7, 735);
insert into public.regimen_level_link (id, level_id, regimen_id) values (517, 3, 610);
insert into public.regimen_level_link (id, level_id, regimen_id) values (518, 3, 611);
insert into public.regimen_level_link (id, level_id, regimen_id) values (525, 3, 620);
insert into public.regimen_level_link (id, level_id, regimen_id) values (597, 3, 664);
insert into public.regimen_level_link (id, level_id, regimen_id) values (527, 7, 737);
insert into public.regimen_level_link (id, level_id, regimen_id) values (528, 7, 736);
insert into public.regimen_level_link (id, level_id, regimen_id) values (540, 3, 625);
insert into public.regimen_level_link (id, level_id, regimen_id) values (541, 3, 605);
insert into public.regimen_level_link (id, level_id, regimen_id) values (542, 3, 606);
insert into public.regimen_level_link (id, level_id, regimen_id) values (543, 3, 607);
insert into public.regimen_level_link (id, level_id, regimen_id) values (598, 3, 686);
insert into public.regimen_level_link (id, level_id, regimen_id) values (599, 3, 687);
insert into public.regimen_level_link (id, level_id, regimen_id) values (600, 1, 667);
insert into public.regimen_level_link (id, level_id, regimen_id) values (554, 7, 744);
insert into public.regimen_level_link (id, level_id, regimen_id) values (555, 3, 634);
insert into public.regimen_level_link (id, level_id, regimen_id) values (556, 3, 601);
insert into public.regimen_level_link (id, level_id, regimen_id) values (557, 1, 592);
insert into public.regimen_level_link (id, level_id, regimen_id) values (558, 3, 602);
insert into public.regimen_level_link (id, level_id, regimen_id) values (559, 3, 603);
insert into public.regimen_level_link (id, level_id, regimen_id) values (560, 3, 604);
insert into public.regimen_level_link (id, level_id, regimen_id) values (562, 1, 595);
insert into public.regimen_level_link (id, level_id, regimen_id) values (563, 1, 804);
insert into public.regimen_level_link (id, level_id, regimen_id) values (564, 3, 612);
insert into public.regimen_level_link (id, level_id, regimen_id) values (565, 7, 739);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1320, 1, 122);
insert into public.regimen_level_link (id, level_id, regimen_id) values (567, 7, 741);
insert into public.regimen_level_link (id, level_id, regimen_id) values (601, 3, 680);
insert into public.regimen_level_link (id, level_id, regimen_id) values (685, 3, 533);
insert into public.regimen_level_link (id, level_id, regimen_id) values (602, 1, 668);
insert into public.regimen_level_link (id, level_id, regimen_id) values (603, 3, 674);
insert into public.regimen_level_link (id, level_id, regimen_id) values (689, 3, 527);
insert into public.regimen_level_link (id, level_id, regimen_id) values (690, 18, 527);
insert into public.regimen_level_link (id, level_id, regimen_id) values (823, 8, 272);
insert into public.regimen_level_link (id, level_id, regimen_id) values (824, 17, 272);
insert into public.regimen_level_link (id, level_id, regimen_id) values (844, 22, 817);
insert into public.regimen_level_link (id, level_id, regimen_id) values (845, 22, 818);
insert into public.regimen_level_link (id, level_id, regimen_id) values (846, 17, 819);
insert into public.regimen_level_link (id, level_id, regimen_id) values (847, 8, 764);
insert into public.regimen_level_link (id, level_id, regimen_id) values (778, 3, 477);
insert into public.regimen_level_link (id, level_id, regimen_id) values (848, 8, 765);
insert into public.regimen_level_link (id, level_id, regimen_id) values (782, 15, 10);
insert into public.regimen_level_link (id, level_id, regimen_id) values (850, 17, 278);
insert into public.regimen_level_link (id, level_id, regimen_id) values (851, 26, 820);
insert into public.regimen_level_link (id, level_id, regimen_id) values (852, 8, 766);
insert into public.regimen_level_link (id, level_id, regimen_id) values (853, 8, 767);
insert into public.regimen_level_link (id, level_id, regimen_id) values (855, 23, 671);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1581, 1, 1073);
insert into public.regimen_level_link (id, level_id, regimen_id) values (908, 29, 284);
insert into public.regimen_level_link (id, level_id, regimen_id) values (909, 26, 825);
insert into public.regimen_level_link (id, level_id, regimen_id) values (912, 30, 288);
insert into public.regimen_level_link (id, level_id, regimen_id) values (922, 17, 207);
insert into public.regimen_level_link (id, level_id, regimen_id) values (923, 2, 208);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1583, 3, 466);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1589, 17, 1077);
insert into public.regimen_level_link (id, level_id, regimen_id) values (927, 3, 826);
insert into public.regimen_level_link (id, level_id, regimen_id) values (928, 6, 826);
insert into public.regimen_level_link (id, level_id, regimen_id) values (929, 6, 827);
insert into public.regimen_level_link (id, level_id, regimen_id) values (930, 6, 828);
insert into public.regimen_level_link (id, level_id, regimen_id) values (933, 1, 830);
insert into public.regimen_level_link (id, level_id, regimen_id) values (935, 1, 832);
insert into public.regimen_level_link (id, level_id, regimen_id) values (998, 3, 483);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1595, 3, 1085);
insert into public.regimen_level_link (id, level_id, regimen_id) values (937, 3, 834);
insert into public.regimen_level_link (id, level_id, regimen_id) values (945, 18, 219);
insert into public.regimen_level_link (id, level_id, regimen_id) values (946, 19, 219);
insert into public.regimen_level_link (id, level_id, regimen_id) values (947, 17, 220);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1000, 8, 416);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1001, 3, 416);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1002, 8, 417);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1003, 3, 418);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1321, 3, 139);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1322, 3, 452);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1596, 3, 1086);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1323, 3, 451);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1324, 3, 440);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1325, 3, 140);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1333, 3, 409);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1597, 3, 1087);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1348, 23, 978);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1349, 23, 979);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1598, 3, 1088);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1599, 3, 1089);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1416, 3, 152);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1417, 3, 444);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1418, 3, 133);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1600, 3, 1090);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1429, 3, 129);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1430, 1, 425);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1431, 3, 496);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1605, 3, 1095);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1445, 1, 430);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1446, 3, 148);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1447, 17, 143);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1448, 1, 434);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1449, 3, 1021);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1455, 3, 1025);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1606, 3, 1096);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1456, 3, 1026);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1607, 3, 1097);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1608, 3, 1098);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1112, 17, 871);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1308, 1, 413);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1113, 17, 872);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1114, 17, 873);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1115, 17, 874);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1309, 1, 403);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1116, 17, 875);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1117, 3, 876);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1310, 1, 404);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1311, 1, 411);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1312, 1, 401);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1326, 1, 414);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1327, 1, 126);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1328, 1, 408);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1329, 3, 141);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1330, 1, 123);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1331, 1, 410);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1332, 1, 132);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1334, 3, 449);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1336, 23, 257);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1337, 23, 258);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1511, 20, 210);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1338, 8, 672);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1568, 3, 469);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1342, 23, 260);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1570, 3, 464);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1344, 26, 263);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1345, 27, 263);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1346, 26, 256);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1347, 23, 255);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1419, 1, 115);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1571, 17, 464);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1420, 1, 420);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1421, 1, 421);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1422, 1, 117);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1423, 1, 426);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1424, 3, 498);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1425, 3, 492);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1572, 3, 465);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1426, 1, 423);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1427, 3, 487);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1428, 3, 128);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1432, 1, 422);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1433, 3, 486);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1434, 2, 399);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1435, 3, 490);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1436, 3, 485);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1437, 3, 484);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1438, 3, 136);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1439, 1, 431);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1440, 17, 138);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1441, 1, 142);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1442, 17, 142);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1443, 3, 145);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1444, 17, 146);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1450, 3, 1022);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1451, 3, 1023);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1452, 3, 1024);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1453, 3, 216);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1454, 3, 217);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1574, 3, 467);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1577, 3, 456);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1579, 6, 1071);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1584, 1, 1074);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1585, 8, 1075);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1586, 1, 835);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1587, 3, 1076);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1588, 1, 1072);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1590, 3, 1078);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1591, 3, 1080);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1592, 3, 1082);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1593, 3, 1083);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1594, 3, 1084);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1601, 3, 1091);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1602, 3, 1092);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1603, 3, 1093);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1604, 3, 1094);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1609, 3, 1099);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1610, 3, 1100);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1611, 3, 1101);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1612, 1, 831);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1613, 3, 1102);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1614, 3, 1103);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1615, 3, 1104);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1616, 1, 1015);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1617, 1, 1013);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1618, 3, 1105);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1619, 3, 1106);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1620, 1, 1014);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1621, 3, 1107);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1622, 3, 1108);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1623, 3, 1109);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1624, 3, 1110);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1625, 3, 1111);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1626, 3, 1112);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1627, 3, 1113);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1628, 3, 1114);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1629, 3, 1115);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1630, 18, 829);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1631, 3, 829);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1632, 3, 1116);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1633, 3, 1117);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1634, 26, 294);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1635, 26, 295);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1636, 26, 293);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1637, 8, 289);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1638, 30, 290);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1639, 19, 571);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1640, 18, 571);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1641, 31, 581);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1642, 8, 562);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1643, 17, 562);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1644, 17, 577);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1645, 26, 566);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1646, 31, 566);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1647, 17, 583);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1648, 18, 583);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1649, 17, 1120);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1650, 30, 1121);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1651, 15, 287);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1652, 30, 1122);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1653, 26, 1123);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1654, 31, 1123);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1655, 26, 1124);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1656, 31, 1124);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1657, 31, 1125);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1658, 30, 1126);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1659, 26, 1127);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1660, 31, 1127);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1661, 17, 1128);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1662, 26, 1129);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1663, 26, 1130);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1664, 31, 1130);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1665, 26, 1131);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1666, 26, 1132);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1667, 31, 1132);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1668, 31, 1133);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1669, 26, 1134);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1670, 31, 1134);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1671, 26, 1135);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1672, 31, 1135);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1673, 26, 1136);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1674, 31, 1136);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1675, 31, 1137);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1676, 31, 1138);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1677, 27, 1139);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1678, 30, 1141);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1679, 1, 701);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1680, 3, 711);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1681, 1, 700);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1682, 1, 699);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1683, 1, 702);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1684, 17, 1142);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1685, 3, 107);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1686, 18, 107);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1687, 3, 861);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1688, 31, 862);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1689, 8, 865);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1690, 1, 844);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1691, 3, 1143);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1692, 3, 1144);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1693, 3, 1145);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1694, 3, 1146);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1695, 3, 1147);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1696, 3, 1148);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1697, 3, 1149);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1698, 3, 1150);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1699, 17, 1151);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1700, 3, 1152);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1701, 3, 1153);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1702, 3, 1154);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1703, 3, 1155);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1704, 3, 1156);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1705, 3, 1157);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1706, 3, 1158);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1707, 3, 1159);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1708, 17, 1160);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1709, 18, 1160);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1710, 23, 1161);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1711, 26, 1162);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1712, 31, 1162);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1713, 22, 1163);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1714, 3, 1164);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1715, 3, 1165);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1350, 31, 980);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1355, 27, 984);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1119, 8, 878);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1120, 3, 878);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1121, 17, 879);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1356, 27, 985);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1357, 27, 986);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1122, 3, 880);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1123, 17, 881);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1124, 2, 882);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1125, 3, 882);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1360, 26, 989);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1127, 3, 178);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1512, 17, 514);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1513, 17, 1040);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1128, 1, 883);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1129, 3, 884);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1367, 17, 994);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1130, 3, 885);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1131, 3, 886);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1132, 3, 887);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1373, 26, 998);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1374, 31, 998);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1133, 3, 888);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1375, 17, 222);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1376, 17, 999);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1384, 26, 1005);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1385, 31, 1005);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1134, 17, 889);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1386, 17, 877);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1387, 26, 1006);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1135, 17, 890);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1136, 22, 891);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1137, 3, 892);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1138, 22, 892);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1139, 22, 893);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1140, 22, 894);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1141, 17, 895);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1142, 3, 896);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1143, 22, 896);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1144, 3, 897);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1145, 22, 897);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1146, 3, 898);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1147, 3, 899);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1148, 17, 900);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1149, 31, 900);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1150, 31, 901);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1151, 22, 902);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1152, 17, 903);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1388, 31, 1006);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1153, 1, 904);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1154, 17, 905);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1155, 17, 906);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1392, 26, 963);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1156, 3, 907);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1393, 31, 963);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1157, 3, 908);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1158, 17, 839);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1159, 3, 838);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1396, 26, 1010);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1397, 31, 1010);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1398, 26, 1011);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1161, 22, 910);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1399, 31, 1011);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1163, 3, 909);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1164, 22, 911);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1165, 3, 912);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1166, 17, 913);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1400, 26, 1012);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1167, 3, 914);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1168, 22, 915);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1514, 17, 211);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1515, 17, 1041);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1516, 15, 809);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1517, 23, 810);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1173, 26, 230);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1174, 31, 230);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1175, 17, 302);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1176, 27, 335);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1401, 31, 1012);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1518, 27, 810);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1182, 3, 437);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1519, 22, 759);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1184, 1, 432);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1520, 18, 695);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1186, 1, 433);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1187, 31, 234);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1188, 26, 229);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1189, 31, 229);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1190, 26, 233);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1191, 31, 233);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1192, 1, 242);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1194, 8, 916);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1195, 17, 916);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1196, 15, 917);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1197, 18, 919);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1198, 31, 919);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1199, 18, 920);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1200, 18, 921);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1201, 26, 922);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1202, 18, 923);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1203, 31, 923);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1204, 26, 924);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1205, 31, 924);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1206, 26, 925);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1207, 31, 925);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1208, 26, 926);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1209, 26, 927);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1407, 3, 1016);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1210, 26, 928);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1211, 31, 928);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1212, 26, 929);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1213, 31, 929);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1214, 26, 930);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1215, 31, 931);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1216, 15, 932);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1217, 26, 936);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1218, 31, 936);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1219, 26, 232);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1220, 31, 232);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1221, 17, 939);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1222, 26, 940);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1223, 31, 940);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1224, 26, 941);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1225, 31, 941);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1411, 17, 144);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1412, 3, 125);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1226, 26, 942);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1227, 31, 942);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1228, 26, 943);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1229, 31, 943);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1230, 26, 944);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1231, 31, 944);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1232, 26, 945);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1233, 31, 945);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1234, 26, 946);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1235, 31, 946);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1236, 26, 947);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1237, 31, 947);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1238, 31, 951);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1239, 17, 951);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1240, 26, 953);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1241, 26, 954);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1242, 31, 954);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1243, 31, 956);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1244, 26, 956);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1245, 31, 957);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1246, 26, 959);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1247, 31, 959);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1248, 26, 960);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1249, 31, 960);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1250, 26, 961);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1251, 31, 961);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1252, 26, 962);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1253, 31, 962);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1524, 23, 1042);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1526, 18, 814);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1256, 30, 965);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1257, 18, 967);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1258, 18, 968);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1413, 3, 127);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1259, 17, 788);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1260, 3, 639);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1414, 1, 147);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1261, 17, 637);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1262, 15, 636);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1263, 15, 635);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1264, 15, 394);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1265, 15, 638);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1266, 3, 790);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1415, 1, 130);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1527, 8, 267);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1530, 8, 268);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1535, 8, 1046);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1537, 26, 1054);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1538, 31, 1054);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1539, 17, 1055);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1541, 3, 419);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1542, 17, 1056);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1546, 17, 1060);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1716, 3, 1166);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1717, 26, 1167);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1718, 31, 1167);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1719, 26, 1168);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1720, 31, 1168);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1721, 26, 1169);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1722, 31, 1169);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1723, 3, 1170);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1724, 3, 1171);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1725, 3, 1172);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1726, 1, 1173);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1728, 1, 300);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1729, 18, 301);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1730, 1, 299);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1733, 23, 324);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1734, 23, 325);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1736, 27, 327);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1737, 23, 1175);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1738, 23, 1176);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1739, 27, 1177);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1740, 23, 334);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1742, 17, 1178);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1744, 17, 303);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1746, 2, 310);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1747, 30, 311);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1749, 18, 1181);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1750, 18, 315);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1751, 1, 316);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1752, 1, 850);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1753, 1, 847);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1754, 23, 322);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1755, 23, 323);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1756, 26, 326);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1757, 27, 1182);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1758, 27, 336);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1759, 23, 1183);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1760, 27, 1184);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1761, 23, 1185);
insert into public.regimen_level_link (id, level_id, regimen_id) values (1762, 1, 1174);




insert into public.drug_regimen_link (id, drug_id, regimen_id) values (0, 97, 502);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1, 83, 347);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2, 8, 503);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (7, 62, 3);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1407, 31, 533);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1408, 160, 533);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (10, 62, 6);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1415, 19, 527);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (25, 31, 14);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (26, 88, 14);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (27, 31, 15);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (28, 31, 16);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (29, 19, 16);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (30, 40, 17);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (31, 63, 17);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (32, 31, 18);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (33, 52, 18);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (34, 52, 19);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (35, 63, 19);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (36, 40, 20);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (37, 31, 20);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (38, 52, 20);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (39, 40, 21);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (40, 52, 21);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (41, 63, 21);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (42, 19, 22);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (43, 68, 31);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (44, 63, 31);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (45, 107, 348);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (46, 31, 23);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (47, 56, 23);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (48, 88, 23);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (49, 31, 24);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (50, 56, 24);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (51, 31, 25);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (52, 52, 25);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (53, 69, 26);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (54, 88, 26);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (55, 88, 27);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (56, 40, 28);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (57, 31, 28);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (58, 88, 28);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (59, 6, 28);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (60, 63, 32);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (61, 123, 33);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (62, 72, 33);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (63, 110, 34);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (64, 45, 35);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (65, 31, 36);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (66, 40, 37);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (67, 123, 38);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (68, 31, 39);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (69, 68, 39);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (70, 40, 40);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (71, 68, 40);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (72, 68, 41);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (73, 63, 41);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (74, 31, 42);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (75, 40, 43);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (76, 31, 43);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (77, 23, 349);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (78, 116, 349);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (79, 40, 44);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (80, 63, 44);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (81, 40, 45);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (82, 56, 46);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (83, 68, 47);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2262, 127, 399);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (85, 88, 48);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (86, 63, 48);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (87, 40, 49);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (88, 68, 49);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (89, 72, 50);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (90, 68, 50);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (91, 68, 51);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (92, 63, 51);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (93, 68, 52);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (94, 115, 53);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (95, 88, 55);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (96, 123, 56);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (97, 88, 56);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (98, 88, 57);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (99, 63, 57);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (100, 88, 58);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (101, 63, 67);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (102, 117, 350);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (103, 123, 59);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (104, 88, 59);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (105, 115, 60);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (106, 88, 60);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (107, 88, 61);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (108, 63, 61);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (109, 123, 62);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (110, 88, 62);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (111, 63, 62);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (112, 88, 63);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (113, 63, 63);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (114, 123, 68);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (115, 63, 68);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (116, 40, 69);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (117, 115, 70);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (118, 88, 71);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1416, 31, 527);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (120, 103, 77);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (121, 15, 78);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1417, 123, 527);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (123, 135, 80);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (124, 19, 80);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (126, 31, 81);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (127, 55, 81);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (128, 115, 82);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (129, 31, 82);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (130, 148, 82);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (131, 31, 83);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (132, 56, 83);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2263, 56, 399);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (134, 31, 84);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (135, 68, 84);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (136, 56, 85);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (137, 68, 85);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (138, 68, 86);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (139, 19, 86);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (140, 72, 93);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (141, 68, 87);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (142, 148, 87);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (143, 31, 88);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (144, 19, 88);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (145, 123, 89);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (146, 135, 89);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (147, 19, 89);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (148, 56, 189);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (149, 71, 189);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (150, 31, 90);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (151, 148, 90);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (152, 136, 91);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (153, 56, 92);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (154, 18, 351);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (155, 124, 351);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (156, 68, 94);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (157, 55, 95);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (158, 148, 96);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (159, 135, 97);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (160, 31, 98);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (161, 143, 190);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (162, 12, 99);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (163, 45, 99);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (164, 155, 99);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (165, 135, 100);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (166, 19, 100);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (167, 135, 101);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (168, 69, 101);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (169, 128, 352);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (170, 31, 102);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (171, 69, 102);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (172, 69, 103);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (173, 19, 104);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (174, 105, 105);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (175, 105, 106);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1986, 171, 789);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1987, 172, 789);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1988, 66, 178);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2093, 45, 413);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2094, 56, 413);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2095, 12, 413);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (194, 12, 113);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (195, 45, 113);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2096, 45, 403);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2097, 56, 403);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2098, 12, 403);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2099, 45, 404);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2100, 56, 404);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2101, 12, 404);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2264, 135, 399);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2265, 6, 399);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2266, 40, 490);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2267, 6, 490);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2268, 56, 485);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2269, 6, 485);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1271, 134, 494);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1272, 17, 494);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1273, 127, 424);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1411, 31, 169);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1412, 88, 169);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1274, 56, 424);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (212, 54, 353);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (213, 33, 353);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (214, 59, 353);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1275, 6, 424);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1276, 3, 495);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1277, 17, 495);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1413, 31, 534);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1414, 68, 534);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1420, 31, 523);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2428, 31, 303);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1421, 31, 525);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1422, 105, 525);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1385, 112, 454);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1386, 77, 454);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2270, 19, 484);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2271, 6, 484);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (230, 99, 354);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (231, 12, 124);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (232, 88, 124);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1545, 31, 12);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1546, 56, 12);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2272, 19, 136);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2273, 135, 136);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1547, 31, 769);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1548, 56, 769);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2429, 45, 303);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2119, 19, 121);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1834, 135, 428);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1617, 41, 251);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1618, 71, 251);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1619, 59, 251);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1620, 45, 251);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1621, 12, 251);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1622, 36, 251);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1623, 155, 251);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2430, 12, 303);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2120, 123, 121);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1735, 71, 286);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1624, 45, 248);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1625, 12, 248);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1626, 155, 248);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1736, 122, 286);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1836, 31, 427);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2121, 45, 407);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2431, 69, 303);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1633, 71, 250);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1634, 12, 250);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1635, 69, 250);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1636, 155, 250);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (264, 135, 153);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (265, 56, 153);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (266, 135, 154);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (267, 19, 154);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (268, 135, 155);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (269, 31, 156);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (270, 19, 156);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (271, 20, 355);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (272, 135, 157);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (273, 68, 157);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (274, 31, 158);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (275, 19, 158);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (276, 10, 159);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (277, 123, 160);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (278, 68, 161);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (279, 143, 191);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (280, 111, 191);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (281, 19, 162);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (282, 105, 164);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (283, 138, 356);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (284, 90, 357);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (285, 31, 165);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (286, 45, 165);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (287, 31, 166);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (288, 45, 166);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (289, 19, 166);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (290, 45, 167);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (291, 56, 188);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (292, 125, 188);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1838, 31, 397);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1839, 135, 415);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1840, 31, 109);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2122, 12, 407);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (297, 164, 358);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (298, 31, 171);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (299, 105, 171);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1841, 45, 109);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1995, 28, 230);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1996, 31, 230);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (303, 135, 180);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (304, 68, 180);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (305, 31, 181);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (306, 68, 181);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (307, 31, 182);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (308, 45, 182);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (309, 65, 182);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (310, 161, 193);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (311, 111, 193);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (312, 94, 194);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (313, 46, 183);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (314, 31, 183);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (315, 69, 183);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (316, 31, 184);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (317, 69, 184);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (318, 31, 185);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (319, 1, 185);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (320, 9, 185);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (321, 19, 185);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (322, 31, 186);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (323, 69, 186);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (324, 9, 186);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (325, 65, 186);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (326, 120, 187);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (327, 71, 187);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (328, 162, 192);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (329, 71, 192);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (330, 36, 262);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (331, 132, 195);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (332, 111, 198);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (333, 126, 200);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (334, 71, 201);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (335, 133, 202);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1842, 12, 109);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1843, 155, 109);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1997, 36, 230);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1998, 69, 230);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1999, 31, 302);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1974, 45, 313);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1975, 12, 313);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1976, 155, 313);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2000, 45, 302);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2001, 12, 302);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2002, 69, 302);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (348, 93, 359);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (349, 50, 359);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2123, 88, 407);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1779, 19, 214);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2124, 45, 439);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2125, 12, 439);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (362, 27, 360);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (363, 37, 360);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1780, 135, 214);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (379, 108, 361);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1781, 56, 215);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1782, 135, 215);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1791, 56, 218);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1792, 68, 218);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1798, 135, 458);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1799, 135, 457);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1800, 135, 460);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1802, 135, 462);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2274, 6, 136);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2432, 31, 310);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2433, 45, 310);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1806, 135, 463);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2434, 1, 311);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2435, 9, 311);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2436, 69, 311);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2439, 12, 316);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2440, 14, 316);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1852, 19, 112);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1853, 135, 112);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2102, 19, 411);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (397, 106, 224);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (398, 116, 224);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2103, 45, 411);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1854, 31, 108);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1855, 69, 108);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1872, 16, 380);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2126, 88, 439);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2127, 45, 122);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2128, 12, 122);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2129, 88, 122);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1877, 53, 386);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2275, 26, 431);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2104, 12, 411);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2441, 155, 316);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2130, 40, 139);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2131, 56, 452);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2132, 135, 452);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2276, 26, 138);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1888, 31, 297);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1889, 12, 297);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1890, 69, 297);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1891, 155, 297);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2105, 19, 401);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2106, 45, 401);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2107, 12, 401);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2339, 148, 514);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2340, 28, 252);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2341, 59, 252);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2342, 45, 252);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2343, 12, 252);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2344, 9, 252);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2345, 36, 252);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2346, 155, 252);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2349, 116, 267);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2350, 80, 267);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2352, 61, 268);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2353, 116, 268);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2354, 12, 268);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2355, 31, 419);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2362, 31, 480);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2363, 31, 481);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2364, 68, 482);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2366, 135, 469);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2368, 135, 464);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2369, 31, 465);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2370, 68, 467);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2373, 85, 456);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2374, 135, 835);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2376, 39, 294);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2382, 71, 290);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2383, 79, 290);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2384, 122, 290);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2385, 10, 571);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2386, 40, 581);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2393, 71, 287);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2394, 122, 287);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2395, 31, 107);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2396, 45, 107);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2397, 12, 107);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2403, 2, 300);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2404, 71, 300);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2405, 155, 300);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2406, 135, 301);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2421, 159, 334);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2422, 36, 334);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2423, 69, 334);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1692, 80, 239);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1693, 59, 231);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (484, 106, 264);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (485, 116, 264);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1694, 12, 231);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1695, 36, 231);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1696, 155, 231);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1703, 71, 228);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1704, 116, 228);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1705, 155, 228);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1719, 79, 291);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (500, 113, 362);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (502, 47, 274);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1720, 59, 281);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (505, 151, 277);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1721, 45, 281);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (507, 79, 280);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (516, 25, 342);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1722, 79, 281);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (542, 31, 296);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (543, 69, 296);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (551, 113, 343);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (552, 117, 344);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (553, 152, 345);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1723, 154, 282);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1724, 79, 282);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1726, 59, 283);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1727, 79, 283);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1728, 12, 283);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1730, 154, 284);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1731, 59, 284);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1732, 31, 284);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1733, 45, 284);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1734, 69, 284);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2133, 19, 451);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2134, 135, 451);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2135, 118, 440);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2136, 12, 440);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2015, 131, 437);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2016, 8, 437);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2437, 12, 315);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2018, 17, 432);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2438, 105, 315);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2020, 30, 433);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2021, 17, 433);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2137, 52, 440);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2022, 106, 234);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2138, 56, 140);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2158, 118, 409);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (583, 31, 307);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (584, 45, 307);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2159, 12, 409);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2160, 52, 409);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2277, 8, 142);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (588, 69, 309);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (589, 1, 309);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (590, 9, 309);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (591, 102, 346);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2278, 17, 145);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2284, 19, 216);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2285, 135, 216);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2286, 68, 216);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2287, 31, 217);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2288, 68, 217);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2295, 56, 535);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2296, 135, 535);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2297, 31, 531);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2298, 88, 531);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2299, 31, 536);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2300, 55, 536);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2301, 19, 170);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2302, 31, 170);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2303, 19, 528);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2304, 105, 528);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2313, 135, 773);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2314, 88, 773);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2315, 115, 7);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2316, 135, 7);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (614, 46, 317);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (615, 156, 317);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (616, 45, 317);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (617, 65, 317);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2317, 88, 7);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2318, 31, 8);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2319, 88, 8);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2320, 31, 774);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2321, 115, 774);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2325, 31, 772);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2442, 71, 322);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2443, 36, 322);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2444, 155, 322);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2445, 163, 326);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2446, 36, 326);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2447, 31, 1174);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2448, 69, 1174);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2449, 31, 305);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2450, 45, 305);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2451, 12, 305);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (634, 59, 321);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (635, 71, 321);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (636, 155, 321);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2452, 69, 305);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (653, 20, 337);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (654, 56, 338);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (655, 91, 338);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (656, 89, 339);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (657, 11, 340);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (658, 78, 341);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (659, 68, 341);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (660, 31, 341);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (661, 48, 341);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (662, 75, 363);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (663, 13, 363);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (664, 59, 363);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (665, 145, 364);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (666, 141, 365);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (667, 141, 366);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (668, 19, 366);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (669, 153, 367);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (670, 42, 368);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (671, 112, 369);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (672, 68, 369);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (673, 29, 370);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (674, 17, 370);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (675, 131, 371);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (676, 8, 371);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (677, 127, 372);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (678, 6, 372);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (679, 56, 372);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (680, 139, 373);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (681, 147, 374);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (682, 84, 375);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (683, 5, 376);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (684, 82, 377);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1552, 19, 212);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (696, 7, 387);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1427, 31, 532);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (706, 12, 398);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (707, 56, 398);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (708, 45, 398);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1428, 148, 532);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1429, 56, 537);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1430, 68, 542);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1431, 19, 538);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1432, 19, 524);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1433, 31, 524);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1434, 19, 526);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1435, 123, 526);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1259, 131, 493);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1260, 8, 493);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1436, 105, 526);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1856, 68, 111);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1437, 85, 543);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1857, 105, 111);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1439, 105, 540);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1442, 31, 546);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1443, 45, 546);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (743, 12, 405);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (744, 56, 405);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (745, 12, 406);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (746, 56, 406);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (747, 45, 406);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1444, 31, 549);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1445, 45, 549);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1446, 12, 549);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1451, 31, 552);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1452, 1, 552);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1453, 45, 554);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1440, 45, 545);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1441, 12, 545);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2023, 150, 235);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1485, 31, 560);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1281, 56, 134);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1282, 135, 134);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (759, 12, 412);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (760, 45, 412);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (761, 19, 412);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1283, 6, 134);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2279, 30, 430);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2280, 30, 148);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2281, 96, 143);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2282, 30, 434);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2283, 8, 434);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1555, 56, 511);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (770, 30, 501);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2139, 45, 414);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2140, 56, 414);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1656, 79, 236);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1657, 45, 247);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1658, 12, 247);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1659, 69, 247);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1486, 12, 560);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1493, 68, 576);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (785, 26, 504);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (786, 17, 505);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1858, 31, 110);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1859, 1, 110);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (791, 96, 506);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2024, 1, 227);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (793, 81, 507);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1860, 9, 110);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1861, 69, 110);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (796, 6, 508);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (797, 58, 509);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1494, 135, 568);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1495, 68, 568);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1496, 31, 567);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1497, 68, 567);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1500, 74, 574);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1501, 70, 584);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2025, 12, 227);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1502, 44, 582);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1503, 19, 573);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1504, 19, 569);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1505, 31, 569);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1862, 100, 381);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2141, 12, 414);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1864, 137, 391);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2026, 9, 227);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2027, 36, 227);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (818, 40, 510);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1865, 137, 392);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1866, 38, 378);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2142, 12, 126);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2143, 52, 126);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1869, 76, 390);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (824, 158, 522);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2028, 69, 227);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2029, 155, 227);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1879, 110, 177);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2144, 86, 408);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2145, 118, 408);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2146, 12, 408);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2147, 52, 408);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2030, 59, 229);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2031, 31, 229);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1697, 24, 241);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2148, 49, 141);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2149, 12, 123);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1511, 55, 579);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1512, 55, 570);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1513, 135, 570);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1515, 105, 575);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1516, 148, 578);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2150, 52, 123);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2151, 88, 123);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2152, 118, 410);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2153, 56, 410);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1304, 6, 489);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1305, 68, 489);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1306, 130, 491);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1307, 6, 491);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1536, 56, 777);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1317, 6, 151);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1537, 50, 776);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1318, 6, 150);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2154, 12, 410);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2155, 52, 410);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2032, 36, 229);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2156, 56, 132);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1323, 21, 436);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1324, 26, 436);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1325, 111, 436);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2157, 12, 132);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2161, 118, 449);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2162, 12, 449);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2163, 52, 449);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2165, 162, 257);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2166, 92, 257);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2167, 36, 257);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2168, 36, 258);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2033, 71, 226);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2034, 45, 226);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1895, 31, 298);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1896, 12, 298);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1897, 155, 298);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1564, 173, 808);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2035, 116, 226);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2036, 12, 226);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2037, 155, 226);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2038, 1, 233);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2039, 116, 233);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2040, 135, 233);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2041, 9, 233);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2042, 69, 233);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2170, 36, 263);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2171, 162, 256);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2172, 92, 256);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2173, 36, 256);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2174, 69, 256);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2175, 92, 255);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2176, 156, 221);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2177, 65, 221);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2178, 45, 221);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2179, 46, 221);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1627, 1, 249);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1628, 12, 249);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1629, 9, 249);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1630, 36, 249);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1631, 69, 249);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1632, 155, 249);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1371, 88, 803);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1372, 115, 738);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1718, 98, 246);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1898, 45, 308);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1454, 19, 547);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1455, 45, 547);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1456, 56, 553);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1899, 14, 308);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1900, 155, 308);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1901, 36, 330);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1902, 36, 331);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1926, 34, 225);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1927, 45, 225);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1457, 68, 553);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1458, 81, 555);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1459, 19, 556);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1460, 19, 544);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (956, 19, 512);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (957, 114, 513);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1928, 12, 225);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (959, 45, 515);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (960, 68, 516);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (961, 35, 517);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (962, 49, 519);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (963, 112, 518);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (964, 140, 520);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1929, 155, 225);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1573, 64, 586);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1461, 135, 544);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1574, 119, 269);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1575, 116, 270);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1576, 106, 270);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1462, 19, 551);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1463, 1, 551);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1464, 43, 558);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1465, 105, 557);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1467, 31, 585);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1468, 46, 585);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1930, 71, 319);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1729, 59, 292);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1931, 45, 319);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1932, 12, 319);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1740, 13, 288);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1741, 59, 288);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1742, 79, 288);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1933, 155, 319);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1934, 45, 320);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1935, 12, 320);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1936, 36, 320);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1937, 155, 320);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1811, 68, 468);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1814, 68, 470);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1815, 146, 459);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1818, 72, 787);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1822, 85, 472);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2193, 65, 223);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2194, 71, 223);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1026, 44, 521);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1829, 68, 483);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2195, 45, 223);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1831, 135, 416);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2062, 73, 384);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2068, 67, 800);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2069, 32, 4);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1469, 69, 585);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1035, 72, 752);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1036, 71, 754);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1037, 116, 754);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1038, 155, 754);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1832, 135, 417);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2070, 123, 5);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1833, 135, 418);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2071, 123, 1);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2077, 2, 2);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2078, 57, 2);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2079, 155, 2);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2080, 2, 794);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2081, 57, 794);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2082, 155, 794);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2083, 123, 796);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2084, 67, 796);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1051, 115, 13);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2196, 46, 223);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2197, 69, 223);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2198, 155, 223);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2220, 19, 115);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2221, 45, 115);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2222, 12, 115);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2223, 6, 115);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2224, 19, 420);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2225, 45, 420);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2226, 12, 420);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2227, 6, 420);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2228, 19, 421);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2229, 45, 421);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2230, 12, 421);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2231, 6, 421);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2232, 45, 117);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2233, 56, 117);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2234, 12, 117);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2235, 6, 117);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2236, 58, 426);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2237, 101, 498);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2238, 96, 498);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2239, 40, 492);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2240, 130, 492);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2241, 118, 423);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2242, 56, 423);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2243, 12, 423);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2244, 6, 423);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2245, 52, 423);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2246, 135, 487);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2247, 6, 487);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2248, 68, 487);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2249, 40, 128);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1308, 19, 135);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1309, 6, 135);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1319, 6, 488);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2250, 130, 128);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2256, 56, 422);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2257, 135, 422);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2258, 6, 422);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2259, 56, 486);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2260, 135, 486);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2261, 6, 486);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1320, 148, 488);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1470, 123, 580);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1472, 56, 564);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1126, 45, 118);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1127, 56, 118);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1473, 135, 564);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1474, 35, 565);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1475, 135, 565);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1478, 19, 563);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1479, 123, 563);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1480, 135, 563);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1487, 12, 559);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1488, 135, 559);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1489, 19, 561);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1490, 31, 561);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1491, 35, 572);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1532, 31, 10);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2305, 55, 541);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2306, 35, 550);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2307, 135, 550);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2308, 19, 548);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1160, 35, 447);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1161, 56, 447);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1336, 21, 435);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2309, 31, 548);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2310, 45, 548);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1164, 52, 791);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1165, 12, 791);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2311, 80, 548);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2312, 66, 79);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2322, 31, 9);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1337, 30, 435);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1338, 111, 435);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2199, 71, 222);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2200, 57, 222);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1580, 12, 265);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1581, 80, 265);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1341, 101, 792);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1342, 96, 792);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2201, 45, 222);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2202, 46, 222);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2203, 12, 222);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2204, 69, 222);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2205, 155, 222);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2206, 68, 144);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2207, 19, 125);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2208, 68, 125);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2209, 40, 127);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2210, 74, 127);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2211, 19, 147);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2212, 19, 130);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1367, 57, 799);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2213, 45, 130);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2214, 12, 130);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2215, 148, 152);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2216, 40, 444);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1750, 156, 204);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1751, 45, 204);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1592, 71, 812);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1593, 80, 812);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1596, 124, 271);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1597, 71, 813);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1598, 124, 813);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1599, 147, 761);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1600, 103, 275);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1601, 103, 815);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1602, 15, 276);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1603, 166, 763);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1604, 165, 762);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1610, 13, 285);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2323, 115, 9);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1752, 45, 768);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2324, 88, 9);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2326, 19, 11);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2327, 31, 11);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1753, 1, 768);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2043, 116, 242);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2044, 71, 232);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2045, 45, 232);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2046, 116, 232);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2047, 12, 232);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2048, 69, 232);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1754, 45, 206);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1755, 1, 206);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1756, 12, 206);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1757, 9, 206);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1758, 69, 206);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1759, 14, 206);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1760, 155, 206);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2049, 155, 232);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2050, 31, 788);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2051, 45, 788);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1761, 45, 205);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1762, 1, 205);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1763, 9, 205);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1764, 45, 209);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1913, 41, 332);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1914, 36, 332);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1915, 41, 333);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1916, 59, 333);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1917, 36, 333);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1918, 69, 333);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2052, 69, 788);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2053, 171, 788);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2054, 22, 790);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2055, 135, 790);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2056, 50, 802);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2057, 85, 801);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2058, 121, 588);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1919, 71, 318);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1920, 57, 318);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1921, 45, 318);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1922, 46, 318);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1923, 12, 318);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1924, 69, 318);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1925, 155, 318);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2059, 109, 587);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2060, 144, 379);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2061, 73, 383);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2063, 149, 389);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2064, 104, 388);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2065, 87, 385);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2066, 95, 382);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2067, 4, 393);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2072, 123, 798);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2073, 135, 798);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2074, 160, 798);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2075, 32, 793);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2217, 148, 444);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2076, 67, 670);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2218, 40, 133);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2219, 56, 133);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2251, 130, 129);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2252, 17, 129);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2253, 142, 425);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2254, 96, 496);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2255, 134, 496);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2328, 19, 778);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2329, 85, 775);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2330, 19, 771);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2331, 31, 771);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2332, 1, 771);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2333, 19, 770);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2334, 31, 770);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2335, 148, 779);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2336, 31, 780);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2337, 148, 780);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2347, 116, 811);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2348, 106, 811);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2351, 18, 273);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2356, 135, 475);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1151, 86, 441);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1152, 118, 441);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1153, 12, 441);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2357, 135, 476);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2358, 135, 474);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2359, 135, 471);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2360, 31, 478);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1158, 45, 446);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1159, 56, 446);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2361, 31, 479);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2365, 146, 473);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2367, 135, 461);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2372, 85, 455);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2375, 85, 829);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1177, 118, 448);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1178, 12, 448);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1179, 52, 448);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2377, 129, 295);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2378, 154, 293);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2379, 59, 289);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2380, 45, 289);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2381, 155, 289);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1382, 19, 119);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1383, 45, 119);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1187, 19, 450);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1188, 68, 450);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2387, 19, 562);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2388, 135, 562);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2389, 69, 577);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2390, 35, 566);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2391, 68, 566);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1194, 19, 453);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1195, 123, 453);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2392, 51, 583);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1199, 45, 131);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1200, 56, 131);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1201, 12, 131);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1205, 40, 445);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1206, 74, 445);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2407, 12, 299);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2408, 135, 299);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1209, 40, 443);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1210, 19, 443);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1211, 40, 442);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1212, 56, 442);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2409, 9, 299);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2410, 69, 299);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1387, 72, 805);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1388, 46, 530);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1389, 1, 530);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1390, 135, 530);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1219, 26, 499);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1220, 140, 499);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1221, 96, 497);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1222, 140, 497);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1223, 140, 500);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1224, 17, 500);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1391, 9, 530);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1392, 31, 529);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1393, 46, 529);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1394, 1, 529);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1395, 9, 529);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1582, 116, 266);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1583, 12, 266);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1398, 31, 172);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1584, 80, 266);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1765, 156, 207);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2411, 155, 299);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2417, 59, 324);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2418, 155, 324);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1585, 80, 272);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1605, 151, 764);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1766, 45, 207);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1606, 151, 765);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1607, 61, 278);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1608, 159, 766);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1609, 170, 767);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1767, 1, 207);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1768, 9, 207);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1938, 31, 304);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1939, 45, 304);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1940, 12, 304);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1769, 31, 208);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1770, 45, 208);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1771, 1, 208);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1774, 69, 827);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1775, 31, 827);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1941, 69, 304);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1942, 155, 304);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1776, 135, 828);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1777, 69, 828);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1793, 40, 219);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1794, 63, 219);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1795, 19, 220);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1796, 135, 220);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1797, 69, 220);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1947, 135, 306);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1948, 69, 306);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1949, 155, 306);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2085, 2, 797);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2086, 67, 797);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2087, 44, 837);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1956, 1, 312);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1957, 135, 312);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1958, 69, 312);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1964, 45, 314);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1965, 1, 314);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1966, 12, 314);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1967, 69, 314);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1968, 155, 314);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2088, 45, 400);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2089, 12, 400);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2090, 45, 114);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2091, 56, 114);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2092, 12, 114);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2108, 19, 402);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2109, 45, 402);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2110, 12, 402);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2111, 19, 116);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2112, 45, 116);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2113, 12, 116);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2114, 19, 438);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2115, 45, 438);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2116, 19, 120);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2117, 45, 120);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2118, 12, 120);


insert into public.ctgs_group (id, title) values (100, 'Leukopenia');
insert into public.ctgs_group (id, title) values (110, 'Thrombocytopenia');
insert into public.ctgs_group (id, title) values (120, 'Anemia');
insert into public.ctgs_group (id, title) values (130, 'Hemorrhage (Clinical)');
insert into public.ctgs_group (id, title) values (140, 'Infection');
insert into public.ctgs_group (id, title) values (150, 'Fever in absence of infection');
insert into public.ctgs_group (id, title) values (160, 'GU');
insert into public.ctgs_group (id, title) values (170, 'GI');
insert into public.ctgs_group (id, title) values (180, 'Liver');
insert into public.ctgs_group (id, title) values (190, 'Pulmonary');
insert into public.ctgs_group (id, title) values (200, 'Cardiac');
insert into public.ctgs_group (id, title) values (210, 'Blood Pressure');
insert into public.ctgs_group (id, title) values (220, 'Skin');
insert into public.ctgs_group (id, title) values (230, 'Allergy');
insert into public.ctgs_group (id, title) values (240, 'Phlebitis');
insert into public.ctgs_group (id, title) values (250, 'Local');
insert into public.ctgs_group (id, title) values (260, 'Alopecia');
insert into public.ctgs_group (id, title) values (270, 'Weight gain/loss');
insert into public.ctgs_group (id, title) values (280, 'Neurologic Sensory');
insert into public.ctgs_group (id, title) values (290, 'Neurologic Motor');
insert into public.ctgs_group (id, title) values (300, 'Neurologic Psych');
insert into public.ctgs_group (id, title) values (310, 'Neurologic Clinical');
insert into public.ctgs_group (id, title) values (320, 'Metabolic');
insert into public.ctgs_group (id, title) values (330, 'Coagulation');


insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (10, 100, 'WBC x 10^^^');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (11, 100, 'Granulocytes/Bands');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (12, 100, 'Lymphocytes');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (13, 110, 'Plt x 10^^^');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (14, 120, 'Hgb');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (15, 130, 'Hemorrhage (Clinical)');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (16, 140, 'Infection');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (17, 150, 'Fever in absence of infection');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (18, 160, 'Creatinine');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (19, 160, 'Proteinuria');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (20, 160, 'Hematuria');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (21, 160, 'BUN');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (22, 170, 'Nausea');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (23, 170, 'Vomiting');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (24, 170, 'Diarrhea');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (25, 170, 'Stomatitis');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (26, 180, 'Bilirubin');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (27, 180, 'Transaminase (SGOT, SGPT)');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (28, 180, 'Alk Phos or 5''nucleotidase');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (29, 180, 'Liver - clinical');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (30, 190, 'Pulmonary');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (31, 200, 'Cardiac dysrhythmias');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (32, 200, 'Cardiac function');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (33, 200, 'Cardiac—ischemia');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (34, 200, 'Cardiac –pericardial');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (35, 210, 'Hypertension');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (36, 210, 'Hypotension');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (37, 220, 'Skin');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (38, 230, 'Allergy');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (39, 240, 'Phlebitis');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (40, 250, 'Local');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (41, 260, 'Alopecia');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (42, 270, 'Weight gain/loss');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (43, 280, 'neuro—sensory');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (44, 280, 'neuro—vision');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (45, 280, 'neuro—haering');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (46, 290, 'neuro—motor');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (47, 290, 'neuro—constipation');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (48, 300, 'neuro—mood');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (49, 310, 'neuro—cortical');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (50, 310, 'neuro—cerebellar');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (51, 310, 'neuro—headache');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (52, 320, 'Hyperglycemia');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (53, 320, 'Hypoglycemia');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (54, 320, 'Amylase');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (55, 320, 'Hypercalcemia');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (56, 320, 'Hypocalcemia');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (57, 320, 'Hypomagnesemia');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (58, 330, 'Fibrinogen');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (59, 330, 'Prothrombin time');
insert into public.ctgs_sub_group (id, ctgs_group_id, title) values (60, 330, 'Partial thromboplastin time');

insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (1, 10, '>= 4.0', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (2, 11, '>= 2.0', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (3, 12, '>= 2.0', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (4, 13, 'WNL', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (5, 14, 'WNL', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (6, 15, 'none', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (7, 16, 'none', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (8, 17, 'none', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (9, 18, 'WNL', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (10, 19, 'No Change', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (11, 20, 'neg', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (12, 21, '< 1.5 x N', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (13, 22, 'none', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (14, 23, 'none', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (15, 24, 'none', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (16, 25, 'none', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (17, 26, 'WNL', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (18, 27, 'WNL', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (19, 28, 'WNL', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (20, 29, 'no change from baseline', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (21, 30, 'none or no change', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (22, 31, 'none', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (23, 32, 'none', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (24, 33, 'none', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (25, 34, 'none', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (26, 35, 'none or no change', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (27, 36, 'none or no change', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (28, 37, 'none or no change', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (29, 38, 'none', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (30, 39, 'none', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (31, 40, 'none', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (32, 41, 'no loss', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (33, 42, '< 5.0%', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (34, 43, 'none or no change', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (35, 44, 'none or no change', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (36, 45, 'none or no change', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (37, 46, 'none or no change', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (38, 47, 'none or no change', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (39, 48, 'No Change', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (40, 49, 'none', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (41, 50, 'none', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (42, 51, 'none', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (43, 52, '<116', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (44, 53, '>64', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (45, 54, 'WNL', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (46, 55, '<10.6', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (47, 56, '>8.4', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (48, 57, '>1.4', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (49, 58, 'WNL', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (50, 59, 'WNL', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (51, 60, 'WNL', 0);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (52, 10, '3.0 – 3.9', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (53, 11, '1.5 – 1.9', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (54, 12, '1.5 – 1.9', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (55, 13, '75.0 – normal', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (56, 14, '10.0 – normal', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (57, 15, 'mild, no transfusion', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (58, 16, 'mild, no active Rx', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (59, 17, '37.1^degC - 38.0^degC ^nl98.7^degF- 100.4^degF', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (60, 18, '< 1.5 x N', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (61, 19, '1+ or <0.3g% or <3g/l', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (62, 20, 'micro only', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (63, 21, '1.5 - 2.5 x N', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (64, 22, 'able to eat reasonable intake', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (65, 23, '1 episode in 24 hours', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (66, 24, 'increase of 2-3 stools/day over pre-Rx', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (67, 25, 'painless ulcers, erythema, or mild soreness', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (68, 27, '<= 2.5xN', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (69, 28, '<= 2.5xN', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (70, 30, 'asymptomatic, with abnormality in PFTs', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (71, 31, 'asymptomatic, transient, requiring no therapy', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (72, 32, 'asymptomatic, decline of resting ejection fraction by less than 20% of baseline value', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (73, 33, 'non-specific T-wave flattening', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (74, 34, 'asymptomatic effusion, no intervension required', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (75, 35, 'asymptomatic, transient increase by >20 mm Hg(D) or to >150/100 if previously WNL. No treatment required', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (76, 36, 'changes requiring no therapy (including transient orthostatic hypotension)', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (77, 37, 'scattered macular or papular eruption or erythema that is asymptomatic', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (78, 38, 'transient rash, drug fever < 38ºC, 100.4ºF', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (79, 39, 'arm', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (80, 40, 'pain', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (81, 41, 'mild hair loss', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (82, 42, '5.0 - 9.9%', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (83, 43, 'mild paresthesias; loss of deep tendon reflexes', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (84, 45, 'asymptomatic, hearing loss on audiometry only', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (85, 46, 'subjective weakness; no objective findings', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (86, 47, 'mild', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (87, 48, 'mild anxiety or depression', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (88, 49, 'mild somnolence or agitation', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (89, 50, 'slight incoordination, dysdiadockinesis', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (90, 51, 'mild', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (91, 52, '116 - 160 ', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (92, 53, '55-64 ', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (93, 54, '<1.5xN ', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (94, 55, '10.6 - 11.5 ', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (95, 56, '8.4 - 7.8 ', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (96, 57, '1.4 - 1.2', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (97, 58, '0.99-0.75xN ', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (98, 59, '1.01-1.25xN', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (99, 60, '1.01-1.66xN', 1);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (100, 10, '2.0 – 2.9', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (101, 11, '1.0 – 1.4', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (102, 12, '1.0 – 1.4', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (103, 13, '50.0 – 74.9', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (104, 14, '8.0 – 10.0', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (105, 15, 'gross, 1-2 units transfusion/episode', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (106, 16, 'Moderate, localized infection requires active Rx', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (107, 17, '38.1^degC - 40.0^degC ^nl100.5^degF - 104.0^degF', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (108, 18, '1.5 - 3.0 x N', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (109, 19, '2-3+ or 0.3 - 1.0g% or 3 - 10g/l', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (110, 20, 'gross, no clots', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (111, 21, '2.6 - 5 x N', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (112, 22, 'intake significantly decreased but can eat', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (113, 23, '2-5 episodes in 24 hours', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (114, 24, 'increase of 4-6 stools/day, or nocturnal stools, or moderate cramping', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (115, 25, 'painful erythema, edema, or ulcers, but can eat', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (116, 26, '<1.5 x N', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (117, 27, '2.6 - 5.0 x N', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (118, 28, '2.6 - 5.0 x N', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (119, 30, 'dyspnea on significant exertion', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (120, 31, 'recurrent or persistent, no therapy required', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (121, 32, 'asymptomatic, decline of resting ejection fraction by more than 20% of baseline value', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (122, 33, 'asymptomatic, ST and T wave changes suggesting ischemia', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (123, 34, 'pericarditis (rub, chest pain, ECG changes)', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (124, 35, 'recurrent or persistent increase by >20 mm Hg', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (125, 36, 'requires fluid replacement or other therapy but not hospitalization', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (126, 37, 'scattered macular or papular eruption or erythema with pruritus or other associated symptoms', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (127, 38, 'urticaria, drug fever $ 38EC, 100.4EF, mild bronchospasm', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (128, 39, 'thrombophlebitis, leg', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (129, 40, 'pain and swelling, with inflammation or phlebitis', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (130, 41, 'pronounced or total hair loss', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (131, 42, '10.0 - 19.9%', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (132, 43, 'mild or moderate objective sensory loss; moderate paresthesias', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (133, 45, 'tinnitus', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (134, 46, 'mild objective weakness without significant impairment of function', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (135, 47, 'moderate', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (136, 48, 'moderate anxiety or depression', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (137, 49, 'moderate somnolence or agitation', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (138, 50, 'intention tremor, dysmetria, slurred speech, nystagmus', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (139, 51, 'moderate or severe but transient', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (140, 52, '161 - 250 ', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (141, 53, '40-54 ', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (142, 54, '1.5-2.0xN ', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (143, 55, '11.6 - 12.5 ', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (144, 56, '7.7 - 7.0', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (145, 57, '1.1 - 0.9', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (146, 58, '0.74-0.50xN ', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (147, 59, '1.26-1.50xN', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (148, 60, '1.67-2.33xN', 2);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (149, 10, '1.0 – 2.9', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (150, 11, '0.5 – 0.9', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (151, 12, '0.5 – 0.9', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (152, 13, '25.0 – 49.9', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (153, 14, '6.5 – 7.9', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (154, 15, 'gross, 3-4 units transfusion/episode', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (155, 16, 'severe, systemic infection requires active Rx, specify site', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (156, 17, '> 40.0^degC (> 104.0^degF) for less than 24 hours', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (157, 18, '3.1-6.0xN', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (158, 19, '4+ or >1.0g% or >10g/l', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (159, 20, 'gross + clots', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (160, 21, '5.1-10xN', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (161, 22, 'no significant intake', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (162, 23, '6-10 episodes in 24 hours', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (163, 24, 'increase of 7-9 stools/day or incontinence, or severe cramping', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (164, 25, 'painful erythema, edema or ulcers, and cannot eat', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (165, 26, '1.5-3.0xN', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (166, 27, '5.1-20.0xN', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (167, 28, '5.1-20.0xN', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (168, 29, 'precoma', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (169, 30, 'dyspnea at normal level of activity', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (170, 31, 'requires treatment', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (171, 32, 'mild CHF, responsive to therapy', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (172, 33, 'angina without evidence for infarction', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (173, 34, 'symptomatic effusion; drainage required', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (174, 35, 'requires therapy', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (175, 36, 'requires therapy and hospitalization; resolves within 48 hours of stopping the agent', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (176, 37, 'generalized symptomatic macular, papular or vesicular eruption', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (177, 38, 'serum sickness, bronchospasm, requires parenteral meds', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (178, 39, 'hospitalization', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (179, 40, 'ulceration', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (180, 42, '>= 20%', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (181, 43, 'severe objective sensory loss or paresthesias that interfere with function', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (182, 44, 'symptomatic subtotal loss of vision', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (183, 45, 'hearing loss interfering with function but correct- able with hearing aid', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (184, 46, 'objective weakness with impairment of function', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (185, 47, 'severe', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (186, 48, 'severe anxiety or depression', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (187, 49, 'severe somnolence, agitation, confusion, disorientation or hallucinations', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (188, 50, 'locomotor ataxia', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (189, 51, 'unrelenting and severe', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (190, 52, '251 - 500 ', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (191, 53, '30-39 ', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (192, 54, '2.1-5.0xN ', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (193, 55, '12.6 - 13.5 ', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (194, 56, '6.9 - 6.1', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (195, 57, '0.8 - 0.6', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (196, 58, '0.49-0.25xN ', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (197, 59, '1.51-2.00xN', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (198, 60, '2.34-3.00xN', 3);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (199, 10, '< 1.0', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (200, 11, '< 0.5', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (201, 12, '< 0.5', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (202, 13, '< 25.0', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (203, 14, '< 6.5', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (204, 15, 'massive, >4 units transfusion/episode', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (205, 16, 'life-threatening, sepsis, specify site', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (206, 17, '>40.0^degC (104.0^degF) for >24 hrs or fever with hypotension', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (207, 18, '>6.0 x N', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (208, 19, 'nephrotic syndrome', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (209, 20, 'requires transfusion', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (210, 21, '>10 x N', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (211, 23, '>10 episodes in 24 hrs or', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (212, 24, 'increase of $10 stools/day or grossly bloody diarrhea, or need for parenteral support', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (213, 25, 'requires parenteral or enteral support', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (214, 26, '>3.0 x N', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (215, 27, '>20.0 x N', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (216, 28, '>20.0 x N', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (217, 29, 'hepatic coma', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (218, 30, 'dyspnea at rest', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (219, 31, 'requires monitoring, or', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (220, 32, 'hypotension or ventricular tachycardia or fibrillation', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (221, 33, 'acute myocardial infarction', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (222, 34, 'tamponade; drainage urgently required', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (223, 35, 'hypertensive crisis', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (224, 36, 'requires therapy and hospitalization for >48 hours after stopping the agent', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (225, 37, 'exfoliative dermatitis or ulcerating dermatitis', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (226, 38, 'anaphylaxis', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (227, 39, 'embolus', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (228, 40, 'plastic surgery indicated', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (229, 44, 'blindness', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (230, 45, 'deafness, not correctable', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (231, 46, 'paralysis', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (232, 47, 'ileus >96 hours', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (233, 48, 'suicidal ideation', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (234, 49, 'coma, seizures, toxic psychosis', 4);
insert into public.ctgs_option (id, ctgs_sub_group_id, title, grade) values (235, 50, 'cerebellar necrosis', 4);
